--
-- PostgreSQL database cluster dump
--

\restrict EDClFKfUYuacQ44lg0FyATv7mXrcefxHc6M4k17Hx4wkcdQl3Yu26h6kgGFFbmh

SET default_transaction_read_only = off;

SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;

--
-- Roles
--

CREATE ROLE trader;
ALTER ROLE trader WITH SUPERUSER INHERIT CREATEROLE CREATEDB LOGIN REPLICATION BYPASSRLS PASSWORD 'SCRAM-SHA-256$4096:QID6uDMSMNKX8clck5KOgA==$CAWpIf3AujRIJJW8A66nCsVA3TCCG4dTG/bWYmvJKk0=:cITsoqSlgNXeP0YqftQ8qsBTJ/4zD/UyxjiBLgLw97Q=';

--
-- User Configurations
--








\unrestrict EDClFKfUYuacQ44lg0FyATv7mXrcefxHc6M4k17Hx4wkcdQl3Yu26h6kgGFFbmh

--
-- Databases
--

--
-- Database "template1" dump
--

\connect template1

--
-- PostgreSQL database dump
--

\restrict Xm4KmlllYiBzCGUbx0mtYc4LegGHi0kIZJn9r2FvFtUZrAxKIelHezPzoOOlqA5

-- Dumped from database version 15.14
-- Dumped by pg_dump version 15.14

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

--
-- PostgreSQL database dump complete
--

\unrestrict Xm4KmlllYiBzCGUbx0mtYc4LegGHi0kIZJn9r2FvFtUZrAxKIelHezPzoOOlqA5

--
-- Database "postgres" dump
--

\connect postgres

--
-- PostgreSQL database dump
--

\restrict iPSND2do0rV0K4soykvEKAMoLcF472pLdqlHBPOmc9MoABC5W20L3af3HN40Hh6

-- Dumped from database version 15.14
-- Dumped by pg_dump version 15.14

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

--
-- PostgreSQL database dump complete
--

\unrestrict iPSND2do0rV0K4soykvEKAMoLcF472pLdqlHBPOmc9MoABC5W20L3af3HN40Hh6

--
-- Database "tradetally" dump
--

--
-- PostgreSQL database dump
--

\restrict DKauiaF7rQePasK8CBZx6ot95rTwiqenGTU4Wwl0PYCJWig5hH8GliOr3YrX0PL

-- Dumped from database version 15.14
-- Dumped by pg_dump version 15.14

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

--
-- Name: tradetally; Type: DATABASE; Schema: -; Owner: trader
--

CREATE DATABASE tradetally WITH TEMPLATE = template0 ENCODING = 'UTF8' LOCALE_PROVIDER = libc LOCALE = 'en_US.utf8';


ALTER DATABASE tradetally OWNER TO trader;

\unrestrict DKauiaF7rQePasK8CBZx6ot95rTwiqenGTU4Wwl0PYCJWig5hH8GliOr3YrX0PL
\connect tradetally
\restrict DKauiaF7rQePasK8CBZx6ot95rTwiqenGTU4Wwl0PYCJWig5hH8GliOr3YrX0PL

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

--
-- Name: achievement_category; Type: TYPE; Schema: public; Owner: trader
--

CREATE TYPE public.achievement_category AS ENUM (
    'behavioral',
    'performance',
    'learning',
    'social',
    'milestone'
);


ALTER TYPE public.achievement_category OWNER TO trader;

--
-- Name: achievement_difficulty; Type: TYPE; Schema: public; Owner: trader
--

CREATE TYPE public.achievement_difficulty AS ENUM (
    'bronze',
    'silver',
    'gold',
    'platinum'
);


ALTER TYPE public.achievement_difficulty OWNER TO trader;

--
-- Name: challenge_status; Type: TYPE; Schema: public; Owner: trader
--

CREATE TYPE public.challenge_status AS ENUM (
    'active',
    'completed',
    'failed',
    'expired'
);


ALTER TYPE public.challenge_status OWNER TO trader;

--
-- Name: cleanup_expired_enrichment_cache(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.cleanup_expired_enrichment_cache() RETURNS integer
    LANGUAGE plpgsql
    AS $$
DECLARE
    deleted_count INTEGER;
BEGIN
    DELETE FROM enrichment_cache 
    WHERE expires_at IS NOT NULL AND expires_at < CURRENT_TIMESTAMP;
    
    GET DIAGNOSTICS deleted_count = ROW_COUNT;
    RETURN deleted_count;
END;
$$;


ALTER FUNCTION public.cleanup_expired_enrichment_cache() OWNER TO trader;

--
-- Name: cleanup_expired_global_enrichment_cache(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.cleanup_expired_global_enrichment_cache() RETURNS integer
    LANGUAGE plpgsql
    AS $$
DECLARE
    deleted_count INTEGER;
BEGIN
    DELETE FROM global_enrichment_cache 
    WHERE expires_at IS NOT NULL AND expires_at < CURRENT_TIMESTAMP;
    
    GET DIAGNOSTICS deleted_count = ROW_COUNT;
    RETURN deleted_count;
END;
$$;


ALTER FUNCTION public.cleanup_expired_global_enrichment_cache() OWNER TO trader;

--
-- Name: cleanup_trade_jobs(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.cleanup_trade_jobs() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    -- Delete jobs that reference the deleted trade
    DELETE FROM job_queue 
    WHERE data->>'tradeId' = OLD.id::text
    OR (data->'tradeIds' ? OLD.id::text);
    
    -- Log the cleanup for debugging
    RAISE NOTICE 'Cleaned up jobs for deleted trade %', OLD.id;
    
    RETURN OLD;
END;
$$;


ALTER FUNCTION public.cleanup_trade_jobs() OWNER TO trader;

--
-- Name: generate_anonymous_name(uuid); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.generate_anonymous_name(user_id uuid) RETURNS character varying
    LANGUAGE plpgsql IMMUTABLE
    AS $$
DECLARE
  prefixes TEXT[] := ARRAY[
    'Shadow', 'Iron', 'Storm', 'Fire', 'Ice', 'Thunder', 'Lightning', 'Dark', 'Bright', 'Silent',
    'Swift', 'Mighty', 'Golden', 'Silver', 'Crimson', 'Azure', 'Emerald', 'Mystic', 'Phantom', 'Stealth',
    'Cyber', 'Neon', 'Quantum', 'Alpha', 'Beta', 'Omega', 'Prime', 'Ultra', 'Mega', 'Hyper',
    'Rogue', 'Elite', 'Savage', 'Wild', 'Fierce', 'Brutal', 'Rapid', 'Turbo', 'Blazing', 'Frozen',
    'Venom', 'Toxic', 'Nuclear', 'Laser', 'Plasma', 'Cosmic', 'Stellar', 'Solar', 'Lunar', 'Nova'
  ];
  
  suffixes TEXT[] := ARRAY[
    'Hunter', 'Wolf', 'Eagle', 'Hawk', 'Tiger', 'Lion', 'Bear', 'Fox', 'Viper', 'Falcon',
    'Warrior', 'Knight', 'Ranger', 'Scout', 'Sniper', 'Assassin', 'Guardian', 'Sentinel', 'Defender', 'Striker',
    'Blade', 'Arrow', 'Bullet', 'Bolt', 'Spike', 'Claw', 'Fang', 'Talon', 'Wing', 'Shield',
    'Storm', 'Blaze', 'Frost', 'Flame', 'Spark', 'Flash', 'Dash', 'Rush', 'Crush', 'Smash',
    'Force', 'Power', 'Might', 'Fury', 'Rage', 'Wrath', 'Steel', 'Stone', 'Rock', 'Crystal'
  ];
  
  hash_value INTEGER;
  prefix_index INTEGER;
  suffix_index INTEGER;
BEGIN
  -- Generate a consistent hash from user_id
  hash_value := abs(hashtext(user_id::text));
  
  -- Use hash to select prefix and suffix with different modulo operations for variety
  prefix_index := (hash_value % array_length(prefixes, 1)) + 1;
  suffix_index := ((hash_value / 13) % array_length(suffixes, 1)) + 1;
  
  -- Return combined username without spaces (like ShadowHunter, IronWolf, etc.)
  RETURN prefixes[prefix_index] || suffixes[suffix_index];
END;
$$;


ALTER FUNCTION public.generate_anonymous_name(user_id uuid) OWNER TO trader;

--
-- Name: generate_enrichment_cache_key(character varying, date, time without time zone); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.generate_enrichment_cache_key(p_symbol character varying, p_entry_date date, p_entry_time time without time zone DEFAULT NULL::time without time zone) RETURNS character varying
    LANGUAGE plpgsql
    AS $$
BEGIN
    IF p_entry_time IS NOT NULL THEN
        RETURN LOWER(p_symbol) || '_' || TO_CHAR(p_entry_date, 'YYYY-MM-DD') || '_' || TO_CHAR(p_entry_time, 'HH24:MI');
    ELSE
        RETURN LOWER(p_symbol) || '_' || TO_CHAR(p_entry_date, 'YYYY-MM-DD');
    END IF;
END;
$$;


ALTER FUNCTION public.generate_enrichment_cache_key(p_symbol character varying, p_entry_date date, p_entry_time time without time zone) OWNER TO trader;

--
-- Name: get_cusip_mapping(character varying, uuid); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.get_cusip_mapping(p_cusip character varying, p_user_id uuid DEFAULT NULL::uuid) RETURNS TABLE(cusip character varying, ticker character varying, company_name character varying, resolution_source character varying, confidence_score integer, verified boolean, is_user_override boolean)
    LANGUAGE plpgsql
    AS $$
BEGIN
  -- First try to find user-specific mapping
  IF p_user_id IS NOT NULL THEN
    RETURN QUERY
    SELECT 
      cm.cusip,
      cm.ticker,
      cm.company_name,
      cm.resolution_source,
      cm.confidence_score,
      cm.verified,
      TRUE as is_user_override
    FROM cusip_mappings cm
    WHERE cm.cusip = p_cusip 
      AND cm.user_id = p_user_id
    LIMIT 1;
    
    -- If user-specific mapping found, return it
    IF FOUND THEN
      RETURN;
    END IF;
  END IF;
  
  -- If no user-specific mapping, try global mapping
  RETURN QUERY
  SELECT 
    cm.cusip,
    cm.ticker,
    cm.company_name,
    cm.resolution_source,
    cm.confidence_score,
    cm.verified,
    FALSE as is_user_override
  FROM cusip_mappings cm
  WHERE cm.cusip = p_cusip 
    AND cm.user_id IS NULL
  ORDER BY cm.confidence_score DESC, cm.created_at ASC
  LIMIT 1;
END;
$$;


ALTER FUNCTION public.get_cusip_mapping(p_cusip character varying, p_user_id uuid) OWNER TO trader;

--
-- Name: get_or_create_global_enrichment_cache(character varying, date); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.get_or_create_global_enrichment_cache(p_symbol character varying, p_trade_date date) RETURNS uuid
    LANGUAGE plpgsql
    AS $$
DECLARE
    cache_id UUID;
BEGIN
    -- Try to find existing cache entry
    SELECT id INTO cache_id
    FROM global_enrichment_cache
    WHERE symbol = p_symbol AND trade_date = p_trade_date;
    
    -- If not found, create new entry
    IF cache_id IS NULL THEN
        INSERT INTO global_enrichment_cache (symbol, trade_date)
        VALUES (p_symbol, p_trade_date)
        RETURNING id INTO cache_id;
    ELSE
        -- Update access tracking
        UPDATE global_enrichment_cache
        SET access_count = access_count + 1,
            last_accessed_at = CURRENT_TIMESTAMP
        WHERE id = cache_id;
    END IF;
    
    RETURN cache_id;
END;
$$;


ALTER FUNCTION public.get_or_create_global_enrichment_cache(p_symbol character varying, p_trade_date date) OWNER TO trader;

--
-- Name: get_or_create_news_cache(character varying, date, jsonb, character varying); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.get_or_create_news_cache(p_symbol character varying, p_news_date date, p_news_events jsonb DEFAULT '[]'::jsonb, p_sentiment character varying DEFAULT NULL::character varying) RETURNS TABLE(cache_id uuid, news_events jsonb, sentiment character varying, was_cached boolean)
    LANGUAGE plpgsql
    AS $$
DECLARE
    existing_record news_cache%ROWTYPE;
    new_record news_cache%ROWTYPE;
BEGIN
    -- Try to find existing cache entry
    SELECT * INTO existing_record 
    FROM news_cache 
    WHERE symbol = p_symbol AND news_date = p_news_date;
    
    IF FOUND THEN
        -- Return existing cached data
        RETURN QUERY SELECT 
            existing_record.id,
            existing_record.news_events,
            existing_record.sentiment,
            TRUE as was_cached;
    ELSE
        -- Create new cache entry
        INSERT INTO news_cache (symbol, news_date, news_events, sentiment)
        VALUES (p_symbol, p_news_date, p_news_events, p_sentiment)
        RETURNING * INTO new_record;
        
        -- Return new data
        RETURN QUERY SELECT 
            new_record.id,
            new_record.news_events,
            new_record.sentiment,
            FALSE as was_cached;
    END IF;
END;
$$;


ALTER FUNCTION public.get_or_create_news_cache(p_symbol character varying, p_news_date date, p_news_events jsonb, p_sentiment character varying) OWNER TO trader;

--
-- Name: log_strategy_classification(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.log_strategy_classification() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    -- Only log if strategy actually changed or if it's a new assignment
    IF (OLD.strategy IS DISTINCT FROM NEW.strategy) OR 
       (OLD.strategy IS NULL AND NEW.strategy IS NOT NULL) THEN
        
        INSERT INTO strategy_classification_history (
            trade_id,
            user_id,
            previous_strategy,
            new_strategy,
            classification_method,
            confidence_score,
            classification_metadata,
            is_manual_override
        ) VALUES (
            NEW.id,
            NEW.user_id,
            OLD.strategy,
            NEW.strategy,
            COALESCE(NEW.classification_method, 'manual'), -- Default to 'manual' if null
            NEW.strategy_confidence,
            NEW.classification_metadata,
            COALESCE(NEW.manual_override, true) -- Default to true if null (manual edit)
        );
    END IF;
    
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.log_strategy_classification() OWNER TO trader;

--
-- Name: log_strategy_classification_change(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.log_strategy_classification_change() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    -- Only log if strategy actually changed or if it's a new assignment
    IF (OLD.strategy IS DISTINCT FROM NEW.strategy) OR 
       (OLD.strategy IS NULL AND NEW.strategy IS NOT NULL) THEN
        
        INSERT INTO strategy_classification_history (
            trade_id,
            user_id,
            previous_strategy,
            new_strategy,
            classification_method,
            confidence_score,
            classification_metadata,
            is_manual_override
        ) VALUES (
            NEW.id,
            NEW.user_id,
            OLD.strategy,
            NEW.strategy,
            NEW.classification_method,
            NEW.strategy_confidence,
            NEW.classification_metadata,
            NEW.manual_override
        );
    END IF;
    
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.log_strategy_classification_change() OWNER TO trader;

--
-- Name: reset_trial_used_on_delete(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.reset_trial_used_on_delete() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    -- If the deleted override was a trial, reset the trial_used flag
    IF OLD.reason ILIKE '%trial%' THEN
        UPDATE users 
        SET trial_used = false, updated_at = CURRENT_TIMESTAMP
        WHERE id = OLD.user_id;
        
        RAISE NOTICE 'Reset trial_used flag for user % after deleting trial override', OLD.user_id;
    END IF;
    
    RETURN OLD;
END;
$$;


ALTER FUNCTION public.reset_trial_used_on_delete() OWNER TO trader;

--
-- Name: resolve_cusip_mapping_conflict(character varying, character varying, character varying, uuid, integer); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.resolve_cusip_mapping_conflict(p_cusip character varying, p_ticker character varying, p_resolution_source character varying, p_user_id uuid DEFAULT NULL::uuid, p_confidence_score integer DEFAULT 100) RETURNS boolean
    LANGUAGE plpgsql
    AS $$
DECLARE
    existing_mapping RECORD;
    conflict_count INTEGER;
BEGIN
    -- Check if there's already a global mapping for this ticker to a different CUSIP
    SELECT cusip, ticker, resolution_source, confidence_score INTO existing_mapping
    FROM cusip_mappings 
    WHERE ticker = p_ticker 
    AND cusip != p_cusip
    AND user_id IS NULL;
    
    IF FOUND THEN
        -- Log the conflict
        RAISE NOTICE 'CONFLICT: Ticker % already mapped to CUSIP % (source: %, confidence: %), attempted new mapping to CUSIP % (source: %, confidence: %)', 
            p_ticker, existing_mapping.cusip, existing_mapping.resolution_source, existing_mapping.confidence_score,
            p_cusip, p_resolution_source, p_confidence_score;
        
        -- If the new mapping has higher confidence, replace the old one
        IF p_confidence_score > existing_mapping.confidence_score THEN
            RAISE NOTICE 'Replacing lower confidence mapping: % → % (confidence %) with % → % (confidence %)',
                existing_mapping.cusip, p_ticker, existing_mapping.confidence_score,
                p_cusip, p_ticker, p_confidence_score;
            
            -- Delete the old mapping
            DELETE FROM cusip_mappings 
            WHERE ticker = p_ticker 
            AND cusip = existing_mapping.cusip
            AND user_id IS NULL;
            
            RETURN TRUE; -- Allow the insert
        ELSE
            RAISE NOTICE 'Rejecting lower confidence mapping: % → % (confidence %) vs existing % → % (confidence %)',
                p_cusip, p_ticker, p_confidence_score,
                existing_mapping.cusip, p_ticker, existing_mapping.confidence_score;
            
            RETURN FALSE; -- Reject the insert
        END IF;
    END IF;
    
    RETURN TRUE; -- No conflict, allow the insert
END;
$$;


ALTER FUNCTION public.resolve_cusip_mapping_conflict(p_cusip character varying, p_ticker character varying, p_resolution_source character varying, p_user_id uuid, p_confidence_score integer) OWNER TO trader;

--
-- Name: FUNCTION resolve_cusip_mapping_conflict(p_cusip character varying, p_ticker character varying, p_resolution_source character varying, p_user_id uuid, p_confidence_score integer); Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON FUNCTION public.resolve_cusip_mapping_conflict(p_cusip character varying, p_ticker character varying, p_resolution_source character varying, p_user_id uuid, p_confidence_score integer) IS 'Helps resolve conflicts when inserting new CUSIP mappings by comparing confidence scores';


--
-- Name: set_trial_used_on_insert(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.set_trial_used_on_insert() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    -- If the new override is a trial, set the trial_used flag
    IF NEW.reason ILIKE '%trial%' THEN
        UPDATE users 
        SET trial_used = true, updated_at = CURRENT_TIMESTAMP
        WHERE id = NEW.user_id;
        
        RAISE NOTICE 'Set trial_used flag for user % after creating trial override', NEW.user_id;
    END IF;
    
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.set_trial_used_on_insert() OWNER TO trader;

--
-- Name: track_sync_changes(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.track_sync_changes() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
DECLARE
    v_entity_type VARCHAR(50);
    v_action VARCHAR(20);
    v_entity_id UUID;
    v_user_id UUID;
    v_change_data JSONB;
BEGIN
    -- Determine entity type based on TG_TABLE_NAME
    CASE TG_TABLE_NAME
        WHEN 'trades' THEN v_entity_type := 'trade';
        WHEN 'trade_journal_entries' THEN v_entity_type := 'journal';
        WHEN 'user_settings' THEN v_entity_type := 'settings';
        WHEN 'users' THEN v_entity_type := 'user_profile';
        ELSE RETURN NEW; -- Skip unknown tables
    END CASE;
    
    -- Determine action
    CASE TG_OP
        WHEN 'INSERT' THEN 
            v_action := 'create';
            v_entity_id := NEW.id;
            v_user_id := COALESCE(NEW.user_id, NEW.id); -- For users table, use id as user_id
            v_change_data := to_jsonb(NEW);
        WHEN 'UPDATE' THEN 
            v_action := 'update';
            v_entity_id := NEW.id;
            v_user_id := COALESCE(NEW.user_id, NEW.id);
            -- Store only changed fields
            v_change_data := jsonb_build_object(
                'old', to_jsonb(OLD),
                'new', to_jsonb(NEW)
            );
        WHEN 'DELETE' THEN 
            v_action := 'delete';
            v_entity_id := OLD.id;
            v_user_id := COALESCE(OLD.user_id, OLD.id);
            v_change_data := to_jsonb(OLD);
    END CASE;
    
    -- Insert sync metadata
    INSERT INTO sync_metadata (user_id, entity_type, entity_id, action, change_data)
    VALUES (v_user_id, v_entity_type, v_entity_id, v_action, v_change_data);
    
    IF TG_OP = 'DELETE' THEN
        RETURN OLD;
    ELSE
        RETURN NEW;
    END IF;
END;
$$;


ALTER FUNCTION public.track_sync_changes() OWNER TO trader;

--
-- Name: update_admin_settings_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_admin_settings_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_admin_settings_updated_at() OWNER TO trader;

--
-- Name: update_behavioral_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_behavioral_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_behavioral_updated_at() OWNER TO trader;

--
-- Name: update_cusip_mappings_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_cusip_mappings_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
  NEW.updated_at = CURRENT_TIMESTAMP;
  RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_cusip_mappings_updated_at() OWNER TO trader;

--
-- Name: update_diary_entries_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_diary_entries_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_diary_entries_updated_at() OWNER TO trader;

--
-- Name: update_enrichment_cache_timestamp(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_enrichment_cache_timestamp() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_enrichment_cache_timestamp() OWNER TO trader;

--
-- Name: update_equity_history_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_equity_history_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_equity_history_updated_at() OWNER TO trader;

--
-- Name: update_equity_snapshots_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_equity_snapshots_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_equity_snapshots_updated_at() OWNER TO trader;

--
-- Name: update_global_enrichment_cache_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_global_enrichment_cache_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_global_enrichment_cache_updated_at() OWNER TO trader;

--
-- Name: update_overconfidence_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_overconfidence_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_overconfidence_updated_at() OWNER TO trader;

--
-- Name: update_round_trip_trades_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_round_trip_trades_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_round_trip_trades_updated_at() OWNER TO trader;

--
-- Name: update_stock_splits_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_stock_splits_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_stock_splits_updated_at() OWNER TO trader;

--
-- Name: update_subscription_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_subscription_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_subscription_updated_at() OWNER TO trader;

--
-- Name: update_symbol_categories_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_symbol_categories_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
  NEW.updated_at = NOW();
  RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_symbol_categories_updated_at() OWNER TO trader;

--
-- Name: update_updated_at(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_updated_at() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
  NEW.updated_at = CURRENT_TIMESTAMP;
  RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_updated_at() OWNER TO trader;

--
-- Name: update_updated_at_column(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.update_updated_at_column() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    NEW.updated_at = CURRENT_TIMESTAMP;
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.update_updated_at_column() OWNER TO trader;

--
-- Name: validate_cusip_ticker_uniqueness(); Type: FUNCTION; Schema: public; Owner: trader
--

CREATE FUNCTION public.validate_cusip_ticker_uniqueness() RETURNS trigger
    LANGUAGE plpgsql
    AS $$
BEGIN
    -- Check if this ticker is already mapped to a different CUSIP
    -- Allow the same mapping (idempotent updates)
    -- Allow user-specific overrides (user_id IS NOT NULL)
    IF EXISTS (
        SELECT 1 FROM cusip_mappings 
        WHERE ticker = NEW.ticker 
        AND cusip != NEW.cusip
        AND user_id IS NULL  -- Only check global mappings
        AND NEW.user_id IS NULL  -- Only apply to global mappings
    ) THEN
        RAISE EXCEPTION 'Ticker % is already mapped to a different CUSIP. Each ticker can only map to one CUSIP globally.', NEW.ticker;
    END IF;
    
    RETURN NEW;
END;
$$;


ALTER FUNCTION public.validate_cusip_ticker_uniqueness() OWNER TO trader;

--
-- Name: FUNCTION validate_cusip_ticker_uniqueness(); Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON FUNCTION public.validate_cusip_ticker_uniqueness() IS 'Prevents duplicate ticker symbols from being mapped to different CUSIPs globally';


SET default_tablespace = '';

SET default_table_access_method = heap;

--
-- Name: achievement_milestones; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.achievement_milestones (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    achievement_id uuid NOT NULL,
    milestone_key character varying(100) NOT NULL,
    achieved_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    value numeric,
    metadata jsonb DEFAULT '{}'::jsonb
);


ALTER TABLE public.achievement_milestones OWNER TO trader;

--
-- Name: achievements; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.achievements (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    key character varying(100) NOT NULL,
    name character varying(255) NOT NULL,
    description text NOT NULL,
    category public.achievement_category NOT NULL,
    difficulty public.achievement_difficulty NOT NULL,
    points integer DEFAULT 10 NOT NULL,
    icon_name character varying(100),
    criteria jsonb NOT NULL,
    is_active boolean DEFAULT true,
    is_repeatable boolean DEFAULT false,
    max_progress integer DEFAULT 1,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.achievements OWNER TO trader;

--
-- Name: price_alerts; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.price_alerts (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    symbol character varying(10) NOT NULL,
    alert_type character varying(20) NOT NULL,
    target_price numeric(15,4),
    change_percent numeric(5,2),
    current_price numeric(15,4),
    is_active boolean DEFAULT true,
    email_enabled boolean DEFAULT true,
    browser_enabled boolean DEFAULT true,
    repeat_enabled boolean DEFAULT false,
    triggered_at timestamp without time zone,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT price_alerts_config_check CHECK (((((alert_type)::text = ANY ((ARRAY['above'::character varying, 'below'::character varying])::text[])) AND (target_price IS NOT NULL)) OR (((alert_type)::text = 'change_percent'::text) AND (change_percent IS NOT NULL)))),
    CONSTRAINT price_alerts_notification_check CHECK (((email_enabled = true) OR (browser_enabled = true)))
);


ALTER TABLE public.price_alerts OWNER TO trader;

--
-- Name: price_monitoring; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.price_monitoring (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    symbol character varying(10) NOT NULL,
    current_price numeric(15,4) NOT NULL,
    previous_price numeric(15,4),
    price_change numeric(15,4),
    percent_change numeric(5,2),
    volume bigint,
    last_updated timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    data_source character varying(20) DEFAULT 'finnhub'::character varying
);


ALTER TABLE public.price_monitoring OWNER TO trader;

--
-- Name: user_settings; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.user_settings (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid,
    email_notifications boolean DEFAULT true,
    public_profile boolean DEFAULT false,
    default_tags text[],
    import_settings jsonb DEFAULT '{}'::jsonb,
    theme character varying(20) DEFAULT 'light'::character varying,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    account_equity numeric(15,2) DEFAULT 0.00,
    trading_strategies text[] DEFAULT '{}'::text[],
    trading_styles text[] DEFAULT '{}'::text[],
    risk_tolerance character varying(20) DEFAULT 'moderate'::character varying,
    primary_markets text[] DEFAULT '{}'::text[],
    experience_level character varying(20) DEFAULT 'intermediate'::character varying,
    average_position_size character varying(20) DEFAULT 'medium'::character varying,
    trading_goals text[] DEFAULT '{}'::text[],
    preferred_sectors text[] DEFAULT '{}'::text[],
    ai_provider character varying(50) DEFAULT 'gemini'::character varying,
    ai_api_key text,
    ai_api_url text,
    ai_model character varying(100),
    statistics_calculation character varying(10) DEFAULT 'average'::character varying,
    CONSTRAINT user_settings_statistics_calculation_check CHECK (((statistics_calculation)::text = ANY ((ARRAY['average'::character varying, 'median'::character varying])::text[]))),
    CONSTRAINT valid_ai_provider CHECK (((ai_provider)::text = ANY ((ARRAY['gemini'::character varying, 'claude'::character varying, 'openai'::character varying, 'ollama'::character varying, 'local'::character varying])::text[])))
);


ALTER TABLE public.user_settings OWNER TO trader;

--
-- Name: COLUMN user_settings.ai_provider; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.user_settings.ai_provider IS 'AI provider for analytics and CUSIP lookup: gemini, claude, openai, ollama, or local';


--
-- Name: COLUMN user_settings.ai_api_key; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.user_settings.ai_api_key IS 'API key for the selected AI provider';


--
-- Name: COLUMN user_settings.ai_api_url; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.user_settings.ai_api_url IS 'Custom URL for local/ollama AI provider';


--
-- Name: COLUMN user_settings.ai_model; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.user_settings.ai_model IS 'Specific model name to use with the AI provider';


--
-- Name: COLUMN user_settings.statistics_calculation; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.user_settings.statistics_calculation IS 'Determines whether to use average or median for analytics calculations (average, median)';


--
-- Name: users; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.users (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    email character varying(255) NOT NULL,
    username character varying(100) NOT NULL,
    password_hash character varying(255) NOT NULL,
    full_name character varying(255),
    avatar_url character varying(500),
    is_verified boolean DEFAULT false,
    is_active boolean DEFAULT true,
    timezone character varying(50) DEFAULT 'UTC'::character varying,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    verification_token character varying(255),
    verification_expires timestamp with time zone,
    reset_token character varying(255),
    reset_expires timestamp with time zone,
    role character varying(20) DEFAULT 'user'::character varying,
    admin_approved boolean DEFAULT true,
    two_factor_secret character varying(255),
    two_factor_enabled boolean DEFAULT false,
    two_factor_backup_codes text[],
    two_factor_enabled_at timestamp without time zone,
    tier character varying(20) DEFAULT 'free'::character varying,
    notify_news_open_positions boolean DEFAULT true,
    notify_earnings_announcements boolean DEFAULT true,
    notify_price_alerts boolean DEFAULT true,
    notify_trade_reminders boolean DEFAULT true,
    notify_market_events boolean DEFAULT false,
    trial_used boolean DEFAULT false,
    CONSTRAINT users_role_check CHECK (((role)::text = ANY ((ARRAY['user'::character varying, 'admin'::character varying, 'owner'::character varying])::text[]))),
    CONSTRAINT users_tier_check CHECK (((tier)::text = ANY ((ARRAY['free'::character varying, 'pro'::character varying])::text[])))
);


ALTER TABLE public.users OWNER TO trader;

--
-- Name: COLUMN users.two_factor_secret; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.two_factor_secret IS 'Base32 encoded secret for TOTP 2FA';


--
-- Name: COLUMN users.two_factor_enabled; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.two_factor_enabled IS 'Whether 2FA is enabled for this user';


--
-- Name: COLUMN users.two_factor_backup_codes; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.two_factor_backup_codes IS 'Array of one-time backup codes for account recovery';


--
-- Name: COLUMN users.two_factor_enabled_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.two_factor_enabled_at IS 'Timestamp when 2FA was first enabled';


--
-- Name: COLUMN users.tier; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.tier IS 'User subscription tier: free or pro (admins get pro by default)';


--
-- Name: COLUMN users.notify_news_open_positions; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.notify_news_open_positions IS 'Send notifications about news events affecting open positions';


--
-- Name: COLUMN users.notify_earnings_announcements; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.notify_earnings_announcements IS 'Send notifications about earnings announcements for watched symbols';


--
-- Name: COLUMN users.notify_price_alerts; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.notify_price_alerts IS 'Send notifications for price alerts and watchlist triggers';


--
-- Name: COLUMN users.notify_trade_reminders; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.notify_trade_reminders IS 'Send notifications for trade-related reminders and updates';


--
-- Name: COLUMN users.notify_market_events; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.users.notify_market_events IS 'Send notifications about general market events and updates';


--
-- Name: active_alerts_with_prices; Type: VIEW; Schema: public; Owner: trader
--

CREATE VIEW public.active_alerts_with_prices AS
 SELECT pa.id,
    pa.user_id,
    pa.symbol,
    pa.alert_type,
    pa.target_price,
    pa.change_percent,
    pa.current_price AS alert_creation_price,
    pa.email_enabled,
    pa.browser_enabled,
    pa.repeat_enabled,
    pa.created_at,
    pm.current_price,
    pm.percent_change,
    pm.last_updated AS price_last_updated,
    u.email,
    us.email_notifications AS user_email_enabled
   FROM (((public.price_alerts pa
     JOIN public.users u ON ((pa.user_id = u.id)))
     LEFT JOIN public.user_settings us ON ((u.id = us.user_id)))
     LEFT JOIN public.price_monitoring pm ON (((pa.symbol)::text = (pm.symbol)::text)))
  WHERE ((pa.is_active = true) AND ((u.tier)::text = 'pro'::text));


ALTER TABLE public.active_alerts_with_prices OWNER TO trader;

--
-- Name: admin_settings; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.admin_settings (
    id integer NOT NULL,
    setting_key character varying(255) NOT NULL,
    setting_value text,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.admin_settings OWNER TO trader;

--
-- Name: admin_settings_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.admin_settings_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.admin_settings_id_seq OWNER TO trader;

--
-- Name: admin_settings_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.admin_settings_id_seq OWNED BY public.admin_settings.id;


--
-- Name: alert_notifications; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.alert_notifications (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    price_alert_id uuid NOT NULL,
    user_id uuid NOT NULL,
    symbol character varying(10) NOT NULL,
    notification_type character varying(20) NOT NULL,
    trigger_price numeric(15,4) NOT NULL,
    target_price numeric(15,4),
    change_percent numeric(5,2),
    message text NOT NULL,
    sent_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    delivery_status character varying(20) DEFAULT 'sent'::character varying,
    error_message text,
    deleted_at timestamp with time zone
);


ALTER TABLE public.alert_notifications OWNER TO trader;

--
-- Name: TABLE alert_notifications; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.alert_notifications IS 'History of all notifications sent to users';


--
-- Name: COLUMN alert_notifications.deleted_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.alert_notifications.deleted_at IS 'Soft delete timestamp for hiding notifications';


--
-- Name: analytics_cache; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.analytics_cache (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid,
    cache_key character varying(255) NOT NULL,
    data jsonb NOT NULL,
    expires_at timestamp with time zone NOT NULL,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.analytics_cache OWNER TO trader;

--
-- Name: api_keys; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.api_keys (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    name character varying(255) NOT NULL,
    key_hash character varying(255) NOT NULL,
    permissions jsonb DEFAULT '["read"]'::jsonb,
    last_used_at timestamp with time zone,
    expires_at timestamp with time zone,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    revoked_at timestamp with time zone,
    key_prefix character varying(20),
    is_active boolean DEFAULT true,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.api_keys OWNER TO trader;

--
-- Name: TABLE api_keys; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.api_keys IS 'API keys for programmatic access (future mobile SDK support)';


--
-- Name: COLUMN api_keys.key_prefix; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.api_keys.key_prefix IS 'First few characters of the key for display purposes';


--
-- Name: COLUMN api_keys.is_active; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.api_keys.is_active IS 'Whether the API key is currently active';


--
-- Name: COLUMN api_keys.updated_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.api_keys.updated_at IS 'Timestamp of when this key was last updated';


--
-- Name: behavioral_alerts; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.behavioral_alerts (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    pattern_id uuid,
    alert_type character varying(50) NOT NULL,
    title character varying(255) NOT NULL,
    message text NOT NULL,
    alert_data jsonb DEFAULT '{}'::jsonb,
    status character varying(20) DEFAULT 'active'::character varying NOT NULL,
    shown_at timestamp with time zone,
    acknowledged_at timestamp with time zone,
    user_response jsonb DEFAULT '{}'::jsonb,
    expires_at timestamp with time zone,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT behavioral_alerts_status_check CHECK (((status)::text = ANY ((ARRAY['active'::character varying, 'acknowledged'::character varying, 'dismissed'::character varying, 'expired'::character varying])::text[])))
);


ALTER TABLE public.behavioral_alerts OWNER TO trader;

--
-- Name: TABLE behavioral_alerts; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.behavioral_alerts IS 'Tracks alerts sent to users about behavioral patterns';


--
-- Name: behavioral_patterns; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.behavioral_patterns (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    pattern_type character varying(50) NOT NULL,
    detected_at timestamp with time zone NOT NULL,
    severity character varying(20) NOT NULL,
    confidence_score numeric(3,2) NOT NULL,
    trigger_trade_id uuid,
    context_data jsonb DEFAULT '{}'::jsonb NOT NULL,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT behavioral_patterns_confidence_score_check CHECK (((confidence_score >= (0)::numeric) AND (confidence_score <= (1)::numeric))),
    CONSTRAINT behavioral_patterns_severity_check CHECK (((severity)::text = ANY ((ARRAY['low'::character varying, 'medium'::character varying, 'high'::character varying])::text[])))
);


ALTER TABLE public.behavioral_patterns OWNER TO trader;

--
-- Name: TABLE behavioral_patterns; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.behavioral_patterns IS 'Stores detected behavioral patterns for users';


--
-- Name: behavioral_settings; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.behavioral_settings (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    revenge_trading_enabled boolean DEFAULT true,
    revenge_trading_sensitivity character varying(20) DEFAULT 'medium'::character varying,
    cooling_period_minutes integer DEFAULT 30,
    enable_trade_blocking boolean DEFAULT false,
    alert_preferences jsonb DEFAULT '{"push": true, "email": false, "toast": true}'::jsonb,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    loss_aversion_sensitivity character varying(10) DEFAULT 'medium'::character varying,
    min_trades_for_analysis integer DEFAULT 20,
    normal_hold_ratio_threshold numeric(3,2) DEFAULT 2.00,
    personality_profiling_enabled boolean DEFAULT true,
    personality_drift_sensitivity character varying(10) DEFAULT 'medium'::character varying,
    peer_comparison_enabled boolean DEFAULT true,
    CONSTRAINT behavioral_settings_revenge_trading_sensitivity_check CHECK (((revenge_trading_sensitivity)::text = ANY ((ARRAY['low'::character varying, 'medium'::character varying, 'high'::character varying])::text[])))
);


ALTER TABLE public.behavioral_settings OWNER TO trader;

--
-- Name: TABLE behavioral_settings; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.behavioral_settings IS 'User preferences for behavioral analytics features';


--
-- Name: challenges; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.challenges (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    key character varying(100) NOT NULL,
    name character varying(255) NOT NULL,
    description text NOT NULL,
    category public.achievement_category NOT NULL,
    start_date timestamp with time zone NOT NULL,
    end_date timestamp with time zone NOT NULL,
    criteria jsonb NOT NULL,
    reward_points integer DEFAULT 50 NOT NULL,
    reward_achievement_id uuid,
    is_community boolean DEFAULT false,
    target_value numeric,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.challenges OWNER TO trader;

--
-- Name: cusip_lookup_queue; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.cusip_lookup_queue (
    id integer NOT NULL,
    cusip character varying(9) NOT NULL,
    status character varying(20) DEFAULT 'pending'::character varying,
    attempts integer DEFAULT 0,
    max_attempts integer DEFAULT 5,
    last_attempt_at timestamp without time zone,
    created_at timestamp without time zone DEFAULT now(),
    error_message text,
    priority integer DEFAULT 1
);


ALTER TABLE public.cusip_lookup_queue OWNER TO trader;

--
-- Name: TABLE cusip_lookup_queue; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.cusip_lookup_queue IS 'Queue for CUSIP to ticker symbol resolution with retry logic';


--
-- Name: COLUMN cusip_lookup_queue.status; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.cusip_lookup_queue.status IS 'pending, processing, completed, failed';


--
-- Name: COLUMN cusip_lookup_queue.priority; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.cusip_lookup_queue.priority IS 'Higher numbers = higher priority';


--
-- Name: cusip_lookup_queue_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.cusip_lookup_queue_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.cusip_lookup_queue_id_seq OWNER TO trader;

--
-- Name: cusip_lookup_queue_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.cusip_lookup_queue_id_seq OWNED BY public.cusip_lookup_queue.id;


--
-- Name: cusip_mappings; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.cusip_mappings (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    cusip character varying(9) NOT NULL,
    ticker character varying(20) NOT NULL,
    company_name character varying(255),
    resolution_source character varying(20) NOT NULL,
    user_id uuid,
    confidence_score integer DEFAULT 100,
    verified boolean DEFAULT false,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    created_by uuid
);


ALTER TABLE public.cusip_mappings OWNER TO trader;

--
-- Name: TABLE cusip_mappings; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.cusip_mappings IS 'CUSIP to ticker symbol mappings with support for global and user-specific overrides';


--
-- Name: COLUMN cusip_mappings.resolution_source; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.cusip_mappings.resolution_source IS 'Source of the mapping: finnhub (global), ai (user-specific), manual (user-specific)';


--
-- Name: COLUMN cusip_mappings.user_id; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.cusip_mappings.user_id IS 'NULL for global mappings from Finnhub, specific user_id for user overrides';


--
-- Name: COLUMN cusip_mappings.confidence_score; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.cusip_mappings.confidence_score IS 'Confidence in the mapping: 100 for Finnhub/manual, lower for AI';


--
-- Name: COLUMN cusip_mappings.verified; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.cusip_mappings.verified IS 'Whether user has confirmed this mapping is correct';


--
-- Name: device_tokens; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.device_tokens (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    device_token character varying(500) NOT NULL,
    platform character varying(20) NOT NULL,
    environment character varying(20) DEFAULT 'production'::character varying,
    bundle_id character varying(255) DEFAULT 'com.tradetally.app'::character varying,
    active boolean DEFAULT true,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT device_tokens_environment_check CHECK (((environment)::text = ANY ((ARRAY['development'::character varying, 'production'::character varying])::text[]))),
    CONSTRAINT device_tokens_platform_check CHECK (((platform)::text = ANY ((ARRAY['ios'::character varying, 'android'::character varying])::text[])))
);


ALTER TABLE public.device_tokens OWNER TO trader;

--
-- Name: TABLE device_tokens; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.device_tokens IS 'Stores APNS device tokens for push notifications';


--
-- Name: devices; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.devices (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    device_name character varying(255) NOT NULL,
    device_type character varying(50),
    device_model character varying(255),
    device_fingerprint character varying(255),
    platform_version character varying(50),
    app_version character varying(50),
    last_active timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    is_trusted boolean DEFAULT false,
    push_token character varying(500),
    push_platform character varying(50),
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT devices_device_type_check CHECK (((device_type)::text = ANY ((ARRAY['ios'::character varying, 'android'::character varying, 'web'::character varying, 'desktop'::character varying])::text[]))),
    CONSTRAINT devices_push_platform_check CHECK (((push_platform)::text = ANY ((ARRAY['fcm'::character varying, 'apns'::character varying, NULL::character varying])::text[])))
);


ALTER TABLE public.devices OWNER TO trader;

--
-- Name: TABLE devices; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.devices IS 'Tracks user devices for mobile app support and multi-device management';


--
-- Name: diary_attachments; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.diary_attachments (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    diary_entry_id uuid NOT NULL,
    file_url character varying(500) NOT NULL,
    file_type character varying(100),
    file_name character varying(255),
    file_size integer,
    uploaded_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.diary_attachments OWNER TO trader;

--
-- Name: TABLE diary_attachments; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.diary_attachments IS 'File attachments (screenshots, charts) for diary entries';


--
-- Name: diary_entries; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.diary_entries (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    entry_date date NOT NULL,
    title character varying(255),
    content text,
    tags text[] DEFAULT '{}'::text[],
    entry_type character varying(20) DEFAULT 'diary'::character varying NOT NULL,
    market_bias character varying(20),
    key_levels text,
    watchlist text[] DEFAULT '{}'::text[],
    followed_plan boolean,
    lessons_learned text,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT diary_entries_entry_type_check CHECK (((entry_type)::text = ANY ((ARRAY['diary'::character varying, 'playbook'::character varying])::text[]))),
    CONSTRAINT diary_entries_market_bias_check CHECK (((market_bias)::text = ANY ((ARRAY['bullish'::character varying, 'bearish'::character varying, 'neutral'::character varying])::text[])))
);


ALTER TABLE public.diary_entries OWNER TO trader;

--
-- Name: TABLE diary_entries; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.diary_entries IS 'Trading journal and playbook entries for users';


--
-- Name: COLUMN diary_entries.entry_type; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.diary_entries.entry_type IS 'Type of entry: diary for daily notes, playbook for trade setups';


--
-- Name: COLUMN diary_entries.market_bias; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.diary_entries.market_bias IS 'Daily market sentiment: bullish, bearish, or neutral';


--
-- Name: COLUMN diary_entries.key_levels; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.diary_entries.key_levels IS 'Important price levels for the trading day';


--
-- Name: COLUMN diary_entries.watchlist; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.diary_entries.watchlist IS 'Array of symbols to watch for trading opportunities';


--
-- Name: COLUMN diary_entries.followed_plan; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.diary_entries.followed_plan IS 'Post-market reflection: whether the trader followed their plan';


--
-- Name: COLUMN diary_entries.lessons_learned; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.diary_entries.lessons_learned IS 'Post-market notes and lessons learned';


--
-- Name: enrichment_cache; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.enrichment_cache (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    symbol character varying(20) NOT NULL,
    entry_date date NOT NULL,
    entry_time time without time zone,
    cache_key character varying(255) NOT NULL,
    strategy character varying(50),
    strategy_confidence integer,
    classification_method character varying(50),
    classification_signals jsonb,
    entry_price numeric(15,6),
    market_cap bigint,
    volume_24h bigint,
    sector character varying(100),
    industry character varying(100),
    rsi_14 numeric(5,2),
    sma_20 numeric(15,6),
    sma_50 numeric(15,6),
    bollinger_upper numeric(15,6),
    bollinger_lower numeric(15,6),
    implied_volatility numeric(8,4),
    beta numeric(8,4),
    news_sentiment_score numeric(5,2),
    news_count_24h integer DEFAULT 0,
    earnings_proximity_days integer,
    typical_mae_percent numeric(8,4),
    typical_mfe_percent numeric(8,4),
    mae_confidence integer,
    data_source character varying(50) DEFAULT 'background_job'::character varying,
    api_provider character varying(50),
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    last_accessed_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    access_count integer DEFAULT 1,
    expires_at timestamp with time zone,
    is_valid boolean DEFAULT true
);


ALTER TABLE public.enrichment_cache OWNER TO trader;

--
-- Name: TABLE enrichment_cache; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.enrichment_cache IS 'Persistent cache for trade enrichment data that survives trade deletion';


--
-- Name: equity_history; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.equity_history (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    date date NOT NULL,
    equity numeric(15,2) NOT NULL,
    pnl numeric(15,2) DEFAULT 0.00,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.equity_history OWNER TO trader;

--
-- Name: equity_snapshots; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.equity_snapshots (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    equity_amount numeric(15,2) NOT NULL,
    snapshot_date date NOT NULL,
    notes text,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.equity_snapshots OWNER TO trader;

--
-- Name: features; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.features (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    feature_key character varying(100) NOT NULL,
    feature_name character varying(255) NOT NULL,
    description text,
    required_tier character varying(20) NOT NULL,
    is_active boolean DEFAULT true,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT features_required_tier_check CHECK (((required_tier)::text = ANY ((ARRAY['free'::character varying, 'pro'::character varying])::text[])))
);


ALTER TABLE public.features OWNER TO trader;

--
-- Name: TABLE features; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.features IS 'Feature definitions and tier requirements';


--
-- Name: gamification_privacy; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.gamification_privacy (
    user_id uuid NOT NULL,
    show_on_leaderboards boolean DEFAULT true,
    anonymous_only boolean DEFAULT false,
    share_achievements boolean DEFAULT true,
    participate_in_challenges boolean DEFAULT true,
    share_with_peer_group boolean DEFAULT true,
    visible_metrics jsonb DEFAULT '["discipline_score", "consistency_score"]'::jsonb,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.gamification_privacy OWNER TO trader;

--
-- Name: global_enrichment_cache; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.global_enrichment_cache (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    symbol character varying(20) NOT NULL,
    trade_date date NOT NULL,
    news_sentiment numeric(3,2),
    news_count integer DEFAULT 0,
    news_summary text,
    major_news_events jsonb,
    market_cap bigint,
    volume bigint,
    avg_volume bigint,
    volatility numeric(5,4),
    sector character varying(100),
    industry character varying(100),
    data_sources jsonb DEFAULT '[]'::jsonb,
    confidence_score integer DEFAULT 100,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    expires_at timestamp with time zone,
    access_count integer DEFAULT 1,
    last_accessed_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.global_enrichment_cache OWNER TO trader;

--
-- Name: TABLE global_enrichment_cache; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.global_enrichment_cache IS 'Global cache for trade enrichment data (news, market data) shared across all users';


--
-- Name: COLUMN global_enrichment_cache.symbol; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.symbol IS 'Stock ticker symbol';


--
-- Name: COLUMN global_enrichment_cache.trade_date; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.trade_date IS 'Date of the trade';


--
-- Name: COLUMN global_enrichment_cache.news_sentiment; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.news_sentiment IS 'Overall news sentiment score (-1.0 to 1.0)';


--
-- Name: COLUMN global_enrichment_cache.major_news_events; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.major_news_events IS 'Array of major news events with titles, sources, sentiment';


--
-- Name: COLUMN global_enrichment_cache.data_sources; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.data_sources IS 'Array of API sources that provided data (finnhub, alpha_vantage, etc)';


--
-- Name: COLUMN global_enrichment_cache.expires_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.expires_at IS 'When this cache entry expires (NULL = never expires)';


--
-- Name: COLUMN global_enrichment_cache.access_count; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.global_enrichment_cache.access_count IS 'How many times this cache entry has been accessed';


--
-- Name: import_logs; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.import_logs (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid,
    broker character varying(50) NOT NULL,
    file_name character varying(255) NOT NULL,
    trades_imported integer DEFAULT 0,
    trades_failed integer DEFAULT 0,
    status character varying(20) NOT NULL,
    error_details jsonb,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    completed_at timestamp with time zone,
    CONSTRAINT import_logs_status_check CHECK (((status)::text = ANY ((ARRAY['pending'::character varying, 'processing'::character varying, 'completed'::character varying, 'failed'::character varying])::text[])))
);


ALTER TABLE public.import_logs OWNER TO trader;

--
-- Name: instance_config; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.instance_config (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    key character varying(255) NOT NULL,
    value jsonb NOT NULL,
    description text,
    is_public boolean DEFAULT false,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.instance_config OWNER TO trader;

--
-- Name: TABLE instance_config; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.instance_config IS 'Stores instance-specific configuration for cloud/self-hosted deployments';


--
-- Name: job_queue; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.job_queue (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    type character varying(50) NOT NULL,
    data jsonb NOT NULL,
    priority integer DEFAULT 3,
    user_id uuid,
    status character varying(20) DEFAULT 'pending'::character varying,
    retry_count integer DEFAULT 0,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    started_at timestamp with time zone,
    completed_at timestamp with time zone,
    result jsonb,
    error text,
    CONSTRAINT job_queue_priority_check CHECK (((priority >= 1) AND (priority <= 5))),
    CONSTRAINT job_queue_status_check CHECK (((status)::text = ANY ((ARRAY['pending'::character varying, 'processing'::character varying, 'completed'::character varying, 'failed'::character varying])::text[])))
);


ALTER TABLE public.job_queue OWNER TO trader;

--
-- Name: leaderboard_entries; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.leaderboard_entries (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    leaderboard_id uuid NOT NULL,
    user_id uuid NOT NULL,
    anonymous_name character varying(100),
    score numeric NOT NULL,
    rank integer,
    metadata jsonb DEFAULT '{}'::jsonb,
    recorded_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.leaderboard_entries OWNER TO trader;

--
-- Name: leaderboards; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.leaderboards (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    key character varying(100) NOT NULL,
    name character varying(255) NOT NULL,
    description text,
    metric_key character varying(100) NOT NULL,
    period_type character varying(20) NOT NULL,
    period_start timestamp with time zone,
    period_end timestamp with time zone,
    min_participants integer DEFAULT 10,
    is_active boolean DEFAULT true,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.leaderboards OWNER TO trader;

--
-- Name: loss_aversion_events; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.loss_aversion_events (
    id integer NOT NULL,
    user_id uuid NOT NULL,
    analysis_start_date date NOT NULL,
    analysis_end_date date NOT NULL,
    avg_winner_hold_time_minutes integer NOT NULL,
    avg_loser_hold_time_minutes integer NOT NULL,
    hold_time_ratio numeric(5,2) NOT NULL,
    total_winning_trades integer NOT NULL,
    total_losing_trades integer NOT NULL,
    premature_profit_exits integer DEFAULT 0,
    extended_loss_holds integer DEFAULT 0,
    estimated_monthly_cost numeric(10,2) DEFAULT 0,
    missed_profit_potential numeric(10,2) DEFAULT 0,
    unnecessary_loss_extension numeric(10,2) DEFAULT 0,
    avg_planned_risk_reward numeric(5,2),
    avg_actual_risk_reward numeric(5,2),
    worst_hold_ratio_symbol character varying(10),
    worst_hold_ratio_value numeric(5,2),
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    avg_missed_profit_percent numeric(5,2) DEFAULT 0
);


ALTER TABLE public.loss_aversion_events OWNER TO trader;

--
-- Name: loss_aversion_events_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.loss_aversion_events_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.loss_aversion_events_id_seq OWNER TO trader;

--
-- Name: loss_aversion_events_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.loss_aversion_events_id_seq OWNED BY public.loss_aversion_events.id;


--
-- Name: loss_aversion_summary; Type: VIEW; Schema: public; Owner: trader
--

CREATE VIEW public.loss_aversion_summary AS
 SELECT u.id AS user_id,
    u.username,
    la.hold_time_ratio,
    la.avg_winner_hold_time_minutes,
    la.avg_loser_hold_time_minutes,
    la.estimated_monthly_cost,
    (la.total_winning_trades + la.total_losing_trades) AS total_trades,
    la.analysis_end_date
   FROM (public.users u
     LEFT JOIN public.loss_aversion_events la ON (((u.id = la.user_id) AND (la.analysis_end_date = ( SELECT max(loss_aversion_events.analysis_end_date) AS max
           FROM public.loss_aversion_events
          WHERE (loss_aversion_events.user_id = u.id))))))
  WHERE (u.is_active = true);


ALTER TABLE public.loss_aversion_summary OWNER TO trader;

--
-- Name: migrations; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.migrations (
    id integer NOT NULL,
    filename character varying(255) NOT NULL,
    applied_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    checksum character varying(64) NOT NULL
);


ALTER TABLE public.migrations OWNER TO trader;

--
-- Name: migrations_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.migrations_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.migrations_id_seq OWNER TO trader;

--
-- Name: migrations_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.migrations_id_seq OWNED BY public.migrations.id;


--
-- Name: news_cache; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.news_cache (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    symbol character varying(20) NOT NULL,
    news_date date NOT NULL,
    news_events jsonb DEFAULT '[]'::jsonb NOT NULL,
    sentiment character varying(20),
    checked_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.news_cache OWNER TO trader;

--
-- Name: notification_preferences; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.notification_preferences (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    price_alerts_enabled boolean DEFAULT true,
    earnings_enabled boolean DEFAULT true,
    news_enabled boolean DEFAULT false,
    email_notifications boolean DEFAULT true,
    push_notifications boolean DEFAULT true,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.notification_preferences OWNER TO trader;

--
-- Name: TABLE notification_preferences; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.notification_preferences IS 'User preferences for different types of notifications';


--
-- Name: notification_read_status; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.notification_read_status (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    notification_type character varying(50) NOT NULL,
    notification_id uuid NOT NULL,
    read_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.notification_read_status OWNER TO trader;

--
-- Name: TABLE notification_read_status; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.notification_read_status IS 'Tracks which notifications each user has read';


--
-- Name: COLUMN notification_read_status.notification_type; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.notification_read_status.notification_type IS 'Type of notification: price_alert, trade_comment';


--
-- Name: COLUMN notification_read_status.notification_id; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.notification_read_status.notification_id IS 'ID of the notification in the respective table';


--
-- Name: notifications; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.notifications (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    type character varying(50) NOT NULL,
    data jsonb NOT NULL,
    read boolean DEFAULT false,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.notifications OWNER TO trader;

--
-- Name: overconfidence_events; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.overconfidence_events (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    win_streak_length integer NOT NULL,
    win_streak_start_date timestamp with time zone NOT NULL,
    win_streak_end_date timestamp with time zone NOT NULL,
    baseline_position_size numeric(15,2) NOT NULL,
    peak_position_size numeric(15,2) NOT NULL,
    position_size_increase_percent numeric(7,2) NOT NULL,
    total_streak_profit numeric(15,2) NOT NULL,
    streak_trades uuid[] DEFAULT '{}'::uuid[],
    severity character varying(20) NOT NULL,
    confidence_score numeric(3,2) NOT NULL,
    outcome_after_streak character varying(20),
    outcome_trade_id uuid,
    outcome_amount numeric(15,2),
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    ai_recommendations jsonb,
    ai_provider character varying(50),
    ai_generated_at timestamp without time zone,
    CONSTRAINT overconfidence_events_confidence_score_check CHECK (((confidence_score >= (0)::numeric) AND (confidence_score <= (1)::numeric))),
    CONSTRAINT overconfidence_events_outcome_after_streak_check CHECK (((outcome_after_streak)::text = ANY ((ARRAY['profit'::character varying, 'loss'::character varying, 'breakeven'::character varying, 'ongoing'::character varying])::text[]))),
    CONSTRAINT overconfidence_events_severity_check CHECK (((severity)::text = ANY ((ARRAY['low'::character varying, 'medium'::character varying, 'high'::character varying])::text[])))
);


ALTER TABLE public.overconfidence_events OWNER TO trader;

--
-- Name: TABLE overconfidence_events; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.overconfidence_events IS 'Stores detected overconfidence events from win streaks';


--
-- Name: COLUMN overconfidence_events.baseline_position_size; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.overconfidence_events.baseline_position_size IS 'Average position size in the 5 trades before the win streak';


--
-- Name: COLUMN overconfidence_events.peak_position_size; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.overconfidence_events.peak_position_size IS 'Largest position size during the win streak';


--
-- Name: COLUMN overconfidence_events.position_size_increase_percent; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.overconfidence_events.position_size_increase_percent IS 'Percentage increase from baseline to peak (supports up to 9999.99%)';


--
-- Name: COLUMN overconfidence_events.ai_recommendations; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.overconfidence_events.ai_recommendations IS 'AI-generated recommendations stored as JSON array';


--
-- Name: COLUMN overconfidence_events.ai_provider; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.overconfidence_events.ai_provider IS 'AI provider used (gemini, claude, openai, etc.)';


--
-- Name: COLUMN overconfidence_events.ai_generated_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.overconfidence_events.ai_generated_at IS 'Timestamp when AI recommendations were generated';


--
-- Name: overconfidence_settings; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.overconfidence_settings (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    detection_enabled boolean DEFAULT true,
    min_streak_length integer DEFAULT 4,
    position_increase_threshold numeric(5,2) DEFAULT 40.0,
    sensitivity character varying(20) DEFAULT 'medium'::character varying,
    alert_preferences jsonb DEFAULT '{"push": true, "email": false, "toast": true}'::jsonb,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT overconfidence_settings_sensitivity_check CHECK (((sensitivity)::text = ANY ((ARRAY['low'::character varying, 'medium'::character varying, 'high'::character varying])::text[])))
);


ALTER TABLE public.overconfidence_settings OWNER TO trader;

--
-- Name: TABLE overconfidence_settings; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.overconfidence_settings IS 'User preferences for overconfidence detection';


--
-- Name: peer_groups; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.peer_groups (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    name character varying(255) NOT NULL,
    criteria jsonb NOT NULL,
    min_members integer DEFAULT 10,
    max_members integer DEFAULT 100,
    is_active boolean DEFAULT true,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.peer_groups OWNER TO trader;

--
-- Name: personality_drift_tracking; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.personality_drift_tracking (
    id integer NOT NULL,
    user_id uuid NOT NULL,
    analysis_date date NOT NULL,
    period_days integer DEFAULT 30,
    previous_primary_personality character varying(20),
    current_primary_personality character varying(20),
    personality_drift_score numeric(3,2) DEFAULT 0,
    hold_time_drift_percent numeric(5,2) DEFAULT 0,
    frequency_drift_percent numeric(5,2) DEFAULT 0,
    risk_tolerance_drift numeric(3,2) DEFAULT 0,
    drift_performance_impact numeric(10,2) DEFAULT 0,
    drift_severity character varying(10) DEFAULT 'low'::character varying,
    drift_recommendations jsonb,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.personality_drift_tracking OWNER TO trader;

--
-- Name: COLUMN personality_drift_tracking.updated_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.personality_drift_tracking.updated_at IS 'Timestamp when the drift analysis was last updated';


--
-- Name: personality_drift_tracking_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.personality_drift_tracking_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.personality_drift_tracking_id_seq OWNER TO trader;

--
-- Name: personality_drift_tracking_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.personality_drift_tracking_id_seq OWNED BY public.personality_drift_tracking.id;


--
-- Name: personality_peer_comparison; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.personality_peer_comparison (
    id integer NOT NULL,
    user_id uuid NOT NULL,
    personality_type character varying(20) NOT NULL,
    peer_group_size integer DEFAULT 0,
    user_avg_return numeric(5,2) DEFAULT 0,
    peer_avg_return numeric(5,2) DEFAULT 0,
    user_sharpe_ratio numeric(4,3) DEFAULT 0,
    peer_avg_sharpe_ratio numeric(4,3) DEFAULT 0,
    user_win_rate numeric(3,2) DEFAULT 0,
    peer_avg_win_rate numeric(3,2) DEFAULT 0,
    return_percentile integer DEFAULT 50,
    consistency_percentile integer DEFAULT 50,
    risk_management_percentile integer DEFAULT 50,
    top_performer_characteristics jsonb,
    improvement_suggestions jsonb,
    comparison_date date NOT NULL,
    peer_data_quality numeric(3,2) DEFAULT 0,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.personality_peer_comparison OWNER TO trader;

--
-- Name: personality_peer_comparison_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.personality_peer_comparison_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.personality_peer_comparison_id_seq OWNER TO trader;

--
-- Name: personality_peer_comparison_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.personality_peer_comparison_id_seq OWNED BY public.personality_peer_comparison.id;


--
-- Name: trading_personality_profiles; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.trading_personality_profiles (
    id integer NOT NULL,
    user_id uuid NOT NULL,
    primary_personality character varying(20) NOT NULL,
    personality_confidence numeric(3,2) NOT NULL,
    scalper_score integer DEFAULT 0,
    momentum_score integer DEFAULT 0,
    mean_reversion_score integer DEFAULT 0,
    swing_score integer DEFAULT 0,
    avg_hold_time_minutes integer NOT NULL,
    avg_trade_frequency_per_day numeric(5,2) DEFAULT 0,
    preferred_timeframes jsonb,
    uses_momentum_indicators boolean DEFAULT false,
    uses_mean_reversion_indicators boolean DEFAULT false,
    uses_volume_analysis boolean DEFAULT false,
    uses_pattern_recognition boolean DEFAULT false,
    risk_tolerance character varying(10) DEFAULT 'medium'::character varying,
    position_sizing_consistency numeric(3,2) DEFAULT 0,
    stop_loss_discipline numeric(3,2) DEFAULT 0,
    personality_performance_score numeric(3,2) DEFAULT 0,
    optimal_strategy_adherence numeric(3,2) DEFAULT 0,
    total_trades_analyzed integer NOT NULL,
    analysis_start_date date NOT NULL,
    analysis_end_date date NOT NULL,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.trading_personality_profiles OWNER TO trader;

--
-- Name: personality_summary; Type: VIEW; Schema: public; Owner: trader
--

CREATE VIEW public.personality_summary AS
 SELECT u.id AS user_id,
    u.username,
    tpp.primary_personality,
    tpp.personality_confidence,
    tpp.avg_hold_time_minutes,
    tpp.avg_trade_frequency_per_day,
    tpp.personality_performance_score,
    tpp.optimal_strategy_adherence,
    pdt.drift_severity,
    pdt.personality_drift_score,
    ppc.return_percentile,
    ppc.peer_avg_return,
    tpp.analysis_end_date
   FROM (((public.users u
     LEFT JOIN public.trading_personality_profiles tpp ON (((u.id = tpp.user_id) AND (tpp.analysis_end_date = ( SELECT max(trading_personality_profiles.analysis_end_date) AS max
           FROM public.trading_personality_profiles
          WHERE (trading_personality_profiles.user_id = u.id))))))
     LEFT JOIN public.personality_drift_tracking pdt ON (((u.id = pdt.user_id) AND (pdt.analysis_date = ( SELECT max(personality_drift_tracking.analysis_date) AS max
           FROM public.personality_drift_tracking
          WHERE (personality_drift_tracking.user_id = u.id))))))
     LEFT JOIN public.personality_peer_comparison ppc ON (((u.id = ppc.user_id) AND (ppc.comparison_date = ( SELECT max(personality_peer_comparison.comparison_date) AS max
           FROM public.personality_peer_comparison
          WHERE (personality_peer_comparison.user_id = u.id))))))
  WHERE (u.is_active = true);


ALTER TABLE public.personality_summary OWNER TO trader;

--
-- Name: personality_trade_analysis; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.personality_trade_analysis (
    id integer NOT NULL,
    user_id uuid NOT NULL,
    trade_id uuid NOT NULL,
    personality_alignment_score numeric(3,2) DEFAULT 0,
    optimal_personality_for_trade character varying(20),
    setup_quality character varying(10),
    pattern_match_score numeric(3,2) DEFAULT 0,
    entry_timing_quality character varying(10),
    exit_timing_quality character varying(10),
    hold_time_appropriateness character varying(10),
    market_regime character varying(20),
    personality_market_fit numeric(3,2) DEFAULT 0,
    trade_specific_recommendations jsonb,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.personality_trade_analysis OWNER TO trader;

--
-- Name: personality_trade_analysis_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.personality_trade_analysis_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.personality_trade_analysis_id_seq OWNER TO trader;

--
-- Name: personality_trade_analysis_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.personality_trade_analysis_id_seq OWNED BY public.personality_trade_analysis.id;


--
-- Name: refresh_tokens; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.refresh_tokens (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    device_id uuid,
    token_hash character varying(255) NOT NULL,
    family_id uuid NOT NULL,
    expires_at timestamp with time zone NOT NULL,
    revoked_at timestamp with time zone,
    revoked_reason character varying(255),
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    used_at timestamp with time zone
);


ALTER TABLE public.refresh_tokens OWNER TO trader;

--
-- Name: TABLE refresh_tokens; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.refresh_tokens IS 'Long-lived refresh tokens for mobile app authentication';


--
-- Name: revenge_trade_tick_analysis; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.revenge_trade_tick_analysis (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    revenge_trade_id uuid NOT NULL,
    trigger_trade_id uuid NOT NULL,
    symbol character varying(10) NOT NULL,
    trade_entry_time timestamp without time zone NOT NULL,
    trade_exit_time timestamp without time zone,
    analysis_window_minutes integer DEFAULT 30 NOT NULL,
    pre_trade_ticks integer DEFAULT 0,
    post_trade_ticks integer DEFAULT 0,
    price_before_entry numeric(10,4),
    price_at_entry numeric(10,4),
    price_at_exit numeric(10,4),
    price_after_exit numeric(10,4),
    price_trend_before character varying(20),
    price_trend_after character varying(20),
    volatility_before numeric(8,4),
    volatility_after numeric(8,4),
    volume_before_avg integer,
    volume_after_avg integer,
    was_chasing_momentum boolean DEFAULT false,
    was_fighting_trend boolean DEFAULT false,
    entry_timing_score numeric(3,2),
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.revenge_trade_tick_analysis OWNER TO trader;

--
-- Name: revenge_trading_events; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.revenge_trading_events (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    trigger_trade_id uuid,
    trigger_loss_amount numeric(15,2),
    trigger_timestamp timestamp with time zone NOT NULL,
    revenge_trades uuid[] DEFAULT '{}'::uuid[],
    total_revenge_trades integer DEFAULT 0 NOT NULL,
    time_window_minutes integer NOT NULL,
    position_size_increase_percent numeric(7,2),
    total_additional_loss numeric(15,2),
    pattern_broken boolean DEFAULT false,
    cooling_period_used boolean DEFAULT false,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.revenge_trading_events OWNER TO trader;

--
-- Name: TABLE revenge_trading_events; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.revenge_trading_events IS 'Specific instances of revenge trading behavior';


--
-- Name: round_trip_trades; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.round_trip_trades (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    symbol character varying(20) NOT NULL,
    entry_time timestamp with time zone NOT NULL,
    exit_time timestamp with time zone,
    entry_price numeric(15,6),
    exit_price numeric(15,6),
    total_quantity numeric(15,6) DEFAULT 0 NOT NULL,
    total_pnl numeric(15,2),
    total_commission numeric(15,2) DEFAULT 0,
    total_fees numeric(15,2) DEFAULT 0,
    pnl_percent numeric(10,4),
    side character varying(10) NOT NULL,
    strategy character varying(50),
    notes text,
    is_completed boolean DEFAULT false,
    trade_count integer DEFAULT 0,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT round_trip_trades_side_check CHECK (((side)::text = ANY ((ARRAY['long'::character varying, 'short'::character varying])::text[])))
);


ALTER TABLE public.round_trip_trades OWNER TO trader;

--
-- Name: stock_split_check_log; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.stock_split_check_log (
    id integer NOT NULL,
    symbol character varying(20),
    last_checked_at timestamp without time zone NOT NULL,
    splits_found integer DEFAULT 0,
    error_message text,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.stock_split_check_log OWNER TO trader;

--
-- Name: stock_split_check_log_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.stock_split_check_log_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.stock_split_check_log_id_seq OWNER TO trader;

--
-- Name: stock_split_check_log_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.stock_split_check_log_id_seq OWNED BY public.stock_split_check_log.id;


--
-- Name: stock_splits; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.stock_splits (
    id integer NOT NULL,
    symbol character varying(20) NOT NULL,
    split_date date NOT NULL,
    from_factor numeric(10,4) NOT NULL,
    to_factor numeric(10,4) NOT NULL,
    ratio numeric(10,4) NOT NULL,
    processed boolean DEFAULT false,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.stock_splits OWNER TO trader;

--
-- Name: stock_splits_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.stock_splits_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.stock_splits_id_seq OWNER TO trader;

--
-- Name: stock_splits_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.stock_splits_id_seq OWNED BY public.stock_splits.id;


--
-- Name: strategy_classification_history; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.strategy_classification_history (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    trade_id uuid NOT NULL,
    user_id uuid NOT NULL,
    previous_strategy character varying(100),
    new_strategy character varying(100) NOT NULL,
    classification_method character varying(50) NOT NULL,
    confidence_score numeric(5,2),
    classification_metadata jsonb,
    is_manual_override boolean DEFAULT false,
    override_reason text,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.strategy_classification_history OWNER TO trader;

--
-- Name: TABLE strategy_classification_history; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.strategy_classification_history IS 'Tracks strategy classification changes for learning and audit purposes';


--
-- Name: subscriptions; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.subscriptions (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    stripe_customer_id character varying(255),
    stripe_subscription_id character varying(255),
    stripe_price_id character varying(255),
    status character varying(50) DEFAULT 'inactive'::character varying NOT NULL,
    current_period_start timestamp with time zone,
    current_period_end timestamp with time zone,
    cancel_at_period_end boolean DEFAULT false,
    canceled_at timestamp with time zone,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.subscriptions OWNER TO trader;

--
-- Name: TABLE subscriptions; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.subscriptions IS 'Stripe subscription data for pro users';


--
-- Name: symbol_categories; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.symbol_categories (
    id integer NOT NULL,
    symbol character varying(20) NOT NULL,
    company_name character varying(255),
    finnhub_industry character varying(255),
    gics_sector character varying(255),
    gics_group character varying(255),
    gics_industry character varying(255),
    gics_sub_industry character varying(255),
    country character varying(100),
    currency character varying(10),
    exchange character varying(50),
    ipo_date date,
    market_cap numeric(20,2),
    phone character varying(50),
    share_outstanding numeric(20,2),
    ticker character varying(20),
    weburl character varying(500),
    logo character varying(500),
    created_at timestamp without time zone DEFAULT now(),
    updated_at timestamp without time zone DEFAULT now()
);


ALTER TABLE public.symbol_categories OWNER TO trader;

--
-- Name: TABLE symbol_categories; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.symbol_categories IS 'Permanent storage for symbol categorization data to avoid repeated API calls';


--
-- Name: COLUMN symbol_categories.market_cap; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.symbol_categories.market_cap IS 'Market capitalization in millions, can have decimal values';


--
-- Name: COLUMN symbol_categories.share_outstanding; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.symbol_categories.share_outstanding IS 'Shares outstanding in millions, can have decimal values';


--
-- Name: symbol_categories_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.symbol_categories_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.symbol_categories_id_seq OWNER TO trader;

--
-- Name: symbol_categories_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.symbol_categories_id_seq OWNED BY public.symbol_categories.id;


--
-- Name: sync_metadata; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.sync_metadata (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    entity_type character varying(50) NOT NULL,
    entity_id uuid NOT NULL,
    action character varying(20) NOT NULL,
    sync_version bigint NOT NULL,
    change_data jsonb,
    device_id uuid,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT sync_metadata_action_check CHECK (((action)::text = ANY ((ARRAY['create'::character varying, 'update'::character varying, 'delete'::character varying])::text[]))),
    CONSTRAINT sync_metadata_entity_type_check CHECK (((entity_type)::text = ANY ((ARRAY['trade'::character varying, 'journal'::character varying, 'settings'::character varying, 'user_profile'::character varying])::text[])))
);


ALTER TABLE public.sync_metadata OWNER TO trader;

--
-- Name: TABLE sync_metadata; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.sync_metadata IS 'Tracks data changes for mobile offline sync capabilities';


--
-- Name: sync_metadata_sync_version_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.sync_metadata_sync_version_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.sync_metadata_sync_version_seq OWNER TO trader;

--
-- Name: sync_metadata_sync_version_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.sync_metadata_sync_version_seq OWNED BY public.sync_metadata.sync_version;


--
-- Name: tags; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.tags (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid,
    name character varying(50) NOT NULL,
    color character varying(7) DEFAULT '#3B82F6'::character varying,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.tags OWNER TO trader;

--
-- Name: tick_data; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.tick_data (
    id integer NOT NULL,
    symbol character varying(10) NOT NULL,
    date date NOT NULL,
    "timestamp" bigint NOT NULL,
    price numeric(10,4) NOT NULL,
    volume integer,
    conditions text[],
    exchange character varying(10),
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.tick_data OWNER TO trader;

--
-- Name: tick_data_cache; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.tick_data_cache (
    id integer NOT NULL,
    symbol character varying(10) NOT NULL,
    date date NOT NULL,
    start_timestamp bigint NOT NULL,
    end_timestamp bigint NOT NULL,
    tick_count integer DEFAULT 0 NOT NULL,
    fetched_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    expires_at timestamp without time zone DEFAULT (CURRENT_TIMESTAMP + '24:00:00'::interval)
);


ALTER TABLE public.tick_data_cache OWNER TO trader;

--
-- Name: tick_data_cache_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.tick_data_cache_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.tick_data_cache_id_seq OWNER TO trader;

--
-- Name: tick_data_cache_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.tick_data_cache_id_seq OWNED BY public.tick_data_cache.id;


--
-- Name: tick_data_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.tick_data_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.tick_data_id_seq OWNER TO trader;

--
-- Name: tick_data_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.tick_data_id_seq OWNED BY public.tick_data.id;


--
-- Name: tier_overrides; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.tier_overrides (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    tier character varying(20) NOT NULL,
    reason text,
    expires_at timestamp with time zone,
    created_by uuid,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    reminder_sent_at timestamp without time zone,
    expiration_sent_at timestamp without time zone,
    CONSTRAINT tier_overrides_tier_check CHECK (((tier)::text = ANY ((ARRAY['free'::character varying, 'pro'::character varying])::text[])))
);


ALTER TABLE public.tier_overrides OWNER TO trader;

--
-- Name: TABLE tier_overrides; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.tier_overrides IS 'Admin-assigned tier overrides';


--
-- Name: trade_attachments; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.trade_attachments (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    trade_id uuid,
    file_url character varying(500) NOT NULL,
    file_type character varying(50) NOT NULL,
    file_name character varying(255) NOT NULL,
    file_size integer,
    uploaded_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.trade_attachments OWNER TO trader;

--
-- Name: trade_comments; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.trade_comments (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    trade_id uuid,
    user_id uuid,
    comment text NOT NULL,
    edited_at timestamp with time zone,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    deleted_at timestamp with time zone
);


ALTER TABLE public.trade_comments OWNER TO trader;

--
-- Name: COLUMN trade_comments.deleted_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trade_comments.deleted_at IS 'Soft delete timestamp for hiding comment notifications';


--
-- Name: trade_hold_patterns; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.trade_hold_patterns (
    id integer NOT NULL,
    user_id uuid NOT NULL,
    trade_id uuid NOT NULL,
    is_winner boolean NOT NULL,
    pnl numeric(10,2) NOT NULL,
    hold_time_minutes integer NOT NULL,
    expected_hold_time_minutes integer,
    exit_reason character varying(50),
    exit_quality_score numeric(3,2),
    max_favorable_excursion numeric(10,2),
    max_adverse_excursion numeric(10,2),
    exit_efficiency numeric(3,2),
    premature_exit boolean DEFAULT false,
    extended_hold boolean DEFAULT false,
    panic_exit boolean DEFAULT false,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.trade_hold_patterns OWNER TO trader;

--
-- Name: trade_hold_patterns_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.trade_hold_patterns_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.trade_hold_patterns_id_seq OWNER TO trader;

--
-- Name: trade_hold_patterns_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.trade_hold_patterns_id_seq OWNED BY public.trade_hold_patterns.id;


--
-- Name: trade_split_adjustments; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.trade_split_adjustments (
    id integer NOT NULL,
    trade_id uuid NOT NULL,
    split_id integer NOT NULL,
    original_quantity numeric(15,4) NOT NULL,
    adjusted_quantity numeric(15,4) NOT NULL,
    original_price numeric(15,4) NOT NULL,
    adjusted_price numeric(15,4) NOT NULL,
    adjustment_ratio numeric(10,4) NOT NULL,
    applied_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.trade_split_adjustments OWNER TO trader;

--
-- Name: trade_split_adjustments_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.trade_split_adjustments_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.trade_split_adjustments_id_seq OWNER TO trader;

--
-- Name: trade_split_adjustments_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.trade_split_adjustments_id_seq OWNED BY public.trade_split_adjustments.id;


--
-- Name: trades; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.trades (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid,
    symbol character varying(20) NOT NULL,
    trade_date date NOT NULL,
    entry_time timestamp with time zone,
    exit_time timestamp with time zone,
    entry_price numeric(15,6) NOT NULL,
    exit_price numeric(15,6),
    quantity numeric(10,4) NOT NULL,
    side character varying(10) NOT NULL,
    commission numeric(15,6) DEFAULT 0,
    fees numeric(15,6) DEFAULT 0,
    pnl numeric(15,2),
    pnl_percent numeric(10,4),
    notes text,
    is_public boolean DEFAULT false,
    broker character varying(50),
    strategy character varying(100),
    setup character varying(100),
    tags text[],
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    executions jsonb,
    mae numeric(15,6) DEFAULT NULL::numeric,
    mfe numeric(15,6) DEFAULT NULL::numeric,
    split_adjusted boolean DEFAULT false,
    original_quantity numeric(15,4),
    original_entry_price numeric(15,4),
    original_exit_price numeric(15,4),
    strategy_confidence numeric(5,2) DEFAULT NULL::numeric,
    classification_method character varying(50) DEFAULT NULL::character varying,
    classification_metadata jsonb,
    manual_override boolean DEFAULT false,
    round_trip_id uuid,
    news_events jsonb DEFAULT '[]'::jsonb,
    has_news boolean DEFAULT false,
    news_sentiment character varying(20),
    news_checked_at timestamp with time zone,
    confidence integer,
    enrichment_status character varying(20) DEFAULT 'pending'::character varying,
    enrichment_completed_at timestamp with time zone,
    CONSTRAINT trades_confidence_check CHECK (((confidence >= 1) AND (confidence <= 10))),
    CONSTRAINT trades_enrichment_status_check CHECK (((enrichment_status)::text = ANY ((ARRAY['pending'::character varying, 'processing'::character varying, 'completed'::character varying, 'failed'::character varying])::text[]))),
    CONSTRAINT trades_side_check CHECK (((side)::text = ANY ((ARRAY['long'::character varying, 'short'::character varying])::text[])))
);


ALTER TABLE public.trades OWNER TO trader;

--
-- Name: COLUMN trades.entry_price; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.entry_price IS 'Entry price with up to 6 decimal places for high precision trading';


--
-- Name: COLUMN trades.exit_price; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.exit_price IS 'Exit price with up to 6 decimal places for high precision trading';


--
-- Name: COLUMN trades.commission; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.commission IS 'Commission paid with up to 6 decimal places';


--
-- Name: COLUMN trades.fees; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.fees IS 'Additional fees with up to 6 decimal places';


--
-- Name: COLUMN trades.mae; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.mae IS 'Maximum Adverse Excursion with up to 6 decimal places';


--
-- Name: COLUMN trades.mfe; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.mfe IS 'Maximum Favorable Excursion with up to 6 decimal places';


--
-- Name: COLUMN trades.strategy_confidence; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.strategy_confidence IS 'Strategy classification confidence as percentage (0-100)';


--
-- Name: COLUMN trades.classification_method; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.classification_method IS 'Method used for classification (time_based, technical_analysis, manual)';


--
-- Name: COLUMN trades.classification_metadata; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.classification_metadata IS 'JSON metadata about classification process and signals';


--
-- Name: COLUMN trades.manual_override; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.manual_override IS 'Whether strategy was manually set by user';


--
-- Name: COLUMN trades.news_events; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.news_events IS 'JSONB array of news articles from trade date containing: headline, summary, url, datetime, sentiment, source';


--
-- Name: COLUMN trades.has_news; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.has_news IS 'Boolean flag indicating if any news events were found for this symbol on the trade date';


--
-- Name: COLUMN trades.news_sentiment; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.news_sentiment IS 'Overall sentiment of news events: positive, negative, neutral, or mixed';


--
-- Name: COLUMN trades.news_checked_at; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.trades.news_checked_at IS 'Timestamp when news was last checked for this trade';


--
-- Name: trades_with_health_analytics; Type: VIEW; Schema: public; Owner: trader
--

CREATE VIEW public.trades_with_health_analytics AS
 SELECT t.id,
    t.user_id,
    t.symbol,
    t.trade_date,
    t.entry_time,
    t.exit_time,
    t.entry_price,
    t.exit_price,
    t.quantity,
    t.side,
    t.commission,
    t.fees,
    t.pnl,
    t.pnl_percent,
    t.notes,
    t.is_public,
    t.broker,
    t.strategy,
    t.setup,
    t.tags,
    t.created_at,
    t.updated_at,
    t.executions,
    t.mae,
    t.mfe,
    t.split_adjusted,
    t.original_quantity,
    t.original_entry_price,
    t.original_exit_price,
    t.strategy_confidence,
    t.classification_method,
    t.classification_metadata,
    t.manual_override,
    t.round_trip_id,
    t.news_events,
    t.has_news,
    t.news_sentiment,
    t.news_checked_at,
    t.confidence,
    t.enrichment_status,
    t.enrichment_completed_at,
        CASE
            WHEN (t.pnl > (0)::numeric) THEN 'profitable'::text
            WHEN (t.pnl < (0)::numeric) THEN 'losing'::text
            ELSE 'breakeven'::text
        END AS trade_outcome
   FROM public.trades t;


ALTER TABLE public.trades_with_health_analytics OWNER TO trader;

--
-- Name: VIEW trades_with_health_analytics; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON VIEW public.trades_with_health_analytics IS 'Enhanced trades view with basic trade outcome categorization';


--
-- Name: trading_personality_profiles_id_seq; Type: SEQUENCE; Schema: public; Owner: trader
--

CREATE SEQUENCE public.trading_personality_profiles_id_seq
    AS integer
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public.trading_personality_profiles_id_seq OWNER TO trader;

--
-- Name: trading_personality_profiles_id_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: trader
--

ALTER SEQUENCE public.trading_personality_profiles_id_seq OWNED BY public.trading_personality_profiles.id;


--
-- Name: user_achievements; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.user_achievements (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    achievement_id uuid NOT NULL,
    earned_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    progress integer DEFAULT 0,
    metadata jsonb DEFAULT '{}'::jsonb
);


ALTER TABLE public.user_achievements OWNER TO trader;

--
-- Name: user_challenges; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.user_challenges (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    challenge_id uuid NOT NULL,
    status public.challenge_status DEFAULT 'active'::public.challenge_status NOT NULL,
    progress numeric DEFAULT 0,
    started_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    completed_at timestamp with time zone,
    metadata jsonb DEFAULT '{}'::jsonb
);


ALTER TABLE public.user_challenges OWNER TO trader;

--
-- Name: user_gamification_stats; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.user_gamification_stats (
    user_id uuid NOT NULL,
    total_points integer DEFAULT 0,
    achievement_count integer DEFAULT 0,
    challenge_count integer DEFAULT 0,
    current_streak_days integer DEFAULT 0,
    longest_streak_days integer DEFAULT 0,
    last_achievement_date timestamp with time zone,
    level integer DEFAULT 1,
    experience_points integer DEFAULT 0,
    badges jsonb DEFAULT '[]'::jsonb,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.user_gamification_stats OWNER TO trader;

--
-- Name: user_peer_groups; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.user_peer_groups (
    user_id uuid NOT NULL,
    peer_group_id uuid NOT NULL,
    joined_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    is_active boolean DEFAULT true
);


ALTER TABLE public.user_peer_groups OWNER TO trader;

--
-- Name: watchlist_items; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.watchlist_items (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    watchlist_id uuid NOT NULL,
    symbol character varying(10) NOT NULL,
    added_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    notes text
);


ALTER TABLE public.watchlist_items OWNER TO trader;

--
-- Name: watchlists; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.watchlists (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    name character varying(100) NOT NULL,
    description text,
    is_default boolean DEFAULT false,
    created_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp without time zone DEFAULT CURRENT_TIMESTAMP
);


ALTER TABLE public.watchlists OWNER TO trader;

--
-- Name: watchlist_summary; Type: VIEW; Schema: public; Owner: trader
--

CREATE VIEW public.watchlist_summary AS
 SELECT w.id,
    w.user_id,
    w.name,
    w.description,
    w.is_default,
    w.created_at,
    w.updated_at,
    count(wi.id) AS item_count,
    count(pa.id) AS alert_count
   FROM ((public.watchlists w
     LEFT JOIN public.watchlist_items wi ON ((w.id = wi.watchlist_id)))
     LEFT JOIN public.price_alerts pa ON (((w.user_id = pa.user_id) AND ((pa.symbol)::text IN ( SELECT watchlist_items.symbol
           FROM public.watchlist_items
          WHERE (watchlist_items.watchlist_id = w.id))) AND (pa.is_active = true))))
  GROUP BY w.id, w.user_id, w.name, w.description, w.is_default, w.created_at, w.updated_at;


ALTER TABLE public.watchlist_summary OWNER TO trader;

--
-- Name: well_known_config; Type: VIEW; Schema: public; Owner: trader
--

CREATE VIEW public.well_known_config AS
 SELECT jsonb_build_object('instance_name', ( SELECT instance_config.value
           FROM public.instance_config
          WHERE ((instance_config.key)::text = 'instance_name'::text)), 'instance_url', ( SELECT instance_config.value
           FROM public.instance_config
          WHERE ((instance_config.key)::text = 'instance_url'::text)), 'api_version', ( SELECT instance_config.value
           FROM public.instance_config
          WHERE ((instance_config.key)::text = 'api_version'::text)), 'api_endpoints', jsonb_build_object('auth', '/api/v1/auth', 'users', '/api/v1/users', 'trades', '/api/v1/trades', 'analytics', '/api/v1/analytics', 'sync', '/api/v1/sync', 'devices', '/api/v1/devices'), 'features', ( SELECT instance_config.value
           FROM public.instance_config
          WHERE ((instance_config.key)::text = 'features'::text)), 'mobile_config', ( SELECT instance_config.value
           FROM public.instance_config
          WHERE ((instance_config.key)::text = 'mobile_config'::text))) AS config;


ALTER TABLE public.well_known_config OWNER TO trader;

--
-- Name: VIEW well_known_config; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON VIEW public.well_known_config IS 'Public view of instance configuration for mobile app discovery';


--
-- Name: win_loss_streaks; Type: TABLE; Schema: public; Owner: trader
--

CREATE TABLE public.win_loss_streaks (
    id uuid DEFAULT gen_random_uuid() NOT NULL,
    user_id uuid NOT NULL,
    streak_type character varying(10) NOT NULL,
    current_length integer DEFAULT 0 NOT NULL,
    streak_start_date timestamp with time zone,
    last_trade_date timestamp with time zone,
    total_pnl numeric(15,2) DEFAULT 0 NOT NULL,
    trade_ids uuid[] DEFAULT '{}'::uuid[],
    baseline_position_size numeric(15,2),
    max_position_size numeric(15,2),
    is_active boolean DEFAULT true,
    created_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    updated_at timestamp with time zone DEFAULT CURRENT_TIMESTAMP,
    CONSTRAINT win_loss_streaks_streak_type_check CHECK (((streak_type)::text = ANY ((ARRAY['win'::character varying, 'loss'::character varying])::text[])))
);


ALTER TABLE public.win_loss_streaks OWNER TO trader;

--
-- Name: TABLE win_loss_streaks; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON TABLE public.win_loss_streaks IS 'Tracks current win/loss streaks for real-time analysis';


--
-- Name: COLUMN win_loss_streaks.baseline_position_size; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON COLUMN public.win_loss_streaks.baseline_position_size IS 'Average position size before current streak started';


--
-- Name: admin_settings id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.admin_settings ALTER COLUMN id SET DEFAULT nextval('public.admin_settings_id_seq'::regclass);


--
-- Name: cusip_lookup_queue id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_lookup_queue ALTER COLUMN id SET DEFAULT nextval('public.cusip_lookup_queue_id_seq'::regclass);


--
-- Name: loss_aversion_events id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.loss_aversion_events ALTER COLUMN id SET DEFAULT nextval('public.loss_aversion_events_id_seq'::regclass);


--
-- Name: migrations id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.migrations ALTER COLUMN id SET DEFAULT nextval('public.migrations_id_seq'::regclass);


--
-- Name: personality_drift_tracking id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_drift_tracking ALTER COLUMN id SET DEFAULT nextval('public.personality_drift_tracking_id_seq'::regclass);


--
-- Name: personality_peer_comparison id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_peer_comparison ALTER COLUMN id SET DEFAULT nextval('public.personality_peer_comparison_id_seq'::regclass);


--
-- Name: personality_trade_analysis id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_trade_analysis ALTER COLUMN id SET DEFAULT nextval('public.personality_trade_analysis_id_seq'::regclass);


--
-- Name: stock_split_check_log id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.stock_split_check_log ALTER COLUMN id SET DEFAULT nextval('public.stock_split_check_log_id_seq'::regclass);


--
-- Name: stock_splits id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.stock_splits ALTER COLUMN id SET DEFAULT nextval('public.stock_splits_id_seq'::regclass);


--
-- Name: symbol_categories id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.symbol_categories ALTER COLUMN id SET DEFAULT nextval('public.symbol_categories_id_seq'::regclass);


--
-- Name: sync_metadata sync_version; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.sync_metadata ALTER COLUMN sync_version SET DEFAULT nextval('public.sync_metadata_sync_version_seq'::regclass);


--
-- Name: tick_data id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tick_data ALTER COLUMN id SET DEFAULT nextval('public.tick_data_id_seq'::regclass);


--
-- Name: tick_data_cache id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tick_data_cache ALTER COLUMN id SET DEFAULT nextval('public.tick_data_cache_id_seq'::regclass);


--
-- Name: trade_hold_patterns id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_hold_patterns ALTER COLUMN id SET DEFAULT nextval('public.trade_hold_patterns_id_seq'::regclass);


--
-- Name: trade_split_adjustments id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_split_adjustments ALTER COLUMN id SET DEFAULT nextval('public.trade_split_adjustments_id_seq'::regclass);


--
-- Name: trading_personality_profiles id; Type: DEFAULT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trading_personality_profiles ALTER COLUMN id SET DEFAULT nextval('public.trading_personality_profiles_id_seq'::regclass);


--
-- Data for Name: achievement_milestones; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.achievement_milestones (id, user_id, achievement_id, milestone_key, achieved_at, value, metadata) FROM stdin;
\.


--
-- Data for Name: achievements; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.achievements (id, key, name, description, category, difficulty, points, icon_name, criteria, is_active, is_repeatable, max_progress, created_at, updated_at) FROM stdin;
53b3b7d5-b6e1-4852-b50b-49abe6da2828	revenge_free_month	Revenge Trading Free Month	Go 30 days without any revenge trading incidents	behavioral	silver	200	\N	{"days": 30, "type": "no_revenge_trades"}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
bd3ef94b-7e35-45f3-ae9a-ddd02cf180fc	cool_head	Cool Head	Use cooling period after 90% of losses	behavioral	bronze	75	\N	{"type": "cooling_period_usage", "percentage": 90}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
ffad7079-8259-4ea4-b91e-3f3b6389dd46	profitable_week	Profitable Week	End the week with positive P&L	performance	bronze	30	\N	{"type": "weekly_pnl", "positive": true}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
43d6b4ad-5599-4a54-b3c8-ac701a4dfe98	consistent_trader	Consistent Trader	Maintain win rate above 50% for 50 trades	performance	silver	100	\N	{"type": "win_rate", "trades": 50, "threshold": 50}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
53ca77f1-423e-4434-bdc9-78c3f394af21	risk_reward_master	Risk Reward Master	Achieve 2:1 risk/reward ratio on 20 trades	performance	gold	300	\N	{"type": "risk_reward", "ratio": 2, "trades": 20}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
fdff745b-961b-4652-b206-4266b17b55ac	pattern_spotter	Pattern Spotter	Identify and document 10 behavioral patterns	learning	bronze	40	\N	{"type": "patterns_identified", "count": 10}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
4f3ed591-46dc-4dee-8510-bfeafa8af445	improvement_focused	Improvement Focused	Complete 5 behavioral challenges	learning	silver	150	\N	{"type": "challenges_completed", "count": 5}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
45c53127-43d8-4a07-8582-43ce1b4adacf	peer_mentor	Peer Mentor	Rank in top 10% of your peer group	social	gold	400	\N	{"type": "peer_rank", "percentile": 90}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
83b52742-6675-4d5d-88c8-fa5069d7afe4	community_contributor	Community Contributor	Participate in 3 community challenges	social	bronze	60	\N	{"type": "community_challenges", "count": 3}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.550767+00
530bd057-c04c-4547-891b-34156e13f23b	revenge_free_week	Revenge Trading Free Week	Go 7 days without any revenge trading incidents	behavioral	bronze	50	\N	{"days": 7, "type": "no_revenge_trades", "linked_challenge": "revenge_free_week"}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.615096+00
b5d7065f-756c-465b-a55c-8b7872170253	risk_manager	Risk Manager	Keep all trades within risk limits for 100 trades	behavioral	silver	150	\N	{"type": "risk_adherence", "trades": 100, "linked_challenge": "risk_management_week"}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.615096+00
bc8bfbc1-057f-4109-84ca-ed72a33e51e8	discipline_master	Discipline Master	Maintain discipline score above 90% for 30 days	behavioral	gold	500	\N	{"days": 30, "type": "discipline_score", "threshold": 90, "linked_challenge": "consistency_challenge"}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.615096+00
3c5320cb-9cc2-43ec-bdef-01652f013d10	dashboard_explorer	Dashboard Explorer	Visit the gamification dashboard for the first time.	learning	bronze	15	\N	{"type": "dashboard_visit", "immediate": true}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
78896be6-2519-49da-8097-9cd588da13c8	achievement_seeker	Achievement Seeker	Check your achievements page for the first time.	learning	bronze	10	\N	{"type": "achievement_page_visit", "immediate": true}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
5c9f0c32-aeb8-4684-80b0-d742b0fa66d3	first_profitable_trade	First Profit	Celebrate your first profitable trade!	performance	bronze	20	\N	{"type": "first_profitable_trade"}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
4b9a68f0-9feb-432a-b6f4-8786fa5232d9	risk_conscious	Risk Conscious	Set a stop loss on your first trade - great risk management!	behavioral	bronze	30	\N	{"type": "first_stop_loss"}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
dc29137b-09b6-4082-be3f-ee4194c68507	profit_taker	Profit Taker	Set a take profit on your first trade - planning for success!	behavioral	bronze	30	\N	{"type": "first_take_profit"}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
ce809e3d-6443-4d35-bada-ae9c01c20385	weekend_warrior	Weekend Warrior	Log a trade on a weekend - dedication pays off!	behavioral	bronze	20	\N	{"type": "weekend_trade"}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
27c163c3-ecfa-441c-838d-9a78dcd10664	night_owl	Night Owl	Log a trade after 8 PM - working the after-hours!	behavioral	bronze	20	\N	{"type": "late_trade", "after_hour": 20}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
0c6136b3-b231-4466-9052-7bb74e296b55	three_day_streak	Three Day Streak	Trade for three consecutive days - building habits!	behavioral	bronze	50	\N	{"days": 3, "type": "trading_streak"}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
a69ec499-8fcf-438d-a7e0-fa39c0d43787	diversified_trader	Diversified Trader	Trade 3 different symbols - spreading your wings!	learning	bronze	35	\N	{"type": "different_symbols", "count": 3}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
58e5510a-369e-4ad2-bd18-cb5f335d64ef	early_bird	Early Bird Trader	Log a trade before 9 AM - catching the early market moves!	behavioral	bronze	20	\N	{"type": "early_trade", "before_hour": 9}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.629517+00
fff95281-3dc7-46a7-8c87-fdcd61fd249e	welcome_aboard	Welcome Aboard!	Welcome to TradeTally! Your journey to better trading starts now.	milestone	bronze	25	\N	{"type": "registration", "immediate": true, "retroactive": true}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.62219+00
377b3e65-9bfe-40f8-b5ba-373b5514d031	tenth_trade	Getting Serious	Log your 10th trade - you are building consistency!	milestone	bronze	40	\N	{"type": "trade_count", "count": 10, "retroactive": true}	t	f	1	2025-09-03 17:47:11.62219+00	2025-09-03 17:47:11.626784+00
26f017b9-30e2-4457-a0a7-aaf2312ad0fd	century_trader	Dedicated Trader	Log 100 trades - you are committed to improving your craft!	milestone	silver	100	\N	{"type": "trade_count", "count": 100}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.626784+00
683268c2-bf11-4207-add4-895ea2984a60	veteran_trader	Master Trader	Log 1000 trades - you have reached mastery level!	milestone	gold	500	\N	{"type": "trade_count", "count": 1000}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.626784+00
bcee9c07-674f-4970-a6f0-02de6083673e	first_trade_logged	Trading Explorer	Log your very first trade - welcome to the trading world!	milestone	bronze	10	\N	{"type": "trade_count", "count": 1, "retroactive": true}	t	f	1	2025-09-03 17:47:11.550767+00	2025-09-03 17:47:11.629517+00
e8f0b7ea-9977-4f59-bf7a-4f7edfc9d104	first_trade_daily	First Trade	Execute your first trade of the day	milestone	bronze	50	\N	{"type": "first_trade_daily"}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
2f84e098-fbc3-412d-8f34-59bb8841a661	quick_flip	Quick Flip	Make a profitable trade within 5 minutes of opening the position	performance	silver	100	\N	{"type": "quick_flip", "max_duration_minutes": 5}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
30af68eb-872a-488d-8625-1fd4ec5853f4	green_day	Green Day	End the trading day with a positive portfolio balance	performance	silver	200	\N	{"type": "green_day"}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
57ef7bdf-1e0d-471a-bc94-4d04e365e35c	streak_master	Streak Master	Achieve 5 consecutive profitable trading days	performance	gold	500	\N	{"days": 5, "type": "profitable_streak"}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
49d1ac9e-9fd3-4969-8519-bad1975276e4	early_bird_market_open	Early Bird	Place a trade within the first 10 minutes of market open	behavioral	bronze	75	\N	{"type": "early_market_trade", "minutes_from_open": 10}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
39768f1a-63ac-4c32-b4f2-82d2542d4133	risk_taker	Risk Taker	Execute a trade with a risk-reward ratio of at least 1:3	behavioral	silver	150	\N	{"type": "risk_reward_ratio", "min_ratio": 3.0}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
c814da43-66c3-4a61-865f-c81d86d69e29	trend_rider	Trend Rider	Profit from a trade by following a confirmed trend	learning	silver	200	\N	{"type": "trend_following_profit"}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
31008388-79c0-47b7-b768-74c3d71679c8	news_trader	News Trader	Make a profitable trade based on a news catalyst	learning	gold	300	\N	{"type": "news_based_profit"}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
ec7eb93a-7a35-423b-9a43-2351a7bb8262	volume_king_i	Volume King	Trade a total of 1,000 shares in a single day	milestone	bronze	100	\N	{"type": "daily_volume", "shares": 1000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
3fd056e5-4f18-44e7-8056-d0075ed8bc62	volume_king_ii	Volume King II	Trade a total of 10,000 shares in a single day	milestone	silver	300	\N	{"type": "daily_volume", "shares": 10000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
8127b385-fcd3-4fd3-850e-1a59cee32195	volume_king_iii	Volume King III	Trade a total of 100,000 shares in a single day	milestone	gold	500	\N	{"type": "daily_volume", "shares": 100000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
4077e5cc-5110-48ac-93f8-b38aa59818de	big_win_i	Big Win	Earn a profit of $500 or more on a single trade	performance	silver	400	\N	{"type": "single_trade_profit", "min_profit": 500}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
2b12d089-8b18-4c6b-afba-f2f981f32d8a	big_win_ii	Big Win II	Earn a profit of $1000 or more on a single trade	performance	gold	600	\N	{"type": "single_trade_profit", "min_profit": 1000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
bb796b96-d02a-4a76-9b5a-e199c94229d5	big_win_iii	Big Win III	Earn a profit of $1500 or more on a single trade	performance	gold	800	\N	{"type": "single_trade_profit", "min_profit": 1500}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
e8e342b8-d82f-4d57-a8b1-84413b28b0a7	high_roller_i	High Roller	Execute a trade with a position size of $5,000 or more	milestone	silver	350	\N	{"type": "position_size", "min_size": 5000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
e1ddbf74-8fbb-4254-bc37-c8ebe99b0f74	high_roller_ii	High Roller II	Execute a trade with a position size of $10,000 or more	milestone	gold	550	\N	{"type": "position_size", "min_size": 10000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
c14a90cc-1a88-4626-8a31-94d1513b8aca	high_roller_iii	High Roller III	Execute a trade with a position size of $25,000 or more	milestone	gold	750	\N	{"type": "position_size", "min_size": 25000}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
c56e84fe-c11c-4daa-8011-621f9703544e	diversifier	Diversifier	Trade in 5 different sectors in one day	learning	silver	250	\N	{"type": "daily_sector_diversity", "min_sectors": 5}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
0f50c347-df03-4621-9042-eefccf608ec3	portfolio_booster	Portfolio Booster	Achieve a 5% portfolio gain in a single week	performance	gold	750	\N	{"type": "weekly_portfolio_gain", "min_percentage": 5.0}	t	f	1	2025-09-03 17:47:11.629517+00	2025-09-03 17:47:11.629517+00
\.


--
-- Data for Name: admin_settings; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.admin_settings (id, setting_key, setting_value, created_at, updated_at) FROM stdin;
5	stripe_publishable_key		2025-09-03 17:47:11.39534	2025-09-03 17:47:11.39534
6	stripe_secret_key		2025-09-03 17:47:11.39534	2025-09-03 17:47:11.39534
7	stripe_price_id_monthly		2025-09-03 17:47:11.39534	2025-09-03 17:47:11.39534
8	stripe_price_id_yearly		2025-09-03 17:47:11.39534	2025-09-03 17:47:11.39534
1	default_ai_provider	ollama	2025-09-03 17:47:11.390533	2025-09-03 20:19:21.746602
2	default_ai_api_key		2025-09-03 17:47:11.390533	2025-09-03 20:19:21.746602
3	default_ai_api_url	http://192.168.2.13:11434	2025-09-03 17:47:11.390533	2025-09-03 20:19:21.746602
4	default_ai_model	gemma3:4b	2025-09-03 17:47:11.390533	2025-09-03 20:19:21.746602
\.


--
-- Data for Name: alert_notifications; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.alert_notifications (id, price_alert_id, user_id, symbol, notification_type, trigger_price, target_price, change_percent, message, sent_at, delivery_status, error_message, deleted_at) FROM stdin;
\.


--
-- Data for Name: analytics_cache; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.analytics_cache (id, user_id, cache_key, data, expires_at, created_at) FROM stdin;
c917bc8b-82fa-4c37-9f7c-f3b5ecefadc8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_analysis_endDate:2024-12-31_limit:20_page:1_startDate:2024-01-01	{"events": [], "pagination": {"page": 1, "limit": 20, "total": 0, "totalPages": 0, "hasNextPage": false, "hasPreviousPage": false}, "statistics": {"lossRate": 0, "profitRate": 0, "successRate": 0, "totalEvents": 0, "avgStreakLength": 0, "lowSeverityCount": 0, "highSeverityCount": 0, "performanceImpact": 0, "totalStreakProfits": 0, "avgPositionIncrease": 0, "mediumSeverityCount": 0, "streaksEndingInLoss": 0, "streaksEndingInProfit": 0, "totalLossesAfterStreaks": 0}, "winStreakAnalysis": {"longestStreak": 0, "avgStreakLength": 0, "avgPositionGrowth": 0}}	2025-09-03 21:00:55.002+00	2025-09-03 19:00:55.002741+00
e3e76da1-cd9d-4839-81ef-607892ce1e5a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	top_missed_trades_limit:50	{"message": "Found 36 trades with significant missed opportunities out of 301 analyzed", "totalAnalyzed": 301, "topMissedTrades": [{"id": "92858781-a01f-4854-8730-2d606385c553", "side": "long", "symbol": "TQQQ", "tradeId": "92858781-a01f-4854-8730-2d606385c553", "exitTime": "2025-04-07T19:19:00.000Z", "quantity": 100, "entryTime": "2025-04-07T19:18:00.000Z", "exitPrice": 41.23, "entryPrice": 41.16, "actualProfit": 4.26, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 15.20737327188941, "maxPriceTime": 1744121100, "minPriceTime": 1744053900, "pullbackTime": 1744131300, "priceAfter1Day": 41.92, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 42.07, "priceAfter30Min": 40.89, "priceAfter4Hours": 42.58, "pullbackOccurred": true, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 40.32}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 12582.2% potential upside", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 12582.2, "potentialAdditionalProfit": {"optimal": 536}}, {"id": "fa3349fb-2321-4a51-9b74-c4c9ad603a8a", "side": "long", "symbol": "TQQQ", "tradeId": "fa3349fb-2321-4a51-9b74-c4c9ad603a8a", "exitTime": "2025-04-07T16:11:00.000Z", "quantity": 100, "entryTime": "2025-04-07T16:11:00.000Z", "exitPrice": 39.23, "entryPrice": 39.14, "actualProfit": 6.27, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 19.143512617894483, "maxPriceTime": 1744121100, "minPriceTime": 1744044900, "pullbackTime": null, "priceAfter1Day": 44.32, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 40.67, "priceAfter30Min": 39.7, "priceAfter4Hours": 42.11, "pullbackOccurred": false, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 39.08}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 11738.4% potential upside", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 11738.4, "potentialAdditionalProfit": {"optimal": 736}}, {"id": "daac3f21-dbec-4000-9f00-a2fe0500af89", "side": "long", "symbol": "TQQQ", "tradeId": "daac3f21-dbec-4000-9f00-a2fe0500af89", "exitTime": "2025-04-07T16:20:00.000Z", "quantity": 200, "entryTime": "2025-04-07T16:14:00.000Z", "exitPrice": 39.51, "entryPrice": 39.42, "actualProfit": 13.55, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 19.007846114907633, "maxPriceTime": 1744121100, "minPriceTime": 1744044900, "pullbackTime": null, "priceAfter1Day": 43.33, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 41.055, "priceAfter30Min": 39.59, "priceAfter4Hours": 42.07, "pullbackOccurred": false, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 39.08}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 10450.2% potential upside", "holdTimeMinutes": 6, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 10450.2, "potentialAdditionalProfit": {"optimal": 1416}}, {"id": "93cae1d7-e20e-4063-8545-de0ccecf072e", "side": "long", "symbol": "TQQQ", "tradeId": "93cae1d7-e20e-4063-8545-de0ccecf072e", "exitTime": "2025-04-07T15:25:00.000Z", "quantity": 100, "entryTime": "2025-04-07T15:25:00.000Z", "exitPrice": 39.09, "entryPrice": 38.97, "actualProfit": 9.27, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 20.209772320286532, "maxPriceTime": 1744121100, "minPriceTime": 1744039500, "pullbackTime": null, "priceAfter1Day": 44.19, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 40.13, "priceAfter30Min": 40.03, "priceAfter4Hours": 40.32, "pullbackOccurred": false, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 38.69}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 8090.6% potential upside", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 8090.6, "potentialAdditionalProfit": {"optimal": 750}}, {"id": "81781831-4f29-4376-accb-5ab857006caf", "side": "long", "symbol": "TQQQ", "tradeId": "81781831-4f29-4376-accb-5ab857006caf", "exitTime": "2025-04-07T16:13:00.000Z", "quantity": 200, "entryTime": "2025-04-07T16:12:00.000Z", "exitPrice": 39.54, "entryPrice": 39.42, "actualProfit": 20.55, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 18.993424380374318, "maxPriceTime": 1744121100, "minPriceTime": 1744044900, "pullbackTime": null, "priceAfter1Day": 44.32, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 41, "priceAfter30Min": 39.42, "priceAfter4Hours": 42.38, "pullbackOccurred": false, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 39.08}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 6861.3% potential upside", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 6861.3, "potentialAdditionalProfit": {"optimal": 1410}}, {"id": "ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f", "side": "long", "symbol": "TQQQ", "tradeId": "ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f", "exitTime": "2025-04-07T15:28:00.000Z", "quantity": 100, "entryTime": "2025-04-07T15:26:00.000Z", "exitPrice": 39.04, "entryPrice": 38.86, "actualProfit": 15.72, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 19.236680327868864, "maxPriceTime": 1744121100, "minPriceTime": 1744044900, "pullbackTime": null, "priceAfter1Day": 44.19, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 40.55, "priceAfter30Min": 39.81, "priceAfter4Hours": 41.43, "pullbackOccurred": false, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 39.08}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 4802.8% potential upside", "holdTimeMinutes": 2, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 4802.8, "potentialAdditionalProfit": {"optimal": 755}}, {"id": "ff735cf4-7022-41f4-8b6d-630fb0ccef3e", "side": "long", "symbol": "TQQQ", "tradeId": "ff735cf4-7022-41f4-8b6d-630fb0ccef3e", "exitTime": "2025-04-07T19:54:00.000Z", "quantity": 200, "entryTime": "2025-04-07T19:49:00.000Z", "exitPrice": 40.92, "entryPrice": 40.68, "actualProfit": 43.54, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 13.000977517106548, "maxPriceTime": 1744121100, "minPriceTime": 1744055700, "pullbackTime": 1744131300, "priceAfter1Day": 41.92, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 41.73, "priceAfter30Min": 41.91, "priceAfter4Hours": 42.71, "pullbackOccurred": true, "maxPriceWithin24Hours": 46.59, "minPriceWithin24Hours": 41.27}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 2604.5% potential upside", "holdTimeMinutes": 5, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 2604.5, "potentialAdditionalProfit": {"optimal": 1134}}, {"id": "000322b7-3fe4-4edb-ac94-44d326f59b8a", "side": "long", "symbol": "SQQQ", "tradeId": "000322b7-3fe4-4edb-ac94-44d326f59b8a", "exitTime": "2025-04-07T18:29:00.000Z", "quantity": 150, "entryTime": "2025-04-07T17:57:00.000Z", "exitPrice": 49.9, "entryPrice": 48.49, "actualProfit": 207.54, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 10.42084168336674, "maxPriceTime": 1744053900, "minPriceTime": 1744113900, "pullbackTime": 1744113900, "priceAfter1Day": 46.07, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 49.881, "priceAfter30Min": 50.24, "priceAfter4Hours": 48.82, "pullbackOccurred": true, "maxPriceWithin24Hours": 51.27, "minPriceWithin24Hours": 46.07}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 99.0% potential upside", "holdTimeMinutes": 32, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 99, "potentialAdditionalProfit": {"optimal": 205.5}}, {"id": "fb07cb4f-b5cd-4b67-8d63-150068297eed", "side": "short", "symbol": "TEVA", "tradeId": "fb07cb4f-b5cd-4b67-8d63-150068297eed", "exitTime": "2025-04-07T16:08:00.000Z", "quantity": 500, "entryTime": "2025-04-07T15:44:00.000Z", "exitPrice": 13.73, "entryPrice": 13.83, "actualProfit": 44.77, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 5.280407865986887, "maxPriceTime": 1744114500, "minPriceTime": 1744044300, "pullbackTime": null, "priceAfter1Day": 13.945, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 13.845, "priceAfter30Min": 13.73, "priceAfter4Hours": 13.97, "pullbackOccurred": false, "maxPriceWithin24Hours": 14.4, "minPriceWithin24Hours": 13.675}, "recommendation": "High missed opportunity: Consider using trailing stops or scaling out positions to capture more of the 61.4% potential upside", "holdTimeMinutes": 24, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 61.4, "potentialAdditionalProfit": {"optimal": 27.5}}, {"id": "0c305292-7e48-432e-9eb3-261892f20416", "side": "long", "symbol": "SQQQ", "tradeId": "0c305292-7e48-432e-9eb3-261892f20416", "exitTime": "2025-04-07T14:38:00.000Z", "quantity": 150, "entryTime": "2025-04-07T13:47:00.000Z", "exitPrice": 52.97, "entryPrice": 52.05, "actualProfit": 131.48, "prematureExit": null, "priceMovement": {"traderType": "scalper", "volatility": 10.892958278270726, "maxPriceTime": 1744039500, "minPriceTime": 1744099200, "pullbackTime": 1744099200, "priceAfter1Day": 47.47, "priceDirection": "up", "analysisHorizon": "Day trading analysis (intraday focus)", "priceAfter1Hour": 50.32, "priceAfter30Min": 52.49, "priceAfter4Hours": 49.17, "pullbackOccurred": true, "maxPriceWithin24Hours": 53.24, "minPriceWithin24Hours": 47.47}, "recommendation": "Moderate missed opportunity: Review exit strategy - you could have captured an additional 30.8% profit", "holdTimeMinutes": 51, "exitQualityScore": null, "hasRealPriceData": true, "missedOpportunityPercent": 30.8, "potentialAdditionalProfit": {"optimal": 40.5}}, {"id": "9acf57c0-fd2f-40de-959a-93bb7a7e2dd5", "side": "long", "symbol": "GRRR", "tradeId": "9acf57c0-fd2f-40de-959a-93bb7a7e2dd5", "exitTime": "2025-04-07T12:28:00.000Z", "quantity": 200, "entryTime": "2025-04-07T12:25:00.000Z", "exitPrice": 15.47, "entryPrice": 15.27, "actualProfit": 36.58, "prematureExit": null, "priceMovement": {"volatility": 24, "priceDirection": "estimated", "maxPriceWithin24Hours": 19.1828, "minPriceWithin24Hours": 11.757200000000001}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 3, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 24, "potentialAdditionalProfit": {"optimal": 8.78}}, {"id": "36839bce-0786-4b92-a3ad-b6fa4360a054", "side": "long", "symbol": "SQQQ", "tradeId": "36839bce-0786-4b92-a3ad-b6fa4360a054", "exitTime": "2025-04-02T21:29:00.000Z", "quantity": 100, "entryTime": "2025-04-02T21:27:00.000Z", "exitPrice": 40.41, "entryPrice": 40.3, "actualProfit": 8.26, "prematureExit": null, "priceMovement": {"volatility": 24, "priceDirection": "estimated", "maxPriceWithin24Hours": 50.108399999999996, "minPriceWithin24Hours": 30.711599999999997}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 2, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 24, "potentialAdditionalProfit": {"optimal": 1.98}}, {"id": "9c40614d-1977-43cc-866d-13ade35b7069", "side": "long", "symbol": "03835L405", "tradeId": "9c40614d-1977-43cc-866d-13ade35b7069", "exitTime": "2025-04-02T21:20:00.000Z", "quantity": 300, "entryTime": "2025-04-02T21:20:00.000Z", "exitPrice": 2.62, "entryPrice": 2.6, "actualProfit": 2.02, "prematureExit": null, "priceMovement": {"volatility": 24, "priceDirection": "estimated", "maxPriceWithin24Hours": 3.2488, "minPriceWithin24Hours": 1.9912}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 24, "potentialAdditionalProfit": {"optimal": 0.48}}, {"id": "3769c3e8-92c6-4f1b-95ed-21f5165bb21b", "side": "short", "symbol": "PENG", "tradeId": "3769c3e8-92c6-4f1b-95ed-21f5165bb21b", "exitTime": "2025-04-02T20:19:00.000Z", "quantity": 100, "entryTime": "2025-04-02T20:09:00.000Z", "exitPrice": 19.51, "entryPrice": 19.91, "actualProfit": 37.77, "prematureExit": null, "priceMovement": {"volatility": 24, "priceDirection": "estimated", "maxPriceWithin24Hours": 24.192400000000003, "minPriceWithin24Hours": 14.827600000000002}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 10, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 24, "potentialAdditionalProfit": {"optimal": 9.06}}, {"id": "8dee3216-7bec-499b-a6b1-8f4b90407d5c", "side": "short", "symbol": "SQQQ", "tradeId": "8dee3216-7bec-499b-a6b1-8f4b90407d5c", "exitTime": "2025-04-07T11:53:00.000Z", "quantity": 100, "entryTime": "2025-04-07T11:53:00.000Z", "exitPrice": 54.73, "entryPrice": 54.89, "actualProfit": 13.22, "prematureExit": null, "priceMovement": {"volatility": 23, "priceDirection": "estimated", "maxPriceWithin24Hours": 67.3179, "minPriceWithin24Hours": 42.1421}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 23, "potentialAdditionalProfit": {"optimal": 3.04}}, {"id": "928ece38-8645-4e62-9e44-35ddca92c249", "side": "long", "symbol": "USAR", "tradeId": "928ece38-8645-4e62-9e44-35ddca92c249", "exitTime": "2025-04-04T13:40:00.000Z", "quantity": 1500, "entryTime": "2025-04-04T13:32:00.000Z", "exitPrice": 9.9, "entryPrice": 9.5, "actualProfit": 588.17, "prematureExit": null, "priceMovement": {"volatility": 23, "priceDirection": "estimated", "maxPriceWithin24Hours": 12.177, "minPriceWithin24Hours": 7.623}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 8, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 23, "potentialAdditionalProfit": {"optimal": 135.28}}, {"id": "68cd30f4-fd97-4a9e-ac1a-3191460787ae", "side": "long", "symbol": "OSRH", "tradeId": "68cd30f4-fd97-4a9e-ac1a-3191460787ae", "exitTime": "2025-04-03T11:39:00.000Z", "quantity": 900, "entryTime": "2025-04-03T11:39:00.000Z", "exitPrice": 2.67, "entryPrice": 2.54, "actualProfit": 102.07, "prematureExit": null, "priceMovement": {"volatility": 23, "priceDirection": "estimated", "maxPriceWithin24Hours": 3.2841, "minPriceWithin24Hours": 2.0559}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 23, "potentialAdditionalProfit": {"optimal": 23.48}}, {"id": "7dca1f5e-8ec9-489f-9bf0-a460a8f2c90d", "side": "long", "symbol": "TIVC", "tradeId": "7dca1f5e-8ec9-489f-9bf0-a460a8f2c90d", "exitTime": "2025-04-03T11:55:00.000Z", "quantity": 600, "entryTime": "2025-04-03T11:55:00.000Z", "exitPrice": 5.28, "entryPrice": 5.15, "actualProfit": 74.02, "prematureExit": null, "priceMovement": {"volatility": 22, "priceDirection": "estimated", "maxPriceWithin24Hours": 6.4416, "minPriceWithin24Hours": 4.1184}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 22, "potentialAdditionalProfit": {"optimal": 16.28}}, {"id": "893477c4-e598-41d8-99bf-bb5eabd07f98", "side": "long", "symbol": "TQQQ", "tradeId": "893477c4-e598-41d8-99bf-bb5eabd07f98", "exitTime": "2025-04-02T20:52:00.000Z", "quantity": 100, "entryTime": "2025-04-02T20:51:00.000Z", "exitPrice": 55.04, "entryPrice": 54.91, "actualProfit": 10.22, "prematureExit": null, "priceMovement": {"volatility": 22, "priceDirection": "estimated", "maxPriceWithin24Hours": 67.1488, "minPriceWithin24Hours": 42.931200000000004}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 22, "potentialAdditionalProfit": {"optimal": 2.25}}, {"id": "1656ca06-e611-4dad-be42-ca2c1dd2f148", "side": "long", "symbol": "BJDX", "tradeId": "1656ca06-e611-4dad-be42-ca2c1dd2f148", "exitTime": "2025-04-07T11:00:00.000Z", "quantity": 300, "entryTime": "2025-04-07T11:00:00.000Z", "exitPrice": 7.94, "entryPrice": 7.79, "actualProfit": 41.42, "prematureExit": null, "priceMovement": {"volatility": 21, "priceDirection": "estimated", "maxPriceWithin24Hours": 9.6074, "minPriceWithin24Hours": 6.272600000000001}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 21, "potentialAdditionalProfit": {"optimal": 8.7}}, {"id": "505d5227-f994-4646-9009-01fde18f317e", "side": "short", "symbol": "ICCT", "tradeId": "505d5227-f994-4646-9009-01fde18f317e", "exitTime": "2025-04-07T13:31:00.000Z", "quantity": 500, "entryTime": "2025-04-07T13:31:00.000Z", "exitPrice": 7.95, "entryPrice": 7.97, "actualProfit": 4.29, "prematureExit": null, "priceMovement": {"volatility": 20, "priceDirection": "estimated", "maxPriceWithin24Hours": 9.54, "minPriceWithin24Hours": 6.36}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 20, "potentialAdditionalProfit": {"optimal": 0.86}}, {"id": "26735ce1-e09d-42ad-ab49-488221134457", "side": "long", "symbol": "DFDV", "tradeId": "26735ce1-e09d-42ad-ab49-488221134457", "exitTime": "2025-04-07T12:47:00.000Z", "quantity": 500, "entryTime": "2025-04-07T12:47:00.000Z", "exitPrice": 9.51, "entryPrice": 9.42, "actualProfit": 38.84, "prematureExit": null, "priceMovement": {"volatility": 20, "priceDirection": "estimated", "maxPriceWithin24Hours": 11.411999999999999, "minPriceWithin24Hours": 7.6080000000000005}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 20, "potentialAdditionalProfit": {"optimal": 7.77}}, {"id": "5a8a6701-def2-46dc-81ba-cbd81d43641a", "side": "long", "symbol": "SQQQ", "tradeId": "5a8a6701-def2-46dc-81ba-cbd81d43641a", "exitTime": "2025-04-07T11:49:00.000Z", "quantity": 100, "entryTime": "2025-04-07T11:36:00.000Z", "exitPrice": 54.79, "entryPrice": 54.3, "actualProfit": 46.22, "prematureExit": null, "priceMovement": {"volatility": 20, "priceDirection": "estimated", "maxPriceWithin24Hours": 65.74799999999999, "minPriceWithin24Hours": 43.832}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 13, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 20, "potentialAdditionalProfit": {"optimal": 9.24}}, {"id": "9615d633-8f42-44f3-96d6-eaebc73eb3b4", "side": "long", "symbol": "TQQQ", "tradeId": "9615d633-8f42-44f3-96d6-eaebc73eb3b4", "exitTime": "2025-04-02T21:24:00.000Z", "quantity": 100, "entryTime": "2025-04-02T21:23:00.000Z", "exitPrice": 54.1, "entryPrice": 54.06, "actualProfit": 1.25, "prematureExit": null, "priceMovement": {"volatility": 20, "priceDirection": "estimated", "maxPriceWithin24Hours": 64.92, "minPriceWithin24Hours": 43.28}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 20, "potentialAdditionalProfit": {"optimal": 0.25}}, {"id": "64c27085-dba9-4e56-b708-c876a172130b", "side": "long", "symbol": "ICCT", "tradeId": "64c27085-dba9-4e56-b708-c876a172130b", "exitTime": "2025-04-03T15:34:00.000Z", "quantity": 900, "entryTime": "2025-04-03T15:34:00.000Z", "exitPrice": 4.85, "entryPrice": 4.76, "actualProfit": 69.92, "prematureExit": null, "priceMovement": {"volatility": 19, "priceDirection": "estimated", "maxPriceWithin24Hours": 5.7715, "minPriceWithin24Hours": 3.9285}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 19, "potentialAdditionalProfit": {"optimal": 13.28}}, {"id": "3f9d46b6-35a4-40b5-b54e-14cca28f55a4", "side": "long", "symbol": "ALLO", "tradeId": "3f9d46b6-35a4-40b5-b54e-14cca28f55a4", "exitTime": "2025-04-07T14:16:00.000Z", "quantity": 1000, "entryTime": "2025-04-07T12:30:00.000Z", "exitPrice": 1.5, "entryPrice": 1.49, "actualProfit": 4.05, "prematureExit": null, "priceMovement": {"volatility": 18, "priceDirection": "estimated", "maxPriceWithin24Hours": 1.77, "minPriceWithin24Hours": 1.23}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 106, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 18, "potentialAdditionalProfit": {"optimal": 0.73}}, {"id": "3c109eec-1435-470f-9527-583f9b0870f7", "side": "long", "symbol": "CNTM", "tradeId": "3c109eec-1435-470f-9527-583f9b0870f7", "exitTime": "2025-04-03T12:01:00.000Z", "quantity": 900, "entryTime": "2025-04-03T12:00:00.000Z", "exitPrice": 0.82, "entryPrice": 0.78, "actualProfit": 25.19, "prematureExit": null, "priceMovement": {"volatility": 18, "priceDirection": "estimated", "maxPriceWithin24Hours": 0.9675999999999999, "minPriceWithin24Hours": 0.6724}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 18, "potentialAdditionalProfit": {"optimal": 4.53}}, {"id": "53f6a156-e9c4-4259-81eb-2197046d5e8b", "side": "short", "symbol": "03835L405", "tradeId": "53f6a156-e9c4-4259-81eb-2197046d5e8b", "exitTime": "2025-04-02T21:19:00.000Z", "quantity": 300, "entryTime": "2025-04-02T21:19:00.000Z", "exitPrice": 2.43, "entryPrice": 2.45, "actualProfit": 2.02, "prematureExit": null, "priceMovement": {"volatility": 18, "priceDirection": "estimated", "maxPriceWithin24Hours": 2.8674, "minPriceWithin24Hours": 1.9926000000000004}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 18, "potentialAdditionalProfit": {"optimal": 0.36}}, {"id": "132b8ee0-affb-401f-b5a0-c5b633f44c9e", "side": "long", "symbol": "CNTM", "tradeId": "132b8ee0-affb-401f-b5a0-c5b633f44c9e", "exitTime": "2025-04-02T13:36:00.000Z", "quantity": 7000, "entryTime": "2025-04-02T12:33:00.000Z", "exitPrice": 1.1, "entryPrice": 1.04, "actualProfit": 319.62, "prematureExit": null, "priceMovement": {"volatility": 17, "priceDirection": "estimated", "maxPriceWithin24Hours": 1.287, "minPriceWithin24Hours": 0.913}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 63, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 17, "potentialAdditionalProfit": {"optimal": 54.34}}, {"id": "17138191-3fe0-40d0-9efa-d0be39302350", "side": "long", "symbol": "DFDV", "tradeId": "17138191-3fe0-40d0-9efa-d0be39302350", "exitTime": "2025-04-07T13:28:00.000Z", "quantity": 500, "entryTime": "2025-04-07T13:28:00.000Z", "exitPrice": 14.94, "entryPrice": 14.34, "actualProfit": 295.47, "prematureExit": null, "priceMovement": {"volatility": 16, "priceDirection": "estimated", "maxPriceWithin24Hours": 17.330399999999997, "minPriceWithin24Hours": 12.5496}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 16, "potentialAdditionalProfit": {"optimal": 47.28}}, {"id": "31e497be-27cd-4c24-a41e-ae831f921000", "side": "long", "symbol": "DFDV", "tradeId": "31e497be-27cd-4c24-a41e-ae831f921000", "exitTime": "2025-04-07T12:45:00.000Z", "quantity": 88, "entryTime": "2025-04-07T12:45:00.000Z", "exitPrice": 9.22, "entryPrice": 9.05, "actualProfit": 12.94, "prematureExit": null, "priceMovement": {"volatility": 16, "priceDirection": "estimated", "maxPriceWithin24Hours": 10.6952, "minPriceWithin24Hours": 7.744800000000001}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 0, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 16, "potentialAdditionalProfit": {"optimal": 2.07}}, {"id": "235831b1-fb49-4533-97d7-a613708c7e02", "side": "long", "symbol": "03835L405", "tradeId": "235831b1-fb49-4533-97d7-a613708c7e02", "exitTime": "2025-04-03T10:32:00.000Z", "quantity": 900, "entryTime": "2025-04-03T10:14:00.000Z", "exitPrice": 3.26, "entryPrice": 3.16, "actualProfit": 78.75, "prematureExit": null, "priceMovement": {"volatility": 16, "priceDirection": "estimated", "maxPriceWithin24Hours": 3.7815999999999996, "minPriceWithin24Hours": 2.7383999999999995}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 18, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 16, "potentialAdditionalProfit": {"optimal": 12.6}}, {"id": "1bbe564d-0de2-41e7-8611-87db9e8146f7", "side": "long", "symbol": "SQQQ", "tradeId": "1bbe564d-0de2-41e7-8611-87db9e8146f7", "exitTime": "2025-04-02T20:38:00.000Z", "quantity": 100, "entryTime": "2025-04-02T20:36:00.000Z", "exitPrice": 39.86, "entryPrice": 39.11, "actualProfit": 72.26, "prematureExit": null, "priceMovement": {"volatility": 16, "priceDirection": "estimated", "maxPriceWithin24Hours": 46.23759999999999, "minPriceWithin24Hours": 33.4824}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 2, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 16, "potentialAdditionalProfit": {"optimal": 11.56}}, {"id": "1e6a01ad-69ee-4302-87ee-46349c30f96b", "side": "long", "symbol": "SIDU", "tradeId": "1e6a01ad-69ee-4302-87ee-46349c30f96b", "exitTime": "2025-04-02T12:31:00.000Z", "quantity": 900, "entryTime": "2025-04-02T12:30:00.000Z", "exitPrice": 1.84, "entryPrice": 1.71, "actualProfit": 109.51, "prematureExit": null, "priceMovement": {"volatility": 16, "priceDirection": "estimated", "maxPriceWithin24Hours": 2.1344, "minPriceWithin24Hours": 1.5456}, "recommendation": "Some missed upside: Consider wider profit targets or technical analysis for better exit timing", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 16, "potentialAdditionalProfit": {"optimal": 17.52}}, {"id": "47150f7a-e354-4e7d-8b9e-817bcfa812f9", "side": "long", "symbol": "SQQQ", "tradeId": "47150f7a-e354-4e7d-8b9e-817bcfa812f9", "exitTime": "2025-04-07T13:13:00.000Z", "quantity": 100, "entryTime": "2025-04-07T13:12:00.000Z", "exitPrice": 54.45, "entryPrice": 54.35, "actualProfit": 7.21, "prematureExit": null, "priceMovement": {"volatility": 15, "priceDirection": "estimated", "maxPriceWithin24Hours": 62.6175, "minPriceWithin24Hours": 46.2825}, "recommendation": "Minor missed opportunity: Exit timing was reasonable given the 15.0% additional potential", "holdTimeMinutes": 1, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 15, "potentialAdditionalProfit": {"optimal": 1.08}}, {"id": "0dd0eb75-158a-4419-9f9b-4b7e87c942ca", "side": "long", "symbol": "SQQQ", "tradeId": "0dd0eb75-158a-4419-9f9b-4b7e87c942ca", "exitTime": "2025-04-07T13:00:00.000Z", "quantity": 100, "entryTime": "2025-04-07T12:58:00.000Z", "exitPrice": 53.94, "entryPrice": 53.36, "actualProfit": 55.23, "prematureExit": null, "priceMovement": {"volatility": 15, "priceDirection": "estimated", "maxPriceWithin24Hours": 62.03099999999999, "minPriceWithin24Hours": 45.849}, "recommendation": "Minor missed opportunity: Exit timing was reasonable given the 15.0% additional potential", "holdTimeMinutes": 2, "exitQualityScore": null, "hasRealPriceData": false, "missedOpportunityPercent": 15, "potentialAdditionalProfit": {"optimal": 8.28}}], "totalMissedProfit": 7411.6, "totalEligibleTrades": 36, "tradesWithRealPriceData": 10, "avgMissedOpportunityPercent": 1606.4}	2025-09-03 23:02:02.593+00	2025-09-03 19:02:02.594232+00
2300f3f9-0cc2-4ee7-8ab6-f107e080ef96	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_analysis_limit:20_page:1	{"events": [{"id": "c8d846ef-93d8-4b27-b08c-89ebcbc0d7a0", "severity": "high", "streakPnl": 340.48, "totalImpact": -5.74, "streakTrades": ["fb07cb4f-b5cd-4b67-8d63-150068297eed", "fa3349fb-2321-4a51-9b74-c4c9ad603a8a", "81781831-4f29-4376-accb-5ab857006caf", "daac3f21-dbec-4000-9f00-a2fe0500af89", "000322b7-3fe4-4edb-ac94-44d326f59b8a", "92858781-a01f-4854-8730-2d606385c553", "ff735cf4-7022-41f4-8b6d-630fb0ccef3e"], "detectionDate": "2025-09-03T19:06:23.322Z", "outcomeStatus": "warning", "outcomeTradeId": "c40d4a7e-5944-4238-a47b-85a4d925ce1b", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 7, "peakPositionSize": 8136, "winStreakEndDate": "2025-04-07T19:54:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "fb07cb4f-b5cd-4b67-8d63-150068297eed", "pnl": "44.77", "fees": "0.00", "side": "short", "symbol": "TEVA", "quantity": "500.0000", "exit_time": "2025-04-07T16:08:00.000Z", "commission": "5.28", "entry_time": "2025-04-07T15:44:00.000Z", "exit_price": "13.73", "entry_price": "13.83", "position_size": "6915.000000"}, {"id": "fa3349fb-2321-4a51-9b74-c4c9ad603a8a", "pnl": "6.27", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T16:11:00.000Z", "commission": "2.73", "entry_time": "2025-04-07T16:11:00.000Z", "exit_price": "39.23", "entry_price": "39.14", "position_size": "3914.000000"}, {"id": "81781831-4f29-4376-accb-5ab857006caf", "pnl": "20.55", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "200.0000", "exit_time": "2025-04-07T16:13:00.000Z", "commission": "4.45", "entry_time": "2025-04-07T16:12:00.000Z", "exit_price": "39.54", "entry_price": "39.42", "position_size": "7884.000000"}, {"id": "daac3f21-dbec-4000-9f00-a2fe0500af89", "pnl": "13.55", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "200.0000", "exit_time": "2025-04-07T16:20:00.000Z", "commission": "4.45", "entry_time": "2025-04-07T16:14:00.000Z", "exit_price": "39.51", "entry_price": "39.42", "position_size": "7884.000000"}, {"id": "000322b7-3fe4-4edb-ac94-44d326f59b8a", "pnl": "207.54", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "150.0000", "exit_time": "2025-04-07T18:29:00.000Z", "commission": "3.84", "entry_time": "2025-04-07T17:57:00.000Z", "exit_price": "49.90", "entry_price": "48.49", "position_size": "7273.500000"}, {"id": "92858781-a01f-4854-8730-2d606385c553", "pnl": "4.26", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T19:19:00.000Z", "commission": "2.74", "entry_time": "2025-04-07T19:18:00.000Z", "exit_price": "41.23", "entry_price": "41.16", "position_size": "4116.000000"}, {"id": "ff735cf4-7022-41f4-8b6d-630fb0ccef3e", "pnl": "43.54", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "200.0000", "exit_time": "2025-04-07T19:54:00.000Z", "commission": "4.46", "entry_time": "2025-04-07T19:49:00.000Z", "exit_price": "40.92", "entry_price": "40.68", "position_size": "8136.000000"}], "winStreakStartDate": "2025-04-07T15:44:00.000Z", "outcomeTradeDetails": {"id": "c40d4a7e-5944-4238-a47b-85a4d925ce1b", "pnl": "-5.74", "fees": "0.00", "side": "short", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T19:58:00.000Z", "commission": "2.74", "entry_time": "2025-04-07T19:58:00.000Z", "exit_price": "41.22", "entry_price": "41.19"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 989.45, "subsequentTradeResult": -5.74}, {"id": "ce1f4c11-93bc-4e06-b8d9-12504fd02a61", "severity": "high", "streakPnl": 879.32, "totalImpact": -1.73, "streakTrades": ["9acf57c0-fd2f-40de-959a-93bb7a7e2dd5", "3f9d46b6-35a4-40b5-b54e-14cca28f55a4", "31e497be-27cd-4c24-a41e-ae831f921000", "26735ce1-e09d-42ad-ab49-488221134457", "0dd0eb75-158a-4419-9f9b-4b7e87c942ca", "aa5bb742-1ede-42a7-9838-5e195319f6c5", "47150f7a-e354-4e7d-8b9e-817bcfa812f9", "17138191-3fe0-40d0-9efa-d0be39302350", "e7ad79ce-34fa-4078-aa75-b3fcb8b17570", "505d5227-f994-4646-9009-01fde18f317e", "0c305292-7e48-432e-9eb3-261892f20416", "93cae1d7-e20e-4063-8545-de0ccecf072e", "ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f"], "detectionDate": "2025-09-03T19:06:23.321Z", "outcomeStatus": "warning", "outcomeTradeId": "5f067d88-03a4-453a-97ea-82002cffed00", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 13, "peakPositionSize": 7807.5, "winStreakEndDate": "2025-04-07T15:28:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "9acf57c0-fd2f-40de-959a-93bb7a7e2dd5", "pnl": "36.58", "fees": "0.00", "side": "long", "symbol": "GRRR", "quantity": "200.0000", "exit_time": "2025-04-07T12:28:00.000Z", "commission": "3.42", "entry_time": "2025-04-07T12:25:00.000Z", "exit_price": "15.47", "entry_price": "15.27", "position_size": "3054.000000"}, {"id": "3f9d46b6-35a4-40b5-b54e-14cca28f55a4", "pnl": "4.05", "fees": "0.00", "side": "long", "symbol": "ALLO", "quantity": "1000.0000", "exit_time": "2025-04-07T14:16:00.000Z", "commission": "8.95", "entry_time": "2025-04-07T12:30:00.000Z", "exit_price": "1.50", "entry_price": "1.49", "position_size": "1490.000000"}, {"id": "31e497be-27cd-4c24-a41e-ae831f921000", "pnl": "12.94", "fees": "0.00", "side": "long", "symbol": "DFDV", "quantity": "88.0000", "exit_time": "2025-04-07T12:45:00.000Z", "commission": "2.02", "entry_time": "2025-04-07T12:45:00.000Z", "exit_price": "9.22", "entry_price": "9.05", "position_size": "796.400000"}, {"id": "26735ce1-e09d-42ad-ab49-488221134457", "pnl": "38.84", "fees": "0.00", "side": "long", "symbol": "DFDV", "quantity": "500.0000", "exit_time": "2025-04-07T12:47:00.000Z", "commission": "5.16", "entry_time": "2025-04-07T12:47:00.000Z", "exit_price": "9.51", "entry_price": "9.42", "position_size": "4710.000000"}, {"id": "0dd0eb75-158a-4419-9f9b-4b7e87c942ca", "pnl": "55.23", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T13:00:00.000Z", "commission": "2.77", "entry_time": "2025-04-07T12:58:00.000Z", "exit_price": "53.94", "entry_price": "53.36", "position_size": "5336.000000"}, {"id": "aa5bb742-1ede-42a7-9838-5e195319f6c5", "pnl": "34.89", "fees": "0.00", "side": "long", "symbol": "DFDV", "quantity": "500.0000", "exit_time": "2025-04-07T13:03:00.000Z", "commission": "6.51", "entry_time": "2025-04-07T13:01:00.000Z", "exit_price": "10.05", "entry_price": "9.97", "position_size": "4985.000000"}, {"id": "47150f7a-e354-4e7d-8b9e-817bcfa812f9", "pnl": "7.21", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T13:13:00.000Z", "commission": "2.79", "entry_time": "2025-04-07T13:12:00.000Z", "exit_price": "54.45", "entry_price": "54.35", "position_size": "5435.000000"}, {"id": "17138191-3fe0-40d0-9efa-d0be39302350", "pnl": "295.47", "fees": "0.00", "side": "long", "symbol": "DFDV", "quantity": "500.0000", "exit_time": "2025-04-07T13:28:00.000Z", "commission": "4.53", "entry_time": "2025-04-07T13:28:00.000Z", "exit_price": "14.94", "entry_price": "14.34", "position_size": "7170.000000"}, {"id": "e7ad79ce-34fa-4078-aa75-b3fcb8b17570", "pnl": "233.35", "fees": "0.00", "side": "long", "symbol": "DFDV", "quantity": "500.0000", "exit_time": "2025-04-07T13:30:00.000Z", "commission": "4.55", "entry_time": "2025-04-07T13:30:00.000Z", "exit_price": "15.62", "entry_price": "15.14", "position_size": "7570.000000"}, {"id": "505d5227-f994-4646-9009-01fde18f317e", "pnl": "4.29", "fees": "0.00", "side": "short", "symbol": "ICCT", "quantity": "500.0000", "exit_time": "2025-04-07T13:31:00.000Z", "commission": "6.71", "entry_time": "2025-04-07T13:31:00.000Z", "exit_price": "7.95", "entry_price": "7.97", "position_size": "3985.000000"}, {"id": "0c305292-7e48-432e-9eb3-261892f20416", "pnl": "131.48", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "150.0000", "exit_time": "2025-04-07T14:38:00.000Z", "commission": "5.78", "entry_time": "2025-04-07T13:47:00.000Z", "exit_price": "52.97", "entry_price": "52.05", "position_size": "7807.500000"}, {"id": "93cae1d7-e20e-4063-8545-de0ccecf072e", "pnl": "9.27", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T15:25:00.000Z", "commission": "2.73", "entry_time": "2025-04-07T15:25:00.000Z", "exit_price": "39.09", "entry_price": "38.97", "position_size": "3897.000000"}, {"id": "ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f", "pnl": "15.72", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T15:28:00.000Z", "commission": "2.28", "entry_time": "2025-04-07T15:26:00.000Z", "exit_price": "39.04", "entry_price": "38.86", "position_size": "3886.000000"}], "winStreakStartDate": "2025-04-07T12:25:00.000Z", "outcomeTradeDetails": {"id": "5f067d88-03a4-453a-97ea-82002cffed00", "pnl": "-1.73", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T15:31:00.000Z", "commission": "2.73", "entry_time": "2025-04-07T15:30:00.000Z", "exit_price": "39.37", "entry_price": "39.36"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 945.46, "subsequentTradeResult": -1.73}, {"id": "686b44d5-bf21-4322-bdae-11dd454a0e4c", "severity": "high", "streakPnl": 171.64, "totalImpact": -302.57, "streakTrades": ["ad7724dd-c41b-4850-a5c2-6ae75efb048e", "5a8a6701-def2-46dc-81ba-cbd81d43641a", "8dee3216-7bec-499b-a6b1-8f4b90407d5c", "ca2141f1-ed0b-4b15-bcfd-67f1d5ce9afb", "cf02fe9b-5e4b-4237-9bb1-57a8a1d6c85d", "fbc846b9-e8c3-443f-ae14-b41ed2fc4608"], "detectionDate": "2025-09-03T19:06:23.320Z", "outcomeStatus": "warning", "outcomeTradeId": "67f88e91-80cf-40fd-b7ca-fc0547495314", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 6, "peakPositionSize": 5509, "winStreakEndDate": "2025-04-07T12:18:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "ad7724dd-c41b-4850-a5c2-6ae75efb048e", "pnl": "6.79", "fees": "0.00", "side": "long", "symbol": "TEVA", "quantity": "100.0000", "exit_time": "2025-04-07T11:34:00.000Z", "commission": "2.21", "entry_time": "2025-04-07T11:31:00.000Z", "exit_price": "14.08", "entry_price": "13.99", "position_size": "1399.000000"}, {"id": "5a8a6701-def2-46dc-81ba-cbd81d43641a", "pnl": "46.22", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T11:49:00.000Z", "commission": "2.78", "entry_time": "2025-04-07T11:36:00.000Z", "exit_price": "54.79", "entry_price": "54.30", "position_size": "5430.000000"}, {"id": "8dee3216-7bec-499b-a6b1-8f4b90407d5c", "pnl": "13.22", "fees": "0.00", "side": "short", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T11:53:00.000Z", "commission": "2.78", "entry_time": "2025-04-07T11:53:00.000Z", "exit_price": "54.73", "entry_price": "54.89", "position_size": "5489.000000"}, {"id": "ca2141f1-ed0b-4b15-bcfd-67f1d5ce9afb", "pnl": "2.22", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T12:04:00.000Z", "commission": "2.78", "entry_time": "2025-04-07T12:02:00.000Z", "exit_price": "54.42", "entry_price": "54.37", "position_size": "5437.000000"}, {"id": "cf02fe9b-5e4b-4237-9bb1-57a8a1d6c85d", "pnl": "90.97", "fees": "0.00", "side": "long", "symbol": "MESA", "quantity": "3500.0000", "exit_time": "2025-04-07T12:10:00.000Z", "commission": "44.58", "entry_time": "2025-04-07T12:04:00.000Z", "exit_price": "0.95", "entry_price": "0.91", "position_size": "3185.000000"}, {"id": "fbc846b9-e8c3-443f-ae14-b41ed2fc4608", "pnl": "12.22", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-07T12:18:00.000Z", "commission": "2.78", "entry_time": "2025-04-07T12:13:00.000Z", "exit_price": "55.24", "entry_price": "55.09", "position_size": "5509.000000"}], "winStreakStartDate": "2025-04-07T11:31:00.000Z", "outcomeTradeDetails": {"id": "67f88e91-80cf-40fd-b7ca-fc0547495314", "pnl": "-302.57", "fees": "0.00", "side": "long", "symbol": "AREB", "quantity": "200.0000", "exit_time": "2025-04-07T12:21:00.000Z", "commission": "4.33", "entry_time": "2025-04-07T12:19:00.000Z", "exit_price": "16.50", "entry_price": "17.99"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 637.68, "subsequentTradeResult": -302.57}, {"id": "1342e1ae-f736-40f2-b569-b6426da71b88", "severity": "high", "streakPnl": 41.26, "totalImpact": -39.77, "streakTrades": ["f478e991-8d68-4532-ac67-1cf8ec62ef05", "53f6a156-e9c4-4259-81eb-2197046d5e8b", "9c40614d-1977-43cc-866d-13ade35b7069", "9615d633-8f42-44f3-96d6-eaebc73eb3b4", "36839bce-0786-4b92-a3ad-b6fa4360a054"], "detectionDate": "2025-09-03T19:06:23.319Z", "outcomeStatus": "warning", "outcomeTradeId": "87dc3b27-f2cc-45b0-91a5-058e39f2dee6", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 5, "peakPositionSize": 5406, "winStreakEndDate": "2025-04-02T21:29:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "f478e991-8d68-4532-ac67-1cf8ec62ef05", "pnl": "27.71", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-02T21:10:00.000Z", "commission": "2.29", "entry_time": "2025-04-02T21:07:00.000Z", "exit_price": "40.10", "entry_price": "39.80", "position_size": "3980.000000"}, {"id": "53f6a156-e9c4-4259-81eb-2197046d5e8b", "pnl": "2.02", "fees": "0.00", "side": "short", "symbol": "03835L405", "quantity": "300.0000", "exit_time": "2025-04-02T21:19:00.000Z", "commission": "3.98", "entry_time": "2025-04-02T21:19:00.000Z", "exit_price": "2.43", "entry_price": "2.45", "position_size": "735.000000"}, {"id": "9c40614d-1977-43cc-866d-13ade35b7069", "pnl": "2.02", "fees": "0.00", "side": "long", "symbol": "03835L405", "quantity": "300.0000", "exit_time": "2025-04-02T21:20:00.000Z", "commission": "3.98", "entry_time": "2025-04-02T21:20:00.000Z", "exit_price": "2.62", "entry_price": "2.60", "position_size": "780.000000"}, {"id": "9615d633-8f42-44f3-96d6-eaebc73eb3b4", "pnl": "1.25", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-02T21:24:00.000Z", "commission": "2.78", "entry_time": "2025-04-02T21:23:00.000Z", "exit_price": "54.10", "entry_price": "54.06", "position_size": "5406.000000"}, {"id": "36839bce-0786-4b92-a3ad-b6fa4360a054", "pnl": "8.26", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-02T21:29:00.000Z", "commission": "2.74", "entry_time": "2025-04-02T21:27:00.000Z", "exit_price": "40.41", "entry_price": "40.30", "position_size": "4030.000000"}], "winStreakStartDate": "2025-04-02T21:07:00.000Z", "outcomeTradeDetails": {"id": "87dc3b27-f2cc-45b0-91a5-058e39f2dee6", "pnl": "-39.77", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-03T10:14:00.000Z", "commission": "2.77", "entry_time": "2025-04-03T10:12:00.000Z", "exit_price": "53.14", "entry_price": "53.51"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 623.89, "subsequentTradeResult": -39.77}, {"id": "07a1932b-810f-4ce5-be36-661f25769817", "severity": "high", "streakPnl": 167.75, "totalImpact": -38.32, "streakTrades": ["3769c3e8-92c6-4f1b-95ed-21f5165bb21b", "1bbe564d-0de2-41e7-8611-87db9e8146f7", "cbb37db1-2e27-48b8-8983-4864192ef4b0", "c94f6bfc-07f9-443f-b82e-e5f4c18cd03b", "893477c4-e598-41d8-99bf-bb5eabd07f98"], "detectionDate": "2025-09-03T19:06:23.317Z", "outcomeStatus": "warning", "outcomeTradeId": "9d03db8e-f1df-4cdc-bad0-1078ed53ba98", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 5, "peakPositionSize": 5491, "winStreakEndDate": "2025-04-02T20:52:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "3769c3e8-92c6-4f1b-95ed-21f5165bb21b", "pnl": "37.77", "fees": "0.00", "side": "short", "symbol": "PENG", "quantity": "100.0000", "exit_time": "2025-04-02T20:19:00.000Z", "commission": "2.23", "entry_time": "2025-04-02T20:09:00.000Z", "exit_price": "19.51", "entry_price": "19.91", "position_size": "1991.000000"}, {"id": "1bbe564d-0de2-41e7-8611-87db9e8146f7", "pnl": "72.26", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-02T20:38:00.000Z", "commission": "2.74", "entry_time": "2025-04-02T20:36:00.000Z", "exit_price": "39.86", "entry_price": "39.11", "position_size": "3911.000000"}, {"id": "cbb37db1-2e27-48b8-8983-4864192ef4b0", "pnl": "36.26", "fees": "0.00", "side": "long", "symbol": "SQQQ", "quantity": "100.0000", "exit_time": "2025-04-02T20:42:00.000Z", "commission": "2.74", "entry_time": "2025-04-02T20:40:00.000Z", "exit_price": "40.08", "entry_price": "39.69", "position_size": "3969.000000"}, {"id": "c94f6bfc-07f9-443f-b82e-e5f4c18cd03b", "pnl": "11.24", "fees": "0.00", "side": "short", "symbol": "03835L405", "quantity": "300.0000", "exit_time": "2025-04-02T20:44:00.000Z", "commission": "3.97", "entry_time": "2025-04-02T20:44:00.000Z", "exit_price": "1.98", "entry_price": "2.03", "position_size": "609.000000"}, {"id": "893477c4-e598-41d8-99bf-bb5eabd07f98", "pnl": "10.22", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "100.0000", "exit_time": "2025-04-02T20:52:00.000Z", "commission": "2.78", "entry_time": "2025-04-02T20:51:00.000Z", "exit_price": "55.04", "entry_price": "54.91", "position_size": "5491.000000"}], "winStreakStartDate": "2025-04-02T20:09:00.000Z", "outcomeTradeDetails": {"id": "9d03db8e-f1df-4cdc-bad0-1078ed53ba98", "pnl": "-38.32", "fees": "0.00", "side": "long", "symbol": "TQQQ", "quantity": "150.0000", "exit_time": "2025-04-02T21:07:00.000Z", "commission": "4.15", "entry_time": "2025-04-02T20:57:00.000Z", "exit_price": "54.76", "entry_price": "54.99"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 635.27, "subsequentTradeResult": -38.32}, {"id": "61e9e722-ac52-4541-8937-20ad0b114afe", "severity": "high", "streakPnl": 385.22, "totalImpact": -16.81, "streakTrades": ["80b7c5dd-3942-4d42-a5c4-161cb9a7bbb3", "24392d48-c56a-49ec-9670-d76c9fd42fdf", "c0a4ba2d-3dce-4b52-a215-02f2838b4fd6", "31f6bc86-a598-49ae-911b-230a978a5044", "db3eff94-4ae7-4076-89e3-97107e905188"], "detectionDate": "2025-09-03T19:06:23.317Z", "outcomeStatus": "warning", "outcomeTradeId": "4f173dc8-a4ce-4042-8280-b237fba06d50", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 5, "peakPositionSize": 9060, "winStreakEndDate": "2025-04-01T16:46:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "80b7c5dd-3942-4d42-a5c4-161cb9a7bbb3", "pnl": "11.74", "fees": "0.00", "side": "long", "symbol": "MLGO", "quantity": "100.0000", "exit_time": "2025-04-01T12:35:00.000Z", "commission": "2.26", "entry_time": "2025-04-01T12:35:00.000Z", "exit_price": "31.05", "entry_price": "30.91", "position_size": "3091.000000"}, {"id": "24392d48-c56a-49ec-9670-d76c9fd42fdf", "pnl": "13.95", "fees": "0.00", "side": "long", "symbol": "MLGO", "quantity": "100.0000", "exit_time": "2025-04-01T12:58:00.000Z", "commission": "2.25", "entry_time": "2025-04-01T12:58:00.000Z", "exit_price": "30.45", "entry_price": "30.29", "position_size": "3029.000000"}, {"id": "c0a4ba2d-3dce-4b52-a215-02f2838b4fd6", "pnl": "225.76", "fees": "0.00", "side": "long", "symbol": "NMAX", "quantity": "50.0000", "exit_time": "2025-04-01T15:01:00.000Z", "commission": "3.24", "entry_time": "2025-04-01T14:58:00.000Z", "exit_price": "147.45", "entry_price": "142.87", "position_size": "7143.500000"}, {"id": "31f6bc86-a598-49ae-911b-230a978a5044", "pnl": "15.32", "fees": "0.00", "side": "long", "symbol": "CSAI", "quantity": "300.0000", "exit_time": "2025-04-01T15:13:00.000Z", "commission": "2.68", "entry_time": "2025-04-01T15:13:00.000Z", "exit_price": "8.41", "entry_price": "8.35", "position_size": "2505.000000"}, {"id": "db3eff94-4ae7-4076-89e3-97107e905188", "pnl": "118.45", "fees": "0.00", "side": "long", "symbol": "CSAI", "quantity": "1000.0000", "exit_time": "2025-04-01T16:46:00.000Z", "commission": "14.08", "entry_time": "2025-04-01T16:39:00.000Z", "exit_price": "9.19", "entry_price": "9.06", "position_size": "9060.000000"}], "winStreakStartDate": "2025-04-01T12:35:00.000Z", "outcomeTradeDetails": {"id": "4f173dc8-a4ce-4042-8280-b237fba06d50", "pnl": "-16.81", "fees": "0.00", "side": "long", "symbol": "CSAI", "quantity": "300.0000", "exit_time": "2025-04-01T16:53:00.000Z", "commission": "2.68", "entry_time": "2025-04-01T16:51:00.000Z", "exit_price": "9.33", "entry_price": "9.38"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 1113.18, "subsequentTradeResult": -16.81}, {"id": "7ed1f3d3-1bcb-4267-9c14-7fbb5bbf763c", "severity": "high", "streakPnl": 88.14, "totalImpact": -15.97, "streakTrades": ["5a7fc032-de9f-4665-9d33-c1c1e484b839", "51779a0f-7d6a-4a09-b86a-5dde1f4f5bdf", "e679892b-c45a-46cb-88bb-c746c357361a", "eb58f21d-dd3f-4c28-b57d-a3be3d73ea3d"], "detectionDate": "2025-09-03T19:06:23.316Z", "outcomeStatus": "warning", "outcomeTradeId": "df78b0d6-c343-439e-ad78-c2fd25db6cf1", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 4, "peakPositionSize": 3198, "winStreakEndDate": "2025-03-28T20:31:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "5a7fc032-de9f-4665-9d33-c1c1e484b839", "pnl": "22.13", "fees": "0.00", "side": "long", "symbol": "MYSZ", "quantity": "600.0000", "exit_time": "2025-03-28T15:26:00.000Z", "commission": "7.93", "entry_time": "2025-03-28T15:23:00.000Z", "exit_price": "1.68", "entry_price": "1.63", "position_size": "978.000000"}, {"id": "51779a0f-7d6a-4a09-b86a-5dde1f4f5bdf", "pnl": "29.62", "fees": "0.00", "side": "long", "symbol": "PRTG", "quantity": "300.0000", "exit_time": "2025-03-28T15:53:00.000Z", "commission": "4.40", "entry_time": "2025-03-28T15:49:00.000Z", "exit_price": "10.26", "entry_price": "10.14", "position_size": "3042.000000"}, {"id": "e679892b-c45a-46cb-88bb-c746c357361a", "pnl": "25.36", "fees": "0.00", "side": "long", "symbol": "PRTG", "quantity": "300.0000", "exit_time": "2025-03-28T16:28:00.000Z", "commission": "2.69", "entry_time": "2025-03-28T16:27:00.000Z", "exit_price": "10.75", "entry_price": "10.66", "position_size": "3198.000000"}, {"id": "eb58f21d-dd3f-4c28-b57d-a3be3d73ea3d", "pnl": "11.03", "fees": "0.00", "side": "long", "symbol": "MYSZ", "quantity": "300.0000", "exit_time": "2025-03-28T20:31:00.000Z", "commission": "3.97", "entry_time": "2025-03-28T20:29:00.000Z", "exit_price": "2.08", "entry_price": "2.03", "position_size": "609.000000"}], "winStreakStartDate": "2025-03-28T15:23:00.000Z", "outcomeTradeDetails": {"id": "df78b0d6-c343-439e-ad78-c2fd25db6cf1", "pnl": "-15.97", "fees": "0.00", "side": "long", "symbol": "CTOR", "quantity": "300.0000", "exit_time": "2025-03-31T11:00:00.000Z", "commission": "3.97", "entry_time": "2025-03-31T10:59:00.000Z", "exit_price": "1.24", "entry_price": "1.28"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 328.23, "subsequentTradeResult": -15.97}, {"id": "6ef2b00c-ca38-4b37-b833-b39d3ae65e76", "severity": "high", "streakPnl": 2850.43, "totalImpact": -104.26, "streakTrades": ["eb3a56e1-d691-47a8-bd70-8d6534dad66c", "ebbe6d1c-d248-4b08-beb8-e8f1792a7024", "e8157493-4baa-4700-8bb6-0e026a9c88b0", "5a23f663-9627-4d03-8366-6a9e6b6a1a7e", "a0f1a3e3-4515-426c-83e5-727426fcf348", "3ff6888d-fc3c-49ee-8a72-9e7747092c02", "a3080211-b8ca-432b-b776-d65e0c83fc7b", "3724f756-08a8-4fd9-8713-b66c7b99e3f9"], "detectionDate": "2025-09-03T19:06:23.315Z", "outcomeStatus": "warning", "outcomeTradeId": "893f9e38-5a18-4c96-a6a8-63b11c177704", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 8, "peakPositionSize": 11385, "winStreakEndDate": "2025-03-28T11:19:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "eb3a56e1-d691-47a8-bd70-8d6534dad66c", "pnl": "5.01", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-27T12:51:00.000Z", "commission": "3.99", "entry_time": "2025-03-27T12:51:00.000Z", "exit_price": "4.62", "entry_price": "4.59", "position_size": "1377.000000"}, {"id": "ebbe6d1c-d248-4b08-beb8-e8f1792a7024", "pnl": "8.03", "fees": "0.00", "side": "long", "symbol": "DRMA", "quantity": "300.0000", "exit_time": "2025-03-27T13:09:00.000Z", "commission": "3.97", "entry_time": "2025-03-27T13:08:00.000Z", "exit_price": "2.23", "entry_price": "2.19", "position_size": "657.000000"}, {"id": "e8157493-4baa-4700-8bb6-0e026a9c88b0", "pnl": "2520.23", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "1900.0000", "exit_time": "2025-03-27T17:45:00.000Z", "commission": "17.44", "entry_time": "2025-03-27T13:34:00.000Z", "exit_price": "5.79", "entry_price": "4.45", "position_size": "8455.000000"}, {"id": "5a23f663-9627-4d03-8366-6a9e6b6a1a7e", "pnl": "3.18", "fees": "0.00", "side": "long", "symbol": "G0447T100", "quantity": "300.0000", "exit_time": "2025-03-27T20:02:00.000Z", "commission": "3.84", "entry_time": "2025-03-27T20:02:00.000Z", "exit_price": "0.94", "entry_price": "0.92", "position_size": "276.000000"}, {"id": "a0f1a3e3-4515-426c-83e5-727426fcf348", "pnl": "2.03", "fees": "0.00", "side": "long", "symbol": "G0447T100", "quantity": "600.0000", "exit_time": "2025-03-27T20:10:00.000Z", "commission": "7.84", "entry_time": "2025-03-27T20:06:00.000Z", "exit_price": "0.99", "entry_price": "0.97", "position_size": "582.000000"}, {"id": "3ff6888d-fc3c-49ee-8a72-9e7747092c02", "pnl": "31.04", "fees": "0.00", "side": "long", "symbol": "PRTG", "quantity": "300.0000", "exit_time": "2025-03-28T10:49:00.000Z", "commission": "4.06", "entry_time": "2025-03-28T10:45:00.000Z", "exit_price": "10.31", "entry_price": "10.20", "position_size": "3060.000000"}, {"id": "a3080211-b8ca-432b-b776-d65e0c83fc7b", "pnl": "110.25", "fees": "0.00", "side": "long", "symbol": "PRTG", "quantity": "600.0000", "exit_time": "2025-03-28T10:59:00.000Z", "commission": "6.33", "entry_time": "2025-03-28T10:57:00.000Z", "exit_price": "11.91", "entry_price": "11.72", "position_size": "7032.000000"}, {"id": "3724f756-08a8-4fd9-8713-b66c7b99e3f9", "pnl": "170.66", "fees": "0.00", "side": "long", "symbol": "PRTG", "quantity": "900.0000", "exit_time": "2025-03-28T11:19:00.000Z", "commission": "8.14", "entry_time": "2025-03-28T11:14:00.000Z", "exit_price": "12.85", "entry_price": "12.65", "position_size": "11385.000000"}], "winStreakStartDate": "2025-03-27T12:51:00.000Z", "outcomeTradeDetails": {"id": "893f9e38-5a18-4c96-a6a8-63b11c177704", "pnl": "-104.26", "fees": "0.00", "side": "long", "symbol": "PRTG", "quantity": "300.0000", "exit_time": "2025-03-28T11:24:00.000Z", "commission": "4.06", "entry_time": "2025-03-28T11:22:00.000Z", "exit_price": "12.43", "entry_price": "12.76"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 1424.5, "subsequentTradeResult": -104.26}, {"id": "8b92d01b-3c26-4f95-a8af-bea5b2b76ff4", "severity": "high", "streakPnl": 1070.02, "totalImpact": -23.94, "streakTrades": ["afd288c2-a475-4a20-9ba3-50dd485b76e6", "4f6d58b9-0d6f-4e9c-9a66-6f3865d84d5f", "68b3b8ab-9f1d-45c1-abc0-bf8035555e63", "42ae21e5-2632-47f2-a457-bbdd84f50661", "5bb82821-e7af-479f-83ed-21fab5df4442", "458a8613-093e-4093-8c00-5821564d75ed", "ee94a294-f5c0-426f-b5a1-3693263cc4bc", "3f84ae58-8e63-4a78-9727-db06233be38e", "b0ff6a90-c803-4cd6-b997-ef1f07b4ce1c", "2dbd6b41-c903-493d-9590-44436552b52f", "ff0b4bf3-137a-4707-a62a-85c9b4eff528", "56c75d2c-a0ca-4294-a6c7-8705a77b273f", "162c256f-d36b-4981-a325-cc91ab4576a9", "71d57a00-d1c1-47ea-8a88-1206e84e169c", "0f0eeef8-e574-412b-b88d-ab4c40a9d74d"], "detectionDate": "2025-09-03T19:06:23.311Z", "outcomeStatus": "warning", "outcomeTradeId": "03ea71e1-32cc-4194-953f-f70c51ca2a1c", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 15, "peakPositionSize": 4068, "winStreakEndDate": "2025-03-26T13:33:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "afd288c2-a475-4a20-9ba3-50dd485b76e6", "pnl": "265.23", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "900.0000", "exit_time": "2025-03-26T11:21:00.000Z", "commission": "11.94", "entry_time": "2025-03-26T11:19:00.000Z", "exit_price": "2.79", "entry_price": "2.48", "position_size": "2232.000000"}, {"id": "4f6d58b9-0d6f-4e9c-9a66-6f3865d84d5f", "pnl": "82.04", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "600.0000", "exit_time": "2025-03-26T11:22:00.000Z", "commission": "7.96", "entry_time": "2025-03-26T11:21:00.000Z", "exit_price": "3.05", "entry_price": "2.89", "position_size": "1734.000000"}, {"id": "68b3b8ab-9f1d-45c1-abc0-bf8035555e63", "pnl": "92.57", "fees": "0.00", "side": "short", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T11:23:00.000Z", "commission": "4.93", "entry_time": "2025-03-26T11:23:00.000Z", "exit_price": "3.25", "entry_price": "3.58", "position_size": "1074.000000"}, {"id": "42ae21e5-2632-47f2-a457-bbdd84f50661", "pnl": "115.70", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "900.0000", "exit_time": "2025-03-26T11:25:00.000Z", "commission": "11.53", "entry_time": "2025-03-26T11:24:00.000Z", "exit_price": "4.10", "entry_price": "3.96", "position_size": "3564.000000"}, {"id": "5bb82821-e7af-479f-83ed-21fab5df4442", "pnl": "36.00", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T11:26:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T11:26:00.000Z", "exit_price": "4.06", "entry_price": "3.93", "position_size": "1179.000000"}, {"id": "458a8613-093e-4093-8c00-5821564d75ed", "pnl": "22.53", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "600.0000", "exit_time": "2025-03-26T11:29:00.000Z", "commission": "7.98", "entry_time": "2025-03-26T11:27:00.000Z", "exit_price": "3.80", "entry_price": "3.75", "position_size": "2250.000000"}, {"id": "ee94a294-f5c0-426f-b5a1-3693263cc4bc", "pnl": "53.00", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T11:31:00.000Z", "commission": "4.00", "entry_time": "2025-03-26T11:30:00.000Z", "exit_price": "4.09", "entry_price": "3.90", "position_size": "1170.000000"}, {"id": "3f84ae58-8e63-4a78-9727-db06233be38e", "pnl": "14.02", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T11:47:00.000Z", "commission": "3.98", "entry_time": "2025-03-26T11:46:00.000Z", "exit_price": "3.51", "entry_price": "3.45", "position_size": "1035.000000"}, {"id": "b0ff6a90-c803-4cd6-b997-ef1f07b4ce1c", "pnl": "18.28", "fees": "0.00", "side": "long", "symbol": "MLGO", "quantity": "300.0000", "exit_time": "2025-03-26T12:08:00.000Z", "commission": "2.72", "entry_time": "2025-03-26T12:07:00.000Z", "exit_price": "13.63", "entry_price": "13.56", "position_size": "4068.000000"}, {"id": "2dbd6b41-c903-493d-9590-44436552b52f", "pnl": "17.01", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T12:33:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T12:32:00.000Z", "exit_price": "4.25", "entry_price": "4.18", "position_size": "1254.000000"}, {"id": "ff0b4bf3-137a-4707-a62a-85c9b4eff528", "pnl": "20.01", "fees": "0.00", "side": "short", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T13:22:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T13:22:00.000Z", "exit_price": "4.17", "entry_price": "4.25", "position_size": "1275.000000"}, {"id": "56c75d2c-a0ca-4294-a6c7-8705a77b273f", "pnl": "35.02", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-26T13:25:00.000Z", "commission": "3.98", "entry_time": "2025-03-26T13:25:00.000Z", "exit_price": "2.69", "entry_price": "2.56", "position_size": "768.000000"}, {"id": "162c256f-d36b-4981-a325-cc91ab4576a9", "pnl": "259.62", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "900.0000", "exit_time": "2025-03-26T13:30:00.000Z", "commission": "11.94", "entry_time": "2025-03-26T13:26:00.000Z", "exit_price": "3.19", "entry_price": "2.89", "position_size": "2601.000000"}, {"id": "71d57a00-d1c1-47ea-8a88-1206e84e169c", "pnl": "7.93", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "600.0000", "exit_time": "2025-03-26T13:31:00.000Z", "commission": "7.97", "entry_time": "2025-03-26T13:30:00.000Z", "exit_price": "4.07", "entry_price": "4.04", "position_size": "2424.000000"}, {"id": "0f0eeef8-e574-412b-b88d-ab4c40a9d74d", "pnl": "31.06", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-26T13:33:00.000Z", "commission": "3.98", "entry_time": "2025-03-26T13:32:00.000Z", "exit_price": "3.48", "entry_price": "3.36", "position_size": "1008.000000"}], "winStreakStartDate": "2025-03-26T11:19:00.000Z", "outcomeTradeDetails": {"id": "03ea71e1-32cc-4194-953f-f70c51ca2a1c", "pnl": "-23.94", "fees": "0.00", "side": "long", "symbol": "OSRH", "quantity": "300.0000", "exit_time": "2025-03-26T13:37:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T13:35:00.000Z", "exit_price": "3.60", "entry_price": "3.67"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 444.72, "subsequentTradeResult": -23.94}, {"id": "5d506d11-18d8-41e7-bb86-85435a277b5a", "severity": "high", "streakPnl": 1289.15, "totalImpact": -39.99, "streakTrades": ["3797bb8f-a239-4e4b-bac7-1930e54220ae", "c7353302-7632-417e-8aa5-d6acd7ff7c74", "8a09a033-4b3c-4212-96b4-b20551f4233f", "b57497ac-0911-4293-aca1-4f2161935162", "c8da70f1-c6fa-41da-b8fe-01b664805c96", "62a5eb7e-c4b4-4bb4-b263-ff699fc35b78", "5ff3ee7e-baf5-4d11-a27c-dab6fb319a35", "e54d2b71-d12e-46ac-b5f7-ce18b6ddd29f", "3ef8d738-cd00-4c3d-b5db-c70730d1b425", "3381ce66-f1cd-44a2-a027-722b502ea98b", "f7552c7a-62c0-4c7c-952f-766793c55bf7", "6d856ffb-e185-4262-8ae2-185e03117cb6", "8b100660-4480-4f09-8c5f-1703166588d6", "d269f0e5-73e8-4336-8e04-ddca7bcdf6cd", "10686b19-3eb2-4961-a1fd-8c10253ee8e3", "b81daf3d-6a4e-4907-8adb-770680affe76", "9dd7b3d9-306b-444f-b015-a1fb35b425d3", "1f978e2f-8857-40ff-af85-6923bf256db4", "fedda064-e9a8-4c19-89c3-a6e08d4ca1fe"], "detectionDate": "2025-09-03T19:06:23.309Z", "outcomeStatus": "warning", "outcomeTradeId": "a89a7148-ccba-4dce-a29c-8a351d95c3fd", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 19, "peakPositionSize": 15903, "winStreakEndDate": "2025-03-26T11:15:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "3797bb8f-a239-4e4b-bac7-1930e54220ae", "pnl": "23.36", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "600.0000", "exit_time": "2025-03-24T20:30:00.000Z", "commission": "5.65", "entry_time": "2025-03-24T20:27:00.000Z", "exit_price": "2.90", "entry_price": "2.85", "position_size": "1710.000000"}, {"id": "c7353302-7632-417e-8aa5-d6acd7ff7c74", "pnl": "60.26", "fees": "0.00", "side": "long", "symbol": "MLGO", "quantity": "300.0000", "exit_time": "2025-03-24T20:32:00.000Z", "commission": "2.74", "entry_time": "2025-03-24T20:32:00.000Z", "exit_price": "16.16", "entry_price": "15.95", "position_size": "4785.000000"}, {"id": "8a09a033-4b3c-4212-96b4-b20551f4233f", "pnl": "4.22", "fees": "0.00", "side": "long", "symbol": "MLGO", "quantity": "300.0000", "exit_time": "2025-03-24T20:36:00.000Z", "commission": "4.71", "entry_time": "2025-03-24T20:34:00.000Z", "exit_price": "16.25", "entry_price": "16.22", "position_size": "4866.000000"}, {"id": "b57497ac-0911-4293-aca1-4f2161935162", "pnl": "17.02", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-24T20:59:00.000Z", "commission": "3.98", "entry_time": "2025-03-24T20:59:00.000Z", "exit_price": "3.27", "entry_price": "3.20", "position_size": "960.000000"}, {"id": "c8da70f1-c6fa-41da-b8fe-01b664805c96", "pnl": "35.52", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "1600.0000", "exit_time": "2025-03-24T21:07:00.000Z", "commission": "13.88", "entry_time": "2025-03-24T21:02:00.000Z", "exit_price": "3.40", "entry_price": "3.37", "position_size": "5392.000000"}, {"id": "62a5eb7e-c4b4-4bb4-b263-ff699fc35b78", "pnl": "485.84", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "1600.0000", "exit_time": "2025-03-25T11:00:00.000Z", "commission": "21.40", "entry_time": "2025-03-25T10:52:00.000Z", "exit_price": "3.31", "entry_price": "3.00", "position_size": "4800.000000"}, {"id": "5ff3ee7e-baf5-4d11-a27c-dab6fb319a35", "pnl": "91.23", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "3000.0000", "exit_time": "2025-03-25T11:11:00.000Z", "commission": "41.77", "entry_time": "2025-03-25T11:01:00.000Z", "exit_price": "3.64", "entry_price": "3.60", "position_size": "10800.000000"}, {"id": "e54d2b71-d12e-46ac-b5f7-ce18b6ddd29f", "pnl": "47.00", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "300.0000", "exit_time": "2025-03-25T11:19:00.000Z", "commission": "4.00", "entry_time": "2025-03-25T11:18:00.000Z", "exit_price": "3.71", "entry_price": "3.54", "position_size": "1062.000000"}, {"id": "3ef8d738-cd00-4c3d-b5db-c70730d1b425", "pnl": "11.00", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "300.0000", "exit_time": "2025-03-25T11:22:00.000Z", "commission": "4.00", "entry_time": "2025-03-25T11:22:00.000Z", "exit_price": "3.70", "entry_price": "3.65", "position_size": "1095.000000"}, {"id": "3381ce66-f1cd-44a2-a027-722b502ea98b", "pnl": "21.05", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "900.0000", "exit_time": "2025-03-25T11:25:00.000Z", "commission": "11.95", "entry_time": "2025-03-25T11:23:00.000Z", "exit_price": "3.99", "entry_price": "3.95", "position_size": "3555.000000"}, {"id": "f7552c7a-62c0-4c7c-952f-766793c55bf7", "pnl": "103.99", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "300.0000", "exit_time": "2025-03-25T11:28:00.000Z", "commission": "4.01", "entry_time": "2025-03-25T11:28:00.000Z", "exit_price": "4.90", "entry_price": "4.54", "position_size": "1362.000000"}, {"id": "6d856ffb-e185-4262-8ae2-185e03117cb6", "pnl": "203.08", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "3100.0000", "exit_time": "2025-03-25T13:33:00.000Z", "commission": "27.92", "entry_time": "2025-03-25T11:29:00.000Z", "exit_price": "5.21", "entry_price": "5.13", "position_size": "15903.000000"}, {"id": "8b100660-4480-4f09-8c5f-1703166588d6", "pnl": "10.51", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "600.0000", "exit_time": "2025-03-25T14:05:00.000Z", "commission": "7.97", "entry_time": "2025-03-25T14:00:00.000Z", "exit_price": "4.11", "entry_price": "4.08", "position_size": "2448.000000"}, {"id": "d269f0e5-73e8-4336-8e04-ddca7bcdf6cd", "pnl": "38.44", "fees": "0.00", "side": "long", "symbol": "DATS", "quantity": "300.0000", "exit_time": "2025-03-25T14:23:00.000Z", "commission": "4.01", "entry_time": "2025-03-25T14:22:00.000Z", "exit_price": "5.25", "entry_price": "5.11", "position_size": "1533.000000"}, {"id": "10686b19-3eb2-4961-a1fd-8c10253ee8e3", "pnl": "17.01", "fees": "0.00", "side": "long", "symbol": "BLNE", "quantity": "300.0000", "exit_time": "2025-03-26T10:50:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T10:50:00.000Z", "exit_price": "3.12", "entry_price": "3.05", "position_size": "915.000000"}, {"id": "b81daf3d-6a4e-4907-8adb-770680affe76", "pnl": "32.01", "fees": "0.00", "side": "short", "symbol": "BLNE", "quantity": "300.0000", "exit_time": "2025-03-26T10:54:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T10:54:00.000Z", "exit_price": "3.59", "entry_price": "3.71", "position_size": "1113.000000"}, {"id": "9dd7b3d9-306b-444f-b015-a1fb35b425d3", "pnl": "2.01", "fees": "0.00", "side": "long", "symbol": "BLNE", "quantity": "300.0000", "exit_time": "2025-03-26T11:00:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T11:00:00.000Z", "exit_price": "4.18", "entry_price": "4.16", "position_size": "1248.000000"}, {"id": "1f978e2f-8857-40ff-af85-6923bf256db4", "pnl": "4.54", "fees": "0.00", "side": "long", "symbol": "LPTX", "quantity": "300.0000", "exit_time": "2025-03-26T11:04:00.000Z", "commission": "3.96", "entry_time": "2025-03-26T11:01:00.000Z", "exit_price": "0.48", "entry_price": "0.45", "position_size": "135.000000"}, {"id": "fedda064-e9a8-4c19-89c3-a6e08d4ca1fe", "pnl": "81.06", "fees": "0.00", "side": "long", "symbol": "BLNE", "quantity": "500.0000", "exit_time": "2025-03-26T11:15:00.000Z", "commission": "7.94", "entry_time": "2025-03-26T11:12:00.000Z", "exit_price": "4.11", "entry_price": "3.93", "position_size": "1965.000000"}], "winStreakStartDate": "2025-03-24T20:27:00.000Z", "outcomeTradeDetails": {"id": "a89a7148-ccba-4dce-a29c-8a351d95c3fd", "pnl": "-39.99", "fees": "0.00", "side": "long", "symbol": "BLNE", "quantity": "300.0000", "exit_time": "2025-03-26T11:18:00.000Z", "commission": "3.99", "entry_time": "2025-03-26T11:17:00.000Z", "exit_price": "4.02", "entry_price": "4.14"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 2029.49, "subsequentTradeResult": -39.99}, {"id": "a59bc481-f117-4a6c-b618-8e56d28096df", "severity": "high", "streakPnl": 365.93, "totalImpact": -46.83, "streakTrades": ["d76d6510-e403-4968-9629-a22390fa7973", "e39104e0-c788-4fe8-9e49-a9440f8272bb", "e26b552a-78a3-4187-b3e7-425af684c9be", "2d660ff0-e017-4d81-bdf2-f13d52a38062", "a7cacfe2-3999-46f9-951e-e43df5950647", "2d6d7520-b1c9-45e4-9bf5-c4634cf70586", "191cd412-4fce-4455-bc20-d6e8e6e1fe03", "16ffb4e2-03be-4ba1-9f8f-7cfc0b69e8ca"], "detectionDate": "2025-09-03T19:06:23.308Z", "outcomeStatus": "warning", "outcomeTradeId": "d112b324-2481-4089-a815-27716c2f7b67", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 8, "peakPositionSize": 15502, "winStreakEndDate": "2025-03-24T20:10:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "d76d6510-e403-4968-9629-a22390fa7973", "pnl": "185.22", "fees": "0.00", "side": "short", "symbol": "GLTO", "quantity": "2300.0000", "exit_time": "2025-03-24T20:46:00.000Z", "commission": "40.43", "entry_time": "2025-03-24T15:05:00.000Z", "exit_price": "6.64", "entry_price": "6.74", "position_size": "15502.000000"}, {"id": "e39104e0-c788-4fe8-9e49-a9440f8272bb", "pnl": "35.48", "fees": "0.00", "side": "short", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-24T18:00:00.000Z", "commission": "3.97", "entry_time": "2025-03-24T18:00:00.000Z", "exit_price": "1.84", "entry_price": "1.97", "position_size": "591.000000"}, {"id": "e26b552a-78a3-4187-b3e7-425af684c9be", "pnl": "41.92", "fees": "0.00", "side": "short", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-24T18:14:00.000Z", "commission": "3.98", "entry_time": "2025-03-24T18:14:00.000Z", "exit_price": "2.96", "entry_price": "3.11", "position_size": "933.000000"}, {"id": "2d660ff0-e017-4d81-bdf2-f13d52a38062", "pnl": "11.52", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-24T18:30:00.000Z", "commission": "3.99", "entry_time": "2025-03-24T18:30:00.000Z", "exit_price": "3.66", "entry_price": "3.61", "position_size": "1083.000000"}, {"id": "a7cacfe2-3999-46f9-951e-e43df5950647", "pnl": "29.31", "fees": "0.00", "side": "short", "symbol": "VVPR", "quantity": "300.0000", "exit_time": "2025-03-24T18:34:00.000Z", "commission": "3.99", "entry_time": "2025-03-24T18:34:00.000Z", "exit_price": "3.66", "entry_price": "3.77", "position_size": "1131.000000"}, {"id": "2d6d7520-b1c9-45e4-9bf5-c4634cf70586", "pnl": "7.77", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "600.0000", "exit_time": "2025-03-24T18:39:00.000Z", "commission": "7.98", "entry_time": "2025-03-24T18:39:00.000Z", "exit_price": "4.07", "entry_price": "4.04", "position_size": "2424.000000"}, {"id": "191cd412-4fce-4455-bc20-d6e8e6e1fe03", "pnl": "20.64", "fees": "0.00", "side": "long", "symbol": "MLGO", "quantity": "100.0000", "exit_time": "2025-03-24T19:26:00.000Z", "commission": "2.66", "entry_time": "2025-03-24T19:25:00.000Z", "exit_price": "12.91", "entry_price": "12.68", "position_size": "1268.000000"}, {"id": "16ffb4e2-03be-4ba1-9f8f-7cfc0b69e8ca", "pnl": "34.07", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "600.0000", "exit_time": "2025-03-24T20:10:00.000Z", "commission": "7.93", "entry_time": "2025-03-24T20:08:00.000Z", "exit_price": "1.53", "entry_price": "1.46", "position_size": "876.000000"}], "winStreakStartDate": "2025-03-24T15:05:00.000Z", "outcomeTradeDetails": {"id": "d112b324-2481-4089-a815-27716c2f7b67", "pnl": "-46.83", "fees": "0.00", "side": "long", "symbol": "TNON", "quantity": "800.0000", "exit_time": "2025-03-24T20:17:00.000Z", "commission": "11.87", "entry_time": "2025-03-24T20:12:00.000Z", "exit_price": "1.59", "entry_price": "1.63"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 1975.79, "subsequentTradeResult": -46.83}, {"id": "b56f22a7-7e93-4e12-beb1-c43a29635cfd", "severity": "high", "streakPnl": 1333.89, "totalImpact": -287.51, "streakTrades": ["45fd6339-4acb-4717-8ec2-9208726517bc", "dcf92b7e-ac88-4266-a916-f8cbeef9b543", "1987808a-98ad-4c49-ba78-af231471c094", "77aface7-4c08-4976-8140-2c25c7daf8a6", "f8ace3aa-7e2e-4d3b-9a1f-c68c73ffb23c", "f2bb1b0a-8319-421f-82f9-47549b502a34", "caede5e8-1ac2-44f2-97ce-e278a62a49fd", "0b461763-0a36-4b57-a649-1763e4e516d4", "d076869e-2043-41eb-b04d-c27e2d677f80", "49d62247-bb6f-4188-b486-b9c601f9c9fc", "111077b9-37e7-4228-9f23-e979dec90afc", "196e98e2-c078-493c-bb3f-d8503abbe88d", "fb53f90a-d57d-4940-abb1-dedf3febb132", "950451ac-b358-4b1b-b151-ace6611a7530", "4af8f79a-e803-401e-998f-6a7c76fa5b9d"], "detectionDate": "2025-09-03T19:06:23.307Z", "outcomeStatus": "warning", "outcomeTradeId": "12571436-4f11-4390-89a5-df99ee53f826", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 15, "peakPositionSize": 8749, "winStreakEndDate": "2025-03-21T16:45:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "45fd6339-4acb-4717-8ec2-9208726517bc", "pnl": "25.14", "fees": "0.00", "side": "long", "symbol": "SCNX", "quantity": "600.0000", "exit_time": "2025-03-18T13:32:00.000Z", "commission": "7.95", "entry_time": "2025-03-18T13:31:00.000Z", "exit_price": "2.99", "entry_price": "2.94", "position_size": "1764.000000"}, {"id": "dcf92b7e-ac88-4266-a916-f8cbeef9b543", "pnl": "39.35", "fees": "0.00", "side": "long", "symbol": "INDP", "quantity": "1200.0000", "exit_time": "2025-03-18T13:44:00.000Z", "commission": "15.85", "entry_time": "2025-03-18T13:42:00.000Z", "exit_price": "1.42", "entry_price": "1.38", "position_size": "1656.000000"}, {"id": "1987808a-98ad-4c49-ba78-af231471c094", "pnl": "4.81", "fees": "0.00", "side": "short", "symbol": "ADTX", "quantity": "300.0000", "exit_time": "2025-03-18T13:47:00.000Z", "commission": "4.01", "entry_time": "2025-03-18T13:47:00.000Z", "exit_price": "6.62", "entry_price": "6.65", "position_size": "1995.000000"}, {"id": "77aface7-4c08-4976-8140-2c25c7daf8a6", "pnl": "66.04", "fees": "0.00", "side": "long", "symbol": "ADTX", "quantity": "600.0000", "exit_time": "2025-03-18T13:48:00.000Z", "commission": "8.03", "entry_time": "2025-03-18T13:48:00.000Z", "exit_price": "6.81", "entry_price": "6.69", "position_size": "4014.000000"}, {"id": "f8ace3aa-7e2e-4d3b-9a1f-c68c73ffb23c", "pnl": "16.83", "fees": "0.00", "side": "long", "symbol": "LAES", "quantity": "1000.0000", "exit_time": "2025-03-18T14:13:00.000Z", "commission": "13.92", "entry_time": "2025-03-18T14:02:00.000Z", "exit_price": "3.49", "entry_price": "3.46", "position_size": "3460.000000"}, {"id": "f2bb1b0a-8319-421f-82f9-47549b502a34", "pnl": "10.15", "fees": "0.00", "side": "long", "symbol": "89357L402", "quantity": "1000.0000", "exit_time": "2025-03-21T11:35:00.000Z", "commission": "13.69", "entry_time": "2025-03-21T11:09:00.000Z", "exit_price": "0.98", "entry_price": "0.96", "position_size": "960.000000"}, {"id": "caede5e8-1ac2-44f2-97ce-e278a62a49fd", "pnl": "42.93", "fees": "0.00", "side": "short", "symbol": "ELAB", "quantity": "300.0000", "exit_time": "2025-03-21T12:05:00.000Z", "commission": "4.02", "entry_time": "2025-03-21T12:05:00.000Z", "exit_price": "8.96", "entry_price": "9.12", "position_size": "2736.000000"}, {"id": "0b461763-0a36-4b57-a649-1763e4e516d4", "pnl": "29.88", "fees": "0.00", "side": "long", "symbol": "ELAB", "quantity": "300.0000", "exit_time": "2025-03-21T12:07:00.000Z", "commission": "3.12", "entry_time": "2025-03-21T12:07:00.000Z", "exit_price": "8.37", "entry_price": "8.26", "position_size": "2478.000000"}, {"id": "d076869e-2043-41eb-b04d-c27e2d677f80", "pnl": "4.16", "fees": "0.00", "side": "long", "symbol": "ELAB", "quantity": "600.0000", "exit_time": "2025-03-21T12:12:00.000Z", "commission": "6.70", "entry_time": "2025-03-21T12:08:00.000Z", "exit_price": "8.19", "entry_price": "8.17", "position_size": "4902.000000"}, {"id": "49d62247-bb6f-4188-b486-b9c601f9c9fc", "pnl": "191.80", "fees": "0.00", "side": "long", "symbol": "VVPR", "quantity": "3000.0000", "exit_time": "2025-03-21T13:37:00.000Z", "commission": "39.62", "entry_time": "2025-03-21T13:30:00.000Z", "exit_price": "1.38", "entry_price": "1.30", "position_size": "3900.000000"}, {"id": "111077b9-37e7-4228-9f23-e979dec90afc", "pnl": "31.57", "fees": "0.00", "side": "long", "symbol": "GLTO", "quantity": "600.0000", "exit_time": "2025-03-21T15:31:00.000Z", "commission": "8.03", "entry_time": "2025-03-21T15:30:00.000Z", "exit_price": "6.87", "entry_price": "6.80", "position_size": "4080.000000"}, {"id": "196e98e2-c078-493c-bb3f-d8503abbe88d", "pnl": "130.23", "fees": "0.00", "side": "short", "symbol": "GLTO", "quantity": "1000.0000", "exit_time": "2025-03-21T15:38:00.000Z", "commission": "11.87", "entry_time": "2025-03-21T15:37:00.000Z", "exit_price": "6.58", "entry_price": "6.72", "position_size": "6720.000000"}, {"id": "fb53f90a-d57d-4940-abb1-dedf3febb132", "pnl": "331.53", "fees": "0.00", "side": "short", "symbol": "GLTO", "quantity": "1300.0000", "exit_time": "2025-03-21T16:02:00.000Z", "commission": "13.47", "entry_time": "2025-03-21T15:52:00.000Z", "exit_price": "6.46", "entry_price": "6.73", "position_size": "8749.000000"}, {"id": "950451ac-b358-4b1b-b151-ace6611a7530", "pnl": "239.64", "fees": "0.00", "side": "short", "symbol": "GLTO", "quantity": "1000.0000", "exit_time": "2025-03-21T16:11:00.000Z", "commission": "10.36", "entry_time": "2025-03-21T16:09:00.000Z", "exit_price": "6.00", "entry_price": "6.25", "position_size": "6250.000000"}, {"id": "4af8f79a-e803-401e-998f-6a7c76fa5b9d", "pnl": "169.83", "fees": "0.00", "side": "short", "symbol": "GLTO", "quantity": "500.0000", "exit_time": "2025-03-21T16:45:00.000Z", "commission": "5.17", "entry_time": "2025-03-21T16:39:00.000Z", "exit_price": "5.55", "entry_price": "5.90", "position_size": "2950.000000"}], "winStreakStartDate": "2025-03-18T13:31:00.000Z", "outcomeTradeDetails": {"id": "12571436-4f11-4390-89a5-df99ee53f826", "pnl": "-287.51", "fees": "0.00", "side": "short", "symbol": "GLTO", "quantity": "1600.0000", "exit_time": "2025-03-21T23:50:00.000Z", "commission": "19.87", "entry_time": "2025-03-21T17:13:00.000Z", "exit_price": "5.98", "entry_price": "5.82"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 1071.53, "subsequentTradeResult": -287.51}, {"id": "485c5135-4a07-4bf3-a924-343bff4c1c99", "severity": "high", "streakPnl": 519.12, "totalImpact": -12.62, "streakTrades": ["aa289251-8d7d-43db-8e72-d917a9774fd7", "33051b0f-5286-4cbe-a6ad-30e05587b975", "998cf11c-e274-4131-ac1c-893d5692e5a1", "b4707007-0ee7-497b-befa-2c9d2e2d7f01", "daa0851c-6944-4444-8ea4-b5592641a76e"], "detectionDate": "2025-09-03T19:06:23.305Z", "outcomeStatus": "warning", "outcomeTradeId": "6bcf93a6-bda1-405f-9938-8148c0357d9c", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 5, "peakPositionSize": 9120, "winStreakEndDate": "2025-03-18T12:55:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "aa289251-8d7d-43db-8e72-d917a9774fd7", "pnl": "96.23", "fees": "0.00", "side": "long", "symbol": "SCNX", "quantity": "1200.0000", "exit_time": "2025-03-18T12:08:00.000Z", "commission": "15.91", "entry_time": "2025-03-18T12:06:00.000Z", "exit_price": "2.76", "entry_price": "2.66", "position_size": "3192.000000"}, {"id": "33051b0f-5286-4cbe-a6ad-30e05587b975", "pnl": "15.01", "fees": "0.00", "side": "long", "symbol": "SCNX", "quantity": "300.0000", "exit_time": "2025-03-18T12:14:00.000Z", "commission": "3.98", "entry_time": "2025-03-18T12:13:00.000Z", "exit_price": "3.00", "entry_price": "2.94", "position_size": "882.000000"}, {"id": "998cf11c-e274-4131-ac1c-893d5692e5a1", "pnl": "24.01", "fees": "0.00", "side": "short", "symbol": "SCNX", "quantity": "300.0000", "exit_time": "2025-03-18T12:15:00.000Z", "commission": "3.98", "entry_time": "2025-03-18T12:15:00.000Z", "exit_price": "3.21", "entry_price": "3.30", "position_size": "990.000000"}, {"id": "b4707007-0ee7-497b-befa-2c9d2e2d7f01", "pnl": "97.08", "fees": "0.00", "side": "long", "symbol": "SCNX", "quantity": "1200.0000", "exit_time": "2025-03-18T12:23:00.000Z", "commission": "15.93", "entry_time": "2025-03-18T12:16:00.000Z", "exit_price": "3.32", "entry_price": "3.23", "position_size": "3876.000000"}, {"id": "daa0851c-6944-4444-8ea4-b5592641a76e", "pnl": "286.79", "fees": "0.00", "side": "long", "symbol": "SCNX", "quantity": "3000.0000", "exit_time": "2025-03-18T12:55:00.000Z", "commission": "28.21", "entry_time": "2025-03-18T12:28:00.000Z", "exit_price": "3.14", "entry_price": "3.04", "position_size": "9120.000000"}], "winStreakStartDate": "2025-03-18T12:06:00.000Z", "outcomeTradeDetails": {"id": "6bcf93a6-bda1-405f-9938-8148c0357d9c", "pnl": "-12.62", "fees": "0.00", "side": "short", "symbol": "BLNE", "quantity": "300.0000", "exit_time": "2025-03-18T12:33:00.000Z", "commission": "3.08", "entry_time": "2025-03-18T12:33:00.000Z", "exit_price": "3.28", "entry_price": "3.25"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 1121.21, "subsequentTradeResult": -12.62}, {"id": "1c01f3b7-d464-49de-91e6-e27cbd523928", "severity": "high", "streakPnl": 152.05, "totalImpact": -21.97, "streakTrades": ["fbe899b1-db53-4523-96ba-e0019ed5b9eb", "1aa7e837-f1cb-4682-9bc0-0d70b3b7dbd1", "d0c629e8-5435-4ddc-8097-666c9d97e827", "b0a66cdd-28ca-46f5-bd64-de5eb0745185"], "detectionDate": "2025-09-03T19:06:23.305Z", "outcomeStatus": "warning", "outcomeTradeId": "79b26b2e-9d44-4c74-867f-f0ed7ae255ca", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 4, "peakPositionSize": 7410, "winStreakEndDate": "2025-03-17T17:08:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "fbe899b1-db53-4523-96ba-e0019ed5b9eb", "pnl": "46.40", "fees": "0.00", "side": "long", "symbol": "SLXN", "quantity": "300.0000", "exit_time": "2025-03-17T12:16:00.000Z", "commission": "3.97", "entry_time": "2025-03-17T12:16:00.000Z", "exit_price": "1.51", "entry_price": "1.34", "position_size": "402.000000"}, {"id": "1aa7e837-f1cb-4682-9bc0-0d70b3b7dbd1", "pnl": "13.46", "fees": "0.00", "side": "long", "symbol": "SLXN", "quantity": "300.0000", "exit_time": "2025-03-17T12:18:00.000Z", "commission": "3.97", "entry_time": "2025-03-17T12:18:00.000Z", "exit_price": "1.63", "entry_price": "1.57", "position_size": "471.000000"}, {"id": "d0c629e8-5435-4ddc-8097-666c9d97e827", "pnl": "26.14", "fees": "0.00", "side": "long", "symbol": "SLXN", "quantity": "1200.0000", "exit_time": "2025-03-17T12:24:00.000Z", "commission": "15.86", "entry_time": "2025-03-17T12:19:00.000Z", "exit_price": "1.57", "entry_price": "1.54", "position_size": "1848.000000"}, {"id": "b0a66cdd-28ca-46f5-bd64-de5eb0745185", "pnl": "66.05", "fees": "0.00", "side": "long", "symbol": "CURR", "quantity": "3000.0000", "exit_time": "2025-03-17T17:08:00.000Z", "commission": "28.17", "entry_time": "2025-03-17T12:34:00.000Z", "exit_price": "2.50", "entry_price": "2.47", "position_size": "7410.000000"}], "winStreakStartDate": "2025-03-17T12:16:00.000Z", "outcomeTradeDetails": {"id": "79b26b2e-9d44-4c74-867f-f0ed7ae255ca", "pnl": "-21.97", "fees": "0.00", "side": "short", "symbol": "00941Q203", "quantity": "300.0000", "exit_time": "2025-03-17T12:57:00.000Z", "commission": "3.97", "entry_time": "2025-03-17T12:57:00.000Z", "exit_price": "1.39", "entry_price": "1.33"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 892.23, "subsequentTradeResult": -21.97}, {"id": "89bc2853-e78d-4022-b9f8-cc6a22bb1dd8", "severity": "high", "streakPnl": 244.05, "totalImpact": -801.28, "streakTrades": ["de1f2f5a-e4b6-4c52-9473-00c7d9d6966d", "5b85a6c1-8463-442e-bf33-a204da3e8521", "e8d85b3c-2bf8-482e-8123-bc8af46a8778", "033f9947-0e4a-4337-a1f9-5993fd0622c8", "02f756ab-6add-43ca-b9aa-f5a2c5c8a45a"], "detectionDate": "2025-09-03T19:06:23.304Z", "outcomeStatus": "warning", "outcomeTradeId": "e5bad97a-6e12-4e94-86ba-c2f49bb4eaa8", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 5, "peakPositionSize": 6020, "winStreakEndDate": "2025-02-18T12:43:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "de1f2f5a-e4b6-4c52-9473-00c7d9d6966d", "pnl": "74.47", "fees": "0.00", "side": "long", "symbol": "PEVM", "quantity": "2000.0000", "exit_time": "2025-02-13T11:02:00.000Z", "commission": "24.81", "entry_time": "2025-02-13T10:42:00.000Z", "exit_price": "0.64", "entry_price": "0.59", "position_size": "1180.000000"}, {"id": "5b85a6c1-8463-442e-bf33-a204da3e8521", "pnl": "24.65", "fees": "0.00", "side": "long", "symbol": "NAKA", "quantity": "2000.0000", "exit_time": "2025-02-14T14:12:00.000Z", "commission": "28.91", "entry_time": "2025-02-13T11:05:00.000Z", "exit_price": "3.04", "entry_price": "3.01", "position_size": "6020.000000"}, {"id": "e8d85b3c-2bf8-482e-8123-bc8af46a8778", "pnl": "36.57", "fees": "0.00", "side": "long", "symbol": "AIFF", "quantity": "200.0000", "exit_time": "2025-02-13T11:24:00.000Z", "commission": "3.10", "entry_time": "2025-02-13T11:22:00.000Z", "exit_price": "14.66", "entry_price": "14.46", "position_size": "2892.000000"}, {"id": "033f9947-0e4a-4337-a1f9-5993fd0622c8", "pnl": "60.00", "fees": "0.00", "side": "long", "symbol": "501506703", "quantity": "2000.0000", "exit_time": "2025-02-18T11:49:00.000Z", "commission": "21.80", "entry_time": "2025-02-18T11:38:00.000Z", "exit_price": "0.64", "entry_price": "0.60", "position_size": "1200.000000"}, {"id": "02f756ab-6add-43ca-b9aa-f5a2c5c8a45a", "pnl": "48.36", "fees": "0.00", "side": "long", "symbol": "PRFX", "quantity": "100.0000", "exit_time": "2025-02-18T12:43:00.000Z", "commission": "2.64", "entry_time": "2025-02-18T12:30:00.000Z", "exit_price": "3.82", "entry_price": "3.31", "position_size": "331.000000"}], "winStreakStartDate": "2025-02-13T10:42:00.000Z", "outcomeTradeDetails": {"id": "e5bad97a-6e12-4e94-86ba-c2f49bb4eaa8", "pnl": "-801.28", "fees": "0.00", "side": "long", "symbol": "SRXH", "quantity": "1000.0000", "exit_time": "2025-03-12T13:30:00.000Z", "commission": "11.23", "entry_time": "2025-02-19T11:30:00.000Z", "exit_price": "1.58", "entry_price": "2.37"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 706.11, "subsequentTradeResult": -801.28}, {"id": "657d20e3-06ea-4881-906d-ce2dc914684f", "severity": "high", "streakPnl": 5228.66, "totalImpact": -4.45, "streakTrades": ["250b9d52-48f6-454b-b412-fdea54fbb46c", "10187771-9876-4cbf-b38e-51c85d157f01", "68368180-d699-43ef-ba2a-e63b6b1a5ce5", "25fabbca-2d3c-4836-866e-b99dc069404f", "fbc2549c-ce4a-42ed-83de-844593b578dd", "0f2042b4-c933-47d9-8955-1b50e56574c8", "9576b0fc-3844-4c16-9847-df9e0dbfda6e"], "detectionDate": "2025-09-03T19:06:23.303Z", "outcomeStatus": "warning", "outcomeTradeId": "f14f7d20-79af-491e-ace9-9f9ddcd67ff5", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 7, "peakPositionSize": 18480, "winStreakEndDate": "2025-02-12T11:31:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "250b9d52-48f6-454b-b412-fdea54fbb46c", "pnl": "10.70", "fees": "0.00", "side": "long", "symbol": "LIPO", "quantity": "400.0000", "exit_time": "2025-02-11T10:59:00.000Z", "commission": "5.94", "entry_time": "2025-02-11T10:58:00.000Z", "exit_price": "5.40", "entry_price": "5.36", "position_size": "2144.000000"}, {"id": "10187771-9876-4cbf-b38e-51c85d157f01", "pnl": "4821.35", "fees": "0.00", "side": "long", "symbol": "VSTTF", "quantity": "24000.0000", "exit_time": "2025-03-12T12:35:00.000Z", "commission": "306.59", "entry_time": "2025-02-11T11:02:00.000Z", "exit_price": "0.98", "entry_price": "0.77", "position_size": "18480.000000"}, {"id": "68368180-d699-43ef-ba2a-e63b6b1a5ce5", "pnl": "90.33", "fees": "0.00", "side": "long", "symbol": "LIPO", "quantity": "1000.0000", "exit_time": "2025-02-11T11:34:00.000Z", "commission": "14.80", "entry_time": "2025-02-11T11:05:00.000Z", "exit_price": "4.92", "entry_price": "4.81", "position_size": "4810.000000"}, {"id": "25fabbca-2d3c-4836-866e-b99dc069404f", "pnl": "31.96", "fees": "0.00", "side": "long", "symbol": "IINN", "quantity": "1000.0000", "exit_time": "2025-02-11T11:45:00.000Z", "commission": "10.14", "entry_time": "2025-02-11T11:40:00.000Z", "exit_price": "0.98", "entry_price": "0.94", "position_size": "940.000000"}, {"id": "fbc2549c-ce4a-42ed-83de-844593b578dd", "pnl": "197.49", "fees": "0.00", "side": "long", "symbol": "AIFF", "quantity": "800.0000", "exit_time": "2025-02-11T11:47:00.000Z", "commission": "9.41", "entry_time": "2025-02-11T11:45:00.000Z", "exit_price": "4.45", "entry_price": "4.19", "position_size": "3352.000000"}, {"id": "0f2042b4-c933-47d9-8955-1b50e56574c8", "pnl": "9.20", "fees": "0.00", "side": "long", "symbol": "TRNR", "quantity": "200.0000", "exit_time": "2025-02-11T12:03:00.000Z", "commission": "2.80", "entry_time": "2025-02-11T12:02:00.000Z", "exit_price": "2.03", "entry_price": "1.97", "position_size": "394.000000"}, {"id": "9576b0fc-3844-4c16-9847-df9e0dbfda6e", "pnl": "67.63", "fees": "0.00", "side": "long", "symbol": "BDRX", "quantity": "200.0000", "exit_time": "2025-02-12T11:31:00.000Z", "commission": "2.37", "entry_time": "2025-02-12T11:31:00.000Z", "exit_price": "6.50", "entry_price": "6.15", "position_size": "1230.000000"}], "winStreakStartDate": "2025-02-11T10:58:00.000Z", "outcomeTradeDetails": {"id": "f14f7d20-79af-491e-ace9-9f9ddcd67ff5", "pnl": "-4.45", "fees": "0.00", "side": "long", "symbol": "BDRX", "quantity": "200.0000", "exit_time": "2025-02-12T11:32:00.000Z", "commission": "3.27", "entry_time": "2025-02-12T11:32:00.000Z", "exit_price": "6.28", "entry_price": "6.29"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 2374.56, "subsequentTradeResult": -4.45}, {"id": "0dd418cb-3ee0-4bde-a403-f01be8588332", "severity": "high", "streakPnl": 1017.19, "totalImpact": -74.35, "streakTrades": ["df6eccc5-a74d-4080-8770-89c2b5df1fe6", "8b01c162-4946-49eb-a2f8-20eaa6d0ca2b", "5e05cb12-ba30-4cf5-92db-e161b9940591", "9028b122-eca8-450f-98a8-5cf515235d62", "206fe5a2-a57d-479d-b633-2b8863ab0ad2", "d4c52114-b262-4053-a962-9b8057fabfa1", "0bb698bb-c87c-43d6-908d-f41df90555bd", "f8d146c7-67d4-44f9-857f-67cc0fb684c0", "e0b51e88-5a66-4335-811c-2d2472013c2b", "12084622-cdf3-468d-9a80-41a84120f3d7", "15aaceb7-6b08-46ba-a959-ceae18232b09", "02cb4570-0f94-45bd-af55-2d6e31acffc3"], "detectionDate": "2025-09-03T19:06:23.303Z", "outcomeStatus": "warning", "outcomeTradeId": "2fc303b7-def0-4e80-b552-b5dc67233d2f", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 12, "peakPositionSize": 11390, "winStreakEndDate": "2025-02-10T11:00:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "df6eccc5-a74d-4080-8770-89c2b5df1fe6", "pnl": "95.32", "fees": "0.00", "side": "long", "symbol": "ACRV", "quantity": "800.0000", "exit_time": "2025-02-05T14:25:00.000Z", "commission": "10.08", "entry_time": "2025-02-05T12:02:00.000Z", "exit_price": "7.09", "entry_price": "6.96", "position_size": "5568.000000"}, {"id": "8b01c162-4946-49eb-a2f8-20eaa6d0ca2b", "pnl": "23.72", "fees": "0.00", "side": "long", "symbol": "LIPO", "quantity": "200.0000", "exit_time": "2025-02-06T11:00:00.000Z", "commission": "4.28", "entry_time": "2025-02-06T10:59:00.000Z", "exit_price": "5.61", "entry_price": "5.47", "position_size": "1094.000000"}, {"id": "5e05cb12-ba30-4cf5-92db-e161b9940591", "pnl": "45.99", "fees": "0.00", "side": "long", "symbol": "PTNT", "quantity": "800.0000", "exit_time": "2025-02-06T11:50:00.000Z", "commission": "11.41", "entry_time": "2025-02-06T11:32:00.000Z", "exit_price": "0.97", "entry_price": "0.89", "position_size": "712.000000"}, {"id": "9028b122-eca8-450f-98a8-5cf515235d62", "pnl": "677.75", "fees": "0.00", "side": "long", "symbol": "CJMB", "quantity": "1700.0000", "exit_time": "2025-02-06T13:37:00.000Z", "commission": "18.59", "entry_time": "2025-02-06T11:43:00.000Z", "exit_price": "7.11", "entry_price": "6.70", "position_size": "11390.000000"}, {"id": "206fe5a2-a57d-479d-b633-2b8863ab0ad2", "pnl": "23.99", "fees": "0.00", "side": "long", "symbol": "EQ", "quantity": "600.0000", "exit_time": "2025-02-06T12:08:00.000Z", "commission": "8.65", "entry_time": "2025-02-06T12:03:00.000Z", "exit_price": "0.98", "entry_price": "0.92", "position_size": "552.000000"}, {"id": "d4c52114-b262-4053-a962-9b8057fabfa1", "pnl": "22.28", "fees": "0.00", "side": "long", "symbol": "71902K303", "quantity": "600.0000", "exit_time": "2025-02-06T18:40:00.000Z", "commission": "7.04", "entry_time": "2025-02-06T12:17:00.000Z", "exit_price": "2.13", "entry_price": "2.08", "position_size": "1248.000000"}, {"id": "0bb698bb-c87c-43d6-908d-f41df90555bd", "pnl": "7.74", "fees": "0.00", "side": "long", "symbol": "LTRY", "quantity": "200.0000", "exit_time": "2025-02-07T11:00:00.000Z", "commission": "4.26", "entry_time": "2025-02-07T10:58:00.000Z", "exit_price": "1.91", "entry_price": "1.85", "position_size": "370.000000"}, {"id": "f8d146c7-67d4-44f9-857f-67cc0fb684c0", "pnl": "43.05", "fees": "0.00", "side": "long", "symbol": "20678X205", "quantity": "400.0000", "exit_time": "2025-02-07T12:01:00.000Z", "commission": "5.23", "entry_time": "2025-02-07T12:01:00.000Z", "exit_price": "3.79", "entry_price": "3.67", "position_size": "1468.000000"}, {"id": "e0b51e88-5a66-4335-811c-2d2472013c2b", "pnl": "49.36", "fees": "0.00", "side": "long", "symbol": "20678X205", "quantity": "3200.0000", "exit_time": "2025-02-07T13:38:00.000Z", "commission": "47.22", "entry_time": "2025-02-07T12:04:00.000Z", "exit_price": "2.92", "entry_price": "2.89", "position_size": "9248.000000"}, {"id": "12084622-cdf3-468d-9a80-41a84120f3d7", "pnl": "14.06", "fees": "0.00", "side": "long", "symbol": "REBN", "quantity": "400.0000", "exit_time": "2025-02-07T12:32:00.000Z", "commission": "5.94", "entry_time": "2025-02-07T12:31:00.000Z", "exit_price": "6.24", "entry_price": "6.19", "position_size": "2476.000000"}, {"id": "15aaceb7-6b08-46ba-a959-ceae18232b09", "pnl": "5.74", "fees": "0.00", "side": "long", "symbol": "PNBK", "quantity": "200.0000", "exit_time": "2025-02-10T10:56:00.000Z", "commission": "4.26", "entry_time": "2025-02-10T10:54:00.000Z", "exit_price": "2.82", "entry_price": "2.77", "position_size": "554.000000"}, {"id": "02cb4570-0f94-45bd-af55-2d6e31acffc3", "pnl": "8.19", "fees": "0.00", "side": "long", "symbol": "PNBK", "quantity": "200.0000", "exit_time": "2025-02-10T11:00:00.000Z", "commission": "3.81", "entry_time": "2025-02-10T10:59:00.000Z", "exit_price": "2.91", "entry_price": "2.85", "position_size": "570.000000"}], "winStreakStartDate": "2025-02-05T12:02:00.000Z", "outcomeTradeDetails": {"id": "2fc303b7-def0-4e80-b552-b5dc67233d2f", "pnl": "-74.35", "fees": "0.00", "side": "long", "symbol": "CLSD", "quantity": "1100.0000", "exit_time": "2025-02-12T16:56:00.000Z", "commission": "16.52", "entry_time": "2025-02-10T11:07:00.000Z", "exit_price": "1.06", "entry_price": "1.12"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 1425.17, "subsequentTradeResult": -74.35}, {"id": "f1256e71-409e-4bf3-9d49-b4820c4db4d8", "severity": "high", "streakPnl": 362.19, "totalImpact": -78.29, "streakTrades": ["82c2a0ff-9feb-406b-bcd5-b57126235d37", "4a70d2b0-d498-4844-9291-fbb698fd43d2", "f65c083f-72da-4b48-a35c-35dc29441ad2", "964239b7-1400-4299-bc02-fdab6113daf0", "f8d5dede-911d-4594-859e-526db89ceb03", "eac89a62-2af1-4146-adc1-a51084bf995d", "5b902936-c3d6-417d-9c14-5c78132e8309", "af6ef801-4581-464f-8f57-7f4c411bfb85"], "detectionDate": "2025-09-03T19:06:23.302Z", "outcomeStatus": "warning", "outcomeTradeId": "7d5c7424-d376-4e2d-a594-bc8a8c571ca9", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 8, "peakPositionSize": 4810, "winStreakEndDate": "2025-02-05T11:22:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "82c2a0ff-9feb-406b-bcd5-b57126235d37", "pnl": "267.50", "fees": "0.00", "side": "long", "symbol": "GWAV", "quantity": "13000.0000", "exit_time": "2025-02-10T11:10:00.000Z", "commission": "126.55", "entry_time": "2025-02-04T12:08:00.000Z", "exit_price": "0.40", "entry_price": "0.37", "position_size": "4810.000000"}, {"id": "4a70d2b0-d498-4844-9291-fbb698fd43d2", "pnl": "4.67", "fees": "0.00", "side": "long", "symbol": "M2R43K362", "quantity": "400.0000", "exit_time": "2025-02-04T12:34:00.000Z", "commission": "5.89", "entry_time": "2025-02-04T12:33:00.000Z", "exit_price": "1.43", "entry_price": "1.41", "position_size": "564.000000"}, {"id": "f65c083f-72da-4b48-a35c-35dc29441ad2", "pnl": "28.74", "fees": "0.00", "side": "long", "symbol": "KTTA", "quantity": "200.0000", "exit_time": "2025-02-05T11:00:00.000Z", "commission": "3.26", "entry_time": "2025-02-05T11:00:00.000Z", "exit_price": "4.12", "entry_price": "3.96", "position_size": "792.000000"}, {"id": "964239b7-1400-4299-bc02-fdab6113daf0", "pnl": "30.72", "fees": "0.00", "side": "short", "symbol": "KTTA", "quantity": "200.0000", "exit_time": "2025-02-05T11:00:00.000Z", "commission": "4.28", "entry_time": "2025-02-05T11:00:00.000Z", "exit_price": "3.57", "entry_price": "3.75", "position_size": "750.000000"}, {"id": "eac89a62-2af1-4146-adc1-a51084bf995d", "pnl": "8.75", "fees": "0.00", "side": "long", "symbol": "KTTA", "quantity": "400.0000", "exit_time": "2025-02-05T11:04:00.000Z", "commission": "6.58", "entry_time": "2025-02-05T11:02:00.000Z", "exit_price": "4.15", "entry_price": "4.11", "position_size": "1644.000000"}, {"id": "f8d5dede-911d-4594-859e-526db89ceb03", "pnl": "0.72", "fees": "0.00", "side": "short", "symbol": "KTTA", "quantity": "200.0000", "exit_time": "2025-02-05T11:02:00.000Z", "commission": "4.28", "entry_time": "2025-02-05T11:02:00.000Z", "exit_price": "4.47", "entry_price": "4.50", "position_size": "900.000000"}, {"id": "5b902936-c3d6-417d-9c14-5c78132e8309", "pnl": "4.98", "fees": "0.00", "side": "long", "symbol": "KTTA", "quantity": "400.0000", "exit_time": "2025-02-05T11:16:00.000Z", "commission": "6.52", "entry_time": "2025-02-05T11:14:00.000Z", "exit_price": "3.89", "entry_price": "3.86", "position_size": "1544.000000"}, {"id": "af6ef801-4581-464f-8f57-7f4c411bfb85", "pnl": "16.11", "fees": "0.00", "side": "long", "symbol": "ACB", "quantity": "400.0000", "exit_time": "2025-02-05T11:22:00.000Z", "commission": "5.93", "entry_time": "2025-02-05T11:20:00.000Z", "exit_price": "4.23", "entry_price": "4.17", "position_size": "1668.000000"}], "winStreakStartDate": "2025-02-04T12:08:00.000Z", "outcomeTradeDetails": {"id": "7d5c7424-d376-4e2d-a594-bc8a8c571ca9", "pnl": "-78.29", "fees": "0.00", "side": "long", "symbol": "KTTA", "quantity": "800.0000", "exit_time": "2025-02-05T12:01:00.000Z", "commission": "11.81", "entry_time": "2025-02-05T11:48:00.000Z", "exit_price": "3.09", "entry_price": "3.17"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 544.08, "subsequentTradeResult": -78.29}, {"id": "9012a709-a808-4893-b7df-964157eb8155", "severity": "high", "streakPnl": 177.52, "totalImpact": -47.66, "streakTrades": ["72be4dd1-3816-4dee-90cb-670106260c4a", "c762905b-72af-467b-b5e3-7320b51d592e", "5d3bd893-e3a9-4d2c-a204-cad9f4546858", "904cd33c-af0a-493f-847d-19bdcfebe5c5", "5fc8db5c-5976-495a-ac58-637330bc58d7", "f413fd79-3fa8-4294-9609-924d7c7ded37", "049e9e1e-c30e-432f-961d-90cd6fe8838c", "85142cd7-901c-4ef8-9616-8be2e7bb8d3e", "fbdc029e-7c7b-4035-bdd9-af4c88bf3bc7"], "detectionDate": "2025-09-03T19:06:23.301Z", "outcomeStatus": "warning", "outcomeTradeId": "3097d30d-c397-4137-a979-2abe3c65f395", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 9, "peakPositionSize": 4545, "winStreakEndDate": "2025-02-04T11:55:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "72be4dd1-3816-4dee-90cb-670106260c4a", "pnl": "5.72", "fees": "0.00", "side": "long", "symbol": "EVAX", "quantity": "200.0000", "exit_time": "2025-02-04T10:58:00.000Z", "commission": "4.28", "entry_time": "2025-02-04T10:57:00.000Z", "exit_price": "4.58", "entry_price": "4.53", "position_size": "906.000000"}, {"id": "c762905b-72af-467b-b5e3-7320b51d592e", "pnl": "3.64", "fees": "0.00", "side": "long", "symbol": "QNTM", "quantity": "200.0000", "exit_time": "2025-02-04T11:04:00.000Z", "commission": "2.36", "entry_time": "2025-02-04T11:04:00.000Z", "exit_price": "5.33", "entry_price": "5.30", "position_size": "1060.000000"}, {"id": "5d3bd893-e3a9-4d2c-a204-cad9f4546858", "pnl": "7.36", "fees": "0.00", "side": "short", "symbol": "QNTM", "quantity": "100.0000", "exit_time": "2025-02-04T11:07:00.000Z", "commission": "2.64", "entry_time": "2025-02-04T11:07:00.000Z", "exit_price": "6.70", "entry_price": "6.80", "position_size": "680.000000"}, {"id": "904cd33c-af0a-493f-847d-19bdcfebe5c5", "pnl": "16.09", "fees": "0.00", "side": "long", "symbol": "QNTM", "quantity": "100.0000", "exit_time": "2025-02-04T11:13:00.000Z", "commission": "3.41", "entry_time": "2025-02-04T11:13:00.000Z", "exit_price": "6.77", "entry_price": "6.57", "position_size": "657.000000"}, {"id": "5fc8db5c-5976-495a-ac58-637330bc58d7", "pnl": "69.66", "fees": "0.00", "side": "long", "symbol": "655187300", "quantity": "500.0000", "exit_time": "2025-02-04T11:29:00.000Z", "commission": "8.10", "entry_time": "2025-02-04T11:24:00.000Z", "exit_price": "9.24", "entry_price": "9.09", "position_size": "4545.000000"}, {"id": "f413fd79-3fa8-4294-9609-924d7c7ded37", "pnl": "32.64", "fees": "0.00", "side": "long", "symbol": "CPIX", "quantity": "200.0000", "exit_time": "2025-02-04T11:31:00.000Z", "commission": "3.36", "entry_time": "2025-02-04T11:31:00.000Z", "exit_price": "3.12", "entry_price": "2.94", "position_size": "588.000000"}, {"id": "049e9e1e-c30e-432f-961d-90cd6fe8838c", "pnl": "18.65", "fees": "0.00", "side": "long", "symbol": "CPIX", "quantity": "400.0000", "exit_time": "2025-02-04T11:33:00.000Z", "commission": "5.91", "entry_time": "2025-02-04T11:32:00.000Z", "exit_price": "2.84", "entry_price": "2.78", "position_size": "1112.000000"}, {"id": "85142cd7-901c-4ef8-9616-8be2e7bb8d3e", "pnl": "19.02", "fees": "0.00", "side": "long", "symbol": "655187300", "quantity": "400.0000", "exit_time": "2025-02-04T11:41:00.000Z", "commission": "8.02", "entry_time": "2025-02-04T11:39:00.000Z", "exit_price": "10.07", "entry_price": "10.00", "position_size": "4000.000000"}, {"id": "fbdc029e-7c7b-4035-bdd9-af4c88bf3bc7", "pnl": "4.74", "fees": "0.00", "side": "long", "symbol": "CPIX", "quantity": "200.0000", "exit_time": "2025-02-04T11:55:00.000Z", "commission": "4.26", "entry_time": "2025-02-04T11:53:00.000Z", "exit_price": "2.89", "entry_price": "2.84", "position_size": "568.000000"}], "winStreakStartDate": "2025-02-04T10:57:00.000Z", "outcomeTradeDetails": {"id": "3097d30d-c397-4137-a979-2abe3c65f395", "pnl": "-47.66", "fees": "0.00", "side": "long", "symbol": "655187300", "quantity": "100.0000", "exit_time": "2025-02-04T12:08:00.000Z", "commission": "3.66", "entry_time": "2025-02-04T12:01:00.000Z", "exit_price": "9.33", "entry_price": "9.77"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 508.6, "subsequentTradeResult": -47.66}, {"id": "8e9bdf94-97c5-45b0-94d2-93325151bce8", "severity": "medium", "streakPnl": 99.11, "totalImpact": -49.46, "streakTrades": ["739cc92c-e324-4f58-804b-6ab85bccbec6", "b2d4f5d0-b77b-4316-bf34-f5ca6e657bc8", "5bce72af-0be3-44da-a29e-3d169ba27466", "34b10885-9bc3-41cd-9fb2-066d0ce26bf1", "cdb79cf8-907b-4ba2-bbcc-9e8bcac052df", "0b67d34c-58b5-4d54-935a-128536c6c5ae", "2f2dc23c-0ba0-4cd9-a061-9b0db752ee79", "273c2288-f98d-42eb-863f-f81d6f3cea4b"], "detectionDate": "2025-09-03T19:06:23.300Z", "outcomeStatus": "warning", "outcomeTradeId": "b2adbbd5-03d7-45f4-9bb9-7dfbbf54bb83", "confidenceScore": 1, "recommendations": ["Consider implementing position sizing rules to limit increases during win streaks", "Set a maximum position size relative to your account", "Take partial profits during extended win streaks"], "winStreakLength": 8, "peakPositionSize": 1170, "winStreakEndDate": "2025-02-03T13:36:00.000Z", "outcomeAfterStreak": "loss", "streakTradeDetails": [{"id": "739cc92c-e324-4f58-804b-6ab85bccbec6", "pnl": "0.76", "fees": "0.00", "side": "short", "symbol": "M97838128", "quantity": "200.0000", "exit_time": "2025-02-03T11:59:00.000Z", "commission": "3.24", "entry_time": "2025-02-03T11:59:00.000Z", "exit_price": "1.29", "entry_price": "1.31", "position_size": "262.000000"}, {"id": "5bce72af-0be3-44da-a29e-3d169ba27466", "pnl": "46.15", "fees": "0.00", "side": "long", "symbol": "SLRX", "quantity": "200.0000", "exit_time": "2025-02-03T12:01:00.000Z", "commission": "2.35", "entry_time": "2025-02-03T12:01:00.000Z", "exit_price": "2.75", "entry_price": "2.51", "position_size": "502.000000"}, {"id": "b2d4f5d0-b77b-4316-bf34-f5ca6e657bc8", "pnl": "9.65", "fees": "0.00", "side": "long", "symbol": "SLRX", "quantity": "200.0000", "exit_time": "2025-02-03T12:02:00.000Z", "commission": "2.35", "entry_time": "2025-02-03T12:01:00.000Z", "exit_price": "2.65", "entry_price": "2.59", "position_size": "518.000000"}, {"id": "34b10885-9bc3-41cd-9fb2-066d0ce26bf1", "pnl": "3.65", "fees": "0.00", "side": "short", "symbol": "SLRX", "quantity": "200.0000", "exit_time": "2025-02-03T12:03:00.000Z", "commission": "2.35", "entry_time": "2025-02-03T12:03:00.000Z", "exit_price": "2.43", "entry_price": "2.46", "position_size": "492.000000"}, {"id": "cdb79cf8-907b-4ba2-bbcc-9e8bcac052df", "pnl": "8.11", "fees": "0.00", "side": "long", "symbol": "890260847", "quantity": "3000.0000", "exit_time": "2025-02-03T12:10:00.000Z", "commission": "31.19", "entry_time": "2025-02-03T12:06:00.000Z", "exit_price": "0.29", "entry_price": "0.28", "position_size": "840.000000"}, {"id": "0b67d34c-58b5-4d54-935a-128536c6c5ae", "pnl": "12.74", "fees": "0.00", "side": "long", "symbol": "CYCN", "quantity": "200.0000", "exit_time": "2025-02-03T12:25:00.000Z", "commission": "3.26", "entry_time": "2025-02-03T12:24:00.000Z", "exit_price": "4.73", "entry_price": "4.65", "position_size": "930.000000"}, {"id": "2f2dc23c-0ba0-4cd9-a061-9b0db752ee79", "pnl": "12.87", "fees": "0.00", "side": "long", "symbol": "REBN", "quantity": "200.0000", "exit_time": "2025-02-03T13:35:00.000Z", "commission": "4.28", "entry_time": "2025-02-03T13:34:00.000Z", "exit_price": "5.46", "entry_price": "5.37", "position_size": "1074.000000"}, {"id": "273c2288-f98d-42eb-863f-f81d6f3cea4b", "pnl": "5.18", "fees": "0.00", "side": "short", "symbol": "REBN", "quantity": "200.0000", "exit_time": "2025-02-03T13:36:00.000Z", "commission": "4.28", "entry_time": "2025-02-03T13:36:00.000Z", "exit_price": "5.80", "entry_price": "5.85", "position_size": "1170.000000"}], "winStreakStartDate": "2025-02-03T11:59:00.000Z", "outcomeTradeDetails": {"id": "b2adbbd5-03d7-45f4-9bb9-7dfbbf54bb83", "pnl": "-49.46", "fees": "0.00", "side": "long", "symbol": "CYCN", "quantity": "400.0000", "exit_time": "2025-02-03T13:41:00.000Z", "commission": "5.92", "entry_time": "2025-02-03T13:40:00.000Z", "exit_price": "4.30", "entry_price": "4.41"}, "baselinePositionSize": 746.8, "positionSizeIncrease": 56.67, "subsequentTradeResult": -49.46}], "pagination": {"page": 1, "limit": 20, "total": 23, "totalPages": 2, "hasNextPage": true, "hasPreviousPage": false}, "statistics": {"lossRate": 100, "profitRate": 0, "successRate": 0, "totalEvents": 23, "avgStreakLength": 8.217391304347826, "lowSeverityCount": 0, "highSeverityCount": 22, "performanceImpact": -19033.79, "totalStreakProfits": 21144.99, "avgPositionIncrease": 952.3260869565217, "mediumSeverityCount": 1, "streaksEndingInLoss": 23, "streaksEndingInProfit": 0, "totalLossesAfterStreaks": 2111.2}, "winStreakAnalysis": {"longestStreak": 19, "avgStreakLength": 8.217391304347826, "avgPositionGrowth": 952.3260869565217}}	2025-09-03 21:06:43.848+00	2025-09-03 19:06:43.850259+00
\.


--
-- Data for Name: api_keys; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.api_keys (id, user_id, name, key_hash, permissions, last_used_at, expires_at, created_at, revoked_at, key_prefix, is_active, updated_at) FROM stdin;
\.


--
-- Data for Name: behavioral_alerts; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.behavioral_alerts (id, user_id, pattern_id, alert_type, title, message, alert_data, status, shown_at, acknowledged_at, user_response, expires_at, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: behavioral_patterns; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.behavioral_patterns (id, user_id, pattern_type, detected_at, severity, confidence_score, trigger_trade_id, context_data, created_at, updated_at) FROM stdin;
b104c545-418e-4b70-856e-77fa9b5620b8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-01-07 11:48:00+00	high	1.00	\N	{"winStreakLength": 6, "peakPositionSize": 10122.22, "totalStreakProfit": 716.5, "baselinePositionSize": 746.8, "overconfidenceEventId": "6032ff0c-686a-49e2-9061-4faa09453a61", "positionSizeIncreasePercent": 1255.4124263524373}	2025-09-03 19:26:33.378442+00	2025-09-03 19:26:33.378442+00
76b2a369-fc1d-480f-b2a3-02578c7ff997	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-01-14 11:31:00+00	high	1.00	\N	{"winStreakLength": 8, "peakPositionSize": 3360, "totalStreakProfit": 3563.44, "baselinePositionSize": 746.8, "overconfidenceEventId": "de328f21-aa2e-4219-bb7b-790b264c686f", "positionSizeIncreasePercent": 349.9196572040707}	2025-09-03 19:26:33.381462+00	2025-09-03 19:26:33.381462+00
c64a3827-d05b-429c-a095-a002ae147785	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-01-31 13:42:00+00	high	1.00	\N	{"winStreakLength": 7, "peakPositionSize": 4110, "totalStreakProfit": 81.93, "baselinePositionSize": 746.8, "overconfidenceEventId": "fad7d421-8e49-4061-8db1-cb067132aeb4", "positionSizeIncreasePercent": 450.3481521156936}	2025-09-03 19:26:33.38419+00	2025-09-03 19:26:33.38419+00
b846b02c-df40-4781-965e-fed7ef06004f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-02-03 11:59:00+00	medium	1.00	\N	{"winStreakLength": 8, "peakPositionSize": 1170, "totalStreakProfit": 99.10999999999999, "baselinePositionSize": 746.8, "overconfidenceEventId": "9ddb3066-c7ee-460e-bc00-2e6dd55035ce", "positionSizeIncreasePercent": 56.66845206213177}	2025-09-03 19:26:33.386282+00	2025-09-03 19:26:33.386282+00
b8761d21-fe2c-4c47-8858-a9496ba1082d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-02-04 10:57:00+00	high	1.00	\N	{"winStreakLength": 9, "peakPositionSize": 4545, "totalStreakProfit": 177.52000000000004, "baselinePositionSize": 746.8, "overconfidenceEventId": "072978fb-8b28-433b-8247-1a58689922d9", "positionSizeIncreasePercent": 508.59667916443493}	2025-09-03 19:26:33.38914+00	2025-09-03 19:26:33.38914+00
76ec3c2f-8c56-463a-8f9b-4b60cf2f3afe	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-02-04 12:08:00+00	high	1.00	\N	{"winStreakLength": 8, "peakPositionSize": 4810, "totalStreakProfit": 362.19000000000005, "baselinePositionSize": 746.8, "overconfidenceEventId": "780c30b7-009c-41f9-bdf8-62f73dda2d22", "positionSizeIncreasePercent": 544.0814140332084}	2025-09-03 19:26:33.391126+00	2025-09-03 19:26:33.391126+00
fc238c50-9e88-4db2-8de3-f5e6373ea6c8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-02-05 12:02:00+00	high	1.00	\N	{"winStreakLength": 12, "peakPositionSize": 11390, "totalStreakProfit": 1017.1899999999999, "baselinePositionSize": 746.8, "overconfidenceEventId": "5b1b8b52-b431-4a8e-a7d6-846981014650", "positionSizeIncreasePercent": 1425.1740760578468}	2025-09-03 19:26:33.393011+00	2025-09-03 19:26:33.393011+00
f01999f4-61e1-4d58-8623-66dac6793ba6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-02-11 10:58:00+00	high	1.00	\N	{"winStreakLength": 7, "peakPositionSize": 18480, "totalStreakProfit": 5228.66, "baselinePositionSize": 746.8, "overconfidenceEventId": "4b9a7e6d-cf8b-4abb-910b-ddfae6db9065", "positionSizeIncreasePercent": 2374.558114622389}	2025-09-03 19:26:33.395361+00	2025-09-03 19:26:33.395361+00
323d1138-4099-47a0-9493-01823fe64e5d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-02-13 10:42:00+00	high	1.00	\N	{"winStreakLength": 5, "peakPositionSize": 6020, "totalStreakProfit": 244.05, "baselinePositionSize": 746.8, "overconfidenceEventId": "6cfdad93-b899-428d-8d43-9fe0019f24f7", "positionSizeIncreasePercent": 706.1060524906268}	2025-09-03 19:26:33.397077+00	2025-09-03 19:26:33.397077+00
6942aa79-9356-42d0-b3ad-55e34210b41e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-17 12:16:00+00	high	1.00	\N	{"winStreakLength": 4, "peakPositionSize": 7410.000000000001, "totalStreakProfit": 152.05, "baselinePositionSize": 746.8, "overconfidenceEventId": "78835393-544d-410a-9163-7ad68e431c90", "positionSizeIncreasePercent": 892.2335297268347}	2025-09-03 19:26:33.399371+00	2025-09-03 19:26:33.399371+00
40b18460-76c8-4f9c-bb69-b55599a155ca	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-18 12:06:00+00	high	1.00	\N	{"winStreakLength": 5, "peakPositionSize": 9120, "totalStreakProfit": 519.12, "baselinePositionSize": 746.8, "overconfidenceEventId": "eb547589-95f1-422b-80d6-ec3071ae5531", "positionSizeIncreasePercent": 1121.2104981253349}	2025-09-03 19:26:33.40122+00	2025-09-03 19:26:33.40122+00
31f912c7-64de-4771-ab0f-07c0fc094173	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-18 13:31:00+00	high	1.00	\N	{"winStreakLength": 15, "peakPositionSize": 8749, "totalStreakProfit": 1333.8899999999999, "baselinePositionSize": 746.8, "overconfidenceEventId": "cf690847-8fce-47c6-b724-cfe4feb46538", "positionSizeIncreasePercent": 1071.531869309052}	2025-09-03 19:26:33.403179+00	2025-09-03 19:26:33.403179+00
334ae076-7770-4c4c-9374-e5919769fe16	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-24 15:05:00+00	high	1.00	\N	{"winStreakLength": 8, "peakPositionSize": 15502, "totalStreakProfit": 365.92999999999995, "baselinePositionSize": 746.8, "overconfidenceEventId": "5646c958-7064-4b57-937f-4aefb2743b46", "positionSizeIncreasePercent": 1975.7900374933051}	2025-09-03 19:26:33.405124+00	2025-09-03 19:26:33.405124+00
879b9332-ac98-4c86-b311-9e31e2e291ae	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-24 20:27:00+00	high	1.00	\N	{"winStreakLength": 19, "peakPositionSize": 15903, "totalStreakProfit": 1289.1499999999999, "baselinePositionSize": 746.8, "overconfidenceEventId": "113cbc97-1edb-49c6-bb9b-83044ac568db", "positionSizeIncreasePercent": 2029.4858061060527}	2025-09-03 19:26:33.406611+00	2025-09-03 19:26:33.406611+00
26868c1c-5d92-40d4-be11-b296a1a09544	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-26 11:19:00+00	high	1.00	\N	{"winStreakLength": 15, "peakPositionSize": 4068, "totalStreakProfit": 1070.02, "baselinePositionSize": 746.8, "overconfidenceEventId": "b9458760-12b4-4cdd-83ef-15d1472676db", "positionSizeIncreasePercent": 444.72415640064276}	2025-09-03 19:26:33.40835+00	2025-09-03 19:26:33.40835+00
6634ea00-db99-4a68-b1be-80e92b64109a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-27 12:51:00+00	high	1.00	\N	{"winStreakLength": 8, "peakPositionSize": 11385, "totalStreakProfit": 2850.43, "baselinePositionSize": 746.8, "overconfidenceEventId": "641b0856-1928-4562-b0f1-57fdf0fed43f", "positionSizeIncreasePercent": 1424.5045527584361}	2025-09-03 19:26:33.409773+00	2025-09-03 19:26:33.409773+00
011eb820-0b99-4fbd-8a67-4552135c8e85	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-03-28 15:23:00+00	high	1.00	\N	{"winStreakLength": 4, "peakPositionSize": 3198, "totalStreakProfit": 88.14, "baselinePositionSize": 746.8, "overconfidenceEventId": "67ef5b5e-1f92-43ea-a25f-265ea9579e72", "positionSizeIncreasePercent": 328.22710230316017}	2025-09-03 19:26:33.411283+00	2025-09-03 19:26:33.411283+00
b3a8024c-a5e3-42e9-877d-8a5d11c570a2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-04-01 12:35:00+00	high	1.00	\N	{"winStreakLength": 5, "peakPositionSize": 9060, "totalStreakProfit": 385.21999999999997, "baselinePositionSize": 746.8, "overconfidenceEventId": "bb4be14f-4e58-4407-9d6f-186abe35a899", "positionSizeIncreasePercent": 1113.176218532405}	2025-09-03 19:26:33.412858+00	2025-09-03 19:26:33.412858+00
b0dfbe1d-d737-4df0-b65b-75f8dcdaeaac	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-04-02 20:09:00+00	high	1.00	\N	{"winStreakLength": 5, "peakPositionSize": 5491, "totalStreakProfit": 167.75, "baselinePositionSize": 746.8, "overconfidenceEventId": "865d1d45-7b4d-4857-99b1-21e222f93370", "positionSizeIncreasePercent": 635.270487412962}	2025-09-03 19:26:33.414161+00	2025-09-03 19:26:33.414161+00
49ee4483-0f0c-46c1-bd4a-923e22ce7815	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-04-02 21:07:00+00	high	1.00	\N	{"winStreakLength": 5, "peakPositionSize": 5406, "totalStreakProfit": 41.26, "baselinePositionSize": 746.8, "overconfidenceEventId": "87166a43-b721-4733-a6bb-b751567ef3dc", "positionSizeIncreasePercent": 623.8885913229781}	2025-09-03 19:26:33.415255+00	2025-09-03 19:26:33.415255+00
15895e21-7671-4591-b897-bf2754200dd2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-04-07 11:31:00+00	high	1.00	\N	{"winStreakLength": 6, "peakPositionSize": 5509, "totalStreakProfit": 171.64000000000001, "baselinePositionSize": 746.8, "overconfidenceEventId": "8944ca9f-d266-4502-bdf6-9bc86d1d7786", "positionSizeIncreasePercent": 637.6807712908409}	2025-09-03 19:26:33.41632+00	2025-09-03 19:26:33.41632+00
b95504ab-a255-4573-b117-498322f152a8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-04-07 12:25:00+00	high	1.00	\N	{"winStreakLength": 13, "peakPositionSize": 7807.5, "totalStreakProfit": 879.32, "baselinePositionSize": 746.8, "overconfidenceEventId": "30ac6dc2-00fc-49e2-9004-9cc834f0a107", "positionSizeIncreasePercent": 945.4606320299947}	2025-09-03 19:26:33.417741+00	2025-09-03 19:26:33.417741+00
e68702c3-f565-4498-bad6-bf83de10c1e4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	overconfidence_bias	2025-04-07 15:44:00+00	high	1.00	\N	{"winStreakLength": 7, "peakPositionSize": 8136, "totalStreakProfit": 340.48, "baselinePositionSize": 746.8, "overconfidenceEventId": "b96ed10c-1b25-49fb-ba2b-32e0c8b11891", "positionSizeIncreasePercent": 989.4483128012855}	2025-09-03 19:26:33.419361+00	2025-09-03 19:26:33.419361+00
\.


--
-- Data for Name: behavioral_settings; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.behavioral_settings (id, user_id, revenge_trading_enabled, revenge_trading_sensitivity, cooling_period_minutes, enable_trade_blocking, alert_preferences, created_at, updated_at, loss_aversion_sensitivity, min_trades_for_analysis, normal_hold_ratio_threshold, personality_profiling_enabled, personality_drift_sensitivity, peer_comparison_enabled) FROM stdin;
\.


--
-- Data for Name: challenges; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.challenges (id, key, name, description, category, start_date, end_date, criteria, reward_points, reward_achievement_id, is_community, target_value, created_at) FROM stdin;
4876991f-80c2-4bb2-99fa-9350b73c7599	consistency_challenge	Consistency Champion	Maintain a positive discipline score above 80% for 5 consecutive trading days.	behavioral	2025-09-03 00:00:00+00	2025-09-13 00:00:00+00	{"type": "maintain_discipline", "threshold": 80, "consecutive_days": 5}	150	\N	f	5	2025-09-03 17:47:11.615096+00
901204df-cb27-4c13-b17a-d2c78d9bba56	profitable_month	Profitable Month Challenge	End the month with positive P&L while maintaining good risk management practices.	performance	2025-09-01 00:00:00+00	2025-09-30 00:00:00+00	{"type": "monthly_profit", "min_trades": 20, "risk_compliance": 80}	300	\N	f	1	2025-09-03 17:47:11.615096+00
1eeac829-069a-436a-9a22-aed516ac99cd	discipline_master_month	Discipline Master Monthly	Achieve and maintain a discipline score above 85% for an entire month.	behavioral	2025-09-01 00:00:00+00	2025-09-30 00:00:00+00	{"days": 30, "type": "maintain_discipline", "threshold": 85}	250	\N	f	30	2025-09-03 17:47:11.615096+00
947d0933-307f-49e1-a758-7de74154a46b	learning_month	Learning & Growth Month	Identify and acknowledge 5 different behavioral patterns in your trading.	learning	2025-09-01 00:00:00+00	2025-09-30 00:00:00+00	{"type": "patterns_identified", "count": 5, "acknowledge": true}	200	\N	f	5	2025-09-03 17:47:11.615096+00
56512453-7404-4d34-837d-185084e2b3ad	community_discipline_q1	Community Discipline Drive Q1	Help the TradeTally community improve overall discipline by 15% this quarter. Every trader's improvement counts!	behavioral	2025-07-01 00:00:00+00	2025-09-30 00:00:00+00	{"type": "community_improvement", "metric": "discipline_score", "baseline_date": "CURRENT_DATE", "target_improvement": 15}	500	\N	t	15	2025-09-03 17:47:11.615096+00
adedb41e-674f-48a2-ba53-88b29ef3a3a7	revenge_trading_reduction	Community Revenge Trading Reduction	Let's work together to reduce revenge trading incidents across the platform by 25% this month.	behavioral	2025-09-01 00:00:00+00	2025-09-30 00:00:00+00	{"type": "community_improvement", "metric": "revenge_trading_rate", "target_improvement": -25}	400	\N	t	25	2025-09-03 17:47:11.615096+00
32411a37-f1ee-4b50-b893-c785892cd569	new_year_fresh_start	New Year, New Trading Habits	Start the year strong by maintaining perfect risk management for your first 25 trades.	behavioral	2025-09-03 00:00:00+00	2025-10-03 00:00:00+00	{"type": "risk_management", "trades": 25, "perfect_compliance": true}	300	\N	f	25	2025-09-03 17:47:11.615096+00
425303db-98ac-441a-b58f-b0301dd5afa8	milestone_hunter	Achievement Milestone Hunter	Earn 3 different achievements in a single month to show your commitment to improvement.	milestone	2025-09-01 00:00:00+00	2025-09-30 00:00:00+00	{"type": "achievements_earned", "count": 3, "timeframe": "month"}	350	\N	f	3	2025-09-03 17:47:11.615096+00
e31005a5-6adb-44d1-84d4-d5db4ba7c9d3	first_week_discipline	First Week Discipline	New to TradeTally? Start building good habits by completing 5 trades with proper risk management.	learning	2025-09-03 00:00:00+00	2025-09-17 00:00:00+00	{"type": "beginner_discipline", "trades": 5, "risk_compliance": 100}	50	\N	f	5	2025-09-03 17:47:11.615096+00
c4bf14b8-eb03-4ab3-aad6-0f523ce80f60	pattern_awareness	Pattern Awareness Challenge	Learn to identify your trading patterns by acknowledging your first behavioral analysis.	learning	2025-09-03 00:00:00+00	2025-09-24 00:00:00+00	{"type": "first_pattern_acknowledgment", "any_pattern": true}	75	\N	f	1	2025-09-03 17:47:11.615096+00
63e4adb4-9189-4672-925f-2c544736067c	peer_mentor	Peer Group Mentor	Reach the top 10% of your peer group in discipline and maintain it for 2 weeks.	social	2025-09-03 00:00:00+00	2025-09-24 00:00:00+00	{"type": "peer_rank", "percentile": 90, "maintain_days": 14}	500	\N	f	14	2025-09-03 17:47:11.615096+00
a29a5b60-9b6b-4008-983e-e3ec5144d98b	revenge_free_week	Revenge Trading Free Week	Go an entire week without any revenge trading incidents. Stay disciplined and break the cycle of emotional trading!	behavioral	2025-09-03 00:00:00+00	2025-09-10 00:00:00+00	{"type": "trades_without_revenge", "start_date": "CURRENT_DATE", "target_trades": 5}	100	530bd057-c04c-4547-891b-34156e13f23b	f	7	2025-09-03 17:47:11.615096+00
f9c64593-b16f-4a2a-a47e-bddd99fd1e1c	risk_management_week	Risk Management Master	Keep all your trades within 2% risk for a full week. Show that you can stick to your risk management rules!	behavioral	2025-09-03 00:00:00+00	2025-09-10 00:00:00+00	{"type": "risk_management", "min_trades": 10, "risk_threshold": 2}	75	b5d7065f-756c-465b-a55c-8b7872170253	f	10	2025-09-03 17:47:11.615096+00
b5b2b12b-d994-4296-86b7-01821a7759a5	elite_consistency	Elite Trader Consistency	Achieve 90%+ discipline score for 30 consecutive trading days. Only for the most dedicated traders!	behavioral	2025-09-03 00:00:00+00	2025-10-18 00:00:00+00	{"type": "maintain_discipline", "threshold": 90, "consecutive_days": 30}	1000	bc8bfbc1-057f-4109-84ca-ed72a33e51e8	f	30	2025-09-03 17:47:11.615096+00
7b01d2af-0c10-4376-9842-b14a5f79cbaf	revenge_free_week_1756921925569	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 17:52:05.569+00	2025-09-10 17:52:05.569+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 17:52:05.570246+00
5dde19cb-c474-4128-a167-0ebc7d340caa	revenge_free_week_1756922056513	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 17:54:16.513+00	2025-09-10 17:54:16.513+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 17:54:16.514445+00
e038de49-ddf9-4cdb-80dc-ed610d62d2e0	revenge_free_week_1756922117649	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 17:55:17.649+00	2025-09-10 17:55:17.649+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 17:55:17.650063+00
2fce4a1e-ce48-4ac9-b9a9-9840222ac613	revenge_free_week_1756922584403	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:03:04.403+00	2025-09-10 18:03:04.403+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:03:04.404466+00
1ebd9ee2-9c77-4235-9dfe-a181433757e4	revenge_free_week_1756922712446	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:05:12.446+00	2025-09-10 18:05:12.446+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:05:12.446816+00
2b1b27fc-c45b-462a-9b28-38f7d2cc37ef	revenge_free_week_1756923110048	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:11:50.048+00	2025-09-10 18:11:50.048+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:11:50.050326+00
efeaf6f7-640f-4980-8c39-8c2f7edeb1c0	revenge_free_week_1756923640383	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:20:40.383+00	2025-09-10 18:20:40.383+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:20:40.383504+00
153f44a9-2665-4b77-9b23-507c9ef83680	revenge_free_week_1756924588483	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:36:28.483+00	2025-09-10 18:36:28.483+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:36:28.483692+00
5f395ed8-42a8-479d-966a-236db35bd782	revenge_free_week_1756924898369	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:41:38.369+00	2025-09-10 18:41:38.369+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:41:38.370316+00
eea18f11-4600-4d74-8995-497e938b1137	revenge_free_week_1756925075793	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:44:35.793+00	2025-09-10 18:44:35.793+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:44:35.794367+00
b633553e-e3ad-4cc8-8292-62b1182273fc	revenge_free_week_1756925180319	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:46:20.319+00	2025-09-10 18:46:20.319+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:46:20.320282+00
ac5316a9-9083-40ac-940b-1617b5bff2c5	revenge_free_week_1756925387638	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:49:47.638+00	2025-09-10 18:49:47.638+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:49:47.639206+00
6de79f36-ea42-45f3-8ac5-5ff4746b2e50	revenge_free_week_1756925872172	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 18:57:52.172+00	2025-09-10 18:57:52.172+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 18:57:52.173149+00
11b4b2aa-e519-40f4-a432-e693aee462c2	revenge_free_week_1756926449990	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 19:07:29.99+00	2025-09-10 19:07:29.99+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 19:07:29.990857+00
fb8f26c2-339c-45d4-b1ca-9121c9520acc	revenge_free_week_1756926898132	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 19:14:58.132+00	2025-09-10 19:14:58.132+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 19:14:58.133141+00
b5bcc2be-3ead-41d1-b69e-5549c4076a99	revenge_free_week_1756927332394	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 19:22:12.394+00	2025-09-10 19:22:12.394+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 19:22:12.395498+00
56784005-57a2-4795-8de4-339e6c01d661	revenge_free_week_1756927478464	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 19:24:38.464+00	2025-09-10 19:24:38.464+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 19:24:38.465851+00
aed2851b-2990-41d3-a5e4-70812898e11a	revenge_free_week_1756927577956	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 19:26:17.956+00	2025-09-10 19:26:17.956+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 19:26:17.956967+00
153e3edf-7b30-4465-a386-0bba4c72e418	revenge_free_week_1756928535881	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 19:42:15.881+00	2025-09-10 19:42:15.881+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 19:42:15.882219+00
8c14fa61-0796-4227-8044-b2142a89f3bf	revenge_free_week_1756929690771	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:01:30.771+00	2025-09-10 20:01:30.771+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:01:30.772017+00
3b5bf0ae-e5a5-48ad-9134-ebcef78a76a3	revenge_free_week_1756930750005	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:19:10.005+00	2025-09-10 20:19:10.005+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:19:10.006345+00
b6ea7b1f-76dd-4e83-923e-47d00104978b	revenge_free_week_1756931302167	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:28:22.167+00	2025-09-10 20:28:22.167+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:28:22.168826+00
50d0c45d-34db-486a-9c55-87ec3ae271db	revenge_free_week_1756931519004	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:31:59.004+00	2025-09-10 20:31:59.004+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:31:59.004455+00
932c0f33-93d8-47a0-984c-2a1d2cc2aa59	revenge_free_week_1756931633633	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:33:53.633+00	2025-09-10 20:33:53.633+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:33:53.633835+00
ba9ff0e5-46f7-4f1e-99f3-371ec8824fd2	revenge_free_week_1756931790388	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:36:30.388+00	2025-09-10 20:36:30.388+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:36:30.389406+00
7e776337-0961-4aca-9f40-7240f96f2ee0	revenge_free_week_1756932115773	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:41:55.773+00	2025-09-10 20:41:55.773+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:41:55.775311+00
9e743e06-0b92-4ffd-9e44-ba5acd63feed	revenge_free_week_1756933139971	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-03 20:58:59.971+00	2025-09-10 20:58:59.971+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-03 20:58:59.972364+00
1978e83d-ae76-4a55-b286-98ce39726f25	revenge_free_week_1758655543192	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-23 19:25:43.192+00	2025-09-30 19:25:43.192+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-23 19:25:43.193759+00
127dd4e5-3db5-4aac-ae3f-bc675672efb9	revenge_free_week_1758655644314	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-23 19:27:24.314+00	2025-09-30 19:27:24.314+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-23 19:27:24.314791+00
deb87c83-0439-4f7d-9724-56b577654972	revenge_free_week_1758655858283	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-23 19:30:58.283+00	2025-09-30 19:30:58.283+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-23 19:30:58.284153+00
b1cbcb58-5b1f-490e-a8ed-85e2d00b7c2a	revenge_free_week_1758656424450	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-23 19:40:24.45+00	2025-09-30 19:40:24.45+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-23 19:40:24.450544+00
9a8a0c50-8c0a-4ace-a72a-7823cff0917d	revenge_free_week_1758660024454	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-23 20:40:24.454+00	2025-09-30 20:40:24.454+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-23 20:40:24.456068+00
c489d52e-046e-42f8-97f8-6eb22a34568a	revenge_free_week_1758663624447	Weekly Revenge Trading Challenge	Go a full week without revenge trading incidents	behavioral	2025-09-23 21:40:24.447+00	2025-09-30 21:40:24.447+00	{"days": 7, "type": "trades_without_revenge"}	100	\N	f	7	2025-09-23 21:40:24.448204+00
\.


--
-- Data for Name: cusip_lookup_queue; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.cusip_lookup_queue (id, cusip, status, attempts, max_attempts, last_attempt_at, created_at, error_message, priority) FROM stdin;
66	87807D509	failed	5	5	2025-09-23 21:13:15.484088	2025-09-03 17:56:34.472657	No symbol found (both Finnhub and AI failed)	2
67	74907L300	failed	5	5	2025-09-23 21:13:22.019884	2025-09-03 17:56:34.473284	No symbol found (both Finnhub and AI failed)	2
103	76135L507	failed	5	5	2025-09-23 23:50:27.01999	2025-09-03 17:56:34.486723	No symbol found (both Finnhub and AI failed)	2
73	74449F209	failed	5	5	2025-09-23 21:13:34.983018	2025-09-03 17:56:34.475779	No symbol found (both Finnhub and AI failed)	2
75	G50716102	failed	5	5	2025-09-23 21:18:38.49674	2025-09-03 17:56:34.476544	No symbol found (both Finnhub and AI failed)	2
49	86800U302	completed	0	5	2025-09-03 20:58:25.395244	2025-09-03 17:56:34.463913	\N	2
50	137404109	completed	0	5	2025-09-03 20:59:00.16256	2025-09-03 17:56:34.464305	\N	2
76	345523203	failed	5	5	2025-09-23 21:18:44.904315	2025-09-03 17:56:34.47693	No symbol found (both Finnhub and AI failed)	2
115	Y1R80M106	failed	5	5	2025-09-24 08:26:57.346407	2025-09-03 17:56:34.491218	No symbol found (both Finnhub and AI failed)	2
69	71880W501	completed	0	5	2025-09-03 21:15:26.012588	2025-09-03 17:56:34.474244	\N	2
3	83548R402	failed	5	5	2025-09-03 20:19:17.171228	2025-09-03 17:56:34.440554	No symbol found (both Finnhub and AI failed)	2
72	89669L207	completed	0	5	2025-09-03 21:20:37.311476	2025-09-03 17:56:34.475397	\N	2
53	03211Q200	completed	0	5	2025-09-03 20:59:16.943192	2025-09-03 17:56:34.465503	\N	2
60	G7185A136	failed	5	5	2025-09-23 20:34:54.467965	2025-09-03 17:56:34.470108	No symbol found (both Finnhub and AI failed)	2
74	62844N406	completed	0	5	2025-09-03 21:20:47.424838	2025-09-03 17:56:34.476183	\N	2
5	45032V207	failed	5	5	2025-09-03 20:19:24.453134	2025-09-03 17:56:34.442503	No symbol found (both Finnhub and AI failed)	2
7	251936100	failed	5	5	2025-09-03 20:24:28.427986	2025-09-03 17:56:34.443988	No symbol found (both Finnhub and AI failed)	2
55	89532M101	completed	0	5	2025-09-03 21:04:24.532007	2025-09-03 17:56:34.466201	\N	2
10	373678606	failed	5	5	2025-09-03 20:24:38.987581	2025-09-03 17:56:34.445621	No symbol found (both Finnhub and AI failed)	2
12	M77798136	failed	5	5	2025-09-03 20:28:25.550942	2025-09-03 17:56:34.447017	No symbol found (both Finnhub and AI failed)	2
14	867781700	failed	5	5	2025-09-03 20:28:32.544687	2025-09-03 17:56:34.448302	No symbol found (both Finnhub and AI failed)	2
57	25401N507	completed	0	5	2025-09-03 21:04:34.910205	2025-09-03 17:56:34.467414	\N	2
15	G8292E102	failed	5	5	2025-09-03 20:28:36.25094	2025-09-03 17:56:34.448862	No symbol found (both Finnhub and AI failed)	2
58	97727L408	completed	0	5	2025-09-03 21:04:38.453361	2025-09-03 17:56:34.469058	\N	2
81	83006G203	failed	5	5	2025-09-23 21:51:29.808735	2025-09-03 17:56:34.478934	No symbol found (both Finnhub and AI failed)	2
83	G5223X159	failed	5	5	2025-09-23 21:51:36.276068	2025-09-03 17:56:34.479619	No symbol found (both Finnhub and AI failed)	2
82	49382L207	completed	0	5	2025-09-23 19:36:48.055333	2025-09-03 17:56:34.479268	\N	2
85	G1893D102	failed	5	5	2025-09-23 21:51:42.765591	2025-09-03 17:56:34.480229	No symbol found (both Finnhub and AI failed)	2
84	185053402	completed	0	5	2025-09-23 19:40:24.660573	2025-09-03 17:56:34.479941	\N	2
87	G7244A119	failed	5	5	2025-09-23 21:57:05.870537	2025-09-03 17:56:34.480945	No symbol found (both Finnhub and AI failed)	2
90	45784G200	failed	5	5	2025-09-23 21:57:25.428771	2025-09-03 17:56:34.482187	No symbol found (both Finnhub and AI failed)	2
91	89854M101	completed	0	5	2025-09-23 19:46:04.054798	2025-09-03 17:56:34.482589	\N	2
92	80359A205	completed	0	5	2025-09-23 19:46:07.605363	2025-09-03 17:56:34.482987	\N	2
93	44170P106	completed	0	5	2025-09-23 19:46:11.052439	2025-09-03 17:56:34.483322	\N	2
94	74765K105	completed	0	5	2025-09-23 19:51:11.586019	2025-09-03 17:56:34.483674	\N	2
96	22890A302	completed	0	5	2025-09-23 19:51:21.796564	2025-09-03 17:56:34.48438	\N	2
97	46121E304	completed	0	5	2025-09-23 19:51:25.309769	2025-09-03 17:56:34.484699	\N	2
46	06682J308	failed	5	5	2025-09-23 19:56:33.083361	2025-09-03 17:56:34.462396	No symbol found (both Finnhub and AI failed)	2
19	G7309R106	failed	5	5	2025-09-03 20:32:09.408765	2025-09-03 17:56:34.450535	No symbol found (both Finnhub and AI failed)	2
59	87169M105	completed	0	5	2025-09-03 21:04:42.376697	2025-09-03 17:56:34.469683	\N	2
21	98936T208	completed	4	5	2025-09-03 20:33:53.891329	2025-09-03 17:56:34.451727	\N	2
47	00974H104	failed	5	5	2025-09-23 19:56:39.573719	2025-09-03 17:56:34.462965	No symbol found (both Finnhub and AI failed)	2
22	92919Y102	completed	4	5	2025-09-03 20:33:59.220094	2025-09-03 17:56:34.452227	\N	2
61	67054R203	completed	0	5	2025-09-03 21:09:50.132983	2025-09-03 17:56:34.470494	\N	2
24	G8976D107	completed	4	5	2025-09-03 20:34:06.406735	2025-09-03 17:56:34.453197	\N	2
48	C00948205	failed	5	5	2025-09-23 19:56:46.105062	2025-09-03 17:56:34.463467	No symbol found (both Finnhub and AI failed)	2
62	09077A106	completed	0	5	2025-09-03 21:09:53.573383	2025-09-03 17:56:34.47089	\N	2
36	M61472136	completed	3	5	2025-09-03 20:36:30.720001	2025-09-03 17:56:34.457951	\N	2
38	G2287A126	completed	3	5	2025-09-03 20:36:38.332907	2025-09-03 17:56:34.458718	\N	2
51	107930109	failed	5	5	2025-09-23 20:02:02.723244	2025-09-03 17:56:34.464734	No symbol found (both Finnhub and AI failed)	2
64	19243B102	completed	0	5	2025-09-03 21:10:03.981959	2025-09-03 17:56:34.471637	\N	2
26	74638P208	completed	4	5	2025-09-03 20:41:55.611909	2025-09-03 17:56:34.454221	\N	2
65	64132R404	completed	0	5	2025-09-03 21:15:04.452849	2025-09-03 17:56:34.472091	\N	2
27	16307X202	completed	4	5	2025-09-03 20:41:59.513827	2025-09-03 17:56:34.454602	\N	2
52	63008J603	failed	5	5	2025-09-23 20:02:09.131584	2025-09-03 17:56:34.465143	No symbol found (both Finnhub and AI failed)	2
29	85237B101	completed	4	5	2025-09-03 20:42:10.157279	2025-09-03 17:56:34.455337	\N	2
31	28622K203	failed	5	5	2025-09-03 20:47:17.944293	2025-09-03 17:56:34.455969	No symbol found (both Finnhub and AI failed)	2
56	963025846	failed	5	5	2025-09-23 20:02:22.410753	2025-09-03 17:56:34.466903	No symbol found (both Finnhub and AI failed)	2
68	37892C106	completed	0	5	2025-09-03 21:15:22.058754	2025-09-03 17:56:34.473831	\N	2
33	74365U107	completed	4	5	2025-09-03 20:47:27.85718	2025-09-03 17:56:34.456607	\N	2
34	G9376R209	failed	5	5	2025-09-03 20:47:34.86628	2025-09-03 17:56:34.457049	No symbol found (both Finnhub and AI failed)	2
71	09057N409	completed	0	5	2025-09-03 21:20:33.814208	2025-09-03 17:56:34.475019	\N	2
40	83558L303	completed	3	5	2025-09-03 20:52:41.357913	2025-09-03 17:56:34.459759	\N	2
41	45781K204	completed	2	5	2025-09-03 20:52:44.896006	2025-09-03 17:56:34.460214	\N	2
42	98944F109	completed	2	5	2025-09-03 20:52:48.364033	2025-09-03 17:56:34.460533	\N	2
77	44486Q103	completed	0	5	2025-09-03 21:26:07.777591	2025-09-03 17:56:34.477293	\N	2
78	75946W405	completed	0	5	2025-09-03 21:26:11.300488	2025-09-03 17:56:34.477747	\N	2
44	230770109	completed	1	5	2025-09-03 20:52:58.321432	2025-09-03 17:56:34.461254	\N	2
79	86633R609	completed	0	5	2025-09-03 21:37:01.474219	2025-09-03 17:56:34.478224	\N	2
80	36254L308	completed	0	5	2025-09-03 21:37:05.044696	2025-09-03 17:56:34.478562	\N	2
101	538146101	completed	0	5	2025-09-23 20:24:04.08994	2025-09-03 17:56:34.486075	\N	2
139	05330T205	completed	0	5	2025-09-24 13:20:03.135305	2025-09-03 17:56:34.500578	\N	2
157	48669G204	failed	5	5	2025-09-24 16:03:46.541013	2025-09-03 17:56:34.507692	No symbol found (both Finnhub and AI failed)	2
180	20678X205	failed	5	5	2025-09-24 17:52:24.25352	2025-09-03 17:56:34.517133	No symbol found (both Finnhub and AI failed)	2
158	14179K101	failed	5	5	2025-09-24 16:03:53.006768	2025-09-03 17:56:34.5085	No symbol found (both Finnhub and AI failed)	2
141	75630B402	completed	0	5	2025-09-24 13:20:13.150619	2025-09-03 17:56:34.501316	\N	2
222	76090R309	failed	5	5	2025-09-24 20:03:43.208192	2025-09-03 17:56:34.534525	No symbol found (both Finnhub and AI failed)	2
106	G6781A102	failed	5	5	2025-09-23 23:50:40.048095	2025-09-03 17:56:34.488079	No symbol found (both Finnhub and AI failed)	2
116	75903M309	completed	0	5	2025-09-23 21:08:04.844704	2025-09-03 17:56:34.491727	\N	2
142	457637700	completed	0	5	2025-09-24 13:20:16.53305	2025-09-03 17:56:34.501837	\N	2
174	53630L209	completed	0	5	2025-09-24 15:09:20.423538	2025-09-03 17:56:34.514826	\N	2
188	49457M106	completed	0	5	2025-09-24 16:04:02.580108	2025-09-03 17:56:34.520347	\N	2
182	185063104	failed	5	5	2025-09-24 17:57:47.883079	2025-09-03 17:56:34.517955	No symbol found (both Finnhub and AI failed)	2
167	75618M305	completed	0	5	2025-09-24 14:20:14.660095	2025-09-03 17:56:34.51196	\N	2
128	90137F400	failed	5	5	2025-09-24 15:14:37.520563	2025-09-03 17:56:34.496503	No symbol found (both Finnhub and AI failed)	2
146	896438504	completed	0	5	2025-09-24 13:25:33.275399	2025-09-03 17:56:34.503398	\N	2
147	74754R301	completed	0	5	2025-09-24 13:25:36.649521	2025-09-03 17:56:34.503932	\N	2
185	59564R807	failed	5	5	2025-09-24 18:03:17.551322	2025-09-03 17:56:34.519232	No symbol found (both Finnhub and AI failed)	2
108	89458T205	failed	5	5	2025-09-24 05:21:45.624958	2025-09-03 17:56:34.488842	No symbol found (both Finnhub and AI failed)	2
117	M82618113	failed	5	5	2025-09-24 13:30:46.89794	2025-09-03 17:56:34.492711	No symbol found (both Finnhub and AI failed)	2
110	80512Q402	failed	5	5	2025-09-24 05:21:52.050288	2025-09-03 17:56:34.489513	No symbol found (both Finnhub and AI failed)	2
176	131100109	completed	0	5	2025-09-24 15:14:46.976304	2025-09-03 17:56:34.515617	\N	2
112	M2361E179	failed	5	5	2025-09-24 05:21:58.426104	2025-09-03 17:56:34.490181	No symbol found (both Finnhub and AI failed)	2
177	29446K106	completed	0	5	2025-09-24 15:14:50.547408	2025-09-03 17:56:34.515972	\N	2
190	08771Y402	completed	0	5	2025-09-24 16:09:29.357193	2025-09-03 17:56:34.521074	\N	2
98	92346X206	completed	0	5	2025-09-23 19:51:28.836308	2025-09-03 17:56:34.485016	\N	2
189	501506703	failed	5	5	2025-09-24 18:14:02.14318	2025-09-03 17:56:34.520675	No symbol found (both Finnhub and AI failed)	2
191	747324101	completed	0	5	2025-09-24 16:09:32.866729	2025-09-03 17:56:34.52145	\N	2
168	74764Y205	completed	0	5	2025-09-24 14:31:03.654056	2025-09-03 17:56:34.512474	\N	2
163	40423R105	failed	5	5	2025-09-24 16:14:37.023356	2025-09-03 17:56:34.510529	No symbol found (both Finnhub and AI failed)	2
122	G47862100	failed	5	5	2025-09-24 14:36:14.056151	2025-09-03 17:56:34.494496	No symbol found (both Finnhub and AI failed)	2
175	696077502	failed	5	5	2025-09-24 17:19:48.270553	2025-09-03 17:56:34.515263	No symbol found (both Finnhub and AI failed)	2
193	00941Q203	failed	5	5	2025-09-24 18:30:25.669221	2025-09-03 17:56:34.522235	No symbol found (both Finnhub and AI failed)	2
200	45339J105	failed	5	5	2025-09-24 19:03:30.100992	2025-09-03 17:56:34.524906	No symbol found (both Finnhub and AI failed)	2
194	44916K106	completed	0	5	2025-09-24 16:20:31.637022	2025-09-03 17:56:34.522666	\N	2
178	71902K303	failed	5	5	2025-09-24 17:36:07.909057	2025-09-03 17:56:34.516347	No symbol found (both Finnhub and AI failed)	2
104	307359885	completed	0	5	2025-09-23 20:24:20.691298	2025-09-03 17:56:34.487207	\N	2
164	107930208	failed	5	5	2025-09-24 16:25:35.795794	2025-09-03 17:56:34.510892	No symbol found (both Finnhub and AI failed)	2
145	G7122D102	failed	5	5	2025-09-24 15:36:24.236542	2025-09-03 17:56:34.503044	No symbol found (both Finnhub and AI failed)	2
172	70261F202	completed	0	5	2025-09-24 14:53:04.506672	2025-09-03 17:56:34.514144	\N	2
165	M97838128	failed	5	5	2025-09-24 16:25:42.338286	2025-09-03 17:56:34.511242	No symbol found (both Finnhub and AI failed)	2
166	890260847	failed	5	5	2025-09-24 16:25:48.847119	2025-09-03 17:56:34.511554	No symbol found (both Finnhub and AI failed)	2
179	54570M207	failed	5	5	2025-09-24 17:46:57.927159	2025-09-03 17:56:34.516737	No symbol found (both Finnhub and AI failed)	2
169	655187300	failed	5	5	2025-09-24 16:41:49.618305	2025-09-03 17:56:34.512965	No symbol found (both Finnhub and AI failed)	2
170	57630J403	failed	5	5	2025-09-24 16:47:16.302716	2025-09-03 17:56:34.513397	No symbol found (both Finnhub and AI failed)	2
151	25400Q105	completed	0	5	2025-09-24 13:41:58.21125	2025-09-03 17:56:34.505358	\N	2
152	67644C104	completed	0	5	2025-09-24 13:42:01.583398	2025-09-03 17:56:34.50575	\N	2
114	G4236L138	failed	5	5	2025-09-24 08:26:50.967523	2025-09-03 17:56:34.490875	No symbol found (both Finnhub and AI failed)	2
154	82670R305	completed	0	5	2025-09-24 13:47:14.856017	2025-09-03 17:56:34.506408	\N	2
111	629444209	completed	0	5	2025-09-23 20:35:13.997287	2025-09-03 17:56:34.489853	\N	2
149	G1281K122	failed	5	5	2025-09-24 15:47:23.756793	2025-09-03 17:56:34.504577	No symbol found (both Finnhub and AI failed)	2
113	731105102	completed	0	5	2025-09-23 20:57:08.705067	2025-09-03 17:56:34.490517	\N	2
173	05156X850	completed	0	5	2025-09-24 15:04:00.191823	2025-09-03 17:56:34.514466	\N	2
181	70336F203	completed	0	5	2025-09-24 15:47:26.762917	2025-09-03 17:56:34.517564	\N	2
119	456948108	completed	0	5	2025-09-23 21:46:02.533002	2025-09-03 17:56:34.493369	\N	2
120	17248W303	completed	0	5	2025-09-23 21:46:06.213922	2025-09-03 17:56:34.493735	\N	2
184	00439U104	completed	0	5	2025-09-24 15:47:43.04573	2025-09-03 17:56:34.518835	\N	2
126	66987P409	completed	0	5	2025-09-24 13:04:12.311101	2025-09-03 17:56:34.49583	\N	2
131	63903P209	completed	0	5	2025-09-24 13:09:38.721013	2025-09-03 17:56:34.497733	\N	2
132	834223604	completed	0	5	2025-09-24 13:09:42.104701	2025-09-03 17:56:34.498176	\N	2
133	317970101	completed	0	5	2025-09-24 13:09:45.486922	2025-09-03 17:56:34.498496	\N	2
134	68764Y207	completed	0	5	2025-09-24 13:14:45.97568	2025-09-03 17:56:34.498863	\N	2
135	29970R303	completed	0	5	2025-09-24 13:14:49.482923	2025-09-03 17:56:34.499201	\N	2
136	02322P309	completed	0	5	2025-09-24 13:14:52.861819	2025-09-03 17:56:34.499562	\N	2
137	696389402	completed	0	5	2025-09-24 13:14:56.242018	2025-09-03 17:56:34.499894	\N	2
160	80603V104	completed	0	5	2025-09-24 13:58:10.620465	2025-09-03 17:56:34.509471	\N	2
161	00534A102	completed	0	5	2025-09-24 13:58:14.045522	2025-09-03 17:56:34.509856	\N	2
156	G8193D104	failed	5	5	2025-09-24 15:58:29.618278	2025-09-03 17:56:34.507261	No symbol found (both Finnhub and AI failed)	2
118	M1R95N100	failed	5	5	2025-09-24 14:03:24.469241	2025-09-03 17:56:34.493081	No symbol found (both Finnhub and AI failed)	2
121	M5R635108	failed	5	5	2025-09-24 14:03:30.892272	2025-09-03 17:56:34.494158	No symbol found (both Finnhub and AI failed)	2
207	880245105	completed	0	5	2025-09-24 16:58:21.666239	2025-09-03 17:56:34.527843	\N	2
208	432705309	completed	0	5	2025-09-24 16:58:25.19069	2025-09-03 17:56:34.528379	\N	2
209	88066N303	completed	0	5	2025-09-24 16:58:28.719777	2025-09-03 17:56:34.528833	\N	2
229	74347G192	completed	0	5	2025-09-24 17:52:33.742436	2025-09-03 17:56:34.537433	\N	2
210	52187K200	completed	0	5	2025-09-24 17:03:42.260652	2025-09-03 17:56:34.529461	\N	2
211	68840D102	completed	0	5	2025-09-24 17:03:45.76654	2025-09-03 17:56:34.53003	\N	2
212	739650109	completed	0	5	2025-09-24 17:03:49.278979	2025-09-03 17:56:34.530607	\N	2
231	74347X831	completed	0	5	2025-09-24 17:52:43.737686	2025-09-03 17:56:34.538303	\N	2
232	888705308	completed	0	5	2025-09-24 18:03:33.823156	2025-09-03 17:56:34.538618	\N	2
233	01438T106	completed	0	5	2025-09-24 18:03:37.335462	2025-09-03 17:56:34.53904	\N	2
215	G0447T100	failed	5	5	2025-09-24 20:03:36.68331	2025-09-03 17:56:34.531722	No symbol found (both Finnhub and AI failed)	2
234	91733P107	completed	0	5	2025-09-24 18:08:51.006502	2025-09-03 17:56:34.53942	\N	2
235	881624209	completed	0	5	2025-09-24 18:08:54.488949	2025-09-03 17:56:34.539955	\N	2
236	590479135	completed	0	5	2025-09-24 18:08:57.998247	2025-09-03 17:56:34.540335	\N	2
237	02919L604	completed	0	5	2025-09-24 18:14:24.637266	2025-09-03 17:56:34.540655	\N	2
224	G9548D104	failed	5	5	2025-09-24 21:02:34.662678	2025-09-03 17:56:34.535355	No symbol found (both Finnhub and AI failed)	2
230	03835L405	failed	5	5	2025-09-24 21:02:47.773841	2025-09-03 17:56:34.53785	No symbol found (both Finnhub and AI failed)	2
239	G37692103	failed	5	5	2025-09-24 22:02:33.677723	2025-09-03 17:56:34.541391	No symbol found (both Finnhub and AI failed)	2
162	G3855L106	failed	5	5	2025-09-24 16:09:13.233521	2025-09-03 17:56:34.510191	No symbol found (both Finnhub and AI failed)	2
43	G4000K175	failed	5	5	2025-09-23 19:25:47.245166	2025-09-03 17:56:34.460873	No symbol found (both Finnhub and AI failed)	2
100	68237Q104	failed	5	5	2025-09-23 22:08:05.140684	2025-09-03 17:56:34.485739	No symbol found (both Finnhub and AI failed)	2
45	N90064101	failed	5	5	2025-09-23 19:25:53.700755	2025-09-03 17:56:34.461769	No symbol found (both Finnhub and AI failed)	2
150	92731L304	completed	0	5	2025-09-24 13:41:54.754278	2025-09-03 17:56:34.504972	\N	2
143	34546R100	failed	5	5	2025-09-24 15:31:01.106186	2025-09-03 17:56:34.502251	No symbol found (both Finnhub and AI failed)	2
213	98139Q308	completed	0	5	2025-09-24 17:09:09.553148	2025-09-03 17:56:34.531032	\N	2
195	609786108	completed	0	5	2025-09-24 16:31:15.059984	2025-09-03 17:56:34.523082	\N	2
238	47100L301	completed	0	5	2025-09-24 18:19:44.705777	2025-09-03 17:56:34.541016	\N	2
196	03969K108	completed	0	5	2025-09-24 16:31:18.514042	2025-09-03 17:56:34.523474	\N	2
241	63008J702	failed	5	5	2025-09-24 22:02:40.199261	2025-09-03 17:56:34.542133	No symbol found (both Finnhub and AI failed)	2
197	757468301	completed	0	5	2025-09-24 16:31:21.873403	2025-09-03 17:56:34.523828	\N	2
1	00853E404	failed	5	5	2025-09-03 20:19:10.583134	2025-09-03 17:56:34.435104	No symbol found (both Finnhub and AI failed)	2
198	80880X104	completed	0	5	2025-09-24 16:36:29.021692	2025-09-03 17:56:34.524211	\N	2
199	277802500	completed	0	5	2025-09-24 16:36:32.41604	2025-09-03 17:56:34.52453	\N	2
2	23816M206	failed	5	5	2025-09-03 20:19:13.909447	2025-09-03 17:56:34.439419	No symbol found (both Finnhub and AI failed)	2
243	31447N204	failed	5	5	2025-09-24 22:02:46.701448	2025-09-03 17:56:34.542883	No symbol found (both Finnhub and AI failed)	2
240	88338H704	completed	0	5	2025-09-24 18:25:05.079695	2025-09-03 17:56:34.541709	\N	2
4	23257B206	failed	5	5	2025-09-03 20:19:20.884264	2025-09-03 17:56:34.441848	No symbol found (both Finnhub and AI failed)	2
216	17331Y109	completed	0	5	2025-09-24 17:14:44.197291	2025-09-03 17:56:34.532277	\N	2
6	151190204	failed	5	5	2025-09-03 20:24:24.735103	2025-09-03 17:56:34.44329	No symbol found (both Finnhub and AI failed)	2
246	G09675102	failed	5	5	2025-09-24 22:02:59.715393	2025-09-03 17:56:34.543999	No symbol found (both Finnhub and AI failed)	2
204	36322Q206	completed	0	5	2025-09-24 16:42:12.112862	2025-09-03 17:56:34.526354	\N	2
217	78577G301	completed	0	5	2025-09-24 17:19:57.856653	2025-09-03 17:56:34.532709	\N	2
205	45259L205	completed	0	5	2025-09-24 16:47:38.670635	2025-09-03 17:56:34.52689	\N	2
8	92840Q202	failed	5	5	2025-09-03 20:24:31.768501	2025-09-03 17:56:34.444539	No symbol found (both Finnhub and AI failed)	2
242	92332W303	completed	0	5	2025-09-24 18:25:15.091824	2025-09-03 17:56:34.542439	\N	2
9	G6055H155	failed	5	5	2025-09-03 20:24:35.43633	2025-09-03 17:56:34.445103	No symbol found (both Finnhub and AI failed)	2
218	09060U606	completed	0	5	2025-09-24 17:20:01.322512	2025-09-03 17:56:34.533079	\N	2
11	45840Y302	failed	5	5	2025-09-03 20:28:22.268839	2025-09-03 17:56:34.446355	No symbol found (both Finnhub and AI failed)	2
219	218352102	completed	0	5	2025-09-24 17:20:04.759469	2025-09-03 17:56:34.533396	\N	2
220	450958301	completed	0	5	2025-09-24 17:30:51.457767	2025-09-03 17:56:34.533757	\N	2
221	20454B104	completed	0	5	2025-09-24 17:30:55.485898	2025-09-03 17:56:34.534226	\N	2
245	90177C200	completed	0	5	2025-09-24 18:35:51.794014	2025-09-03 17:56:34.543607	\N	2
223	65250K105	completed	0	5	2025-09-24 17:36:17.331555	2025-09-03 17:56:34.53496	\N	2
225	44148G204	completed	0	5	2025-09-24 17:36:27.380937	2025-09-03 17:56:34.535733	\N	2
202	89357L402	failed	5	5	2025-09-24 19:03:43.139142	2025-09-03 17:56:34.525606	No symbol found (both Finnhub and AI failed)	2
226	826165201	completed	0	5	2025-09-24 17:41:53.870527	2025-09-03 17:56:34.536127	\N	2
13	78642D101	failed	5	5	2025-09-03 20:28:29.251544	2025-09-03 17:56:34.44779	No symbol found (both Finnhub and AI failed)	2
227	207944109	completed	0	5	2025-09-24 17:47:20.282677	2025-09-03 17:56:34.536547	\N	2
16	47714H308	failed	5	5	2025-09-03 20:31:59.173935	2025-09-03 17:56:34.449287	No symbol found (both Finnhub and AI failed)	2
17	14817C107	failed	5	5	2025-09-03 20:32:02.46042	2025-09-03 17:56:34.449629	No symbol found (both Finnhub and AI failed)	2
18	Q9379E105	failed	5	5	2025-09-03 20:32:06.126274	2025-09-03 17:56:34.450086	No symbol found (both Finnhub and AI failed)	2
20	84757T105	failed	5	5	2025-09-03 20:32:13.068158	2025-09-03 17:56:34.451128	No symbol found (both Finnhub and AI failed)	2
23	83193D203	completed	4	5	2025-09-03 20:34:02.83049	2025-09-03 17:56:34.452631	\N	2
25	64113L202	completed	4	5	2025-09-03 20:34:10.035022	2025-09-03 17:56:34.453582	\N	2
37	05344R302	completed	3	5	2025-09-03 20:36:34.560544	2025-09-03 17:56:34.458372	\N	2
39	G9442G120	processing	3	5	2025-09-03 20:36:42.443522	2025-09-03 17:56:34.459203	No symbol found (both Finnhub and AI failed)	2
28	H57830137	failed	5	5	2025-09-03 20:42:07.149569	2025-09-03 17:56:34.454981	No symbol found (both Finnhub and AI failed)	2
30	23255M204	completed	4	5	2025-09-03 20:42:13.738995	2025-09-03 17:56:34.455644	\N	2
32	G3662E105	failed	5	5	2025-09-03 20:47:24.849076	2025-09-03 17:56:34.456277	No symbol found (both Finnhub and AI failed)	2
35	G989MC106	failed	5	5	2025-09-03 20:47:41.334285	2025-09-03 17:56:34.457445	No symbol found (both Finnhub and AI failed)	2
63	M79549107	failed	5	5	2025-09-23 21:13:08.956078	2025-09-03 17:56:34.471232	No symbol found (both Finnhub and AI failed)	2
144	44967K302	completed	0	5	2025-09-24 13:25:23.437392	2025-09-03 17:56:34.502585	\N	2
70	M77798144	failed	5	5	2025-09-23 21:13:28.430116	2025-09-03 17:56:34.474623	No symbol found (both Finnhub and AI failed)	2
95	97264L100	failed	5	5	2025-09-23 22:02:28.994379	2025-09-03 17:56:34.484038	No symbol found (both Finnhub and AI failed)	2
159	73017P102	failed	5	5	2025-09-24 16:03:59.567993	2025-09-03 17:56:34.509037	No symbol found (both Finnhub and AI failed)	2
183	87978U108	failed	5	5	2025-09-24 17:57:54.375072	2025-09-03 17:56:34.518443	No symbol found (both Finnhub and AI failed)	2
99	G6096M122	failed	5	5	2025-09-23 22:07:58.687414	2025-09-03 17:56:34.485456	No symbol found (both Finnhub and AI failed)	2
127	28059P303	failed	5	5	2025-09-24 15:14:31.033978	2025-09-03 17:56:34.496123	No symbol found (both Finnhub and AI failed)	2
54	83013Q806	failed	5	5	2025-09-23 20:02:15.904004	2025-09-03 17:56:34.465827	No symbol found (both Finnhub and AI failed)	2
129	09076W109	failed	5	5	2025-09-24 15:19:54.61821	2025-09-03 17:56:34.496839	No symbol found (both Finnhub and AI failed)	2
130	79400X404	failed	5	5	2025-09-24 15:20:01.125794	2025-09-03 17:56:34.497264	No symbol found (both Finnhub and AI failed)	2
214	249845405	failed	5	5	2025-09-24 20:03:30.11787	2025-09-03 17:56:34.531391	No symbol found (both Finnhub and AI failed)	2
138	M7S13T102	failed	5	5	2025-09-24 15:25:24.380416	2025-09-03 17:56:34.500264	No symbol found (both Finnhub and AI failed)	2
109	42237K508	completed	0	5	2025-09-23 20:35:04.104933	2025-09-03 17:56:34.489171	\N	2
102	343927109	failed	5	5	2025-09-23 23:50:20.47196	2025-09-03 17:56:34.486394	No symbol found (both Finnhub and AI failed)	2
186	M53637100	failed	5	5	2025-09-24 18:03:24.187346	2025-09-03 17:56:34.519622	No symbol found (both Finnhub and AI failed)	2
105	G55032166	failed	5	5	2025-09-23 23:50:33.639234	2025-09-03 17:56:34.48765	No symbol found (both Finnhub and AI failed)	2
140	42328V801	failed	5	5	2025-09-24 15:30:54.459872	2025-09-03 17:56:34.500948	No symbol found (both Finnhub and AI failed)	2
187	71910P203	failed	5	5	2025-09-24 18:08:41.51464	2025-09-03 17:56:34.519985	No symbol found (both Finnhub and AI failed)	2
107	G67927114	failed	5	5	2025-09-23 23:50:46.513239	2025-09-03 17:56:34.488482	No symbol found (both Finnhub and AI failed)	2
148	G9520U116	failed	5	5	2025-09-24 15:36:30.791879	2025-09-03 17:56:34.504268	No symbol found (both Finnhub and AI failed)	2
171	M2R43K362	failed	5	5	2025-09-24 16:47:22.730351	2025-09-03 17:56:34.513767	No symbol found (both Finnhub and AI failed)	2
86	M8186D122	failed	5	5	2025-09-23 21:56:59.404299	2025-09-03 17:56:34.480641	No symbol found (both Finnhub and AI failed)	2
228	G8232Y101	failed	5	5	2025-09-24 21:02:41.213725	2025-09-03 17:56:34.5369	No symbol found (both Finnhub and AI failed)	2
123	81728A108	failed	5	5	2025-09-24 14:36:20.484288	2025-09-03 17:56:34.49482	No symbol found (both Finnhub and AI failed)	2
88	142922103	failed	5	5	2025-09-23 21:57:12.311875	2025-09-03 17:56:34.481242	No symbol found (both Finnhub and AI failed)	2
89	G08908124	failed	5	5	2025-09-23 21:57:18.831671	2025-09-03 17:56:34.481651	No symbol found (both Finnhub and AI failed)	2
153	62856X201	failed	5	5	2025-09-24 15:58:16.710727	2025-09-03 17:56:34.506072	No symbol found (both Finnhub and AI failed)	2
124	97382D501	failed	5	5	2025-09-24 14:41:43.403996	2025-09-03 17:56:34.495165	No symbol found (both Finnhub and AI failed)	2
244	G041JN130	failed	5	5	2025-09-24 22:02:53.164626	2025-09-03 17:56:34.543207	No symbol found (both Finnhub and AI failed)	2
125	G33277131	failed	5	5	2025-09-24 14:41:49.883429	2025-09-03 17:56:34.495494	No symbol found (both Finnhub and AI failed)	2
155	G2161Y125	failed	5	5	2025-09-24 15:58:23.18441	2025-09-03 17:56:34.506772	No symbol found (both Finnhub and AI failed)	2
192	G14492121	failed	5	5	2025-09-24 18:30:19.231661	2025-09-03 17:56:34.521774	No symbol found (both Finnhub and AI failed)	2
201	G79483106	failed	5	5	2025-09-24 19:03:36.594716	2025-09-03 17:56:34.52525	No symbol found (both Finnhub and AI failed)	2
203	73017P201	failed	5	5	2025-09-24 19:03:49.620403	2025-09-03 17:56:34.525987	No symbol found (both Finnhub and AI failed)	2
206	G6077Y301	failed	5	5	2025-09-24 19:03:56.138512	2025-09-03 17:56:34.527362	No symbol found (both Finnhub and AI failed)	2
\.


--
-- Data for Name: cusip_mappings; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.cusip_mappings (id, cusip, ticker, company_name, resolution_source, user_id, confidence_score, verified, created_at, updated_at, created_by) FROM stdin;
\.


--
-- Data for Name: device_tokens; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.device_tokens (id, user_id, device_token, platform, environment, bundle_id, active, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: devices; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.devices (id, user_id, device_name, device_type, device_model, device_fingerprint, platform_version, app_version, last_active, is_trusted, push_token, push_platform, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: diary_attachments; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.diary_attachments (id, diary_entry_id, file_url, file_type, file_name, file_size, uploaded_at) FROM stdin;
\.


--
-- Data for Name: diary_entries; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.diary_entries (id, user_id, entry_date, title, content, tags, entry_type, market_bias, key_levels, watchlist, followed_plan, lessons_learned, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: enrichment_cache; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.enrichment_cache (id, symbol, entry_date, entry_time, cache_key, strategy, strategy_confidence, classification_method, classification_signals, entry_price, market_cap, volume_24h, sector, industry, rsi_14, sma_20, sma_50, bollinger_upper, bollinger_lower, implied_volatility, beta, news_sentiment_score, news_count_24h, earnings_proximity_days, typical_mae_percent, typical_mfe_percent, mae_confidence, data_source, api_provider, created_at, updated_at, last_accessed_at, access_count, expires_at, is_valid) FROM stdin;
\.


--
-- Data for Name: equity_history; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.equity_history (id, user_id, date, equity, pnl, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: equity_snapshots; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.equity_snapshots (id, user_id, equity_amount, snapshot_date, notes, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: features; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.features (id, feature_key, feature_name, description, required_tier, is_active, created_at, updated_at) FROM stdin;
62fa1935-c868-405e-a654-f3aace1729d5	behavioral_alerts	Behavioral Alerts	Real-time alerts for problematic trading behaviors	pro	t	2025-09-03 17:47:11.440969+00	2025-09-03 17:47:11.440969+00
59428bbb-7332-40ad-8aba-304315b0f449	behavioral_analytics	Behavioral Analytics	Advanced behavioral pattern analysis including revenge trading detection	pro	t	2025-09-03 17:47:11.440969+00	2025-09-03 17:47:11.461243+00
631d9dc4-869f-4f35-b78e-5908b5cd7f0b	revenge_trading_detection	Revenge Trading Detection	Detect and alert on revenge trading patterns	pro	t	2025-09-03 17:47:11.440969+00	2025-09-03 17:47:11.461243+00
1f6bb8e6-4b47-4890-8e84-78af04e25573	trade_blocking	Automatic Trade Blocking	Block trades during high-risk emotional periods	pro	t	2025-09-03 17:47:11.440969+00	2025-09-03 17:47:11.461243+00
63799a58-d4b3-4635-bb2b-48855a67ec1f	overconfidence_analytics	Overconfidence Analytics	Detect overconfidence patterns from win streaks and position size increases	pro	t	2025-09-03 17:47:11.462831+00	2025-09-03 17:47:11.462831+00
fd3ff160-4958-44c8-8115-3378e42e0d1e	overconfidence_alerts	Overconfidence Alerts	Real-time alerts for overconfidence behavior during trading	pro	t	2025-09-03 17:47:11.462831+00	2025-09-03 17:47:11.462831+00
e7f9bc23-abba-4b1d-929b-a81ab78ae15a	watchlists	Stock Watchlists	Create and manage stock watchlists with real-time tracking	pro	t	2025-09-03 17:47:11.527167+00	2025-09-03 17:47:11.527167+00
1bcc197b-3d83-4198-8698-922e02cd981f	price_alerts	Price Alerts	Set up email and browser notifications for price targets	pro	t	2025-09-03 17:47:11.527167+00	2025-09-03 17:47:11.527167+00
dff14fb7-9f72-4344-b47f-6a8baf864373	realtime_monitoring	Real-time Price Monitoring	Real-time price updates and monitoring for watchlist items	pro	t	2025-09-03 17:47:11.527167+00	2025-09-03 17:47:11.527167+00
\.


--
-- Data for Name: gamification_privacy; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.gamification_privacy (user_id, show_on_leaderboards, anonymous_only, share_achievements, participate_in_challenges, share_with_peer_group, visible_metrics, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: global_enrichment_cache; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.global_enrichment_cache (id, symbol, trade_date, news_sentiment, news_count, news_summary, major_news_events, market_cap, volume, avg_volume, volatility, sector, industry, data_sources, confidence_score, created_at, updated_at, expires_at, access_count, last_accessed_at) FROM stdin;
\.


--
-- Data for Name: import_logs; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.import_logs (id, user_id, broker, file_name, trades_imported, trades_failed, status, error_details, created_at, completed_at) FROM stdin;
d400a913-c254-4cc6-b4ab-43ebb3239495	2d96cef2-7502-44ff-a7a9-17713d4a7a42	lightspeed	all-lightspeed-safe-profit.csv	428	0	completed	{"duplicates": 0}	2025-09-03 18:46:54.030121+00	2025-09-03 18:49:22.27682+00
\.


--
-- Data for Name: instance_config; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.instance_config (id, key, value, description, is_public, created_at, updated_at) FROM stdin;
c8d6cf8a-f6e0-4541-adc0-3b5f0acf26f6	instance_name	"TradeTally"	Display name for this instance	t	2025-09-03 17:47:11.269514+00	2025-09-03 17:47:11.269514+00
55ceda7a-5dc5-4316-955e-cf1b24fd9fcb	instance_url	""	Base URL for this instance	t	2025-09-03 17:47:11.269514+00	2025-09-03 17:47:11.269514+00
222fdcbd-10d2-4153-a089-6a00c45992ab	api_version	"v1"	Current API version	t	2025-09-03 17:47:11.269514+00	2025-09-03 17:47:11.269514+00
420dd861-8308-45f6-8855-81490ba27dec	features	{"api_keys": false, "webhooks": false, "mobile_sync": true, "multi_device": true, "offline_mode": true, "biometric_auth": true, "push_notifications": false}	Feature flags for this instance	t	2025-09-03 17:47:11.269514+00	2025-09-03 17:47:11.269514+00
ea17a4ef-8b73-4fc2-be1d-4dc5eb136820	mobile_config	{"min_app_version": "1.0.0", "offline_cache_days": 30, "refresh_token_days": 30, "force_update_version": null, "max_devices_per_user": 10, "sync_interval_seconds": 300, "session_timeout_minutes": 15}	Mobile app configuration	t	2025-09-03 17:47:11.269514+00	2025-09-03 17:47:11.269514+00
a0f4d51f-87f9-436f-9fad-3c046353b2a0	security_config	{"mfa_enabled": false, "cors_origins": ["http://localhost:5173"], "require_https": true, "password_min_length": 8, "rate_limit_requests": 1000, "password_require_special": false, "rate_limit_window_minutes": 15, "session_idle_timeout_minutes": 60}	Security configuration	f	2025-09-03 17:47:11.269514+00	2025-09-03 17:47:11.269514+00
a99563a6-27bc-4a29-b8c2-e64fd54cdc2d	billing_enabled	false	Enable Stripe billing integration	f	2025-09-03 17:47:11.39534+00	2025-09-03 17:47:11.39534+00
21986d6c-4743-47da-8869-d11dab1af4bc	stripe_webhook_endpoint_secret	""	Stripe webhook endpoint secret for signature verification	f	2025-09-03 17:47:11.39534+00	2025-09-03 17:47:11.39534+00
\.


--
-- Data for Name: job_queue; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.job_queue (id, type, data, priority, user_id, status, retry_count, created_at, started_at, completed_at, result, error) FROM stdin;
b8abdb4b-ba2e-4f3c-bcaa-49d06457ca89	cusip_resolution	{"cusips": ["74449F209"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.71151+00	2025-09-03 18:01:17.914601+00	2025-09-03 18:01:23.498273+00	{"success": true, "cusipCount": 1}	\N
868e7ad1-cec3-4344-a3e2-28f796560b00	cusip_resolution	{"cusips": ["890260847"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.877126+00	2025-09-03 18:01:22.921192+00	2025-09-03 18:01:24.547951+00	{"success": true, "cusipCount": 1}	\N
1ff4043f-b9ed-45b3-ab64-8187d970cf98	strategy_classification	{"tradeId": "235831b1-fb49-4533-97d7-a613708c7e02"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.667898+00	2025-09-03 18:49:58.234349+00	2025-09-03 18:49:58.245697+00	{"processed": 1}	\N
ff64826a-53e6-47ab-9048-1f64d04569a9	strategy_classification	{"tradeId": "53f6a156-e9c4-4259-81eb-2197046d5e8b"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.672145+00	2025-09-03 18:49:59.242296+00	2025-09-03 18:49:59.263486+00	{"processed": 1}	\N
35acea5a-256a-45f6-b73a-bb6e710138b3	strategy_classification	{"tradeId": "c94f6bfc-07f9-443f-b82e-e5f4c18cd03b"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.67421+00	2025-09-03 18:49:59.739685+00	2025-09-03 18:49:59.746392+00	{"processed": 1}	\N
d7a0880b-8a8f-42a2-a86b-c18f0f985cd9	strategy_classification	{"tradeId": "d84ded0e-a97c-4f17-87a7-60a7d3b1e696"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.677334+00	2025-09-03 18:50:00.240192+00	2025-09-03 18:50:00.263639+00	{"processed": 1}	\N
23b7fe40-086a-4890-893c-e17d0d92227a	cusip_resolution	{"cusips": ["03835L405"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.668994+00	2025-09-03 18:49:58.234178+00	2025-09-03 18:50:00.271674+00	{"success": true, "cusipCount": 1}	\N
a2a0f14c-d450-4de2-951b-b05c8e0d8f60	cusip_resolution	{"cusips": ["03835L405"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.671212+00	2025-09-03 18:49:58.737756+00	2025-09-03 18:50:00.749015+00	{"success": true, "cusipCount": 1}	\N
373cf143-2dac-48e6-b538-9265c0705931	strategy_classification	{"tradeId": "5a23f663-9627-4d03-8366-6a9e6b6a1a7e"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.685468+00	2025-09-03 18:50:01.74733+00	2025-09-03 18:50:01.751466+00	{"processed": 1}	\N
bdadff05-df08-4490-a48f-34c709a26463	strategy_classification	{"tradeId": "f2bb1b0a-8319-421f-82f9-47549b502a34"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.688402+00	2025-09-03 18:50:02.250486+00	2025-09-03 18:50:02.268074+00	{"processed": 1}	\N
87e636a4-b5a5-4c28-89f7-2da12a2a8847	strategy_classification	{"tradeId": "79b26b2e-9d44-4c74-867f-f0ed7ae255ca"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.691514+00	2025-09-03 18:50:02.749512+00	2025-09-03 18:50:02.754117+00	{"processed": 1}	\N
76bc269a-3d2d-4e04-b432-fe710c25696a	cusip_resolution	{"cusips": ["76090R309"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.678516+00	2025-09-03 18:50:01.246871+00	2025-09-03 18:50:02.871124+00	{"success": true, "cusipCount": 1}	\N
c0045f63-bd55-49a9-abd0-419a28a822bb	cusip_resolution	{"cusips": ["G0447T100"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.683907+00	2025-09-03 18:50:03.2501+00	2025-09-03 18:50:05.021205+00	{"success": true, "cusipCount": 1}	\N
7e9d9bb1-25db-4c93-bc54-43145e04f4e4	cusip_resolution	{"cusips": ["G0447T100"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.686669+00	2025-09-03 18:50:05.25675+00	2025-09-03 18:50:06.920445+00	{"success": true, "cusipCount": 1}	\N
8994ea5c-7a2d-4304-ad4f-b618460f97fe	cusip_resolution	{"cusips": ["03835L405"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.675776+00	2025-09-03 18:50:31.096156+00	2025-09-03 18:50:32.819433+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 8994ea5c-7a2d-4304-ad4f-b618460f97fe timed out after 30000ms
2055781d-8a0c-4dbd-82ed-4366b061ac1e	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.698331+00	2025-09-03 18:00:19.128558+00	2025-09-03 18:00:20.780839+00	{"success": true, "cusipCount": 1}	\N
465872f8-1b80-448b-b58f-eccea1afb2c0	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.700699+00	2025-09-03 18:00:20.634453+00	2025-09-03 18:00:22.190534+00	{"success": true, "cusipCount": 1}	\N
d48b7474-7b93-4554-a4ee-77f14a823c7b	cusip_resolution	{"cusips": ["74907L300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.717273+00	2025-09-03 18:00:25.163359+00	2025-09-03 18:00:27.077794+00	{"success": true, "cusipCount": 1}	\N
46d6788c-eda7-4215-bafa-15c315b2c40e	cusip_resolution	{"cusips": ["74907L300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.724762+00	2025-09-03 18:00:27.877824+00	2025-09-03 18:00:29.873111+00	{"success": true, "cusipCount": 1}	\N
60649d01-d197-45ab-bbfa-678f4d2c2237	cusip_resolution	{"cusips": ["87807D509"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.728034+00	2025-09-03 18:00:29.199897+00	2025-09-03 18:00:30.751883+00	{"success": true, "cusipCount": 1}	\N
dc65ea81-d22d-4196-a37c-fb965f997fe9	cusip_resolution	{"cusips": ["M79549107"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.7309+00	2025-09-03 18:00:31.223416+00	2025-09-03 18:00:33.575265+00	{"success": true, "cusipCount": 1}	\N
0eb04991-b9dc-47db-9376-2e187209824d	cusip_resolution	{"cusips": ["M79549107"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.734191+00	2025-09-03 18:00:32.878543+00	2025-09-03 18:00:34.589735+00	{"success": true, "cusipCount": 1}	\N
f8c7e4c6-815d-43b3-8338-e5bc9f842595	cusip_resolution	{"cusips": ["M79549107"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.739968+00	2025-09-03 18:00:36.248563+00	2025-09-03 18:00:38.386572+00	{"success": true, "cusipCount": 1}	\N
5b80a86a-f4bf-4f4a-8c9b-37dcb94f7f5c	cusip_resolution	{"cusips": ["M79549107"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.753966+00	2025-09-03 18:00:37.885065+00	2025-09-03 18:00:39.823716+00	{"success": true, "cusipCount": 1}	\N
7b2a9006-69a6-4320-8376-525235684600	cusip_resolution	{"cusips": ["83013Q806"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.7883+00	2025-09-03 18:00:40.778995+00	2025-09-03 18:00:42.58261+00	{"success": true, "cusipCount": 1}	\N
5e89fc74-8a8f-41d0-ab30-46da05ed920a	cusip_resolution	{"cusips": ["63008J603"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.799449+00	2025-09-03 18:00:42.79004+00	2025-09-03 18:00:45.134549+00	{"success": true, "cusipCount": 1}	\N
c18bd5fc-9e62-4542-989b-37c3f484ea8a	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.706513+00	2025-09-03 18:00:51.869047+00	2025-09-03 18:00:53.837085+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job c18bd5fc-9e62-4542-989b-37c3f484ea8a timed out after 30000ms
c388b668-d4f1-4430-bd8d-30496160527c	cusip_resolution	{"cusips": ["963025846"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.864503+00	2025-09-03 18:01:07.913317+00	2025-09-03 18:01:09.945758+00	{"success": true, "cusipCount": 1}	\N
d0f113d2-39cf-4738-8f12-83035d27cb70	cusip_resolution	{"cusips": ["963025846"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.867451+00	2025-09-03 18:01:12.913316+00	2025-09-03 18:01:14.482469+00	{"success": true, "cusipCount": 1}	\N
c0ec1634-a91d-4483-b82e-7013c3053b44	cusip_resolution	{"cusips": ["655187300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.884461+00	2025-09-03 18:01:25.536576+00	2025-09-03 18:01:27.049991+00	{"success": true, "cusipCount": 1}	\N
b7550b40-2b75-481d-bf65-3a565a2d80f3	cusip_resolution	{"cusips": ["23257B206"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.853597+00	2025-09-03 18:01:27.044785+00	2025-09-03 18:01:28.595354+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job b7550b40-2b75-481d-bf65-3a565a2d80f3 timed out after 30000ms
379f3c3b-ff14-4f0d-9f5c-416fe7992da0	cusip_resolution	{"cusips": ["655187300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.88832+00	2025-09-03 18:01:27.548576+00	2025-09-03 18:01:29.893911+00	{"success": true, "cusipCount": 1}	\N
9b8cc916-a210-46d9-9ba9-b15fc103f267	cusip_resolution	{"cusips": ["501506703"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.898371+00	2025-09-03 18:01:29.057208+00	2025-09-03 18:01:30.960356+00	{"success": true, "cusipCount": 1}	\N
09f03313-4b9b-405b-a382-0ee935481c8d	cusip_resolution	{"cusips": ["142922103"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.901124+00	2025-09-03 18:01:29.560517+00	2025-09-03 18:01:31.439076+00	{"success": true, "cusipCount": 1}	\N
d5c54500-3296-4322-b9db-dbfc1f168131	cusip_resolution	{"cusips": ["23257B206"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.860945+00	2025-09-03 18:01:48.140233+00	2025-09-03 18:02:04.760353+00	{"success": true, "cusipCount": 1}	\N
c0ae7481-a2d3-4304-9d22-5230d0cf4d50	cusip_resolution	{"cusips": ["655187300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.894965+00	2025-09-03 18:02:17.809265+00	2025-09-03 18:02:28.866621+00	{"success": true, "cusipCount": 1}	\N
a26b8c93-7847-4952-9ee6-3a27ed845ff1	strategy_classification	{"tradeId": "2ab76c62-abe4-42d2-88d9-010d7cf790e0"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.699103+00	2025-09-03 18:50:03.751048+00	2025-09-03 18:50:03.75429+00	{"processed": 1}	\N
16d53517-5b6e-44fe-badd-c1f290cbf8e4	strategy_classification	{"tradeId": "5f97cdc2-e673-422a-a110-26002c488c35"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.704644+00	2025-09-03 18:50:04.75545+00	2025-09-03 18:50:04.77036+00	{"processed": 1}	\N
52c0a93d-632e-4e7f-9568-232ce4cccf73	strategy_classification	{"tradeId": "e0b51e88-5a66-4335-811c-2d2472013c2b"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.707356+00	2025-09-03 18:50:05.257138+00	2025-09-03 18:50:05.270442+00	{"processed": 1}	\N
7f2b5175-0d25-4bd7-8a76-70b1a5bdda49	strategy_classification	{"tradeId": "f8d146c7-67d4-44f9-857f-67cc0fb684c0"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.709906+00	2025-09-03 18:50:05.756343+00	2025-09-03 18:50:05.759994+00	{"processed": 1}	\N
2474295b-cb84-4f95-bbd6-adfe76ecb70a	strategy_classification	{"tradeId": "2bb5b4e5-7d2c-4407-b93a-06544bbdd15a"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.715688+00	2025-09-03 18:50:06.763699+00	2025-09-03 18:50:06.775352+00	{"processed": 1}	\N
fedddd6f-3eca-4031-8a4c-5047eb3f2c5c	strategy_classification	{"tradeId": "cb9d5b07-7943-454f-a01b-7cb1b1082cf7"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.718764+00	2025-09-03 18:50:07.27123+00	2025-09-03 18:50:07.320589+00	{"processed": 1}	\N
d4e1505a-211f-4c09-96f6-4fbe1433d2e5	cusip_resolution	{"cusips": ["00941Q203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.693067+00	2025-09-03 18:50:07.673012+00	2025-09-03 18:50:09.475511+00	{"success": true, "cusipCount": 1}	\N
c08c695b-357e-47fa-91ac-0656d8a43e62	cusip_resolution	{"cusips": ["G14492121"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.69646+00	2025-09-03 18:50:09.792702+00	2025-09-03 18:50:11.432007+00	{"success": true, "cusipCount": 1}	\N
5b74e2fe-172f-456d-ad9a-438aade24189	cusip_resolution	{"cusips": ["87978U108"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.70292+00	2025-09-03 18:50:12.672975+00	2025-09-03 18:50:14.253182+00	{"success": true, "cusipCount": 1}	\N
2e7a0661-b406-4649-9ce2-14349fd189eb	cusip_resolution	{"cusips": ["20678X205"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.705966+00	2025-09-03 18:50:13.810465+00	2025-09-03 18:50:16.047179+00	{"success": true, "cusipCount": 1}	\N
17aa4ad8-6480-4c7c-b5b5-4fcd44a87a7b	cusip_resolution	{"cusips": ["20678X205"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.711013+00	2025-09-03 18:50:17.67335+00	2025-09-03 18:50:19.66094+00	{"success": true, "cusipCount": 1}	\N
de432cb3-20a2-451b-86b0-3db4263c88d8	cusip_resolution	{"cusips": ["71902K303"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.714093+00	2025-09-03 18:50:18.330562+00	2025-09-03 18:50:19.936593+00	{"success": true, "cusipCount": 1}	\N
9ab0f54e-7d45-4ecf-a292-eaef47890cdb	cusip_resolution	{"cusips": ["71902K303"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.720395+00	2025-09-03 18:50:22.533079+00	2025-09-03 18:50:24.247775+00	{"success": true, "cusipCount": 1}	\N
88a78233-617e-44a9-a339-532ae6d103f3	cusip_resolution	{"cusips": ["71902K303"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.724571+00	2025-09-03 18:50:22.673771+00	2025-09-03 18:50:24.956651+00	{"success": true, "cusipCount": 1}	\N
b0420053-8681-41c4-b78f-db4ccbeafcc1	cusip_resolution	{"cusips": ["M61472136"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.80971+00	2025-09-03 18:00:45.305239+00	2025-09-03 18:00:47.334244+00	{"success": true, "cusipCount": 1}	\N
1a0c9d5b-eee5-429a-908d-e8f0592fc284	cusip_resolution	{"cusips": ["28622K203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.823416+00	2025-09-03 18:00:47.89372+00	2025-09-03 18:00:50.227954+00	{"success": true, "cusipCount": 1}	\N
a40c286e-0638-4c3c-bd49-a2a434db7f1c	cusip_resolution	{"cusips": ["G7309R106"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.827967+00	2025-09-03 18:00:49.838911+00	2025-09-03 18:00:51.921933+00	{"success": true, "cusipCount": 1}	\N
1ac1e088-61c1-4a34-8713-94a2eec0959c	cusip_resolution	{"cusips": ["92840Q202"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.835577+00	2025-09-03 18:00:52.899145+00	2025-09-03 18:00:54.414709+00	{"success": true, "cusipCount": 1}	\N
abbc12ea-a33c-4b62-bca6-e24a3814aa88	cusip_resolution	{"cusips": ["92840Q202"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.844088+00	2025-09-03 18:00:54.359474+00	2025-09-03 18:00:55.947129+00	{"success": true, "cusipCount": 1}	\N
23f93311-d789-4360-92ac-9a00d00f3734	cusip_resolution	{"cusips": ["89458T205"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.817466+00	2025-09-03 18:51:12.334713+00	2025-09-03 18:51:14.272748+00	{"success": true, "cusipCount": 1}	\N
ad49e067-6cd6-45ec-b822-97204c3a69e0	cusip_resolution	{"cusips": ["74449F209"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	2	2025-09-03 18:00:17.713887+00	2025-09-03 18:01:23.52508+00	2025-09-03 18:01:25.070026+00	{"success": true, "cusipCount": 1}	Timeout retry 2: Job ad49e067-6cd6-45ec-b822-97204c3a69e0 timed out after 30000ms
64964a55-1c0f-4bfd-a04a-0e73f6eae167	cusip_resolution	{"cusips": ["97264L100"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.687963+00	2025-09-03 18:00:18.12204+00	2025-09-03 18:00:20.439428+00	{"success": true, "cusipCount": 1}	\N
2e0d901b-bf1d-4ce4-bbec-f61f60f36fbc	cusip_resolution	{"cusips": ["45784G200"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.691406+00	2025-09-03 18:00:18.622583+00	2025-09-03 18:00:20.633964+00	{"success": true, "cusipCount": 1}	\N
524c1255-1b73-4cd1-a3dd-ebd4c428fe3c	cusip_resolution	{"cusips": ["23257B206"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.848955+00	2025-09-03 18:01:26.54139+00	2025-09-03 18:01:28.604236+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 524c1255-1b73-4cd1-a3dd-ebd4c428fe3c timed out after 30000ms
b5503acc-3720-41b6-b7d0-f99fb92850fd	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.703514+00	2025-09-03 18:00:21.136288+00	2025-09-03 18:00:22.830156+00	{"success": true, "cusipCount": 1}	\N
d5dd66e2-482d-463f-bbd3-48d74f6041c1	cusip_resolution	{"cusips": ["73017P102"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.757252+00	2025-09-03 18:51:17.697136+00	2025-09-03 18:51:34.597295+00	{"success": true, "cusipCount": 1}	\N
4c48f4f8-d0e0-4482-903c-00e3e5d61675	cusip_resolution	{"cusips": ["107930109"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.906186+00	2025-09-03 18:01:31.069425+00	2025-09-03 18:01:33.052283+00	{"success": true, "cusipCount": 1}	\N
9be881a2-ae3e-4fd0-90c6-399abb88546b	cusip_resolution	{"cusips": ["74449F209"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.709143+00	2025-09-03 18:00:22.646023+00	2025-09-03 18:00:24.920738+00	{"success": true, "cusipCount": 1}	\N
311730c3-0d6a-4c97-bf65-1300380da37e	strategy_classification	{"tradeId": "398dbe31-4866-4a53-b8b5-5a7dccf7af0e"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.665109+00	2025-09-03 18:49:57.733449+00	2025-09-03 18:49:57.748666+00	{"processed": 1}	\N
a009d00d-ec77-4af6-9564-421dd59e6570	cusip_resolution	{"cusips": ["142922103"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.90396+00	2025-09-03 18:02:00.200851+00	2025-09-03 18:02:02.440441+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job a009d00d-ec77-4af6-9564-421dd59e6570 timed out after 30000ms
d34bb41b-c207-4474-8700-994f1a30e50c	cusip_resolution	{"cusips": ["M79549107"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.736631+00	2025-09-03 18:00:33.73373+00	2025-09-03 18:00:35.805528+00	{"success": true, "cusipCount": 1}	\N
5fe4b696-4479-42e2-a20d-3d4817348372	cusip_resolution	{"cusips": ["28622K203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.817868+00	2025-09-03 18:00:47.825878+00	2025-09-03 18:00:49.60218+00	{"success": true, "cusipCount": 1}	\N
742c7377-efc9-4ede-ab9c-d31eb0d60839	cusip_resolution	{"cusips": ["M77798136"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.831483+00	2025-09-03 18:00:52.3509+00	2025-09-03 18:00:53.925394+00	{"success": true, "cusipCount": 1}	\N
79716759-16b9-4d2c-9bc6-0a901fa23eaa	strategy_classification	{"tradeId": "4a70d2b0-d498-4844-9291-fbb698fd43d2"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.726201+00	2025-09-03 18:50:08.276862+00	2025-09-03 18:50:08.287758+00	{"processed": 1}	\N
e3cdeb59-3ed4-4cd4-abcd-80b823adcd4f	strategy_classification	{"tradeId": "e7f6cc69-3367-42db-bd98-dda2521714f4"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.731706+00	2025-09-03 18:50:09.293858+00	2025-09-03 18:50:09.313227+00	{"processed": 1}	\N
4bbc6df3-1945-47d2-a1c2-cf13f7e2bd7d	strategy_classification	{"tradeId": "424f4d85-a70f-4bff-a5bb-5dd8ec8e207f"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.734211+00	2025-09-03 18:50:09.794605+00	2025-09-03 18:50:09.81928+00	{"processed": 1}	\N
77f12db4-2d01-4b8e-8871-47f9699a0615	strategy_classification	{"tradeId": "faf5f61f-5673-4275-ac70-a2a13569b711"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.752407+00	2025-09-03 18:50:10.798766+00	2025-09-03 18:50:10.803451+00	{"processed": 1}	\N
5e4db972-33e0-44a5-992e-560258a463cd	strategy_classification	{"tradeId": "bc40c0af-d521-42e3-a1c0-1a2daf7b644e"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.755723+00	2025-09-03 18:50:11.303912+00	2025-09-03 18:50:11.316016+00	{"processed": 1}	\N
c7722736-95a6-41d6-902c-1329d6d93521	strategy_classification	{"tradeId": "51fdf604-f317-4d2b-ab59-48667bdc8613"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.761701+00	2025-09-03 18:50:12.305661+00	2025-09-03 18:50:12.317544+00	{"processed": 1}	\N
5768c2fb-f44a-4698-b4b5-e5d9d9b6507b	strategy_classification	{"tradeId": "7259c54e-37d5-457a-81fd-23890fc19a73"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.764386+00	2025-09-03 18:50:12.806527+00	2025-09-03 18:50:12.81663+00	{"processed": 1}	\N
8f49678f-fcdf-485e-814d-82ff7f181bd9	strategy_classification	{"tradeId": "53c2ed15-e333-40bc-8fba-f83547ead9c2"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.769005+00	2025-09-03 18:50:13.811082+00	2025-09-03 18:50:13.819577+00	{"processed": 1}	\N
88ddbe48-3ce2-4911-88cd-df04f45b1004	cusip_resolution	{"cusips": ["M2R43K362"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.727614+00	2025-09-03 18:50:24.563905+00	2025-09-03 18:50:26.463775+00	{"success": true, "cusipCount": 1}	\N
a0d6ef2b-33ba-4751-adf7-be6f8442de63	cusip_resolution	{"cusips": ["40423R105"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.732787+00	2025-09-03 18:50:27.676664+00	2025-09-03 18:50:29.945021+00	{"success": true, "cusipCount": 1}	\N
1589f9ed-8bfa-4370-aa47-6a7be9e35d91	cusip_resolution	{"cusips": ["40423R105"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.742612+00	2025-09-03 18:50:28.582275+00	2025-09-03 18:50:30.641868+00	{"success": true, "cusipCount": 1}	\N
3f794943-654a-4993-bc1a-21c46d6259ce	cusip_resolution	{"cusips": ["40423R105"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.749578+00	2025-09-03 18:50:31.596225+00	2025-09-03 18:50:33.217781+00	{"success": true, "cusipCount": 1}	\N
131ac58f-ec39-4af0-a148-4d9833a1e542	cusip_resolution	{"cusips": ["G2161Y125"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.767843+00	2025-09-03 18:50:35.632003+00	2025-09-03 18:50:38.079317+00	{"success": true, "cusipCount": 1}	\N
fa56862b-825c-4ab4-8f72-6fbd2f6f5778	cusip_resolution	{"cusips": ["G2161Y125"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.76988+00	2025-09-03 18:50:37.680713+00	2025-09-03 18:50:39.582047+00	{"success": true, "cusipCount": 1}	\N
8c703583-6250-4d04-996f-65ef1d412f51	cusip_resolution	{"cusips": ["74907L300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.720286+00	2025-09-03 18:00:27.1863+00	2025-09-03 18:00:28.857721+00	{"success": true, "cusipCount": 1}	\N
23a1c8cb-d7a1-4267-aed7-e2feda491884	cusip_resolution	{"cusips": ["G33277131"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.800671+00	2025-09-03 18:51:05.794205+00	2025-09-03 18:51:07.341185+00	{"success": true, "cusipCount": 1}	\N
95c6de14-4007-44d0-9e61-44fcbdf337e7	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.804929+00	2025-09-03 18:51:07.691938+00	2025-09-03 18:51:09.728723+00	{"success": true, "cusipCount": 1}	\N
ca2f1bc8-b7fe-473f-b55f-216fe9fc6955	cusip_resolution	{"cusips": ["M79549107"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.782244+00	2025-09-03 18:00:38.764465+00	2025-09-03 18:00:40.372916+00	{"success": true, "cusipCount": 1}	\N
8daa22f1-c32f-4ac5-864e-969e90c85771	cusip_resolution	{"cusips": ["G9442G120"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.803666+00	2025-09-03 18:00:42.890717+00	2025-09-03 18:00:45.370468+00	{"success": true, "cusipCount": 1}	\N
f42dca2f-3a62-429b-8c72-b43dbd0ff264	cusip_resolution	{"cusips": ["92840Q202"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:00:17.839447+00	2025-09-03 18:00:53.861792+00	2025-09-03 18:00:56.282486+00	{"success": true, "cusipCount": 1}	\N
e9cd64ed-4b62-4b03-855e-ff704829d900	cusip_resolution	{"cusips": ["23257B206"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:00:17.85814+00	2025-09-03 18:01:47.934086+00	2025-09-03 18:02:00.115704+00	{"success": true, "cusipCount": 1}	\N
7ce6ccfd-b830-45b0-9ded-44a13fcf4c69	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.806949+00	2025-09-03 18:51:07.816658+00	2025-09-03 18:51:09.755986+00	{"success": true, "cusipCount": 1}	\N
ebee7cfd-b0d7-4439-acc0-d50684a1ab35	cusip_resolution	{"cusips": ["81728A108"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.811112+00	2025-09-03 18:51:09.822501+00	2025-09-03 18:51:12.053412+00	{"success": true, "cusipCount": 1}	\N
5b1eebe7-8b0b-4678-a6b7-35ef5bd8859e	cusip_resolution	{"cusips": ["89458T205"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.814448+00	2025-09-03 18:51:11.328847+00	2025-09-03 18:51:12.965155+00	{"success": true, "cusipCount": 1}	\N
cc70a497-2fe7-43d6-bceb-2316e0462aac	cusip_resolution	{"cusips": ["76135L507"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.825953+00	2025-09-03 18:51:14.846292+00	2025-09-03 18:51:16.940877+00	{"success": true, "cusipCount": 1}	\N
2f621902-18c7-49cf-aa20-64bfb68e1819	cusip_resolution	{"cusips": ["90137F400"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.784093+00	2025-09-03 18:51:19.360383+00	2025-09-03 18:51:43.516897+00	{"success": true, "cusipCount": 1}	\N
754d2bc8-1d1e-4ce9-abf6-91040e62734e	cusip_resolution	{"cusips": ["92840Q202"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.792265+00	2025-09-03 18:51:48.055413+00	2025-09-03 18:51:54.674998+00	{"success": true, "cusipCount": 1}	\N
ed2e3f12-0a84-427b-bc60-7e2c4fa5da6f	strategy_classification	{"tradeId": "72194188-48e1-4e87-a8d7-e792c6dad79d"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.771042+00	2025-09-03 18:50:14.31063+00	2025-09-03 18:50:14.315673+00	{"processed": 1}	\N
ffa319b7-7deb-41c9-8c8f-d13f9fdc3d44	strategy_classification	{"tradeId": "c9c0b43f-cb0e-4383-b51d-58d570d253de"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.778881+00	2025-09-03 18:50:14.814634+00	2025-09-03 18:50:14.82273+00	{"processed": 1}	\N
51a56c8a-cddf-4619-8d4c-cf61a07a4965	cusip_resolution	{"cusips": ["G33277131"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	2	2025-09-03 18:49:57.798378+00	2025-09-03 18:52:20.260066+00	2025-09-03 18:52:22.350031+00	{"success": true, "cusipCount": 1}	Timeout retry 2: Job 51a56c8a-cddf-4619-8d4c-cf61a07a4965 timed out after 30000ms
03857bb1-510d-4ba2-9a3e-f4dd543570b9	strategy_classification	{"tradeId": "3d5859f3-7ce0-4980-93df-21b2f733f258"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.783334+00	2025-09-03 18:50:15.817897+00	2025-09-03 18:50:15.827624+00	{"processed": 1}	\N
60e3b26b-7f90-4339-8aa3-77c29fde8bb1	strategy_classification	{"tradeId": "6f5b1051-d41c-4c99-a689-31065f053154"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.785133+00	2025-09-03 18:50:16.33485+00	2025-09-03 18:50:16.345643+00	{"processed": 1}	\N
2222fdba-764e-49c1-833d-213abf5c7d52	strategy_classification	{"tradeId": "00220d91-0366-440a-9069-479875535d4e"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.789453+00	2025-09-03 18:50:17.328125+00	2025-09-03 18:50:17.33477+00	{"processed": 1}	\N
2ff6eee7-6492-4ce1-8611-dececc16cba9	strategy_classification	{"tradeId": "75418968-359d-4b3a-ae19-3dfbdf72a088"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.794825+00	2025-09-03 18:50:17.829591+00	2025-09-03 18:50:17.832549+00	{"processed": 1}	\N
2b42e84f-7e42-4540-be5b-a7e410d8c4ec	strategy_classification	{"tradeId": "5eb6a4f1-4bec-4d41-91a3-2f3d9fe36750"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.799717+00	2025-09-03 18:50:18.834315+00	2025-09-03 18:50:18.852569+00	{"processed": 1}	\N
0012e21c-9b6d-4bab-824b-e5213d1b2d22	strategy_classification	{"tradeId": "2817070c-bf93-4443-9bad-ab7bd79aa0b5"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.801954+00	2025-09-03 18:50:19.342966+00	2025-09-03 18:50:19.360898+00	{"processed": 1}	\N
ffe76be2-f6c4-4aab-a1be-7e415af43548	strategy_classification	{"tradeId": "c8c472ea-06da-43c6-af94-bdf28d969fc1"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.804048+00	2025-09-03 18:50:19.851542+00	2025-09-03 18:50:19.858873+00	{"processed": 1}	\N
af7f7d0e-a806-42a8-853d-32beeb7fd38b	strategy_classification	{"tradeId": "0b112c0a-4a3b-4dd5-8f17-4410286c3dc0"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.808101+00	2025-09-03 18:50:20.843829+00	2025-09-03 18:50:20.847098+00	{"processed": 1}	\N
45852e9a-9025-4db0-82f0-5eee39355a91	strategy_classification	{"tradeId": "1258401a-b7d8-43b8-8f76-03d2458bc650"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.810188+00	2025-09-03 18:50:21.347942+00	2025-09-03 18:50:21.353956+00	{"processed": 1}	\N
ef0678cb-0520-43b9-9199-af0d664a21eb	strategy_classification	{"tradeId": "f672940c-e4f1-4db8-b4cb-90f3dc9b8c7b"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.81585+00	2025-09-03 18:50:22.533225+00	2025-09-03 18:50:22.546845+00	{"processed": 1}	\N
c267d2db-7a6b-4fb4-a109-7384c3085ecb	strategy_classification	{"tradeId": "f08d29e6-a1b5-4519-9d14-db7dca34c27d"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.819099+00	2025-09-03 18:50:23.041412+00	2025-09-03 18:50:23.060151+00	{"processed": 1}	\N
0aed8d1d-0182-4fef-8f72-f5ee81c300b6	cusip_resolution	{"cusips": ["42328V801"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.780272+00	2025-09-03 18:50:40.163736+00	2025-09-03 18:50:41.8914+00	{"success": true, "cusipCount": 1}	\N
4e3fb770-2d9c-4b62-87e3-55068523a42a	cusip_resolution	{"cusips": ["42328V801"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.782364+00	2025-09-03 18:50:42.173582+00	2025-09-03 18:50:43.971498+00	{"success": true, "cusipCount": 1}	\N
9ec36309-5abf-4b71-907e-826bfcf931b4	cusip_resolution	{"cusips": ["73017P102"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.760207+00	2025-09-03 18:51:03.276022+00	2025-09-03 18:51:05.289934+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 9ec36309-5abf-4b71-907e-826bfcf931b4 timed out after 30000ms
dd5476c9-76db-4e80-85aa-8c6822d1b179	cusip_resolution	{"cusips": ["890260847"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.82875+00	2025-09-03 18:51:16.857835+00	2025-09-03 18:51:18.91317+00	{"success": true, "cusipCount": 1}	\N
222c1df8-2918-4788-8400-6498980d7434	cusip_resolution	{"cusips": ["655187300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.831421+00	2025-09-03 18:51:17.357951+00	2025-09-03 18:51:19.352155+00	{"success": true, "cusipCount": 1}	\N
ff4d025c-d366-401c-9e77-1ed2895658b9	strategy_classification	{"tradeId": "9c40614d-1977-43cc-866d-13ade35b7069"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.670272+00	2025-09-03 18:49:58.741769+00	2025-09-03 18:49:58.758089+00	{"processed": 1}	\N
b73dd3c8-ba0d-4880-bfab-0c9b1119d1b0	cusip_resolution	{"cusips": ["03835L405"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.666552+00	2025-09-03 18:49:57.732986+00	2025-09-03 18:49:59.689966+00	{"success": true, "cusipCount": 1}	\N
63ac6aee-0bcf-437e-b862-3d40e3f2accd	strategy_classification	{"tradeId": "f9ee3e7d-bc03-469d-9de9-3448b0b84f87"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.679832+00	2025-09-03 18:50:00.745008+00	2025-09-03 18:50:00.756299+00	{"processed": 1}	\N
dc42ec4f-bc34-485d-b886-73635d182c71	strategy_classification	{"tradeId": "a0f1a3e3-4515-426c-83e5-727426fcf348"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.682537+00	2025-09-03 18:50:01.247347+00	2025-09-03 18:50:01.279351+00	{"processed": 1}	\N
30f1c77f-650f-4923-9488-f7f2535ae2d9	cusip_resolution	{"cusips": ["501506703"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.839483+00	2025-09-03 18:51:22.699299+00	2025-09-03 18:51:24.722927+00	{"success": true, "cusipCount": 1}	\N
a6b5c457-a972-42aa-83a4-69c393847297	strategy_classification	{"tradeId": "4af9d7e1-aaf4-4368-aa59-a20c4d19b534"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.695152+00	2025-09-03 18:50:03.250386+00	2025-09-03 18:50:03.262733+00	{"processed": 1}	\N
16b0c7f3-429f-4969-89bd-5829d7c17ed7	strategy_classification	{"tradeId": "128ed5f7-1a98-4aac-8080-2311dbbc6dc6"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.701718+00	2025-09-03 18:50:04.252346+00	2025-09-03 18:50:04.269255+00	{"processed": 1}	\N
7ae50efa-f83d-4cb6-aa99-3f70176d4fd9	cusip_resolution	{"cusips": ["76090R309"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.680896+00	2025-09-03 18:50:02.671549+00	2025-09-03 18:50:04.738036+00	{"success": true, "cusipCount": 1}	\N
8e5c8d18-1709-4127-ada4-6f884b30a94e	strategy_classification	{"tradeId": "a801d84c-b16a-47f1-b9d0-d314571b7aab"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.712614+00	2025-09-03 18:50:06.256759+00	2025-09-03 18:50:06.271869+00	{"processed": 1}	\N
c3a11d28-1a42-4726-a156-5948b9d5371d	strategy_classification	{"tradeId": "d4c52114-b262-4053-a962-9b8057fabfa1"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.72292+00	2025-09-03 18:50:07.773526+00	2025-09-03 18:50:07.781331+00	{"processed": 1}	\N
29570fb8-ce8e-4146-92bd-965034b27083	strategy_classification	{"tradeId": "739cc92c-e324-4f58-804b-6ab85bccbec6"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.729095+00	2025-09-03 18:50:08.786364+00	2025-09-03 18:50:08.799334+00	{"processed": 1}	\N
3fb2df6d-5bb3-423f-94f6-1adc2ff82efb	cusip_resolution	{"cusips": ["89357L402"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.690041+00	2025-09-03 18:50:07.270723+00	2025-09-03 18:50:09.354629+00	{"success": true, "cusipCount": 1}	\N
d4852cfe-0f4b-4565-919d-4ed7f97e5c72	strategy_classification	{"tradeId": "a9702cb2-b03f-4c96-9562-3ae6c4695ead"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.748235+00	2025-09-03 18:50:10.293131+00	2025-09-03 18:50:10.296266+00	{"processed": 1}	\N
8f904f2f-d90a-423d-b8f9-63cdbfffe085	strategy_classification	{"tradeId": "1d3d6253-6416-402c-ab37-1f9f9dc83086"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.758893+00	2025-09-03 18:50:11.805273+00	2025-09-03 18:50:11.821014+00	{"processed": 1}	\N
7f1267fc-2744-4daa-9d1d-95b8c570970d	strategy_classification	{"tradeId": "930b3522-3e92-4fa7-84a4-444ba83d0890"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.766823+00	2025-09-03 18:50:13.308719+00	2025-09-03 18:50:13.312056+00	{"processed": 1}	\N
01ee6d06-840e-43fd-9aca-246aa9e7b804	cusip_resolution	{"cusips": ["G14492121"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.700291+00	2025-09-03 18:50:11.807704+00	2025-09-03 18:50:13.566549+00	{"success": true, "cusipCount": 1}	\N
d08cd793-43d6-46c4-bfc8-33513a006d78	strategy_classification	{"tradeId": "a4a35db5-1357-432e-8bea-32af44c1c284"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.781467+00	2025-09-03 18:50:15.313903+00	2025-09-03 18:50:15.322025+00	{"processed": 1}	\N
efa9e6a2-7236-4445-9123-9ea7ff1e4410	strategy_classification	{"tradeId": "cfc81afd-0e4d-413a-a84f-7601d0e94801"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.787411+00	2025-09-03 18:50:16.828372+00	2025-09-03 18:50:16.833638+00	{"processed": 1}	\N
0b8974e2-70c3-437d-a50e-9a5d30d51814	cusip_resolution	{"cusips": ["20678X205"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.708587+00	2025-09-03 18:50:16.333674+00	2025-09-03 18:50:18.29187+00	{"success": true, "cusipCount": 1}	\N
208c381f-4795-40bf-bb0f-b2fa9f322e56	strategy_classification	{"tradeId": "b86166ad-8871-4c58-9423-505825070d76"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.797321+00	2025-09-03 18:50:18.331877+00	2025-09-03 18:50:18.341221+00	{"processed": 1}	\N
fcb22936-e9a4-44fc-89ef-05977e3eb2aa	strategy_classification	{"tradeId": "36fe0338-75d9-4c0a-96a8-fc85fde12b63"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.806051+00	2025-09-03 18:50:20.343076+00	2025-09-03 18:50:20.360015+00	{"processed": 1}	\N
89e6cd35-e9ca-45d4-8f61-8662b45f84fb	strategy_classification	{"tradeId": "3beb6591-f283-4add-b80d-3ec074784e03"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.812391+00	2025-09-03 18:50:21.851919+00	2025-09-03 18:50:21.870125+00	{"processed": 1}	\N
ebf12f84-07a7-4d86-9939-e7e5baf74437	cusip_resolution	{"cusips": ["655187300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.834297+00	2025-09-03 18:51:50.574581+00	2025-09-03 18:51:52.24332+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job ebf12f84-07a7-4d86-9939-e7e5baf74437 timed out after 30000ms
52912569-451b-4bdc-94b6-17bbbce10fc0	strategy_classification	{"tradeId": "23081800-5567-4b1b-8475-a9c4ff7fa5de"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.824771+00	2025-09-03 18:50:24.049449+00	2025-09-03 18:50:24.06478+00	{"processed": 1}	\N
05b218d6-8b55-4ec4-ba14-d4f3483c226f	strategy_classification	{"tradeId": "cdb79cf8-907b-4ba2-bbcc-9e8bcac052df"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.827216+00	2025-09-03 18:50:24.555615+00	2025-09-03 18:50:24.57839+00	{"processed": 1}	\N
e5944744-e526-4afd-aa77-18c4d36a1820	strategy_classification	{"tradeId": "85142cd7-901c-4ef8-9616-8be2e7bb8d3e"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.832981+00	2025-09-03 18:50:25.573489+00	2025-09-03 18:50:25.596438+00	{"processed": 1}	\N
0fe03166-8f9c-4f77-9e62-94b3065e27cc	strategy_classification	{"tradeId": "5fc8db5c-5976-495a-ac58-637330bc58d7"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.835787+00	2025-09-03 18:50:26.070981+00	2025-09-03 18:50:26.106421+00	{"processed": 1}	\N
6e173e62-12b7-4c2c-97e0-20ba67e06966	cusip_resolution	{"cusips": ["71902K303"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.717094+00	2025-09-03 18:50:20.342755+00	2025-09-03 18:50:21.93385+00	{"success": true, "cusipCount": 1}	\N
41166321-9e52-4bac-bd7f-745cf7ec1fb9	strategy_classification	{"tradeId": "3097d30d-c397-4137-a979-2abe3c65f395"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.830244+00	2025-09-03 18:50:25.060492+00	2025-09-03 18:50:25.079534+00	{"processed": 1}	\N
911c3681-67c9-48a8-a782-50e05c31d392	cusip_resolution	{"cusips": ["G2161Y125"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.765531+00	2025-09-03 18:51:04.286274+00	2025-09-03 18:51:06.141668+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 911c3681-67c9-48a8-a782-50e05c31d392 timed out after 30000ms
0dabb96a-edca-4a3c-8c53-7eafbe6d2c25	cusip_resolution	{"cusips": ["03835L405"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.672873+00	2025-09-03 18:50:30.089762+00	2025-09-03 18:50:32.021472+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 0dabb96a-edca-4a3c-8c53-7eafbe6d2c25 timed out after 30000ms
dcc7055a-4b10-4da5-ae82-76f1a193afa5	cusip_resolution	{"cusips": ["97382D501"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.809029+00	2025-09-03 18:51:08.820065+00	2025-09-03 18:51:10.866973+00	{"success": true, "cusipCount": 1}	\N
4ad471f9-a46e-4308-b198-4560cc972955	cusip_resolution	{"cusips": ["40423R105"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.754165+00	2025-09-03 18:50:32.10184+00	2025-09-03 18:50:33.758355+00	{"success": true, "cusipCount": 1}	\N
e32dcf90-edf3-4554-9f24-9e75fe9dce8b	cusip_resolution	{"cusips": ["89458T205"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.820318+00	2025-09-03 18:51:12.693269+00	2025-09-03 18:51:14.811321+00	{"success": true, "cusipCount": 1}	\N
14d9bd8f-5b2d-4320-8951-a4434a7b1f60	cusip_resolution	{"cusips": ["655187300"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.836992+00	2025-09-03 18:51:21.374288+00	2025-09-03 18:51:23.500545+00	{"success": true, "cusipCount": 1}	\N
6388a076-58eb-4206-8cd6-6f2fc71dc267	strategy_classification	{"tradeId": "3ebde700-4b11-465a-8e1c-7553c59db044"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.822445+00	2025-09-03 18:50:23.540716+00	2025-09-03 18:50:23.548941+00	{"processed": 1}	\N
f5a00547-bd32-47d7-860d-10dd8a605ead	strategy_classification	{"tradeId": "033f9947-0e4a-4337-a1f9-5993fd0622c8"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.838397+00	2025-09-03 18:50:26.577372+00	2025-09-03 18:50:26.600478+00	{"processed": 1}	\N
bb4d79be-3400-4fe8-ad60-308dc568c5ab	cusip_resolution	{"cusips": ["M97838128"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.730219+00	2025-09-03 18:50:26.575503+00	2025-09-03 18:50:28.323392+00	{"success": true, "cusipCount": 1}	\N
b7f06a72-b07b-4bbf-a673-20126ec01f89	cusip_resolution	{"cusips": ["83006G203"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.802887+00	2025-09-03 18:51:06.290906+00	2025-09-03 18:51:08.359723+00	{"success": true, "cusipCount": 1}	\N
7c4bf3cc-a873-4d32-afe3-afb1c458c799	cusip_resolution	{"cusips": ["48669G204"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.762876+00	2025-09-03 18:50:33.617009+00	2025-09-03 18:50:35.527964+00	{"success": true, "cusipCount": 1}	\N
a0b7a364-0765-4306-b844-e590c644a707	cusip_resolution	{"cusips": ["34546R100"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	0	2025-09-03 18:49:57.772745+00	2025-09-03 18:50:38.148139+00	2025-09-03 18:50:39.8885+00	{"success": true, "cusipCount": 1}	\N
2f94db90-15ca-43e9-9514-bf6cddcf43fc	cusip_resolution	{"cusips": ["90137F400"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.786036+00	2025-09-03 18:51:14.344389+00	2025-09-03 18:51:16.645713+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 2f94db90-15ca-43e9-9514-bf6cddcf43fc timed out after 30000ms
47999780-6087-435e-8c3b-307617c130af	cusip_resolution	{"cusips": ["G55032166"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.823579+00	2025-09-03 18:51:43.520975+00	2025-09-03 18:51:45.573827+00	{"success": true, "cusipCount": 1}	Timeout retry 1: Job 47999780-6087-435e-8c3b-307617c130af timed out after 30000ms
a9b3f37c-c621-446d-a845-b9e50edb9dd6	cusip_resolution	{"cusips": ["28059P303"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.788341+00	2025-09-03 18:51:47.712704+00	2025-09-03 18:51:49.781248+00	{"success": true, "cusipCount": 1}	\N
56ccccad-50a3-4690-9961-9ff288e2be45	cusip_resolution	{"cusips": ["G33277131"], "userId": "2d96cef2-7502-44ff-a7a9-17713d4a7a42"}	2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	completed	1	2025-09-03 18:49:57.795945+00	2025-09-03 18:51:48.5616+00	2025-09-03 18:51:59.289255+00	{"success": true, "cusipCount": 1}	\N
\.


--
-- Data for Name: leaderboard_entries; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.leaderboard_entries (id, leaderboard_id, user_id, anonymous_name, score, rank, metadata, recorded_at) FROM stdin;
82dcdc0e-6b75-4f73-9696-3f2fb0742d59	bfc917c9-00c7-4cc5-a3d0-bdc9fffa88d4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	13246.77	1	{"win_rate": 70.99, "avg_trade": 31.24, "total_pnl": 13246.77, "trade_count": 424}	2025-09-25 19:21:40.582229+00
ab377fb4-8786-44f5-a3c6-6bbaf85f8320	66f8a761-bbbb-4177-87b4-89ca43c7fb59	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	4821.35	1	{"best_trade_pnl": 4821.35, "best_trade_date": "2025-03-12T12:35:00+00:00", "best_trade_symbol": "VSTTF"}	2025-09-25 19:21:40.606773+00
0fcb1c2a-d106-4f50-b723-bdcc8de761ee	16ec2022-85b6-43c2-ba44-014729df0138	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	-3085.06	1	{"worst_trade_pnl": -3085.06, "worst_trade_date": "2025-04-02T19:34:00+00:00", "worst_trade_symbol": "SBFM"}	2025-09-25 19:21:40.611743+00
b4887d60-b487-488f-a286-f0fbfe8ff401	e2d77673-59d5-4feb-bd73-f7855362360d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	0.08	1	{"avg_pnl": 31.24, "win_rate": 70.99, "avg_volume": 2532, "volatility": 392.27, "total_trades": 424, "consistency_score": 0.08}	2025-09-25 19:21:40.615232+00
a6f25e70-850a-4c19-bd25-3e0196e1dcdb	bfc917c9-00c7-4cc5-a3d0-bdc9fffa88d4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	13246.77	1	{"win_rate": 70.99, "avg_trade": 31.24, "total_pnl": 13246.77, "trade_count": 424}	2025-09-24 22:02:30.885587+00
a6f9a775-8e03-4b6b-903a-18b3a2a586b4	66f8a761-bbbb-4177-87b4-89ca43c7fb59	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	4821.35	1	{"best_trade_pnl": 4821.35, "best_trade_date": "2025-03-12T12:35:00+00:00", "best_trade_symbol": "VSTTF"}	2025-09-24 22:02:30.897394+00
33c312fc-1c17-4289-b55b-80bea0201a81	16ec2022-85b6-43c2-ba44-014729df0138	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	-3085.06	1	{"worst_trade_pnl": -3085.06, "worst_trade_date": "2025-04-02T19:34:00+00:00", "worst_trade_symbol": "SBFM"}	2025-09-24 22:02:30.901237+00
f12beaeb-956c-4a2f-9ed9-6342c2abe0ec	e2d77673-59d5-4feb-bd73-f7855362360d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	0.08	1	{"avg_pnl": 31.24, "win_rate": 70.99, "avg_volume": 2532, "volatility": 392.27, "total_trades": 424, "consistency_score": 0.08}	2025-09-24 22:02:30.905831+00
0fc0b5e2-5b7e-4094-8da9-d32c79280f7d	bfc917c9-00c7-4cc5-a3d0-bdc9fffa88d4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	13246.27	1	{"win_rate": 70.99, "avg_trade": 31.24, "total_pnl": 13246.27, "trade_count": 424}	2025-09-03 20:58:59.999848+00
c11c0d1e-8321-4fea-b8b8-865b55503170	66f8a761-bbbb-4177-87b4-89ca43c7fb59	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	4821.35	1	{"best_trade_pnl": 4821.35, "best_trade_date": "2025-03-12T12:35:00+00:00", "best_trade_symbol": "VSTTF"}	2025-09-03 20:59:00.010779+00
285588c1-5458-4c17-b804-98c960e3ab46	16ec2022-85b6-43c2-ba44-014729df0138	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	-3085.06	1	{"worst_trade_pnl": -3085.06, "worst_trade_date": "2025-04-02T19:34:00+00:00", "worst_trade_symbol": "SBFM"}	2025-09-03 20:59:00.013298+00
39a4a956-1b3e-4a35-98f2-e5b307ba0921	e2d77673-59d5-4feb-bd73-f7855362360d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	0.08	1	{"avg_pnl": 31.24, "win_rate": 70.99, "avg_volume": 2532, "volatility": 392.27, "total_trades": 424, "consistency_score": 0.08}	2025-09-03 20:59:00.017058+00
b4892cb5-20f9-451a-814f-50a54ae817d2	bfc917c9-00c7-4cc5-a3d0-bdc9fffa88d4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	13246.27	1	{"win_rate": 70.99, "avg_trade": 31.24, "total_pnl": 13246.27, "trade_count": 424}	2025-09-04 00:34:54.583802+00
6a6f1a93-90ef-4900-a550-a56b4e7a5058	66f8a761-bbbb-4177-87b4-89ca43c7fb59	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	4821.35	1	{"best_trade_pnl": 4821.35, "best_trade_date": "2025-03-12T12:35:00+00:00", "best_trade_symbol": "VSTTF"}	2025-09-04 00:34:54.592327+00
9dcf13f6-5b93-4fa3-bb52-1565312e432a	16ec2022-85b6-43c2-ba44-014729df0138	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	-3085.06	1	{"worst_trade_pnl": -3085.06, "worst_trade_date": "2025-04-02T19:34:00+00:00", "worst_trade_symbol": "SBFM"}	2025-09-04 00:34:54.595883+00
4f239f67-1ffd-466f-a7f7-a122cd7e530b	e2d77673-59d5-4feb-bd73-f7855362360d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	0.08	1	{"avg_pnl": 31.24, "win_rate": 70.99, "avg_volume": 2532, "volatility": 392.27, "total_trades": 424, "consistency_score": 0.08}	2025-09-04 00:34:54.598699+00
63bbc063-fd66-438a-ac47-653334278bfd	bfc917c9-00c7-4cc5-a3d0-bdc9fffa88d4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	13246.27	1	{"win_rate": 70.99, "avg_trade": 31.24, "total_pnl": 13246.27, "trade_count": 424}	2025-09-23 21:40:24.462736+00
35533d70-823a-4ca9-aced-5bb6290defac	66f8a761-bbbb-4177-87b4-89ca43c7fb59	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	4821.35	1	{"best_trade_pnl": 4821.35, "best_trade_date": "2025-03-12T12:35:00+00:00", "best_trade_symbol": "VSTTF"}	2025-09-23 21:40:24.472383+00
99689041-562b-4390-a67a-3f48ae0273f9	16ec2022-85b6-43c2-ba44-014729df0138	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	-3085.06	1	{"worst_trade_pnl": -3085.06, "worst_trade_date": "2025-04-02T19:34:00+00:00", "worst_trade_symbol": "SBFM"}	2025-09-23 21:40:24.47533+00
0b941d7b-e095-428f-a9e4-50bfc1a7b791	e2d77673-59d5-4feb-bd73-f7855362360d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LightningAssassin	0.08	1	{"avg_pnl": 31.24, "win_rate": 70.99, "avg_volume": 2532, "volatility": 392.27, "total_trades": 424, "consistency_score": 0.08}	2025-09-23 21:40:24.478909+00
\.


--
-- Data for Name: leaderboards; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.leaderboards (id, key, name, description, metric_key, period_type, period_start, period_end, min_participants, is_active, created_at) FROM stdin;
bfc917c9-00c7-4cc5-a3d0-bdc9fffa88d4	total_pnl	All-Time P&L Rankings	Total profit/loss across all trades	total_pnl	all_time	\N	\N	10	t	2025-09-03 17:47:11.679969+00
a8f0ffbc-10c2-45d8-83a9-908c6ea07391	monthly_pnl	Monthly P&L Rankings	Profit/loss for the current month	monthly_pnl	monthly	\N	\N	10	t	2025-09-03 17:47:11.679969+00
9df321d8-6874-4e73-95e8-c2a698129e31	weekly_pnl	Weekly P&L Rankings	Profit/loss for the current week	weekly_pnl	weekly	\N	\N	10	t	2025-09-03 17:47:11.679969+00
66f8a761-bbbb-4177-87b4-89ca43c7fb59	best_trade	Best Single Trade	Highest profit from a single trade	best_trade	all_time	\N	\N	10	t	2025-09-03 17:47:11.679969+00
16ec2022-85b6-43c2-ba44-014729df0138	worst_trade	Worst Single Trade	Largest loss from a single trade	worst_trade	all_time	\N	\N	10	t	2025-09-03 17:47:11.679969+00
e2d77673-59d5-4feb-bd73-f7855362360d	consistency_score	Most Consistent Trader	Based on volume traded and average P&L	consistency_score	all_time	\N	\N	10	t	2025-09-03 17:47:11.679969+00
\.


--
-- Data for Name: loss_aversion_events; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.loss_aversion_events (id, user_id, analysis_start_date, analysis_end_date, avg_winner_hold_time_minutes, avg_loser_hold_time_minutes, hold_time_ratio, total_winning_trades, total_losing_trades, premature_profit_exits, extended_loss_holds, estimated_monthly_cost, missed_profit_potential, unnecessary_loss_extension, avg_planned_risk_reward, avg_actual_risk_reward, worst_hold_ratio_symbol, worst_hold_ratio_value, created_at, updated_at, avg_missed_profit_percent) FROM stdin;
1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2025-01-02	2025-04-07	390	729	1.87	301	123	291	4	1230.29	3481.17	455.75	2.00	0.75	G33277131	99.99	2025-09-03 19:03:49.165117	2025-09-03 19:03:49.165117	99.99
\.


--
-- Data for Name: migrations; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.migrations (id, filename, applied_at, checksum) FROM stdin;
1	001_add_owner_role.sql	2025-09-03 17:47:11.229729+00	c0f3cc5a12c18a32c68e918e437b4dd545ae941c8b0b2a54ab511534c2f7b38c
2	002_add_mobile_support_tables.sql	2025-09-03 17:47:11.234683+00	7544e27cdfbfe85ba55bbe01945bd3db3ccf358e638cea6c10e535e451298737
3	003_add_instance_configuration.sql	2025-09-03 17:47:11.269514+00	c8324f6cbd2a1f65ebe7d2c0e0876988e95e89c7bb555148ce4d8debc5dd183e
4	004_add_executions_field.sql	2025-09-03 17:47:11.27715+00	8591a1dd107870e6ea6030f54fbe8485205f11dccfd4bb65e944a70ca3736396
5	005_create_cusip_queue.sql	2025-09-03 17:47:11.278933+00	d367b887954aaa988722e6079fa5b320ddd282799236eaad0320df43740a43f0
6	006_add_mae_mfe_columns.sql	2025-09-03 17:47:11.286068+00	4dcbd223c675494ff81d8755c855466b447716864a351ad992cd8bbc21df2284
7	007_change_quantity_to_decimal.sql	2025-09-03 17:47:11.288027+00	e41d29a9ed90012b0c8855d4884b805ea19ce868fc98136fddc37131b74560c7
8	008_add_equity_tracking.sql	2025-09-03 17:47:11.28961+00	c2a66bc894e812c0124f3893e295d4b1bb988fb6edbcc57b867c777533cfcd14
9	009_add_symbol_categories.sql	2025-09-03 17:47:11.296536+00	b7efd8ac232a081ffdd61a0e2d69429f3dec80bf84de62e0bfb5f8781b7f0152
10	010_fix_symbol_categories_types.sql	2025-09-03 17:47:11.302678+00	ba64ec5f03611937ea5e60029f9962c8454c34f76b834d8c984d95c5b015a259
11	011_add_2fa_support.sql	2025-09-03 17:47:11.30906+00	79c6bf06b4ed767dc4b0725f105cabdd942a196933bdca62cf964746125979e3
12	012_add_missing_export_fields.sql	2025-09-03 17:47:11.311726+00	93b3c76cc5a31346f505750062eb30fc089a3f47fa0b10b4383f9f6ea98e694b
13	013_increase_price_precision.sql	2025-09-03 17:47:11.348195+00	25310e47b03edc90315f962707f2cd828c8f0d2e6efab4fcf56ecc73b18bf9ed
14	014_revert_price_precision.sql	2025-09-03 17:47:11.360754+00	bff73198d616e96b0119f04ff130bc893529eab1a1afb5a578c6eafef66af113
15	015_fix_zero_quantities.sql	2025-09-03 17:47:11.370004+00	b20bd794f69038635e5ffdc65ff726952ab02e27789d7e9d2355f8cebb92faff
16	016_enhance_api_keys_table.sql	2025-09-03 17:47:11.373269+00	8e4be4de584945f616c55ac9309277f64707cc87eb0cdf86066f5322ba727c58
17	017_add_ai_provider_settings.sql	2025-09-03 17:47:11.388338+00	173a142d73dcffcb82176ce98a330ca3c4d1d0b3b69762d1c0720f76f997ec41
18	018_add_admin_ai_settings.sql	2025-09-03 17:47:11.390533+00	004bb42525b17b9701be538a7014ce1a99e4c8abb36a22dc27ba47de90603315
19	019_add_user_tiers_and_subscriptions.sql	2025-09-03 17:47:11.39534+00	e73783715533d0f7b061405a2e0a53f2b0d066f7ea23e8c8b6980ef0b30505d0
20	019_fix_trade_dates_timezone.sql	2025-09-03 17:47:11.411999+00	ecc21a34347a27529ee2eb959adb7c8e1907a60d9d103b38f9e59f9fda86f7b5
21	020_add_stock_splits_tracking.sql	2025-09-03 17:47:11.414538+00	abd1a3de8bac937a9cf097d90dec6d4d882eca17f8a1fe2467092b092321073e
22	020_create_cusip_mappings.sql	2025-09-03 17:47:11.427891+00	ae8ee4a0589a454c3d13b7fc686b7f59d4ae7985e235c95f072ce396696ebc01
23	020_set_admin_users_to_pro_tier.sql	2025-09-03 17:47:11.439027+00	86457a4d7a95d241fe67f25b8fb97ed7fd13659344cb7d953d4a4aa9edad1795
24	021_create_behavioral_analytics_tables.sql	2025-09-03 17:47:11.440969+00	93e968c4a66bc5ff5b04317eaeea0e1d494020aba72ac72ea611d7fcf9156aa0
25	022_add_behavioral_analytics_feature.sql	2025-09-03 17:47:11.461243+00	b4d497254e9d3acda69e75eb934f61e330767cc664143aa1e3fac11ee6580f45
26	022_create_overconfidence_analytics.sql	2025-09-03 17:47:11.462831+00	79c3245a1b8037c5c3ab6a07fd753b20d6d6ffc83554c903a71e84afe21b68e7
27	023_create_loss_aversion_analytics.sql	2025-09-03 17:47:11.479797+00	1a44f585bf9ff72eff38c863d708d332b8597c73d7e6ab1075f038194d183095
28	023_create_tick_data_table.sql	2025-09-03 17:47:11.490613+00	ee2d3cd03a5c08248066352641962228581d69c0946a8fa49fcc7085d0023f2b
29	024_create_trading_personality_profiling.sql	2025-09-03 17:47:11.506849+00	ee3e4810ff05a296e812a68477f534f83c832b47015d6d2968516d02be6a2757
30	025_create_watchlist_system.sql	2025-09-03 17:47:11.527167+00	18d78b0145345fe3bd02f21a66984e105b1adbd383cedaeba29708c78221c7ad
31	026_create_gamification_system.sql	2025-09-03 17:47:11.550767+00	52f4c8e2527861b97302d04fd25e626d1152fc3909602bd0e5c6d6559eed9d0a
32	027_insert_default_challenges.sql	2025-09-03 17:47:11.615096+00	8775c91bee7433bdc65ae94193c59ea3e1c7121f4f61696fc64a6c85029674df
33	028_update_anonymous_usernames.sql	2025-09-03 17:47:11.618693+00	92f06da32f29c3a9c31c6251e3b511ff304d476bbafde4ba50583fcc0e657078
34	029_add_avg_missed_profit_percent.sql	2025-09-03 17:47:11.620482+00	deb1d88fb78a9a7053a69ded410aac83310918bc1607267d399819a8173b1982
35	029_add_easy_achievements.sql	2025-09-03 17:47:11.62219+00	c38cac446704db60b7869f400ea181e441697724e11218bd79376458ad7e8c4d
36	030_fix_user_achievements_constraint.sql	2025-09-03 17:47:11.623992+00	9f1bb65084852091de4b9ff1c0b690f9ff80b9433da7e485b41da1d4338f6a24
37	031_remove_trivial_achievements.sql	2025-09-03 17:47:11.626784+00	4e1ce2689184117476d3a1ba03d84bfad5673c9f09f7942bc70815380793fe67
38	032_add_trading_achievements.sql	2025-09-03 17:47:11.629517+00	73b4a917384885fbe9b984fd6b916b28ef5c7371b51c1e2bccac793ab54aef62
39	033_fix_overconfidence_position_size_field.sql	2025-09-03 17:47:11.63141+00	8fceca1c8958d2e39d0c1ab5d9622c8af276f09ac58ed3e264c9b3718b360883
40	034_fix_personality_drift_tracking_table.sql	2025-09-03 17:47:11.633193+00	8dc6f745cf59644b45d16aca79fb2306b1bedfcfb5af5e3206e478eb33068d68
41	035_add_personality_drift_unique_constraint.sql	2025-09-03 17:47:11.635095+00	1f47476efc26f5989f764e48b29df0b8c641969be8b292096df8212af7e1c787
42	036_add_ai_recommendations_to_overconfidence.sql	2025-09-03 17:47:11.638011+00	7261bc4833bdefd09b14774752465f2c2b121306e344b8dba33825aaaf44e620
43	037_add_strategy_classification_fields.sql	2025-09-03 17:47:11.641436+00	a4f1fd03d72e4b2995f58d05450395c6b5bc9fba823848cca1ae64b542365024
44	039_create_round_trip_trades_table.sql	2025-09-03 17:47:11.649573+00	1e9ee7582bf40e293d6c87c720c27e8648d5bb3a68a605fe1a6289b24fa19ab7
45	040_create_enrichment_cache.sql	2025-09-03 17:47:11.659386+00	757b87d423349031def923a38b804037d8c8d7fc8ec725bff1dec5682caa1b13
46	041_add_news_columns_to_trades.sql	2025-09-03 17:47:11.669008+00	157617f50bf458d6a4db3e3b2d4f6034aeec2ecbdc37ac0acf35c6f68499a554
47	042_fix_trade_dates_timezone.sql	2025-09-03 17:47:11.674152+00	ecc21a34347a27529ee2eb959adb7c8e1907a60d9d103b38f9e59f9fda86f7b5
48	043_add_statistics_calculation_preference.sql	2025-09-03 17:47:11.676759+00	db0995c69d253c029524f3148e6221c94083db8278ca40a59f1334715642748d
49	044_update_leaderboards_to_pnl_based.sql	2025-09-03 17:47:11.679969+00	738114b7ad89427c964ec4b647997dbbed3ca7ae32683959a45fe42cebbcdd97
50	045_add_admin_approved_column.sql	2025-09-03 17:47:11.682188+00	41882833e65ce7ff0faecf712de172a31b6ab83330b676c9b1138de620db2012
51	046_add_trading_profile_fields.sql	2025-09-03 17:47:11.685078+00	57ad2215ad258acbdb4c21a6d358bb6d9744c423452ac39e0cc2af9d6cb7148a
52	047_add_push_notification_tables.sql	2025-09-03 17:47:11.688759+00	e4b9b0c658029e874a68abb0e0ce926de5ff501036b717fc25cbb8d74917b767
53	048_create_notification_read_status.sql	2025-09-03 17:47:11.700883+00	0a2090def4abde5583ad09efe3f363659e96d48093d1d3b7a602a6d8b0ac19f3
54	049_add_trial_email_tracking.sql	2025-09-03 17:47:11.708014+00	3221692b91d30b8abe8e9a33015eb71874397d70256508211d8bde873957014d
55	026_add_trade_confidence_field.sql	2025-09-03 17:52:05.500571+00	a211ff51f5f67d3701db10873216e0b9077296f90bab159eadbc3499bc5ce630
56	038_create_job_queue.sql	2025-09-03 17:52:05.508287+00	9e7b4cb788c30d93dba97fdec72e28abd94d13e5a18d1ca28b3eee6117111c77
57	050_add_trade_job_cascade_delete.sql	2025-09-03 17:52:05.519878+00	a3aa2894a260ce810a029794cee8716fe9f4c10e00e4a632b5e79ed812a68a89
58	051_add_notification_preferences.sql	2025-09-03 17:52:05.523281+00	7fd08b38addb8038c849e6898b71132e6dc3c3cea742a8577f575781d2aafa09
59	052_create_global_enrichment_cache.sql	2025-09-03 17:52:05.527084+00	cf5f2cff9f3dc09bac425c5b85668e0bb90a70a11daf6819c2a2d4b30699f77d
60	053_prevent_duplicate_cusip_mappings.sql	2025-09-03 17:52:05.533871+00	b7063ba63690c426426a2921725bf883ab0ac78e947e250be3b9781da7ae0291
61	054_fix_entry_exit_time_nullable.sql	2025-09-03 17:52:05.536791+00	b3bee6b26816639f4e74f6a655977a73f9620dda629335e2343d9bb46d82bdf0
62	055_remove_duplicate_trades.sql	2025-09-03 17:52:05.543673+00	badba7dbbf725966a6960bcc961445f0876c96de0e3984b2313d6f93d68d54db
63	057_fix_classification_trigger.sql	2025-09-03 17:52:05.544455+00	5cf12b2a00763a3477e909316f7254421f4cf6e919c005a156b6eb6f26013763
64	add_admin_approved_column.sql	2025-09-03 17:52:05.548978+00	7cf193476616a561ee1e77b98f77229dc10151bc20c610561ed72b25621b07ac
65	add_trading_profile_fields.sql	2025-09-03 17:52:05.550614+00	7a88c29ace850b6964b17c40291f78385f5dfdb79226f5157efc343fe28473e2
66	add_trial_used_column.sql	2025-09-03 17:52:05.552767+00	1a12cf0a8ff9be263d109ac09dd808ef5d005cacbd5c3896ef6762147f381a93
67	create_news_cache.sql	2025-09-03 17:52:05.555967+00	ae848872e083f871c4a58cb5cab400d83a05d9c5b786d8c4db75b15b5639d739
68	058_fix_strategy_confidence_precision.sql	2025-09-23 19:25:42.709873+00	e2646bc524e078d41980e74b57d4a785a8100055559aef4cb7a2dc34bd0fcf77
69	059_create_diary_system.sql	2025-09-23 19:25:42.721256+00	8857bc1ebd7182e74dce2def9fea3972e296b77d82886965222f6e19a7064012
70	060_ensure_schema_consistency.sql	2025-09-23 19:25:42.7377+00	c92c556a837408adb2ff3c3efd9644a8f7205cacde4b3d5b39e1cf8a6ea5935b
101	063_restore_price_precision.sql	2025-09-25 17:34:53.140499+00	15d89f527bd1d31e6194fd13c4c3efe9c67a3f7314a7b570cdd83ec2636258d2
\.


--
-- Data for Name: news_cache; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.news_cache (id, symbol, news_date, news_events, sentiment, checked_at, created_at) FROM stdin;
94b82477-3641-4c7d-8b8c-1346c02381c7	107930109	2024-12-11	[]	\N	2025-09-03 17:56:35.648066+00	2025-09-03 17:56:35.648066+00
4c6fbf2c-6ea6-4d36-a62f-570342f92793	142922103	2024-12-24	[]	\N	2025-09-03 17:56:35.916613+00	2025-09-03 17:56:35.916613+00
662d463b-93bb-42b6-81e6-3380e6e2e4e5	501506703	2025-02-18	[]	\N	2025-09-03 17:56:36.487027+00	2025-09-03 17:56:36.487027+00
631cd2cb-a68e-4338-aa60-f646d5342fd9	655187300	2025-02-04	[]	\N	2025-09-03 17:56:37.021236+00	2025-09-03 17:56:37.021236+00
05e8953b-acef-4157-96fa-c8081a47cfb9	890260847	2025-02-03	[]	\N	2025-09-03 17:56:38.069336+00	2025-09-03 17:56:38.069336+00
3cb1631b-790b-4a3b-a3d3-e41f2d496b8b	963025846	2024-12-13	[]	\N	2025-09-03 17:56:38.41285+00	2025-09-03 17:56:38.41285+00
88c0b7d1-b0eb-4b36-a969-5be107f55a26	AGFY	2024-11-05	[{"url": "https://finnhub.io/api/news?id=b1b8c9e52a7cba85ad6a9643517875b4174006c917006a7add204626c0d76feb", "source": "Yahoo", "summary": "TROY, Mich., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that its Board of Directors has approved a $20 million convertible secured note (the “Financing”), of which $10M will be drawn upon at closing, from a wholly-owned subsidiary of Green Thumb Industries Inc. (“Green Thumb”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis", "datetime": "2024-11-05T12:00:00.000Z", "headline": "Agrify Secures Financing from Green Thumb Industries and Announces New Leadership", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:39.123198+00	2025-09-03 17:56:39.123198+00
36a77a10-e36b-4de1-a377-41ca6bf5440f	DATS	2024-11-06	[]	\N	2025-09-03 17:56:39.419365+00	2025-09-03 17:56:39.419365+00
2edb3bf0-9b29-4361-91ba-5fcbb7f626f0	DATS	2025-03-25	[{"url": "https://finnhub.io/api/news?id=845a8530cbbe56da7ca98f0696960ef7f7fc0b59986c1e8ea7c58e71953e9339", "source": "Yahoo", "summary": "Company to sponsor and participate in the upcoming Photo Managers Conference 2025, the premier conference for photo professionals New Brunswick, NJ, March 25, 2025 (GLOBE NEWSWIRE) -- DatChat, Inc. (Nasdaq: DATS) (“DatChat” or the “Company”), a secure messaging and social media company, today announced that its Myseum Social Media Platform for storing and sharing digital photos and content is now available as a download on Apple iOS and Android devices. The Company also announced its sponsorship", "datetime": "2025-03-25T12:40:00.000Z", "headline": "DatChat Launches Myseum Social Media Platform for Apple iOS and Android Platforms", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:40.773158+00	2025-09-03 17:56:40.773158+00
510b24c4-a45e-41df-9b1b-0d465089f569	SONN	2024-11-06	[{"url": "https://finnhub.io/api/news?id=21203a0272c460c88b8f8a607f6e1cef536df958f45132f2d05a2d3b212f0dc9", "source": "Yahoo", "summary": "PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the \\"Company\\" or \\"Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the pricing of an underwritten public offering of 1,111,111 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and common warrants to purchase up to an aggregate of 2,222,222 shares of common stock. Each sh", "datetime": "2024-11-06T18:20:00.000Z", "headline": "Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8d39638e011feb9f5f6015f23b765af0fd4dff6e6124c19f537b9c5aca36f124", "source": "Yahoo", "summary": "Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP) IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet’s FHAB platform which Sonnet believes could present an important oncology possibility The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability", "datetime": "2024-11-06T13:30:00.000Z", "headline": "Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:41.258656+00	2025-09-03 17:56:41.258656+00
af944c20-befe-49f1-8216-1ff175228b27	SONN	2024-12-04	[{"url": "https://finnhub.io/api/news?id=dd7c283c17a27c8a0447de9168383bd5ccd385fc24a97a76526588a8190b0b97", "source": "Yahoo", "summary": "Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the \\"Company\\" or \\"Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the publication of extensive discovery, development and preclinical data on SON-1010 demonstrating its mechanism of action in Frontiers in Immuno", "datetime": "2024-12-04T14:20:00.000Z", "headline": "Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:42.219391+00	2025-09-03 17:56:42.219391+00
d2b97b3a-32a8-4f5c-9040-6744aa1851ce	SONN	2024-12-09	[{"url": "https://finnhub.io/api/news?id=0153562e9fecb90ab427503e2bc952d6dc5bda2dfcd39f7357cf5b6fcdfc1fc2", "source": "Yahoo", "summary": "PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the \\"Company\\" or \\"Sonnet\\") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sale of an aggregate of 1,085,325 shares of its common stock (or common stock equivalents in lieu thereof) (the “Registered Direct Shares”) and warrants to purchase up to an aggregate of", "datetime": "2024-12-09T20:42:00.000Z", "headline": "Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=10e202a21fe87d5b61e1cd7888e7a3f6943ff20ba798b1da38ab402b07400596", "source": "Yahoo", "summary": "The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21 (48%) evaluable monotherapy patients, and importantly included one patient dosed at the MTD who had a partial response (PR) by RESIST criteria (a 45% decrease from baseline) Together, these data suggest clinical benefit when SON-1010 is administered as a monot", "datetime": "2024-12-09T13:45:00.000Z", "headline": "Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:42.537315+00	2025-09-03 17:56:42.537315+00
336b5fff-f50c-4e04-b96a-51b1e0f909d8	23257B206	2024-11-07	[]	\N	2025-09-03 17:56:44.914486+00	2025-09-03 17:56:44.914486+00
300c0948-004d-4b2e-b0b9-6e4d10bc5024	ISPC	2024-12-20	[{"url": "https://finnhub.io/api/news?id=6dac981160333103744075763354f4fc8d2445599431b151f85359b48d5cd286", "source": "Yahoo", "summary": "Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide.The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical research and investment. Market reports indicate that cancer", "datetime": "2024-12-20T13:30:00.000Z", "headline": "iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:46.571073+00	2025-09-03 17:56:46.571073+00
fdd7e206-5db7-4c4d-ae66-6bbaf3d7e098	BTCT	2024-11-13	[]	\N	2025-09-03 17:56:52.216722+00	2025-09-03 17:56:52.216722+00
09d28a6b-1440-453d-b2de-50d551d71ce4	SONN	2024-12-10	[{"url": "https://finnhub.io/api/news?id=0153562e9fecb90ab427503e2bc952d6dc5bda2dfcd39f7357cf5b6fcdfc1fc2", "source": "Yahoo", "summary": "PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the \\"Company\\" or \\"Sonnet\\") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sale of an aggregate of 1,085,325 shares of its common stock (or common stock equivalents in lieu thereof) (the “Registered Direct Shares”) and warrants to purchase up to an aggregate of", "datetime": "2024-12-09T20:42:00.000Z", "headline": "Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=10e202a21fe87d5b61e1cd7888e7a3f6943ff20ba798b1da38ab402b07400596", "source": "Yahoo", "summary": "The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21 (48%) evaluable monotherapy patients, and importantly included one patient dosed at the MTD who had a partial response (PR) by RESIST criteria (a 45% decrease from baseline) Together, these data suggest clinical benefit when SON-1010 is administered as a monot", "datetime": "2024-12-09T13:45:00.000Z", "headline": "Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:44.144683+00	2025-09-03 17:56:44.144683+00
f92298e2-499c-4f8f-9c18-ff85383b65d2	ISPC	2024-11-07	[{"url": "https://finnhub.io/api/news?id=261fa23d7cbc261b4b81bcdaa3b4e23fce563b39cf091a1e44752067b8470c45", "source": "Yahoo", "summary": "WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments. The expanded inventory includes highly", "datetime": "2024-11-07T12:30:00.000Z", "headline": "iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=f5d0a0c564ef58c229227ac2d762a5fdfa5d17bf777d4e861814dc64fef19605", "source": "Yahoo", "summary": "LEXINGTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2024. \\"The third quarter was a period of continued strategic transformation for iSpecimen, primarily driven by several key initiati", "datetime": "2024-11-07T12:00:00.000Z", "headline": "iSpecimen Reports Third Quarter 2024 Results", "sentiment": "neutral"}]	positive	2025-09-03 17:56:46.257627+00	2025-09-03 17:56:46.257627+00
5fcb999f-c3f2-4147-9630-8fad52c341f9	92840Q202	2025-01-10	[]	\N	2025-09-03 17:56:48.934207+00	2025-09-03 17:56:48.934207+00
a48a4d04-3539-4601-8f21-f1ab163dd347	CELU	2024-11-07	[{"url": "https://finnhub.io/api/news?id=66d50237200ff6ec99fe183c816eb4df5996abba55d77cf7692edd87350c86b8", "source": "Yahoo", "summary": "Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its HistoryCelularity Filed its Second Quarter Form 10-Q and is Now Current With its Quarterly Report Filings FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a regenerative and cellular medicine co", "datetime": "2024-11-07T13:00:00.000Z", "headline": "Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:47.401865+00	2025-09-03 17:56:47.401865+00
5b21b476-5c8e-4c82-b7f9-7f1e74d2a212	DEVS	2024-11-08	[{"url": "https://finnhub.io/api/news?id=7992263809b70ae2bf9b1c129570d9b0ff2a0f3efcbf1da31bae748fc661eaa6", "source": "Yahoo", "summary": "Transactions increase total portfolio of purchased carbon credit inventory to 3.7 million creditsAdvances the Company's strategic plan to broaden and diversify its asset portfolio, as a complement to its carbon management and project investment businessesCompany appoints Carl Stanton and Wray Thorn to its Board of DirectorsSacramento, California--(Newsfile Corp. - November 8, 2024) - DevvStream Corp. (NASDAQ: DEVS) (\\"DevvStream\\" or the \\"Company\\"), a leading carbon credit project co-development a", "datetime": "2024-11-08T12:30:00.000Z", "headline": "DevvStream Adds 2.5 Million Credits to Existing Carbon Portfolio; Announces Changes to Board of Directors", "sentiment": "positive"}]	positive	2025-09-03 17:56:47.58833+00	2025-09-03 17:56:47.58833+00
09cc33cb-289a-4251-92cf-30c12b2c254c	92840Q202	2024-11-08	[]	\N	2025-09-03 17:56:48.23484+00	2025-09-03 17:56:48.23484+00
2c9a45ec-484c-438a-8240-704070ebb240	BTCT	2024-11-12	[]	\N	2025-09-03 17:56:49.648173+00	2025-09-03 17:56:49.648173+00
45e8bf4d-f205-4c19-af9a-c11319dc5754	BTCT	2025-01-17	[]	\N	2025-09-03 17:56:52.467893+00	2025-09-03 17:56:52.467893+00
9c058196-fa1f-4634-9b36-56b99078fc7a	TRNR	2024-11-21	[]	\N	2025-09-03 17:56:54.149282+00	2025-09-03 17:56:54.149282+00
677ebbae-dfbb-422e-ad2e-0f7e303267c4	TRNR	2024-12-18	[{"url": "https://finnhub.io/api/news?id=a234b12bf68003ca5d2521b730628d747052c3e22691f8de963942d07fec0162", "source": "Yahoo", "summary": "Three-Year Agreement Expected to Generate more than $0.5million in Revenue, and Covers France and French Regions France is the Second-Largest Fitness Market in the EU AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Interactive Strength Inc. (NASDAQ:TRNR) ...", "datetime": "2024-12-18T13:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Secures 162 Unit CLMBR Commitment and Signs Exclusive Distribution Agreement With Planet Fitness SAS for France", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:55.252081+00	2025-09-03 17:56:55.252081+00
b922120d-0b77-4140-bdf5-45104e0c6c9b	M77798136	2024-11-19	[]	\N	2025-09-03 17:56:57.274436+00	2025-09-03 17:56:57.274436+00
c81e6ac5-d856-43df-bf0d-8701e46d7662	JTAI	2024-11-22	[{"url": "https://finnhub.io/api/news?id=e819c28eb9adb7086dd67b5c10e15cdf74b741d8e0987a42ed2ef3da15f31980", "source": "Yahoo", "summary": "LAS VEGAS, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Jet.AI Inc., an innovative private aviation and artificial intelligence company, announced a fleet purchase agreement with Textron Aviation Inc. for the purchase of three Cessna Citation CJ4 Gen2 aircraft. With deliveries scheduled for Q2, Q3 and Q4 of 2026, the new aircraft will join the Jet.AI fleet as part of a brand-new CJ4 Gen2 fractional program. Jet.AI offers fractional jet ownership for individuals and businesses seeking flexible and convenien", "datetime": "2024-11-22T13:30:00.000Z", "headline": "Jet.AI Signs Agreement on Cessna Citation CJ4 Gen2 Fleet Order from Textron Aviation for Fractional Program", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:00.450454+00	2025-09-03 17:57:00.450454+00
313e9c47-fb30-4da4-a2ba-a86f8bc20738	VSTTF	2024-12-18	[]	\N	2025-09-03 17:57:02.821305+00	2025-09-03 17:57:02.821305+00
7c6fd281-81ce-48af-bc50-dcca40a97106	ZENA	2024-12-12	[{"url": "https://finnhub.io/api/news?id=6adc62e2fd695029793be2faed19b530ddd72e9eb139a86fc0d4be9e622005bc", "source": "Yahoo", "summary": "TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (\\"ZenaTech\\"), a technology company specializing in AI (Artificial Intelligence) drone solutions, Drone-as-a-Service (DaaS), Quantum Computing solutions, and enterprise SaaS (Software-as-a-Service) solutions, today announces the launch of a Quantum Computing project for traffic optimization and weather forecasting using the company’s drones. The project, called Sky Traffic, was developed following interest receive", "datetime": "2024-12-12T12:30:00.000Z", "headline": "ZenaTech Launches Quantum Computing Project for Traffic Optimization and Weather Forecasting Using Drones", "sentiment": "positive"}]	positive	2025-09-03 17:57:05.798447+00	2025-09-03 17:57:05.798447+00
9f91d98a-065c-4c53-9b4b-57ca42d30c7b	ZENA	2025-01-07	[{"url": "https://finnhub.io/api/news?id=d2df7544439c4dc84ed6b46ed9fa730103b320199f4b71ee617e2fb49ce8f869", "source": "Yahoo", "summary": "VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (\\"ZenaTech\\"), a technology company specializing in AI (Artificial Intelligence) drone solutions driven by Quantum Computing, Drones as a Service, and enterprise SaaS, announces that it has signed an LOI (Letter of Intent) to acquire a workforce scheduling software company with which it plans to develop quantum computing-driven solutions. The software is intended to increase productivity for mu", "datetime": "2025-01-07T12:30:00.000Z", "headline": "ZenaTech to Acquire Workforce Scheduling Software Company in Order to Use Quantum Computing to Increase Productivity for Multinational Corporations", "sentiment": "positive"}]	positive	2025-09-03 17:57:06.342015+00	2025-09-03 17:57:06.342015+00
bfcdd745-3f43-4fc1-9630-662bba7f6fb9	NLSP	2025-01-08	[{"url": "https://finnhub.io/api/news?id=b65806d881ab447ddce2243aa1b780f8c7994edb374431ac04484cdea588e7a8", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announce the successful completion of the initi", "datetime": "2025-01-08T12:42:00.000Z", "headline": "NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025", "sentiment": "positive"}]	positive	2025-09-03 17:57:10.267411+00	2025-09-03 17:57:10.267411+00
094bd925-5679-47b1-89b3-bccac225c761	NLSP	2025-01-28	[{"url": "https://finnhub.io/api/news?id=e7ff5006c80c61d0070ba1e3c1c4b7d4336d43876faf6869a18e05ab2f6ee235", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (\\"NLS\\" or the \\"Company\\"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global health crisis and was recently declared a national public health emergency by the new Trump adminis", "datetime": "2025-01-28T12:30:00.000Z", "headline": "NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence", "sentiment": "positive"}]	positive	2025-09-03 17:57:10.9586+00	2025-09-03 17:57:10.9586+00
9a7ef7a4-03df-4e7a-a18e-707916730526	GOVX	2024-11-12	[{"url": "https://finnhub.io/api/news?id=c2861d1104f05d8640b453a7c2789262b22acc2aa55031f5035ccefacd866b50", "source": "SeekingAlpha", "summary": "GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call November 12, 2024 4:30 PM ETCompany ParticipantsMax Gadicke - Investor RelationsDavid Dodd - Chairman...", "datetime": "2024-11-12T23:33:14.000Z", "headline": "GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=2fe2e6e8cda8664433bca245715b344b8f75e42a5987e6dec9bd358b2f133df5", "source": "Yahoo", "summary": "Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax", "datetime": "2024-11-12T21:00:00.000Z", "headline": "GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=30b8645f32348c8d63728b6e728ce9209455b70b01f6a99077ae503d345c0387", "source": "Yahoo", "summary": "Alliance Global Partners analyst James Molloy initiated coverage of GeoVax Labs (GOVX) with a Buy rating and $15 price target Lead candidate GEO-CM04S1 is a “potentially best-in-class” COVID-19 prophylactic with potential in both healthy and immunocompromised patients, notes the analyst, who attributes $12.25 per share in value to CMO4S1. The firm also attributes $2 per share in value to Gedeptin, a head and neck cancer injectable therapeutic that the company is also advancing, along with cash a", "datetime": "2024-11-12T12:07:31.000Z", "headline": "GeoVax Labs initiated with a Buy at Alliance Global Partners", "sentiment": "positive"}]	positive	2025-09-03 17:56:53.109231+00	2025-09-03 17:56:53.109231+00
5005c478-1d2c-4e32-9d2a-8670bf9941e7	TRNR	2024-11-14	[{"url": "https://finnhub.io/api/news?id=eb765686989dbeb6cafd2bc0723a5c03ecf24edd995f0b64d9139091d6923c8f", "source": "Yahoo", "summary": "Net Loss and Earnings per Diluted Share of $7.1 million and $1.53 Adjusted EBITDA was a $2.3 million loss, a $1.0 million improvement versus third quarter of 2023 The Company achieved third quarter revenue guidance of $2.0 million, a growth of 325% ...", "datetime": "2024-11-14T12:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Reports Third Quarter 2024 Results", "sentiment": "positive"}]	positive	2025-09-03 17:56:53.589681+00	2025-09-03 17:56:53.589681+00
9175432f-5def-44ca-848a-10c35d958ed9	TRNR	2024-11-19	[{"url": "https://finnhub.io/api/news?id=045e95f9f8306294640bbdbcfecd886be81f8c6295b030013ed9a44a0a2314eb", "source": "Yahoo", "summary": "Interactive Strength Inc. (NASDAQ:TRNR) shares are trading higher premarket on Tuesday. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia. Armah Sports Group, which is expanding its two brands—premium brand B_Fit and high-end concept Optimo—has secured a $48 million credit facility to support further club expansion in key Saudi cities. Trent Ward, Co-", "datetime": "2024-11-19T14:05:38.000Z", "headline": "Interactive Strength Shares Jump As Saudi Fitness Chain Adopts CLMBR Machines: Details", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=303352fbaf14b045faa6543c99c2f3bb50640c1872da2b38a0f7bed9b1a1917d", "source": "Yahoo", "summary": "Armah Sports Group is a leading operator in Saudi Arabia, with twelve locations across two brands and additional concepts in development CLMBRs are being installed in three of Armah Sports Group's B_FIT nine locations, with a further roll out being ...", "datetime": "2024-11-19T12:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Drives CLMBR Growth in Saudi Arabia With Multiple Installations Across Armah Sports Group's B_FIT brand", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ef1724b317f08134c650fcd36746dba5aaa634b53ccd6852db882e2453a94df8", "source": "Yahoo", "summary": "The Atheltic Business Show features Military and College/High School buyers, which represent some of the biggest customer segments in the fitness equipment industry CLMBR has made strong inroads into Military and College/High School, with numerous ...", "datetime": "2024-11-18T12:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Expands CLMBR’s Presence with Military and College Accounts by Exhibiting at the Athletic Business Show on November 19-22", "sentiment": "neutral"}]	positive	2025-09-03 17:56:53.863549+00	2025-09-03 17:56:53.863549+00
4dea1535-abef-4cc4-a68d-0af9405c9928	SPAI	2024-11-19	[{"url": "https://finnhub.io/api/news?id=7e65d5f21e9392d006f283f0a95988ab7f05562489a17ddcde20824f401d7f04", "source": "Yahoo", "summary": "AVENTURA, Fla., November 19, 2024--Safe Pro Expects 200+% Year-Over-Year Increase in Fourth Quarter Revenue Driven by Record Sales", "datetime": "2024-11-19T13:03:00.000Z", "headline": "Safe Pro Expects 200+% Year-Over-Year Increase in Fourth Quarter Revenue Driven by Record Sales", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:57.521146+00	2025-09-03 17:56:57.521146+00
da495e66-2a39-47fc-b391-8a31faa0e101	SPAI	2024-11-20	[{"url": "https://finnhub.io/api/news?id=9ba27c7cc064464ab45a7c18a9962205f227f275923c42ea9bd5a8108d4992a7", "source": "Yahoo", "summary": "AVENTURA, Fla., November 20, 2024--Safe Pro Group Inc. (Nasdaq: SPAI) (\\"Safe Pro\\" or the \\"Company\\"), a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, today announced that on November 19, 2024 it was been awarded its first patent from the United States Patent and Trademark Office (\\"USPTO\\"), for its groundbreaking technology that identifies, locates and maps explosives through its Artificial intelligence (\\"AI\\")-powered SpotlightAI™ drone image", "datetime": "2024-11-20T13:03:00.000Z", "headline": "Safe Pro Awarded US Patent for Disruptive AI Drone Imagery Technology, a Groundbreaking Innovation Helping to Protect Millions of Lives Globally", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7e65d5f21e9392d006f283f0a95988ab7f05562489a17ddcde20824f401d7f04", "source": "Yahoo", "summary": "AVENTURA, Fla., November 19, 2024--Safe Pro Expects 200+% Year-Over-Year Increase in Fourth Quarter Revenue Driven by Record Sales", "datetime": "2024-11-19T13:03:00.000Z", "headline": "Safe Pro Expects 200+% Year-Over-Year Increase in Fourth Quarter Revenue Driven by Record Sales", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:57.861451+00	2025-09-03 17:56:57.861451+00
ada96e1f-0487-425d-856e-0020dde420d4	SBFM	2024-11-22	[{"url": "https://finnhub.io/api/news?id=01b70b35b0685cdead6d57a19292233b6fe512f8ddb7fe48322db91de1f8d346", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals ...", "datetime": "2024-11-22T13:00:00.000Z", "headline": "Sunshine Biopharma Launches a New Generic Prescription Drug", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:58.889424+00	2025-09-03 17:56:58.889424+00
bc5ccc77-3030-41d5-a64e-13eaf58327c7	SBFM	2025-04-02	[{"url": "https://finnhub.io/api/news?id=bbe9312d254ae911454864e251877ca1ffbdcf14386f454f732aa5a50f18470e", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, ...", "datetime": "2025-04-02T17:20:00.000Z", "headline": "Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=865be0a113449dbc5bf2a1140822c155d1abd9fd239033a547e493c41351672c", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (\\"We\\", \\"Our\\", the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology ...", "datetime": "2025-04-02T12:00:00.000Z", "headline": "Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=232798cd3ea7e8d451347b503419f1ddeefa7f71baa0cb5696ee2d8da099d175", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals ...", "datetime": "2025-04-01T21:09:00.000Z", "headline": "Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year", "sentiment": "positive"}]	neutral	2025-09-03 17:56:59.871861+00	2025-09-03 17:56:59.871861+00
a744ba01-6741-401e-a53b-e5714376a1ca	TRNR	2024-12-12	[{"url": "https://finnhub.io/api/news?id=e672c86cfb2a2aa95f02774cb509cc2436f6154083ed675a0c57af50638235bc", "source": "Yahoo", "summary": "Interactive Strength Inc. (NASDAQ:TRNR) shares are surging premarket on Thursday after the company inked a non-binding letter of intent and exclusivity agreement to acquire a connected-fitness equipment company. The target company has over $40 million in revenue and positive EBITDA, in a 100% equity consideration transaction. This acquisition supports its strategy of leveraging its public listing to acquire profitable, high-growth businesses in the fragmented global health & wellness market. The", "datetime": "2024-12-12T14:11:53.000Z", "headline": "Interactive Strength Set To Acquire Fitness Equipment Company In Equity Swap, Eyeing Revenue And Market Expansion", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=63e1551b656e222a7a667676455b893d1adcae539525d8912161f7c2a19e5d01", "source": "Yahoo", "summary": "Interactive Strength Inc. (Nasdaq:TRNR) (\\"TRNR\\" or \\"the Company\\"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced that the Company has signed a non-binding letter of intent and exclusivity agreement ...", "datetime": "2024-12-12T12:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Signs Exclusive Letter of Intent to Acquire Scaled and Profitable, Connected-Fitness Equipment Business", "sentiment": "neutral"}]	positive	2025-09-03 17:56:54.498688+00	2025-09-03 17:56:54.498688+00
46f84c4c-3089-435e-8f6d-66219840c396	TRNR	2025-02-11	[{"url": "https://finnhub.io/api/news?id=fed798df6edf4dd2cc3cea1603cd3183889129e89998cd2554447ab08b04acd6", "source": "Yahoo", "summary": "AUSTIN, TX / ACCESS Newswire / February 11, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) (\\"TRNR\\" or \\"the Company\\"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced it had signed a binding transaction ...", "datetime": "2025-02-11T13:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Signs Binding Agreement to Acquire Sportstech, a Profitable $40M+ Revenue Connected-Fitness Equipment Business", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:55.944487+00	2025-09-03 17:56:55.944487+00
abc0a7c7-75a0-4481-b1a8-6b407f1347e4	TRNR	2025-04-08	[{"url": "https://finnhub.io/api/news?id=6e7f14c954a81206fdaafad88270360bf586ec6acee52c28441bd085aa73148e", "source": "Yahoo", "summary": "Transaction Expected to Help TRNR Generate More than $65M in 2025 Revenue on a Pro Forma basis Wattbike is the Leading, Indoor-Bike Brand for Elite-Athlete Training and is Used by Olympians and Professional Sports Teams Worldwide - Including the NFL, ...", "datetime": "2025-04-08T11:00:00.000Z", "headline": "Interactive Strength Inc. (NASDAQ \\"TRNR\\") Signs Binding Agreement to Acquire Wattbike, a $15M+, Omni-Channel, Connected, Indoor- Performance-Bike Business", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:57.048952+00	2025-09-03 17:56:57.048952+00
729cad88-4f0f-44fb-a596-26a09b7279b1	SPAI	2025-01-30	[{"url": "https://finnhub.io/api/news?id=c8eb256aab1f4c166f03e1b4328c903a8412e4a540c0a5a9f76e80fb8864a8f6", "source": "Yahoo", "summary": "AVENTURA, Fla., January 30, 2025--Safe Pro Group Inc. (Nasdaq: SPAI) (\\"Safe Pro\\" or the \\"Company\\"), a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, today announced that it has entered into a multi-year Memorandum of Understanding (MOU) with NIBULON Ltd. (NIBULON) to cooperate on addressing Ukraine’s agriculture crisis which has sustained billions in damages and losses due to the ongoing war.", "datetime": "2025-01-30T13:02:00.000Z", "headline": "Safe Pro Enters Multi-Year Agreement for its Patented Drone AI Demining Platform with Ukraine’s Leading Grain Export and Agricultural Organization NIBULON Ltd.", "sentiment": "neutral"}]	neutral	2025-09-03 17:56:58.583089+00	2025-09-03 17:56:58.583089+00
3391ab27-28de-4004-a0f0-d2110123e9c0	SAVA	2024-11-25	[{"url": "https://finnhub.io/api/news?id=e29d4551bd386c1098f74b01ba3f5e8188ed3adda3cb867e888fd23cd981699d", "source": "Yahoo", "summary": "Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing.", "datetime": "2024-11-25T21:15:28.000Z", "headline": "Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ca427da14bb9703c310a0a9165fcbe2a34454d61561ad6839dcd4cc38ea2f88a", "source": "Yahoo", "summary": "Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest phase three trial goals on its Alzheimer's treatment drug, simufilam. Yahoo Finance senior health reporter Anjalee Khemlani breaks down the story to Market Domination's Julie Hyman and Josh Lipton and what this all means for Cassava, especially as simufilam was its only drug in development at this time. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.", "datetime": "2024-11-25T20:57:17.000Z", "headline": "Cassava Sciences plummets over 80% on Alzheimer's trial fail", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=6adc61711621244b11e574176e94f62af3d41a48713d47d9b8e26c7b931df9e4", "source": "Yahoo", "summary": "Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.", "datetime": "2024-11-25T18:42:31.000Z", "headline": "Cassava Sciences stock plummets after Phase III Alzheimer’s fail", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=e7325aa4d02363ff21f35542aa0f1f86c0b843cb1de3356a6d84d07dd99939e4", "source": "Yahoo", "summary": "Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results, but its problems started way before that.", "datetime": "2024-11-25T17:31:00.000Z", "headline": "Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=5ce7ed0a927118b06319d82284adad48e0e694b68ea2d678984591f97d68e316", "source": "Yahoo", "summary": "The treatment didn’t show a significant reduction in cognitive or functional decline compared with a placebo.", "datetime": "2024-11-25T15:06:00.000Z", "headline": "Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=19b1beea015e8d4b813f9eb852995e033bb230d0631a1a02201a621ac7d2df7c", "source": "Yahoo", "summary": "Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints. In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant financial and emotional stakes. The co-primary endpoint", "datetime": "2024-11-25T14:27:54.000Z", "headline": "Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ab49117ffe33a0b8f875c10a27a1053a86f8227ec41bcebc471359dcaafdf622", "source": "Yahoo", "summary": "Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug aimed at treating Alzheimer’s disease failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.", "datetime": "2024-11-25T14:19:08.000Z", "headline": "Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=ff320f42c57462623ea4388a7453658f0d9c94beaeb4ba26d4411bddb4926510", "source": "Yahoo", "summary": "Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam continued to demonstrate an overall favorable safety profile Cassava intends to present the data at an upcoming medical meeting The Company will hold a webcast today, November 25, 2024, at 8:00 AM ET AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Com", "datetime": "2024-11-25T12:30:00.000Z", "headline": "Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=2e414cc1277557403c23bcfffba1d889e12ea489057583ad6fadfc7987ac6b47", "source": "Finnhub", "summary": "Cassava Corporate Update Call November 25, 2024 1 Topline data from the Phase 3 ReThink-ALZ study did not meet...", "datetime": "2024-11-25T10:53:08.000Z", "headline": "Cassava Sciences : Corporate Update Call Presentation - November 25, 2024", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=35c20e09ae64ee2304316c672094ed7b7505e3fec222552eef102603b8d75763", "source": "Finnhub", "summary": "Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in...", "datetime": "2024-11-25T07:39:09.000Z", "headline": "Cassava Sciences : Topline Phase 3 Data Did Not Meet Co Primary Endpoints Form 8 K", "sentiment": "neutral"}]	negative	2025-09-03 17:57:01.755273+00	2025-09-03 17:57:01.755273+00
6fbafd85-8cde-4724-bd44-840273782c51	VSTTF	2024-11-25	[]	\N	2025-09-03 17:57:02.100781+00	2025-09-03 17:57:02.100781+00
dc4bf732-b47d-4c0d-8c83-3357bd48b8e7	ZENA	2024-11-26	[]	\N	2025-09-03 17:57:05.015267+00	2025-09-03 17:57:05.015267+00
9d4c3bf1-43e9-42b2-8afe-4c48f04af16a	ZENA	2024-12-03	[{"url": "https://finnhub.io/api/news?id=f9b0e6d13709e74cb3e6720afeb2538971ea07f40ce4bd2eefbf19747ad33f40", "source": "Yahoo", "summary": "TORONTO, Ontario, Dec. 03, 2024 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (\\"ZenaTech\\"), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, announces that its Taiwan-based Spider Vision Sensors Ltd. subsidiary has signed a partnership agreement with Suntek Global, a Taiwan-based certified electronics manufacturer of vision systems, to collaborate on design and manufacturing of Blue UAS (Unmann", "datetime": "2024-12-03T12:30:00.000Z", "headline": "ZenaTech’s Spider Vision Sensors Ltd. Signs Partnership Agreement for Blue UAS and NDAA Compliant AI Drone Cameras for US Defense", "sentiment": "positive"}]	positive	2025-09-03 17:57:05.32913+00	2025-09-03 17:57:05.32913+00
f7eb0cee-7b46-4a6d-9303-c4d93fef0185	ZENA	2025-01-10	[{"url": "https://finnhub.io/api/news?id=3fa830a7cf8cc6917020558d26f919d68acc91b70994210fb57055a4c97a8afc", "source": "Finnhub", "summary": "VANCOUVER, British Columbia, Jan. 10, 2025 -- ZenaTech, Inc. , a technology company specializing in AI drone solutions driven by Quantum Computing, Drones as a Service, and enterprise SaaS,...", "datetime": "2025-01-10T07:31:04.000Z", "headline": "ZenaTech’s ZenaDrone Multipurpose AI Drone Applies for FAA Part 137 Crop Sprayer Certification for Agricultural and Wildfire Industry Use", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:06.810042+00	2025-09-03 17:57:06.810042+00
2550ad28-bc8c-4bb3-8fdb-b476f9e9835c	SMTK	2024-11-26	[{"url": "https://finnhub.io/api/news?id=1c6a9b051794a86113c72d3337967a9d0be303e8955076a8625ba59249caf260", "source": "Yahoo", "summary": "Smartkem (NASDAQ: SMTK), positioned to power the next generation of displays using its disruptive organic thin-film transistors (OTFTs), has partnered with AUO, the largest display manufacturer in Taiwan, to jointly develop the world's first advanced rollable, transparent microLED display using Smartkem's technology.", "datetime": "2024-11-25T12:05:00.000Z", "headline": "Smartkem and AUO Partner to Develop a New Generation of Rollable, Transparent MicroLED Displays", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:07.531058+00	2025-09-03 17:57:07.531058+00
91d93c34-202c-48ef-9c11-059fac714d0d	TOYO	2024-11-26	[{"url": "https://finnhub.io/api/news?id=5ad3fc49e1592def9ca60e31ed9b6ce24a306b019c3ecc41adde53fffe4a51ea", "source": "Yahoo", "summary": "TOYO Co., Ltd (Nasdaq: TOYO) (\\"TOYO\\" or the \\"Company\\"), a solar solution company, is pleased to announce the execution of a significant contract valued at $150 million to supply high efficiency solar cells to a prominent solar module manufacturer. This landmark agreement underscores the Company's commitment to advancing sustainable energy and supporting the global transition towards renewable resources.", "datetime": "2024-11-26T13:00:00.000Z", "headline": "TOYO Co., Ltd Secures $150 million Contract to Supply Solar Cells to a Leading Solar Module Manufacturer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a31c552cedeaa987787e0a9d6ee9ec53e253690c2bc5360fcb6e86937ced07aa", "source": "Yahoo", "summary": "TOYO Co., Ltd (Nasdaq: TOYO) (\\"TOYO\\" or the \\"Company\\"), a solar solution company, today announced that the Company will participate in two Clean Energy conferences in NYC hosted by Jefferies and Bank of America on December 4th and 5th. The company's Chairman and CEO, Mr. Junsei Ryu, and President, Mr. Simon Shi, will be available for one-on-one meetings with institutional investors at the conferences.", "datetime": "2024-11-25T14:00:00.000Z", "headline": "TOYO Co., Ltd to Participate in Clean Energy Conferences in NYC on December 4th and 5th", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8e9f2537add4bee120cfb7847207fcd4fecc437849added8998b1b92109e57d4", "source": "Yahoo", "summary": "TOYO Co., Ltd (Nasdaq: TOYO) (\\"TOYO\\" or the \\"Company\\"), a solar solution company, today announced it has agreed to acquire 100% of membership interests in Solar Plus Technology Texas LLC(\\"Solar Plus\\") located in Houston metropolitan area, Texas, via its subsidiary TOYO Solar LLC.", "datetime": "2024-11-25T13:00:00.000Z", "headline": "TOYO Co., Ltd to Acquire Solar Module Manufacturing Facility in Texas", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:07.800935+00	2025-09-03 17:57:07.800935+00
48b01c5e-c691-4d3e-8945-bcb92c0f64c2	WKEY	2024-12-20	[]	\N	2025-09-03 17:58:44.577282+00	2025-09-03 17:58:44.577282+00
1dd35dff-b313-4a57-90c8-5e88d71dabbf	KXIN	2024-12-24	[]	\N	2025-09-03 18:00:07.316998+00	2025-09-03 18:00:07.316998+00
be7694f6-8459-4dd7-be79-bd551085a1e9	SKK	2024-11-22	[]	\N	2025-09-03 17:57:00.172952+00	2025-09-03 17:57:00.172952+00
2894418b-ec5f-4f9b-9683-346f33910096	VSTTF	2025-02-11	[]	\N	2025-09-03 17:57:03.999314+00	2025-09-03 17:57:03.999314+00
5c8c973e-1ccc-44e5-b6c4-31ace9b74fcd	G7309R106	2024-11-25	[]	\N	2025-09-03 17:57:04.352542+00	2025-09-03 17:57:04.352542+00
450e4890-cdf8-4035-96f3-9dc572184549	MDAI	2024-11-26	[{"url": "https://finnhub.io/api/news?id=effac6009f87d7ebd95d37bfe78950f8f507a7a4121e010004165e475f0eb786", "source": "Yahoo", "summary": "DALLAS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the repricing of its 8,433,333 publicly-traded common share purchase warrants with an exercise price of $11.50 per share to $2.75 per share, effective following its twenty day notice requirement. The warrants currently trade on", "datetime": "2024-11-26T15:17:00.000Z", "headline": "Spectral AI Announces Repricing of its Public Warrants", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:04.546767+00	2025-09-03 17:57:04.546767+00
c07c8a51-3a8c-462b-acde-0827ef9b11d2	VSEE	2024-11-26	[{"url": "https://finnhub.io/api/news?id=d0e50864441e163a14bd4dbb8e64fafa55f8805c588179b7aa0edc45de52f674", "source": "Yahoo", "summary": "SAN JOSE, Calif., November 26, 2024--VSee Health, Inc. (Nasdaq: VSEE) is pleased to invite investors to a webinar on December 3, 2024, at 4:15 p.m. ET.", "datetime": "2024-11-26T13:00:00.000Z", "headline": "Join VSee Health’s Exclusive Live Investor Webinar and Q&A Session on December 3", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:07.206957+00	2025-09-03 17:57:07.206957+00
9ea7cef0-db03-487a-8ed9-feb1d0ea35c1	NLSP	2024-12-03	[{"url": "https://finnhub.io/api/news?id=4c45a4acc824e367bdbfe1e9706d1c787e1a96c2996c6897835ed3a87aa88965", "source": "Yahoo", "summary": "ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential of its dual orexin receptor agonist (DOXA) ...", "datetime": "2024-12-03T12:40:00.000Z", "headline": "NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:09.705513+00	2025-09-03 17:57:09.705513+00
909b4b72-a82e-492e-84e9-52aa94bd2eb5	NLSP	2024-12-30	[{"url": "https://finnhub.io/api/news?id=e3faad0130cb8f3c598bf7d91ae4070f97dc3fb3e8349079288389ca5211cda3", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced today that NLS has file", "datetime": "2024-12-30T12:30:00.000Z", "headline": "NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger", "sentiment": "positive"}]	positive	2025-09-03 17:57:09.939926+00	2025-09-03 17:57:09.939926+00
11c9a07c-ab1a-42ae-a1ca-3bbea14528ba	NCPL	2024-11-26	[{"url": "https://finnhub.io/api/news?id=a94f4f9f9aa1297c9c8e213fa8fa60335ffa214277e8b0656d9c1ae28abf8712", "source": "Yahoo", "summary": "BOSTON, MA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced that its wholly-owned subsidiary, Netcapital Securities Inc. (“NSI”), has received approval from the Financial Industry Regulatory Authority (\\"FINRA\\") to become a FINRA-member broker-dealer. Key Highlights: Netcapital Securities Inc. is specifically approved to engage in the following types of business: private placements of securities", "datetime": "2024-11-26T13:30:00.000Z", "headline": "Netcapital Secures FINRA Approval for Broker-Dealer License", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:08.656635+00	2025-09-03 17:57:08.656635+00
1bbacffe-4670-47a0-bf0e-5ec5ecaf3435	PPBT	2024-12-02	[{"url": "https://finnhub.io/api/news?id=b4a0cd660a76438607033d621668a4d762e5edb6a4fc94ba26164173ceb43ee1", "source": "Yahoo", "summary": "Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with", "datetime": "2024-12-02T12:00:00.000Z", "headline": "Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer", "sentiment": "positive"}]	positive	2025-09-03 17:57:08.873279+00	2025-09-03 17:57:08.873279+00
a7a606cd-1c84-4182-9546-26689465ae40	CTNT	2024-12-03	[{"url": "https://finnhub.io/api/news?id=a5960800a0fde780f6c0a8c5ed7becb8ffb77ab7446696cb24aaa281d775d466", "source": "SeekingAlpha", "summary": "Super Micro jumps as internal review finds no misconduct. SpaceX considers tender offer that boosts valuation to $350 billion - report. Cheetah Net Supply Chain to acquire TW & EW.", "datetime": "2024-12-03T06:52:31.000Z", "headline": "Wall Street Breakfast Podcast: Super Micro Clears Misconduct Cloud", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8b69900c1a9e91a65ae51580d4c9d4d5d291345fd4c501713f8d4840b4beec18", "source": "Yahoo", "summary": "IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq CM: CTNT) today announced that it has executed definitive agreements (the “Agreements”) for the acquisition (the “Acquisition”) of TW & EW Services Inc, a California-based labor and logistics service provider (“TW & EW”). The Acquisition is expected to close on or about December 4, 2024. With TW & EW’s integration, Cheetah expects to capitalize on additional service opport", "datetime": "2024-12-03T03:10:00.000Z", "headline": "Cheetah Net Supply Chain Service Inc. Signs Definitive Agreements to Acquire TW & EW", "sentiment": "neutral"}]	neutral	2025-09-03 17:57:09.149465+00	2025-09-03 17:57:09.149465+00
df4bdf71-2f26-4790-973a-ae22fb717255	NLSP	2025-01-31	[{"url": "https://finnhub.io/api/news?id=1410b4eae8e440a685ed31dcefe293454e022478ddf874ca82b41fe2ab0610f0", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are pleased to announce that in a special gene", "datetime": "2025-01-31T12:30:00.000Z", "headline": "Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9db868b831a3aac1bc60c4b02c6f1158f3747a05f4b17498e2537d80e81ff517", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (\\"NLS\\" or the \\"Company\\"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).", "datetime": "2025-01-30T12:30:00.000Z", "headline": "NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting", "sentiment": "neutral"}]	positive	2025-09-03 17:58:12.122955+00	2025-09-03 17:58:12.122955+00
e08ff2f6-3df1-47cc-b2ba-517c139a8f51	NLSP	2025-02-10	[{"url": "https://finnhub.io/api/news?id=96c4da49a260e6291f10dd59318e9449a207d1b6abb2495eb2aebb271f341161", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a leading biotechno", "datetime": "2025-02-10T12:30:00.000Z", "headline": "NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:13.17948+00	2025-09-03 17:58:13.17948+00
67ea7555-dd69-4e77-97e7-3b90c4804e3b	SRM	2024-12-04	[{"url": "https://finnhub.io/api/news?id=d35935ac65a3e83ac0f36f2554469c962ef9653376bee49d4338a1caf76e256e", "source": "Yahoo", "summary": "Jupiter, FL, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SRM Entertainment, Inc. (Nasdaq: SRM) (the “Company,” or “SRM”, a leading provider of creative and high-quality licensed media-themed merchandise, today announced that its online sales on Amazon have surged by over 417% since September. This exceptional growth is driven by strong customer demand for the company's high-margin products and is expected to have a significant positive impact on its financial performance. \\"Amazon offers a tremendous platf", "datetime": "2024-12-04T12:30:00.000Z", "headline": "SRM Entertainment's Amazon Sales Surge Over 400% in Three Months, Fueling Strong Financial Performance", "sentiment": "positive"}]	positive	2025-09-03 17:58:14.277982+00	2025-09-03 17:58:14.277982+00
d78bcf41-f060-45b7-aac1-a7466fe6a454	CYCN	2024-12-04	[]	\N	2025-09-03 17:58:14.600508+00	2025-09-03 17:58:14.600508+00
837d5111-99ed-4778-ba00-1774b670c325	CYCN	2025-01-31	[]	\N	2025-09-03 17:58:14.860378+00	2025-09-03 17:58:14.860378+00
d77cf129-0ee5-457e-90cc-b2e5ac47676e	CYCN	2025-02-03	[]	\N	2025-09-03 17:58:15.53372+00	2025-09-03 17:58:15.53372+00
dad20573-db62-4de4-a6c7-2ad718ee540a	28622K203	2024-12-04	[]	\N	2025-09-03 17:58:16.043494+00	2025-09-03 17:58:16.043494+00
47758b3c-1bf1-4746-8002-13a8b635139b	FGL	2024-12-04	[{"url": "https://finnhub.io/api/news?id=9ba9e77669bad7dc636613c8936378cbe0820f6c9f62a4520727b88da0b9aeb1", "source": "Yahoo", "summary": "KUALA LUMPUR, Malaysia, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Founder Group Limited (NASDAQ: FGL) (“Founder Group” or the “Company”), is proud to announce that it has been awarded a conditional Letter of Award (LOA), valued at approximately US$68 million (around RM299,260,000), for the development of a 100-megawatt solar farm in Tanjung Malim, Malaysia. Spanning 900 acres, the solar farm will serve as a critical energy source, providing 100MW of export capacity to power an advanced AI data center in", "datetime": "2024-12-04T13:33:00.000Z", "headline": "Founder Group Secures Conditional Letter of Award Worth Approximately US$68 Million for a 100MW Solar Farm in Malaysia", "sentiment": "positive"}]	positive	2025-09-03 17:58:16.371+00	2025-09-03 17:58:16.371+00
ffab3973-bd1c-4dbd-a44e-bc6aa8b17702	TARA	2024-12-05	[{"url": "https://finnhub.io/api/news?id=896f11bf72eb8c8417b926163ad50d1384470bed65e5bf60921ed2343ca04155", "source": "Yahoo", "summary": "TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from", "datetime": "2024-12-05T12:00:00.000Z", "headline": "Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC", "sentiment": "positive"}]	positive	2025-09-03 17:58:16.676555+00	2025-09-03 17:58:16.676555+00
bfb3c764-816c-48b1-832f-0e8e0d0f709d	VVPR	2025-01-13	[]	\N	2025-09-03 17:58:18.072195+00	2025-09-03 17:58:18.072195+00
ef01b14e-596f-4efa-ad05-b0a60bad2276	VVPR	2025-03-21	[{"url": "https://finnhub.io/api/news?id=3236f528d9b769cf6bda9e1e94985092a926e1569a566642aa3e4c8a19976aca", "source": "Yahoo", "summary": "Business Combination Agreement with CCTS originally announced in August 2024 Combined pro forma enterprise value of US$904m assumes no public trust redemptions for CCTS Parties working to close the transaction by Q2, calendar 2025 LONDON, March 21, 2025 (GLOBE NEWSWIRE) -- Tembo E-LV B.V. (“Tembo”), a subsidiary of Nasdaq-listed B Corporation, VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\"), today announced that it is working closely with CCTS (“Cactus Acquisition Corp.", "datetime": "2025-03-21T13:15:00.000Z", "headline": "Tembo E-LV Progresses Business Combination Agreement with CCTS at a Combined Enterprise Value Of US$904m", "sentiment": "positive"}]	positive	2025-09-03 17:58:20.209487+00	2025-09-03 17:58:20.209487+00
e772124e-9db4-4a0c-a4a9-e91390122d77	M61472136	2024-12-06	[]	\N	2025-09-03 17:58:27.622301+00	2025-09-03 17:58:27.622301+00
bfe88a82-d609-4d6c-a55b-80279a6521c2	VVPR	2024-12-05	[{"url": "https://finnhub.io/api/news?id=fc2a1ddef1602c1ea44274792b37850974db1104e8abc43178ac530fc65aa2ff", "source": "SeekingAlpha", "summary": "VivoPower International PLC (NASDAQ:VVPR) Q4 2024 Earnings Conference Call December 5, 2024 4:45 PM ETCorporate ParticipantsConference Call...", "datetime": "2024-12-05T21:14:47.000Z", "headline": "VivoPower International PLC (VVPR) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8ddd80da6f1a1f35666420e253770720a9ae85a9f85dfc95d3b2f1a046cfd89c", "source": "Yahoo", "summary": "Caret Digital has selected renewable-powered hosting facilities in Wisconsin and Oregon with an initial fleet ramping up to 1,000 Antminer L9s to be activated Annualised revenue potential of up to US$25m based on current Dogecoin prices, with annualised cash EBITDA of up to US$12m Dogecoin mining is consistent with Caret Digital’s Power-to-X strategy that seeks to activate the highest and best use cases for renewable power capacity Economics of Dogecoin mining have improved markedly with an esti", "datetime": "2024-12-05T13:15:00.000Z", "headline": "VivoPower’s Caret Digital to activate Dogecoin mining operations, with revenue and profitable cashflow generation by early January 2025", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:17.716002+00	2025-09-03 17:58:17.716002+00
6fa9014f-cc73-4250-add2-4cd46d926bec	VVPR	2025-03-26	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	positive	2025-09-03 17:58:22.445771+00	2025-09-03 17:58:22.445771+00
c55a1394-6b51-4d67-9d67-ac9fd9be376c	VVPR	2025-03-27	[{"url": "https://finnhub.io/api/news?id=d8f694dc53e9725168ec0e14e4dd2975df464bbde6c0da80e80a96cdd27bc14e", "source": "Yahoo", "summary": "LONDON, March 27, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") has agreed to grant Energi Holdings Limited (“Energi”) an exclusivity period of 8 weeks to conduct due diligence subject to Energi increasing its non-binding all-cash takeover proposal to acquire the non-affiliated shareholders of VivoPower at an enterprise valuation of US$180 million. This represents an increase from US$120 million. Energi is an Abu Dhabi-headquartered energy sol", "datetime": "2025-03-27T17:15:00.000Z", "headline": "VivoPower Agrees to Grant Exclusivity to Energi Subject to Increase in Non-Binding All-Cash Takeover Offer to Enterprise Value of US$180 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}]	positive	2025-09-03 17:58:25.548602+00	2025-09-03 17:58:25.548602+00
c56cafa6-65ef-4e7c-84a5-7f3481b287fa	AKYA	2025-01-10	[{"url": "https://finnhub.io/api/news?id=085459cbf2ffc1a0977f977eb9147dc80f63cf8b3915b1170f3d5172fe9c648f", "source": "Finnhub", "summary": "Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Akoya Biosciences, Inc. to Quanterix Corporation ....", "datetime": "2025-01-10T17:36:03.000Z", "headline": "AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=dafdccf86b194006aff1ee00ea1cab3691931f8b6369ed06c1ecd3ad40c4e91f", "source": "Yahoo", "summary": "Quanterix (QTRX) and Akoya Biosciences (AKYA) said Friday they entered into a definitive merger agre", "datetime": "2025-01-10T12:49:28.000Z", "headline": "Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=87781754a6378257e1b272734a83712c4f67ac4a484dad9ac1ec2e93b2e06b74", "source": "Yahoo", "summary": "BILLERICA, Mass. and MARLBOROUGH, Mass., January 10, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.", "datetime": "2025-01-10T12:00:00.000Z", "headline": "Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=5842f157937f4ad0e45ac03665a9ba8d5ba75497e783ee028f42fe94c41e21c8", "source": "Finnhub", "summary": "Ademi LLP is investigating Akoya for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix.Click here to learn how to join our investigation and obtain...", "datetime": "2025-01-10T09:48:03.000Z", "headline": "Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=03b92323f0a4dcbbd75f3e189a149f2b05da85cc39dbb9a85d352357db663bf4", "source": "Finnhub", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya...", "datetime": "2025-01-10T08:22:04.000Z", "headline": "AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:38.102915+00	2025-09-03 17:58:38.102915+00
9adfd870-43dd-4636-b04e-e033e36a859f	AGRI	2024-12-10	[]	\N	2025-09-03 17:58:38.757663+00	2025-09-03 17:58:38.757663+00
85968efc-d428-4bb3-9159-514b09f13eef	SMCI	2024-12-10	[{"url": "https://finnhub.io/api/news?id=c182e0e02a1cd97a8b54239a3de8b92cf91f640cb87e0209594d6884f332c08b", "source": "Yahoo", "summary": "The S&P 500 fell 0.3% on Tuesday, Dec. 10, as the cooldown from last week's record-setting rally continued ahead of key inflation data.", "datetime": "2024-12-10T22:35:13.000Z", "headline": "S&P 500 Gains and Losses Today: Walgreens Pops Following Reports of Buyout Talks", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=d74c30e2bdf033e5e1b2bd63fc0888ec0744b4cd4b46cb089176434bf7fa99a4", "source": "Yahoo", "summary": "Supermicro has avoided being delisted and gave analysts some encouraging news. So why is the stock falling?", "datetime": "2024-12-10T20:43:45.000Z", "headline": "Why Super Micro Computer Stock Is Sinking Today", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=a65e21013819cf807e6eaf0693091c74b249dd27eaef10e0ac801f61504016ae", "source": "Yahoo", "summary": "Charles Liang: Super Micro Stock Safe as Filing Deadline Looms", "datetime": "2024-12-10T18:47:21.000Z", "headline": "Super Micro CEO Confirms Plan to Meet Nasdaq Filing Deadline Amid Delisting Concerns", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=0e1ade1e7f498ae11b1991112b7c48e699365e0b92759a7283c4e41e28988a81", "source": "Yahoo", "summary": "Fears are mounting that Super Micro will drop out of the Nasdaq 100 index, despite staging a remarkable comeback since the surprise exit of its auditor in October.", "datetime": "2024-12-10T18:36:00.000Z", "headline": "Super Micro Stock Tumbles. It  Could Get Knocked Out of Nasdaq 100.", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=319e8043f8e6d12b9486696e3921ccf25a91e21484a3c0e4fbc161764097be42", "source": "Yahoo", "summary": "Data center operators appear to be sticking with Super Micro Computer as the AI server maker deals with financial reporting issues.", "datetime": "2024-12-10T18:27:12.000Z", "headline": "Supermicro Customers Staying Put While Investors Flee", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=3f3270fddb6f20205c93b0a63456500a5108aae1c736663c30c211d8e7358481", "source": "Yahoo", "summary": "Investing.com -- Super Micro Computer Inc (NASDAQ:SMCI) would not face delisting from the Nasdaq, CEO Charles Liang said on Tuesday in a Reuters interview, assuring that necessary financial filings would be completed by February.", "datetime": "2024-12-10T18:11:12.000Z", "headline": "Super Micro confident Nasdaq delisting would not happen amid audit scandal", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=0859ecff1f98c4c520870471f339e3de4b5b04030a1d915f1b73a30a998b01aa", "source": "Yahoo", "summary": "Super Micro tackles filing delays with leadership changes amid Nasdaq compliance extension to February 2025", "datetime": "2024-12-10T18:10:59.000Z", "headline": "Super Micro Shares Drop as Nasdaq Grants Filing Extension, Leadership Shake-Up Announced", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=2842f80aa437063838e50406a8483b1abb440c31bc6cc3bf766fa7e9bf5be539", "source": "SeekingAlpha", "summary": "Super Micro Computer shows strong margin recovery and technical strength. Find out why SMCI stock is a buy for short-term trades before FY 2025 Q1 earnings.", "datetime": "2024-12-10T17:39:56.000Z", "headline": "Super Micro Computer: Our Best 2025 Swing Trade Idea (Technical Analysis)", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ab747c2e7df67f2d865762696e9c985bf7f1be2132f945eedfb72b2206c41c0e", "source": "MarketWatch", "summary": "Tech Down as Trade War Fears Linger -- Tech Roundup", "datetime": "2024-12-10T17:38:00.000Z", "headline": "Tech Down as Trade War Fears Linger -- Tech Roundup", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=b204b76221d18b09eff7684cbdcbc3145e63080aae59bd90ab146089e4922523", "source": "MarketWatch", "summary": "How the Nasdaq 100 Remakes Itself Every December", "datetime": "2024-12-06T19:15:00.000Z", "headline": "How the Nasdaq 100 Remakes Itself Every December", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:39.248439+00	2025-09-03 17:58:39.248439+00
4d9d0e0e-3650-461e-a012-b18fc5a1df54	CADL	2024-12-11	[{"url": "https://finnhub.io/api/news?id=6218289aa5ac63d12eaa7ba69b34d11ee8f66516842b67086b3c61ad05e0e3cf", "source": "Yahoo", "summary": "Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study.", "datetime": "2024-12-11T21:09:56.000Z", "headline": "Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c93170efa22b823500e7d115d524562af498a98626542aa9ddc114bf5e77a210", "source": "Yahoo", "summary": "By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients. “We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy […]", "datetime": "2024-12-11T18:07:16.000Z", "headline": "Candel Therapeutics Prostate Cancer Therapy Shows Promise", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=dbfd62adb66414944949dbfbe7abf13592d215895edd4c797435b2f740b9f088", "source": "Yahoo", "summary": "The company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study.", "datetime": "2024-12-11T15:32:50.000Z", "headline": "Candel Therapeutics stock up 172% after Phase III prostate cancer success", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=2d2c17f4676acf2cee146830809a3315c9867bd5fc52c45eea955ae1a6b812b4", "source": "Yahoo", "summary": "On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. The trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug (valacyclovir) combined with the standard of care compared to the standard of care alone. CAN-2409, when administered with valacyclovir, is des", "datetime": "2024-12-11T14:19:44.000Z", "headline": "Candel Therapeutics Stock Surges Over 100% - Here's Why", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5ba26c78f2d4f4a500f1fd512be75deffecaf7eaa04797b6333249f0789cbcba", "source": "SeekingAlpha", "summary": "Candel Therapeutics' CAN-2409 shows a 14.5% improvement in prostate cancer survival. Discover why CADL stock stays a \\"Buy\\" despite operational challenges.", "datetime": "2024-12-11T12:19:15.000Z", "headline": "Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=cefb9f628dd9d48a48366332e2e04f0ea70e826d7330089f23a1847e4baa7c4a", "source": "Yahoo", "summary": "Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE", "datetime": "2024-12-11T12:00:00.000Z", "headline": "Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9669b8afd0d86ad4666fe928d3446fc32da031159848225ce34cc50086cdaf1f", "source": "Finnhub", "summary": "Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival ...", "datetime": "2024-12-11T07:49:04.000Z", "headline": "Candel Therapeutics : Announces CAN 2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease Free Survival Form 8 K", "sentiment": "neutral"}]	positive	2025-09-03 17:58:39.403885+00	2025-09-03 17:58:39.403885+00
a2a6e74f-df75-4534-a277-06259f4daf8b	AMPG	2024-12-11	[{"url": "https://finnhub.io/api/news?id=865bea4e475ecb008c8930d2a88c59e6f20725dba5707e4a9a762b04e97366c5", "source": "Yahoo", "summary": "HAUPPAUGE, N.Y., Dec. 11, 2024 (GLOBE NEWSWIRE) -- AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, proudly announces the successful development and deployment of its proprietary low-noise cryogenic High Electron Mo", "datetime": "2024-12-11T13:30:00.000Z", "headline": "AmpliTech Group Powers The Quantum Computing Revolution With Cutting-Edge Low-Noise Cryogenic HEMT Amplifiers", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:40.429318+00	2025-09-03 17:58:40.429318+00
681ca9e6-a4e3-4708-97a1-1807dbf1b5ed	83013Q806	2024-12-12	[]	\N	2025-09-03 17:58:41.014057+00	2025-09-03 17:58:41.014057+00
e08d86e1-129f-49b8-9275-fd214958d719	DVLT	2024-12-23	[]	\N	2025-09-03 18:00:03.81472+00	2025-09-03 18:00:03.81472+00
740c611c-cad1-46a5-a5d2-3e81be31e9ea	PIKM	2024-12-23	[]	\N	2025-09-03 18:00:07.143582+00	2025-09-03 18:00:07.143582+00
2b9545ea-2d77-445b-8aed-e2158755152c	VVPR	2025-03-24	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:20.457611+00	2025-09-03 17:58:20.457611+00
a39d4542-84a8-4951-9357-11eefff2a141	G9442G120	2024-12-06	[]	\N	2025-09-03 17:58:30.945125+00	2025-09-03 17:58:30.945125+00
b493fd1d-29ca-4183-b919-a129564d2770	ZEO	2024-12-09	[]	\N	2025-09-03 17:58:32.441315+00	2025-09-03 17:58:32.441315+00
135c91a3-cc0b-479a-af9b-d730cf689863	CPIX	2024-12-10	[{"url": "https://finnhub.io/api/news?id=c4783e733bd30c3efa25cee01bd743166fab4b89d80357d0bfa2c50cf5b36e4e", "source": "Yahoo", "summary": "FDA approval of Acetadote's simplified dosing propels Cumberland Pharmaceuticals' stock to a 90% single-day surge", "datetime": "2024-12-10T18:39:12.000Z", "headline": "Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=b10aeeaf3d972ce3babaf420cce3469d9f9b0cf03b2514391a91f6e5533275e0", "source": "Yahoo", "summary": "On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen. Acetaminophen, a common over-the-counter pain reliever and fever reducer, is the leading cause of acute liver failure in the United States. Eac", "datetime": "2024-12-10T17:08:21.000Z", "headline": "Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=34d6962715bca4cc9887e763b0ae45d2885750ad9ae61ddd0ca834b09cc47107", "source": "Yahoo", "summary": "Health care stocks were steady premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV)", "datetime": "2024-12-10T14:07:35.000Z", "headline": "Sector Update: Health Care Stocks Steady Pre-Bell Tuesday", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ab9d3f8e5aec7bf94422909801c5654a7629ce84581f1b9f410bdb7fa4db4bde", "source": "Yahoo", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1.", "datetime": "2024-12-09T21:05:00.000Z", "headline": "FDA APPROVES ACETADOTE® sNDA", "sentiment": "neutral"}]	positive	2025-09-03 17:58:35.353782+00	2025-09-03 17:58:35.353782+00
3ad20511-9d89-42d2-9826-7e15930922a9	QURE	2024-12-10	[{"url": "https://finnhub.io/api/news?id=812e8ba0e02bb9107297dc8e8a1a78dec96110cd1e72c5bf03ecf029a2c38e56", "source": "SeekingAlpha", "summary": "uniQure's AMT-130 shows promising results for Huntingtonâs disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.", "datetime": "2024-12-10T17:20:46.000Z", "headline": "uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=147d399d3bec5c3ef987dff8117830b076dcd4ad927642dc72c4a57ddb7bef7f", "source": "Yahoo", "summary": "UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.", "datetime": "2024-12-10T15:19:00.000Z", "headline": "UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f913c11533b3a48fd8a31162c580e1d44bc84efe23f4bd79ec2f405f6596bf85", "source": "Yahoo", "summary": "UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment.", "datetime": "2024-12-10T14:34:00.000Z", "headline": "UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d0010338b7dcec99f05d53f19c5b619ff3bf830a2d28c3be9b7de52c38c4746c", "source": "Yahoo", "summary": "The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an accelerated approval application.", "datetime": "2024-12-10T12:07:00.000Z", "headline": "UniQure shares soar on chance of speedy approval for Huntington’s therapy", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=4236aac132c3fd71e0cd6c6e3200ec78ec34d2f499501ebc8d3f73a789f446d0", "source": "Yahoo", "summary": "~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE)", "datetime": "2024-12-10T12:05:00.000Z", "headline": "uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=52f61d2b222e2afa0f56d6bbdfc6e2051e768efacb1241b691dc145cdcc0b0db", "source": "Finnhub", "summary": "By Chris Wack UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a...", "datetime": "2024-12-10T10:19:08.000Z", "headline": "UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=0cf87f3089b1d9768e62536e5bcfdb8fa6a312bf6edc23d16a6187554a899ad0", "source": "Finnhub", "summary": "uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease ~ U.S. Food and Drug Administration agrees that data...", "datetime": "2024-12-10T07:26:04.000Z", "headline": "UniQure N : Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT 130 in Huntington’s Disease Form 8 K", "sentiment": "neutral"}]	positive	2025-09-03 17:58:36.856492+00	2025-09-03 17:58:36.856492+00
532d7a2f-5aa6-471f-bb47-fde7c9b10edc	63008J603	2024-12-11	[]	\N	2025-09-03 17:58:39.719441+00	2025-09-03 17:58:39.719441+00
0aa9800f-5ceb-4f97-b18f-45a47e5e3071	AMPG	2024-12-24	[]	\N	2025-09-03 17:58:40.691766+00	2025-09-03 17:58:40.691766+00
1138a64a-b15d-439b-8772-8867d9faf913	IMRX	2024-12-12	[{"url": "https://finnhub.io/api/news?id=b9d7feb167af47b16f0912fae245369306b8e2d2b6c631e84edfdf095d0e6f82", "source": "Yahoo", "summary": "- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX", "datetime": "2024-12-12T13:00:00.000Z", "headline": "Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:42.027245+00	2025-09-03 17:58:42.027245+00
d6584f4d-0af6-4c1e-92d7-9f6dcc9ed6eb	MTVA	2024-12-18	[{"url": "https://finnhub.io/api/news?id=ed1db45cffce8642edccd02f264f50cbb21166c491c8f36d490722b3094d4789", "source": "Yahoo", "summary": "MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). Part 1 of this Phase 2a trial is exploring DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in combination with sita", "datetime": "2024-12-18T13:01:00.000Z", "headline": "MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:52.886014+00	2025-09-03 17:58:52.886014+00
89905a36-5960-4425-ad94-a2074e2e2375	RKDA	2024-12-05	[{"url": "https://finnhub.io/api/news?id=db161f4d658ef97bd94a346956e0e28badfdcc27107972bedd98779d73a918c3", "source": "Yahoo", "summary": "Arcadia Biosciences (RKDA) shares were up more than 209% in recent Thursday premarket activity follo", "datetime": "2024-12-05T14:00:20.000Z", "headline": "Arcadia Biosciences to Combine With Roosevelt Resources; Shares Surge Pre-Bell", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=dd1c1918f674b6ce7cce4dd302eb3159a42ac171425b0bf26d65b27cfeb5052a", "source": "Yahoo", "summary": "DALLAS, December 05, 2024--Arcadia Biosciences, Inc.® (Nasdaq: RKDA) and Roosevelt Resources LP announced today that they have entered into a definitive securities exchange agreement which, when completed, will combine the two companies in an all-stock transaction. Under the terms of the agreement, Arcadia will issue to the partners of Roosevelt shares of Arcadia common stock at the closing of the transaction in exchange for all of the equity interests in Roosevelt. Following the closing of the", "datetime": "2024-12-05T13:02:00.000Z", "headline": "Arcadia Biosciences (RKDA) Enters Into Business Combination Agreement with Roosevelt Resources in All-Stock Transaction", "sentiment": "neutral"}]	positive	2025-09-03 17:58:26.757506+00	2025-09-03 17:58:26.757506+00
f5b7cb74-232f-4a14-aad5-bbe3973f5010	ZBAO	2024-12-06	[{"url": "https://finnhub.io/api/news?id=abacddb842b6b7db863b13978f5c2c9aaa2630bedd53b74841bee550cf113cf4", "source": "Yahoo", "summary": "Shanghai, China--(Newsfile Corp. - December 5, 2024) - Zhibao Technology Inc. (NASDAQ: ZBAO) (\\"Zhibao\\" or the \\"Company\\"), a leading and high growth InsurTech company primarily engaged in providing digital insurance brokerage services through its operating entities in China, today announced a strategic partnership with PICC Property and Casualty Company Limited (\\"PICC\\") and Munich Re Beijing to launch a new generation of medical insurance products in China. The first product to launch under this", "datetime": "2024-12-05T21:01:00.000Z", "headline": "Zhibao Technology Launches New Partnership with PICC & Munich Re to Develop New Medical Insurance Products in China", "sentiment": "positive"}]	positive	2025-09-03 17:58:26.983439+00	2025-09-03 17:58:26.983439+00
a1a96e9b-a28e-44c4-b7c6-491c6973fe5b	ALBT	2024-12-06	[]	\N	2025-09-03 17:58:28.144102+00	2025-09-03 17:58:28.144102+00
cf123316-2e15-4498-bdd2-8715f43e17f8	ADD	2024-12-26	[]	\N	2025-09-03 17:58:29.001549+00	2025-09-03 17:58:29.001549+00
268221f9-7dde-4fb3-afa2-6164ce0be8ff	SNOA	2024-12-06	[{"url": "https://finnhub.io/api/news?id=4b3f6b1a2beaf2beaaef3f71e3529017c0dc264454758b00b0f6e756647d2d7e", "source": "Yahoo", "summary": "BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...", "datetime": "2024-12-05T13:30:00.000Z", "headline": "Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:31.819901+00	2025-09-03 17:58:31.819901+00
6eb9fd93-1020-485b-b616-592582f7fe22	LDTCF	2024-12-09	[]	\N	2025-09-03 17:58:33.321573+00	2025-09-03 17:58:33.321573+00
e522c8ef-aca2-477f-abb3-c5ac37f7cc7d	CPIX	2025-02-04	[{"url": "https://finnhub.io/api/news?id=9030e52ad3bfe9a484daa6217b808b0cce52fa96040d6bff3267e91602e0aceb", "source": "Yahoo", "summary": "On Tuesday, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on T", "datetime": "2025-02-04T18:31:48.000Z", "headline": "Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f87241a2a5ca3d165cf15c0296cce343fe1127046e593469bebcc27b288f1e14", "source": "Yahoo", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac c", "datetime": "2025-02-04T12:30:00.000Z", "headline": "Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease", "sentiment": "positive"}]	positive	2025-09-03 17:58:35.624998+00	2025-09-03 17:58:35.624998+00
9c3da425-d217-4513-a207-b007e1a5ffbe	BNZI	2025-01-30	[]	\N	2025-09-03 17:58:37.33197+00	2025-09-03 17:58:37.33197+00
ec73316b-e6bb-4b8b-ab64-1b43c62bd661	NUKK	2024-12-17	[{"url": "https://finnhub.io/api/news?id=0d955e447c34197eb7b024e27d0196b36d884b3649f473c8b8788a8fe674461d", "source": "Yahoo", "summary": "Dec 17, 2024 - Nukkleus, Inc. (NASDAQ: NUKK), a pioneer in the fintech sector traditionally focused on the cryptocurrency market, announced that it has successfully acquired a 51% controlling stake in Star 26 Capital Inc., a defense acquisition company holding 95% ownership in RIMON. RIMON is a leading Israeli supplier of critical components for the Iron Dome missile defense system, as well as other defense and tactical solutions.", "datetime": "2024-12-17T15:42:00.000Z", "headline": "Nukkleus, Inc. Achieves Strategic Milestone with Acquisition of a Controlling Stake in Star 26 a Defense-focus acquisition company and a provider of Israel's Iron Dome Missile Defense System", "sentiment": "positive"}]	positive	2025-09-03 17:58:48.98353+00	2025-09-03 17:58:48.98353+00
c1d1ffca-9da1-4d09-9780-0c533fcebfb2	CGTX	2024-12-18	[{"url": "https://finnhub.io/api/news?id=a5c12cdf24055c2a1c8070283178a74e7831d04bc6161cf397c0c40ce82fccaa", "source": "Yahoo", "summary": "- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company de", "datetime": "2024-12-18T12:22:00.000Z", "headline": "Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies", "sentiment": "positive"}]	positive	2025-09-03 17:58:52.574063+00	2025-09-03 17:58:52.574063+00
15b99a87-e160-406d-a529-042689e800fa	87807D509	2024-12-18	[]	\N	2025-09-03 17:58:53.539758+00	2025-09-03 17:58:53.539758+00
236bb98c-2e96-415d-9b8c-a60bc0238c80	ADD	2024-12-06	[{"url": "https://finnhub.io/api/news?id=1b103e337d64f95cfb9bcfd2ee5a4371e2e3bc7fc4e59cf0da26f594d034eba1", "source": "Yahoo", "summary": "NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Color Star Technology Co., Ltd. (Nasdaq: ADD) (“Color Star” or the “Company”), an entertainment technology company with a global network that focuses on the application of technology and artificial intelligence in the entertainment industry, announced today that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s ordinary", "datetime": "2024-12-05T21:05:00.000Z", "headline": "Color Star Technology Regains Compliance with Nasdaq Minimum Closing Bid Price Rule", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:28.747261+00	2025-09-03 17:58:28.747261+00
13d14067-77fa-4c29-af05-0fcc5b1e6607	ADD	2025-01-14	[]	\N	2025-09-03 17:58:29.92395+00	2025-09-03 17:58:29.92395+00
dda36c84-9538-4c21-81d8-cb26fb4822a6	IPHA	2024-12-09	[{"url": "https://finnhub.io/api/news?id=913b300b29b527e63b12029e86d417a666ebb3037077d062fd5d1f712cd11e99", "source": "Yahoo", "summary": "MARSEILLE, France, December 09, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\\"Innate\\" or the \\"Company\\") today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California.", "datetime": "2024-12-09T06:00:00.000Z", "headline": "Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:32.159873+00	2025-09-03 17:58:32.159873+00
06e6679d-61d4-4098-b085-4b75d89ed613	GRRR	2024-12-09	[{"url": "https://finnhub.io/api/news?id=8af66f18132f16c7a987f77a5d62cbf99df96f8a7b528f6e7d22da3bd45a3bc8", "source": "Yahoo", "summary": "London, United Kingdom--(Newsfile Corp. - December 9, 2024) - Gorilla Technology Group Inc. (NASDAQ: GRRR) (\\"Gorilla\\" or the \\"Company\\"), is thrilled to announce a groundbreaking partnership with Edgecore Networks, a leader in open networking and AI infrastructure solutions. This collaboration propels Gorilla into a new frontier with the introduction of its Self-Branded Exclusive AI GPUs, powered by Intel's Gaudi architecture through Edgecore's advanced hardware platforms.Leveraging Edgecore's pr", "datetime": "2024-12-09T13:00:00.000Z", "headline": "Gorilla Technology Launches Self-Branded AI GPUs in Groundbreaking Partnership with Edgecore Networks", "sentiment": "positive"}]	positive	2025-09-03 17:58:33.62247+00	2025-09-03 17:58:33.62247+00
9f81315d-5631-4880-9b73-e1acf8e47a3c	GRRR	2025-04-07	[{"url": "https://finnhub.io/api/news?id=50a9909eacfdd29b4384b0083d7130ab660ccb508152478c69ba5237511aa453", "source": "Yahoo", "summary": "Bangkok, Thailand--(Newsfile Corp. - April 7, 2025) - Gorilla Technology Group Inc. (NASDAQ: GRRR) (\\"Gorilla\\" or the \\"Company\\") today, announced a landmark partnership with Toyota Material Handling Warehouse Solutions (Thailand), to co-develop intelligent warehouse automation technologies for Toyota's global customers.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10783/247571_2c1947b94486287d_001full.jpgThis collaboration brings together Gorilla'", "datetime": "2025-04-07T12:00:00.000Z", "headline": "Gorilla Technology Group Signs Strategic Partnership with Toyota Material Handling Solutions (Thailand) to Power Global Smart Warehousing Transformation", "sentiment": "positive"}]	positive	2025-09-03 17:58:34.839903+00	2025-09-03 17:58:34.839903+00
30f9f9f6-944c-4128-8279-30ea06c45f9f	BNZI	2024-12-10	[{"url": "https://finnhub.io/api/news?id=259ad46591acbffba4636969cc5d9a37b8800a2b5d678b38751e0847fc653608", "source": "Yahoo", "summary": "Banzai Adds Enterprise-Grade Branded Video Creation and Management Solution OpenReel to Growing Product Family SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has signed a definitive agreement to acquire OpenReel, a leading digital video creation platform. OpenReel enables companies to rapidly create high-quality,", "datetime": "2024-12-10T18:57:00.000Z", "headline": "Banzai Announces Definitive Agreement to Acquire OpenReel, Growing TTM Revenue 152% to $10.9M", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:37.156518+00	2025-09-03 17:58:37.156518+00
e9bc625a-945d-4085-afe7-e5363a2084a5	AKYA	2024-12-10	[{"url": "https://finnhub.io/api/news?id=a94e56083b2aef44dd524309018233e1d942e9b6329eb1a41749118d66eebc4c", "source": "Yahoo", "summary": "Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic diseaseMARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology", "datetime": "2024-12-10T13:15:00.000Z", "headline": "Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=9834528c25025ce69716c1cd67e46612aab74dff73fd92f78d077b130f91cb23", "source": "Yahoo", "summary": "MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that Nature Methods, one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious “Method of the Year 2024”, recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry’s largest installed base of 1300 instruments", "datetime": "2024-12-09T13:00:00.000Z", "headline": "Nature Methods Names Spatial Proteomics \\"Method of the Year 2024\\" — Akoya Biosciences Celebrates Industry Milestone", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:37.602062+00	2025-09-03 17:58:37.602062+00
d934f283-e948-475c-a242-92bdd6d1d4c1	M79549107	2024-12-30	[]	\N	2025-09-03 17:58:52.040498+00	2025-09-03 17:58:52.040498+00
e13e35f4-4b99-4014-b9bb-18e492feb55b	74907L300	2024-12-18	[]	\N	2025-09-03 17:58:54.088687+00	2025-09-03 17:58:54.088687+00
943cabed-eef5-4737-894a-137ac8361ed0	TRVI	2024-12-12	[{"url": "https://finnhub.io/api/news?id=79d2b2de0efe1dc34f49338eb7c0dbe716ce8b8d5dda93195f2560c50cc1caa7", "source": "Yahoo", "summary": "On Thursday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with", "datetime": "2024-12-12T14:47:23.000Z", "headline": "Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=5960efc4920c083a0d75b167985f1f8579808494c44646ef28d8bd11bcff67d0", "source": "Yahoo", "summary": "Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, which requires no change to the current sample size for the tri", "datetime": "2024-12-12T12:30:00.000Z", "headline": "Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:41.275479+00	2025-09-03 17:58:41.275479+00
99a51eef-1829-457f-bdea-e5b5ca895ef0	IMRX	2025-01-07	[{"url": "https://finnhub.io/api/news?id=858486cf31fac31479e451f86768ff5bb542de1ec949144c48593d792f377c20", "source": "Yahoo", "summary": "On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a", "datetime": "2025-01-07T14:28:53.000Z", "headline": "Why Is Immuneering Stock Trading Higher On Tuesday?", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=17a81dc7da182ea37f859d3a14a62f450e9721566f0bae170867a5915e68698a", "source": "Yahoo", "summary": "Immuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate I", "datetime": "2025-01-07T14:00:04.000Z", "headline": "Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=00eab8732be9d542fd32e33704a7b549a1921acb0312823b1012c4ddf5d0fb9b", "source": "Yahoo", "summary": "- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial dat", "datetime": "2025-01-07T12:00:00.000Z", "headline": "Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms", "sentiment": "positive"}]	positive	2025-09-03 17:58:42.368368+00	2025-09-03 17:58:42.368368+00
9373c7cf-9af7-4dbb-b5f1-fef0a05f04bd	DBGI	2024-12-13	[{"url": "https://finnhub.io/api/news?id=5d02b1710948dd8e16f8d9ef6e0b1e05f024b7ed424fd06de39b374badba1979", "source": "Yahoo", "summary": "Austin, TX, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Digital Brands Group, Inc. (“DBG”) (NASDAQ: DBGI), a curated collection of luxury lifestyle brands, today announces the first 45 day results since it entered into a marketing partnership on October 21, 2024, with VAYNERCOMMERCE, https://vaynercommerce.com/. VAYNERCOMMERCE is a full service digital growth agency created by Gary Vaynerchuk, also known as GARYVEE. VAYNERCOMMERCE’s services aim to help digital companies scale their online presence and re", "datetime": "2024-12-12T20:00:00.000Z", "headline": "DBG Announces First 45 Day Results with VAYNERCOMMERCE resulting in a 224% increase in digital revenue", "sentiment": "positive"}]	positive	2025-09-03 17:58:43.33827+00	2025-09-03 17:58:43.33827+00
ec4d1564-2d11-447b-acb0-29552a35db8f	WKEY	2024-12-13	[]	\N	2025-09-03 17:58:44.005938+00	2025-09-03 17:58:44.005938+00
d32d78f6-d7ff-482d-b81c-243fef075ba5	PRTG	2024-12-17	[{"url": "https://finnhub.io/api/news?id=634e230bf53693372abd87e919a4d162e9205a85cd494784f2f185409342c1e8", "source": "Yahoo", "summary": "Nukkleus (NUKK) said Tuesday it acquired a 51% controlling stake in Star 26 Capital, a defense acqui", "datetime": "2024-12-17T18:54:50.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c05e20488faaec7361d5eb37c83e5e9364c3971d2e6c8c044a207c571fc0ccb8", "source": "Yahoo", "summary": "WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Immunova, LLC, (“Immunova”) a private Connecticut-based biotechnology company. Under the terms of the LOI, Portage and Immunova have agreed to negotiate a definitive o", "datetime": "2024-12-17T12:00:00.000Z", "headline": "Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:45.153163+00	2025-09-03 17:58:45.153163+00
99159da1-f340-4ddd-9553-8d2cc39ed8c2	OPTX	2024-12-17	[{"url": "https://finnhub.io/api/news?id=48b1889e9f13dfc1c0ba964d020391eed7fb6e06723de46ebc21d0efe0d72312", "source": "Yahoo", "summary": "ROCHESTER, NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (“Syntec Optics” or the “Company”) (Nasdaq: OPTX), a leading provider of mission-critical products to advanced technology defense, biomedical, and communications equipment manufacturers, today announced the appointment of Michael J. Ransford as Site Manager. In this role, Ransford will oversee technology and operations. With over 30 years of experience in engineering, operations, and business leadership, Ransford", "datetime": "2024-12-16T21:15:00.000Z", "headline": "Mike Ransford Joins Syntec Optics (Nasdaq: OPTX) as Site Manager", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:44.852749+00	2025-09-03 17:58:44.852749+00
c75361bd-8a05-4157-a985-88e12e95d6fa	PRTG	2025-03-28	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:45.731207+00	2025-09-03 17:58:45.731207+00
86ef6735-2531-413f-b2e2-3c6f60f9f537	BMEA	2024-12-17	[{"url": "https://finnhub.io/api/news?id=807f99f72387fd124af7236476d1b43bdb046e6c77990c8999bcf26aa1e6a669", "source": "Yahoo", "summary": "On Tuesday, Biomea Fusion Inc. (NASDAQ:BMEA) revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D). Icovamenib was investigated in three different dosing arms with a primary follow-up after 26 weeks: Arm A at 100mg QD (once daily) for 8 weeks, Arm B at 100mg QD for 12 weeks, and Arm C at 100 mg QD for 8 weeks and 100mg BID (twice daily) for 4 weeks. Also Read: FDA Removes Clinical Hold On Biomea Fusion’s Early-Stage Trials For Potential", "datetime": "2024-12-17T15:41:09.000Z", "headline": "Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=05023da8afe29f73654d8560a55f6e2cb77e0261c48c30eda48da084004e0971", "source": "Yahoo", "summary": "Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 with statistical significance, after only 12 weeks of dosing icovamenib with 100 mgIcovamenib was well-tolerated, with no adverse-event re", "datetime": "2024-12-17T13:10:00.000Z", "headline": "Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=aebd4b57312c77da6d09cd4ce85155f7d3b6bc52b3e3e1c739aee26d87ad420b", "source": "Yahoo", "summary": "Tuesday, December 17, 2024 at 8:00 am ESTREDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from CO", "datetime": "2024-12-16T23:15:00.000Z", "headline": "Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)", "sentiment": "neutral"}]	neutral	2025-09-03 17:58:50.48652+00	2025-09-03 17:58:50.48652+00
82c466de-9265-4743-bbe0-6f25969b907e	M79549107	2024-12-18	[]	\N	2025-09-03 17:58:50.724959+00	2025-09-03 17:58:50.724959+00
adf8bc71-438a-458f-912f-2850823a0e8a	VRAR	2024-12-19	[{"url": "https://finnhub.io/api/news?id=5b37a861dd5d907d2ceac07f3a208ac16d0ae0c6f4ba10bd0b6df3d3790cbec4", "source": "Yahoo", "summary": "NEW YORK, NY / ACCESSWIRE / December 19, 2024 /The Glimpse Group, Inc. (\\"Glimpse\\") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality (\\"VR\\"), Augmented Reality (\\"AR\\") and Spatial ...", "datetime": "2024-12-19T12:00:00.000Z", "headline": "Brightline Interactive Enters into an Agreement with the U.S. Navy for an Immersive, AI-Driven Simulator System", "sentiment": "neutral"}]	neutral	2025-09-03 17:59:55.732465+00	2025-09-03 17:59:55.732465+00
58383fd2-50cf-47fa-b31d-509c54524b49	PHIO	2024-12-19	[{"url": "https://finnhub.io/api/news?id=6cbad6f2e58b734eb18d0dc1882f04da04ce0a7ec6fe8a7b64a771ffb66044d3", "source": "Yahoo", "summary": "Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 437,192 shares of its common stock at a purchase price of $2.635 per share in a registered ..", "datetime": "2024-12-19T19:28:00.000Z", "headline": "Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=d0398a39b255cbf3260229426ad0c02f31a88c8f08dce14d1563b892e8a386fb", "source": "Yahoo", "summary": "Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells. Phio announced today that the Safety Monitoring Committee", "datetime": "2024-12-19T12:45:00.000Z", "headline": "Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762", "sentiment": "positive"}]	neutral	2025-09-03 17:59:56.43395+00	2025-09-03 17:59:56.43395+00
02e72857-de1e-440a-a41c-76ea2b6e74a8	PHIO	2025-01-13	[{"url": "https://finnhub.io/api/news?id=8c2026ef82db60b6e199ae71783045ef89c5978e7fd785ae6fd3f98079e7f0d5", "source": "Yahoo", "summary": "On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2", "datetime": "2025-01-13T17:45:44.000Z", "headline": "Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=7527449cac05f687e796b5ba1764927dd1b6de08cb32c15c0684d74fb9ae2d1c", "source": "Yahoo", "summary": "Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2", "datetime": "2025-01-13T12:45:00.000Z", "headline": "Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762", "sentiment": "neutral"}]	positive	2025-09-03 17:59:56.7179+00	2025-09-03 17:59:56.7179+00
6e56baa9-8cbe-4691-aa2b-08dd6c37ddad	74449F209	2024-12-19	[]	\N	2025-09-03 17:59:58.990946+00	2025-09-03 17:59:58.990946+00
0f065a70-7675-45d3-adf7-6c0fdedb390d	MYSZ	2024-12-20	[]	\N	2025-09-03 17:59:59.51992+00	2025-09-03 17:59:59.51992+00
ada523f2-4d69-49cf-becc-110bd0c3dd31	PHIO	2025-01-14	[{"url": "https://finnhub.io/api/news?id=2751a7aad6b7a417941efc3d2ccb5aeb051efedad81df35b79ba0ee39421499d", "source": "Yahoo", "summary": "Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,063,670 shares of its common stock at a purchase price of $3.00 per share in a registered ..", "datetime": "2025-01-14T12:00:00.000Z", "headline": "Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=8c2026ef82db60b6e199ae71783045ef89c5978e7fd785ae6fd3f98079e7f0d5", "source": "Yahoo", "summary": "On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2", "datetime": "2025-01-13T17:45:44.000Z", "headline": "Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=7527449cac05f687e796b5ba1764927dd1b6de08cb32c15c0684d74fb9ae2d1c", "source": "Yahoo", "summary": "Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2", "datetime": "2025-01-13T12:45:00.000Z", "headline": "Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762", "sentiment": "neutral"}]	neutral	2025-09-03 17:59:56.953861+00	2025-09-03 17:59:56.953861+00
8abc51b0-ecc0-4c2f-b6fc-dc6355f6eab2	PRFX	2024-12-19	[]	\N	2025-09-03 17:59:57.253065+00	2025-09-03 17:59:57.253065+00
a1a9fcfc-b525-424a-b64e-e1402e4a11a6	PRFX	2025-02-18	[{"url": "https://finnhub.io/api/news?id=378b5652bb219f615111472f1696d37d3446cc53500f952007f20bf90418f6c0", "source": "Yahoo", "summary": "DeepSolar brings new customer base in creation, including major utility-scalesolar operators and independent power producers, whilebreaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (\\"PainReform\\" or the \\"Company\\"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established ther", "datetime": "2025-02-18T13:30:00.000Z", "headline": "PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity", "sentiment": "positive"}]	positive	2025-09-03 17:59:57.589137+00	2025-09-03 17:59:57.589137+00
add09658-6741-4385-9409-e372bec9cc3f	BPTH	2024-12-19	[{"url": "https://finnhub.io/api/news?id=c49ff2dc40baea8185b6121222223bac7e12e515d2e07e774015777dc8531b69", "source": "Yahoo", "summary": "Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 DiabetesHOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1", "datetime": "2024-12-19T12:00:00.000Z", "headline": "Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity", "sentiment": "neutral"}]	neutral	2025-09-03 17:59:57.827459+00	2025-09-03 17:59:57.827459+00
75e4bade-c92b-4584-9ff3-6e692aa90533	TPET	2024-12-19	[{"url": "https://finnhub.io/api/news?id=8859013d90916d00c8fa32a33ecb74dd8bc623353fb0f148c42bcd4303a20d3b", "source": "Yahoo", "summary": "Bakersfield, CA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Trio Petroleum Corp (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, today is pleased to announce that it has entered into a non-binding Letter of Intent (“LOI”) for the acquisition of a 100% working interest in certain petroleum and natural gas properties held by Novacor Exploration Ltd. (“Novacor”), which are located in the prolific Lloydminster, Saskatchewan heavy oil region (the “Acquisition”). In the", "datetime": "2024-12-19T13:30:00.000Z", "headline": "Trio to acquire producing oil and gas assets in prolific heavy oil region of Saskatchewan Canada", "sentiment": "neutral"}]	neutral	2025-09-03 17:59:58.034232+00	2025-09-03 17:59:58.034232+00
a47d7067-cb07-41da-80fa-537de24b8507	TPET	2025-01-16	[{"url": "https://finnhub.io/api/news?id=a4985ce8bdbd6d275781668c109a4d93e689b6bae9d12fc33f6845eeb28f19f6", "source": "Yahoo", "summary": "Bakersfield, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Trio Petroleum Corp (NYSE American: “TPET”, “Trio” or the “Company”), a California-based oil and gas company, announced that as of January 7,2025, the Company had fully repaid senior secured convertible promissory notes with an aggregate principal of $1.6 million (the “Notes”). The Notes were issued in connection with two separate financings funded by two institutional investors (the “Investors”) in in April 2024 and June of 2024. As previously", "datetime": "2025-01-16T13:30:00.000Z", "headline": "Company retires remaining Outstanding Convertible Investments", "sentiment": "neutral"}]	neutral	2025-09-03 17:59:58.35392+00	2025-09-03 17:59:58.35392+00
df07e6d8-3ba1-49d6-a49d-6593814ea88b	APM	2024-12-31	[{"url": "https://finnhub.io/api/news?id=f8dc8c65c17baf8e06c8ad1532d78b908e7a0494da3729710aade5709e377d09", "source": "Yahoo", "summary": "Biopharmaceutical company Aptorum Group Ltd. (NASDAQ:APM) saw its pre-market stock price on Tuesday jump by nearly 300 percent, with investor optimism fueled by the company’s improved earnings performance during the first half of the year. As of 8:49 AM, the company’s share price was already trading as much as 270.48 percent at $5.02 apiece. Last […]", "datetime": "2024-12-31T15:17:51.000Z", "headline": "Why Aptorum Group (APM) Jumped Nearly 300% at Pre-Market Trading", "sentiment": "positive"}]	positive	2025-09-03 18:00:18.786627+00	2025-09-03 18:00:18.786627+00
9904e9f1-1f43-4c6d-a99f-9b189e0c9945	NITO	2025-01-03	[{"url": "https://finnhub.io/api/news?id=bb1ace1e2d4ff0a08ed2715ac8bb01838f737a8d396959052f9c528f2cd479e7", "source": "Yahoo", "summary": "N2OFF will hold approximately 70% ownership in the projects, further enhancing its presence in the European energy storage market Neve Yarak, Israel, Jan. 03, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today that on January 3 2025 it has signed a binding LOI with Solterra Ltd’s subsidiary ,Soltera Brand Services Italy (“SBSI”), a company that", "datetime": "2025-01-03T12:55:00.000Z", "headline": "N2OFF and Solterra Brand Services Italy executed a binding LOI to Develop Two 98MWp Battery Storage Projects in Sicily", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8226768fb2fbd5c44b51905e399d777fe7923051df0d9889428ef5f05827e10d", "source": "Yahoo", "summary": "The approval was obtained from the Melz Municipal Committee in connection with the submission of Solterra’s statutory plan for the PV Project Neve Yarak, Israel, Jan. 02, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation in the agri- tech sector, is pleased to announce progress in its collaborative solar photovoltaic (PV) project in Melz, Germany, developed by Solterra Renewa", "datetime": "2025-01-02T13:05:00.000Z", "headline": "N2OFF, Inc. Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:28.356873+00	2025-09-03 18:00:28.356873+00
a3e5d9fe-293d-41c7-b4e7-9a6f80fbf407	MYSZ	2024-12-27	[{"url": "https://finnhub.io/api/news?id=de3e01ec6789687fd6fee8991addbc2bbf41d2a493de54bf0db5a3f559a6e103", "source": "Yahoo", "summary": "The company is expanding its e-commerce platform, Orgad, into European markets.", "datetime": "2024-12-27T17:24:00.000Z", "headline": "MySize Shares Surge Over 112% Pre-Market as Company Projects $15M Revenue for 2025", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9b7227fb63cb2668dde8ab2522934032c38355c273a0bc4abf42cad7d2ce87f6", "source": "Yahoo", "summary": "MySize, Inc. (NASDAQ: MYSZ)", "datetime": "2024-12-27T13:00:00.000Z", "headline": "MySize present year over year growth,  2025 targets $15M Revenue,  Anticipates Strong 2024 Finish close to 100% Growth from 2022", "sentiment": "positive"}]	positive	2025-09-03 18:00:00.099526+00	2025-09-03 18:00:00.099526+00
161a34c9-4dd3-42a2-9d3f-de4312b8d4fc	MYSZ	2025-03-28	[{"url": "https://finnhub.io/api/news?id=cd09eca8bb5a63801e46e9020b783614a52c11d6f9496f375c8b74b129f56a6f", "source": "Yahoo", "summary": "MySize, Inc. (NASDAQ: MYSZ) (TASE: MYSZ.TA) (\\"MySize\\" or the \\"Company\\"), an omnichannel e-commerce platform and provider of AI-driven sizing solutions for the retail industry, today reported financial and operational results for the twelve months ended December 31, 2024.", "datetime": "2025-03-28T12:30:00.000Z", "headline": "MySize Reports 2024 Full-Year Financial Results: Revenue Grows 18% to $8.26 Million and Cash Reserves More Than Double", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:01.138698+00	2025-09-03 18:00:01.138698+00
40792b80-ea59-4b2b-8382-db33dd26e592	NVNI	2024-12-20	[]	\N	2025-09-03 18:00:01.851627+00	2025-09-03 18:00:01.851627+00
a6772dba-f121-4755-9432-bdf918dea45b	NVNI	2025-01-29	[]	\N	2025-09-03 18:00:02.56573+00	2025-09-03 18:00:02.56573+00
ebf48442-4cd1-4ad7-8af6-617e5fba3ccd	FRSX	2024-12-20	[{"url": "https://finnhub.io/api/news?id=845f16aa8adeb68d915828cfe8ecb62863b11780be937fc79a85425fd62f1de3", "source": "Yahoo", "summary": "Ness Ziona, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that its wholly owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net” or “Eye-Net Mobile”) has entered into a multi-phase agreement with SoftBank Corp. (Tokyo: 9434) (“SoftBank”) and a leading Japanese vehicle manufacturer. The collaboration aims to evaluate Eye-Net’s cutting-edge cellular vehicle-to-everythin", "datetime": "2024-12-20T11:40:00.000Z", "headline": "Foresight: Eye-Net and SoftBank Join Forces with Japanese Automaker to Advance Cellular V2X Technology for Enhanced Road Safety", "sentiment": "positive"}]	positive	2025-09-03 18:00:02.873558+00	2025-09-03 18:00:02.873558+00
f124ff80-c2d7-4c75-bf5a-97c78f3b89c3	HUMA	2024-12-20	[{"url": "https://finnhub.io/api/news?id=1ac529b4c84078ab9a70689deea31b3dc384a91ef5384233e4c77c78f6e1f16d", "source": "Finnhub", "summary": "Humacyte Announces FDA Approval of SYMVESS™ for the Treatment of Extremity Vascular Trauma - SYMVESS is a first-in-class bioengineered human tissue designed to be a universally...", "datetime": "2024-12-20T16:34:14.000Z", "headline": "Humacyte : Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel tyod) for the Treatment of Extremity Vascular Trauma Form 8 K", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=174f37147f514cbb0c71be8f03f907bb404462076dc0d03c71ba47b2dafe472d", "source": "Finnhub", "summary": "By Denny Jacob Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults. Shares were trading around...", "datetime": "2024-12-20T07:12:22.000Z", "headline": "Humacyte Shares Surge 38% on FDA Approval of Symvess", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=177c551f67a20a7dba1582ab0a8b0e6712faab5e89675373bc7a1e1889653f59", "source": "Finnhub", "summary": "NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. of a class action securities lawsuit. ...", "datetime": "2024-12-20T05:46:19.000Z", "headline": "Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=6bacf3334ed094e1ab89d31ef28af3588b00646a61a4157d8a55b29d339154ae", "source": "Yahoo", "summary": "– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection – – Highly experienced sales team already recruited and trained in preparation for commercial launch – DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform co", "datetime": "2024-12-20T03:47:00.000Z", "headline": "Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=0a02cb35194f9840a4c8cb336e1087ac44703817b5fc62da20841ff2886759e3", "source": "Finnhub", "summary": "Humacyte, Inc. announced that the U.S. Food and Drug Administration has granted a full approval for SYMVESS for use in adults as a vascular conduit for extremity arterial injury when urgent...", "datetime": "2024-12-19T22:47:00.000Z", "headline": "Humacyte Announces FDA Approval of SYMVESS for the Treatment of Extremity Vascular Trauma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=2a0ceea6eda01ebda2665e976d76fe57f3347360b8992ac52a05c8a491d83566", "source": "Finnhub", "summary": "LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against...", "datetime": "2024-12-19T13:27:05.000Z", "headline": "HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=efccc0a226ae3dcc01e3be3fcbfaf5e6cb1ad24019846788b661a330980d99bc", "source": "Finnhub", "summary": "NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. . ...", "datetime": "2024-12-19T05:46:18.000Z", "headline": "Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA", "sentiment": "neutral"}]	positive	2025-09-03 18:00:03.179534+00	2025-09-03 18:00:03.179534+00
384450db-e495-4bc6-b8c6-774040e33b8b	RELI	2024-12-23	[{"url": "https://finnhub.io/api/news?id=5bf83eb57a65423cf4a0b08c78667b856884e77de10d9f34ad3deed9263fc630", "source": "Yahoo", "summary": "OneFirm Approach Delivering Results - Drives Increased Revenue, Reduced Expenses, and Growing EBITDA Spetner Acquisition Nears Final Stages, Strengthening Company’s Future Prospects LAKEWOOD, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today provided a year-end review of its operations, as well as a look to the future. Ezra Beyman, Chairman and Chief Executive Officer of Reliance commented, “2024 has been a transformative", "datetime": "2024-12-23T13:30:00.000Z", "headline": "Reliance Global Group Reflects on a Transformative Year and Looks Ahead to 2025", "sentiment": "positive"}]	positive	2025-09-03 18:00:03.418832+00	2025-09-03 18:00:03.418832+00
e72e6b44-6fb2-449a-931f-8776f95a6699	GTBP	2024-12-23	[]	\N	2025-09-03 18:00:04.572053+00	2025-09-03 18:00:04.572053+00
5bd385b2-5255-4470-84ae-2afcef9a5e59	83006G203	2024-12-23	[]	\N	2025-09-03 18:00:04.912965+00	2025-09-03 18:00:04.912965+00
2a050d6c-0e5e-4af3-b049-b6ac6c1e34f3	83006G203	2025-01-08	[]	\N	2025-09-03 18:00:06.056258+00	2025-09-03 18:00:06.056258+00
616cfee6-1640-491f-8598-b02c82045fce	83006G203	2025-01-29	[]	\N	2025-09-03 18:00:06.79533+00	2025-09-03 18:00:06.79533+00
c7866a36-bb8e-429f-a1bc-c9fa179ba21d	CMND	2024-12-24	[{"url": "https://finnhub.io/api/news?id=2d5558e6a725f0ece6b1bf05f0bfbdfd5e94757e47b8ba3df347c552c21707a3", "source": "Yahoo", "summary": "Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \\"Company\\"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medic", "datetime": "2024-12-24T11:55:00.000Z", "headline": "Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:07.59027+00	2025-09-03 18:00:07.59027+00
5649d9ca-2cb7-403c-a7db-44bd47519816	CREV	2024-12-24	[{"url": "https://finnhub.io/api/news?id=6876a36c87f7e0fe34d64e75ff8bfa89da8fca84353b5f991fcfd1aefe8702d8", "source": "Yahoo", "summary": "GEELONG, Australia, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the \\"Company\\"), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that it has reached an agreement with Orion Infrastructure Capital (\\"OIC\\") for a further US$25 million financing, which will be released in five tranches, each equal to US$5 million, subject to satisfying certain release conditions. In connection with", "datetime": "2024-12-23T22:35:00.000Z", "headline": "Carbon Revolution Secures New $25 Million Financing Agreement with OIC and Existing Lenders", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:07.940428+00	2025-09-03 18:00:07.940428+00
ecff4714-2f4c-4bd6-9fe5-7fca6f600868	RVSN	2024-12-24	[{"url": "https://finnhub.io/api/news?id=6701a76ce0603659f57738eb0e4814e20a6393739325e3d02d3a9717303b2116", "source": "Yahoo", "summary": "The TCCO committee operates under the auspices of the American Association of Railroads (AAR), with its Technology Roadmap Program managed by MxV Rail Ra’anana, Israel, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, today announced it has joined MxV Rail’s Technology Roadmap Program, a distinguished body responsible for formulating minimum interoperable require", "datetime": "2024-12-24T13:15:00.000Z", "headline": "Rail Vision to Join MxV Rail’s Technology Roadmap Program to Improve Safety and Efficiency of Rail Operations in North America", "sentiment": "positive"}]	positive	2025-09-03 18:00:09.163857+00	2025-09-03 18:00:09.163857+00
7b1637c8-6e23-4643-afe2-32c8f2004b2e	RVSN	2025-01-07	[{"url": "https://finnhub.io/api/news?id=e2e426d344f9d2b8a0c8d812142a4a0f035321dd6d845f5a94f8829245bfd351", "source": "Yahoo", "summary": "Collaboration targets inclusion in major rail safety tenders, aiming for thousands of locomotives in India to be outfitted with state-of-the-art technologies Ra’anana, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, announced today the signing of a binding Memorandum of Understanding (MOU) with Sujan Ventures, a division of the esteemed Sujan Group, a pr", "datetime": "2025-01-07T12:45:00.000Z", "headline": "Rail Vision Signs Exclusive Agreement with Leading Indian Rail Supplier to Penetrate the Indian Rail Market", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:09.690584+00	2025-09-03 18:00:09.690584+00
66421791-862c-431b-b3f8-31162da76187	QSI	2024-12-27	[]	\N	2025-09-03 18:00:15.179706+00	2025-09-03 18:00:15.179706+00
1286d236-bd91-4989-87ed-4cb7bd1c1609	71902K303	2025-03-31	[]	\N	2025-09-03 18:47:40.045565+00	2025-09-03 18:47:40.045565+00
6235b06a-b7ba-4417-875d-c57b201f0f9e	LTRY	2025-02-07	[]	\N	2025-09-03 18:47:40.345081+00	2025-09-03 18:47:40.345081+00
99aaaecf-7361-4af1-b721-5dcc689d4233	20678X205	2025-02-07	[]	\N	2025-09-03 18:47:41.370028+00	2025-09-03 18:47:41.370028+00
8d518349-3cbf-4275-b97c-1e57367310a8	RVSN	2024-12-27	[{"url": "https://finnhub.io/api/news?id=404a46989dcba769ed4178e669ef1b5583df4071427e4a16000b0dee105c1b4a", "source": "Yahoo", "summary": "Rail Vision Ltd. (NASDAQ:RVSN) saw its shares rise on Friday after announcing a major achievement in railway safety. The company revealed it had received certification approval for the installation of its MainLine Systems on Israel Railways’ passenger locomotives. This milestone triggers a $300,000 milestone payment and positions Rail Vision for potential future volume procurement from Israel Railways. CEO Shahar Hania emphasized that the certification demonstrates Rail Vision’s commitment to ex", "datetime": "2024-12-27T16:15:06.000Z", "headline": "What's Going On With Rail Vision Stock On Friday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=4c4abda6523ef468709610968e2d5e2e02a20e880c5f835d70f5ea759003d525", "source": "Yahoo", "summary": "This achievement aims to support Israel Railways future volume procurement The approval also triggers an immediate $300,000 payment Ra’anana, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, today announced the achievement of a critical project and regulatory milestone: certification approval for the installation of its MainLine Systems on Israel Railways", "datetime": "2024-12-27T13:30:00.000Z", "headline": "Rail Vision Receives Israel Railways Regulation Approval for its MainLine Products", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=affc6b0edb2e4b2c9fe12406c458f4f38e3061805da7425b36453e9356be44a3", "source": "Yahoo", "summary": "The programme sets minimum interoperability standards and supports system development to enhance rail safety.", "datetime": "2024-12-26T12:47:37.000Z", "headline": "Rail Vision joins MxV Rail’s safety technology programme", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:09.459922+00	2025-09-03 18:00:09.459922+00
dd93ad18-01a6-4e1f-9044-c3b433031a4f	BAOS	2024-12-24	[]	\N	2025-09-03 18:00:11.687921+00	2025-09-03 18:00:11.687921+00
033a2026-553e-463e-9454-35d26ea247cb	HOUR	2024-12-26	[]	\N	2025-09-03 18:00:14.879614+00	2025-09-03 18:00:14.879614+00
04e8d332-bf0e-4fe9-aa52-55eaede97ca5	BFRG	2024-12-27	[{"url": "https://finnhub.io/api/news?id=720197e90337435ca9760b9d56f6f7210d667a72b4a39a78dad60703cffd3c45", "source": "Yahoo", "summary": "GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (\\"BullFrog AI\\" or the \\"Company\\"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to stockholders from its CEO Vin Singh. Dear Fellow Stockholders, As the year comes to a close, I want to extend my deepest gratitude for your unwavering support and belief in", "datetime": "2024-12-27T13:00:00.000Z", "headline": "BullFrog AI Issues Letter to Stockholders", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:16.001636+00	2025-09-03 18:00:16.001636+00
ce67e15e-c0a6-439e-8942-fda3afd6d34c	INTZ	2024-12-30	[]	\N	2025-09-03 18:00:17.800185+00	2025-09-03 18:00:17.800185+00
186f63b7-2fb4-4f37-82e2-d7355500159b	VRME	2024-12-31	[]	\N	2025-09-03 18:00:18.479794+00	2025-09-03 18:00:18.479794+00
70b7df0f-9c19-4d00-b859-94e3f180a33e	APM	2025-01-03	[{"url": "https://finnhub.io/api/news?id=42abea41e659376601e663ead3a0f07ba06b56ef0465d9bce650575f4bff3d73", "source": "Yahoo", "summary": "NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (\\"Aptorum Group\\" or the \\"Company\\"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at", "datetime": "2025-01-02T15:55:00.000Z", "headline": "Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering", "sentiment": "negative"}]	negative	2025-09-03 18:00:19.19561+00	2025-09-03 18:00:19.19561+00
3203cd39-ac75-481a-94c6-fc646887d527	68237Q104	2024-12-31	[]	\N	2025-09-03 18:00:19.374973+00	2025-09-03 18:00:19.374973+00
450c4059-c7c7-4838-b321-ed7915c28a46	LPSN	2024-12-31	[{"url": "https://finnhub.io/api/news?id=b8cc19d9194b69040607241f8dfb8c321e38d4eeaa589c84516c97410dfa0f26", "source": "Yahoo", "summary": "LivePerson, Inc. (Nasdaq: LPSN) is providing confirmatory notice, in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4), of recent grants of equity-based incentive awards that LivePerson made under the LivePerson Inc. 2018 Inducement Plan (the \\"Inducement Plan\\").", "datetime": "2024-12-30T22:30:00.000Z", "headline": "LivePerson Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:21.895602+00	2025-09-03 18:00:21.895602+00
8656ea82-ddce-49d8-bd07-1cc361664380	FLYE	2024-12-31	[]	\N	2025-09-03 18:00:22.172539+00	2025-09-03 18:00:22.172539+00
3f2f950b-3e31-47fd-9adf-2a709c3c0b3f	76135L507	2025-01-02	[]	\N	2025-09-03 18:00:22.8224+00	2025-09-03 18:00:22.8224+00
5a7e6cad-bc7f-4cae-9c54-ff286e76664d	FFAI	2025-01-02	[]	\N	2025-09-03 18:00:23.098961+00	2025-09-03 18:00:23.098961+00
bafac1fa-b209-4ce1-9205-b9694f3d08fb	OST	2025-01-02	[{"url": "https://finnhub.io/api/news?id=e334b53f6391d42548a0c438a6f59bb44094351c76e072885988425845ae5529", "source": "Yahoo", "summary": "Nanjing, China, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces the Company will participate in the Consumer Electronics Show 2025 (“CES 2025”), one of the world’s premier technology trade shows. CES 2025 is scheduled to take place from January 7 to 10, 2025, at the Las Vegas Convention Center in Las Vegas, NV., which allows the Company to meet new partners, and it is also whe", "datetime": "2025-01-02T13:30:00.000Z", "headline": "Ostin Technology Group Announces Participation at CES 2025, Inspiring Greatness with Latest Pintura Products at the Premier Global Technology Trade Show", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:26.915296+00	2025-09-03 18:00:26.915296+00
f340ca35-37c5-4cbf-8eed-74ab61c93901	RVSN	2025-01-22	[{"url": "https://finnhub.io/api/news?id=1b7562086867ffaf83cf5c889ae05f9619a0f4b869a03adb9307c8977696f442", "source": "Yahoo", "summary": "Collaboration focuses on major rail safety tenders, targeting the installation of advanced technologies on thousands of locomotives across India Ra’anana, Israel, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, recently announced the signing of a binding Memorandum of Understanding (MOU) with Sujan Ventures, a division of the esteemed Sujan Group, a premier tech", "datetime": "2025-01-22T12:44:00.000Z", "headline": "Rail Vision Enters Indian Market with an Agreement to Potentially Supply Safety Systems for Thousands of Locomotives", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:10.726967+00	2025-09-03 18:00:10.726967+00
c273a7b1-6c29-447e-99f2-6d58454ca951	PWM	2024-12-24	[]	\N	2025-09-03 18:00:11.017568+00	2025-09-03 18:00:11.017568+00
9b4f3967-5ddf-4217-b6bc-0c454f7738d3	BAOS	2025-01-06	[]	\N	2025-09-03 18:00:12.786732+00	2025-09-03 18:00:12.786732+00
41e95f40-7742-4192-851f-ac360c1ad281	45784G200	2024-12-26	[]	\N	2025-09-03 18:00:13.038015+00	2025-09-03 18:00:13.038015+00
2018e2a5-3ea3-42c4-9289-aaa26c194f05	OCTO	2024-12-30	[]	\N	2025-09-03 18:00:17.206741+00	2025-09-03 18:00:17.206741+00
bc81cdcd-8b56-4ca3-8857-d52c9a5a7212	BJDX	2024-12-31	[]	\N	2025-09-03 18:00:19.738796+00	2025-09-03 18:00:19.738796+00
e810d347-2180-4255-b022-dd88f8d0b5e3	SCPX	2025-01-03	[]	\N	2025-09-03 18:00:28.05572+00	2025-09-03 18:00:28.05572+00
2c187b63-59bc-4d12-a271-c60cf85b7a7b	PSNYW	2025-01-03	[{"url": "https://finnhub.io/api/news?id=a2299f2c40ce516830ba9a5af921f87b2829d071664ca5286a8d5aafe5221e63", "source": "SeekingAlpha", "summary": "Tesla's Q4 delivery miss and potential threats from Trump's EV policy could impact TSLA's premium valuation in 2025. See why I'm going to keep my sell rating.", "datetime": "2025-01-03T10:24:01.000Z", "headline": "Tesla: Major Q4 Delivery Disappointment", "sentiment": "negative"}]	negative	2025-09-03 18:01:30.693291+00	2025-09-03 18:01:30.693291+00
98c77235-c42f-4252-8254-9001153b0750	GFAI	2025-01-06	[]	\N	2025-09-03 18:01:30.982957+00	2025-09-03 18:01:30.982957+00
72099b35-a631-43e8-b692-2f2c0b05dcdb	RHEP	2025-01-06	[]	\N	2025-09-03 18:01:32.631986+00	2025-09-03 18:01:32.631986+00
7e6952b1-29db-46b4-a9b5-cbcee6c6cc8f	CING	2025-01-07	[{"url": "https://finnhub.io/api/news?id=3d074b755d44363dd67714b8456bef0021e5d627f3f55b2f1f83689cb55b16ba", "source": "Yahoo", "summary": "No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidat", "datetime": "2025-01-07T12:30:00.000Z", "headline": "Final Study Completed for Cingulate’s Lead Asset CTx-1301", "sentiment": "positive"}]	positive	2025-09-03 18:01:35.266183+00	2025-09-03 18:01:35.266183+00
6ddccc51-261b-4e7a-a315-d2a391050194	AMOD	2025-01-30	[{"url": "https://finnhub.io/api/news?id=5c9b9193ec2e3272341044b124fccbfba74d44e9776e416ef625e1470d838b70", "source": "Yahoo", "summary": "CORNELIUS, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus”, “AMOD”, or the “Company”), in a statement today, through Alpha Modus CEO William Alessi, emphasized the company's strong fundamentals, ongoing growth strategy, and commitment to delivering value to shareholders amidst what he described as \\"uninformed speculation\\" by certain market participants. \\"The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and", "datetime": "2025-01-30T13:00:00.000Z", "headline": "Alpha Modus CEO Addresses Market Volatility and its Recent SPAC Merger", "sentiment": "positive"}]	positive	2025-09-03 18:01:36.930155+00	2025-09-03 18:01:36.930155+00
6a4ba1be-43a6-478d-aca4-e064b79eb7c9	INVZ	2025-01-07	[{"url": "https://finnhub.io/api/news?id=591e7515543a092012ddb94ecc8870c14ef6251f794fff32d9cef8a46b30dd06", "source": "Yahoo", "summary": "Innoviz Technologies Ltd. (Nasdaq: INVZ) (the \\"Company\\" or \\"Innoviz\\"), a leading Tier-1 supplier of high-performance, automotive-grade LiDAR sensors and perception software, is proud to announce its latest technological advancements, which will be showcased at CES 2025. Highlighting the power of its perception software, Innoviz will demonstrate how it runs seamlessly with the NVIDIA DRIVE AGX Orin platform, offering a range of software-driven features designed to accelerate autonomous driving ap", "datetime": "2025-01-07T13:00:00.000Z", "headline": "Innoviz, in Collaboration with NVIDIA, Showcasing Cutting-Edge Perception Software with NVIDIA DRIVE AGX Orin at CES 2025, Unveiling New Software-Driven Features", "sentiment": "positive"}]	positive	2025-09-03 18:01:37.246156+00	2025-09-03 18:01:37.246156+00
9f41e2db-7a1f-456f-84cd-dfe9a384608f	CURR	2025-03-17	[]	\N	2025-09-03 18:01:40.484468+00	2025-09-03 18:01:40.484468+00
38297a74-b2f8-43cf-9019-fec9c48b88e1	BIAF	2025-01-13	[{"url": "https://finnhub.io/api/news?id=dfc549f4bcd89b7ec044be3cbfca25332e4b151dc56705cd1666e4b52fe17a15", "source": "Yahoo", "summary": "SAN ANTONIO, January 13, 2025--bioAffinity Technologies reports positive results of the 2024 beta test market launch of CyPath Lung in Texas.", "datetime": "2025-01-13T13:00:00.000Z", "headline": "bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung", "sentiment": "positive"}]	positive	2025-09-03 18:01:44.969088+00	2025-09-03 18:01:44.969088+00
bcf0610e-130c-42e4-b2d4-44abe37b14c4	SLRX	2025-03-26	[{"url": "https://finnhub.io/api/news?id=c9b4ab05b7668186ee08b505e99e79292ae30003ca211c7d0c59a1d74749e420", "source": "Yahoo", "summary": "These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3), show the potential for Decoy’s novel platform to address both significant commercial opportunities and emerging viral threats with a single moleculeCAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate therap", "datetime": "2025-03-26T12:00:00.000Z", "headline": "Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses", "sentiment": "positive"}]	positive	2025-09-03 18:01:46.074333+00	2025-09-03 18:01:46.074333+00
15a52e79-9b2f-4471-841f-530911d7b11f	AIFF	2025-01-14	[{"url": "https://finnhub.io/api/news?id=72af5da11b7dc93c2be2dcf5d4f59b0a2cf2bfaf455517c3126893447ed1ff50", "source": "Yahoo", "summary": "Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patientsKENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research to assess a patient’s brain age - an estimat", "datetime": "2025-01-14T12:45:00.000Z", "headline": "Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform", "sentiment": "positive"}]	positive	2025-09-03 18:01:49.302936+00	2025-09-03 18:01:49.302936+00
840009c0-1d80-437e-b5f0-551bf38b07b6	20678X205	2025-02-10	[]	\N	2025-09-03 18:47:42.274309+00	2025-09-03 18:47:42.274309+00
4d447321-da40-4254-b81e-9284f83d81dc	TCRX	2024-12-26	[{"url": "https://finnhub.io/api/news?id=537390947795063cf4b80414645bb013c13c401bb10a2bc002b754dc66a46f98", "source": "Yahoo", "summary": "WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an", "datetime": "2024-12-26T12:00:00.000Z", "headline": "TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=2834814c404c3368b8a3593b29b74434c8e29dc634850f0031f7bfa58550e037", "source": "Finnhub", "summary": "Item 1.01. Entry into a Material Definitive Agreement. On December 26, 2024, TScan...", "datetime": "2024-12-26T08:14:20.000Z", "headline": "TScan Therapeutics : Material Agreement Form 8 K", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=88bfedbae432672f79b7b794ab4f8488d32a25679faca56d7f9085b582084df6", "source": "Yahoo", "summary": "Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to their...", "datetime": "2024-12-25T10:26:24.000Z", "headline": "With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing", "sentiment": "positive"}]	neutral	2025-09-03 18:00:14.197281+00	2025-09-03 18:00:14.197281+00
892ccfb4-84e7-40d1-ac78-2465a72b12c8	PDYN	2024-12-26	[]	\N	2025-09-03 18:00:14.563834+00	2025-09-03 18:00:14.563834+00
ff707eb8-4b63-47dd-be05-ecb895bb3ee9	97264L100	2024-12-27	[]	\N	2025-09-03 18:00:16.611956+00	2025-09-03 18:00:16.611956+00
282b118f-c570-4a84-8769-3f8e4f94d783	NRXP	2025-01-03	[{"url": "https://finnhub.io/api/news?id=ff0031d1903c141ea96a1f12d4cb1c18b9b3bad898fe63898182d7e7247c79a0", "source": "Yahoo", "summary": "HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD. The Company has previously announced non-binding Letters of Intent and banking intent for initial clinic acquisitions and has disclosed its intent to acquire and integrate clinics generating a more than $", "datetime": "2025-01-03T13:03:00.000Z", "headline": "HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=824bdc26c13814a27a78bd968d9c18d279c76a74d9103110f8b04a3aac2b4185", "source": "Yahoo", "summary": "HOPE Therapeutics, Inc., (\\"HOPE,\\" the \\"Company\\"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (\\"NRx\\") (Nasdaq: NRXP), today announced the planned acquisition of the Kadima Neuropsychiatry Institute (Kadima) of La Jolla, CA, per the previously announced Letter of Intent, for the HOPE network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide a", "datetime": "2025-01-02T13:03:00.000Z", "headline": "Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:28.898837+00	2025-09-03 18:00:28.898837+00
0a45efe5-24c4-45c3-b8e3-cd0b273771c8	CURR	2025-01-08	[{"url": "https://finnhub.io/api/news?id=04091ad3ff6a8d1693107a9cf5ca05b97a9662e05706e7daaf9338fd9b4299c7", "source": "Yahoo", "summary": "SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, crypt", "datetime": "2025-01-08T12:00:00.000Z", "headline": "CURRENC Debuts SEAMLESS AI Call Centre Solutions", "sentiment": "positive"}]	positive	2025-09-03 18:01:37.886078+00	2025-09-03 18:01:37.886078+00
ce01e691-8c44-4fbe-93fa-7c34739872a6	81728A108	2025-01-08	[]	\N	2025-09-03 18:01:40.998217+00	2025-09-03 18:01:40.998217+00
0ebd1554-c66b-4286-931e-7d05112c5db9	G33277131	2025-01-10	[]	\N	2025-09-03 18:01:41.929842+00	2025-09-03 18:01:41.929842+00
31008947-7227-4ebc-aaa3-20ac907eed52	ATPC	2025-01-13	[]	\N	2025-09-03 18:01:42.764556+00	2025-09-03 18:01:42.764556+00
f5b8eb04-d47c-4410-a78d-f341eee26a9f	SLRX	2025-01-13	[{"url": "https://finnhub.io/api/news?id=b81de13f6931e293d1f02c58cb9618c5ab6282b60931e3b8a9c10d148b09a89a", "source": "Yahoo", "summary": "Health care stocks advanced late Monday afternoon, with the NYSE Health Care Index up 0.9% and the H", "datetime": "2025-01-13T21:08:28.000Z", "headline": "Sector Update: Health Care Stocks Rise Late Afternoon", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=f1f302e488d86e5703bee7a68f61eb68931e421cff7260de4f9d6af6a1bacde5", "source": "Yahoo", "summary": "Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer HOUSTON and CAMBRIDGE", "datetime": "2025-01-13T13:00:00.000Z", "headline": "Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement", "sentiment": "positive"}]	positive	2025-09-03 18:01:45.266419+00	2025-09-03 18:01:45.266419+00
6ee9b9f5-31a9-4980-8018-ec39bd34d6b4	SLRX	2025-02-03	[{"url": "https://finnhub.io/api/news?id=a5e75afa0bafe0dc41dd6d57322488fa6ed89477b58a6c3e16c5df248309012d", "source": "Yahoo", "summary": "HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT047349", "datetime": "2025-02-03T13:00:00.000Z", "headline": "Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:45.527989+00	2025-09-03 18:01:45.527989+00
bd57a2e7-b638-44bf-8659-cd7e30446416	XHLD	2025-03-24	[{"url": "https://finnhub.io/api/news?id=81163ccb9c9e8bd97ffa62d104d576b0906e471134bad53b121e3105ba280adc", "source": "Yahoo", "summary": "TEN Holdings, Inc. (NASDAQ: XHLD) (\\"TEN Holdings\\" or the \\"Company\\"), a provider of event planning, production, and broadcasting services, today announced the Company's ability to add conversational artificial intelligence (\\"AI\\") solutions to its service offering through a new partnership announced by V-Cube Inc., its controlling shareholder.", "datetime": "2025-03-24T13:15:00.000Z", "headline": "TEN Holdings, Inc. to Add Conversational AI Solutions to Service Portfolio", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:19.19305+00	2025-09-03 18:48:19.19305+00
8420a9e3-b3d8-4e1e-9cf0-04c146dbe98f	BJDX	2025-04-07	[{"url": "https://finnhub.io/api/news?id=b1667048767b94a30ddcd18336eac7bebf8bddba5a011061cad95c2ab2738b4e", "source": "Yahoo", "summary": "ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exe", "datetime": "2025-04-07T21:21:00.000Z", "headline": "Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds", "sentiment": "neutral"}]	neutral	2025-09-03 18:00:20.71933+00	2025-09-03 18:00:20.71933+00
5a843a0e-affe-4233-8f5f-a1080582bdba	G55032166	2025-01-02	[]	\N	2025-09-03 18:00:23.653666+00	2025-09-03 18:00:23.653666+00
6a1517a3-72ea-4aa3-914e-35d325d512e0	ORIS	2025-01-02	[]	\N	2025-09-03 18:00:23.954866+00	2025-09-03 18:00:23.954866+00
5bf1ecec-9730-4cc6-a3af-05e134871c2b	89458T205	2025-01-03	[]	\N	2025-09-03 18:00:27.885734+00	2025-09-03 18:00:27.885734+00
0c2d35bb-62a4-409f-8c34-6f1fa2ef2609	GDTC	2025-01-06	[{"url": "https://finnhub.io/api/news?id=64a423768f0957fcb793daebe363b20b5443c103fbd20846137659061986e356", "source": "Yahoo", "summary": "Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR", "datetime": "2025-01-06T14:11:56.000Z", "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Monday", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=86eea0da54032c59e53d4cea145b02627138ae89c9a5469a351af1827863ad29", "source": "Yahoo", "summary": "SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement (“BRCA”) with Mumbai-based SunAct Cancer Institute Private Limited", "datetime": "2025-01-06T12:00:00.000Z", "headline": "CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India", "sentiment": "positive"}]	positive	2025-09-03 18:01:32.128318+00	2025-09-03 18:01:32.128318+00
892d7859-c649-4b9c-bbf4-39dacf50bc7e	SPRC	2025-01-06	[{"url": "https://finnhub.io/api/news?id=66425d71666fe7675d514f28b7a68f4d7e7c2300bec647c47b306f13ebe7f146", "source": "Yahoo", "summary": "On Monday, SciSparc Ltd (NASDAQ:SPRC) stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro. SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND), the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, t", "datetime": "2025-01-06T16:04:50.000Z", "headline": "Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=64a423768f0957fcb793daebe363b20b5443c103fbd20846137659061986e356", "source": "Yahoo", "summary": "Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR", "datetime": "2025-01-06T14:11:56.000Z", "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Monday", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=93235a14622b416af33b4959b879e097eba70ab171cdc4fde7730c4f9a1a4a6e", "source": "Yahoo", "summary": "TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\\"Company\\" or \\"SciSparc\\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-tre", "datetime": "2025-01-06T12:50:00.000Z", "headline": "SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment", "sentiment": "positive"}]	positive	2025-09-03 18:01:33.469548+00	2025-09-03 18:01:33.469548+00
5dbbd251-a794-4be3-a437-5fab866928d2	ARBE	2025-01-06	[{"url": "https://finnhub.io/api/news?id=17b99f4bf3c870ed034fdab2faf97e4c1513a1499184d1f1f6e83e0df89fcee9", "source": "Yahoo", "summary": "Arbe Robotics Ltd. (NASDAQ: ARBE) (TASE: ARBE), a global leader in Perception Radar solutions, announced today that in collaboration with NVIDIA, Arbe is enhancing free space mapping and AI-driven capabilities to further advance the automotive industry. Arbe will showcase its groundbreaking ultra-high-definition radar that is revolutionizing vehicle safety and autonomy at CES 2025.", "datetime": "2025-01-06T13:00:00.000Z", "headline": "Arbe Collaborates with NVIDIA to Enhance Radar-Based Free Space Mapping and AI-Driven Capabilities", "sentiment": "positive"}]	positive	2025-09-03 18:01:34.166821+00	2025-09-03 18:01:34.166821+00
64d455eb-032e-4b95-936d-ce3241dc2428	MSAI	2025-01-07	[{"url": "https://finnhub.io/api/news?id=1f7c9d078c8fea44fddb66ce9531fb9576283626d5de7476ce6cb466f1d29c28", "source": "Yahoo", "summary": "HOUSTON, TX / ACCESSWIRE / January 6, 2025 / MultiSensor AI Holdings, Inc. (\\"MultiSensor AI,\\" \\"MSAI\\" or \\"Company\\") (Nasdaq:MSAI), a pioneer in the emerging industrial AI-driven condition-based maintenance and process solution industry, today announced ...", "datetime": "2025-01-06T21:05:00.000Z", "headline": "MultiSensorAI Announces Next Steps in Leadership Optimization Plan as it Prepares for Rapid Growth", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:34.704679+00	2025-09-03 18:01:34.704679+00
f4c2f75c-10df-42ce-9a97-415a3195e033	AMOD	2025-01-07	[{"url": "https://finnhub.io/api/news?id=f9a9c83057220ae856bbfc0c098b8d20bca04e538fc17d6d2bee4ce9b08c82df", "source": "Yahoo", "summary": "CORNELIUS, N.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus” or the “Company”), announces a major milestone with the issuance of its 9th patent, further solidifying its position at the forefront of artificial intelligence solutions. On December 24, 2024, the United States Patent and Trademark Office issued Alpha Modus, Corp., the wholly owned subsidiary of the Company, its latest patent, United States Patent Number 12,175,484, titled “Methods for Pe", "datetime": "2025-01-06T14:00:00.000Z", "headline": "Alpha Modus Secures 9th AI Patent, Strengthening Leadership in Retail Innovation", "sentiment": "positive"}]	positive	2025-09-03 18:01:36.109546+00	2025-09-03 18:01:36.109546+00
16efc165-68fd-415e-8c56-c23729b424ae	97382D501	2025-01-08	[]	\N	2025-09-03 18:01:41.306988+00	2025-09-03 18:01:41.306988+00
70847a6e-f0f1-4dda-bbeb-705d35a5921e	NBY	2025-01-10	[]	\N	2025-09-03 18:01:42.441493+00	2025-09-03 18:01:42.441493+00
153037e1-a0de-4c48-87a4-4e97a911d7a5	28059P303	2025-01-13	[]	\N	2025-09-03 18:01:43.120879+00	2025-09-03 18:01:43.120879+00
e7e4c04e-ee5d-40af-839a-c524e837f1f3	90137F400	2025-01-13	[]	\N	2025-09-03 18:01:44.154926+00	2025-09-03 18:01:44.154926+00
8a027a43-b6c9-4652-b709-2216eca03f88	AIFF	2025-02-13	[]	\N	2025-09-03 18:01:50.638055+00	2025-09-03 18:01:50.638055+00
229c1237-af56-4427-9bf1-0fa62cbe2e02	OSTX	2025-01-15	[{"url": "https://finnhub.io/api/news?id=9da81f6a78a9ae540903179a9d0212b90b4213190dbcdc03af5e7cf572438be4", "source": "Yahoo", "summary": "NEW YORK, January 15, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res", "datetime": "2025-01-15T14:17:00.000Z", "headline": "OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:51.570636+00	2025-09-03 18:01:51.570636+00
2f926a07-eb15-473d-b49f-89117d5b18c5	42328V801	2025-01-21	[]	\N	2025-09-03 18:01:55.920216+00	2025-09-03 18:01:55.920216+00
d1ab250e-e948-422b-ab35-f4a9090cf298	NMHI	2025-01-14	[{"url": "https://finnhub.io/api/news?id=b32df0ae814aec7bcdae1af1b68bcce66f66f6bc98383585d40fc66495ab7d69", "source": "Yahoo", "summary": "Nature's Miracle Holding Inc. (NASDAQ: NMHI) (\\"Nature's Miracle\\" or the \\"Company\\"), a leader in vertical farming technology and infrastructure, today announced that on January 13, 2025, the Company received written notice (the \\"Notice\\") from The Nasdaq Stock Market LLC (\\"Nasdaq\\") indicating that the Nasdaq Hearings Panel has determined to delist the Company's common stock and warrants from Nasdaq due to the Company's failure to comply with minimum shareholder's equity requirement under Nasdaq Li", "datetime": "2025-01-14T22:50:00.000Z", "headline": "Nature's Miracle Holding Inc. Announces Receipt of Delisting Notification from Nasdaq", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d674c7ec68ef60ae21fd56de4160369a13812c9c07f0b9750436bb6df2be8cea", "source": "Yahoo", "summary": "ONTARIO, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nature's Miracle Holding, Inc. (Nasdaq: NMHI) (\\"Nature's Miracle\\"), a growing agriculture technology company providing equipment and services to growers, announced that it entered into a Securities Purchase Agreement (\\"SPA\\") with a single institutional investor (\\"Investor\\") on January 10, 2025. The SPA allows Nature's Miracle, subject to customary conditions, to sell up to $29.7 million in the aggregate of a newly-designated class of convertible", "datetime": "2025-01-14T13:00:00.000Z", "headline": "D. Boral Capital Served as Placement Agent to Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a660732b97cfc421c096058a8b59ea83bfb7da6ef695391141754c616ab939ca", "source": "Yahoo", "summary": "Nature's Miracle Holding, Inc. (Nasdaq: NMHI) (\\"Nature's Miracle\\"), a growing agriculture technology company providing equipment and services to growers, announced that it entered into a Securities Purchase Agreement (\\"SPA\\") with a single institutional investor (\\"Investor\\") on January 10, 2025. The SPA allows Nature's Miracle, subject to customary conditions, to sell up to $29.7 million in the aggregate of a newly-designated class of convertible preferred stock to the Investor.", "datetime": "2025-01-13T13:30:00.000Z", "headline": "Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:46.364101+00	2025-09-03 18:01:46.364101+00
622c5d4c-0465-46ca-b688-1b1b85245f67	SNGX	2025-01-14	[{"url": "https://finnhub.io/api/news?id=c1e8119804cc3d57b0db8ee20d5ec5c44ba86183027d85afece11a26128f030b", "source": "Yahoo", "summary": "Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneou", "datetime": "2025-01-14T12:30:00.000Z", "headline": "HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8dfc7063a6832057868b867b5684107fd39a0866aa2551d8783d686d25dea37d", "source": "Yahoo", "summary": "On Tuesday, Soligenix Inc. (NASDAQ:SNGX) announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL), a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection. Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with H", "datetime": "2025-01-14T12:15:17.000Z", "headline": "EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=56933bfa73b28ef1846fdfdb4da8cad6d78654a23675087a954f90e36f12b0e6", "source": "Yahoo", "summary": "By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Additional Positive Data for IIS of HyBryte in CTCL On January 14, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced additional positive data from the open-label, investigator-initiated study (IIS) of HyBryte (synthetic hypericin) for patients with cutaneous T cell lymphoma (CTCL) for up to 12 months. During the study", "datetime": "2025-01-14T10:09:00.000Z", "headline": "SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:49.024617+00	2025-09-03 18:01:49.024617+00
c0e6feaa-2977-4bcf-82d6-189fe9cf45bc	AIFF	2025-02-11	[{"url": "https://finnhub.io/api/news?id=81a18e819c550c5882e75dd4666fc209656b6d8c8dc7892c8190a6782590a88e", "source": "Yahoo", "summary": "Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For the first time, Firefly also unveils a new strategic initiative to build the world’s first foundation model of the human brain using its BNA™ technology KENMORE, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain", "datetime": "2025-02-11T12:45:00.000Z", "headline": "Firefly Neuroscience Accepted into NVIDIA Connect Program", "sentiment": "positive"}]	positive	2025-09-03 18:01:49.836856+00	2025-09-03 18:01:49.836856+00
16518e0b-7cb3-4565-b76e-8f795b2c6cb6	AMBO	2025-01-16	[{"url": "https://finnhub.io/api/news?id=e3c609add8f8f87503af823dcee9cdea8ee3c39249f061ca88fd3904e4dd55b6", "source": "Yahoo", "summary": "Argus Research, an independent investment research firm, has launched Equity Report coverage on Ambow Education Holding Ltd. (NYSEAM:AMBO).", "datetime": "2025-01-16T12:45:00.000Z", "headline": "Argus Research Initiates Equity Report Coverage on Ambow Education Holding Ltd. (NYSEAM: AMBO)", "sentiment": "positive"}]	positive	2025-09-03 18:01:53.677726+00	2025-09-03 18:01:53.677726+00
60c58fdc-9bda-46b6-807a-d61c4435b2bf	EVAX	2025-01-15	[{"url": "https://finnhub.io/api/news?id=ca5e503ec80efc095a01914cc1f27ebebab4d509dc088d8841f3fe3632bfcbd0", "source": "Yahoo", "summary": "Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company’s lead asset EVX-01. Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advance", "datetime": "2025-01-15T13:00:00.000Z", "headline": "Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=594dea30c64b0f28efca79b189fe800ed67d96d32658ae4265dd5cf720e5bc12", "source": "Yahoo", "summary": "By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it", "datetime": "2025-01-15T10:13:00.000Z", "headline": "EVAX Adjusts Share Ratio", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c57419828a2689de2ea134e6e3b0cdc5e86c756ecdad54dfea49c7eb8f7ca07f", "source": "Yahoo", "summary": "COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing ten (10) ordinary shares to a new ADS ratio of one", "datetime": "2025-01-14T21:05:00.000Z", "headline": "Evaxion announces completion of ADS ratio change", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:52.739693+00	2025-09-03 18:01:52.739693+00
3923997f-1eb0-45f1-a0ab-d4b421dbe324	EVAX	2025-02-04	[]	\N	2025-09-03 18:01:53.031359+00	2025-09-03 18:01:53.031359+00
43ba6d66-6ed8-4bd9-967f-cbbce38d96c9	PALI	2025-01-16	[{"url": "https://finnhub.io/api/news?id=1c1235d6788561ba9753ed16ce6b40fccede5d217c4f678cc46e8516d470caf2", "source": "Yahoo", "summary": "Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeut", "datetime": "2025-01-16T13:00:00.000Z", "headline": "Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis", "sentiment": "positive"}]	positive	2025-09-03 18:01:54.212111+00	2025-09-03 18:01:54.212111+00
2b9af743-ed90-4652-bfd9-2e8e42ad40ff	PRZO	2025-01-17	[]	\N	2025-09-03 18:01:54.728743+00	2025-09-03 18:01:54.728743+00
c997cf2c-45f9-42b5-b935-e81b6d0ecc7c	AMIX	2025-01-17	[{"url": "https://finnhub.io/api/news?id=16c1296f0b6b2c17d21343402aeb7a19bb150c0174686961ab41b1626a70a1f7", "source": "Yahoo", "summary": "Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a", "datetime": "2025-01-17T13:00:00.000Z", "headline": "Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025", "sentiment": "positive"}]	positive	2025-09-03 18:01:55.388849+00	2025-09-03 18:01:55.388849+00
396cd0b4-06ca-41ed-9043-6f76f9794b33	NIXX	2025-01-21	[{"url": "https://finnhub.io/api/news?id=affb77fe8b7000dd33fe67fbd4b71882de85f9e2092ed6f30d5b09a43854a687", "source": "Yahoo", "summary": "Nixxy, Inc, (NASDAQ:NIXX), or \\"Nixxy\\" or the \\"Company,\\" today announced it has commenced a private offering (the \\"Offering\\"), subject to market and other conditions, of up to $50 million aggregate principal amount of its zero-coupon convertible notes ...", "datetime": "2025-01-21T13:07:00.000Z", "headline": "Nixxy Commences Private Offering of up to $50 million of Bitcoin Secured Convertible Notes", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:56.931621+00	2025-09-03 18:01:56.931621+00
88d04e4a-7838-4746-88a1-7fe37daf6d3f	34546R100	2025-01-27	[]	\N	2025-09-03 18:01:58.928953+00	2025-09-03 18:01:58.928953+00
c9a6746f-f374-45b6-b70d-1135cfbe186b	INM	2025-01-21	[{"url": "https://finnhub.io/api/news?id=2d06fbf6b200a5e1d16d9195267041a570cb6b2f411cb1e8b0371e8940c00cdb", "source": "Yahoo", "summary": "INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile showed a reduction of several key neuroinflammatory genes in the brainVancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\\"InMed\\" or the \\"Company\\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candid", "datetime": "2025-01-21T12:30:00.000Z", "headline": "InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study", "sentiment": "positive"}]	positive	2025-09-03 18:01:57.468499+00	2025-09-03 18:01:57.468499+00
830dd1ef-da59-4187-a472-c5fc25d762c0	JG	2025-01-27	[{"url": "https://finnhub.io/api/news?id=3aea8f15c6be52c1b82b23dda61d9ea316691eb8f2f682eb73bcad87cbb9a057", "source": "Yahoo", "summary": "The integration expands GPTBots.ai's ecosystem.", "datetime": "2025-01-27T17:22:00.000Z", "headline": "Aurora Mobile Shares Rise 136% After Integrating DeepSeek R1 into AI Platform", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=f64d808e6aeef2818e2a04747f990d0bb556bdc10e7a0894712fa185b650dff5", "source": "Yahoo", "summary": "SHENZHEN, China, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its leading enterprise AI agent platform, GPTBots.ai, has integrated the innovative DeepSeek R1 large language model (LLM). This addition further enhances GPTBots.ai’s robust ecosystem of AI capabilities, which already includes some of the most advanced LLMs in the marke", "datetime": "2025-01-27T10:00:00.000Z", "headline": "Aurora Mobile’s GPTBots.ai Integrates DeepSeek R1 LLM", "sentiment": "positive"}]	positive	2025-09-03 18:01:58.418906+00	2025-09-03 18:01:58.418906+00
370f757b-177c-43fd-ae29-005a740ecc5e	BACK	2025-01-28	[{"url": "https://finnhub.io/api/news?id=44252f2ef5006128c4baa2163b6ad3317e26b1d9471faa3dc9d79adef7a3fc13", "source": "Yahoo", "summary": "Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond. Why Proteins Matter – Beyond Genomics Although genomics (gene-based) testing has become common, pa", "datetime": "2025-01-27T21:10:00.000Z", "headline": "IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies", "sentiment": "neutral"}]	neutral	2025-09-03 18:01:59.635167+00	2025-09-03 18:01:59.635167+00
2bfdd20c-60b7-4007-bd51-96373d5140dc	YIBO	2025-01-28	[]	\N	2025-09-03 18:02:00.15631+00	2025-09-03 18:02:00.15631+00
541fc2b1-d1a1-4b41-9928-024500c75130	TRIB	2025-01-28	[{"url": "https://finnhub.io/api/news?id=9f8be03b27134adbe9020329bf576b7196098ffb19e47ebacff3b85b24f6242d", "source": "Yahoo", "summary": "Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system.", "datetime": "2025-01-28T12:20:00.000Z", "headline": "Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology", "sentiment": "positive"}]	positive	2025-09-03 18:02:00.411432+00	2025-09-03 18:02:00.411432+00
fb4aa9c9-6e90-4092-b69d-a782dfb06984	QLGN	2025-01-28	[{"url": "https://finnhub.io/api/news?id=bd07aac134ca4d0237e501d6de07f36e78b01ca46fb3cb8f41bdf97b6874f670", "source": "Yahoo", "summary": "Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)announced today they will be the first investors participating in the 2025 bridge round of funding for NanoSynex. NanoSynex will be raising up to $500,000. “We are very excited to participate and be the first investors to commit in this round of funding for NanoSynex. The technology they are developing will help the world of Antimicrobia", "datetime": "2025-01-28T13:00:00.000Z", "headline": "Qualigen to participate in next funding round for NanoSynex", "sentiment": "neutral"}]	neutral	2025-09-03 18:02:01.096777+00	2025-09-03 18:02:01.096777+00
3327850f-58f4-474b-af2d-3998380dde0a	UCAR	2025-01-29	[{"url": "https://finnhub.io/api/news?id=a9002575e3ae6d79af3cd2138fde768f7d1b48fd1a5c6316c32ce7a393351080", "source": "Yahoo", "summary": "U Power Limited (Nasdaq: UCAR) (the \\"Company\\" or \\"U Power\\"), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced that it has signed a cooperation agreement with Ezzy Transporter (Thailand) Company Limited (\\"Ezzy Transporter\\") to establish Greendrive Tech Co. Ltd., (\\"Greendrive\\" or the \\"Joint Venture\\"), a joint venture company dedicated to the market expansion and sale of electric vehicles in Thailand. Per the", "datetime": "2025-01-29T12:00:00.000Z", "headline": "U Power and Ezzy Transporter Establish Joint Venture to Bring UOTTA Battery-Swapping Solutions to Thailand", "sentiment": "positive"}]	positive	2025-09-03 18:02:01.433086+00	2025-09-03 18:02:01.433086+00
554064ff-70b0-4f50-9d38-ae5402a35742	UCAR	2025-03-24	[{"url": "https://finnhub.io/api/news?id=e4ad0929efa9306291262043aaac7e88c94d23866c244d020fc3f69c213d8313", "source": "Yahoo", "summary": "U Power Limited (Nasdaq: UCAR), a world leader in rapid battery swapping technology for EV's, (\\"U Power\\" or the \\"Company\\") announced today that it has signed a joint venture agreement between its Thai subsidiary, U SWAP, and SUSCO Public Company Limited (BK: SUSCO), a publicly listed energy provider with a robust network of fueling stations throughout Thailand. The joint venture will deploy U Power's innovative UOTTA battery-swapping technology across SUSCO's extensive station network, significa", "datetime": "2025-03-24T11:00:00.000Z", "headline": "U Power Limited (Nasdaq: UCAR) Announces Landmark Joint Venture with SUSCO, Targeting Thailand's Multi-Billion EV Infrastructure Boom", "sentiment": "positive"}]	positive	2025-09-03 18:02:02.450522+00	2025-09-03 18:02:02.450522+00
ac56062e-0b2c-4158-b67b-400e74c3722a	SLXN	2025-03-17	[{"url": "https://finnhub.io/api/news?id=b5fbf77b14685bae1e7e69bed5384ec5f1979c6aa58a3004a3ae6a19d018049c", "source": "Yahoo", "summary": "NEW YORK, March 17, 2025--PESG Research releases a report covering Silexion Therapeutics’ (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.", "datetime": "2025-03-17T12:15:00.000Z", "headline": "PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment", "sentiment": "positive"}]	positive	2025-09-03 18:02:03.719786+00	2025-09-03 18:02:03.719786+00
fad5f840-3fe3-4570-88a2-4ed522386f0b	71902K303	2025-03-27	[]	\N	2025-09-03 18:47:39.464831+00	2025-09-03 18:47:39.464831+00
9c551a58-98ae-4dfd-9b5f-003d80659c95	SLXN	2025-01-29	[{"url": "https://finnhub.io/api/news?id=fafbc20caf3be19205db4b0718e57543ff1f4808c712614aa6be945bc2b33073", "source": "Yahoo", "summary": "Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary s", "datetime": "2025-01-29T22:30:00.000Z", "headline": "Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=58218e7f2578ddbd46e80ced376534616f451395edf3a59e8383cd68ce3ec7d2", "source": "Yahoo", "summary": "NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions.", "datetime": "2025-01-29T14:59:00.000Z", "headline": "PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=38fced3dc7bfaaef73fe9ab6b13805a869ab85564a5b87ca2871a9bd6550d474", "source": "Yahoo", "summary": "New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastasesCayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new pre", "datetime": "2025-01-28T13:29:00.000Z", "headline": "Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models", "sentiment": "positive"}]	positive	2025-09-03 18:02:03.119412+00	2025-09-03 18:02:03.119412+00
1ec1fc5d-2217-4dd8-be03-220bbf023b69	DJT	2025-01-29	[{"url": "https://finnhub.io/api/news?id=513eab4debea95b224fdc37848eaaf81b02c0d6a0e89e139fee672f569c88c8c", "source": "SeekingAlpha", "summary": "Trump Media's strategy of diversifying into multiple sectors without establishing a strong foothold in any one area is concerning and unsustainable. Learn more on DJT stock here.", "datetime": "2025-01-29T18:07:08.000Z", "headline": "Trump Media & Technology Group Stock Soars On A Nothingburger", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8811ffb68be81a7d61db1f11a8128efcfc38117e93221781cebf3bc94df8c8a6", "source": "Finnhub", "summary": "WASHINGTON — Meta has agreed to pay $25 million to settle a lawsuit filed by President Donald Trump against the company after it suspended his accounts following the Jan. 6, 2021, attack on the...", "datetime": "2025-01-29T17:57:00.000Z", "headline": "Meta agrees to pay $25 million to settle lawsuit from Trump after Jan. 6 suspension", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=adeae802aed265e7de852169300bd0fb1f8445708307e353511ca7c76a1db0a7", "source": "Yahoo", "summary": "Yahoo Finance host Josh Lipton dives into the latest Wall Street stock news on today's segment of Market Minute. Trump Media & Technology (DJT, DJTWW) stock is moving higher after it announced it will expand into the financial services market. The company has secured funding of up to $250 million, which will be custodied by Charles Schwab (SCHW). Shares of T-Mobile (TMUS) also rose after the company issued strong guidance based on its fourth quarter earnings results. The company expects to add 5.5 million to 6 million new paid subscribers in 2025. Finally, Teva Pharmaceutical (TEVA) stock is under pressure after the company issued a softer-than-expected outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Angel Smith", "datetime": "2025-01-29T17:43:34.000Z", "headline": "Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9bbfe439f83efd0539fa6a768a86a9a09c77d9b479ed78190b8f6a2fa03b3d91", "source": "Yahoo", "summary": "Trump Media & Technology Group (DJT, DJTWW) has announced plans to enter the financial services sector, unveiling a new division called Truth.Fi. The expansion will be backed by up to $250 million in funding from Charles Schwab (SCHW). The company plans to roll out various investment products and services through Truth.Fi in 2025. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith", "datetime": "2025-01-29T16:16:23.000Z", "headline": "Trump Media to enter financial sector with Truth.Fi", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9178864a59d4ce41cd417a2dcaf31eeac62f0c70453868d25b08308bcc5ac45c", "source": "Yahoo", "summary": "Carson Block, founder and chief investment officer of Muddy Waters Capital, said he \\"wouldn't touch\\" meme coins.", "datetime": "2025-01-29T15:27:41.000Z", "headline": "Meme coins a sign of 'speculative frenzy' in markets, famed short seller says", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8f684c24f5641f57385e9baad049235ad02dafdf6e8fc5737a51a5698f10a961", "source": "SeekingAlpha", "summary": "Trump's focus on meme coins like TRUMP and MELANIA has affected the growth of Truth Social. The stock has had irrational values, but at some point it will trade based on fundamentals.", "datetime": "2025-01-29T15:03:17.000Z", "headline": "Trump Media: Mostly Ignored By The President", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=0e023576d688971eebf77719a91a920e71c5e838539b92429487f6ee2a235c46", "source": "Yahoo", "summary": "Trump Media & Technology Group will expand into financial services.", "datetime": "2025-01-29T14:59:00.000Z", "headline": "DJT stock pops after Trump Media announces expansion into financial services", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=196c2e8fcf587cdb6676409c26b20186e95306f77339de2154bdee1472de3777", "source": "Yahoo", "summary": "Trump Media jumped early Wednesday after it announced it is wading into the financial services world.", "datetime": "2025-01-29T14:53:25.000Z", "headline": "Why Donald Trump Stock Is Surging After A 12% Decline This Month", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bdf3851577de61d3a2aac9281167f4a5f2c32638fc6251f38e787722465d326d", "source": "Finnhub", "summary": "TMTG Launches Truth.Fi Brand, Plans to Build Investment Vehicles Based on America-First Principles SARASOTA, Fla., Jan. 29, 2025 -- Trump Media and Technology Group Corp. , operator of the...", "datetime": "2025-01-29T08:32:03.000Z", "headline": "Trump Media Announces Expansion into Financial Services", "sentiment": "positive"}]	positive	2025-09-03 18:02:05.510476+00	2025-09-03 18:02:05.510476+00
76a1239d-9836-4815-84cd-c46a5b95939d	SGN	2025-01-29	[{"url": "https://finnhub.io/api/news?id=4f93c92814bcf8644a2801d8b8d10d4f343f99422496ff790e3e82bd7aa07412", "source": "Yahoo", "summary": "Expected acquisition of Swifty Global would contribute strong historical financials and significant growth potentialSCOTTSDALE, Arizona, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a Stock Purchase Agreement (SPA) to acquire 99.13% of the issued and outstanding capital stock of", "datetime": "2025-01-29T14:00:00.000Z", "headline": "Signing Day Sports Executes Stock Purchase Agreement to Acquire Majority of Capital Stock of Dear Cashmere Group Holding Company d/b/a Swifty Global", "sentiment": "positive"}]	positive	2025-09-03 18:02:06.938326+00	2025-09-03 18:02:06.938326+00
ea29585a-a554-4733-858c-fd3a6b9fc7e6	SGN	2025-01-31	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	neutral	2025-09-03 18:02:07.17484+00	2025-09-03 18:02:07.17484+00
3deee84e-84e2-4230-89b6-9fab0c224013	CRGX	2025-01-30	[{"url": "https://finnhub.io/api/news?id=e88438f4a26cdccc6611c64dddb60ccdf3d048357dc90eaf3053a3f50030c552", "source": "Yahoo", "summary": "Cargo Therapeutics (CRGX) shares tumbled 74% after the company said Wednesday it plans to discontinu", "datetime": "2025-01-30T18:56:33.000Z", "headline": "Top Midday Decliners", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=d3f211f12f40eef1bbbe37c2ae2c58b1fe3015f7f9a0694a422f58775b09c316", "source": "Yahoo", "summary": "Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.", "datetime": "2025-01-30T09:34:37.000Z", "headline": "Cargo to drop lead CAR-T therapy, lay off staff after study setback", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=a68d8781f4c8d59d8ede7470603cec8f9645437390f4c4e10f1f705545478c09", "source": "Yahoo", "summary": "CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a workforce reduction of approximately 50%.Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation,", "datetime": "2025-01-29T21:05:00.000Z", "headline": "CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=61d81a1f11d7b2612b6f342c43ef69f986e9ccc0b98d95b26c9cc7a6adf5e2c6", "source": "Finnhub", "summary": "The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. for violations of the securities laws.INVESTIGATION DETAILS: The investigation...", "datetime": "2025-01-29T20:21:04.000Z", "headline": "CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=25b7788a2c1a501cdbadda49ac232c54c25e02646f5fe847cf6264f02b85c438", "source": "Finnhub", "summary": "The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. for violations of the securities...", "datetime": "2025-01-29T19:46:04.000Z", "headline": "CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a423d9f752b4cb7ca990a4ef78253d3beaceda570cd341f46029cf6b1ec4af07", "source": "Finnhub", "summary": "By Connor Hart Tesla logged higher revenue in the fourth quarter. The electric-car maker's revenue increased to $25.71 billion from $25.17 billion a year earlier. The company said that automotive...", "datetime": "2025-01-29T19:16:40.000Z", "headline": "Stocks to Watch : Tesla, IBM, Microsoft, Lam Research, Cargo Therapeutics", "sentiment": "neutral"}]	negative	2025-09-03 18:02:09.865256+00	2025-09-03 18:02:09.865256+00
82aa9403-6af4-4b83-be47-b61f3776d155	73017P102	2025-01-30	[]	\N	2025-09-03 18:02:10.031733+00	2025-09-03 18:02:10.031733+00
1b3c9945-fd37-45ac-a875-a51dd71ec30a	VINC	2025-01-29	[{"url": "https://finnhub.io/api/news?id=f615be7f0767739e2f8c6b7da6e7aee4bdafa9f3ded66fcc1395cbdd4c0e9e67", "source": "Yahoo", "summary": "Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory’s anti-TROP2", "datetime": "2025-01-29T13:00:00.000Z", "headline": "Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258", "sentiment": "positive"}]	positive	2025-09-03 18:02:04.656258+00	2025-09-03 18:02:04.656258+00
1cb17a51-0b42-49b5-a8e8-a6e3052ebcb2	OCEA	2025-01-29	[{"url": "https://finnhub.io/api/news?id=a53e2981dd7932f87f6aa6dddf87c4bd69558dc61f10153589ea1ee224609a4a", "source": "Yahoo", "summary": "Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Health (NIH) to advance their groundbreaking malaria vaccine research. In parallel, recent U.S. Food and Drug Administration (FDA) Guidance on lipid-encapsulated vaccines may offer an expedited development pathway for their innovative approa", "datetime": "2025-01-29T13:30:00.000Z", "headline": "Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway", "sentiment": "neutral"}]	neutral	2025-09-03 18:02:05.765522+00	2025-09-03 18:02:05.765522+00
9bacda73-fad0-4c1b-903a-8cc01dacbc60	SKBL	2025-01-30	[]	\N	2025-09-03 18:02:09.001548+00	2025-09-03 18:02:09.001548+00
9b1d382d-4475-4d16-b2f4-efe5dcbf32d7	48669G204	2025-01-30	[]	\N	2025-09-03 18:02:09.21287+00	2025-09-03 18:02:09.21287+00
57155da6-99cc-4594-90f1-7e24bf7a1ce5	TNFA	2025-01-29	[{"url": "https://finnhub.io/api/news?id=57291b5032cab20681f134339b548806b1722b69eb4b4ea08babeb4711d322ad", "source": "Yahoo", "summary": "BALTIMORE, January 29, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (\\"TNF\\" or the \\"Company\\"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management.", "datetime": "2025-01-29T14:15:00.000Z", "headline": "TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment", "sentiment": "neutral"}]	neutral	2025-09-03 18:02:06.603732+00	2025-09-03 18:02:06.603732+00
d1f543a0-817a-45fc-9ac6-b07b2a186f9f	G2161Y125	2025-01-30	[]	\N	2025-09-03 18:02:07.7103+00	2025-09-03 18:02:07.7103+00
0b0f4061-1d64-45b8-bb2c-1493b6252bfa	CHEK	2025-01-03	[]	\N	2025-09-03 18:46:56.59274+00	2025-09-03 18:46:56.59274+00
9b4791c3-a42a-424b-a9d6-d5ae8d47d01b	STAI	2025-01-30	[{"url": "https://finnhub.io/api/news?id=5b3ee9905d4e142c8d85f9dbfcb8a432817664926bf26ea99a81a91a88518697", "source": "Yahoo", "summary": "Buford, GA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems, Inc. (NASDAQ: STAI, ScanTech, or ScanTech AI), a security solutions provider offering one of the world’s most advanced non-intrusive “fixed-gantry” CT screening technologies, proudly announced today the successful deployment and operational launch of its cutting-edge ‘fixed-gantry’ computed tomography (CT) security scanners at multiple nuclear power facilities across Canada. Ontario Power Generation (OPG) has chosen ScanTech’s ne", "datetime": "2025-01-30T13:30:00.000Z", "headline": "ScanTech AI Systems, Inc. Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation", "sentiment": "positive"}]	positive	2025-09-03 18:47:19.894471+00	2025-09-03 18:47:19.894471+00
03a36516-7220-462c-b590-58d7bf48e61e	AISP	2025-01-31	[{"url": "https://finnhub.io/api/news?id=88940fdfb7bce0df112bde4b9d53d4325d92d49d3b615b79a5c298029c0fe80e", "source": "Yahoo", "summary": "Acropolis Enterprise Video and Data Management Platform Supports Operational and Physical Security Requirements for Global Locations REDMOND, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today announced it has been awarded an additional one (1) year system maintenance and sustainment contract for an existing Fortune 100 customer leveraging the Com", "datetime": "2025-01-31T13:31:00.000Z", "headline": "Airship AI Secures Follow-On Seven-Figure Contract Award with Fortune 100 Transportation & E-Commerce Company", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:20.987142+00	2025-09-03 18:47:20.987142+00
24ecddc6-2c65-47f3-b676-ae5c4b052859	IVVD	2025-02-03	[{"url": "https://finnhub.io/api/news?id=59000260091f558fe26ca5ae28df9f3b14438aa08075c584f20fd49621209a48", "source": "Yahoo", "summary": "Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administrationPhase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are supported by antiviral activity data from Invivyd's standard virologic assessments Pooled, blinded adverse events (AEs) to date are mild or moderate and thus far deemed unrelated to study drug or largely related to injection site reaction or infusion r", "datetime": "2025-02-03T12:00:00.000Z", "headline": "Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ee90f6bf4e3470efe035346c7054811d20aaa7e2e9ce77fbde0050fe7832f7b4", "source": "Yahoo", "summary": "Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 millionPreliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction compared to Q3 2024 operating costs and expenses of $71.6 millionPreliminary ending 2024 cash and cash equivalents of $69.3 million and $10.9 million of accounts receivableContinues to target near-term (by end of 1H 2025) profitability with existing cash and ca", "datetime": "2025-02-03T11:55:00.000Z", "headline": "Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability", "sentiment": "positive"}]	positive	2025-09-03 18:47:21.614471+00	2025-09-03 18:47:21.614471+00
59a4f07f-0807-4061-ab0a-d72421744c36	GHRS	2025-02-03	[{"url": "https://finnhub.io/api/news?id=42485621b4a2f95abc93d044f0f1dd7419e1c87a99478e33257f8025fbdf8175", "source": "Yahoo", "summary": "DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase u", "datetime": "2025-02-03T21:03:00.000Z", "headline": "GH Research Announces Proposed Public Offering", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c7f5f73d963aa5097935f4145ac1cd2855178dba60a163c4a756e360c0f1be01", "source": "Yahoo", "summary": "The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.", "datetime": "2025-02-03T12:07:00.000Z", "headline": "Shares of psychedelics biotech nearly double on depression data", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c7da7ca8a11b41ccc48e1074e3de4e9d792f4478df535a41e84852afe1d5dd7f", "source": "Yahoo", "summary": "Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerat", "datetime": "2025-02-03T12:00:00.000Z", "headline": "GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:22.845844+00	2025-09-03 18:47:22.845844+00
5e886e02-1697-4cfa-bb1e-e13dccf2c0d2	40423R105	2025-02-03	[]	\N	2025-09-03 18:47:23.391655+00	2025-09-03 18:47:23.391655+00
176142de-7b8e-4d17-bbc6-87678ca03a6f	GWAV	2025-02-04	[{"url": "https://finnhub.io/api/news?id=062a80aa391534d1a163e1e3e8e456e3cc48d4c8deab8360c3605f9d64b6e499", "source": "Yahoo", "summary": "Greenwave Technology Solutions, Inc. (\\"Greenwave\\" or the \\"Company\\") (Nasdaq: GWAV), a leader in metal recycling, is raising revenue guidance to $47–$50 million for FY 2025 following President Trump's announcement of sweeping tariffs on steel, aluminum, and copper imports.", "datetime": "2025-02-04T13:08:00.000Z", "headline": "Greenwave Technology Solutions, Inc. Raises Revenue Guidance to $47-$50 Million for FY 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8727ea3006fc2ad862078b89c232cb0f902a20607dc3b42cc3f5eecc8c975148", "source": "Yahoo", "summary": "Greenwave Technology Solutions, Inc. (\\"Greenwave\\" or the \\"Company\\") (Nasdaq: GWAV), a leader in metal recycling, is primed for significant revenue acceleration following President Trump's announcement of sweeping tariffs on steel, aluminum, and copper imports. These aggressive trade measures are expected to drive sharp price increases for domestically sourced metals, positioning Greenwave as a critical supplier in an increasingly protectionist market.", "datetime": "2025-02-03T09:10:00.000Z", "headline": "Greenwave Technology Solutions, Inc. Poised for Explosive Growth Amid New Steel, Aluminum, and Copper Tariffs", "sentiment": "positive"}]	positive	2025-09-03 18:47:29.362719+00	2025-09-03 18:47:29.362719+00
3f867eb8-6018-41c4-8d63-be14462c3a80	M2R43K362	2025-02-04	[]	\N	2025-09-03 18:47:32.066079+00	2025-09-03 18:47:32.066079+00
9704975a-6811-452c-8377-c1f5d5fb9cc3	BCTX	2025-02-03	[{"url": "https://finnhub.io/api/news?id=c0ce088af795798f9298fe3e62162dd9e87d602987171efa57090fcfd98c8e8a", "source": "Yahoo", "summary": "PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, o", "datetime": "2025-02-03T21:45:00.000Z", "headline": "BriaCell Therapeutics Announces Proposed Public Offering of Common Shares", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f30ca29e08bba61a8ba4f3a50b5158a92539169a4b6f1303ccdde456a3b9951a", "source": "Yahoo", "summary": "Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity related to the treatment; Patient remains on studyUnprecedented result in first patient dosed supports Bria-OTS™ personalized immunotherapy approachOngoing Phase 1/2a dose escalation study to evaluate Bria-OTS™, BriaCell's personalized off-the-shelf immunotherapy in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE N", "datetime": "2025-02-03T12:30:00.000Z", "headline": "BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:23.960967+00	2025-09-03 18:47:23.960967+00
3d4d9838-c74b-41ec-8341-cfd146f90499	M97838128	2025-02-03	[]	\N	2025-09-03 18:47:24.596244+00	2025-09-03 18:47:24.596244+00
594f933e-a5f4-4693-877a-ba5ad1c1f39e	REBN	2025-02-03	[]	\N	2025-09-03 18:47:25.408855+00	2025-09-03 18:47:25.408855+00
fd78c302-ea57-48d1-af31-ab8d4a6ccd76	REBN	2025-02-07	[{"url": "https://finnhub.io/api/news?id=65bda1312d31902fe4ed0fd6115e0506d92f324fbd9eea7d76db93cec33ab21f", "source": "Yahoo", "summary": "Financing Provides Operating Liquidity and Positions Reborn Coffee for Expansive Growth, Flagship Openings, and Industry InnovationBREA, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (Nasdaq: REBN), a leader in the specialty coffee market, today announced has entered into a securities purchase agreement and a common stock purchase agreement for up to a total of $60 million in financing commitments with Arena Investors, LP (“Arena”) and Arena Business Solutions Global SPC II, Ltd.", "datetime": "2025-02-07T13:31:00.000Z", "headline": "Reborn Coffee Announces Financing Commitments of up to $60.0 Million", "sentiment": "positive"}]	positive	2025-09-03 18:47:26.660856+00	2025-09-03 18:47:26.660856+00
3df572e5-eb89-43db-bfb0-279bfb50d2ae	QNTM	2025-02-04	[{"url": "https://finnhub.io/api/news?id=e2613f638487e696e17ce83b65327a3520df4e3e0d1e9dad9dc1b90db2b1904f", "source": "Yahoo", "summary": "SAN JOSE, Calif., February 04, 2025--Quantum® Corporation (NASDAQ: QMCO) (\\"Quantum\\" or the \\"Company\\"), a leader in solutions for AI and unstructured data, today announced it will release financial results for its fiscal third quarter 2025 on Wednesday, February 12, 2025, after the markets close.", "datetime": "2025-02-04T13:00:00.000Z", "headline": "Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ba9dc503ad8d72f44fbe383ed26af80f4f3af9458bcfe541b9b016a868672394", "source": "Yahoo", "summary": "Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and HangoverTORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-bl", "datetime": "2025-02-04T12:03:00.000Z", "headline": "Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:27.136579+00	2025-09-03 18:47:27.136579+00
27af9f2e-bce8-4cba-bda2-1c7eac2f1b17	QNTM	2025-03-28	[{"url": "https://finnhub.io/api/news?id=9334826f12a2f741a3a5d0b9598484b2b75cba683f3f770c7ab401c86d4cab17", "source": "Yahoo", "summary": "Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets TORONTO, ONTARIO / ACCESS Newswire / March 28, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ...", "datetime": "2025-03-28T13:15:00.000Z", "headline": "Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=3799878c81cbac5e365e06c90113701719302605769aace442f8e48c2e588153", "source": "Yahoo", "summary": "TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company. Mr. Terry Lynch Mr. Lynch is widely known and respecte", "datetime": "2025-03-27T11:00:00.000Z", "headline": "Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors", "sentiment": "neutral"}]	positive	2025-09-03 18:47:28.090171+00	2025-09-03 18:47:28.090171+00
7ee0c21d-ce5e-4bfb-9195-cf6a153ec733	GWAV	2025-02-12	[{"url": "https://finnhub.io/api/news?id=360873b82af8890e94fe9c08d22942b320e167ab36604e9af1b290192e9e14cc", "source": "Yahoo", "summary": "Greenwave Technology Solutions, Inc. (Nasdaq: GWAV) (\\"Greenwave\\" or the \\"Company\\"), today announced it is preparing for significant demand increases for its 100% domestically-sourced scrap metal products, including steel, aluminum, copper, and zorba. Prices for domestic scrap metal have surged in February 2025 and are expected to go higher.", "datetime": "2025-02-11T16:00:00.000Z", "headline": "Greenwave Technology Solutions, Inc. Preparing for Massive Demand Influx Amid 25% Tariffs on Steel and Aluminum Without Exceptions or Exemptions", "sentiment": "positive"}]	positive	2025-09-03 18:47:31.544571+00	2025-09-03 18:47:31.544571+00
6951133f-2314-4e1a-887a-d64c853f4072	ACB	2025-02-05	[{"url": "https://finnhub.io/api/news?id=240f6514b371be9599638ed2aae6dcad2a0c6027f55ffaede4d9ab1338e92fd1", "source": "Yahoo", "summary": "International medical cannabis revenue grew 112%.", "datetime": "2025-02-05T19:42:52.000Z", "headline": "Aurora Cannabis Reports Record Revenue and Profit in Q3 Fiscal 2025", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=df0e1acb072b065107caf97041302ca010e1b062f14abfe86a53edc9968e592d", "source": "Yahoo", "summary": "ACB earnings call for the period ending December 31, 2024.", "datetime": "2025-02-05T19:15:17.000Z", "headline": "Aurora Cannabis (ACB) Q3 2025 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=68ca33ee6de23dfdfaeb8de3d59001a74ee098a1a2e95d10262265fc425bb128", "source": "Yahoo", "summary": "Aurora Cannabis (ACB) delivered earnings and revenue surprises of 50% and 9.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?", "datetime": "2025-02-05T13:50:03.000Z", "headline": "Aurora Cannabis Inc. (ACB) Surpasses Q3 Earnings and Revenue Estimates", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=39164d4b66ac68569fd9f9277302e4cd8508d6c8d7e958abf71338de3a155b2c", "source": "SeekingAlpha", "summary": "Aurora Cannabis Inc. (NASDAQ:ACB) Q3 2025 Earnings Conference Call February 5, 2025 8:00 AM ETCompany ParticipantsKevin Niland - Director of Strategic...", "datetime": "2025-02-05T12:23:55.000Z", "headline": "Aurora Cannabis Inc. (ACB) Q3 2025 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=14ee4e7903cc914538da19915123c61589cf45b8ac0b98139bdc6602edd613fa", "source": "SeekingAlpha", "summary": "The following slide deck was published by Aurora Cannabis Inc.", "datetime": "2025-02-05T11:14:15.000Z", "headline": "Aurora Cannabis Inc. 2025 Q3 - Results - Earnings Call Presentation", "sentiment": "neutral"}]	positive	2025-09-03 18:47:33.713888+00	2025-09-03 18:47:33.713888+00
3635ec4b-fca1-420e-aeb5-a0310d2088b4	71902K303	2025-02-06	[]	\N	2025-09-03 18:47:39.136067+00	2025-09-03 18:47:39.136067+00
a93af65d-d385-4da8-94e2-002a4e4dcf7a	KTTA	2025-02-05	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	positive	2025-09-03 18:47:32.32735+00	2025-09-03 18:47:32.32735+00
f68999bf-38d3-4e34-8269-cb68fd679916	LIPO	2025-02-11	[{"url": "https://finnhub.io/api/news?id=964bcaab94c0c973a42fd48a8f64b2a1e04749161a512d3cbbb4fe39e3589a33", "source": "Yahoo", "summary": "Firefly Neuroscience (AIFF) shares were up more than 170% in recent trading after the company said i", "datetime": "2025-02-11T18:34:07.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=16a0a2a94181f0de31e160a0402834d4accab79ab22bbd25abffe834ac08c35e", "source": "Yahoo", "summary": "Lipella Pharmaceuticals' (LIPO) shares jumped nearly 35% in recent Tuesday trading after the company", "datetime": "2025-02-11T18:10:01.000Z", "headline": "Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=0079ff882ecc21e6393b28014d7d3eaae7f77f3d954ec1b49c9252839b2a0216", "source": "Yahoo", "summary": "On Tuesday, Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (OLP). LP-310 demonstrated a strong safety profile, with no product-related serious adverse events (SAEs) or patient dropouts. The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks 1,", "datetime": "2025-02-11T15:52:36.000Z", "headline": "Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=96678b45f5e24e63fb23f5e2f96f185a7e769e17f79e03af6e6feff5cc59dc89", "source": "Yahoo", "summary": "LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) --", "datetime": "2025-02-11T10:46:00.000Z", "headline": "Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus", "sentiment": "positive"}]	positive	2025-09-03 18:47:36.376033+00	2025-09-03 18:47:36.376033+00
f16aa575-e21c-430b-940e-12b81e29da78	PTNT	2025-02-06	[]	\N	2025-09-03 18:47:36.917936+00	2025-09-03 18:47:36.917936+00
68ef4675-ae70-499d-9421-9c6f8e74d9a7	CJMB	2025-02-06	[{"url": "https://finnhub.io/api/news?id=4756f3bceb34f6bf1e27ee223aec73a196dcce96327ec5af6ed6c07d31a3a991", "source": "Yahoo", "summary": "SPRING BRANCH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the closing of its previously announced initial public offering (the “Offering”) of 1,280,000 shares (the “Shares”) of common stock (“Common Stock”) at an initial public offerin", "datetime": "2025-02-06T21:29:00.000Z", "headline": "Callan JMB Announces Closing of $5.12 Million Initial Public Offering", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:37.852563+00	2025-09-03 18:47:37.852563+00
bbb96cee-89c9-4ea3-8a6b-18294b7207c6	EQ	2025-02-06	[{"url": "https://finnhub.io/api/news?id=98ded5096b9dead40deb7a620cbe10ad7ab2b2c13b6de29399023f067e1bf3c3", "source": "Yahoo", "summary": "Itolizumab achieved a clinical remission rate of 23.3% in ulcerative colitis patients.", "datetime": "2025-02-06T21:18:49.000Z", "headline": "Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=af92eb458d193862fdb2653083b127e89c2cf2093405a6686edccfe8c3fce11c", "source": "Yahoo", "summary": "LA JOLLA, Calif., February 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC).", "datetime": "2025-02-06T13:00:00.000Z", "headline": "Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis", "sentiment": "positive"}]	positive	2025-09-03 18:47:38.165102+00	2025-09-03 18:47:38.165102+00
ecacf381-e07b-4c0a-a420-9d1581e71b51	PNBK	2025-02-10	[]	\N	2025-09-03 18:47:42.950986+00	2025-09-03 18:47:42.950986+00
c2e15d37-aab3-4de7-9282-2bf39a56c871	ACRV	2025-02-05	[{"url": "https://finnhub.io/api/news?id=a08790abad74390c7835ce5660f761a452d5f5ff2e4fe2c47d38f51d22c2a810", "source": "Yahoo", "summary": "We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to take a look at where Acrivon Therapeutics, Inc. (NASDAQ:ACRV) stands against other AI news and ratings investors are keeping their eye on. How AI Is Shaping Global Power and Innovation Josh […]", "datetime": "2025-02-05T20:45:31.000Z", "headline": "Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=3af5da94ee252a1ae6e25b37ee3051c93c97ee4d99a82eb3089279f754369f69", "source": "Yahoo", "summary": "The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with endometrial cancer and other tumor types Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient selection (p-value = 0.009) Drug-tailor", "datetime": "2025-02-05T13:00:00.000Z", "headline": "Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5cee45d540b006f65d6cee17b522c46c1c60dcdea5114d62fef4d93a9a04ae08", "source": "Finnhub", "summary": "By Chris Wack Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the...", "datetime": "2025-02-05T08:36:41.000Z", "headline": "Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification", "sentiment": "neutral"}]	positive	2025-09-03 18:47:34.776395+00	2025-09-03 18:47:34.776395+00
90d19de1-5b92-44c3-b82c-4804e55efb35	LIPO	2025-02-06	[{"url": "https://finnhub.io/api/news?id=f35a17dd18547671af7bcdadeb19952898e5d1e7ec009a014fa6d6a09f7f470b", "source": "Yahoo", "summary": "PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to provide tar", "datetime": "2025-02-06T11:00:00.000Z", "headline": "Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:35.468319+00	2025-09-03 18:47:35.468319+00
fd3e3865-7918-4f3b-ac9b-17c4c539189e	87978U108	2025-02-10	[]	\N	2025-09-03 18:47:44.571044+00	2025-09-03 18:47:44.571044+00
31ed92ba-8d53-4541-92ce-c0093c932aa2	BDRX	2025-02-10	[{"url": "https://finnhub.io/api/news?id=e5504cdbf4b7d3cfdd52375215e667f260bfcdbff1d2d8c184068d5926465c47", "source": "Yahoo", "summary": "February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and", "datetime": "2025-02-10T13:30:00.000Z", "headline": "Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:47.364697+00	2025-09-03 18:47:47.364697+00
2b96249f-c688-4e3c-9f2a-49286c27932d	BDRX	2025-02-12	[{"url": "https://finnhub.io/api/news?id=cc30cd99c35e016ef7340d00fde49bbf2315ee92c5f986684133392bad4703b2", "source": "Yahoo", "summary": "Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration ...", "datetime": "2025-02-12T12:30:00.000Z", "headline": "Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status", "sentiment": "positive"}]	positive	2025-09-03 18:47:48.009442+00	2025-09-03 18:47:48.009442+00
bbfbc17a-301f-468b-99e7-8f7c4809818b	SRXH	2025-02-19	[]	\N	2025-09-03 18:47:52.058439+00	2025-09-03 18:47:52.058439+00
0fdb1681-28b1-49a9-830f-3cd168c42c51	CAPS	2025-03-17	[]	\N	2025-09-03 18:47:54.220331+00	2025-09-03 18:47:54.220331+00
29070750-7005-459d-9096-a8d9e3f9d958	RDHL	2025-03-18	[{"url": "https://finnhub.io/api/news?id=2918b67360b5cd2bb7825d08c3b9656e03298d5f22b7a5724898ab7f83617203", "source": "Yahoo", "summary": "RedHill Biopharma Ltd. (NASDAQ: RDHL) (\\"RedHill\\" or the \\"Company\\"), a specialty biopharmaceutical company, today announced its plan to submit a UK Marketing Authorisation Application (MAA) for Talicia for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP), a fast-track regulatory process for UK drug approvals based on a recognized reference approval. Utilizing the U.S. Food and Dr", "datetime": "2025-03-18T11:00:00.000Z", "headline": "RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:58.12476+00	2025-09-03 18:47:58.12476+00
c1e8e605-4456-41ea-a715-6468f64648cc	INDP	2025-03-18	[{"url": "https://finnhub.io/api/news?id=eba570c8fc2da7c9c824c9259684691ecb6548995401b2872eacfa4d5349c491", "source": "Yahoo", "summary": "New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumorsNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhib", "datetime": "2025-03-18T12:00:00.000Z", "headline": "Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab", "sentiment": "positive"}]	positive	2025-09-03 18:48:06.092757+00	2025-09-03 18:48:06.092757+00
b83f785e-c831-4b06-a576-8add8872a54e	MLGO	2025-04-01	[]	\N	2025-09-03 18:48:17.490301+00	2025-09-03 18:48:17.490301+00
5793dbe9-8d5b-4f69-8ac2-3dac8a396e83	TNON	2025-03-24	[{"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:20.651741+00	2025-09-03 18:48:20.651741+00
b0cd961c-ae1f-4244-9ec1-f82eac32596d	CSAI	2025-04-01	[{"url": "https://finnhub.io/api/news?id=1c305e3d9070bd3da5013665aae1d807284abdc536599e6d72338f7df32caa92", "source": "Yahoo", "summary": "Broad-Based Sales Growth: New Customers Up 30%, Subscriptions Up 48%, Remote Guarding Up 404%, Hardware Sales Up 250% AI Surveillance Platform Proves Effective, Scalable, and Regulation-Ready PALO ALTO, CA, March 31, 2025 (GLOBE NEWSWIRE) -- Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a cloud-based video surveillance platform with artificial intelligence (“AI”) and computer vision analytics, today provided a business update and reported financial", "datetime": "2025-03-31T20:30:00.000Z", "headline": "Cloudastructure Reports 2024 Year-End Results: Revenue Up 124% Year-over-Year; Gross Profit Turns Positive", "sentiment": "positive"}]	positive	2025-09-03 18:48:50.341993+00	2025-09-03 18:48:50.341993+00
ab1bd5b4-9119-43b9-9bae-ae6503a0b95b	CLSD	2025-02-10	[{"url": "https://finnhub.io/api/news?id=d36b9597fb65a841996c31e0bac4c32967e00a80f76d8119a9d53192b5c67603", "source": "Yahoo", "summary": "- BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design -ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and", "datetime": "2025-02-10T12:05:00.000Z", "headline": "Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:43.898926+00	2025-09-03 18:47:43.898926+00
c0b35c45-4417-4a0b-aa3b-f538c318c54a	IINN	2025-02-11	[{"url": "https://finnhub.io/api/news?id=5006e31038ef0336f4897e8950743333093a4345429716ae96566236f41755ac", "source": "Yahoo", "summary": "Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (\\"Inspira\\" or the \\"Company\\"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections.", "datetime": "2025-02-11T12:00:00.000Z", "headline": "Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=53ba033a97aa2faf0fe77e3fe9c9e9057151262de866f1c95b5fe8afba714b2e", "source": "Yahoo", "summary": "On Tuesday, Inspira Technologies OXY B.H.N. (NASDAQ:IINN) announced positive initial results from its previously reported collaboration with Ennocure MedTech to develop a novel bio-electronic treatment for preventing bloodstream infections. In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over 24 hours. The technology, which uses physical electric stimulation rather than chemic", "datetime": "2025-02-11T11:45:42.000Z", "headline": "EXCLUSIVE: Inspira and Ennocure's Bio-Electronic Tech Uses Electric Stimulation to Help Prevent IV-Related Infections", "sentiment": "positive"}]	positive	2025-09-03 18:47:49.861075+00	2025-09-03 18:47:49.861075+00
ba1ae4d4-1f14-4819-8385-c23dbd5b5394	PEVM	2025-02-13	[]	\N	2025-09-03 18:47:50.863636+00	2025-09-03 18:47:50.863636+00
0834dd00-618c-4c8d-b8b8-88fdbaad12cb	G14492121	2025-03-14	[]	\N	2025-09-03 18:47:52.769949+00	2025-09-03 18:47:52.769949+00
44d9fb02-9dc4-47a9-8f02-5a221b7e145c	00941Q203	2025-03-17	[]	\N	2025-09-03 18:47:54.637885+00	2025-09-03 18:47:54.637885+00
91dff839-f938-460c-bc48-cde7cd8c7115	HYPR	2025-03-17	[{"url": "https://finnhub.io/api/news?id=4515376e525f46df259efc45fcdadc081fceac8cfe28504f42be3531e38f2cc1", "source": "Yahoo", "summary": "GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. “I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on", "datetime": "2025-03-17T20:05:00.000Z", "headline": "Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=71e4c69c8073282280f091c5d2a391a686c573a56f9e5c5232b587b5bf73ea82", "source": "SeekingAlpha", "summary": "Hyperfine, Inc. (NASDAQ:HYPR) Q4 2024 Results Conference Call March 17, 2025 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz -...", "datetime": "2025-03-17T19:43:03.000Z", "headline": "Hyperfine, Inc. (HYPR) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=fb8457042d6c01dfcffa711cfe0dbd261b9a0437daae04314970025f6d1ff181", "source": "Yahoo", "summary": "GUILFORD, Conn., March 17, 2025--Hyperfine and NVIDIA collaboration aims to make portable MRI faster, smarter, and more accessible worldwide.", "datetime": "2025-03-17T13:00:00.000Z", "headline": "Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation", "sentiment": "positive"}]	positive	2025-09-03 18:47:55.284409+00	2025-09-03 18:47:55.284409+00
3b8891c6-7912-4890-8641-4670fc9ae149	SCNX	2025-03-18	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	positive	2025-09-03 18:48:00.833747+00	2025-09-03 18:48:00.833747+00
81a47508-4210-4960-b031-6631141a9ad7	SQQQ	2025-04-07	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	negative	2025-09-03 18:48:57.91521+00	2025-09-03 18:48:57.91521+00
8f384dbb-4322-4a90-8f94-34d80ec5aa3b	GRCE	2025-02-10	[{"url": "https://finnhub.io/api/news?id=53217ca2f5742f77ae868a2a4b8ddca1a62a14489b994fc670cee19f6c143b42", "source": "Yahoo", "summary": "Grace Therapeutics (GRCE) rose nearly 8% in recent Monday trading after it said it entered into secu", "datetime": "2025-02-10T18:44:08.000Z", "headline": "Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=251611d572bb994eabef6fc5fe7c2c403940117dc7498a2a0d3285efcd84818a", "source": "Yahoo", "summary": "On Monday, Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH). aSAH is bleeding over the brain’s surface in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. The study met its primary endpoint and provides evidence of clinical benefit compared to orally administere", "datetime": "2025-02-10T17:05:59.000Z", "headline": "Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=54e534aba4b37bef1b4867191df9fd3b73bf4229ff3badcaf1aed8b91f9e60ee", "source": "Yahoo", "summary": "Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in potential warrant exercise proceeds for an aggregate of up to approximately $30 million in potential total gross proceeds PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therap", "datetime": "2025-02-10T13:05:00.000Z", "headline": "Grace Therapeutics Announces Private Placement Financing of up to $30 Million", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f83b017c51f0c1bb5f53f42fdfb2963fabe0c86565b1ee665f337ae636308989", "source": "Yahoo", "summary": "Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion t", "datetime": "2025-02-10T13:01:00.000Z", "headline": "Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH", "sentiment": "neutral"}]	positive	2025-09-03 18:47:46.147163+00	2025-09-03 18:47:46.147163+00
a0a00326-c65d-4faf-8005-88b25c4499e2	NAKA	2025-02-13	[]	\N	2025-09-03 18:47:51.430042+00	2025-09-03 18:47:51.430042+00
9b4466b0-2c60-4138-bf61-31fc9886bd5b	MGRM	2025-03-17	[{"url": "https://finnhub.io/api/news?id=0e586474c64d48762e820521c7cc5e2bf04a62baeb5d843942d2956b9b6917f4", "source": "Yahoo", "summary": "Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its ...", "datetime": "2025-03-17T11:00:00.000Z", "headline": "Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System", "sentiment": "neutral"}]	neutral	2025-09-03 18:47:56.173367+00	2025-09-03 18:47:56.173367+00
6ca9d1a0-e133-4e9f-82d6-c3e4a7cdf4d7	ARQT	2025-03-17	[{"url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96", "source": "SeekingAlpha", "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.", "datetime": "2025-03-17T22:58:23.000Z", "headline": "Why Organon Is A Top Pick For Income Investors", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=e7540a7d1c7f21e68df2ef163e5026b02cf0a66a473fe1cde09a540729d800f6", "source": "Yahoo", "summary": "Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, announced today that Health Canada has approved PrZORYVE® (roflumilast cream 0.15%), for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. The approval of this once-daily topical cream formulation of roflumilast marks a significant milestone, providing Canadian patients, caregivers and healthcare providers with a novel, steroid", "datetime": "2025-03-17T11:00:00.000Z", "headline": "ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age", "sentiment": "positive"}]	positive	2025-09-03 18:47:57.574239+00	2025-09-03 18:47:57.574239+00
d05a7b3b-e01b-4a92-a4a8-8984fc743214	ADTX	2025-03-18	[{"url": "https://finnhub.io/api/news?id=f6393d9fd646e3f36925909a988d8d67f0d3e01e60de59dd8228b1e53d961241", "source": "Yahoo", "summary": "Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the", "datetime": "2025-03-18T11:22:00.000Z", "headline": "Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=42b92a2a1b2c83725d57a0eb037509bf9f934b21388806c4842833c110dd196e", "source": "Yahoo", "summary": "MOUNTAIN VIEW, Calif., March 17, 2025--Aditxt, Inc. (NASDAQ: ADTX) (\\"Aditxt\\" or the \\"Company\\"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2", "datetime": "2025-03-17T12:15:00.000Z", "headline": "Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025", "sentiment": "positive"}]	positive	2025-09-03 18:47:59.598821+00	2025-09-03 18:47:59.598821+00
816e184d-9b6d-4214-a2a8-49b52b4def0f	BLNE	2025-03-18	[{"url": "https://finnhub.io/api/news?id=d67550b3d4b9eb51ac6e554349b7e54a23aa125bc8825062dee22486407d1987", "source": "Yahoo", "summary": "Any Insiders Who Purchase Stock Must Hold For at Least 6 Months Providence, Rhode Island--(Newsfile Corp. - March 18, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE) today announced that its Board of Directors has approved a limited waiver of the company's insider trading policy, permitting board members and officers to purchase company stock. This decision comes in response to requests from at least two directors who believe the stock is currently undervalued.Under the terms of ...", "datetime": "2025-03-18T21:50:00.000Z", "headline": "Beeline Board of Directors Approves Waiver of Insider Trading Policy", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=aeb79658fac56532257a4d2c908905428b6bc585d62559e85a7637c2262c88b8", "source": "Yahoo", "summary": "Bob 2.0: The Next Evolution in AI-Powered Mortgage Sales Providence, Rhode Island--(Newsfile Corp. - March 18, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), a leader in AI-driven mortgage technology, has launched Bob 2.0, the next evolution of its AI-powered sales agent, driving a 6X increase in qualified leads over human agents while running 24/7 at minimal cost.\\"Bob changes the game for scaling front-end mortgage operations,\\" said Nick Liuzza, CEO of Beeline. \\"With Bob we're able ...", "datetime": "2025-03-18T13:00:00.000Z", "headline": "Beeline's AI Sales Agent 'Bob 2.0' Delivers 6X More Leads than Human Chat - Revolutionizing Mortgage Sales at Near Zero Cost", "sentiment": "positive"}]	positive	2025-09-03 18:48:02.641924+00	2025-09-03 18:48:02.641924+00
d04927d5-7286-414a-9222-c4af03e45093	USAR	2025-04-04	[]	\N	2025-09-03 18:49:14.797719+00	2025-09-03 18:49:14.797719+00
72b5e202-7748-46dc-ae45-dde9b125e582	BLNE	2025-03-26	[{"url": "https://finnhub.io/api/news?id=d3155706ee7117688f1940006c5ebf8f2e1ee00a753a3c11d9b035e0942acfb8", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 26, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-26T16:42:00.000Z", "headline": "Beeline CEO Invests Another $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c9c2575420a71e98eb3b106ce9f32f0317fc850400bf857287013e9e3f58df84", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 25, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-25T12:30:00.000Z", "headline": "Beeline CEO Invests an Additional $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:03.355912+00	2025-09-03 18:48:03.355912+00
195b5d39-5863-489a-9173-ebe9cd71a2fc	LAES	2025-03-18	[{"url": "https://finnhub.io/api/news?id=47e1694a65b7fdc24016645f6e6a8774ae6b3ce2dc36db916b8ca2579774e3c8", "source": "Yahoo", "summary": "SEALSQ (NasdaqCM:LAES) experienced a 45% price surge last week, a period marked by significant corporate developments. The launch of a $20 million SEALQUANTUM.com investment underscores the company's commitment to advancing quantum computing and AI. Additionally, the establishment of SEALSQ Singapore Ltd aims to bolster its semiconductor capabilities in Asia. These moves align with broader trends in technological advancement, drawing investor interest despite overall market declines. While...", "datetime": "2025-03-18T18:14:38.000Z", "headline": "SEALSQ (NasdaqCM:LAES) Surges 45% With Launch Of US$20 Million SEALQUANTUM.com Investment", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=39725fa94d0a1005035cb75e913f48e650114c631d56a70513696fac8f8d69f4", "source": "Yahoo", "summary": "Geneva, Switzerland, March 18, 2025 (GLOBE NEWSWIRE) -- Technology Powered by WISeKey Root of Trust Installed in Over 6 Billion Devices SEALSQ NASDAQ QUANTUM DAYhttps://youtu.be/V1mikulV3LA?si=gOMpL4TKr4VTS3TR SEALSQ Corp (NASDAQ: LAES) (\\"SEALSQ\\" or \\"Company\\"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that 1.75 billion devices worldwide have been secured by its microprocessors since the Compa", "datetime": "2025-03-18T14:00:00.000Z", "headline": "SEALSQ Achieves a New Milestone: Secures 1.75 Billion Devices Worldwide with Hybrid Cryptographic Model, as Demand for Post-Quantum Chips Accelerates", "sentiment": "positive"}]	positive	2025-09-03 18:48:06.675435+00	2025-09-03 18:48:06.675435+00
d501e87a-4e46-4ccd-946c-87e0b0dd95aa	89357L402	2025-03-21	[]	\N	2025-09-03 18:48:07.001482+00	2025-09-03 18:48:07.001482+00
8b1fd693-f615-444e-9257-f5136b02ed32	MLGO	2025-03-24	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:13.39605+00	2025-09-03 18:48:13.39605+00
da6fc1a3-bf4d-44c6-b89a-e2f2dfe4dec1	MLGO	2025-03-26	[{"url": "https://finnhub.io/api/news?id=93ca8e0620df899e4a210a0c4ebb6764c83627cc05200d09ae2d9359f1c4da21", "source": "SeekingAlpha", "summary": "Discover why MicroAlgo Inc.'s stock rally lacks fundamentals, driven by debt repayment tactics. Explore risks and projected drop to $3.50. Click for my MLGO update.", "datetime": "2025-03-26T12:49:01.000Z", "headline": "MicroAlgo: Rally Has No Legs", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=19607bf1608d2fc202f6712f589f2c15c20f620afc9905bc89f87596f2ef7fa4", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where MicroAlgo Inc. (NASDAQ:MLGO) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the green […]", "datetime": "2025-03-25T12:49:15.000Z", "headline": "Why MicroAlgo (MLGO) Skyrocketed on Monday?", "sentiment": "positive"}]	positive	2025-09-03 18:48:15.999726+00	2025-09-03 18:48:15.999726+00
3c30454f-6161-4dba-975b-ba0065285de9	MLGO	2025-03-28	[{"url": "https://finnhub.io/api/news?id=cc03e1992fc827281bf6a106ede84b21a6fab1d58a0edfced68e843eceb5a3c7", "source": "Yahoo", "summary": "WiMi Hologram Cloud (WiMi) announced it has increased its stake in MicroAlgo (MLGO) to 67.65% and committed to a ten-year lock-up period for all currently owned MicroAlgo shares. As of March 27, WIMI Hologram Cloud holds 40,000 Class A ordinary shares, 1,810,658 Class A ordinary shares (restricted), and 44,878,261 Class B ordinary shares of MicroAlgo, representing a total equity stake of 67.65% of MicroAlgo’s total shares outstanding. WIMI has no plans to sell or otherwise dispose of any Microal", "datetime": "2025-03-28T13:21:12.000Z", "headline": "WiMi Hologram Cloud raises stake in MicroAlgo to 67.65%", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=3b4ef94eebd23444c12abf9dca1ae3438f9c8650ffc021e80ca125a4830eaea3", "source": "Yahoo", "summary": "We recently published a list of 12 Popular Penny Stocks on Robinhood to Watch. In this article, we are going to take a look at where MicroAlgo Inc. (NASDAQ:MLGO) stands against other popular penny stocks on Robinhood to watch. The stock market is navigating a complex landscape influenced by geopolitical tensions, trade policies, and shifting […]", "datetime": "2025-03-27T14:10:04.000Z", "headline": "Is MicroAlgo Inc. (MLGO) the Popular Penny Stock on Robinhood to Watch?", "sentiment": "positive"}]	positive	2025-09-03 18:48:16.555577+00	2025-09-03 18:48:16.555577+00
0cb1a385-9d80-488b-b63f-d94bbf3dbf06	ELAB	2025-03-21	[{"url": "https://finnhub.io/api/news?id=3aef48fa16edc60c5a2e3c64d9749026d538d026a64067ed4eed21b4f55fefb6", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company’s common stock, par value $0.0001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market und", "datetime": "2025-03-21T18:41:00.000Z", "headline": "PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=7b013e1a4688d9084c056076b9e18efdaa7c21274318bf685ee9c256c6bdc9e9", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. Details of these transactions are available in the Company’s Form 8-K filings on www.sec.gov. The Company will consider repurchasing additional shares from other investors who wish to sell, subject to market conditions and other considerations. Share", "datetime": "2025-03-21T12:00:00.000Z", "headline": "PMGC Holdings Announces Share Repurchases from Existing Shareholders", "sentiment": "neutral"}]	negative	2025-09-03 18:48:07.486541+00	2025-09-03 18:48:07.486541+00
8a4ec30b-d1a7-4d3a-8282-e58208536c1a	GLTO	2025-03-21	[]	\N	2025-09-03 18:48:08.874688+00	2025-09-03 18:48:08.874688+00
3e7d48e8-da98-473f-8e6d-247845df96b1	GLTO	2025-03-24	[]	\N	2025-09-03 18:48:11.190544+00	2025-09-03 18:48:11.190544+00
5b3076b7-9896-4496-9b9b-b93f43f07924	IBO	2025-03-21	[{"url": "https://finnhub.io/api/news?id=0902a7f5bb78284122f61fd30561a0eba5779ff83029c4ab1b17857244a9e4d0", "source": "Yahoo", "summary": "HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO)", "datetime": "2025-03-21T18:38:00.000Z", "headline": "Impact Biomedical Inc. Announcement Stock Activity/Pricing", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=39f8399fcef159c9ae4b619c65d83ffeba22571e7fd939769a532ae875bce39a", "source": "Yahoo", "summary": "We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Impact Biomedical Inc. (NYSEAMERICAN:IBO) stands against other micro-, small-cap firms that dominate Thursday’s gains. The stock market edged lower on Thursday, erasing gains from the previous trading day that was […]", "datetime": "2025-03-21T10:34:43.000Z", "headline": "Why Impact Biomedical Inc. (IBO) Surged On Thursday?", "sentiment": "positive"}]	positive	2025-09-03 18:48:12.334414+00	2025-09-03 18:48:12.334414+00
1cf9787e-c450-482e-b5b5-67a4b2b2881f	PROP	2025-03-26	[{"url": "https://finnhub.io/api/news?id=a4a0591f541a0221be8b0572b44794b39b69664ef8e5d53eba312f7c3c59c8ae", "source": "Yahoo", "summary": "Pro-Forma Reserve Data Pro-Forma Reserve Data Reconciliation of Non-GAAP Measure Reconciliation of Non-GAAP Measure Expands footprint in DJ Basin to ~55,000 net acres and inventory life to ~10 years Increases average daily production by ~25,700 net BOEPD Immediately accretive and maintains strong balance sheet Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company,” “Prairie,” “we,” “our” or “us”), today announced the successful closing of its previous", "datetime": "2025-03-26T22:45:00.000Z", "headline": "Prairie Operating Co. Completes Transformative Acquisition from Bayswater", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=83ba72412d03dcc5995e1bd6e0a5192bdb6c6e362927bc1eb9b90d7affe4052c", "source": "Yahoo", "summary": "HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Prairie Operating Co. (“Prairie,” the “Company,” “we,” or “our”) (Nasdaq: PROP) announced today the pricing of an underwritten public offering of $38.5 million (the “Common Stock Offering”) of shares of its common stock, par value $0.01 (“Common Stock”) at a price to the public of $4.50 per share. The underwriters have a 30-day option to purchase up to an aggregate value of $5.8 million of additional shares of Common Stock. Net proceeds to Prairie from", "datetime": "2025-03-25T02:35:00.000Z", "headline": "Prairie Operating Co. Announces Pricing of Common Stock Offering", "sentiment": "neutral"}]	positive	2025-09-03 18:48:34.217915+00	2025-09-03 18:48:34.217915+00
cb75ed23-f92e-4140-b350-33baee349087	THAR	2025-03-24	[{"url": "https://finnhub.io/api/news?id=e10ba4b5191fb575a4d18adca8967bd4d0b25212c373014da1976612152574be", "source": "Yahoo", "summary": "BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (\\"Tharimmune\\" or the \\"Company\\"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...", "datetime": "2025-03-24T12:00:00.000Z", "headline": "Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:20.117581+00	2025-09-03 18:48:20.117581+00
7bf1bece-b54e-4812-90d0-12fe41f15fae	TNON	2025-03-25	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:22.471619+00	2025-09-03 18:48:22.471619+00
1b3fb416-b749-44c4-8d83-90749615cd76	OSRH	2025-04-03	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	positive	2025-09-03 18:48:32.208716+00	2025-09-03 18:48:32.208716+00
93af534c-cfd5-4d25-86e4-78d7c7bb2936	WKSP	2025-03-27	[{"url": "https://finnhub.io/api/news?id=947ad62ab78197dae2ad761ed74cc9ef482fc529b0bb33bd60ac9094ffb88725", "source": "SeekingAlpha", "summary": "Worksport Ltd. (NASDAQ:WKSP) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ETCompany ParticipantsSteven Rossi - CEOMichael Johnston - CFOFaran Ali...", "datetime": "2025-03-27T22:03:42.000Z", "headline": "Worksport Ltd. (WKSP) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ec70e42aa4b83dfa2b3a5762cf25d356a87b465b326401dddef7171eea3f9fae", "source": "Yahoo", "summary": "Company Outlines Strong Momentum in Margins, Revenue, and Business Growth Entering 2025 West Seneca, New York--(Newsfile Corp. - March 27, 2025) - Worksport Ltd. (NASDAQ: WKSP) (\\"Worksport\\" or the \\"Company\\"), a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, today announced financial results and significant operational achievements for fiscal year 2024. Marking a transformational year with record reve", "datetime": "2025-03-27T11:46:00.000Z", "headline": "Worksport Ltd. Reports Fiscal Year 2024 Results, Achieves 455% Year-Over-Year Revenue Growth", "sentiment": "positive"}]	positive	2025-09-03 18:48:35.087388+00	2025-09-03 18:48:35.087388+00
8e75c3e6-15ec-4c92-9a50-b5c2d6ffdf92	DRMA	2025-03-27	[{"url": "https://finnhub.io/api/news?id=dc12715f203cb808edbfb01a7515a88d4a93255326160a73a983fe696729ca80", "source": "Yahoo", "summary": "Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) (\\"Dermata\\" or the \\"Company\\"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events", "datetime": "2025-03-27T12:00:00.000Z", "headline": "BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:35.98937+00	2025-09-03 18:48:35.98937+00
2fc75ee1-c6ed-4b02-b87c-5eaff1ef59a8	BCDA	2025-03-31	[{"url": "https://finnhub.io/api/news?id=dfc056157315d933f70980cdca71714042ac559904fbdff5255d838b9583a978", "source": "SeekingAlpha", "summary": "BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter Altman -...", "datetime": "2025-03-31T23:30:56.000Z", "headline": "BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7f199eb721b316b4dfe8d59453c86b7935fde655197942e4b4d8454ccffac457", "source": "Yahoo", "summary": "SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register fo", "datetime": "2025-03-31T17:39:00.000Z", "headline": "BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=9740c76341b4c831b7267673738310ce0ba2bc4be2b4fff58098e51749e6d165", "source": "Yahoo", "summary": "Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell TherapyPatient improvements through two years suggest single dos", "datetime": "2025-03-31T12:00:00.000Z", "headline": "Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years", "sentiment": "positive"}]	positive	2025-09-03 18:48:41.581845+00	2025-09-03 18:48:41.581845+00
427b7e2a-dde8-4dd0-9252-6f7d7b14d8de	ICCT	2025-04-01	[]	\N	2025-09-03 18:48:42.884694+00	2025-09-03 18:48:42.884694+00
cf6ed349-1103-40c5-a02c-fd841264d561	LPTX	2025-03-26	[{"url": "https://finnhub.io/api/news?id=d77a774ea29a7677409eab718e629ac5c4de250e2cc83799f23fd0dfca4a0ffd", "source": "Yahoo", "summary": "Leap Therapeutics, Inc. (NASDAQ:LPTX) presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm). The trial enrolled patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The updated analysis shared on Wednesday includes the overall r", "datetime": "2025-03-26T17:29:11.000Z", "headline": "Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=b7538ee6822a1a11f04f904db759e723e588f458830c99ee5645edbb282f0963", "source": "Yahoo", "summary": "Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that s", "datetime": "2025-03-26T12:31:51.000Z", "headline": "Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ec276ebf79d7c3a3a4daefc53fb2457cf836847965ff8b4d27008e9111b895f9", "source": "Yahoo", "summary": "Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.", "datetime": "2025-03-26T11:05:00.000Z", "headline": "Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f7bcb5f2d3877d7a3a20e4e9fa7e6009a3523054c52668476272d74c18af64bc", "source": "Yahoo", "summary": "Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, global study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal", "datetime": "2025-03-26T11:00:00.000Z", "headline": "Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study", "sentiment": "positive"}]	positive	2025-09-03 18:48:26.100089+00	2025-09-03 18:48:26.100089+00
396e1828-ed00-44a0-adc9-f8e2fe2c0ee8	OSRH	2025-03-26	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	positive	2025-09-03 18:48:26.99672+00	2025-09-03 18:48:26.99672+00
4a90e981-3ac4-42f8-ad7f-486950118dd3	G0447T100	2025-03-27	[]	\N	2025-09-03 18:48:36.377858+00	2025-09-03 18:48:36.377858+00
23a2f7dd-3ea0-45f6-9637-f1d32955602f	CTOR	2025-03-31	[]	\N	2025-09-03 18:48:40.798237+00	2025-09-03 18:48:40.798237+00
cbe99eaa-fe0b-410b-b059-ed0fa641ab7b	NWTG	2025-03-31	[{"url": "https://finnhub.io/api/news?id=79163191a40436280aca77950677bea6b2a0f28f8a0dfb8b3b4dff1a61df9316", "source": "Yahoo", "summary": "CAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (Nasdaq: NWTG), a developer of performance-focused golf equipment, today announced it will host an earnings call to discuss its fourth quarter and full-year 2024 financial results on Monday, March 31, 2025 at 4:30PM ET. Earnings Call Details• Date: March 31, 2025• Time: 4:30 PM ET• Participant Listening Options: Participant Listening: 1-877-407-0779 or 1 201-389-0914Callme™: https://callme.viavid.com/viavid/?call", "datetime": "2025-03-31T18:05:00.000Z", "headline": "Newton Golf Company to Host Fourth Quarter and Full-Year 2024 Earnings Call on March 31, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bb0deecca1f87093052f92898e9bab0c709e3193bba3ef9b8057b3f5f127a631", "source": "Yahoo", "summary": "Report includes tenfold revenue growth and significant gross margin expansionCAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (Nasdaq: NWTG) (“Newton Golf” or the “Company”), a leader in premium golf equipment innovation, today announces financial results for the fourth quarter and full year ended Dec. 31, 2024. The Company delivered record revenue growth, strong margin expansion, and continued operational momentum, supported by strategic product launches, inte", "datetime": "2025-03-31T11:00:00.000Z", "headline": "Newton Golf Company Announces Fourth Quarter and Full Year 2024 Financial Results", "sentiment": "positive"}]	positive	2025-09-03 18:48:41.126525+00	2025-09-03 18:48:41.126525+00
39648f82-fb8a-4e96-adfb-6f0dcd617d05	CORT	2025-03-31	[{"url": "https://finnhub.io/api/news?id=1de1314ae942b362cadb9a69cc55dd3edfebcdeee9bdf1ca03a85dbe0dae47a5", "source": "Yahoo", "summary": "US benchmark equity indexes are on track to close mixed on Monday, as markets get ready for more tar", "datetime": "2025-03-31T19:50:42.000Z", "headline": "Equity Markets Mixed Ahead of Tariff Announcements", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=eb0fa99f6b53f82b141706719c880d2a56cc2419566809d3c5fd7a8b5ddfafb8", "source": "Yahoo", "summary": "Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).", "datetime": "2025-03-31T18:48:45.000Z", "headline": "Why Is Corcept (CORT) Stock Soaring Today", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=06e177117db570d6d58941d7a02bbf5c45cf4da59bf7df0a1e6982c002d71606", "source": "Yahoo", "summary": "Corcept Therapeutics (NasdaqCM:CORT) recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for platinum-resistant ovarian cancer. This announcement, emphasizing a significant improvement in progression-free and overall survival, aligns with the company’s 8% share price uptick over the last quarter. Despite broader market challenges and a slide in major indices like the S&P 500 and Nasdaq, Corcept’s...", "datetime": "2025-03-31T18:39:01.000Z", "headline": "Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5a69c2ec12e45ff16f1991de6cff7fce00f0bf9c0a57f65974d650755842e607", "source": "Yahoo", "summary": "Josh Lipton takes a closer look at the top stories on Wall Street on today's Market Minute: NewsMax (NMAX) stock skyrockets after going public, Celsius Holdings (CELH) pops on a Truist analyst upgrade, and Corcept Therapeutics (CORT) climbs on positive drug trial results.Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.", "datetime": "2025-03-31T17:20:39.000Z", "headline": "NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=41e545936b2d448c6d025af9d81cb969a6e898e02379823870ae787b99832a8d", "source": "Yahoo", "summary": "Here are some stocks on the move for Monday, March 31. Yum Brands (YUM) is searching for a new CEO as current head David Gibbs plans to retire in early 2026, after 36 years with the company. Corcept Therapeutics (CORT) shares are rising after a successful trial for its ovarian cancer drug. Shares of Hut 8 (HUT) are on the move after announcing a new venture with the Trump family to launch a bitcoin mining venture. To watch more expert insights and analysis on the latest market action, check out more Wealth here.", "datetime": "2025-03-31T15:51:17.000Z", "headline": "Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21e142fb339f93299400de8d6b6c678b21870e2e58f47f25a49f02544aa2a06b", "source": "Finnhub", "summary": "Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The company's...", "datetime": "2025-03-31T13:41:03.000Z", "headline": "Corcept's ovarian cancer drug cuts disease progression in study, shares jump", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=2e2fce8effdf56bce168eedb2b9fd3039695b0948a7cf0a80f606e9bf7c2badf", "source": "Yahoo", "summary": "Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to tre", "datetime": "2025-03-31T12:38:57.000Z", "headline": "Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bd0256efb4c2d703b28306c7bc33e6e1b82bdfc7a0e22441169960d576ec4fdb", "source": "Yahoo", "summary": "REDWOOD CITY, Calif., March 31, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progressi", "datetime": "2025-03-31T12:00:00.000Z", "headline": "Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer", "sentiment": "positive"}]	positive	2025-09-03 18:48:42.551652+00	2025-09-03 18:48:42.551652+00
ceb9a041-c1ec-43fc-abcb-8beceab1f4e8	ICCT	2025-04-03	[]	\N	2025-09-03 18:48:43.465513+00	2025-09-03 18:48:43.465513+00
897c365b-ec10-422d-91ef-d81aa9006dd6	ICCT	2025-04-07	[]	\N	2025-09-03 18:48:46.173424+00	2025-09-03 18:48:46.173424+00
bc6485c6-eea8-4367-91d7-b4dd01bd67ef	CMPX	2025-04-01	[{"url": "https://finnhub.io/api/news?id=fc2fac104b7e4481c2d20564b8202667db3df00699d7f313d5b431796600a096", "source": "Yahoo", "summary": "Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.The", "datetime": "2025-04-01T11:00:00.000Z", "headline": "Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=59e0fdd339dd4de1204aca64d1054bb349887484f8d25fec6fdde5ba876d4fcb", "source": "Yahoo", "summary": "Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecifi", "datetime": "2025-03-31T20:05:00.000Z", "headline": "Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:47.275756+00	2025-09-03 18:48:47.275756+00
0d9b599b-af71-437b-9c0a-e7c9921e3d46	76090R309	2025-04-01	[]	\N	2025-09-03 18:48:47.82614+00	2025-09-03 18:48:47.82614+00
02db0c25-4fdc-475b-a246-2648e8f98450	76090R309	2025-04-02	[]	\N	2025-09-03 18:48:48.485538+00	2025-09-03 18:48:48.485538+00
9e7afdb4-3e14-4961-8f7b-d5a5aa142750	NMAX	2025-04-01	[{"url": "https://finnhub.io/api/news?id=024740b04506c7e924c4ab06d1de663f0638da4feb9508ff8039ac1cb0680b1c", "source": "Yahoo", "summary": "Newsmax's (NMAX) stock skyrocketed an incredible 735% following its initial public offering (IPO), with founder Christopher Ruddy's stake now worth $8.4 billion. Market Domination Overtime host Josh Lipton and Barron associate editor Al Root highlight the wealth generated by this spike while noting that analysts advise against chasing these volatile moves. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.", "datetime": "2025-04-01T20:42:27.000Z", "headline": "Newsmax stock continues to skyrocket after IPO", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=9e5b391fd534e001329a62e6f0ef7c14278c2a454d034b4482029994ffd3722b", "source": "SeekingAlpha", "summary": "Newsmax stock soared 1,236%, but overvaluation, net losses, and litigation risks make it a high-risk investment.", "datetime": "2025-04-01T16:57:37.000Z", "headline": "Newsmax Is Significantly Overvalued And Deserves To Plummet", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=26ea3998f243c700240dbc79735342d3ead9c5f4a9e38b384221c16254256bd0", "source": "Yahoo", "summary": "On today's Market Minute, Julie Hyman takes a closer look at the trending stories on Wall Street, including NewsMax (NMAX) extending its post–initial public offering (IPO) gains, Jefferies downgrading airline stocks Delta (DAL), American Airlines (AAL), and Southwest (LUV), and rising sales for General Motors (GM). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.", "datetime": "2025-04-01T16:17:20.000Z", "headline": "NewsMax surges, airlines downgraded, GM sales rise: Market Minute", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=158a77000c60c960b030c606011cc14c571e725a8d8c18a09541a68494f36ee8", "source": "SeekingAlpha", "summary": "Despite strong revenue growth and no debt, Newsmax's cash burn and operating losses pose some short-term financial risks. Read more about NMAX stock here.", "datetime": "2025-04-01T16:06:17.000Z", "headline": "Newsmax: Sell The IPO Craze", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=00614d7e5747898fac217a4b0ab86a8d90f0d186ca972a98f35a649d2cb01b13", "source": "Yahoo", "summary": "Trading was halted multiple times due to volatility, with 6.17 million shares exchanged.", "datetime": "2025-04-01T15:54:34.000Z", "headline": "Newsmax Shares Surge More Than 700% in Volatile Market Debut", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=680cd3d0dc3a2375f78c3c079d4b503fd932dc1848b9713fc2572a55beb4bda6", "source": "SeekingAlpha", "summary": "Newsmax Inc.'s 17x surge defies fundamentals and faces profitability challenges. Here's why experts urge caution on highly speculative NMAX stock.", "datetime": "2025-04-01T15:30:45.000Z", "headline": "Newsmax: Beware A 'Meme' Stock Dislocated From Fundamentals", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=b9f3ae81a0ad2400755dbe576ae553a58036ce0d8da85e9539e3424e3bebf51f", "source": "Yahoo", "summary": "Newsmax stock (NMAX) soared as high as 173% Tuesday, extending its massive 735% gain on Monday following the conservative cable news outlet’s IPO.", "datetime": "2025-04-01T14:07:53.000Z", "headline": "Newsmax stock soars, pushing market cap north of $20 billion after shocking IPO success", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a94b0d0c89e39ba1bcc4dc5830614136c6cc8bcf7cedd2d777f8d4c11d0a4176", "source": "Yahoo", "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.", "datetime": "2025-04-01T12:55:00.000Z", "headline": "NYSE Content advisory: Pre-Market Update + Newsmax Shares Pop 735% in NYSE Debut", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=e92a43e26322a7ec3b975f09eea1c32513789248ddc55a3769aa5ea3ff54aff8", "source": "SeekingAlpha", "summary": "Goldman Sachs has cut its S&P 500 target for the second time this month as its economists raised their projection of a U.S. recession to 35%.", "datetime": "2025-03-31T15:06:00.000Z", "headline": "Wall Street Lunch: Goldman Gets Gun-Shy", "sentiment": "neutral"}]	positive	2025-09-03 18:48:49.34603+00	2025-09-03 18:48:49.34603+00
c53c46f5-0a56-46d0-a883-2d876299003f	WTF	2025-04-02	[{"url": "https://finnhub.io/api/news?id=c7b06e7569a544bfa7c0d614fce2d5c29a8cbf7fc42cf1313bb044a25e728e6b", "source": "SeekingAlpha", "summary": "Waton Financial's IPO saw extreme volatility, with shares surging to $20 before falling to $8. Find out why I expect WTF stock return to its IPO level of $4.", "datetime": "2025-04-02T15:30:13.000Z", "headline": "Waton Financial: Complex Structure Poses Downside Risk", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=cb6a39e667666dd948356d9ce6b51c0979777531382103ebd84d0f7c205d9fb8", "source": "Yahoo", "summary": "HONG KONG, April 02, 2025 (GLOBE NEWSWIRE) -- Waton Financial Limited (“WTF” or the “Company”), a British Virgin Islands-incorporated holding company that provides securities brokerage and financial technology services primarily through its Hong Kong subsidiaries, Waton Securities International Limited and Waton Technology International Limited, today announced the closing of its initial public offering of 4,375,000 ordinary shares, no par value per share (the “Ordinary Shares”), at a public off", "datetime": "2025-04-02T15:20:00.000Z", "headline": "Waton Financial Limited Announces Closing of Initial Public Offering with Simultaneous Full Exercise of the Over-Allotment Option", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d142fa2be19116e2d0c11a22a1a294459d349ce4b4eba5315c8cddb44c61876b", "source": "Yahoo", "summary": "HONG KONG, April 01, 2025 (GLOBE NEWSWIRE) -- Waton Financial Limited (“WTF” or the “Company”), a British Virgin Islands-incorporated holding company that provides of securities brokerage and financial technology services primarily through its Hong Kong subsidiaries, Waton Securities International Limited and Waton Technology International Limited, today announced the pricing of its initial public offering of an aggregate of 4,375,000 ordinary shares, no par value per share (the “Ordinary Shares", "datetime": "2025-04-01T15:00:00.000Z", "headline": "Waton Financial Limited Announces Pricing of Initial Public Offering", "sentiment": "neutral"}]	negative	2025-09-03 18:48:51.646403+00	2025-09-03 18:48:51.646403+00
17f74d6b-946d-4eb8-8bd5-70c1bb5e9acc	CNTM	2025-04-03	[{"url": "https://finnhub.io/api/news?id=485e35221b06bd6036247f1662ad99ffd31c7f660a70fd429e60328677bb3372", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, yesterday announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity (implying a $46.5 million equi", "datetime": "2025-04-03T12:00:00.000Z", "headline": "ConnectM Board to Evaluate $46.5 Million Buy-Out Offer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d1ad68a524da7f550ec475136ace61d229514ce9616a6f6fba939351046dabcd", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.", "datetime": "2025-04-02T12:00:00.000Z", "headline": "ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:54.910387+00	2025-09-03 18:48:54.910387+00
742f2a93-58ae-4398-83fb-b726016578b4	SQQQ	2025-04-02	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	positive	2025-09-03 18:48:55.760366+00	2025-09-03 18:48:55.760366+00
e8ede19c-6722-4062-8a79-3e3fd6e073ba	HOTH	2025-04-02	[{"url": "https://finnhub.io/api/news?id=7ba8a5c66aaca544e7489bc53d53c7d651f3df9d45cc84ac4f55d40715a19b49", "source": "Yahoo", "summary": "Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's di", "datetime": "2025-04-02T12:02:00.000Z", "headline": "Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=a76e014a2b2b356c964086e2b6e8fc4f3b9009933d22629289fa1760a07f71f7", "source": "Yahoo", "summary": "Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-ALZ, in improving cognitive function and reducing neuroinflammation in Alzheimer's disease (AD).", "datetime": "2025-04-02T11:58:00.000Z", "headline": "Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours", "sentiment": "positive"}]	positive	2025-09-03 18:48:52.30982+00	2025-09-03 18:48:52.30982+00
604a31a1-d37e-4e7a-bc78-45b64dc30e4f	SIDU	2025-04-02	[{"url": "https://finnhub.io/api/news?id=9f05814eeaf8d0c71cd8f40eb28da8a428aa640014a3a14fd9ae42a9f97fab70", "source": "Yahoo", "summary": "CAPE CANAVERAL, Fla., April 02, 2025--Sidus Space (NASDAQ: SIDU) (the \\"Company\\" or \\"Sidus\\"), an innovative, agile space mission enabler, announced today the decision to move forward with, and broaden the scope of, a preliminary agreement valued at approximately $120 million with Lonestar Data Holdings. The agreement defines the collaboration between Sidus and Lonestar to design, build and provide on-orbit support for six lunar data storage spacecraft, marking a significant milestone in advancing", "datetime": "2025-04-02T12:30:00.000Z", "headline": "Sidus Space Signs Extended and Amended Preliminary $120M Agreement with Lonestar for Lunar Data Storage Spacecraft", "sentiment": "positive"}]	positive	2025-09-03 18:48:53.542455+00	2025-09-03 18:48:53.542455+00
8ede2dbc-e2a6-437f-89d5-c82dad4d7795	CNTM	2025-04-02	[{"url": "https://finnhub.io/api/news?id=d1ad68a524da7f550ec475136ace61d229514ce9616a6f6fba939351046dabcd", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.", "datetime": "2025-04-02T12:00:00.000Z", "headline": "ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors", "sentiment": "neutral"}]	neutral	2025-09-03 18:48:53.890319+00	2025-09-03 18:48:53.890319+00
3c1d5fac-70c9-4386-9f00-9d04df39f5b0	03835L405	2025-04-02	[]	\N	2025-09-03 18:49:01.749565+00	2025-09-03 18:49:01.749565+00
21686bf4-7c9f-4fc3-b3a7-5b870a24ced8	03835L405	2025-04-03	[]	\N	2025-09-03 18:49:02.414458+00	2025-09-03 18:49:02.414458+00
b2d44b3c-e5e8-4a48-9960-804e71b7a062	TQQQ	2025-04-02	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	positive	2025-09-03 18:49:03.745448+00	2025-09-03 18:49:03.745448+00
3d424c19-4ea4-4f52-ad92-8bbdcfca7bc2	TQQQ	2025-04-03	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}]	positive	2025-09-03 18:49:05.180798+00	2025-09-03 18:49:05.180798+00
30d1d67d-ae93-400c-b752-184324850881	TQQQ	2025-04-07	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	negative	2025-09-03 18:49:06.009231+00	2025-09-03 18:49:06.009231+00
69912af1-6492-4d3d-92fb-437b3d83e7bb	PENG	2025-04-02	[{"url": "https://finnhub.io/api/news?id=aa8903c4b74963f72b6e8b94fe332e881d0b1638f26ed519179f5beac5c0a86b", "source": "Yahoo", "summary": "MILPITAS, Calif., April 02, 2025--Penguin Solutions today reported financial results for Q2 fiscal 2025 and the planned retirement of COO & President of Integrated Memory Jack Pacheco.", "datetime": "2025-04-02T20:05:00.000Z", "headline": "Penguin Solutions Reports Q2 Fiscal 2025 Financial Results", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=98838a64d97d7d4825e0bb00c87da92c7b0dcaf460e63d1b7ce81611a943f289", "source": "SeekingAlpha", "summary": "Penguin Solutions, Inc. (NASDAQ:PENG) Q2 2025 Earnings Conference Call April 2, 2025 4:30 PM ETCompany ParticipantsSuzanne Schmidt - Investor RelationsMark...", "datetime": "2025-04-02T19:28:34.000Z", "headline": "Penguin Solutions, Inc. (PENG) Q2 2025 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ed08ec8f97f2da5b2b6fbd96b371628677de5a9ef335fdc9232d1d5aa6f5e7a8", "source": "SeekingAlpha", "summary": "The following slide deck was published by Penguin Solutions, Inc.", "datetime": "2025-04-02T16:28:56.000Z", "headline": "Penguin Solutions, Inc. 2025 Q2 - Results - Earnings Call Presentation", "sentiment": "neutral"}]	neutral	2025-09-03 18:49:10.256681+00	2025-09-03 18:49:10.256681+00
ef4d000f-9858-4c00-93ac-e4af259d1e99	TIVC	2025-04-03	[]	\N	2025-09-03 18:49:11.194606+00	2025-09-03 18:49:11.194606+00
ee65caa7-1433-497e-a728-69b3fb166405	ALDX	2025-04-03	[{"url": "https://finnhub.io/api/news?id=e752008d38f5074628f34260cf8ef0378f9cccf813c43b2bd268208a43c25d2f", "source": "Yahoo", "summary": "Shares of Aldeyra Therapeutics plummeted nearly 75% Thursday morning after the Food and Drug Administration said the company's dry eye disease drug has not proven to be effective in enough studies.", "datetime": "2025-04-03T14:24:53.000Z", "headline": "Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddac3ec28edf1a9120e6c9e61a99416560ab779431870f20e5baf28e22ba2211", "source": "Finnhub", "summary": "Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. for potential violations of the federal securities laws.If you invested in Aldeyra...", "datetime": "2025-04-03T12:35:03.000Z", "headline": "ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d96a5cf9603791058105a7dd42537339269a298f2066f23d2e9cce8d817ad3f7", "source": "Yahoo", "summary": "LEXINGTON, Mass., April 03, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing", "datetime": "2025-04-03T12:00:00.000Z", "headline": "Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease", "sentiment": "neutral"}]	neutral	2025-09-03 18:49:13.039245+00	2025-09-03 18:49:13.039245+00
5eda197a-e311-440e-9248-fa8f45f20ef8	MESA	2025-04-07	[{"url": "https://finnhub.io/api/news?id=35c58f6a5c3a08a455dc7abd226974504f569d00abd8fcb4f511c44d34439c59", "source": "Yahoo", "summary": "Mesa Air and Republic Airways are joining forces, wiping debt and betting big on a unified regional flight empire.", "datetime": "2025-04-07T19:47:50.000Z", "headline": "Two Struggling Airlines Just Merged to Create a $1.9B Powerhouse--Here's What Investors Need to Know", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8bb6487d6bf03a55e0d8fb4f32f3cd42d9ea3d4a032195a4746832ccf2a5bd5d", "source": "SeekingAlpha", "summary": "", "datetime": "2025-04-07T15:55:40.000Z", "headline": "Mesa Air Group Merger With Republic Airways Was The Only Outcome", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5f8e3182bf4e83599026c2e19771c337cb6773b0aed372b78085d14ec3b7914a", "source": "Yahoo", "summary": "Mesa Air's (MESA) shares jumped intraday Monday after the Mesa Airlines parent agreed to merge with", "datetime": "2025-04-07T15:25:59.000Z", "headline": "Mesa Air Strikes All-Stock Deal to Merge With Republic Airways", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=58d4ca3b66826c9671087c1d0384474cdb59d253f4be4e1d863dc48e42125693", "source": "Yahoo", "summary": "Republic Airways and Mesa Air Group have agreed to merge and create a publicly-traded regional airline in an all-stock transaction.", "datetime": "2025-04-07T14:47:00.000Z", "headline": "Republic Airways, Mesa Air to Merge", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=6a794a09200435a3fbecab6b886e0e065423da59338a30e831b171e9e6e131d2", "source": "Yahoo", "summary": "Mesa Air Group shares soared Monday morning on news the carrier had agreed to merge with fellow regional carrier Republic Airways in an all-stock transaction.", "datetime": "2025-04-07T13:57:46.000Z", "headline": "Mesa Air Group Stock Soars as Regional Carrier Agrees To Merge With Republic Airways", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=356fb07541e46ca851278e09fa24a3ba278af95b5055c42cd0ac3b4af4024aa2", "source": "Yahoo", "summary": "Republic Airways and Mesa Air Group Inc. are combining in an all-stock deal that will create a regional airline with access to more planes to service routes.  Specific financial terms of the deal weren't disclosed in a statement Monday.  Republic, started in 1974, has a fleet of more than 240 Embraer 170/175 aircraft and carried about 17.5 million passengers on more than 300,000 flights last year.", "datetime": "2025-04-07T12:50:46.000Z", "headline": "Regional airlines Republic Airways, Mesa Air Group are combining in an all-stock deal", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=3a094a801a6787ea4f186d2776bfe8d0ec85becac3532015b7b8d7409ec4e9e2", "source": "SeekingAlpha", "summary": "Our top story so far, the stock market has gone from edgy to jumpy to as nervous as a long-tailed cat in a room full of rocking chairs â if youâll forgive the technical terms.", "datetime": "2025-04-07T12:33:00.000Z", "headline": "Wall Street Lunch: Volatility Rules The Day", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bd315f12419830d1217fc689ccee1f89a2e0f332fe39c05e7defb35a4027c81d", "source": "Yahoo", "summary": "The combined company, which would operate as Republic Airways Holdings Inc, will have a single fleet of about 310 Embraer 170/175 aircraft.  Republic shareholders would own 88% of the combined company, while Mesa's would own a minimum of 6% and up to 12% depending on meeting certain pre-closing criteria.  The combined company is expected to remain listed on the Nasdaq under a new ticker symbol \\"RJET\\".", "datetime": "2025-04-07T12:04:12.000Z", "headline": "Mesa Air, Republic Airways in merger deal to create larger regional airline", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=e3646cf37864d1b7ab52bf3032281e3ef770b7e8b00fb3c5ba66061c58ec5d23", "source": "Yahoo", "summary": "Mesa Air Group Inc (MESA) and Republic Airways Holdings said Monday that they have entered into a de", "datetime": "2025-04-07T11:30:42.000Z", "headline": "Mesa Air Group to Merge With Republic Airways in All-Stock Transaction", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a631ab1fa207c7581e309c061f9b99648a07e4093993a4d0a41d3cea4805eb6d", "source": "Yahoo", "summary": "Republic Airways Holdings Inc. and Mesa Air Group, Inc. (NASDAQ: MESA) today announced that they have entered into a definitive agreement to merge and create a leading publicly-traded regional airline company in an all-stock transaction. Upon closing, the combined company will be renamed Republic Airways Holdings Inc. and is expected to remain NASDAQ-listed under the new ticker symbol \\"RJET\\".", "datetime": "2025-04-07T10:58:00.000Z", "headline": "Republic Airways and Mesa Air Group to Combine, Creating America's Regional Airline of Choice", "sentiment": "neutral"}]	positive	2025-09-03 18:49:18.111468+00	2025-09-03 18:49:18.111468+00
969c7770-524e-4571-821f-8f904c6c6c0a	ALLO	2025-04-07	[{"url": "https://finnhub.io/api/news?id=4313f8f1d029f8f0be12c05a9827c4e29bdb1a75c14d5f1b55586d37c835d0ec", "source": "Yahoo", "summary": "Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therapeutic Benefit, Expanding Treatment Potential Across a Range of Autoimmune IndicationsLeverages Proprietary Dagger® Technology to Reduce or Eliminate Lymphodepletion, Potentially Expanding Access to a Broader Patient PopulationPhase 1 RESOLUTION Trial Initiation Planned for Mid-2025 with Initial Proof", "datetime": "2025-04-07T12:30:00.000Z", "headline": "Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma", "sentiment": "neutral"}]	neutral	2025-09-03 18:49:20.176921+00	2025-09-03 18:49:20.176921+00
d37a3172-b89b-48a3-bb93-9095ac689389	TEVA	2025-04-07	[{"url": "https://finnhub.io/api/news?id=dc380499b6c5b10aa2cdb8fbb47da9a9e3a531ceccfc66f5c5a7e588b1a8ac60", "source": "Yahoo", "summary": "EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsun", "datetime": "2025-04-07T12:00:00.000Z", "headline": "Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=aa061066f0d21ee9afc2e2c0bcb1ef758ad19033735560bf36f2f265ca57ed56", "source": "Yahoo", "summary": "If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva’s dedication to expanding access to innovat", "datetime": "2025-04-07T11:30:00.000Z", "headline": "Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention", "sentiment": "neutral"}]	positive	2025-09-03 18:49:16.938676+00	2025-09-03 18:49:16.938676+00
8dbf22ed-75de-4443-b6f4-a1b27fb5c9da	DFDV	2025-04-07	[]	\N	2025-09-03 18:49:20.432408+00	2025-09-03 18:49:20.432408+00
fd5d02dc-8633-47ac-bd55-6c46e38bdf28	AREB	2025-04-07	[{"url": "https://finnhub.io/api/news?id=8ab2b1e511bb0fde04e2bf94c1d31a65dd9292f0b5f235bc65b30f19dbd559d4", "source": "Yahoo", "summary": "American Rebel Holdings Inc. Forged in Freedom, Fueled by Growth, Focused on the Future Forged in Freedom, Fueled by Growth, Focused on the Future NASHVILLE, TN, April 07, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), the creator of American Rebel Beer (americanrebelbeer.com) and a leading provider of safes, personal security, and patriotic lifestyle apparel, today issued a corporate update summarizing several recent developments that", "datetime": "2025-04-07T12:15:00.000Z", "headline": "American Rebel Holdings Issues Corporate Update Highlighting Recent Key Milestones and Strategic Growth Initiatives", "sentiment": "positive"}]	positive	2025-09-03 18:49:18.977347+00	2025-09-03 18:49:18.977347+00
\.


--
-- Data for Name: notification_preferences; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.notification_preferences (id, user_id, price_alerts_enabled, earnings_enabled, news_enabled, email_notifications, push_notifications, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: notification_read_status; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.notification_read_status (id, user_id, notification_type, notification_id, read_at, created_at) FROM stdin;
\.


--
-- Data for Name: notifications; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.notifications (id, user_id, type, data, read, created_at) FROM stdin;
ef977b5c-50a0-47af-b6df-a7b5a41f9c95	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.736Z", "achievement": {"id": "bcee9c07-674f-4970-a6f0-02de6083673e", "name": "Trading Explorer", "points": 10, "icon_name": null, "difficulty": "bronze", "description": "Log your very first trade - welcome to the trading world!"}}	f	2025-09-03 17:56:35.746047+00
fe744aee-250e-4c77-bc41-ff9fad03dea2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.747Z", "achievement": {"id": "78896be6-2519-49da-8097-9cd588da13c8", "name": "Achievement Seeker", "points": 10, "icon_name": null, "difficulty": "bronze", "description": "Check your achievements page for the first time."}}	f	2025-09-03 17:56:35.748164+00
bee0954d-6c26-43fa-8f6b-f66dede3335f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.748Z", "achievement": {"id": "3c5320cb-9cc2-43ec-bdef-01652f013d10", "name": "Dashboard Explorer", "points": 15, "icon_name": null, "difficulty": "bronze", "description": "Visit the gamification dashboard for the first time."}}	f	2025-09-03 17:56:35.749428+00
0e66686e-cb58-4617-b285-33ff857dd2fd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.749Z", "achievement": {"id": "fff95281-3dc7-46a7-8c87-fdcd61fd249e", "name": "Welcome Aboard!", "points": 25, "icon_name": null, "difficulty": "bronze", "description": "Welcome to TradeTally! Your journey to better trading starts now."}}	f	2025-09-03 17:56:35.750727+00
e7688e26-4aea-4a76-8b86-e48582701d13	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 3, "oldLevel": 1, "timestamp": "2025-09-03T17:56:35.954Z"}	f	2025-09-03 17:56:35.956991+00
c509b989-5fa2-4a69-b89e-9f0a34149469	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.967Z", "achievement": {"id": "5c9f0c32-aeb8-4684-80b0-d742b0fa66d3", "name": "First Profit", "points": 20, "icon_name": null, "difficulty": "bronze", "description": "Celebrate your first profitable trade!"}}	f	2025-09-03 17:56:35.968523+00
5f76ad89-98d7-4e2a-9157-c0b5f41c48a8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.969Z", "achievement": {"id": "2f84e098-fbc3-412d-8f34-59bb8841a661", "name": "Quick Flip", "points": 100, "icon_name": null, "difficulty": "silver", "description": "Make a profitable trade within 5 minutes of opening the position"}}	f	2025-09-03 17:56:35.969666+00
d2e35b60-8302-4f28-ab42-19d2c622e0a9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:35.970Z", "achievement": {"id": "39768f1a-63ac-4c32-b4f2-82d2542d4133", "name": "Risk Taker", "points": 150, "icon_name": null, "difficulty": "silver", "description": "Execute a trade with a risk-reward ratio of at least 1:3"}}	f	2025-09-03 17:56:35.970754+00
f28eda35-3a89-4e4b-bd50-d893cd987b9a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 4, "oldLevel": 3, "timestamp": "2025-09-03T17:56:36.516Z"}	f	2025-09-03 17:56:36.518961+00
c82ca826-bb2d-417b-b47e-b65fe980a1f7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:36.528Z", "achievement": {"id": "a69ec499-8fcf-438d-a7e0-fa39c0d43787", "name": "Diversified Trader", "points": 35, "icon_name": null, "difficulty": "bronze", "description": "Trade 3 different symbols - spreading your wings!"}}	f	2025-09-03 17:56:36.528991+00
79de0ce7-982c-4fba-bb53-8a956294618a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:36.529Z", "achievement": {"id": "ec7eb93a-7a35-423b-9a43-2351a7bb8262", "name": "Volume King", "points": 100, "icon_name": null, "difficulty": "bronze", "description": "Trade a total of 1,000 shares in a single day"}}	f	2025-09-03 17:56:36.52974+00
cbcfcd51-6aa5-4c1a-8a58-59575a817de3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:38.468Z", "achievement": {"id": "377b3e65-9bfe-40f8-b5ba-373b5514d031", "name": "Getting Serious", "points": 40, "icon_name": null, "difficulty": "bronze", "description": "Log your 10th trade - you are building consistency!"}}	f	2025-09-03 17:56:38.469491+00
2d0d2657-f1d0-4c9c-a3f6-b00ac8e36dfe	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 6, "oldLevel": 4, "timestamp": "2025-09-03T17:56:44.180Z"}	f	2025-09-03 17:56:44.184757+00
c7bdb151-2b43-40f9-8e4a-d7b724de22f0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:44.196Z", "achievement": {"id": "4077e5cc-5110-48ac-93f8-b38aa59818de", "name": "Big Win", "points": 400, "icon_name": null, "difficulty": "silver", "description": "Earn a profit of $500 or more on a single trade"}}	f	2025-09-03 17:56:44.197614+00
f4edaef6-fccc-4a55-960e-2417f3b75a1d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 7, "oldLevel": 6, "timestamp": "2025-09-03T17:56:48.971Z"}	f	2025-09-03 17:56:48.971777+00
f4001389-8279-471a-b740-751a164c7348	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:48.987Z", "achievement": {"id": "57ef7bdf-1e0d-471a-bc94-4d04e365e35c", "name": "Streak Master", "points": 500, "icon_name": null, "difficulty": "gold", "description": "Achieve 5 consecutive profitable trading days"}}	f	2025-09-03 17:56:48.988007+00
5fd98505-ee43-4692-85d2-1cf2ae5a528a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 8, "oldLevel": 7, "timestamp": "2025-09-03T17:56:54.533Z"}	f	2025-09-03 17:56:54.533953+00
564c83e3-e643-4aaf-a67b-c64aecc48f27	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:54.542Z", "achievement": {"id": "43d6b4ad-5599-4a54-b3c8-ac701a4dfe98", "name": "Consistent Trader", "points": 100, "icon_name": null, "difficulty": "silver", "description": "Maintain win rate above 50% for 50 trades"}}	f	2025-09-03 17:56:54.543097+00
a3aa9d70-c317-4515-b2ba-40e2db543788	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 9, "oldLevel": 8, "timestamp": "2025-09-03T17:56:59.906Z"}	f	2025-09-03 17:56:59.907433+00
f3ccaf08-630b-4015-8d88-cce2aac812bd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:56:59.914Z", "achievement": {"id": "e8e342b8-d82f-4d57-a8b1-84413b28b0a7", "name": "High Roller", "points": 350, "icon_name": null, "difficulty": "silver", "description": "Execute a trade with a position size of $5,000 or more"}}	f	2025-09-03 17:56:59.915178+00
9b414943-645a-4a04-8396-dbc8251216ad	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 13, "oldLevel": 9, "timestamp": "2025-09-03T17:57:04.058Z"}	f	2025-09-03 17:57:04.059578+00
d565491d-2d64-4752-8f55-6f19c4fa5dc8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:57:04.069Z", "achievement": {"id": "3fd056e5-4f18-44e7-8056-d0075ed8bc62", "name": "Volume King II", "points": 300, "icon_name": null, "difficulty": "silver", "description": "Trade a total of 10,000 shares in a single day"}}	f	2025-09-03 17:57:04.070428+00
ff6792d2-4887-4000-9ab2-bc48a24cca69	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:57:04.070Z", "achievement": {"id": "e1ddbf74-8fbb-4254-bc37-c8ebe99b0f74", "name": "High Roller II", "points": 550, "icon_name": null, "difficulty": "gold", "description": "Execute a trade with a position size of $10,000 or more"}}	f	2025-09-03 17:57:04.071253+00
bb075fd7-f6a4-4838-836d-fb8d288b866f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:57:04.071Z", "achievement": {"id": "2b12d089-8b18-4c6b-afba-f2f981f32d8a", "name": "Big Win II", "points": 600, "icon_name": null, "difficulty": "gold", "description": "Earn a profit of $1000 or more on a single trade"}}	f	2025-09-03 17:57:04.072065+00
74bb10ac-dde4-4eaa-b482-367b43b5319b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:57:04.072Z", "achievement": {"id": "bb796b96-d02a-4a76-9b5a-e199c94229d5", "name": "Big Win III", "points": 800, "icon_name": null, "difficulty": "gold", "description": "Earn a profit of $1500 or more on a single trade"}}	f	2025-09-03 17:57:04.073065+00
c5e74ac4-9af0-401c-b469-f4ab0e550cbc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:58:12.172Z", "achievement": {"id": "26f017b9-30e2-4457-a0a7-aaf2312ad0fd", "name": "Dedicated Trader", "points": 100, "icon_name": null, "difficulty": "silver", "description": "Log 100 trades - you are committed to improving your craft!"}}	f	2025-09-03 17:58:12.173324+00
8892b85b-5e83-4d9e-87e3-e43473c9f262	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T17:58:21.511Z", "achievement": {"id": "27c163c3-ecfa-441c-838d-9a78dcd10664", "name": "Night Owl", "points": 20, "icon_name": null, "difficulty": "bronze", "description": "Log a trade after 8 PM - working the after-hours!"}}	f	2025-09-03 17:58:21.513813+00
008219e1-3fad-4c01-b2cf-bdef9a488ca2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T18:21:21.768Z", "achievement": {"id": "58e5510a-369e-4ad2-bd18-cb5f335d64ef", "name": "Early Bird Trader", "points": 20, "icon_name": null, "difficulty": "bronze", "description": "Log a trade before 9 AM - catching the early market moves!"}}	f	2025-09-03 18:21:21.771289+00
88a7214b-9429-4a8f-94d2-4f7db6a0a095	2d96cef2-7502-44ff-a7a9-17713d4a7a42	level_up	{"newLevel": 14, "oldLevel": 13, "timestamp": "2025-09-03T18:48:42.579Z"}	f	2025-09-03 18:48:42.581792+00
7fa8bb29-514b-4515-85f5-b4ba2d9dc908	2d96cef2-7502-44ff-a7a9-17713d4a7a42	achievement_earned	{"timestamp": "2025-09-03T18:48:42.592Z", "achievement": {"id": "c14a90cc-1a88-4626-8a31-94d1513b8aca", "name": "High Roller III", "points": 750, "icon_name": null, "difficulty": "gold", "description": "Execute a trade with a position size of $25,000 or more"}}	f	2025-09-03 18:48:42.593282+00
\.


--
-- Data for Name: overconfidence_events; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.overconfidence_events (id, user_id, win_streak_length, win_streak_start_date, win_streak_end_date, baseline_position_size, peak_position_size, position_size_increase_percent, total_streak_profit, streak_trades, severity, confidence_score, outcome_after_streak, outcome_trade_id, outcome_amount, created_at, updated_at, ai_recommendations, ai_provider, ai_generated_at) FROM stdin;
6032ff0c-686a-49e2-9061-4faa09453a61	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6	2025-01-07 11:48:00+00	2025-01-08 11:07:00+00	746.80	10122.22	1255.41	716.50	{b28fc1c7-0cb7-44bb-8c1f-837b1dc8a24a,1ac5e0d6-031d-4e17-a7aa-0a65718ccadc,7de4aa93-8a0a-487e-b540-b827ccf8d160,1ab12991-84a2-4e5f-bb85-7d42872346fd,56dc5aee-f080-465f-9d9e-b5968659da26,43752dc2-e08c-41c4-921b-3e60f9843cb0}	high	1.00	loss	02f78421-577a-4de2-92a3-a0e622963a01	-47.67	2025-09-03 19:26:33.376471+00	2025-09-03 19:26:33.376471+00	\N	\N	\N
de328f21-aa2e-4219-bb7b-790b264c686f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8	2025-01-14 11:31:00+00	2025-01-16 11:51:00+00	746.80	3360.00	349.92	3563.44	{974d7d4d-f474-4033-b5a1-b4d1373e646e,72e613a2-674a-4961-a327-11f8fad348b2,8bd0e5e6-71f1-4259-b86c-3d9106d90228,ac4e0559-820b-4349-bc31-8b95ad804393,5209998d-fb00-4f44-9fed-0ac459c2489c,a7f14c00-ccce-4831-9e32-7ee463c9b3f5,82bc8ec8-77fe-4e01-b27d-6f22b007c87e,fb78ffa1-367c-467d-a940-37e8d4cdd01c}	high	1.00	loss	9966d738-cac2-4d67-a6f6-8773cb7ed773	-42.15	2025-09-03 19:26:33.3804+00	2025-09-03 19:26:33.3804+00	\N	\N	\N
fad7d421-8e49-4061-8db1-cb067132aeb4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7	2025-01-31 13:42:00+00	2025-02-03 11:38:00+00	746.80	4110.00	450.35	81.93	{ab0f0a4e-dc3d-418a-b691-d4ea03fb26c8,d0e2a1c4-3c27-48b7-8bb7-e044501668b7,2ff19a0b-8da6-4ba8-b276-1fd699a0bd8b,a9702cb2-b03f-4c96-9562-3ae6c4695ead,faf5f61f-5673-4275-ac70-a2a13569b711,424f4d85-a70f-4bff-a5bb-5dd8ec8e207f,e7f6cc69-3367-42db-bd98-dda2521714f4}	high	1.00	loss	f9330748-45fa-4445-b2a0-34cedf265cbe	-7.86	2025-09-03 19:26:33.382729+00	2025-09-03 19:26:33.382729+00	\N	\N	\N
9ddb3066-c7ee-460e-bc00-2e6dd55035ce	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8	2025-02-03 11:59:00+00	2025-02-03 13:36:00+00	746.80	1170.00	56.67	99.11	{739cc92c-e324-4f58-804b-6ab85bccbec6,b2d4f5d0-b77b-4316-bf34-f5ca6e657bc8,5bce72af-0be3-44da-a29e-3d169ba27466,34b10885-9bc3-41cd-9fb2-066d0ce26bf1,cdb79cf8-907b-4ba2-bbcc-9e8bcac052df,0b67d34c-58b5-4d54-935a-128536c6c5ae,2f2dc23c-0ba0-4cd9-a061-9b0db752ee79,273c2288-f98d-42eb-863f-f81d6f3cea4b}	medium	1.00	loss	b2adbbd5-03d7-45f4-9bb9-7dfbbf54bb83	-49.46	2025-09-03 19:26:33.384989+00	2025-09-03 19:26:33.384989+00	\N	\N	\N
072978fb-8b28-433b-8247-1a58689922d9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9	2025-02-04 10:57:00+00	2025-02-04 11:55:00+00	746.80	4545.00	508.60	177.52	{72be4dd1-3816-4dee-90cb-670106260c4a,c762905b-72af-467b-b5e3-7320b51d592e,5d3bd893-e3a9-4d2c-a204-cad9f4546858,904cd33c-af0a-493f-847d-19bdcfebe5c5,5fc8db5c-5976-495a-ac58-637330bc58d7,f413fd79-3fa8-4294-9609-924d7c7ded37,049e9e1e-c30e-432f-961d-90cd6fe8838c,85142cd7-901c-4ef8-9616-8be2e7bb8d3e,fbdc029e-7c7b-4035-bdd9-af4c88bf3bc7}	high	1.00	loss	3097d30d-c397-4137-a979-2abe3c65f395	-47.66	2025-09-03 19:26:33.38773+00	2025-09-03 19:26:33.38773+00	\N	\N	\N
780c30b7-009c-41f9-bdf8-62f73dda2d22	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8	2025-02-04 12:08:00+00	2025-02-05 11:22:00+00	746.80	4810.00	544.08	362.19	{82c2a0ff-9feb-406b-bcd5-b57126235d37,4a70d2b0-d498-4844-9291-fbb698fd43d2,f65c083f-72da-4b48-a35c-35dc29441ad2,964239b7-1400-4299-bc02-fdab6113daf0,f8d5dede-911d-4594-859e-526db89ceb03,eac89a62-2af1-4146-adc1-a51084bf995d,5b902936-c3d6-417d-9c14-5c78132e8309,af6ef801-4581-464f-8f57-7f4c411bfb85}	high	1.00	loss	7d5c7424-d376-4e2d-a594-bc8a8c571ca9	-78.29	2025-09-03 19:26:33.390214+00	2025-09-03 19:26:33.390214+00	\N	\N	\N
5b1b8b52-b431-4a8e-a7d6-846981014650	2d96cef2-7502-44ff-a7a9-17713d4a7a42	12	2025-02-05 12:02:00+00	2025-02-10 11:00:00+00	746.80	11390.00	1425.17	1017.19	{df6eccc5-a74d-4080-8770-89c2b5df1fe6,8b01c162-4946-49eb-a2f8-20eaa6d0ca2b,5e05cb12-ba30-4cf5-92db-e161b9940591,9028b122-eca8-450f-98a8-5cf515235d62,206fe5a2-a57d-479d-b633-2b8863ab0ad2,d4c52114-b262-4053-a962-9b8057fabfa1,0bb698bb-c87c-43d6-908d-f41df90555bd,f8d146c7-67d4-44f9-857f-67cc0fb684c0,e0b51e88-5a66-4335-811c-2d2472013c2b,12084622-cdf3-468d-9a80-41a84120f3d7,15aaceb7-6b08-46ba-a959-ceae18232b09,02cb4570-0f94-45bd-af55-2d6e31acffc3}	high	1.00	loss	2fc303b7-def0-4e80-b552-b5dc67233d2f	-74.35	2025-09-03 19:26:33.391911+00	2025-09-03 19:26:33.391911+00	\N	\N	\N
4b9a7e6d-cf8b-4abb-910b-ddfae6db9065	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7	2025-02-11 10:58:00+00	2025-02-12 11:31:00+00	746.80	18480.00	2374.56	5228.66	{250b9d52-48f6-454b-b412-fdea54fbb46c,10187771-9876-4cbf-b38e-51c85d157f01,68368180-d699-43ef-ba2a-e63b6b1a5ce5,25fabbca-2d3c-4836-866e-b99dc069404f,fbc2549c-ce4a-42ed-83de-844593b578dd,0f2042b4-c933-47d9-8955-1b50e56574c8,9576b0fc-3844-4c16-9847-df9e0dbfda6e}	high	1.00	loss	f14f7d20-79af-491e-ace9-9f9ddcd67ff5	-4.45	2025-09-03 19:26:33.394195+00	2025-09-03 19:26:33.394195+00	\N	\N	\N
6cfdad93-b899-428d-8d43-9fe0019f24f7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5	2025-02-13 10:42:00+00	2025-02-18 12:43:00+00	746.80	6020.00	706.11	244.05	{de1f2f5a-e4b6-4c52-9473-00c7d9d6966d,5b85a6c1-8463-442e-bf33-a204da3e8521,e8d85b3c-2bf8-482e-8123-bc8af46a8778,033f9947-0e4a-4337-a1f9-5993fd0622c8,02f756ab-6add-43ca-b9aa-f5a2c5c8a45a}	high	1.00	loss	e5bad97a-6e12-4e94-86ba-c2f49bb4eaa8	-801.28	2025-09-03 19:26:33.396206+00	2025-09-03 19:26:33.396206+00	\N	\N	\N
78835393-544d-410a-9163-7ad68e431c90	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4	2025-03-17 12:16:00+00	2025-03-17 17:08:00+00	746.80	7410.00	892.23	152.05	{fbe899b1-db53-4523-96ba-e0019ed5b9eb,1aa7e837-f1cb-4682-9bc0-0d70b3b7dbd1,d0c629e8-5435-4ddc-8097-666c9d97e827,b0a66cdd-28ca-46f5-bd64-de5eb0745185}	high	1.00	loss	79b26b2e-9d44-4c74-867f-f0ed7ae255ca	-21.97	2025-09-03 19:26:33.398361+00	2025-09-03 19:26:33.398361+00	\N	\N	\N
eb547589-95f1-422b-80d6-ec3071ae5531	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5	2025-03-18 12:06:00+00	2025-03-18 12:55:00+00	746.80	9120.00	1121.21	519.12	{aa289251-8d7d-43db-8e72-d917a9774fd7,33051b0f-5286-4cbe-a6ad-30e05587b975,998cf11c-e274-4131-ac1c-893d5692e5a1,b4707007-0ee7-497b-befa-2c9d2e2d7f01,daa0851c-6944-4444-8ea4-b5592641a76e}	high	1.00	loss	6bcf93a6-bda1-405f-9938-8148c0357d9c	-12.62	2025-09-03 19:26:33.40036+00	2025-09-03 19:26:33.40036+00	\N	\N	\N
cf690847-8fce-47c6-b724-cfe4feb46538	2d96cef2-7502-44ff-a7a9-17713d4a7a42	15	2025-03-18 13:31:00+00	2025-03-21 16:45:00+00	746.80	8749.00	1071.53	1333.89	{45fd6339-4acb-4717-8ec2-9208726517bc,dcf92b7e-ac88-4266-a916-f8cbeef9b543,1987808a-98ad-4c49-ba78-af231471c094,77aface7-4c08-4976-8140-2c25c7daf8a6,f8ace3aa-7e2e-4d3b-9a1f-c68c73ffb23c,f2bb1b0a-8319-421f-82f9-47549b502a34,caede5e8-1ac2-44f2-97ce-e278a62a49fd,0b461763-0a36-4b57-a649-1763e4e516d4,d076869e-2043-41eb-b04d-c27e2d677f80,49d62247-bb6f-4188-b486-b9c601f9c9fc,111077b9-37e7-4228-9f23-e979dec90afc,196e98e2-c078-493c-bb3f-d8503abbe88d,fb53f90a-d57d-4940-abb1-dedf3febb132,950451ac-b358-4b1b-b151-ace6611a7530,4af8f79a-e803-401e-998f-6a7c76fa5b9d}	high	1.00	loss	12571436-4f11-4390-89a5-df99ee53f826	-287.51	2025-09-03 19:26:33.402195+00	2025-09-03 19:26:33.402195+00	\N	\N	\N
5646c958-7064-4b57-937f-4aefb2743b46	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8	2025-03-24 15:05:00+00	2025-03-24 20:10:00+00	746.80	15502.00	1975.79	365.93	{d76d6510-e403-4968-9629-a22390fa7973,e39104e0-c788-4fe8-9e49-a9440f8272bb,e26b552a-78a3-4187-b3e7-425af684c9be,2d660ff0-e017-4d81-bdf2-f13d52a38062,a7cacfe2-3999-46f9-951e-e43df5950647,2d6d7520-b1c9-45e4-9bf5-c4634cf70586,191cd412-4fce-4455-bc20-d6e8e6e1fe03,16ffb4e2-03be-4ba1-9f8f-7cfc0b69e8ca}	high	1.00	loss	d112b324-2481-4089-a815-27716c2f7b67	-46.83	2025-09-03 19:26:33.404312+00	2025-09-03 19:26:33.404312+00	\N	\N	\N
113cbc97-1edb-49c6-bb9b-83044ac568db	2d96cef2-7502-44ff-a7a9-17713d4a7a42	19	2025-03-24 20:27:00+00	2025-03-26 11:15:00+00	746.80	15903.00	2029.49	1289.15	{3797bb8f-a239-4e4b-bac7-1930e54220ae,c7353302-7632-417e-8aa5-d6acd7ff7c74,8a09a033-4b3c-4212-96b4-b20551f4233f,b57497ac-0911-4293-aca1-4f2161935162,c8da70f1-c6fa-41da-b8fe-01b664805c96,62a5eb7e-c4b4-4bb4-b263-ff699fc35b78,5ff3ee7e-baf5-4d11-a27c-dab6fb319a35,e54d2b71-d12e-46ac-b5f7-ce18b6ddd29f,3ef8d738-cd00-4c3d-b5db-c70730d1b425,3381ce66-f1cd-44a2-a027-722b502ea98b,f7552c7a-62c0-4c7c-952f-766793c55bf7,6d856ffb-e185-4262-8ae2-185e03117cb6,8b100660-4480-4f09-8c5f-1703166588d6,d269f0e5-73e8-4336-8e04-ddca7bcdf6cd,10686b19-3eb2-4961-a1fd-8c10253ee8e3,b81daf3d-6a4e-4907-8adb-770680affe76,9dd7b3d9-306b-444f-b015-a1fb35b425d3,1f978e2f-8857-40ff-af85-6923bf256db4,fedda064-e9a8-4c19-89c3-a6e08d4ca1fe}	high	1.00	loss	a89a7148-ccba-4dce-a29c-8a351d95c3fd	-39.99	2025-09-03 19:26:33.406032+00	2025-09-03 19:26:33.406032+00	\N	\N	\N
b9458760-12b4-4cdd-83ef-15d1472676db	2d96cef2-7502-44ff-a7a9-17713d4a7a42	15	2025-03-26 11:19:00+00	2025-03-26 13:33:00+00	746.80	4068.00	444.72	1070.02	{afd288c2-a475-4a20-9ba3-50dd485b76e6,4f6d58b9-0d6f-4e9c-9a66-6f3865d84d5f,68b3b8ab-9f1d-45c1-abc0-bf8035555e63,42ae21e5-2632-47f2-a457-bbdd84f50661,5bb82821-e7af-479f-83ed-21fab5df4442,458a8613-093e-4093-8c00-5821564d75ed,ee94a294-f5c0-426f-b5a1-3693263cc4bc,3f84ae58-8e63-4a78-9727-db06233be38e,b0ff6a90-c803-4cd6-b997-ef1f07b4ce1c,2dbd6b41-c903-493d-9590-44436552b52f,ff0b4bf3-137a-4707-a62a-85c9b4eff528,56c75d2c-a0ca-4294-a6c7-8705a77b273f,162c256f-d36b-4981-a325-cc91ab4576a9,71d57a00-d1c1-47ea-8a88-1206e84e169c,0f0eeef8-e574-412b-b88d-ab4c40a9d74d}	high	1.00	loss	03ea71e1-32cc-4194-953f-f70c51ca2a1c	-23.94	2025-09-03 19:26:33.407333+00	2025-09-03 19:26:33.407333+00	\N	\N	\N
641b0856-1928-4562-b0f1-57fdf0fed43f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8	2025-03-27 12:51:00+00	2025-03-28 11:19:00+00	746.80	11385.00	1424.50	2850.43	{eb3a56e1-d691-47a8-bd70-8d6534dad66c,ebbe6d1c-d248-4b08-beb8-e8f1792a7024,e8157493-4baa-4700-8bb6-0e026a9c88b0,5a23f663-9627-4d03-8366-6a9e6b6a1a7e,a0f1a3e3-4515-426c-83e5-727426fcf348,3ff6888d-fc3c-49ee-8a72-9e7747092c02,a3080211-b8ca-432b-b776-d65e0c83fc7b,3724f756-08a8-4fd9-8713-b66c7b99e3f9}	high	1.00	loss	893f9e38-5a18-4c96-a6a8-63b11c177704	-104.26	2025-09-03 19:26:33.409156+00	2025-09-03 19:26:33.409156+00	\N	\N	\N
67ef5b5e-1f92-43ea-a25f-265ea9579e72	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4	2025-03-28 15:23:00+00	2025-03-28 20:31:00+00	746.80	3198.00	328.23	88.14	{5a7fc032-de9f-4665-9d33-c1c1e484b839,51779a0f-7d6a-4a09-b86a-5dde1f4f5bdf,e679892b-c45a-46cb-88bb-c746c357361a,eb58f21d-dd3f-4c28-b57d-a3be3d73ea3d}	high	1.00	loss	df78b0d6-c343-439e-ad78-c2fd25db6cf1	-15.97	2025-09-03 19:26:33.410497+00	2025-09-03 19:26:33.410497+00	\N	\N	\N
bb4be14f-4e58-4407-9d6f-186abe35a899	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5	2025-04-01 12:35:00+00	2025-04-01 16:46:00+00	746.80	9060.00	1113.18	385.22	{80b7c5dd-3942-4d42-a5c4-161cb9a7bbb3,24392d48-c56a-49ec-9670-d76c9fd42fdf,c0a4ba2d-3dce-4b52-a215-02f2838b4fd6,31f6bc86-a598-49ae-911b-230a978a5044,db3eff94-4ae7-4076-89e3-97107e905188}	high	1.00	loss	4f173dc8-a4ce-4042-8280-b237fba06d50	-16.81	2025-09-03 19:26:33.411899+00	2025-09-03 19:26:33.411899+00	\N	\N	\N
865d1d45-7b4d-4857-99b1-21e222f93370	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5	2025-04-02 20:09:00+00	2025-04-02 20:52:00+00	746.80	5491.00	635.27	167.75	{3769c3e8-92c6-4f1b-95ed-21f5165bb21b,1bbe564d-0de2-41e7-8611-87db9e8146f7,cbb37db1-2e27-48b8-8983-4864192ef4b0,c94f6bfc-07f9-443f-b82e-e5f4c18cd03b,893477c4-e598-41d8-99bf-bb5eabd07f98}	high	1.00	loss	9d03db8e-f1df-4cdc-bad0-1078ed53ba98	-38.32	2025-09-03 19:26:33.413628+00	2025-09-03 19:26:33.413628+00	\N	\N	\N
87166a43-b721-4733-a6bb-b751567ef3dc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5	2025-04-02 21:07:00+00	2025-04-02 21:29:00+00	746.80	5406.00	623.89	41.26	{f478e991-8d68-4532-ac67-1cf8ec62ef05,53f6a156-e9c4-4259-81eb-2197046d5e8b,9c40614d-1977-43cc-866d-13ade35b7069,9615d633-8f42-44f3-96d6-eaebc73eb3b4,36839bce-0786-4b92-a3ad-b6fa4360a054}	high	1.00	loss	87dc3b27-f2cc-45b0-91a5-058e39f2dee6	-39.77	2025-09-03 19:26:33.41471+00	2025-09-03 19:26:33.41471+00	\N	\N	\N
8944ca9f-d266-4502-bdf6-9bc86d1d7786	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6	2025-04-07 11:31:00+00	2025-04-07 12:18:00+00	746.80	5509.00	637.68	171.64	{ad7724dd-c41b-4850-a5c2-6ae75efb048e,5a8a6701-def2-46dc-81ba-cbd81d43641a,8dee3216-7bec-499b-a6b1-8f4b90407d5c,ca2141f1-ed0b-4b15-bcfd-67f1d5ce9afb,cf02fe9b-5e4b-4237-9bb1-57a8a1d6c85d,fbc846b9-e8c3-443f-ae14-b41ed2fc4608}	high	1.00	loss	67f88e91-80cf-40fd-b7ca-fc0547495314	-302.57	2025-09-03 19:26:33.415745+00	2025-09-03 19:26:33.415745+00	\N	\N	\N
30ac6dc2-00fc-49e2-9004-9cc834f0a107	2d96cef2-7502-44ff-a7a9-17713d4a7a42	13	2025-04-07 12:25:00+00	2025-04-07 15:28:00+00	746.80	7807.50	945.46	879.32	{9acf57c0-fd2f-40de-959a-93bb7a7e2dd5,3f9d46b6-35a4-40b5-b54e-14cca28f55a4,31e497be-27cd-4c24-a41e-ae831f921000,26735ce1-e09d-42ad-ab49-488221134457,0dd0eb75-158a-4419-9f9b-4b7e87c942ca,aa5bb742-1ede-42a7-9838-5e195319f6c5,47150f7a-e354-4e7d-8b9e-817bcfa812f9,17138191-3fe0-40d0-9efa-d0be39302350,e7ad79ce-34fa-4078-aa75-b3fcb8b17570,505d5227-f994-4646-9009-01fde18f317e,0c305292-7e48-432e-9eb3-261892f20416,93cae1d7-e20e-4063-8545-de0ccecf072e,ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f}	high	1.00	loss	5f067d88-03a4-453a-97ea-82002cffed00	-1.73	2025-09-03 19:26:33.417097+00	2025-09-03 19:26:33.417097+00	\N	\N	\N
b96ed10c-1b25-49fb-ba2b-32e0c8b11891	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7	2025-04-07 15:44:00+00	2025-04-07 19:54:00+00	746.80	8136.00	989.45	340.48	{fb07cb4f-b5cd-4b67-8d63-150068297eed,fa3349fb-2321-4a51-9b74-c4c9ad603a8a,81781831-4f29-4376-accb-5ab857006caf,daac3f21-dbec-4000-9f00-a2fe0500af89,000322b7-3fe4-4edb-ac94-44d326f59b8a,92858781-a01f-4854-8730-2d606385c553,ff735cf4-7022-41f4-8b6d-630fb0ccef3e}	high	1.00	loss	c40d4a7e-5944-4238-a47b-85a4d925ce1b	-5.74	2025-09-03 19:26:33.41843+00	2025-09-03 19:26:33.41843+00	\N	\N	\N
\.


--
-- Data for Name: overconfidence_settings; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.overconfidence_settings (id, user_id, detection_enabled, min_streak_length, position_increase_threshold, sensitivity, alert_preferences, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: peer_groups; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.peer_groups (id, name, criteria, min_members, max_members, is_active, created_at) FROM stdin;
\.


--
-- Data for Name: personality_drift_tracking; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.personality_drift_tracking (id, user_id, analysis_date, period_days, previous_primary_personality, current_primary_personality, personality_drift_score, hold_time_drift_percent, frequency_drift_percent, risk_tolerance_drift, drift_performance_impact, drift_severity, drift_recommendations, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: personality_peer_comparison; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.personality_peer_comparison (id, user_id, personality_type, peer_group_size, user_avg_return, peer_avg_return, user_sharpe_ratio, peer_avg_sharpe_ratio, user_win_rate, peer_avg_win_rate, return_percentile, consistency_percentile, risk_management_percentile, top_performer_characteristics, improvement_suggestions, comparison_date, peer_data_quality, created_at) FROM stdin;
\.


--
-- Data for Name: personality_trade_analysis; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.personality_trade_analysis (id, user_id, trade_id, personality_alignment_score, optimal_personality_for_trade, setup_quality, pattern_match_score, entry_timing_quality, exit_timing_quality, hold_time_appropriateness, market_regime, personality_market_fit, trade_specific_recommendations, created_at) FROM stdin;
\.


--
-- Data for Name: price_alerts; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.price_alerts (id, user_id, symbol, alert_type, target_price, change_percent, current_price, is_active, email_enabled, browser_enabled, repeat_enabled, triggered_at, created_at, updated_at) FROM stdin;
10b43fc7-8f5d-4bff-82ee-cfef807a4896	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PYXS	below	1.4000	\N	1.4750	t	f	t	f	\N	2025-09-03 18:06:14.13624	2025-09-03 18:06:14.13624
\.


--
-- Data for Name: price_monitoring; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.price_monitoring (id, symbol, current_price, previous_price, price_change, percent_change, volume, last_updated, data_source) FROM stdin;
a4df8c75-7a79-4873-a428-30f14e5284e2	PYXS	2.0800	2.0800	-0.0900	-4.15	\N	2025-09-25 19:22:40.734492	finnhub
\.


--
-- Data for Name: refresh_tokens; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.refresh_tokens (id, user_id, device_id, token_hash, family_id, expires_at, revoked_at, revoked_reason, created_at, used_at) FROM stdin;
\.


--
-- Data for Name: revenge_trade_tick_analysis; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.revenge_trade_tick_analysis (id, user_id, revenge_trade_id, trigger_trade_id, symbol, trade_entry_time, trade_exit_time, analysis_window_minutes, pre_trade_ticks, post_trade_ticks, price_before_entry, price_at_entry, price_at_exit, price_after_exit, price_trend_before, price_trend_after, volatility_before, volatility_after, volume_before_avg, volume_after_avg, was_chasing_momentum, was_fighting_trend, entry_timing_score, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: revenge_trading_events; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.revenge_trading_events (id, user_id, trigger_trade_id, trigger_loss_amount, trigger_timestamp, revenge_trades, total_revenge_trades, time_window_minutes, position_size_increase_percent, total_additional_loss, pattern_broken, cooling_period_used, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: round_trip_trades; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.round_trip_trades (id, user_id, symbol, entry_time, exit_time, entry_price, exit_price, total_quantity, total_pnl, total_commission, total_fees, pnl_percent, side, strategy, notes, is_completed, trade_count, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: stock_split_check_log; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.stock_split_check_log (id, symbol, last_checked_at, splits_found, error_message, created_at) FROM stdin;
1	CURR	2025-09-24 21:02:31.115296	0	\N	2025-09-03 18:03:05.111704
2	PYXS	2025-09-24 21:02:31.420579	0	\N	2025-09-03 18:49:47.895721
3	SLRX	2025-09-24 21:02:31.792448	4	\N	2025-09-03 18:49:48.648976
4	SONN	2025-09-24 21:02:32.147532	3	\N	2025-09-03 18:49:49.125497
\.


--
-- Data for Name: stock_splits; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.stock_splits (id, symbol, split_date, from_factor, to_factor, ratio, processed, created_at, updated_at) FROM stdin;
1	SLRX	2025-08-18	15.0000	1.0000	0.0667	t	2025-09-03 18:49:48.645659	2025-09-24 21:02:31.778052
2	SONN	2024-09-30	8.0000	1.0000	0.1250	t	2025-09-03 18:49:49.110299	2025-09-24 21:02:32.146433
\.


--
-- Data for Name: strategy_classification_history; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.strategy_classification_history (id, trade_id, user_id, previous_strategy, new_strategy, classification_method, confidence_score, classification_metadata, is_manual_override, override_reason, created_at) FROM stdin;
\.


--
-- Data for Name: subscriptions; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.subscriptions (id, user_id, stripe_customer_id, stripe_subscription_id, stripe_price_id, status, current_period_start, current_period_end, cancel_at_period_end, canceled_at, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: symbol_categories; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.symbol_categories (id, symbol, company_name, finnhub_industry, gics_sector, gics_group, gics_industry, gics_sub_industry, country, currency, exchange, ipo_date, market_cap, phone, share_outstanding, ticker, weburl, logo, created_at, updated_at) FROM stdin;
1	OST	Ostin Technology Group Co Ltd	Electrical Equipment	\N	\N	\N	\N	CN	USD	NASDAQ NMS - GLOBAL MARKET	2022-04-27	9.84	862558595234	6.00	OST	http://ostin-technology.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950800264296.png	2025-09-03 18:49:22.614091	2025-09-03 18:49:22.614091
2	SNGX	Soligenix Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	1994-04-04	13.33	16095388200	4.29	SNGX	https://www.soligenix.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/SNGX.png	2025-09-03 18:49:25.058248	2025-09-03 18:49:25.058248
3	GFAI	Guardforce AI Co Ltd	Commercial Services & Supplies	\N	\N	\N	\N	SG	USD	NASDAQ NMS - GLOBAL MARKET	2020-09-08	23.13	6529736011	21.02	GFAI	https://www.guardforceai.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950742392876.png	2025-09-03 18:49:27.376534	2025-09-03 18:49:27.376534
4	INM	InMed Pharmaceuticals Inc	Pharmaceuticals	\N	\N	\N	\N	CA	USD	NASDAQ NMS - GLOBAL MARKET	2001-06-21	4.32	16046697207	2.00	INM	https://www.inmedpharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/INM.png	2025-09-03 18:49:29.742029	2025-09-03 18:49:29.742029
5	DATS	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	DATS	\N	\N	2025-09-03 18:49:32.523312	2025-09-03 18:49:32.523312
6	RVSN	Rail Vision Ltd	Electrical Equipment	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2022-03-31	19.16	97299577706	52.21	RVSN	https://www.railvision.io/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950521240016.png	2025-09-03 18:49:35.175317	2025-09-03 18:49:35.175317
7	655187300	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	655187300	\N	\N	2025-09-03 18:49:37.543762	2025-09-03 18:49:37.543762
8	LAES	Sealsq Corp	Semiconductors	\N	\N	\N	\N	CH	USD	NASDAQ NMS - GLOBAL MARKET	2023-05-19	381.66	\N	122.01	LAES	https://www.sealsq.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950848777906.png	2025-09-03 18:49:39.963815	2025-09-03 18:49:39.963815
9	NVNI	Nvni Group Ltd	Technology	\N	\N	\N	\N	KY	BRL	NASDAQ NMS - GLOBAL MARKET	2021-11-04	20.51	551156423370	34.55	NVNI	https://www.nuvini.co/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950838581406.png	2025-09-03 18:49:42.763148	2025-09-03 18:49:42.763148
10	M2R43K362	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	M2R43K362	\N	\N	2025-09-03 18:49:45.141261	2025-09-03 18:49:45.141261
11	VSTTF	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	VSTTF	\N	\N	2025-09-03 19:00:26.119114	2025-09-03 19:00:26.119114
12	EVAX	Evaxion A/S	Biotechnology	\N	\N	\N	\N	DK	USD	NASDAQ NMS - GLOBAL MARKET	2021-02-05	17.37	\N	6.32	EVAX	https://evaxion.ai/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950379203836.png	2025-09-03 19:00:28.778361	2025-09-03 19:00:28.778361
13	VVPR	VivoPower International PLC	Utilities	\N	\N	\N	\N	GB	USD	NASDAQ NMS - GLOBAL MARKET	2016-12-29	48.64	442036675158	10.11	VVPR	https://vivopower.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/VVPR.png	2025-09-03 19:00:31.426662	2025-09-03 19:00:31.426662
14	GLTO	Galecto Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-10-29	3.97	14570705210	1.32	GLTO	https://galecto.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950731393566.png	2025-09-03 19:00:33.850545	2025-09-03 19:00:33.850545
15	CORT	Corcept Therapeutics Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2004-04-15	7521.43	16506888803	105.37	CORT	https://www.corcept.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/CORT.png	2025-09-03 19:00:36.31303	2025-09-03 19:00:36.31303
16	TNON	Tenon Medical Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-04-27	10.83	14086495760	8.88	TNON	https://www.tenonmed.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950379325246.png	2025-09-03 19:00:38.746955	2025-09-03 19:00:38.746955
17	OSRH	OSR Holdings Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-02-10	15.63	14256357700	21.59	OSRH	https://osr-holdings.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950825153326.png	2025-09-03 19:00:41.176752	2025-09-03 19:00:41.176752
18	CJMB	Callan JMB Inc	Logistics & Transportation	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2025-02-05	21.60	18304380395	4.48	CJMB	https://callanjmb.com/	\N	2025-09-03 19:00:43.543139	2025-09-03 19:00:43.543139
19	AMOD	Alpha Modus Holdings Inc	Technology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-10-25	43.22	17042525050	41.96	AMOD	https://www.insightacqcorp.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950003389236.png	2025-09-03 19:00:46.073114	2025-09-03 19:00:46.073114
20	DFDV	DeFi Development Corp	Financial Services	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-07-25	345.56	15615594111	21.05	DFDV	https://defidevcorp.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950810792236.png	2025-09-03 19:00:48.521552	2025-09-03 19:00:48.521552
21	USAR	USA Rare Earth Inc	Metals & Mining	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-05-25	1360.08	18138676155	97.43	USAR	https://www.usare.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950850676006.png	2025-09-03 19:00:54.193502	2025-09-03 19:00:54.193502
22	SQQQ	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	SQQQ	\N	\N	2025-09-03 19:00:56.857214	2025-09-03 19:00:56.857214
23	SCNX	Scienture Holdings Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-02-18	20.28	18002610281	19.36	SCNX	https://www.trxadehealth.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/MEDS.png	2025-09-03 19:00:59.278156	2025-09-03 19:00:59.278156
24	CNTM	ConnectM Technology Solutions Inc	Electrical Equipment	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-05-11	0.21	16173951333	35.51	CNTM	https://www.connectm.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950825063516.png	2025-09-03 19:01:01.686735	2025-09-03 19:01:01.686735
25	QNTM	Quantum Biopharma Ltd	Pharmaceuticals	\N	\N	\N	\N	CA	USD	CANADIAN NATIONAL STOCK EXCHANGE	2018-05-29	88.07	14168548884	3.82	QNTM.CN	https://www.quantumbiopharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/HUGE.CN.png	2025-09-03 19:01:04.044886	2025-09-03 19:01:04.044886
26	PRTG	Portage Biotech Inc	Biotechnology	\N	\N	\N	\N	VG	USD	NASDAQ NMS - GLOBAL MARKET	2013-10-28	15.86	4167377600	2.28	PRTG	https://portagebiotech.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950402454306.png	2025-09-03 19:01:06.428671	2025-09-03 19:01:06.428671
27	AIFF	Firefly Neuroscience Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	1993-10-27	36.16	18882376412	13.39	AIFF	https://fireflyneuro.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950820149846.png	2025-09-03 19:01:08.892891	2025-09-03 19:01:08.892891
28	ARQT	Arcutis Biotherapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-01-31	1836.95	18054185006	119.91	ARQT	https://arcutis.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950715153366.png	2025-09-03 19:01:11.697416	2025-09-03 19:01:11.697416
29	NMAX	Newsmax Inc	Media	\N	\N	\N	\N	US	USD	NEW YORK STOCK EXCHANGE, INC.	2025-03-31	1801.54	15616861165	129.05	NMAX	https://ir.newsmax.com/overview/default.aspx	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950876982796.png	2025-09-03 19:01:14.121344	2025-09-03 19:01:14.121344
30	CURR	CURRENC Group Inc	Financial Services	\N	\N	\N	\N	SG	USD	NASDAQ NMS - GLOBAL MARKET	2021-11-19	129.34	19175193948	76.08	CURR	https://www.currencgroup.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950801816826.png	2025-09-03 19:01:16.761408	2025-09-03 19:01:16.761408
31	20678X205	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	20678X205	\N	\N	2025-09-03 19:01:22.325056	2025-09-03 19:01:22.325056
32	83006G203	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	83006G203	\N	\N	2025-09-03 19:01:24.674724	2025-09-03 19:01:24.674724
33	ADTX	Aditxt Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-06-19	5.18	19094880844	4.98	ADTX	https://aditxt.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950632365786.png	2025-09-03 19:01:27.467577	2025-09-03 19:01:27.467577
34	LIPO	Lipella Pharmaceuticals Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-12-20	2.73	14129010315	4.47	LIPO	https://lipella.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950191513456.png	2025-09-03 19:01:29.918149	2025-09-03 19:01:29.918149
35	CSAI	Cloudastructure Inc	Technology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2025-01-30	26.72	12126711020	18.04	CSAI	https://cloudastructure.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950578293466.png	2025-09-03 19:01:32.672039	2025-09-03 19:01:32.672039
36	JG	Aurora Mobile Ltd	Technology	\N	\N	\N	\N	CN	CNY	NASDAQ NMS - GLOBAL MARKET	2018-07-26	62.38	8675583881462	4.05	JG	https://www.jiguang.cn/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950646203396.png	2025-09-03 19:01:35.135142	2025-09-03 19:01:35.135142
37	SIDU	Sidus Space Inc	Aerospace & Defense	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-12-15	30.79	13216135620	25.45	SIDU	https://sidusspace.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950675124806.png	2025-09-03 19:01:37.983764	2025-09-03 19:01:37.983764
39	ACRV	Acrivon Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-11-15	42.15	16172078979	31.46	ACRV	https://acrivon.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950637337356.png	2025-09-03 19:01:42.664726	2025-09-03 19:01:42.664726
40	MESA	Mesa Air Group Inc	Airlines	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2018-08-10	51.50	16026854000	41.87	MESA	https://www.mesa-air.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/MESA.png	2025-09-03 19:01:45.044662	2025-09-03 19:01:45.044662
43	BLNE	Beeline Holdings Inc	Beverages	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2013-07-22	32.95	19718884264	19.61	BLNE	https://www.eastsidedistilling.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950363980606.png	2025-09-03 19:01:55.47622	2025-09-03 19:01:55.47622
38	NLSP	NLS Pharmaceutics AG	Pharmaceuticals	\N	\N	\N	\N	CH	USD	NASDAQ NMS - GLOBAL MARKET	2021-01-29	7.41	41445122150	3.60	NLSP	https://nlspharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950573607826.png	2025-09-03 19:01:40.348423	2025-09-03 19:01:40.348423
41	SLXN	Silexion Therapeutics Corp	Biotechnology	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2021-02-17	5.28	97286286005	0.73	SLXN	https://www.moringaac.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950797085196.png	2025-09-03 19:01:50.319781	2025-09-03 19:01:50.319781
58	NBY	NovaBay Pharmaceuticals Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2007-10-26	13.28	15108998800	5.82	NBY	https://novabay.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/NBY.png	2025-09-03 19:02:35.271973	2025-09-03 19:02:35.271973
59	INDP	Indaptus Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2012-09-07	6.81	16464272727	1.11	INDP	https://indaptusrx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950801483196.png	2025-09-03 19:02:38.013166	2025-09-03 19:02:38.013166
60	TQQQ	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	TQQQ	\N	\N	2025-09-03 19:02:40.352094	2025-09-03 19:02:40.352094
42	OSTX	OS Therapies Inc	Biotechnology	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2024-08-01	70.80	14102977793	31.65	OSTX	https://ostherapies.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950653647366.png	2025-09-03 19:01:53.07182	2025-09-03 19:01:53.07182
44	ELAB	PMGC Holdings Inc	Consumer products	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-11-21	8.42	18884454886	1.48	ELAB	https://pmgcholdings.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950813810106.png	2025-09-03 19:01:57.903511	2025-09-03 19:01:57.903511
45	PEVM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	PEVM	\N	\N	2025-09-03 19:02:00.33439	2025-09-03 19:02:00.33439
46	CMPX	Compass Therapeutics Inc.	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-11-13	588.49	16175008099	171.57	CMPX	https://www.compasstherapeutics.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950645707896.png	2025-09-03 19:02:02.692516	2025-09-03 19:02:02.692516
47	BCDA	BioCardia Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	1996-11-13	11.46	16502260123	5.80	BCDA	https://www.biocardia.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/BCDA.png	2025-09-03 19:02:05.471422	2025-09-03 19:02:05.471422
48	AKYA	Akoya Biosciences Inc	Life Sciences Tools & Services	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-04-16	64.44	18558968401	49.95	AKYA	https://www.akoyabio.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950567288836.png	2025-09-03 19:02:07.807663	2025-09-03 19:02:07.807663
49	CING	Cingulate Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-10-07	20.19	19139422300	5.41	CING	https://www.cingulate.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950813573906.png	2025-09-03 19:02:10.229023	2025-09-03 19:02:10.229023
50	501506703	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	501506703	\N	\N	2025-09-03 19:02:12.523422	2025-09-03 19:02:12.523422
51	SLRX	Salarius Pharmaceuticals Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2015-01-29	2.53	13467720346	0.51	SLRX	https://salariuspharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/SLRX.png	2025-09-03 19:02:17.820897	2025-09-03 19:02:17.820897
52	CPIX	Cumberland Pharmaceuticals Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2009-08-11	55.20	18774842700	14.96	CPIX	https://www.cumberlandpharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/942961385366.png	2025-09-03 19:02:20.571054	2025-09-03 19:02:20.571054
53	TEVA	Teva Pharmaceutical Industries Ltd	Pharmaceuticals	\N	\N	\N	\N	IL	USD	TEL AVIV STOCK EXCHANGE	1951-01-01	70530.58	97239148213	1146.84	TEVA.TA	https://www.tevapharm.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/TEVA.TA.png	2025-09-03 19:02:23.172664	2025-09-03 19:02:23.172664
54	PRFX	PainReform Ltd	Pharmaceuticals	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2020-09-01	2.78	97237177051	2.01	PRFX	https://painreform.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950355552076.png	2025-09-03 19:02:25.5719	2025-09-03 19:02:25.5719
55	PTNT	Palatin Technologies Inc	Biotechnology	\N	\N	\N	\N	US	USD	NYSE MKT LLC	1999-12-21	9.90	16094952200	0.97	PTN	https://www.palatin.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/PTN.png	2025-09-03 19:02:28.293734	2025-09-03 19:02:28.293734
56	HOTH	Hoth Therapeutics Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2019-02-15	16.97	16467562997	13.26	HOTH	https://hoththerapeutics.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950564080466.png	2025-09-03 19:02:30.649075	2025-09-03 19:02:30.649075
57	GHRS	GH Research PLC	Pharmaceuticals	\N	\N	\N	\N	IE	USD	NASDAQ NMS - GLOBAL MARKET	2021-06-25	864.05	35314378334	62.03	GHRS	http://www.ghres.com	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950802013366.png	2025-09-03 19:02:32.962725	2025-09-03 19:02:32.962725
61	PENG	Penguin Solutions Inc	Semiconductors	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2017-05-24	1249.24	14159542800	52.40	PENG	https://www.penguinsolutions.com/en-us	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/SGH.png	2025-09-03 19:02:45.646072	2025-09-03 19:02:45.646072
62	AMIX	Autonomix Medical Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2024-01-29	7.33	18322777816	5.92	AMIX	https://autonomix.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950434669776.png	2025-09-03 19:02:48.391056	2025-09-03 19:02:48.391056
63	GRRR	Gorilla Technology Group Inc	Technology	\N	\N	\N	\N	GB	USD	NASDAQ NMS - GLOBAL MARKET	2021-05-10	379.03	442039880574	22.67	GRRR	https://www.gorilla-technology.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950230974096.png	2025-09-03 19:02:51.040967	2025-09-03 19:02:51.040967
64	WTF	Waton Financial Ltd	Financial Services	\N	\N	\N	\N	HK	USD	NASDAQ NMS - GLOBAL MARKET	2025-04-01	231.72	85228531818	48.24	WTF	\N	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950907289436.png	2025-09-03 19:02:53.673931	2025-09-03 19:02:53.673931
65	40423R105	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	40423R105	\N	\N	2025-09-03 19:02:56.087185	2025-09-03 19:02:56.087185
66	RHEP	Regional Health Properties Inc	Health Care	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2017-10-02	6.98	16788695116	3.84	RHE	https://regionalhealthproperties.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950539431776.png	2025-09-03 19:02:58.463429	2025-09-03 19:02:58.463429
67	REBN	Reborn Coffee Inc	Retail	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-08-12	14.12	17147846369	5.41	REBN	https://reborncoffee.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950564154666.png	2025-09-03 19:03:00.778768	2025-09-03 19:03:00.778768
68	IINN	Inspira Technologies Oxy BHN Ltd	Health Care	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2021-07-13	30.23	97299664488	25.62	IINN	https://inspira-technologies.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950761654866.png	2025-09-03 19:03:03.149307	2025-09-03 19:03:03.149307
69	BIAF	bioAffinity Technologies Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-08-26	6.74	12106985334	28.47	BIAF	https://bioaffinitytech.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950460417586.png	2025-09-03 19:03:05.520859	2025-09-03 19:03:05.520859
70	MYSZ	My Size Inc	Technology	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2005-09-12	3.84	97236009030	3.26	MYSZ	https://mysizeid.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/MYSZ.png	2025-09-03 19:03:08.142542	2025-09-03 19:03:08.142542
71	DJT	Trump Media & Technology Group Corp	Media	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-08-06	4732.31	19417357346	279.87	DJT	https://tmtgcorp.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/DWAC.png	2025-09-03 19:03:13.456669	2025-09-03 19:03:13.456669
72	NAKA	Kindly MD Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2024-05-31	1741.43	13853888220	376.12	NAKA	https://kindlymd.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950834540306.png	2025-09-03 19:03:15.80033	2025-09-03 19:03:15.80033
73	EQ	Equillium Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2018-10-12	102.35	18584125302	59.50	EQ	https://www.equilliumbio.com/home/default.aspx	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/EQ.png	2025-09-03 19:03:18.184072	2025-09-03 19:03:18.184072
74	THAR	Tharimmune Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-01-12	30.67	13027432995	4.64	THAR	https://tharimmune.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950813767026.png	2025-09-03 19:03:20.588063	2025-09-03 19:03:20.588063
75	GDTC	CytoMed Therapeutics Ltd	Biotechnology	\N	\N	\N	\N	SG	SGD	NASDAQ NMS - GLOBAL MARKET	2023-04-14	23.53	65603824911	11.54	GDTC	https://w2.cytomed.sg	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950694330206.png	2025-09-03 19:03:22.947562	2025-09-03 19:03:22.947562
76	42328V801	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	42328V801	\N	\N	2025-09-03 19:03:25.294016	2025-09-03 19:03:25.294016
77	28059P303	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	28059P303	\N	\N	2025-09-03 19:03:27.652724	2025-09-03 19:03:27.652724
78	WKSP	Worksport Ltd	Auto Components	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2001-06-21	20.13	18885548789	6.64	WKSP	https://worksport.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/942959002326.png	2025-09-03 19:03:30.043197	2025-09-03 19:03:30.043197
80	PHIO	Phio Pharmaceuticals Corp	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2012-05-10	12.14	15087673861	5.73	PHIO	https://phiopharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/PHIO.png	2025-09-03 19:03:34.795297	2025-09-03 19:03:34.795297
83	PNBK	Patriot National Bancorp Inc	Banking	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	1994-08-31	146.76	12033247500	97.19	PNBK	https://bankpatriot.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/PNBK.png	2025-09-03 19:03:44.763419	2025-09-03 19:03:44.763419
84	NITO	N2OFF Inc	Chemicals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2010-05-26	7.16	1972544561349	33.36	NITO	https://savefoods.co/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950870536236.png	2025-09-03 19:03:47.143713	2025-09-03 19:03:47.143713
88	89357L402	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	89357L402	\N	\N	2025-09-03 19:03:57.389973	2025-09-03 19:03:57.389973
89	TRNR	Interactive Strength Inc	Leisure Products	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-04-28	6.08	13106978655	1.55	TRNR	https://www.formelife.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950711479836.png	2025-09-03 19:04:00.144272	2025-09-03 19:04:00.144272
90	92840Q202	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	92840Q202	\N	\N	2025-09-03 19:04:02.83146	2025-09-03 19:04:02.83146
91	GRCE	Grace Therapeutics, Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2013-03-07	41.35	16093221602	13.83	GRCE	https://www.gracetx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950906495556.png	2025-09-03 19:04:08.162046	2025-09-03 19:04:08.162046
93	LTRY	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	LTRY	\N	\N	2025-09-03 19:04:13.275972	2025-09-03 19:04:13.275972
99	G0447T100	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G0447T100	\N	\N	2025-09-03 19:04:28.538893	2025-09-03 19:04:28.538893
100	LPTX	Leap Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2017-01-24	12.20	16177140360	41.44	LPTX	https://www.leaptx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/LPTX.png	2025-09-03 19:04:31.162581	2025-09-03 19:04:31.162581
102	BTCT	BTC Digital Ltd	Technology	\N	\N	\N	\N	CN	USD	NASDAQ NMS - GLOBAL MARKET	2018-10-17	23.89	118675582945250	9.52	BTCT	https://btct.investorroom.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950728080396.png	2025-09-03 19:04:38.811875	2025-09-03 19:04:38.811875
108	M97838128	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	M97838128	\N	\N	2025-09-03 19:04:53.889335	2025-09-03 19:04:53.889335
111	97382D501	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	97382D501	\N	\N	2025-09-03 19:05:04.456471	2025-09-03 19:05:04.456471
112	PYXS	Pyxis Oncology Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-10-08	82.48	16172219059	62.02	PYXS	https://pyxisoncology.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950708259806.png	2025-09-03 19:05:07.10064	2025-09-03 19:05:07.10064
79	MGRM	Monogram Technologies Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-05-18	240.54	17185763205	40.63	MGRM	https://www.monogramtechnologies.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950683325816.png	2025-09-03 19:03:32.434838	2025-09-03 19:03:32.434838
81	AISP	Airship AI Holdings Inc	Technology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-03-19	135.61	18774624250	31.91	AISP	https://ir.airship.ai/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950869484366.png	2025-09-03 19:03:40.065236	2025-09-03 19:03:40.065236
82	ACB	Aurora Cannabis Inc	Pharmaceuticals	\N	\N	\N	\N	CA	CAD	TORONTO STOCK EXCHANGE	2007-09-26	417.76	16043625207	56.25	ACB.TO	https://www.auroramj.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/ACB.TO.png	2025-09-03 19:03:42.428076	2025-09-03 19:03:42.428076
85	FFAI	Faraday Future Intelligent Electric Inc	Automobiles	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-07-24	305.40	16465029845	146.83	FFAI	https://www.ff.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950748507876.png	2025-09-03 19:03:49.566286	2025-09-03 19:03:49.566286
86	SPAI	Safe Pro Group Inc	Aerospace & Defense	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2024-08-28	98.95	17864094030	18.17	SPAI	https://safeprogroup.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950840521086.png	2025-09-03 19:03:52.325883	2025-09-03 19:03:52.325883
87	ARBE	Arbe Robotics Ltd	Electrical Equipment	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2020-10-08	131.45	972737969804	108.67	ARBE	https://arberobotics.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950600691946.png	2025-09-03 19:03:54.953209	2025-09-03 19:03:54.953209
92	890260847	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	890260847	\N	\N	2025-09-03 19:04:10.518603	2025-09-03 19:04:10.518603
94	STAI	ScanTech AI Systems Inc	Electrical Equipment	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-03-14	22.09	14706550886	48.26	STAI	https://www.scantechais.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950374785876.png	2025-09-03 19:04:15.630606	2025-09-03 19:04:15.630606
95	AMBO	Ambow Education Holding Ltd	Diversified Consumer Services	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2010-08-05	9.91	16196848954	5.24	AMBO	https://www.ambow.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950007902136.png	2025-09-03 19:04:18.386998	2025-09-03 19:04:18.386998
96	INVZ	Innoviz Technologies Ltd	Electrical Equipment	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2020-05-05	312.37	972747003692	200.77	INVZ	https://innoviz.tech/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950517679136.png	2025-09-03 19:04:20.999864	2025-09-03 19:04:20.999864
97	QLGN	Qualigen Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2015-06-24	3.03	17609189165	1.70	QLGN	https://qlgntx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/QLGN.png	2025-09-03 19:04:23.366104	2025-09-03 19:04:23.366104
98	81728A108	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	81728A108	\N	\N	2025-09-03 19:04:25.742363	2025-09-03 19:04:25.742363
101	ALLO	Allogene Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2018-10-11	248.51	16504572700	221.88	ALLO	https://allogene.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950633106796.png	2025-09-03 19:04:36.44106	2025-09-03 19:04:36.44106
103	IMRX	Immuneering Corp	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-07-30	217.55	16175008080	36.32	IMRX	https://immuneering.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950355456166.png	2025-09-03 19:04:41.109904	2025-09-03 19:04:41.109904
104	SCPX	Scorpius Holdings Inc	Biotechnology	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2013-07-24	0.13	19192407133	61.14	SCPX	https://www.nighthawkbio.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/HTBX.png	2025-09-03 19:04:43.886795	2025-09-03 19:04:43.886795
105	VINC	Vincerx Pharma Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-03-10	0.16	16508006676	5.23	VINC	https://vincerx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950733414056.png	2025-09-03 19:04:46.256764	2025-09-03 19:04:46.256764
106	BACK	IMAC Holdings Inc	Biotechnology	\N	\N	\N	\N	US	USD	OTC MARKETS	2019-02-13	0.30	18442664622	3.78	BACK	https://imacregeneration.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950646424836.png	2025-09-03 19:04:48.989022	2025-09-03 19:04:48.989022
107	IVVD	Invivyd Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-08-06	200.80	17818190080	209.38	IVVD	https://invivyd.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950761615346.png	2025-09-03 19:04:51.400293	2025-09-03 19:04:51.400293
109	48669G204	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	48669G204	\N	\N	2025-09-03 19:04:56.322404	2025-09-03 19:04:56.322404
110	G55032166	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G55032166	\N	\N	2025-09-03 19:04:58.708697	2025-09-03 19:04:58.708697
113	SONN	Sonnet Biotherapeutics Holdings Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2005-07-27	21.41	16093752227	6.75	SONN	https://www.sonnetbio.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/SONN.png	2025-09-03 19:05:09.543925	2025-09-03 19:05:09.543925
114	PRZO	Parazero Technologies Ltd	Electrical Equipment	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2023-07-27	25.52	97236885252	18.76	PRZO	https://parazero.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950821598326.png	2025-09-03 19:05:12.021509	2025-09-03 19:05:12.021509
115	NWTG	Newton Golf Company Inc	Leisure Products	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-08-15	8.39	18337766659	4.61	NWTG	https://newtongolfco.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950834000856.png	2025-09-03 19:05:14.777772	2025-09-03 19:05:14.777772
116	ZENA	ZenaTech Inc	Technology	\N	\N	\N	\N	CA	CAD	NASDAQ NMS - GLOBAL MARKET	2024-10-01	169.19	16472491622	32.98	ZENA	https://www.zenatech.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950763893826.png	2025-09-03 19:05:17.166696	2025-09-03 19:05:17.166696
117	BNZI	Banzai International Inc	Technology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2020-12-23	11.69	12064141777	3.46	BNZI	https://www.banzai.io/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950792204106.png	2025-09-03 19:05:19.567086	2025-09-03 19:05:19.567086
118	TNFA	TNF Pharmaceuticals Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2008-07-24	853.05	18568488698	176.62	TNFA	https://tnfpharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950871078906.png	2025-09-03 19:05:22.312415	2025-09-03 19:05:22.312415
119	MSAI	MultiSensor AI Holdings Inc	Electrical Equipment	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-10-19	23.50	18668610788	34.57	MSAI	https://investors.multisensorai.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950813793906.png	2025-09-03 19:05:24.674595	2025-09-03 19:05:24.674595
120	G33277131	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G33277131	\N	\N	2025-09-03 19:05:26.998499	2025-09-03 19:05:26.998499
121	73017P102	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	73017P102	\N	\N	2025-09-03 19:05:32.330426	2025-09-03 19:05:32.330426
122	KTTA	Pasithea Therapeutics Corp	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-08-13	6.69	17025144174	7.44	KTTA	https://www.pasithea.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950797051836.png	2025-09-03 19:05:34.704357	2025-09-03 19:05:34.704357
123	HYPR	Hyperfine Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-01-27	95.08	18667966767	78.58	HYPR	https://hyperfinemri.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950029177606.png	2025-09-03 19:05:37.046347	2025-09-03 19:05:37.046347
124	NRXP	NRX Pharmaceuticals Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2017-11-20	61.80	14842546134	23.77	NRXP	https://www.nrxpharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/NRXP.png	2025-09-03 19:05:39.417293	2025-09-03 19:05:39.417293
125	CHEK	Check Cap Ltd	Health Care	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2015-02-19	4.10	97248303401	5.85	CHEK	https://check-cap.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/CHEK.png	2025-09-03 19:05:41.765387	2025-09-03 19:05:41.765387
126	OCEA	Ocean Biomedical Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-09-15	1.63	16469082658	232.37	OCEA	https://www.oceanbiomedical.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950811409676.png	2025-09-03 19:05:44.064549	2025-09-03 19:05:44.064549
127	BCTX	Briacell Therapeutics Corp	Biotechnology	\N	\N	\N	\N	CA	USD	TORONTO STOCK EXCHANGE	2006-10-12	20.14	16049211810	1.88	BCT.TO	https://briacell.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/BCT.TO.png	2025-09-03 19:05:46.849823	2025-09-03 19:05:46.849823
131	TRIB	Trinity Biotech PLC	Health Care	\N	\N	\N	\N	IE	USD	NASDAQ NMS - GLOBAL MARKET	1992-10-21	26.36	1135312955111	74.53	TRIB	https://www.trinitybiotech.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/942958748606.png	2025-09-03 19:05:59.506106	2025-09-03 19:05:59.506106
128	SPRC	Scisparc Ltd	Pharmaceuticals	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2021-12-22	1.30	97236103100	0.53	SPRC	https://scisparc.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/942962810876.png	2025-09-03 19:05:49.472432	2025-09-03 19:05:49.472432
129	89458T205	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	89458T205	\N	\N	2025-09-03 19:05:51.854857	2025-09-03 19:05:51.854857
130	BAOS	Baosheng Media Group Holdings Ltd	Media	\N	\N	\N	\N	CN	USD	NASDAQ NMS - GLOBAL MARKET	2021-02-08	4.37	861082088021	1.53	BAOS	https://www.bsacme.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950760900316.png	2025-09-03 19:05:54.236765	2025-09-03 19:05:54.236765
132	CTOR	Citius Oncology Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-10-14	157.52	13476270058	78.37	CTOR	https://citiusonc.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950902512016.png	2025-09-03 19:06:02.277428	2025-09-03 19:06:02.277428
133	90137F400	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	90137F400	\N	\N	2025-09-03 19:06:04.68283	2025-09-03 19:06:04.68283
134	SGN	Signing Day Sports Inc	Technology	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2023-11-14	6.16	16024817440	3.95	SGN	https://www.signingdaysports.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950821659466.png	2025-09-03 19:06:07.001357	2025-09-03 19:06:07.001357
135	76135L507	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	76135L507	\N	\N	2025-09-03 19:06:09.789742	2025-09-03 19:06:09.789742
136	DRMA	Dermata Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-08-13	3.94	18582230882	0.68	DRMA	https://www.dermatarx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950805177506.png	2025-09-03 19:06:12.208861	2025-09-03 19:06:12.208861
137	00941Q203	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	00941Q203	\N	\N	2025-09-03 19:06:14.975748	2025-09-03 19:06:14.975748
138	NMHI	Nature's Miracle Holding Inc	Machinery	\N	\N	\N	\N	US	USD	OTC MARKETS	2022-09-03	1.94	18884203694	12.52	NMHI	https://www.nature-miracle.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950836345576.png	2025-09-03 19:06:17.428177	2025-09-03 19:06:17.428177
139	TIVC	Tivic Health Systems Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-11-11	3.30	18882766888	1.08	TIVC	https://tivichealth.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950813785246.png	2025-09-03 19:06:20.202228	2025-09-03 19:06:20.202228
140	ATPC	Agape ATP Corp	Health Care	\N	\N	\N	\N	MY	USD	NASDAQ NMS - GLOBAL MARKET	2018-09-17	66.01	60327325716	50.01	ATPC	https://www.agapeatpgroup.com/index.php/agape-atp-corporation/introduction	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950577660626.png	2025-09-03 19:06:22.852227	2025-09-03 19:06:22.852227
141	ALDX	Aldeyra Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2014-05-02	344.40	17817614904	59.90	ALDX	https://www.aldeyra.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/ALDX.png	2025-09-03 19:06:28.15356	2025-09-03 19:06:28.15356
142	76090R309	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	76090R309	\N	\N	2025-09-03 19:06:30.470757	2025-09-03 19:06:30.470757
143	PALI	Palisade Bio Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2006-12-20	6.04	18587044900	9.12	PALI	https://palisadebio.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/PALI.png	2025-09-03 19:06:32.852548	2025-09-03 19:06:32.852548
144	CRGX	Cargo Therapeutics LLC	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2023-11-10	216.19	16504998950	48.36	CRGX	https://cargo-tx.com	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950838611276.png	2025-09-03 19:06:35.225028	2025-09-03 19:06:35.225028
145	APM	Aptorum Group Ltd	Biotechnology	\N	\N	\N	\N	GB	USD	NASDAQ NMS - GLOBAL MARKET	2018-12-18	13.29	85239537700	7.14	APM	https://www.aptorumgroup.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/APM.png	2025-09-03 19:06:37.633431	2025-09-03 19:06:37.633431
146	CYCN	Cyclerion Therapeutics Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2019-03-18	8.38	16176217722	3.34	CYCN	https://www.cyclerion.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950678438316.png	2025-09-03 19:06:40.384829	2025-09-03 19:06:40.384829
147	ORIS	Oriental Rise Holdings Ltd	Food Products	\N	\N	\N	\N	CN	USD	NASDAQ NMS - GLOBAL MARKET	2024-10-17	2.75	865938386777	22.01	ORIS	\N	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950800449726.png	2025-09-03 19:06:42.772489	2025-09-03 19:06:42.772489
148	TPET	Trio Petroleum Corp	Energy	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2023-04-18	8.58	1447581192515	7.52	TPET	https://www.triopetro.com	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950835385276.png	2025-09-03 19:06:45.185278	2025-09-03 19:06:45.185278
149	SKBL	Skyline Builders Group Holding Ltd	Construction	\N	\N	\N	\N	HK	USD	NASDAQ NMS - GLOBAL MARKET	2025-01-23	28.79	85228119688	28.23	SKBL	\N	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950906636536.png	2025-09-03 19:06:47.595174	2025-09-03 19:06:47.595174
150	BDRX	Biodexa Pharmaceuticals PLC	Biotechnology	\N	\N	\N	\N	GB	GBP	NASDAQ NMS - GLOBAL MARKET	2014-12-08	0.37	4401235888300	0.62	BDRX	https://www.biodexapharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/MTPH.L.png	2025-09-03 19:06:49.960439	2025-09-03 19:06:49.960439
151	G2161Y125	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G2161Y125	\N	\N	2025-09-03 19:06:55.502168	2025-09-03 19:06:55.502168
152	PROP	Prairie Operating Co	Energy	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2008-09-04	120.67	17134244247	50.28	PROP	https://prairieopco.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/942970980736.png	2025-09-03 19:06:57.923966	2025-09-03 19:06:57.923966
153	ADD	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	ADD	\N	\N	2025-09-03 19:07:00.935269	2025-09-03 19:07:00.935269
154	87978U108	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	87978U108	\N	\N	2025-09-03 19:07:03.544884	2025-09-03 19:07:03.544884
155	CLSD	Clearside Biomedical Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2016-06-02	26.62	16782703631	78.51	CLSD	https://clearsidebio.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/CLSD.png	2025-09-03 19:07:05.933292	2025-09-03 19:07:05.933292
156	PSNYW	Polestar Automotive Holding UK PLC	Automobiles	\N	\N	\N	\N	SE	USD	NASDAQ NMS - GLOBAL MARKET	2022-06-24	2925.44	4680070708822	2329.77	PSNY	http://www.polestar.com	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950813744166.png	2025-09-03 19:07:08.268645	2025-09-03 19:07:08.268645
157	CAPS	Capstone Holding Corp	Trading Companies & Distributors	\N	\N	\N	\N	US	USD	OTC MARKETS	1993-02-04	6.59	18559227786	5.58	CAPS	https://capstoneholdingcorp.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/942959074936.png	2025-09-03 19:07:10.61717	2025-09-03 19:07:10.61717
158	YIBO	Planet Image International Ltd	Commercial Services & Supplies	\N	\N	\N	\N	CN	USD	NASDAQ NMS - GLOBAL MARKET	2024-01-25	66.81	867907138216	53.88	YIBO	https://www.yibomk.com	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950742351676.png	2025-09-03 19:07:13.373791	2025-09-03 19:07:13.373791
159	IBO	Impact Biomedical Inc	Pharmaceuticals	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2024-09-16	7.31	15852321500	12.19	IBO	https://www.impactbiomedinc.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950736806116.png	2025-09-03 19:07:16.215971	2025-09-03 19:07:16.215971
160	NIXX	Nixxy Inc	Professional Services	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	1994-04-06	34.58	18777088868	20.83	NIXX	https://www.recruiter.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/RCRT.png	2025-09-03 19:07:18.615351	2025-09-03 19:07:18.615351
161	34546R100	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	34546R100	\N	\N	2025-09-03 19:07:23.823139	2025-09-03 19:07:23.823139
162	XHLD	TEN Holdings Inc	Media	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2025-02-13	11.25	18009099598	35.18	XHLD	https://www.tenholdingsinc.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950923235636.png	2025-09-03 19:07:26.180719	2025-09-03 19:07:26.180719
163	AREB	American Rebel Holdings Inc	Commercial Services & Supplies	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2016-02-01	6.02	18332673235	7.87	AREB	https://americanrebel.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950464567506.png	2025-09-03 19:08:21.413562	2025-09-03 19:08:21.413562
164	MLGO	MicroAlgo Inc	Technology	\N	\N	\N	\N	CN	CNY	NASDAQ NMS - GLOBAL MARKET	2021-02-11	109.82	8675588600589	12.44	MLGO	http://www.microalgor.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950792339096.png	2025-09-03 19:08:24.247294	2025-09-03 19:08:24.247294
169	ICCT	iCoreConnect Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2022-02-25	0.00	18888107706	4.88	ICCT	https://www.icoreconnect.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950821468556.png	2025-09-03 19:08:36.213254	2025-09-03 19:08:36.213254
173	RDHL	Redhill Biopharma Ltd	Pharmaceuticals	\N	\N	\N	\N	IL	USD	NASDAQ NMS - GLOBAL MARKET	2011-02-01	3.09	97235413131	918.14	RDHL	https://www.redhillbio.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/RDHL.png	2025-09-03 19:08:48.67205	2025-09-03 19:08:48.67205
174	SBFM	Sunshine Biopharma Inc	Biotechnology	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2008-08-15	6.56	19543300684	4.56	SBFM	https://www.sunshinebiopharma.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950004659366.png	2025-09-03 19:08:51.425718	2025-09-03 19:08:51.425718
165	GWAV	Greenwave Technology Solutions Inc	Commercial Services & Supplies	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2015-03-03	3.57	18004905020	0.57	GWAV	https://www.gwav.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950402696076.png	2025-09-03 19:08:26.60208	2025-09-03 19:08:26.60208
166	BJDX	Bluejay Diagnostics Inc	Health Care	\N	\N	\N	\N	US	USD	NASDAQ NMS - GLOBAL MARKET	2021-11-10	2.05	19786310152	1.49	BJDX	https://bluejaydx.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950545624296.png	2025-09-03 19:08:28.987212	2025-09-03 19:08:28.987212
167	03835L405	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	03835L405	\N	\N	2025-09-03 19:08:31.38974	2025-09-03 19:08:31.38974
168	71902K303	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	71902K303	\N	\N	2025-09-03 19:08:33.773623	2025-09-03 19:08:33.773623
170	SRXH	SRx Health Solutions Inc	Retail	\N	\N	\N	\N	US	USD	NYSE MKT LLC	2010-06-16	13.38	16468464280	15.41	SRXH	https://srxhealth.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950679443506.png	2025-09-03 19:08:38.637322	2025-09-03 19:08:38.637322
171	G14492121	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	G14492121	\N	\N	2025-09-03 19:08:41.040405	2025-09-03 19:08:41.040405
172	UCAR	U Power Ltd	Retail	\N	\N	\N	\N	CN	CNY	NASDAQ NMS - GLOBAL MARKET	2023-04-20	9.63	862168593598	4.86	UCAR	https://www.upincar.com/	https://static2.finnhub.io/file/publicdatany/finnhubimage/stock_logo/950836911176.png	2025-09-03 19:08:43.458153	2025-09-03 19:08:43.458153
\.


--
-- Data for Name: sync_metadata; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.sync_metadata (id, user_id, entity_type, entity_id, action, sync_version, change_data, device_id, created_at) FROM stdin;
\.


--
-- Data for Name: tags; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.tags (id, user_id, name, color, created_at) FROM stdin;
\.


--
-- Data for Name: tick_data; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.tick_data (id, symbol, date, "timestamp", price, volume, conditions, exchange, created_at, updated_at) FROM stdin;
\.


--
-- Data for Name: tick_data_cache; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.tick_data_cache (id, symbol, date, start_timestamp, end_timestamp, tick_count, fetched_at, expires_at) FROM stdin;
\.


--
-- Data for Name: tier_overrides; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.tier_overrides (id, user_id, tier, reason, expires_at, created_by, created_at, updated_at, reminder_sent_at, expiration_sent_at) FROM stdin;
\.


--
-- Data for Name: trade_attachments; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.trade_attachments (id, trade_id, file_url, file_type, file_name, file_size, uploaded_at) FROM stdin;
\.


--
-- Data for Name: trade_comments; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.trade_comments (id, trade_id, user_id, comment, edited_at, created_at, updated_at, deleted_at) FROM stdin;
\.


--
-- Data for Name: trade_hold_patterns; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.trade_hold_patterns (id, user_id, trade_id, is_winner, pnl, hold_time_minutes, expected_hold_time_minutes, exit_reason, exit_quality_score, max_favorable_excursion, max_adverse_excursion, exit_efficiency, premature_exit, extended_hold, panic_exit, created_at) FROM stdin;
1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	23081800-5567-4b1b-8475-a9c4ff7fa5de	f	-17.24	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.169189
2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	62612778-e860-486b-a39d-27d72702be43	t	12.13	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.172002
3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3ebde700-4b11-465a-8e1c-7553c59db044	t	0.73	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.172959
4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f7bf7090-f053-4b76-b3df-e3e87299c6b8	f	-41.25	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.173851
5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	bde2f6d3-8a9b-4b3d-9d0c-4da94e0a7e5f	t	41.80	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.174887
6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0443a999-541e-4a77-b215-39d5b3597122	t	52.55	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.175572
7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f08d29e6-a1b5-4519-9d14-db7dca34c27d	f	-1.92	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.176298
8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f672940c-e4f1-4db8-b4cb-90f3dc9b8c7b	f	-6.45	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.17698
9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3beb6591-f283-4add-b80d-3ec074784e03	f	-4.14	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.177621
10	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0cf9a9b9-7066-4372-8551-7d9a448736bb	t	4.22	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.178199
11	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3232c5b8-a343-4a4d-8a01-c6ff1a5580fa	f	-3.26	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.178778
12	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f2d4db7b-fac8-4b03-82e5-b2992ac63b33	t	0.06	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.179497
13	2d96cef2-7502-44ff-a7a9-17713d4a7a42	450ff732-a16e-4e1c-a1ed-a6bbc28bf074	t	1.38	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.180037
14	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7f3e3cf8-cdcb-48bb-b71c-0c6b02dc19e7	t	2.74	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.18059
15	2d96cef2-7502-44ff-a7a9-17713d4a7a42	de95e36a-904c-45d2-a18d-a8656d6b7fc9	t	3.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.181301
16	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6f0c2707-8a41-49f9-a9f3-ef9325527424	f	-5.26	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.181829
17	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4c1e5b72-06bd-41a2-8cb5-b57cdd6725a7	f	-7.27	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.182246
18	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4fbd9f1b-1efb-4dca-8632-41630f97becc	f	-39.76	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.182693
19	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2a8db9da-fef2-4153-abf5-ab8d4e79985b	f	-1.25	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.183149
20	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b84c4ff9-0957-4572-805f-07c31bb9b313	t	7.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.183543
21	2d96cef2-7502-44ff-a7a9-17713d4a7a42	12c8b550-a4f1-4b5f-ac39-f6162291c663	f	-85.73	5	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.183958
22	2d96cef2-7502-44ff-a7a9-17713d4a7a42	dac851a9-3aa8-4bc1-91dd-f0355634fb7d	f	-5.67	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.18435
23	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0e9841bb-5d77-4cb9-8cdf-46d9b686ceb0	t	23.03	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.184789
24	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ec2118c0-1d4a-4719-bf27-dfb451fbad04	t	32.19	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.185197
25	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c39bbcad-78bb-4355-bdb9-d428be00ba0f	f	-12.98	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.18564
26	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1ea5db6b-dd24-4695-96b1-fb3a1b4e80a4	f	-6.49	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.186095
27	2d96cef2-7502-44ff-a7a9-17713d4a7a42	33d4ed27-b349-4aed-b48e-0d063203af2a	t	11.37	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.186908
28	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d52ede45-d3b0-498c-9dab-51449b14a1e6	f	-3.18	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.187372
29	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c5d25d5e-fab7-4bd2-8e78-fe091f988fc3	f	-2.28	3	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.187844
30	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f709ddd6-456c-4f1b-831c-31fb626c18c7	f	-0.30	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.188353
31	2d96cef2-7502-44ff-a7a9-17713d4a7a42	481056fe-1402-4176-8316-60af2e225c57	t	63.86	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.189247
32	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7751bbfc-a944-44fc-a26f-95cfe9cf2d01	f	-2.28	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.190032
33	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0f6b6a53-20bb-46e5-93b2-67f066b2e218	f	-9.89	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.190685
34	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b28fc1c7-0cb7-44bb-8c1f-837b1dc8a24a	t	626.24	33148	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.191581
35	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1ac5e0d6-031d-4e17-a7aa-0a65718ccadc	t	4.72	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.192224
36	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7de4aa93-8a0a-487e-b540-b827ccf8d160	t	6.37	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.192699
37	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1ab12991-84a2-4e5f-bb85-7d42872346fd	t	37.19	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.193169
38	2d96cef2-7502-44ff-a7a9-17713d4a7a42	56dc5aee-f080-465f-9d9e-b5968659da26	t	37.49	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.193656
39	2d96cef2-7502-44ff-a7a9-17713d4a7a42	43752dc2-e08c-41c4-921b-3e60f9843cb0	t	4.49	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.194147
40	2d96cef2-7502-44ff-a7a9-17713d4a7a42	02f78421-577a-4de2-92a3-a0e622963a01	f	-47.67	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.194583
41	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e3857dd9-7e80-47bb-aaf6-eaa7798f3921	t	62.35	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.195034
42	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1258401a-b7d8-43b8-8f76-03d2458bc650	t	5.51	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.195559
43	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a014df91-49e3-41d5-967b-060f8451ba9d	t	35.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.195972
44	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0b112c0a-4a3b-4dd5-8f17-4410286c3dc0	t	0.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.196378
45	2d96cef2-7502-44ff-a7a9-17713d4a7a42	36fe0338-75d9-4c0a-96a8-fc85fde12b63	t	125.19	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.196747
46	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c8c472ea-06da-43c6-af94-bdf28d969fc1	t	19.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.197247
47	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5eb6a4f1-4bec-4d41-91a3-2f3d9fe36750	t	4.50	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.197683
48	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b86166ad-8871-4c58-9423-505825070d76	f	-5.36	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.198141
49	2d96cef2-7502-44ff-a7a9-17713d4a7a42	00220d91-0366-440a-9069-479875535d4e	t	8.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.198542
50	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f22c3d0e-bbdf-4ccd-88f5-e892dbd7304a	t	57.87	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.198973
51	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7315f222-dd5f-4e83-9f1d-dd289c43e978	t	9.64	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.199531
52	2d96cef2-7502-44ff-a7a9-17713d4a7a42	75418968-359d-4b3a-ae19-3dfbdf72a088	f	-2.40	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.200091
53	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9945d4fd-d3ac-4f61-be3a-00ac97bdeaee	f	-2.28	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.200517
54	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e73b4b82-2eae-4938-9589-7670a569e723	f	-0.78	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.201086
55	2d96cef2-7502-44ff-a7a9-17713d4a7a42	84346238-c8e3-44aa-8cf4-51738bfd5106	t	41.45	7	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.201595
56	2d96cef2-7502-44ff-a7a9-17713d4a7a42	19607175-0f9f-4aee-a3d3-008fc152d1c2	f	-25.25	3	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.202079
57	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cfc81afd-0e4d-413a-a84f-7601d0e94801	t	19.99	16179	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.202562
58	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6f5b1051-d41c-4c99-a689-31065f053154	t	79.42	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.203036
59	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3d5859f3-7ce0-4980-93df-21b2f733f258	f	-96.27	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.203452
60	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f0b1e381-c5bb-425e-b79d-badd58e5adaf	f	-31.25	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.203851
61	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d27209d0-304a-47f0-b381-95e190cba31d	t	38.75	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.204238
62	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b4056382-a4c3-4f3e-97f5-1e22e22ffa33	t	20.19	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.204668
63	2d96cef2-7502-44ff-a7a9-17713d4a7a42	46604636-a78b-4bda-8880-2871ba64bfff	t	30.76	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.205388
64	2d96cef2-7502-44ff-a7a9-17713d4a7a42	20e2c5ac-a1c2-4b9c-bc33-0267b52bb8e6	t	0.37	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.205989
65	2d96cef2-7502-44ff-a7a9-17713d4a7a42	eed5b0db-7103-4e85-9cbc-7b5b71f1aad9	t	11.17	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.206467
66	2d96cef2-7502-44ff-a7a9-17713d4a7a42	514fae0b-1f20-4a09-9425-64a2e02cbc4d	f	-64.34	5	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.206946
67	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5d1df466-58eb-4c7e-b0c4-0d1ccbef0b87	f	-23.25	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.207399
68	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f8d6d5ee-83db-4785-88b7-80083ed1b269	f	-2.35	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.207896
69	2d96cef2-7502-44ff-a7a9-17713d4a7a42	974d7d4d-f474-4033-b5a1-b4d1373e646e	t	88.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.208262
70	2d96cef2-7502-44ff-a7a9-17713d4a7a42	72e613a2-674a-4961-a327-11f8fad348b2	t	42.72	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.208634
71	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8bd0e5e6-71f1-4259-b86c-3d9106d90228	t	20.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.209164
72	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ac4e0559-820b-4349-bc31-8b95ad804393	t	7.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.209504
73	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5209998d-fb00-4f44-9fed-0ac459c2489c	t	17.45	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.210086
74	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a7f14c00-ccce-4831-9e32-7ee463c9b3f5	t	63.18	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.210408
75	2d96cef2-7502-44ff-a7a9-17713d4a7a42	82bc8ec8-77fe-4e01-b27d-6f22b007c87e	t	3316.12	12963	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.210726
76	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fb78ffa1-367c-467d-a940-37e8d4cdd01c	t	6.75	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.211293
77	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9966d738-cac2-4d67-a6f6-8773cb7ed773	f	-42.15	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.211707
78	2d96cef2-7502-44ff-a7a9-17713d4a7a42	418044f8-928f-4004-acb0-3230da5a3b84	t	4.75	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.212153
79	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4de25751-3e80-4f39-849e-a1ae796e2c0b	f	-41.26	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.212478
80	2d96cef2-7502-44ff-a7a9-17713d4a7a42	52b342d9-fa2d-4b4d-8626-ecf6ece1b8c5	t	10.10	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.212848
81	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1d8c203d-cefc-4472-beef-d1b0efdc3af3	t	32.74	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.213194
82	2d96cef2-7502-44ff-a7a9-17713d4a7a42	edbcb884-0764-476c-8ee1-d9743564f99a	t	4.75	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.21349
83	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0507fa14-61b5-4840-86f8-cd3f9b78e4e0	f	-11.25	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.213955
84	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b3b213af-9f93-48a2-8f0e-fe2379854377	t	0.75	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.214308
85	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6038f779-28f7-40d7-ac65-a4d7c1e56b78	t	3.92	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.21466
86	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a4a35db5-1357-432e-8bea-32af44c1c284	f	-1.25	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.215076
87	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c9c0b43f-cb0e-4383-b51d-58d570d253de	t	22.74	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.215489
88	2d96cef2-7502-44ff-a7a9-17713d4a7a42	44964d1e-77de-4a87-bb80-ff2bf02553ac	f	-153.54	258	\N	\N	0.82	\N	\N	\N	f	f	f	2025-09-03 19:03:49.215988
89	2d96cef2-7502-44ff-a7a9-17713d4a7a42	96647307-c0e3-4eaf-9564-42d52fb6f56b	t	9.75	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.216363
90	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7ce0f34c-dfe2-44b6-910c-f3454fbf8a75	f	-24.08	4	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.216676
91	2d96cef2-7502-44ff-a7a9-17713d4a7a42	770eedb1-ac75-4664-b48a-4a2811219c62	f	-132.68	16	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.21696
92	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a8de21e7-b693-4da8-b7dd-5d38b039ee63	t	111.56	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.217252
93	2d96cef2-7502-44ff-a7a9-17713d4a7a42	72194188-48e1-4e87-a8d7-e792c6dad79d	f	-231.84	8	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.217593
94	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b6aa655a-09fc-4fa0-add4-dd4b35c1643c	t	1.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.217953
95	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d455e82b-7d92-4715-9d22-57a7adddccb6	f	-99.94	5	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.218261
96	2d96cef2-7502-44ff-a7a9-17713d4a7a42	be3f1c6c-44ca-451b-a82c-40d9ab595fbd	t	1.91	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.218649
97	2d96cef2-7502-44ff-a7a9-17713d4a7a42	20767967-25e0-4c11-9284-831061a528d5	f	-15.22	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.218986
98	2d96cef2-7502-44ff-a7a9-17713d4a7a42	acbfad78-2057-47a9-be1b-25be582cc165	t	0.75	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.219344
99	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8083af56-3243-41c0-99b5-c89eddc76c28	t	5.86	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.219652
100	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2817070c-bf93-4443-9bad-ab7bd79aa0b5	t	5.74	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.219943
101	2d96cef2-7502-44ff-a7a9-17713d4a7a42	500a3a77-7286-484f-afe8-42e6a582a3a2	f	-41.80	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.220237
102	2d96cef2-7502-44ff-a7a9-17713d4a7a42	efd87d9d-f87a-4f8c-9d18-b27e3aa1ad55	f	-1.25	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.220534
103	2d96cef2-7502-44ff-a7a9-17713d4a7a42	39eb8837-d36d-4591-ace8-3bc3fccd02e5	t	1.74	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.220813
104	2d96cef2-7502-44ff-a7a9-17713d4a7a42	17795b19-e326-42e5-9129-796656c62427	t	27.73	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.221149
105	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6fb7ebf1-b92b-4cd3-af53-b5d3872ff846	t	0.94	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.221428
106	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6392597c-d274-409a-89f1-a759ea3bb647	f	-8.36	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.221703
107	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a9643134-38a3-43d6-863f-b5f70f300c96	f	-1.76	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.22199
108	2d96cef2-7502-44ff-a7a9-17713d4a7a42	11b6beb7-94d6-443a-9e51-d83ed57a0a49	f	-7.85	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.222266
109	2d96cef2-7502-44ff-a7a9-17713d4a7a42	904d448f-c904-466d-adb7-d7e950a66ff7	t	7.66	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.222551
110	2d96cef2-7502-44ff-a7a9-17713d4a7a42	576a8ac6-d85a-45fd-9b35-a1f88b0a0706	f	-1.25	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.222913
111	2d96cef2-7502-44ff-a7a9-17713d4a7a42	53c2ed15-e333-40bc-8fba-f83547ead9c2	t	10.76	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.223194
112	2d96cef2-7502-44ff-a7a9-17713d4a7a42	930b3522-3e92-4fa7-84a4-444ba83d0890	f	-1.24	3	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.223467
113	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0fefbdd2-46e5-4bea-9d91-e928b6a6d095	f	-54.19	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.223733
114	2d96cef2-7502-44ff-a7a9-17713d4a7a42	51fdf604-f317-4d2b-ab59-48667bdc8613	t	0.75	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.224019
115	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c4d8ce81-3bf4-4978-be00-5bdf3509fa29	f	-37.83	356	\N	\N	0.76	\N	\N	\N	f	f	f	2025-09-03 19:03:49.22447
116	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1d3d6253-6416-402c-ab37-1f9f9dc83086	f	-2.55	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.224973
117	2d96cef2-7502-44ff-a7a9-17713d4a7a42	bc40c0af-d521-42e3-a1c0-1a2daf7b644e	f	-1.25	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.225321
118	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f9748321-fb32-40a9-ac51-a53a6cb1d0f0	t	11.77	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.225604
119	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7259c54e-37d5-457a-81fd-23890fc19a73	f	-68.78	10	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.225886
120	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c2568a2a-4e8b-402b-b7bc-57d82f457c31	t	17.67	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.226149
121	2d96cef2-7502-44ff-a7a9-17713d4a7a42	35f41a3c-7aa9-4d9d-bd36-4f1177b7ac7d	t	6.75	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.226413
122	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cbc9d0a2-69b1-467e-80e3-2365d10ba91a	f	-3.25	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.226705
123	2d96cef2-7502-44ff-a7a9-17713d4a7a42	081d46ba-dde9-4753-8bbe-b9bfafdc953b	t	13.47	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.226998
124	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8236e8c4-a2a6-48e8-947d-c2efc7c53a4e	t	10.74	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.227356
125	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b8e8fc3f-bab3-4b0f-b41e-44c8fabea1f8	t	2.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.227626
126	2d96cef2-7502-44ff-a7a9-17713d4a7a42	605aaa3e-9ae5-4ad6-b6b3-454116864081	f	-3.98	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.227894
127	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7bf11f1c-6711-4db4-940c-84e059226599	f	-44.99	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.228173
128	2d96cef2-7502-44ff-a7a9-17713d4a7a42	41aff738-540f-4c35-9794-e39312511c91	t	30.23	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.228446
129	2d96cef2-7502-44ff-a7a9-17713d4a7a42	968abd8b-902d-49b6-ad08-e7fafe0ab590	t	3.75	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.228734
130	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6d5d2e96-c5ad-4507-86ba-17ac97abcbf0	f	-1.25	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.229022
131	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d0a16cc7-8052-4af9-90f9-fa0895269dc3	f	-1.27	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.229286
132	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9f329ed3-68ec-4a30-a7c7-c21b3e4c86ea	t	17.28	6	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.229756
133	2d96cef2-7502-44ff-a7a9-17713d4a7a42	759b2da3-fbba-49fb-9626-a7a2078b903b	t	12.22	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.230063
134	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b6074954-cf82-4d3a-9042-02640c302437	f	-6.30	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.230336
135	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ab0f0a4e-dc3d-418a-b691-d4ea03fb26c8	t	2.30	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.230591
136	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d0e2a1c4-3c27-48b7-8bb7-e044501668b7	t	1.57	51	\N	\N	0.11	\N	\N	\N	t	f	f	2025-09-03 19:03:49.230882
137	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2ff19a0b-8da6-4ba8-b276-1fd699a0bd8b	t	45.75	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.231147
138	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a9702cb2-b03f-4c96-9562-3ae6c4695ead	t	4.68	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.23141
139	2d96cef2-7502-44ff-a7a9-17713d4a7a42	faf5f61f-5673-4275-ac70-a2a13569b711	t	6.53	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.23167
140	2d96cef2-7502-44ff-a7a9-17713d4a7a42	424f4d85-a70f-4bff-a5bb-5dd8ec8e207f	t	9.67	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.232004
141	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e7f6cc69-3367-42db-bd98-dda2521714f4	t	11.43	9	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.232344
142	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f9330748-45fa-4445-b2a0-34cedf265cbe	f	-7.86	6	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.232633
143	2d96cef2-7502-44ff-a7a9-17713d4a7a42	739cc92c-e324-4f58-804b-6ab85bccbec6	t	0.76	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.232927
144	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b2d4f5d0-b77b-4316-bf34-f5ca6e657bc8	t	9.65	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.233199
145	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5bce72af-0be3-44da-a29e-3d169ba27466	t	46.15	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.233467
146	2d96cef2-7502-44ff-a7a9-17713d4a7a42	34b10885-9bc3-41cd-9fb2-066d0ce26bf1	t	3.65	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.233822
147	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cdb79cf8-907b-4ba2-bbcc-9e8bcac052df	t	8.11	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.234189
148	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0b67d34c-58b5-4d54-935a-128536c6c5ae	t	12.74	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.234618
149	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2f2dc23c-0ba0-4cd9-a061-9b0db752ee79	t	12.87	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.234905
150	2d96cef2-7502-44ff-a7a9-17713d4a7a42	273c2288-f98d-42eb-863f-f81d6f3cea4b	t	5.18	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.235215
151	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b2adbbd5-03d7-45f4-9bb9-7dfbbf54bb83	f	-49.46	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.235498
152	2d96cef2-7502-44ff-a7a9-17713d4a7a42	72be4dd1-3816-4dee-90cb-670106260c4a	t	5.72	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.235764
153	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c762905b-72af-467b-b5e3-7320b51d592e	t	3.64	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.236087
154	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5d3bd893-e3a9-4d2c-a204-cad9f4546858	t	7.36	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.236402
155	2d96cef2-7502-44ff-a7a9-17713d4a7a42	904cd33c-af0a-493f-847d-19bdcfebe5c5	t	16.09	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.236741
156	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5fc8db5c-5976-495a-ac58-637330bc58d7	t	69.66	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.237075
157	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f413fd79-3fa8-4294-9609-924d7c7ded37	t	32.64	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.237354
158	2d96cef2-7502-44ff-a7a9-17713d4a7a42	049e9e1e-c30e-432f-961d-90cd6fe8838c	t	18.65	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.23762
159	2d96cef2-7502-44ff-a7a9-17713d4a7a42	85142cd7-901c-4ef8-9616-8be2e7bb8d3e	t	19.02	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.237992
160	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fbdc029e-7c7b-4035-bdd9-af4c88bf3bc7	t	4.74	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.238338
161	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3097d30d-c397-4137-a979-2abe3c65f395	f	-47.66	7	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.238679
162	2d96cef2-7502-44ff-a7a9-17713d4a7a42	82c2a0ff-9feb-406b-bcd5-b57126235d37	t	267.50	8582	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.238984
163	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4a70d2b0-d498-4844-9291-fbb698fd43d2	t	4.67	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.239245
164	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f65c083f-72da-4b48-a35c-35dc29441ad2	t	28.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.239621
165	2d96cef2-7502-44ff-a7a9-17713d4a7a42	964239b7-1400-4299-bc02-fdab6113daf0	t	30.72	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.239909
166	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f8d5dede-911d-4594-859e-526db89ceb03	t	0.72	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.240181
167	2d96cef2-7502-44ff-a7a9-17713d4a7a42	eac89a62-2af1-4146-adc1-a51084bf995d	t	8.75	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.240441
168	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5b902936-c3d6-417d-9c14-5c78132e8309	t	4.98	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.240704
169	2d96cef2-7502-44ff-a7a9-17713d4a7a42	af6ef801-4581-464f-8f57-7f4c411bfb85	t	16.11	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.240974
170	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7d5c7424-d376-4e2d-a594-bc8a8c571ca9	f	-78.29	13	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.241251
171	2d96cef2-7502-44ff-a7a9-17713d4a7a42	df6eccc5-a74d-4080-8770-89c2b5df1fe6	t	95.32	143	\N	\N	0.31	\N	\N	\N	t	f	f	2025-09-03 19:03:49.241521
172	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8b01c162-4946-49eb-a2f8-20eaa6d0ca2b	t	23.72	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.241809
173	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5e05cb12-ba30-4cf5-92db-e161b9940591	t	45.99	18	\N	\N	0.04	\N	\N	\N	t	f	f	2025-09-03 19:03:49.242105
174	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9028b122-eca8-450f-98a8-5cf515235d62	t	677.75	114	\N	\N	0.24	\N	\N	\N	t	f	f	2025-09-03 19:03:49.242384
175	2d96cef2-7502-44ff-a7a9-17713d4a7a42	206fe5a2-a57d-479d-b633-2b8863ab0ad2	t	23.99	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.242636
176	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d4c52114-b262-4053-a962-9b8057fabfa1	t	22.28	383	\N	\N	0.82	\N	\N	\N	f	f	f	2025-09-03 19:03:49.243246
177	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0bb698bb-c87c-43d6-908d-f41df90555bd	t	7.74	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.243645
178	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f8d146c7-67d4-44f9-857f-67cc0fb684c0	t	43.05	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.243944
179	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e0b51e88-5a66-4335-811c-2d2472013c2b	t	49.36	94	\N	\N	0.20	\N	\N	\N	t	f	f	2025-09-03 19:03:49.244208
180	2d96cef2-7502-44ff-a7a9-17713d4a7a42	12084622-cdf3-468d-9a80-41a84120f3d7	t	14.06	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.244482
181	2d96cef2-7502-44ff-a7a9-17713d4a7a42	15aaceb7-6b08-46ba-a959-ceae18232b09	t	5.74	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.244748
182	2d96cef2-7502-44ff-a7a9-17713d4a7a42	02cb4570-0f94-45bd-af55-2d6e31acffc3	t	8.19	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.245035
183	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2fc303b7-def0-4e80-b552-b5dc67233d2f	f	-74.35	3229	\N	\N	0.10	\N	\N	\N	f	t	f	2025-09-03 19:03:49.245293
184	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c58ae0cb-b66a-45c4-ae27-0d61eadaab5e	t	18.38	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.246015
185	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6483d304-d727-4f43-9038-ee0240dc2e6a	t	8.75	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.246352
186	2d96cef2-7502-44ff-a7a9-17713d4a7a42	128ed5f7-1a98-4aac-8080-2311dbbc6dc6	f	-68.18	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.246678
187	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8bd25f9d-aef8-4ac0-af2b-a8bea75bfaac	t	8.29	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.248364
188	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e33cc384-92a8-4451-a2fe-ae95b626c122	t	5.11	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.248894
189	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5f97cdc2-e673-422a-a110-26002c488c35	t	62.87	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.24924
190	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a24911f5-2b21-4f98-b631-f16d1c3d874c	f	-328.55	10	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.249585
191	2d96cef2-7502-44ff-a7a9-17713d4a7a42	250b9d52-48f6-454b-b412-fdea54fbb46c	t	10.70	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.250049
192	2d96cef2-7502-44ff-a7a9-17713d4a7a42	10187771-9876-4cbf-b38e-51c85d157f01	t	4821.35	41853	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.250395
193	2d96cef2-7502-44ff-a7a9-17713d4a7a42	68368180-d699-43ef-ba2a-e63b6b1a5ce5	t	90.33	29	\N	\N	0.06	\N	\N	\N	t	f	f	2025-09-03 19:03:49.250722
194	2d96cef2-7502-44ff-a7a9-17713d4a7a42	25fabbca-2d3c-4836-866e-b99dc069404f	t	31.96	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.251065
195	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fbc2549c-ce4a-42ed-83de-844593b578dd	t	197.49	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.251366
196	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0f2042b4-c933-47d9-8955-1b50e56574c8	t	9.20	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.251649
197	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9576b0fc-3844-4c16-9847-df9e0dbfda6e	t	67.63	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.251993
198	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f14f7d20-79af-491e-ace9-9f9ddcd67ff5	f	-4.45	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.252327
199	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5e614ef9-7ecc-4a50-afd3-996269c89a4a	t	45.62	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.252608
200	2d96cef2-7502-44ff-a7a9-17713d4a7a42	dfae9fb7-c6ce-4e67-97cf-f49f01503f2d	t	160.99	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.252927
201	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d99e6b18-c18f-41ec-babe-198081ca9f94	f	-688.03	51335	\N	\N	0.10	\N	\N	\N	f	t	f	2025-09-03 19:03:49.253313
202	2d96cef2-7502-44ff-a7a9-17713d4a7a42	de1f2f5a-e4b6-4c52-9473-00c7d9d6966d	t	74.47	20	\N	\N	0.04	\N	\N	\N	t	f	f	2025-09-03 19:03:49.253578
203	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5b85a6c1-8463-442e-bf33-a204da3e8521	t	24.65	1627	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.253876
204	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e8d85b3c-2bf8-482e-8123-bc8af46a8778	t	36.57	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.254152
205	2d96cef2-7502-44ff-a7a9-17713d4a7a42	033f9947-0e4a-4337-a1f9-5993fd0622c8	t	60.00	11	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.254484
206	2d96cef2-7502-44ff-a7a9-17713d4a7a42	02f756ab-6add-43ca-b9aa-f5a2c5c8a45a	t	48.36	13	\N	\N	0.03	\N	\N	\N	t	f	f	2025-09-03 19:03:49.254793
207	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e5bad97a-6e12-4e94-86ba-c2f49bb4eaa8	f	-801.28	30360	\N	\N	0.10	\N	\N	\N	f	t	f	2025-09-03 19:03:49.255115
208	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2ab76c62-abe4-42d2-88d9-010d7cf790e0	t	81.91	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.255381
209	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4af9d7e1-aaf4-4368-aa59-a20c4d19b534	f	-938.71	13	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.255646
210	2d96cef2-7502-44ff-a7a9-17713d4a7a42	61b5a4fb-7568-43e4-b4e9-fd07d49cc906	f	-93.78	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.255956
211	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fbe899b1-db53-4523-96ba-e0019ed5b9eb	t	46.40	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.25624
212	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1aa7e837-f1cb-4682-9bc0-0d70b3b7dbd1	t	13.46	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.256496
213	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d0c629e8-5435-4ddc-8097-666c9d97e827	t	26.14	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.256773
214	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b0a66cdd-28ca-46f5-bd64-de5eb0745185	t	66.05	274	\N	\N	0.59	\N	\N	\N	f	f	f	2025-09-03 19:03:49.257051
215	2d96cef2-7502-44ff-a7a9-17713d4a7a42	79b26b2e-9d44-4c74-867f-f0ed7ae255ca	f	-21.97	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.257312
216	2d96cef2-7502-44ff-a7a9-17713d4a7a42	74418d14-6696-4ab5-a1cd-0241d50029ec	f	-4.92	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.257586
217	2d96cef2-7502-44ff-a7a9-17713d4a7a42	46e59ae1-76e6-4475-b1f6-dd394b5c0733	t	1.45	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.257962
218	2d96cef2-7502-44ff-a7a9-17713d4a7a42	62ead7bc-01b2-4062-b4f3-dbe1ecea33e2	t	33.50	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.258266
219	2d96cef2-7502-44ff-a7a9-17713d4a7a42	95074c72-0a8d-47ef-a831-8039da34cdb5	f	-15.62	7	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.258537
220	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6ca06a91-d87c-4792-82f5-311757ac1747	t	240.01	7	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.258858
221	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d87c1991-d9b9-4d5f-a407-c3605d38dc9e	t	73.53	11	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.259211
222	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a0094961-5f4a-4d10-9ea5-eaf27c696530	f	-1474.69	2856	\N	\N	0.10	\N	\N	\N	f	t	f	2025-09-03 19:03:49.259498
223	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d0bd2cf0-3643-4476-8d9a-f62e067a885f	t	65.86	10	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.259771
224	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ab3342cc-6cab-4d63-8b3d-c0e786c63696	t	14.02	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.260058
225	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c73a8d3d-e3d5-454d-96d3-10de2141bfb5	f	-30.99	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.260328
226	2d96cef2-7502-44ff-a7a9-17713d4a7a42	aa289251-8d7d-43db-8e72-d917a9774fd7	t	96.23	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.260594
227	2d96cef2-7502-44ff-a7a9-17713d4a7a42	33051b0f-5286-4cbe-a6ad-30e05587b975	t	15.01	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.260874
228	2d96cef2-7502-44ff-a7a9-17713d4a7a42	998cf11c-e274-4131-ac1c-893d5692e5a1	t	24.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.261243
229	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b4707007-0ee7-497b-befa-2c9d2e2d7f01	t	97.08	7	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.261551
230	2d96cef2-7502-44ff-a7a9-17713d4a7a42	daa0851c-6944-4444-8ea4-b5592641a76e	t	286.79	27	\N	\N	0.06	\N	\N	\N	t	f	f	2025-09-03 19:03:49.261845
231	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6bcf93a6-bda1-405f-9938-8148c0357d9c	f	-12.62	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.262992
232	2d96cef2-7502-44ff-a7a9-17713d4a7a42	45fd6339-4acb-4717-8ec2-9208726517bc	t	25.14	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.263344
233	2d96cef2-7502-44ff-a7a9-17713d4a7a42	dcf92b7e-ac88-4266-a916-f8cbeef9b543	t	39.35	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.263727
234	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1987808a-98ad-4c49-ba78-af231471c094	t	4.81	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.26444
235	2d96cef2-7502-44ff-a7a9-17713d4a7a42	77aface7-4c08-4976-8140-2c25c7daf8a6	t	66.04	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.264977
236	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f8ace3aa-7e2e-4d3b-9a1f-c68c73ffb23c	t	16.83	11	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.265413
237	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f2bb1b0a-8319-421f-82f9-47549b502a34	t	10.15	26	\N	\N	0.06	\N	\N	\N	t	f	f	2025-09-03 19:03:49.265856
238	2d96cef2-7502-44ff-a7a9-17713d4a7a42	caede5e8-1ac2-44f2-97ce-e278a62a49fd	t	42.93	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.26622
239	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0b461763-0a36-4b57-a649-1763e4e516d4	t	29.88	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.266538
240	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d076869e-2043-41eb-b04d-c27e2d677f80	t	4.16	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.266972
241	2d96cef2-7502-44ff-a7a9-17713d4a7a42	49d62247-bb6f-4188-b486-b9c601f9c9fc	t	191.80	7	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.267257
242	2d96cef2-7502-44ff-a7a9-17713d4a7a42	111077b9-37e7-4228-9f23-e979dec90afc	t	31.57	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.267574
243	2d96cef2-7502-44ff-a7a9-17713d4a7a42	196e98e2-c078-493c-bb3f-d8503abbe88d	t	130.23	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.26792
244	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fb53f90a-d57d-4940-abb1-dedf3febb132	t	331.53	10	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.268222
245	2d96cef2-7502-44ff-a7a9-17713d4a7a42	950451ac-b358-4b1b-b151-ace6611a7530	t	239.64	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.268548
246	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4af8f79a-e803-401e-998f-6a7c76fa5b9d	t	169.83	6	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.268856
247	2d96cef2-7502-44ff-a7a9-17713d4a7a42	12571436-4f11-4390-89a5-df99ee53f826	f	-287.51	397	\N	\N	0.73	\N	\N	\N	f	f	f	2025-09-03 19:03:49.269152
248	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b77f707e-e944-448e-b73f-218c3f5bab3d	f	-128.19	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.269458
249	2d96cef2-7502-44ff-a7a9-17713d4a7a42	15009cd4-a7a3-443f-bf34-061167e05e77	f	-371.65	42	\N	\N	0.97	\N	\N	\N	f	f	f	2025-09-03 19:03:49.269843
250	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4720c7ae-6539-4e3f-a917-9436902f5c4b	t	22.84	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.270132
251	2d96cef2-7502-44ff-a7a9-17713d4a7a42	325d714e-4f59-4377-9dd0-fbde9cfc3d89	f	-959.43	85	\N	\N	0.94	\N	\N	\N	f	f	f	2025-09-03 19:03:49.270444
252	2d96cef2-7502-44ff-a7a9-17713d4a7a42	954da3e6-e3a4-4e77-9adf-291ddf0cec62	t	1149.98	173	\N	\N	0.37	\N	\N	\N	t	f	f	2025-09-03 19:03:49.270756
253	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9bd9b0b2-006e-4bb5-937a-5faec46c3977	f	-0.74	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.271094
254	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d03bb4de-26ca-4e02-b6b9-8a854e1201c8	t	24.17	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.271472
255	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5913fb72-aaa1-4cda-9739-e976034114a2	f	-7.33	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.271783
256	2d96cef2-7502-44ff-a7a9-17713d4a7a42	dd4c580f-9b76-43d7-b17c-22cdc51d6b15	t	6.00	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.272125
257	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d3f335eb-c006-4345-bce8-c2c656e2b849	f	-317.14	10	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.272424
258	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d76d6510-e403-4968-9629-a22390fa7973	t	185.22	341	\N	\N	0.73	\N	\N	\N	f	f	f	2025-09-03 19:03:49.272709
259	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e39104e0-c788-4fe8-9e49-a9440f8272bb	t	35.48	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.273017
260	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e26b552a-78a3-4187-b3e7-425af684c9be	t	41.92	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.273335
261	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2d660ff0-e017-4d81-bdf2-f13d52a38062	t	11.52	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.27362
262	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a7cacfe2-3999-46f9-951e-e43df5950647	t	29.31	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.273958
263	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2d6d7520-b1c9-45e4-9bf5-c4634cf70586	t	7.77	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.274395
264	2d96cef2-7502-44ff-a7a9-17713d4a7a42	191cd412-4fce-4455-bc20-d6e8e6e1fe03	t	20.64	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.274695
265	2d96cef2-7502-44ff-a7a9-17713d4a7a42	16ffb4e2-03be-4ba1-9f8f-7cfc0b69e8ca	t	34.07	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.275
266	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d112b324-2481-4089-a815-27716c2f7b67	f	-46.83	5	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.275301
267	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3797bb8f-a239-4e4b-bac7-1930e54220ae	t	23.36	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.275602
268	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c7353302-7632-417e-8aa5-d6acd7ff7c74	t	60.26	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.275928
269	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8a09a033-4b3c-4212-96b4-b20551f4233f	t	4.22	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.27622
270	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b57497ac-0911-4293-aca1-4f2161935162	t	17.02	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.276511
271	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c8da70f1-c6fa-41da-b8fe-01b664805c96	t	35.52	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.276786
272	2d96cef2-7502-44ff-a7a9-17713d4a7a42	62a5eb7e-c4b4-4bb4-b263-ff699fc35b78	t	485.84	8	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.277044
273	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5ff3ee7e-baf5-4d11-a27c-dab6fb319a35	t	91.23	10	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.277325
274	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e54d2b71-d12e-46ac-b5f7-ce18b6ddd29f	t	47.00	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.277676
275	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3ef8d738-cd00-4c3d-b5db-c70730d1b425	t	11.00	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.277961
276	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3381ce66-f1cd-44a2-a027-722b502ea98b	t	21.05	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.278244
277	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f7552c7a-62c0-4c7c-952f-766793c55bf7	t	103.99	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.2785
278	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6d856ffb-e185-4262-8ae2-185e03117cb6	t	203.08	124	\N	\N	0.26	\N	\N	\N	t	f	f	2025-09-03 19:03:49.278797
279	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8b100660-4480-4f09-8c5f-1703166588d6	t	10.51	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.279121
280	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d269f0e5-73e8-4336-8e04-ddca7bcdf6cd	t	38.44	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.279529
281	2d96cef2-7502-44ff-a7a9-17713d4a7a42	10686b19-3eb2-4961-a1fd-8c10253ee8e3	t	17.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.27985
282	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b81daf3d-6a4e-4907-8adb-770680affe76	t	32.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.280252
283	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9dd7b3d9-306b-444f-b015-a1fb35b425d3	t	2.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.280525
284	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1f978e2f-8857-40ff-af85-6923bf256db4	t	4.54	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.280847
285	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fedda064-e9a8-4c19-89c3-a6e08d4ca1fe	t	81.06	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.281142
286	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a89a7148-ccba-4dce-a29c-8a351d95c3fd	f	-39.99	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.281466
287	2d96cef2-7502-44ff-a7a9-17713d4a7a42	afd288c2-a475-4a20-9ba3-50dd485b76e6	t	265.23	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.281741
288	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4f6d58b9-0d6f-4e9c-9a66-6f3865d84d5f	t	82.04	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.282034
289	2d96cef2-7502-44ff-a7a9-17713d4a7a42	68b3b8ab-9f1d-45c1-abc0-bf8035555e63	t	92.57	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.282295
290	2d96cef2-7502-44ff-a7a9-17713d4a7a42	42ae21e5-2632-47f2-a457-bbdd84f50661	t	115.70	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.28259
291	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5bb82821-e7af-479f-83ed-21fab5df4442	t	36.00	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.282897
292	2d96cef2-7502-44ff-a7a9-17713d4a7a42	458a8613-093e-4093-8c00-5821564d75ed	t	22.53	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.283273
293	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ee94a294-f5c0-426f-b5a1-3693263cc4bc	t	53.00	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.283695
294	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3f84ae58-8e63-4a78-9727-db06233be38e	t	14.02	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.284005
295	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b0ff6a90-c803-4cd6-b997-ef1f07b4ce1c	t	18.28	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.284626
296	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2dbd6b41-c903-493d-9590-44436552b52f	t	17.01	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.284987
297	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ff0b4bf3-137a-4707-a62a-85c9b4eff528	t	20.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.285277
298	2d96cef2-7502-44ff-a7a9-17713d4a7a42	56c75d2c-a0ca-4294-a6c7-8705a77b273f	t	35.02	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.285638
299	2d96cef2-7502-44ff-a7a9-17713d4a7a42	162c256f-d36b-4981-a325-cc91ab4576a9	t	259.62	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.285943
300	2d96cef2-7502-44ff-a7a9-17713d4a7a42	71d57a00-d1c1-47ea-8a88-1206e84e169c	t	7.93	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.286219
301	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0f0eeef8-e574-412b-b88d-ab4c40a9d74d	t	31.06	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.286477
302	2d96cef2-7502-44ff-a7a9-17713d4a7a42	03ea71e1-32cc-4194-953f-f70c51ca2a1c	f	-23.94	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.286788
303	2d96cef2-7502-44ff-a7a9-17713d4a7a42	b722780f-e60f-4c30-a1e8-596bdb0ed80c	t	20.52	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.287145
304	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a2f73356-ba8b-48c6-a9dc-f04644e5c101	t	15.72	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.287466
305	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a8061495-601e-446e-896d-87d8d6f8f384	t	35.60	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.287747
306	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4705d87c-65cb-4a76-92e5-a0d4cff9da04	f	-171.06	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.288012
307	2d96cef2-7502-44ff-a7a9-17713d4a7a42	dd47c96b-8995-4071-b871-ae804b0fae21	f	-59.59	4	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.288277
308	2d96cef2-7502-44ff-a7a9-17713d4a7a42	18e2b356-2ef2-4f93-8eb6-c034b68446df	t	30.18	6	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.288568
309	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c2ed2a4c-bf32-40fc-94d7-d1211bab990c	t	19.58	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.288854
310	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cb9d5b07-7943-454f-a01b-7cb1b1082cf7	t	12.69	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.289212
311	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2bb5b4e5-7d2c-4407-b93a-06544bbdd15a	f	-555.43	24	\N	\N	0.98	\N	\N	\N	f	f	f	2025-09-03 19:03:49.289492
312	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ba0efabf-e22a-4cdc-aaa9-da9c42f7f635	f	-23.56	6	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.289753
313	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3f6cb6dd-c954-4854-8dae-5bf9c2f20f33	t	11.03	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.290023
314	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ec5d9fc4-bbf3-4b1b-b518-50c3df98785a	t	20.03	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.290313
315	2d96cef2-7502-44ff-a7a9-17713d4a7a42	09bd04f2-bcc6-47cf-a9e1-500284bc9e1a	f	-33.97	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.29059
316	2d96cef2-7502-44ff-a7a9-17713d4a7a42	eb3a56e1-d691-47a8-bd70-8d6534dad66c	t	5.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.290951
317	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ebbe6d1c-d248-4b08-beb8-e8f1792a7024	t	8.03	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.291212
318	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e8157493-4baa-4700-8bb6-0e026a9c88b0	t	2520.23	251	\N	\N	0.54	\N	\N	\N	f	f	f	2025-09-03 19:03:49.291516
319	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5a23f663-9627-4d03-8366-6a9e6b6a1a7e	t	3.18	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.291808
320	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a0f1a3e3-4515-426c-83e5-727426fcf348	t	2.03	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.292093
321	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3ff6888d-fc3c-49ee-8a72-9e7747092c02	t	31.04	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.292376
322	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a3080211-b8ca-432b-b776-d65e0c83fc7b	t	110.25	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.29263
323	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3724f756-08a8-4fd9-8713-b66c7b99e3f9	t	170.66	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.293858
324	2d96cef2-7502-44ff-a7a9-17713d4a7a42	893f9e38-5a18-4c96-a6a8-63b11c177704	f	-104.26	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.294261
325	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c476ea71-35fa-4264-b958-8dd116fc2978	t	43.01	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.294553
326	2d96cef2-7502-44ff-a7a9-17713d4a7a42	76c8e4f6-4681-4011-a5e0-e655022a9b29	f	-160.87	3	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.294863
327	2d96cef2-7502-44ff-a7a9-17713d4a7a42	97a8667a-2240-4f1e-86a9-18cd5038096d	t	64.12	14	\N	\N	0.03	\N	\N	\N	t	f	f	2025-09-03 19:03:49.29516
328	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3cf8fff2-8750-4d57-80dc-86421bc9387c	f	-3.64	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.295625
329	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2bdf28d4-af23-4e13-b493-1a7a399a9d45	t	267.69	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.295897
330	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c88b2bd1-a7c9-4927-9f69-27a50deb1459	f	-89.43	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.296159
331	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2c8f0724-3812-430d-ab0e-738690928c44	t	57.33	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.296426
332	2d96cef2-7502-44ff-a7a9-17713d4a7a42	87d2444f-2b39-4bd8-9e18-866d4edf98a9	f	-3.73	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.296693
333	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5a7fc032-de9f-4665-9d33-c1c1e484b839	t	22.13	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.296988
334	2d96cef2-7502-44ff-a7a9-17713d4a7a42	51779a0f-7d6a-4a09-b86a-5dde1f4f5bdf	t	29.62	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.297293
335	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e679892b-c45a-46cb-88bb-c746c357361a	t	25.36	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.298549
336	2d96cef2-7502-44ff-a7a9-17713d4a7a42	eb58f21d-dd3f-4c28-b57d-a3be3d73ea3d	t	11.03	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.29916
337	2d96cef2-7502-44ff-a7a9-17713d4a7a42	df78b0d6-c343-439e-ad78-c2fd25db6cf1	f	-15.97	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.29952
338	2d96cef2-7502-44ff-a7a9-17713d4a7a42	02d73ba3-e784-4be7-9fc3-a2c6da522f51	f	-0.97	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.299814
339	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f2b12f67-17b1-4aa1-973e-67571694b7d6	t	69.96	4	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.300101
340	2d96cef2-7502-44ff-a7a9-17713d4a7a42	682443f0-e9be-4766-beb4-e17648e03f80	t	1813.46	81	\N	\N	0.17	\N	\N	\N	t	f	f	2025-09-03 19:03:49.300388
341	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a801d84c-b16a-47f1-b9d0-d314571b7aab	f	-26.97	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.301047
342	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6e116a2e-b7bb-4fdf-bf72-482039eec344	t	13.07	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.301438
343	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7c777208-253d-4da7-9e54-81e7d0f4523b	t	70.46	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.301811
344	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f9ee3e7d-bc03-469d-9de9-3448b0b84f87	f	-1.00	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.302159
345	2d96cef2-7502-44ff-a7a9-17713d4a7a42	80b7c5dd-3942-4d42-a5c4-161cb9a7bbb3	t	11.74	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.302534
346	2d96cef2-7502-44ff-a7a9-17713d4a7a42	24392d48-c56a-49ec-9670-d76c9fd42fdf	t	13.95	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.302847
347	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c0a4ba2d-3dce-4b52-a215-02f2838b4fd6	t	225.76	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.303205
348	2d96cef2-7502-44ff-a7a9-17713d4a7a42	31f6bc86-a598-49ae-911b-230a978a5044	t	15.32	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.303548
349	2d96cef2-7502-44ff-a7a9-17713d4a7a42	db3eff94-4ae7-4076-89e3-97107e905188	t	118.45	7	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.303839
350	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4f173dc8-a4ce-4042-8280-b237fba06d50	f	-16.81	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.304232
351	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d300d5e6-9917-4ffd-8b19-9f93470fbea5	t	33.68	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.304605
352	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d84ded0e-a97c-4f17-87a7-60a7d3b1e696	f	-31.40	8	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.304947
353	2d96cef2-7502-44ff-a7a9-17713d4a7a42	796d760f-af6b-4a1f-8deb-af00c9bf855e	f	-0.96	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.305317
354	2d96cef2-7502-44ff-a7a9-17713d4a7a42	87f421d1-426a-4c93-ba22-e8bf3de7a71b	t	46.72	17	\N	\N	0.04	\N	\N	\N	t	f	f	2025-09-03 19:03:49.305703
355	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1e6a01ad-69ee-4302-87ee-46349c30f96b	t	109.51	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.306188
356	2d96cef2-7502-44ff-a7a9-17713d4a7a42	14da47b2-006a-406f-b89e-1c9584f1afe6	f	-3.39	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.306469
357	2d96cef2-7502-44ff-a7a9-17713d4a7a42	132b8ee0-affb-401f-b5a0-c5b633f44c9e	t	319.62	63	\N	\N	0.13	\N	\N	\N	t	f	f	2025-09-03 19:03:49.306737
358	2d96cef2-7502-44ff-a7a9-17713d4a7a42	6a9d198c-ee73-439e-8a5d-efef2dedf106	f	-3085.06	355	\N	\N	0.76	\N	\N	\N	f	f	f	2025-09-03 19:03:49.307023
359	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3769c3e8-92c6-4f1b-95ed-21f5165bb21b	t	37.77	10	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.307289
360	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1bbe564d-0de2-41e7-8611-87db9e8146f7	t	72.26	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.307576
361	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cbb37db1-2e27-48b8-8983-4864192ef4b0	t	36.26	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.307892
362	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c94f6bfc-07f9-443f-b82e-e5f4c18cd03b	t	11.24	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.308172
363	2d96cef2-7502-44ff-a7a9-17713d4a7a42	893477c4-e598-41d8-99bf-bb5eabd07f98	t	10.22	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.308423
364	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9d03db8e-f1df-4cdc-bad0-1078ed53ba98	f	-38.32	10	\N	\N	0.99	\N	\N	\N	f	f	f	2025-09-03 19:03:49.308683
365	2d96cef2-7502-44ff-a7a9-17713d4a7a42	f478e991-8d68-4532-ac67-1cf8ec62ef05	t	27.71	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.30895
366	2d96cef2-7502-44ff-a7a9-17713d4a7a42	53f6a156-e9c4-4259-81eb-2197046d5e8b	t	2.02	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.30922
367	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9c40614d-1977-43cc-866d-13ade35b7069	t	2.02	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.30948
368	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9615d633-8f42-44f3-96d6-eaebc73eb3b4	t	1.25	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.309778
369	2d96cef2-7502-44ff-a7a9-17713d4a7a42	36839bce-0786-4b92-a3ad-b6fa4360a054	t	8.26	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.310072
370	2d96cef2-7502-44ff-a7a9-17713d4a7a42	87dc3b27-f2cc-45b0-91a5-058e39f2dee6	f	-39.77	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.310391
371	2d96cef2-7502-44ff-a7a9-17713d4a7a42	235831b1-fb49-4533-97d7-a613708c7e02	t	78.75	18	\N	\N	0.04	\N	\N	\N	t	f	f	2025-09-03 19:03:49.310661
372	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e62c8aa4-1ad0-41a1-af3a-119919eeffc6	f	-20.41	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.311017
373	2d96cef2-7502-44ff-a7a9-17713d4a7a42	398dbe31-4866-4a53-b8b5-5a7dccf7af0e	f	-623.80	44	\N	\N	0.97	\N	\N	\N	f	f	f	2025-09-03 19:03:49.311363
374	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fd2f2f59-6cce-4d88-a1c8-35a580f20a9b	t	99.37	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.31169
375	2d96cef2-7502-44ff-a7a9-17713d4a7a42	68cd30f4-fd97-4a9e-ac1a-3191460787ae	t	102.07	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.312049
376	2d96cef2-7502-44ff-a7a9-17713d4a7a42	bb43f686-6cd2-4a57-9f0d-445499ff5f8d	t	69.09	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.312423
377	2d96cef2-7502-44ff-a7a9-17713d4a7a42	68e49e64-dee6-443e-8c3f-6de1cb9b0fcb	f	-76.99	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.312775
378	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7dca1f5e-8ec9-489f-9bf0-a460a8f2c90d	t	74.02	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.313226
379	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3c109eec-1435-470f-9527-583f9b0870f7	t	25.19	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.313625
380	2d96cef2-7502-44ff-a7a9-17713d4a7a42	aad108ec-d370-4264-a75f-99809db33d6d	t	2.04	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.313952
381	2d96cef2-7502-44ff-a7a9-17713d4a7a42	d1dd9d94-14f5-46a7-9556-57f9db0c39d5	f	-1.94	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.31424
382	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c993702b-013c-4e59-89f7-3ec809dc3c64	f	-6.98	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.314511
383	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cab9d6dd-2ba3-4f2a-8967-a1dd03b28e81	t	485.61	152	\N	\N	0.32	\N	\N	\N	t	f	f	2025-09-03 19:03:49.314796
384	2d96cef2-7502-44ff-a7a9-17713d4a7a42	353b46bd-3c8f-4dc2-b5cb-e6db63a40dbf	f	-21.59	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.315118
385	2d96cef2-7502-44ff-a7a9-17713d4a7a42	26ac1359-5827-4b80-af7d-114a800d416e	f	-166.88	3	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.315414
386	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cf488d3e-5ddf-436b-8824-d6c24a39ee0e	f	-307.58	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.315689
387	2d96cef2-7502-44ff-a7a9-17713d4a7a42	64c27085-dba9-4e56-b708-c876a172130b	t	69.92	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.315989
388	2d96cef2-7502-44ff-a7a9-17713d4a7a42	7eb3f5d6-1663-470b-86d5-7043d28973ab	f	-247.56	4	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.316277
389	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e0d9feff-35eb-4300-ba28-45e98a9b6b7d	t	175.37	9	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.316548
390	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4764ad8d-dde2-4642-8d3c-3fa837a5bacf	f	-687.54	34	\N	\N	0.98	\N	\N	\N	f	f	f	2025-09-03 19:03:49.316851
391	2d96cef2-7502-44ff-a7a9-17713d4a7a42	928ece38-8645-4e62-9e44-35ddca92c249	t	588.17	8	\N	\N	0.02	\N	\N	\N	t	f	f	2025-09-03 19:03:49.317114
392	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1656ca06-e611-4dad-be42-ca2c1dd2f148	t	41.42	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.317409
393	2d96cef2-7502-44ff-a7a9-17713d4a7a42	1226c5bc-737f-4689-906d-574c4a62317d	f	-88.03	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.317702
394	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4f6ef56d-cb65-4a1f-b6d5-e2698e0f478d	f	-431.78	7	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.317972
395	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ad7724dd-c41b-4850-a5c2-6ae75efb048e	t	6.79	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.318265
396	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5a8a6701-def2-46dc-81ba-cbd81d43641a	t	46.22	13	\N	\N	0.03	\N	\N	\N	t	f	f	2025-09-03 19:03:49.318554
397	2d96cef2-7502-44ff-a7a9-17713d4a7a42	8dee3216-7bec-499b-a6b1-8f4b90407d5c	t	13.22	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.318811
398	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ca2141f1-ed0b-4b15-bcfd-67f1d5ce9afb	t	2.22	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.319105
399	2d96cef2-7502-44ff-a7a9-17713d4a7a42	cf02fe9b-5e4b-4237-9bb1-57a8a1d6c85d	t	90.97	6	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.319357
400	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fbc846b9-e8c3-443f-ae14-b41ed2fc4608	t	12.22	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.319658
401	2d96cef2-7502-44ff-a7a9-17713d4a7a42	67f88e91-80cf-40fd-b7ca-fc0547495314	f	-302.57	2	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.319982
402	2d96cef2-7502-44ff-a7a9-17713d4a7a42	9acf57c0-fd2f-40de-959a-93bb7a7e2dd5	t	36.58	3	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.320374
403	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3f9d46b6-35a4-40b5-b54e-14cca28f55a4	t	4.05	106	\N	\N	0.23	\N	\N	\N	t	f	f	2025-09-03 19:03:49.320712
404	2d96cef2-7502-44ff-a7a9-17713d4a7a42	31e497be-27cd-4c24-a41e-ae831f921000	t	12.94	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.321081
405	2d96cef2-7502-44ff-a7a9-17713d4a7a42	26735ce1-e09d-42ad-ab49-488221134457	t	38.84	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.321383
406	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0dd0eb75-158a-4419-9f9b-4b7e87c942ca	t	55.23	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.321651
407	2d96cef2-7502-44ff-a7a9-17713d4a7a42	aa5bb742-1ede-42a7-9838-5e195319f6c5	t	34.89	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.321997
408	2d96cef2-7502-44ff-a7a9-17713d4a7a42	47150f7a-e354-4e7d-8b9e-817bcfa812f9	t	7.21	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.322309
409	2d96cef2-7502-44ff-a7a9-17713d4a7a42	17138191-3fe0-40d0-9efa-d0be39302350	t	295.47	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.322687
410	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e7ad79ce-34fa-4078-aa75-b3fcb8b17570	t	233.35	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.323
411	2d96cef2-7502-44ff-a7a9-17713d4a7a42	505d5227-f994-4646-9009-01fde18f317e	t	4.29	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.323299
412	2d96cef2-7502-44ff-a7a9-17713d4a7a42	0c305292-7e48-432e-9eb3-261892f20416	t	131.48	51	\N	\N	0.11	\N	\N	\N	t	f	f	2025-09-03 19:03:49.323595
413	2d96cef2-7502-44ff-a7a9-17713d4a7a42	93cae1d7-e20e-4063-8545-de0ccecf072e	t	9.27	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.32386
414	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f	t	15.72	2	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.324193
415	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5f067d88-03a4-453a-97ea-82002cffed00	f	-1.73	1	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.324515
416	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fb07cb4f-b5cd-4b67-8d63-150068297eed	t	44.77	24	\N	\N	0.05	\N	\N	\N	t	f	f	2025-09-03 19:03:49.32483
417	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fa3349fb-2321-4a51-9b74-c4c9ad603a8a	t	6.27	0	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.325127
418	2d96cef2-7502-44ff-a7a9-17713d4a7a42	81781831-4f29-4376-accb-5ab857006caf	t	20.55	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.325394
419	2d96cef2-7502-44ff-a7a9-17713d4a7a42	daac3f21-dbec-4000-9f00-a2fe0500af89	t	13.55	6	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.325688
420	2d96cef2-7502-44ff-a7a9-17713d4a7a42	000322b7-3fe4-4edb-ac94-44d326f59b8a	t	207.54	32	\N	\N	0.07	\N	\N	\N	t	f	f	2025-09-03 19:03:49.325958
421	2d96cef2-7502-44ff-a7a9-17713d4a7a42	92858781-a01f-4854-8730-2d606385c553	t	4.26	1	\N	\N	0.00	\N	\N	\N	t	f	f	2025-09-03 19:03:49.326256
422	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ff735cf4-7022-41f4-8b6d-630fb0ccef3e	t	43.54	5	\N	\N	0.01	\N	\N	\N	t	f	f	2025-09-03 19:03:49.326558
423	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c40d4a7e-5944-4238-a47b-85a4d925ce1b	f	-5.74	0	\N	\N	1.00	\N	\N	\N	f	f	f	2025-09-03 19:03:49.32893
424	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4da614e0-15e4-4bb5-8be4-ee476dd82c74	f	-47.59	59	\N	\N	0.96	\N	\N	\N	f	f	f	2025-09-03 19:03:49.32932
\.


--
-- Data for Name: trade_split_adjustments; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.trade_split_adjustments (id, trade_id, split_id, original_quantity, adjusted_quantity, original_price, adjusted_price, adjustment_ratio, applied_at) FROM stdin;
1	5532b1b7-4c5b-4db5-9fac-e0059310fabb	1	10000.0000	667.0000	0.9500	14.2400	0.0667	2025-09-03 18:58:00.015311
\.


--
-- Data for Name: trades; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.trades (id, user_id, symbol, trade_date, entry_time, exit_time, entry_price, exit_price, quantity, side, commission, fees, pnl, pnl_percent, notes, is_public, broker, strategy, setup, tags, created_at, updated_at, executions, mae, mfe, split_adjusted, original_quantity, original_entry_price, original_exit_price, strategy_confidence, classification_method, classification_metadata, manual_override, round_trip_id, news_events, has_news, news_sentiment, news_checked_at, confidence, enrichment_status, enrichment_completed_at) FROM stdin;
7f3e3cf8-cdcb-48bb-b71c-0c6b02dc19e7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NITO	2025-01-03	2025-01-03 11:55:00+00	2025-01-03 11:56:00+00	1.490000	1.530000	200.0000	long	4.260000	0.000000	2.74	0.9195	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.341843+00	2025-09-03 18:46:56.343229+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:56.338Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=bb1ace1e2d4ff0a08ed2715ac8bb01838f737a8d396959052f9c528f2cd479e7", "source": "Yahoo", "summary": "N2OFF will hold approximately 70% ownership in the projects, further enhancing its presence in the European energy storage market Neve Yarak, Israel, Jan. 03, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today that on January 3 2025 it has signed a binding LOI with Solterra Ltd’s subsidiary ,Soltera Brand Services Italy (“SBSI”), a company that", "datetime": "2025-01-03T12:55:00.000Z", "headline": "N2OFF and Solterra Brand Services Italy executed a binding LOI to Develop Two 98MWp Battery Storage Projects in Sicily", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8226768fb2fbd5c44b51905e399d777fe7923051df0d9889428ef5f05827e10d", "source": "Yahoo", "summary": "The approval was obtained from the Melz Municipal Committee in connection with the submission of Solterra’s statutory plan for the PV Project Neve Yarak, Israel, Jan. 02, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation in the agri- tech sector, is pleased to announce progress in its collaborative solar photovoltaic (PV) project in Melz, Germany, developed by Solterra Renewa", "datetime": "2025-01-02T13:05:00.000Z", "headline": "N2OFF, Inc. Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:56.341+00	5	completed	2025-09-03 18:46:56.343229+00
77aface7-4c08-4976-8140-2c25c7daf8a6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ADTX	2025-03-18	2025-03-18 13:48:00+00	2025-03-18 13:48:00+00	6.690000	6.810000	600.0000	long	8.030000	0.000000	66.04	1.6454	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:00.170431+00	2025-09-03 18:48:00.172483+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:00.165Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f6393d9fd646e3f36925909a988d8d67f0d3e01e60de59dd8228b1e53d961241", "source": "Yahoo", "summary": "Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the", "datetime": "2025-03-18T11:22:00.000Z", "headline": "Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=42b92a2a1b2c83725d57a0eb037509bf9f934b21388806c4842833c110dd196e", "source": "Yahoo", "summary": "MOUNTAIN VIEW, Calif., March 17, 2025--Aditxt, Inc. (NASDAQ: ADTX) (\\"Aditxt\\" or the \\"Company\\"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2", "datetime": "2025-03-17T12:15:00.000Z", "headline": "Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:00.17+00	5	completed	2025-09-03 18:48:00.172483+00
7de4aa93-8a0a-487e-b540-b827ccf8d160	2d96cef2-7502-44ff-a7a9-17713d4a7a42	INVZ	2025-01-07	2025-01-07 12:01:00+00	2025-01-07 12:01:00+00	2.200000	2.290000	100.0000	long	2.630000	0.000000	6.37	2.8955	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.752215+00	2025-09-03 18:47:00.755167+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:00.748Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=591e7515543a092012ddb94ecc8870c14ef6251f794fff32d9cef8a46b30dd06", "source": "Yahoo", "summary": "Innoviz Technologies Ltd. (Nasdaq: INVZ) (the \\"Company\\" or \\"Innoviz\\"), a leading Tier-1 supplier of high-performance, automotive-grade LiDAR sensors and perception software, is proud to announce its latest technological advancements, which will be showcased at CES 2025. Highlighting the power of its perception software, Innoviz will demonstrate how it runs seamlessly with the NVIDIA DRIVE AGX Orin platform, offering a range of software-driven features designed to accelerate autonomous driving ap", "datetime": "2025-01-07T13:00:00.000Z", "headline": "Innoviz, in Collaboration with NVIDIA, Showcasing Cutting-Edge Perception Software with NVIDIA DRIVE AGX Orin at CES 2025, Unveiling New Software-Driven Features", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.752+00	5	completed	2025-09-03 18:47:00.755167+00
d52ede45-d3b0-498c-9dab-51449b14a1e6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SPRC	2025-01-06	2025-01-06 12:08:00+00	2025-01-06 12:09:00+00	1.060000	1.050000	100.0000	long	2.180000	0.000000	-3.18	-3.0000	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:58.519651+00	2025-09-03 18:46:58.523107+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:58.514Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=66425d71666fe7675d514f28b7a68f4d7e7c2300bec647c47b306f13ebe7f146", "source": "Yahoo", "summary": "On Monday, SciSparc Ltd (NASDAQ:SPRC) stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro. SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND), the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, t", "datetime": "2025-01-06T16:04:50.000Z", "headline": "Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=64a423768f0957fcb793daebe363b20b5443c103fbd20846137659061986e356", "source": "Yahoo", "summary": "Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR", "datetime": "2025-01-06T14:11:56.000Z", "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Monday", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=93235a14622b416af33b4959b879e097eba70ab171cdc4fde7730c4f9a1a4a6e", "source": "Yahoo", "summary": "TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\\"Company\\" or \\"SciSparc\\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-tre", "datetime": "2025-01-06T12:50:00.000Z", "headline": "SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:58.519+00	5	completed	2025-09-03 18:46:58.523107+00
24392d48-c56a-49ec-9670-d76c9fd42fdf	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-04-01	2025-04-01 12:58:00+00	2025-04-01 12:58:00+00	30.290000	30.450000	100.0000	long	2.250000	0.000000	13.95	0.4606	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:18.135514+00	2025-09-03 18:48:18.136532+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:18.133Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:18.135+00	5	completed	2025-09-03 18:48:18.136532+00
5fc8db5c-5976-495a-ac58-637330bc58d7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	655187300	2025-02-04	2025-02-04 11:24:00+00	2025-02-04 11:29:00+00	9.090000	9.240000	500.0000	long	8.100000	0.000000	69.66	1.5331	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.068175+00	2025-09-03 18:50:26.108127+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:46:55.064Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.067+00	5	completed	2025-09-03 18:50:26.108127+00
033f9947-0e4a-4337-a1f9-5993fd0622c8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	501506703	2025-02-18	2025-02-18 11:38:00+00	2025-02-18 11:49:00+00	0.600000	0.640000	2000.0000	long	21.800000	0.000000	60.00	5.0125	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:46:54.759649+00	2025-09-03 18:50:26.606911+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 11, "analysisTimestamp": "2025-09-03T18:46:54.755Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:54.759+00	5	completed	2025-09-03 18:50:26.606911+00
7751bbfc-a944-44fc-a26f-95cfe9cf2d01	2d96cef2-7502-44ff-a7a9-17713d4a7a42	IMRX	2025-01-07	2025-01-07 11:38:00+00	2025-01-07 11:38:00+00	3.760000	3.770000	200.0000	long	4.280000	0.000000	-2.28	-0.3032	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:59.981408+00	2025-09-03 18:46:59.985231+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:59.974Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=858486cf31fac31479e451f86768ff5bb542de1ec949144c48593d792f377c20", "source": "Yahoo", "summary": "On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a", "datetime": "2025-01-07T14:28:53.000Z", "headline": "Why Is Immuneering Stock Trading Higher On Tuesday?", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=17a81dc7da182ea37f859d3a14a62f450e9721566f0bae170867a5915e68698a", "source": "Yahoo", "summary": "Immuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate I", "datetime": "2025-01-07T14:00:04.000Z", "headline": "Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=00eab8732be9d542fd32e33704a7b549a1921acb0312823b1012c4ddf5d0fb9b", "source": "Yahoo", "summary": "- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial dat", "datetime": "2025-01-07T12:00:00.000Z", "headline": "Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:59.98+00	5	completed	2025-09-03 18:46:59.985231+00
1ab12991-84a2-4e5f-bb85-7d42872346fd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-01-08	2025-01-08 11:03:00+00	2025-01-08 11:04:00+00	2.030000	2.240000	200.0000	long	3.810000	0.000000	37.19	9.1601	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.759759+00	2025-09-03 18:47:00.761274+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:00.757Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=04091ad3ff6a8d1693107a9cf5ca05b97a9662e05706e7daaf9338fd9b4299c7", "source": "Yahoo", "summary": "SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, crypt", "datetime": "2025-01-08T12:00:00.000Z", "headline": "CURRENC Debuts SEAMLESS AI Call Centre Solutions", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.759+00	5	completed	2025-09-03 18:47:00.761274+00
47150f7a-e354-4e7d-8b9e-817bcfa812f9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 13:12:00+00	2025-04-07 13:13:00+00	54.350000	54.450000	100.0000	long	2.790000	0.000000	7.21	0.1327	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:00.256084+00	2025-09-03 18:49:00.259055+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:00.249Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:00.255+00	5	completed	2025-09-03 18:49:00.259055+00
02f78421-577a-4de2-92a3-a0e622963a01	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-01-08	2025-01-08 11:09:00+00	2025-01-08 11:10:00+00	3.880000	3.660000	200.0000	long	3.270000	0.000000	-47.67	-6.1402	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:02.057486+00	2025-09-03 18:47:02.058545+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:02.054Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=04091ad3ff6a8d1693107a9cf5ca05b97a9662e05706e7daaf9338fd9b4299c7", "source": "Yahoo", "summary": "SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, crypt", "datetime": "2025-01-08T12:00:00.000Z", "headline": "CURRENC Debuts SEAMLESS AI Call Centre Solutions", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:02.057+00	5	completed	2025-09-03 18:47:02.058545+00
b4056382-a4c3-4f3e-97f5-1e22e22ffa33	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-01-13	2025-01-13 11:59:00+00	2025-01-13 12:00:00+00	1.820000	1.940000	200.0000	long	3.810000	0.000000	20.19	5.5467	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.981004+00	2025-09-03 18:47:05.983351+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:05.978Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:05.98+00	5	completed	2025-09-03 18:47:05.983351+00
49d62247-bb6f-4188-b486-b9c601f9c9fc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-21	2025-03-21 13:30:00+00	2025-03-21 13:37:00+00	1.300000	1.380000	3000.0000	long	39.620000	0.000000	191.80	4.9072	Round trip: 6 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:06.195384+00	2025-09-03 18:47:06.196931+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:47:06.190Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3236f528d9b769cf6bda9e1e94985092a926e1569a566642aa3e4c8a19976aca", "source": "Yahoo", "summary": "Business Combination Agreement with CCTS originally announced in August 2024 Combined pro forma enterprise value of US$904m assumes no public trust redemptions for CCTS Parties working to close the transaction by Q2, calendar 2025 LONDON, March 21, 2025 (GLOBE NEWSWIRE) -- Tembo E-LV B.V. (“Tembo”), a subsidiary of Nasdaq-listed B Corporation, VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\"), today announced that it is working closely with CCTS (“Cactus Acquisition Corp.", "datetime": "2025-03-21T13:15:00.000Z", "headline": "Tembo E-LV Progresses Business Combination Agreement with CCTS at a Combined Enterprise Value Of US$904m", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:06.195+00	5	completed	2025-09-03 18:47:06.196931+00
b86166ad-8871-4c58-9423-505825070d76	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G33277131	2025-01-10	2025-01-10 10:57:00+00	2025-01-10 10:57:00+00	0.470000	0.460000	200.0000	long	3.620000	0.000000	-5.36	-5.6804	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.723369+00	2025-09-03 18:50:18.342318+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:04.717Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.722+00	5	completed	2025-09-03 18:50:18.342318+00
85142cd7-901c-4ef8-9616-8be2e7bb8d3e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	655187300	2025-02-04	2025-02-04 11:39:00+00	2025-02-04 11:41:00+00	10.000000	10.070000	400.0000	long	8.020000	0.000000	19.02	0.4753	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.36016+00	2025-09-03 18:50:25.597829+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:46:55.357Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.36+00	5	completed	2025-09-03 18:50:25.597829+00
ab3342cc-6cab-4d63-8b3d-c0e786c63696	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:05:00+00	2025-03-18 12:05:00+00	2.370000	2.430000	300.0000	long	3.980000	0.000000	14.02	1.9719	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:00.842449+00	2025-09-03 18:48:00.844053+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:00.173Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:00.842+00	5	completed	2025-09-03 18:48:00.844053+00
f7bf7090-f053-4b76-b3df-e3e87299c6b8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ORIS	2025-01-02	2025-01-02 11:14:00+00	2025-01-02 11:15:00+00	2.840000	2.650000	200.0000	long	3.250000	0.000000	-41.25	-7.2623	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.682076+00	2025-09-03 18:46:55.683333+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:55.678Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.681+00	5	completed	2025-09-03 18:46:55.683333+00
1ac5e0d6-031d-4e17-a7aa-0a65718ccadc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	IMRX	2025-01-07	2025-01-07 11:56:00+00	2025-01-07 11:56:00+00	5.220000	5.170000	200.0000	short	4.280000	0.000000	4.72	0.4525	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.233329+00	2025-09-03 18:47:00.234761+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:00.229Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=858486cf31fac31479e451f86768ff5bb542de1ec949144c48593d792f377c20", "source": "Yahoo", "summary": "On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a", "datetime": "2025-01-07T14:28:53.000Z", "headline": "Why Is Immuneering Stock Trading Higher On Tuesday?", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=17a81dc7da182ea37f859d3a14a62f450e9721566f0bae170867a5915e68698a", "source": "Yahoo", "summary": "Immuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate I", "datetime": "2025-01-07T14:00:04.000Z", "headline": "Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=00eab8732be9d542fd32e33704a7b549a1921acb0312823b1012c4ddf5d0fb9b", "source": "Yahoo", "summary": "- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial dat", "datetime": "2025-01-07T12:00:00.000Z", "headline": "Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.232+00	5	completed	2025-09-03 18:47:00.234761+00
bde2f6d3-8a9b-4b3d-9d0c-4da94e0a7e5f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OST	2025-01-02	2025-01-02 11:15:00+00	2025-01-02 11:15:00+00	5.350000	5.570000	200.0000	long	2.440000	0.000000	41.80	3.9074	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.962887+00	2025-09-03 18:46:55.964161+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:55.958Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e334b53f6391d42548a0c438a6f59bb44094351c76e072885988425845ae5529", "source": "Yahoo", "summary": "Nanjing, China, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces the Company will participate in the Consumer Electronics Show 2025 (“CES 2025”), one of the world’s premier technology trade shows. CES 2025 is scheduled to take place from January 7 to 10, 2025, at the Las Vegas Convention Center in Las Vegas, NV., which allows the Company to meet new partners, and it is also whe", "datetime": "2025-01-02T13:30:00.000Z", "headline": "Ostin Technology Group Announces Participation at CES 2025, Inspiring Greatness with Latest Pintura Products at the Premier Global Technology Trade Show", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:55.962+00	5	completed	2025-09-03 18:46:55.964161+00
b84c4ff9-0957-4572-805f-07c31bb9b313	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NITO	2025-01-03	2025-01-03 12:19:00+00	2025-01-03 12:19:00+00	2.200000	2.260000	200.0000	long	4.260000	0.000000	7.74	1.7591	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.364227+00	2025-09-03 18:46:56.36534+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.359Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=bb1ace1e2d4ff0a08ed2715ac8bb01838f737a8d396959052f9c528f2cd479e7", "source": "Yahoo", "summary": "N2OFF will hold approximately 70% ownership in the projects, further enhancing its presence in the European energy storage market Neve Yarak, Israel, Jan. 03, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today that on January 3 2025 it has signed a binding LOI with Solterra Ltd’s subsidiary ,Soltera Brand Services Italy (“SBSI”), a company that", "datetime": "2025-01-03T12:55:00.000Z", "headline": "N2OFF and Solterra Brand Services Italy executed a binding LOI to Develop Two 98MWp Battery Storage Projects in Sicily", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8226768fb2fbd5c44b51905e399d777fe7923051df0d9889428ef5f05827e10d", "source": "Yahoo", "summary": "The approval was obtained from the Melz Municipal Committee in connection with the submission of Solterra’s statutory plan for the PV Project Neve Yarak, Israel, Jan. 02, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation in the agri- tech sector, is pleased to announce progress in its collaborative solar photovoltaic (PV) project in Melz, Germany, developed by Solterra Renewa", "datetime": "2025-01-02T13:05:00.000Z", "headline": "N2OFF, Inc. Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:56.363+00	5	completed	2025-09-03 18:46:56.36534+00
cdb79cf8-907b-4ba2-bbcc-9e8bcac052df	2d96cef2-7502-44ff-a7a9-17713d4a7a42	890260847	2025-02-03	2025-02-03 12:06:00+00	2025-02-03 12:10:00+00	0.280000	0.290000	3000.0000	long	31.190000	0.000000	8.11	0.9672	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.370128+00	2025-09-03 18:50:24.579937+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:46:55.367Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.369+00	5	completed	2025-09-03 18:50:24.579937+00
dac851a9-3aa8-4bc1-91dd-f0355634fb7d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GFAI	2025-01-06	2025-01-06 11:01:00+00	2025-01-06 11:01:00+00	2.830000	2.840000	200.0000	short	3.250000	0.000000	-5.67	-1.0025	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.836409+00	2025-09-03 18:46:56.838682+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.832Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.836+00	5	completed	2025-09-03 18:46:56.838682+00
0c305292-7e48-432e-9eb3-261892f20416	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 13:47:00+00	2025-04-07 14:38:00+00	52.050000	52.970000	150.0000	long	5.780000	0.000000	131.48	1.6839	Round trip: 4 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:49:00.559937+00	2025-09-03 18:49:00.561506+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 51, "analysisTimestamp": "2025-09-03T18:49:00.556Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:00.559+00	5	completed	2025-09-03 18:49:00.561506+00
f2d4db7b-fac8-4b03-82e5-b2992ac63b33	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCPX	2025-01-03	2025-01-03 11:52:00+00	2025-01-03 11:52:00+00	0.750000	0.770000	200.0000	long	3.970000	0.000000	0.06	0.0398	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.316167+00	2025-09-03 18:46:56.318258+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.312Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.316+00	5	completed	2025-09-03 18:46:56.318258+00
0f6b6a53-20bb-46e5-93b2-67f066b2e218	2d96cef2-7502-44ff-a7a9-17713d4a7a42	RVSN	2025-01-07	2025-01-07 11:45:00+00	2025-01-07 11:46:00+00	1.660000	1.650000	400.0000	long	5.890000	0.000000	-9.89	-1.4895	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.243302+00	2025-09-03 18:47:00.245503+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:00.238Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e2e426d344f9d2b8a0c8d812142a4a0f035321dd6d845f5a94f8829245bfd351", "source": "Yahoo", "summary": "Collaboration targets inclusion in major rail safety tenders, aiming for thousands of locomotives in India to be outfitted with state-of-the-art technologies Ra’anana, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, announced today the signing of a binding Memorandum of Understanding (MOU) with Sujan Ventures, a division of the esteemed Sujan Group, a pr", "datetime": "2025-01-07T12:45:00.000Z", "headline": "Rail Vision Signs Exclusive Agreement with Leading Indian Rail Supplier to Penetrate the Indian Rail Market", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:00.243+00	5	completed	2025-09-03 18:47:00.245503+00
2a8db9da-fef2-4153-abf5-ab8d4e79985b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NITO	2025-01-03	2025-01-03 12:18:00+00	2025-01-03 12:18:00+00	2.140000	2.150000	200.0000	long	3.250000	0.000000	-1.25	-0.2921	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.355768+00	2025-09-03 18:46:56.357546+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.352Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=bb1ace1e2d4ff0a08ed2715ac8bb01838f737a8d396959052f9c528f2cd479e7", "source": "Yahoo", "summary": "N2OFF will hold approximately 70% ownership in the projects, further enhancing its presence in the European energy storage market Neve Yarak, Israel, Jan. 03, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today that on January 3 2025 it has signed a binding LOI with Solterra Ltd’s subsidiary ,Soltera Brand Services Italy (“SBSI”), a company that", "datetime": "2025-01-03T12:55:00.000Z", "headline": "N2OFF and Solterra Brand Services Italy executed a binding LOI to Develop Two 98MWp Battery Storage Projects in Sicily", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8226768fb2fbd5c44b51905e399d777fe7923051df0d9889428ef5f05827e10d", "source": "Yahoo", "summary": "The approval was obtained from the Melz Municipal Committee in connection with the submission of Solterra’s statutory plan for the PV Project Neve Yarak, Israel, Jan. 02, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation in the agri- tech sector, is pleased to announce progress in its collaborative solar photovoltaic (PV) project in Melz, Germany, developed by Solterra Renewa", "datetime": "2025-01-02T13:05:00.000Z", "headline": "N2OFF, Inc. Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:56.355+00	5	completed	2025-09-03 18:46:56.357546+00
4fbd9f1b-1efb-4dca-8632-41630f97becc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	APM	2025-01-03	2025-01-03 12:10:00+00	2025-01-03 12:11:00+00	2.700000	2.520000	200.0000	long	4.260000	0.000000	-39.76	-7.3766	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.607229+00	2025-09-03 18:46:56.609376+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:56.600Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=42abea41e659376601e663ead3a0f07ba06b56ef0465d9bce650575f4bff3d73", "source": "Yahoo", "summary": "NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (\\"Aptorum Group\\" or the \\"Company\\"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at", "datetime": "2025-01-02T15:55:00.000Z", "headline": "Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering", "sentiment": "negative"}]	t	negative	2025-09-03 18:46:56.606+00	5	completed	2025-09-03 18:46:56.609376+00
12c8b550-a4f1-4b5f-ac39-f6162291c663	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PSNYW	2025-01-03	2025-01-03 12:25:00+00	2025-01-03 12:30:00+00	0.590000	0.490000	800.0000	long	9.530000	0.000000	-85.73	-18.3043	Round trip: 4 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:46:56.831046+00	2025-09-03 18:46:56.832179+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:46:56.828Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a2299f2c40ce516830ba9a5af921f87b2829d071664ca5286a8d5aafe5221e63", "source": "SeekingAlpha", "summary": "Tesla's Q4 delivery miss and potential threats from Trump's EV policy could impact TSLA's premium valuation in 2025. See why I'm going to keep my sell rating.", "datetime": "2025-01-03T10:24:01.000Z", "headline": "Tesla: Major Q4 Delivery Disappointment", "sentiment": "negative"}]	t	negative	2025-09-03 18:46:56.83+00	5	completed	2025-09-03 18:46:56.832179+00
c39bbcad-78bb-4355-bdb9-d428be00ba0f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BAOS	2025-01-06	2025-01-06 11:30:00+00	2025-01-06 11:31:00+00	5.600000	5.550000	200.0000	long	4.280000	0.000000	-12.98	-1.1594	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:58.501587+00	2025-09-03 18:46:58.503403+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:58.492Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:58.501+00	5	completed	2025-09-03 18:46:58.503403+00
f672940c-e4f1-4db8-b4cb-90f3dc9b8c7b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	89458T205	2025-01-03	2025-01-03 11:08:00+00	2025-01-03 11:08:00+00	0.860000	0.880000	200.0000	short	3.090000	0.000000	-6.45	-3.7496	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.261557+00	2025-09-03 18:50:22.548131+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.259Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.261+00	5	completed	2025-09-03 18:50:22.548131+00
23081800-5567-4b1b-8475-a9c4ff7fa5de	2d96cef2-7502-44ff-a7a9-17713d4a7a42	76135L507	2025-01-02	2025-01-02 11:02:00+00	2025-01-02 11:02:00+00	1.300000	1.230000	200.0000	long	3.240000	0.000000	-17.24	-6.6308	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.377748+00	2025-09-03 18:50:24.067314+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:55.371Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.377+00	5	completed	2025-09-03 18:50:24.067314+00
770eedb1-ac75-4664-b48a-4a2811219c62	2d96cef2-7502-44ff-a7a9-17713d4a7a42	RVSN	2025-01-22	2025-01-22 11:48:00+00	2025-01-22 12:04:00+00	1.120000	1.000000	1000.0000	long	14.700000	0.000000	-132.68	-11.8678	Round trip: 5 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:00.472973+00	2025-09-03 18:47:00.473797+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 16, "analysisTimestamp": "2025-09-03T18:47:00.470Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1b7562086867ffaf83cf5c889ae05f9619a0f4b869a03adb9307c8977696f442", "source": "Yahoo", "summary": "Collaboration focuses on major rail safety tenders, targeting the installation of advanced technologies on thousands of locomotives across India Ra’anana, Israel, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, recently announced the signing of a binding Memorandum of Understanding (MOU) with Sujan Ventures, a division of the esteemed Sujan Group, a premier tech", "datetime": "2025-01-22T12:44:00.000Z", "headline": "Rail Vision Enters Indian Market with an Agreement to Potentially Supply Safety Systems for Thousands of Locomotives", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:00.472+00	5	completed	2025-09-03 18:47:00.473797+00
62612778-e860-486b-a39d-27d72702be43	2d96cef2-7502-44ff-a7a9-17713d4a7a42	FFAI	2025-01-02	2025-01-02 11:03:00+00	2025-01-02 11:04:00+00	3.090000	3.170000	200.0000	long	5.270000	0.000000	12.13	1.9656	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.395261+00	2025-09-03 18:46:55.398013+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:55.379Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.394+00	5	completed	2025-09-03 18:46:55.398013+00
0443a999-541e-4a77-b215-39d5b3597122	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OST	2025-01-02	2025-01-02 11:16:00+00	2025-01-02 11:16:00+00	5.690000	5.410000	200.0000	short	3.830000	0.000000	52.55	4.6162	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.254156+00	2025-09-03 18:46:56.255047+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.252Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e334b53f6391d42548a0c438a6f59bb44094351c76e072885988425845ae5529", "source": "Yahoo", "summary": "Nanjing, China, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces the Company will participate in the Consumer Electronics Show 2025 (“CES 2025”), one of the world’s premier technology trade shows. CES 2025 is scheduled to take place from January 7 to 10, 2025, at the Las Vegas Convention Center in Las Vegas, NV., which allows the Company to meet new partners, and it is also whe", "datetime": "2025-01-02T13:30:00.000Z", "headline": "Ostin Technology Group Announces Participation at CES 2025, Inspiring Greatness with Latest Pintura Products at the Premier Global Technology Trade Show", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:56.253+00	5	completed	2025-09-03 18:46:56.255047+00
3ebde700-4b11-465a-8e1c-7553c59db044	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G55032166	2025-01-02	2025-01-02 11:07:00+00	2025-01-02 11:07:00+00	6.090000	6.110000	200.0000	long	3.270000	0.000000	0.73	0.0599	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.676328+00	2025-09-03 18:50:23.550967+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:55.671Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.675+00	5	completed	2025-09-03 18:50:23.550967+00
6f0c2707-8a41-49f9-a9f3-ef9325527424	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NRXP	2025-01-03	2025-01-03 12:03:00+00	2025-01-03 12:04:00+00	3.370000	3.370000	200.0000	long	3.800000	0.000000	-5.26	-0.7799	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.370431+00	2025-09-03 18:46:56.373863+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:56.366Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff0031d1903c141ea96a1f12d4cb1c18b9b3bad898fe63898182d7e7247c79a0", "source": "Yahoo", "summary": "HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD. The Company has previously announced non-binding Letters of Intent and banking intent for initial clinic acquisitions and has disclosed its intent to acquire and integrate clinics generating a more than $", "datetime": "2025-01-03T13:03:00.000Z", "headline": "HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Subsidiary, Will Host an Investor Workshop for Qualified Institutional Investors at the Mar-A-Lago Club During the Week of January 6, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=824bdc26c13814a27a78bd968d9c18d279c76a74d9103110f8b04a3aac2b4185", "source": "Yahoo", "summary": "HOPE Therapeutics, Inc., (\\"HOPE,\\" the \\"Company\\"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (\\"NRx\\") (Nasdaq: NRXP), today announced the planned acquisition of the Kadima Neuropsychiatry Institute (Kadima) of La Jolla, CA, per the previously announced Letter of Intent, for the HOPE network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide a", "datetime": "2025-01-02T13:03:00.000Z", "headline": "Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:56.37+00	5	completed	2025-09-03 18:46:56.373863+00
4c1e5b72-06bd-41a2-8cb5-b57cdd6725a7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CHEK	2025-01-03	2025-01-03 12:04:00+00	2025-01-03 12:05:00+00	1.790000	1.780000	200.0000	long	4.270000	0.000000	-7.27	-2.0307	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.597862+00	2025-09-03 18:46:56.59933+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:56.375Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.597+00	5	completed	2025-09-03 18:46:56.59933+00
0e9841bb-5d77-4cb9-8cdf-46d9b686ceb0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GDTC	2025-01-06	2025-01-06 11:16:00+00	2025-01-06 11:17:00+00	7.000000	7.140000	200.0000	long	4.280000	0.000000	23.03	1.6450	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:57.511053+00	2025-09-03 18:46:57.516127+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:57.498Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=64a423768f0957fcb793daebe363b20b5443c103fbd20846137659061986e356", "source": "Yahoo", "summary": "Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR", "datetime": "2025-01-06T14:11:56.000Z", "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Monday", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=86eea0da54032c59e53d4cea145b02627138ae89c9a5469a351af1827863ad29", "source": "Yahoo", "summary": "SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement (“BRCA”) with Mumbai-based SunAct Cancer Institute Private Limited", "datetime": "2025-01-06T12:00:00.000Z", "headline": "CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:57.51+00	5	completed	2025-09-03 18:46:57.516127+00
ec2118c0-1d4a-4719-bf27-dfb451fbad04	2d96cef2-7502-44ff-a7a9-17713d4a7a42	RHEP	2025-01-06	2025-01-06 11:24:00+00	2025-01-06 11:24:00+00	5.350000	5.170000	200.0000	short	3.930000	0.000000	32.19	3.0084	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:57.830253+00	2025-09-03 18:46:57.831942+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:57.826Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:57.83+00	5	completed	2025-09-03 18:46:57.831942+00
0cf9a9b9-7066-4372-8551-7d9a448736bb	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCPX	2025-01-03	2025-01-03 11:40:00+00	2025-01-03 11:40:00+00	0.570000	0.600000	200.0000	long	3.760000	0.000000	4.22	3.7345	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.270428+00	2025-09-03 18:46:56.273867+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.266Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.27+00	5	completed	2025-09-03 18:46:56.273867+00
b28fc1c7-0cb7-44bb-8c1f-837b1dc8a24a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMOD	2025-01-07	2025-01-07 11:48:00+00	2025-01-30 12:16:00+00	2.020000	2.160000	5011.0000	long	45.500000	0.000000	626.24	6.1745	Round trip: 13 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:00.722303+00	2025-09-03 18:47:00.723084+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 33148, "analysisTimestamp": "2025-09-03T18:47:00.720Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f9a9c83057220ae856bbfc0c098b8d20bca04e538fc17d6d2bee4ce9b08c82df", "source": "Yahoo", "summary": "CORNELIUS, N.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus” or the “Company”), announces a major milestone with the issuance of its 9th patent, further solidifying its position at the forefront of artificial intelligence solutions. On December 24, 2024, the United States Patent and Trademark Office issued Alpha Modus, Corp., the wholly owned subsidiary of the Company, its latest patent, United States Patent Number 12,175,484, titled “Methods for Pe", "datetime": "2025-01-06T14:00:00.000Z", "headline": "Alpha Modus Secures 9th AI Patent, Strengthening Leadership in Retail Innovation", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.722+00	5	completed	2025-09-03 18:47:00.723084+00
de95e36a-904c-45d2-a18d-a8656d6b7fc9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NITO	2025-01-03	2025-01-03 12:02:00+00	2025-01-03 12:02:00+00	1.730000	1.690000	200.0000	short	4.260000	0.000000	3.74	1.0809	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.348942+00	2025-09-03 18:46:56.35064+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.344Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=bb1ace1e2d4ff0a08ed2715ac8bb01838f737a8d396959052f9c528f2cd479e7", "source": "Yahoo", "summary": "N2OFF will hold approximately 70% ownership in the projects, further enhancing its presence in the European energy storage market Neve Yarak, Israel, Jan. 03, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today that on January 3 2025 it has signed a binding LOI with Solterra Ltd’s subsidiary ,Soltera Brand Services Italy (“SBSI”), a company that", "datetime": "2025-01-03T12:55:00.000Z", "headline": "N2OFF and Solterra Brand Services Italy executed a binding LOI to Develop Two 98MWp Battery Storage Projects in Sicily", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8226768fb2fbd5c44b51905e399d777fe7923051df0d9889428ef5f05827e10d", "source": "Yahoo", "summary": "The approval was obtained from the Melz Municipal Committee in connection with the submission of Solterra’s statutory plan for the PV Project Neve Yarak, Israel, Jan. 02, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\\\\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation in the agri- tech sector, is pleased to announce progress in its collaborative solar photovoltaic (PV) project in Melz, Germany, developed by Solterra Renewa", "datetime": "2025-01-02T13:05:00.000Z", "headline": "N2OFF, Inc. Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:56.347+00	5	completed	2025-09-03 18:46:56.35064+00
43752dc2-e08c-41c4-921b-3e60f9843cb0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-01-08	2025-01-08 11:05:00+00	2025-01-08 11:07:00+00	3.030000	3.060000	400.0000	long	7.510000	0.000000	4.49	0.3705	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:02.050358+00	2025-09-03 18:47:02.051611+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:02.047Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=04091ad3ff6a8d1693107a9cf5ca05b97a9662e05706e7daaf9338fd9b4299c7", "source": "Yahoo", "summary": "SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, crypt", "datetime": "2025-01-08T12:00:00.000Z", "headline": "CURRENC Debuts SEAMLESS AI Call Centre Solutions", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:02.05+00	5	completed	2025-09-03 18:47:02.051611+00
33d4ed27-b349-4aed-b48e-0d063203af2a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ARBE	2025-01-06	2025-01-06 12:02:00+00	2025-01-06 12:02:00+00	2.860000	3.000000	100.0000	long	2.630000	0.000000	11.37	3.9755	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:58.53146+00	2025-09-03 18:46:58.535417+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:58.524Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=17b99f4bf3c870ed034fdab2faf97e4c1513a1499184d1f1f6e83e0df89fcee9", "source": "Yahoo", "summary": "Arbe Robotics Ltd. (NASDAQ: ARBE) (TASE: ARBE), a global leader in Perception Radar solutions, announced today that in collaboration with NVIDIA, Arbe is enhancing free space mapping and AI-driven capabilities to further advance the automotive industry. Arbe will showcase its groundbreaking ultra-high-definition radar that is revolutionizing vehicle safety and autonomy at CES 2025.", "datetime": "2025-01-06T13:00:00.000Z", "headline": "Arbe Collaborates with NVIDIA to Enhance Radar-Based Free Space Mapping and AI-Driven Capabilities", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:58.531+00	5	completed	2025-09-03 18:46:58.535417+00
e3857dd9-7e80-47bb-aaf6-eaa7798f3921	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-01-08	2025-01-08 11:10:00+00	2025-01-08 11:11:00+00	3.880000	3.550000	200.0000	short	4.280000	0.000000	62.35	8.0283	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:02.364401+00	2025-09-03 18:47:02.365629+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:02.361Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=04091ad3ff6a8d1693107a9cf5ca05b97a9662e05706e7daaf9338fd9b4299c7", "source": "Yahoo", "summary": "SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, crypt", "datetime": "2025-01-08T12:00:00.000Z", "headline": "CURRENC Debuts SEAMLESS AI Call Centre Solutions", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:02.364+00	5	completed	2025-09-03 18:47:02.365629+00
b0a66cdd-28ca-46f5-bd64-de5eb0745185	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-03-17	2025-03-17 12:34:00+00	2025-03-17 17:08:00+00	2.470000	2.500000	3000.0000	long	28.170000	0.000000	66.05	0.8919	Round trip: 5 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:02.672632+00	2025-09-03 18:47:02.677895+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 274, "analysisTimestamp": "2025-09-03T18:47:02.662Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:02.671+00	5	completed	2025-09-03 18:47:02.677895+00
c73a8d3d-e3d5-454d-96d3-10de2141bfb5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:06:00+00	2025-03-18 12:06:00+00	2.820000	2.730000	300.0000	long	3.990000	0.000000	-30.99	-3.6631	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:00.850225+00	2025-09-03 18:48:00.85167+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:00.845Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:00.85+00	5	completed	2025-09-03 18:48:00.85167+00
3232c5b8-a343-4a4d-8a01-c6ff1a5580fa	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCPX	2025-01-03	2025-01-03 11:41:00+00	2025-01-03 11:41:00+00	0.560000	0.560000	200.0000	short	2.720000	0.000000	-3.26	-2.9159	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.306679+00	2025-09-03 18:46:56.311503+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.275Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.306+00	5	completed	2025-09-03 18:46:56.311503+00
c2568a2a-4e8b-402b-b7bc-57d82f457c31	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMOD	2025-01-30	2025-01-30 12:22:00+00	2025-01-30 12:23:00+00	2.880000	2.980000	200.0000	long	3.250000	0.000000	17.67	3.0677	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.730818+00	2025-09-03 18:47:00.73258+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:00.723Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=5c9b9193ec2e3272341044b124fccbfba74d44e9776e416ef625e1470d838b70", "source": "Yahoo", "summary": "CORNELIUS, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus”, “AMOD”, or the “Company”), in a statement today, through Alpha Modus CEO William Alessi, emphasized the company's strong fundamentals, ongoing growth strategy, and commitment to delivering value to shareholders amidst what he described as \\"uninformed speculation\\" by certain market participants. \\"The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and", "datetime": "2025-01-30T13:00:00.000Z", "headline": "Alpha Modus CEO Addresses Market Volatility and its Recent SPAC Merger", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.729+00	5	completed	2025-09-03 18:47:00.73258+00
c5d25d5e-fab7-4bd2-8e78-fe091f988fc3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MSAI	2025-01-07	2025-01-07 11:18:00+00	2025-01-07 11:21:00+00	4.160000	4.160000	200.0000	long	3.260000	0.000000	-2.28	-0.2744	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:58.549058+00	2025-09-03 18:46:58.552037+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:46:58.544Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1f7c9d078c8fea44fddb66ce9531fb9576283626d5de7476ce6cb466f1d29c28", "source": "Yahoo", "summary": "HOUSTON, TX / ACCESSWIRE / January 6, 2025 / MultiSensor AI Holdings, Inc. (\\"MultiSensor AI,\\" \\"MSAI\\" or \\"Company\\") (Nasdaq:MSAI), a pioneer in the emerging industrial AI-driven condition-based maintenance and process solution industry, today announced ...", "datetime": "2025-01-06T21:05:00.000Z", "headline": "MultiSensorAI Announces Next Steps in Leadership Optimization Plan as it Prepares for Rapid Growth", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:58.548+00	5	completed	2025-09-03 18:46:58.552037+00
f709ddd6-456c-4f1b-831c-31fb626c18c7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ZENA	2025-01-07	2025-01-07 11:33:00+00	2025-01-07 11:33:00+00	8.080000	8.060000	200.0000	short	4.300000	0.000000	-0.30	-0.0186	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:59.078566+00	2025-09-03 18:46:59.080398+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:59.073Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d2df7544439c4dc84ed6b46ed9fa730103b320199f4b71ee617e2fb49ce8f869", "source": "Yahoo", "summary": "VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (\\"ZenaTech\\"), a technology company specializing in AI (Artificial Intelligence) drone solutions driven by Quantum Computing, Drones as a Service, and enterprise SaaS, announces that it has signed an LOI (Letter of Intent) to acquire a workforce scheduling software company with which it plans to develop quantum computing-driven solutions. The software is intended to increase productivity for mu", "datetime": "2025-01-07T12:30:00.000Z", "headline": "ZenaTech to Acquire Workforce Scheduling Software Company in Order to Use Quantum Computing to Increase Productivity for Multinational Corporations", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:59.078+00	5	completed	2025-09-03 18:46:59.080398+00
e73b4b82-2eae-4938-9589-7670a569e723	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ZENA	2025-01-10	2025-01-10 11:31:00+00	2025-01-10 11:33:00+00	7.160000	7.170000	400.0000	long	5.140000	0.000000	-0.78	-0.0272	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:59.33131+00	2025-09-03 18:46:59.33219+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:46:59.328Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3fa830a7cf8cc6917020558d26f919d68acc91b70994210fb57055a4c97a8afc", "source": "Finnhub", "summary": "VANCOUVER, British Columbia, Jan. 10, 2025 -- ZenaTech, Inc. , a technology company specializing in AI drone solutions driven by Quantum Computing, Drones as a Service, and enterprise SaaS,...", "datetime": "2025-01-10T07:31:04.000Z", "headline": "ZenaTech’s ZenaDrone Multipurpose AI Drone Applies for FAA Part 137 Crop Sprayer Certification for Agricultural and Wildfire Industry Use", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:46:59.331+00	5	completed	2025-09-03 18:46:59.33219+00
75418968-359d-4b3a-ae19-3dfbdf72a088	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G33277131	2025-01-10	2025-01-10 11:08:00+00	2025-01-10 11:09:00+00	0.370000	0.370000	200.0000	long	2.480000	0.000000	-2.40	-3.2345	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.731759+00	2025-09-03 18:50:17.832994+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:04.724Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.731+00	5	completed	2025-09-03 18:50:17.832994+00
7315f222-dd5f-4e83-9f1d-dd289c43e978	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AKYA	2025-01-10	2025-01-10 11:05:00+00	2025-01-10 11:06:00+00	4.060000	4.120000	200.0000	long	2.360000	0.000000	9.64	1.1872	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.090968+00	2025-09-03 18:47:05.092421+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:05.088Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=085459cbf2ffc1a0977f977eb9147dc80f63cf8b3915b1170f3d5172fe9c648f", "source": "Finnhub", "summary": "Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Akoya Biosciences, Inc. to Quanterix Corporation ....", "datetime": "2025-01-10T17:36:03.000Z", "headline": "AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=dafdccf86b194006aff1ee00ea1cab3691931f8b6369ed06c1ecd3ad40c4e91f", "source": "Yahoo", "summary": "Quanterix (QTRX) and Akoya Biosciences (AKYA) said Friday they entered into a definitive merger agre", "datetime": "2025-01-10T12:49:28.000Z", "headline": "Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=87781754a6378257e1b272734a83712c4f67ac4a484dad9ac1ec2e93b2e06b74", "source": "Yahoo", "summary": "BILLERICA, Mass. and MARLBOROUGH, Mass., January 10, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.", "datetime": "2025-01-10T12:00:00.000Z", "headline": "Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=5842f157937f4ad0e45ac03665a9ba8d5ba75497e783ee028f42fe94c41e21c8", "source": "Finnhub", "summary": "Ademi LLP is investigating Akoya for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix.Click here to learn how to join our investigation and obtain...", "datetime": "2025-01-10T09:48:03.000Z", "headline": "Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=03b92323f0a4dcbbd75f3e189a149f2b05da85cc39dbb9a85d352357db663bf4", "source": "Finnhub", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya...", "datetime": "2025-01-10T08:22:04.000Z", "headline": "AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:05.09+00	5	completed	2025-09-03 18:47:05.092421+00
d27209d0-304a-47f0-b381-95e190cba31d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PHIO	2025-01-13	2025-01-13 11:47:00+00	2025-01-13 11:48:00+00	2.410000	2.620000	200.0000	long	3.250000	0.000000	38.75	8.0394	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.966758+00	2025-09-03 18:47:05.968271+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:05.963Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=8c2026ef82db60b6e199ae71783045ef89c5978e7fd785ae6fd3f98079e7f0d5", "source": "Yahoo", "summary": "On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2", "datetime": "2025-01-13T17:45:44.000Z", "headline": "Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=7527449cac05f687e796b5ba1764927dd1b6de08cb32c15c0684d74fb9ae2d1c", "source": "Yahoo", "summary": "Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2", "datetime": "2025-01-13T12:45:00.000Z", "headline": "Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:05.966+00	5	completed	2025-09-03 18:47:05.968271+00
481056fe-1402-4176-8316-60af2e225c57	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CING	2025-01-07	2025-01-07 11:35:00+00	2025-01-07 11:36:00+00	5.830000	6.000000	400.0000	long	4.140000	0.000000	63.86	2.7384	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:59.958861+00	2025-09-03 18:46:59.971735+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:59.947Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3d074b755d44363dd67714b8456bef0021e5d627f3f55b2f1f83689cb55b16ba", "source": "Yahoo", "summary": "No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidat", "datetime": "2025-01-07T12:30:00.000Z", "headline": "Final Study Completed for Cingulate’s Lead Asset CTx-1301", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:59.957+00	5	completed	2025-09-03 18:46:59.971735+00
450ff732-a16e-4e1c-a1ed-a6bbc28bf074	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCPX	2025-01-03	2025-01-03 11:53:00+00	2025-01-03 11:53:00+00	0.830000	0.800000	200.0000	short	4.040000	0.000000	1.38	0.8342	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.331227+00	2025-09-03 18:46:56.336217+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.320Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.33+00	5	completed	2025-09-03 18:46:56.336217+00
2d51fc87-6038-42e9-9eb8-1fcb8ca5b620	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SONN	2025-01-06	2025-01-06 13:44:00+00	\N	1.980000	\N	2500.0000	short	9.310000	0.000000	0.00	0.0000	Open position: 1 executions	f	lightspeed	position	\N	{}	2025-09-03 18:46:58.538515+00	2025-09-03 18:46:58.542258+00	[]	\N	\N	f	\N	\N	\N	80.00	basic_time_based	{"signals": [], "holdTimeMinutes": 345903, "analysisTimestamp": "2025-09-03T18:46:58.537Z"}	f	\N	[]	f	\N	\N	5	completed	2025-09-03 18:46:58.542258+00
00220d91-0366-440a-9069-479875535d4e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	92840Q202	2025-01-10	2025-01-10 10:59:00+00	2025-01-10 10:59:00+00	3.230000	3.160000	200.0000	short	4.260000	0.000000	8.74	1.3550	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.745538+00	2025-09-03 18:50:17.335898+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:04.738Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.745+00	5	completed	2025-09-03 18:50:17.335898+00
cbc9d0a2-69b1-467e-80e3-2365d10ba91a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMOD	2025-01-30	2025-01-30 12:35:00+00	2025-01-30 12:35:00+00	2.850000	2.850000	200.0000	long	3.250000	0.000000	-3.25	-0.5702	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.737615+00	2025-09-03 18:47:00.740002+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:00.733Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=5c9b9193ec2e3272341044b124fccbfba74d44e9776e416ef625e1470d838b70", "source": "Yahoo", "summary": "CORNELIUS, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus”, “AMOD”, or the “Company”), in a statement today, through Alpha Modus CEO William Alessi, emphasized the company's strong fundamentals, ongoing growth strategy, and commitment to delivering value to shareholders amidst what he described as \\"uninformed speculation\\" by certain market participants. \\"The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and", "datetime": "2025-01-30T13:00:00.000Z", "headline": "Alpha Modus CEO Addresses Market Volatility and its Recent SPAC Merger", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.737+00	5	completed	2025-09-03 18:47:00.740002+00
56dc5aee-f080-465f-9d9e-b5968659da26	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-01-08	2025-01-08 11:04:00+00	2025-01-08 11:04:00+00	2.840000	2.730000	400.0000	short	7.510000	0.000000	37.49	3.3031	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:01.488714+00	2025-09-03 18:47:01.489982+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:01.485Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=04091ad3ff6a8d1693107a9cf5ca05b97a9662e05706e7daaf9338fd9b4299c7", "source": "Yahoo", "summary": "SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced the launch of its SEAMLESS AI Call Centre Solutions, a suite of AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance companies, telecommunications companies, government agencies, crypt", "datetime": "2025-01-08T12:00:00.000Z", "headline": "CURRENC Debuts SEAMLESS AI Call Centre Solutions", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:01.488+00	5	completed	2025-09-03 18:47:01.489982+00
a31095e1-970e-481f-918a-72b0c285ce1b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CURR	2025-03-18	2025-03-18 13:08:00+00	\N	2.050000	\N	2000.0000	long	13.650000	0.000000	0.00	0.0000	Open position: 4 executions	f	lightspeed	position	\N	{}	2025-09-03 18:47:02.688265+00	2025-09-03 18:47:02.689934+00	[]	\N	\N	f	\N	\N	\N	80.00	basic_time_based	{"signals": [], "holdTimeMinutes": 243699, "analysisTimestamp": "2025-09-03T18:47:02.687Z"}	f	\N	[]	f	\N	\N	5	completed	2025-09-03 18:47:02.689934+00
acbfad78-2057-47a9-be1b-25be582cc165	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-01-28	2025-01-28 11:35:00+00	2025-01-28 11:36:00+00	2.160000	2.180000	200.0000	long	3.250000	0.000000	0.75	0.1736	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:02.717741+00	2025-09-03 18:47:02.720754+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:02.709Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e7ff5006c80c61d0070ba1e3c1c4b7d4336d43876faf6869a18e05ab2f6ee235", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (\\"NLS\\" or the \\"Company\\"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global health crisis and was recently declared a national public health emergency by the new Trump adminis", "datetime": "2025-01-28T12:30:00.000Z", "headline": "NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:02.717+00	5	completed	2025-09-03 18:47:02.720754+00
f22c3d0e-bbdf-4ccd-88f5-e892dbd7304a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AKYA	2025-01-10	2025-01-10 11:01:00+00	2025-01-10 11:01:00+00	4.200000	3.890000	200.0000	short	3.830000	0.000000	57.87	6.8893	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:05.085844+00	2025-09-03 18:47:05.087358+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:05.083Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=085459cbf2ffc1a0977f977eb9147dc80f63cf8b3915b1170f3d5172fe9c648f", "source": "Finnhub", "summary": "Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Akoya Biosciences, Inc. to Quanterix Corporation ....", "datetime": "2025-01-10T17:36:03.000Z", "headline": "AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=dafdccf86b194006aff1ee00ea1cab3691931f8b6369ed06c1ecd3ad40c4e91f", "source": "Yahoo", "summary": "Quanterix (QTRX) and Akoya Biosciences (AKYA) said Friday they entered into a definitive merger agre", "datetime": "2025-01-10T12:49:28.000Z", "headline": "Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=87781754a6378257e1b272734a83712c4f67ac4a484dad9ac1ec2e93b2e06b74", "source": "Yahoo", "summary": "BILLERICA, Mass. and MARLBOROUGH, Mass., January 10, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.", "datetime": "2025-01-10T12:00:00.000Z", "headline": "Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=5842f157937f4ad0e45ac03665a9ba8d5ba75497e783ee028f42fe94c41e21c8", "source": "Finnhub", "summary": "Ademi LLP is investigating Akoya for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix.Click here to learn how to join our investigation and obtain...", "datetime": "2025-01-10T09:48:03.000Z", "headline": "Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=03b92323f0a4dcbbd75f3e189a149f2b05da85cc39dbb9a85d352357db663bf4", "source": "Finnhub", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya...", "datetime": "2025-01-10T08:22:04.000Z", "headline": "AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:05.085+00	5	completed	2025-09-03 18:47:05.087358+00
19607175-0f9f-4aee-a3d3-008fc152d1c2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ATPC	2025-01-13	2025-01-13 11:19:00+00	2025-01-13 11:22:00+00	2.550000	2.440000	200.0000	long	3.250000	0.000000	-25.25	-4.9510	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.112586+00	2025-09-03 18:47:05.114324+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:47:05.107Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:05.112+00	5	completed	2025-09-03 18:47:05.114324+00
1ea5db6b-dd24-4695-96b1-fb3a1b4e80a4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SPRC	2025-01-06	2025-01-06 11:54:00+00	2025-01-06 11:56:00+00	0.990000	0.970000	200.0000	long	3.210000	0.000000	-6.49	-3.2881	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:58.510279+00	2025-09-03 18:46:58.512352+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:46:58.505Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=66425d71666fe7675d514f28b7a68f4d7e7c2300bec647c47b306f13ebe7f146", "source": "Yahoo", "summary": "On Monday, SciSparc Ltd (NASDAQ:SPRC) stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro. SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND), the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, t", "datetime": "2025-01-06T16:04:50.000Z", "headline": "Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=64a423768f0957fcb793daebe363b20b5443c103fbd20846137659061986e356", "source": "Yahoo", "summary": "Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR", "datetime": "2025-01-06T14:11:56.000Z", "headline": "Sector Update: Health Care Stocks Edge Higher Premarket Monday", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=93235a14622b416af33b4959b879e097eba70ab171cdc4fde7730c4f9a1a4a6e", "source": "Yahoo", "summary": "TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\\"Company\\" or \\"SciSparc\\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-tre", "datetime": "2025-01-06T12:50:00.000Z", "headline": "SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment", "sentiment": "positive"}]	t	positive	2025-09-03 18:46:58.509+00	5	completed	2025-09-03 18:46:58.512352+00
000322b7-3fe4-4edb-ac94-44d326f59b8a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 17:57:00+00	2025-04-07 18:29:00+00	48.490000	49.900000	150.0000	long	3.840000	0.000000	207.54	2.8533	Round trip: 3 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:49:00.765829+00	2025-09-03 18:49:00.76719+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 32, "analysisTimestamp": "2025-09-03T18:49:00.761Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:00.765+00	5	completed	2025-09-03 18:49:00.76719+00
081d46ba-dde9-4753-8bbe-b9bfafdc953b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMOD	2025-01-30	2025-01-30 13:43:00+00	2025-01-30 13:43:00+00	4.890000	5.050000	100.0000	long	2.640000	0.000000	13.47	2.7549	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:00.743918+00	2025-09-03 18:47:00.747167+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:00.740Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=5c9b9193ec2e3272341044b124fccbfba74d44e9776e416ef625e1470d838b70", "source": "Yahoo", "summary": "CORNELIUS, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus”, “AMOD”, or the “Company”), in a statement today, through Alpha Modus CEO William Alessi, emphasized the company's strong fundamentals, ongoing growth strategy, and commitment to delivering value to shareholders amidst what he described as \\"uninformed speculation\\" by certain market participants. \\"The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and", "datetime": "2025-01-30T13:00:00.000Z", "headline": "Alpha Modus CEO Addresses Market Volatility and its Recent SPAC Merger", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:00.743+00	5	completed	2025-09-03 18:47:00.747167+00
a014df91-49e3-41d5-967b-060f8451ba9d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-01-08	2025-01-08 11:44:00+00	2025-01-08 11:44:00+00	3.180000	2.980000	200.0000	short	4.260000	0.000000	35.74	5.6195	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:02.702683+00	2025-09-03 18:47:02.705972+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:02.696Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b65806d881ab447ddce2243aa1b780f8c7994edb374431ac04484cdea588e7a8", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announce the successful completion of the initi", "datetime": "2025-01-08T12:42:00.000Z", "headline": "NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:02.702+00	5	completed	2025-09-03 18:47:02.705972+00
53f6a156-e9c4-4259-81eb-2197046d5e8b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	03835L405	2025-04-02	2025-04-02 21:19:00+00	2025-04-02 21:19:00+00	2.450000	2.430000	300.0000	short	3.980000	0.000000	2.02	0.2748	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:01.759491+00	2025-09-03 18:49:59.26475+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:01.754Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:01.759+00	5	completed	2025-09-03 18:49:59.26475+00
96647307-c0e3-4eaf-9564-42d52fb6f56b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	INM	2025-01-21	2025-01-21 11:35:00+00	2025-01-21 11:36:00+00	7.250000	7.370000	100.0000	long	2.250000	0.000000	9.75	1.3448	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.450624+00	2025-09-03 18:47:15.45182+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:15.448Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2d06fbf6b200a5e1d16d9195267041a570cb6b2f411cb1e8b0371e8940c00cdb", "source": "Yahoo", "summary": "INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile showed a reduction of several key neuroinflammatory genes in the brainVancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\\"InMed\\" or the \\"Company\\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candid", "datetime": "2025-01-21T12:30:00.000Z", "headline": "InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:15.45+00	5	completed	2025-09-03 18:47:15.45182+00
a4a35db5-1357-432e-8bea-32af44c1c284	2d96cef2-7502-44ff-a7a9-17713d4a7a42	42328V801	2025-01-21	2025-01-21 11:02:00+00	2025-01-21 11:03:00+00	1.080000	1.090000	200.0000	long	3.250000	0.000000	-1.25	-0.5787	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.043297+00	2025-09-03 18:50:15.324171+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:15.037Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:15.043+00	5	completed	2025-09-03 18:50:15.324171+00
41aff738-540f-4c35-9794-e39312511c91	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-01-31	2025-01-31 11:30:00+00	2025-01-31 11:32:00+00	2.970000	2.900000	600.0000	short	11.770000	0.000000	30.23	1.6955	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:03.360454+00	2025-09-03 18:47:03.361438+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:03.357Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1410b4eae8e440a685ed31dcefe293454e022478ddf874ca82b41fe2ab0610f0", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are pleased to announce that in a special gene", "datetime": "2025-01-31T12:30:00.000Z", "headline": "Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9db868b831a3aac1bc60c4b02c6f1158f3747a05f4b17498e2537d80e81ff517", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (\\"NLS\\" or the \\"Company\\"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).", "datetime": "2025-01-30T12:30:00.000Z", "headline": "NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:03.36+00	5	completed	2025-09-03 18:47:03.361438+00
9bd9b0b2-006e-4bb5-937a-5faec46c3977	2d96cef2-7502-44ff-a7a9-17713d4a7a42	THAR	2025-03-24	2025-03-24 12:04:00+00	2025-03-24 12:04:00+00	1.660000	1.650000	300.0000	short	3.980000	0.000000	-0.74	-0.1485	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:20.120378+00	2025-09-03 18:48:20.121768+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:19.474Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e10ba4b5191fb575a4d18adca8967bd4d0b25212c373014da1976612152574be", "source": "Yahoo", "summary": "BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (\\"Tharimmune\\" or the \\"Company\\"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...", "datetime": "2025-03-24T12:00:00.000Z", "headline": "Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:20.12+00	5	completed	2025-09-03 18:48:20.121768+00
968abd8b-902d-49b6-ad08-e7fafe0ab590	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-01-31	2025-01-31 11:33:00+00	2025-01-31 11:34:00+00	3.200000	3.240000	200.0000	long	4.270000	0.000000	3.75	0.5859	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:03.367516+00	2025-09-03 18:47:03.369505+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:03.362Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1410b4eae8e440a685ed31dcefe293454e022478ddf874ca82b41fe2ab0610f0", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are pleased to announce that in a special gene", "datetime": "2025-01-31T12:30:00.000Z", "headline": "Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9db868b831a3aac1bc60c4b02c6f1158f3747a05f4b17498e2537d80e81ff517", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (\\"NLS\\" or the \\"Company\\"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).", "datetime": "2025-01-30T12:30:00.000Z", "headline": "NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:03.367+00	5	completed	2025-09-03 18:47:03.369505+00
c58ae0cb-b66a-45c4-ae27-0d61eadaab5e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-02-10	2025-02-10 11:31:00+00	2025-02-10 11:32:00+00	2.890000	2.940000	600.0000	long	9.760000	0.000000	18.38	1.0601	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:03.890219+00	2025-09-03 18:47:03.891357+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:03.886Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=96c4da49a260e6291f10dd59318e9449a207d1b6abb2495eb2aebb271f341161", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a leading biotechno", "datetime": "2025-02-10T12:30:00.000Z", "headline": "NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:03.889+00	5	completed	2025-09-03 18:47:03.891357+00
9945d4fd-d3ac-4f61-be3a-00ac97bdeaee	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AKYA	2025-01-10	2025-01-10 11:14:00+00	2025-01-10 11:14:00+00	4.400000	4.390000	200.0000	short	4.280000	0.000000	-2.28	-0.2591	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.095711+00	2025-09-03 18:47:05.098102+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:05.093Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=085459cbf2ffc1a0977f977eb9147dc80f63cf8b3915b1170f3d5172fe9c648f", "source": "Finnhub", "summary": "Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Akoya Biosciences, Inc. to Quanterix Corporation ....", "datetime": "2025-01-10T17:36:03.000Z", "headline": "AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=dafdccf86b194006aff1ee00ea1cab3691931f8b6369ed06c1ecd3ad40c4e91f", "source": "Yahoo", "summary": "Quanterix (QTRX) and Akoya Biosciences (AKYA) said Friday they entered into a definitive merger agre", "datetime": "2025-01-10T12:49:28.000Z", "headline": "Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=87781754a6378257e1b272734a83712c4f67ac4a484dad9ac1ec2e93b2e06b74", "source": "Yahoo", "summary": "BILLERICA, Mass. and MARLBOROUGH, Mass., January 10, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.", "datetime": "2025-01-10T12:00:00.000Z", "headline": "Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=5842f157937f4ad0e45ac03665a9ba8d5ba75497e783ee028f42fe94c41e21c8", "source": "Finnhub", "summary": "Ademi LLP is investigating Akoya for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix.Click here to learn how to join our investigation and obtain...", "datetime": "2025-01-10T09:48:03.000Z", "headline": "Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=03b92323f0a4dcbbd75f3e189a149f2b05da85cc39dbb9a85d352357db663bf4", "source": "Finnhub", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. to Quanterix Corporation for 0.318 shares of Quanterix common stock for each share of Akoya...", "datetime": "2025-01-10T08:22:04.000Z", "headline": "AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:05.095+00	5	completed	2025-09-03 18:47:05.098102+00
f0b1e381-c5bb-425e-b79d-badd58e5adaf	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PHIO	2025-01-13	2025-01-13 11:47:00+00	2025-01-13 11:47:00+00	2.590000	2.450000	200.0000	long	3.250000	0.000000	-31.25	-6.0328	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.961598+00	2025-09-03 18:47:05.962914+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:05.958Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=8c2026ef82db60b6e199ae71783045ef89c5978e7fd785ae6fd3f98079e7f0d5", "source": "Yahoo", "summary": "On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2", "datetime": "2025-01-13T17:45:44.000Z", "headline": "Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=7527449cac05f687e796b5ba1764927dd1b6de08cb32c15c0684d74fb9ae2d1c", "source": "Yahoo", "summary": "Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2", "datetime": "2025-01-13T12:45:00.000Z", "headline": "Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:05.961+00	5	completed	2025-09-03 18:47:05.962914+00
aa289251-8d7d-43db-8e72-d917a9774fd7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:06:00+00	2025-03-18 12:08:00+00	2.660000	2.760000	1200.0000	long	15.910000	0.000000	96.23	3.0126	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:01.116569+00	2025-09-03 18:48:01.118195+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:01.113Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:01.116+00	5	completed	2025-09-03 18:48:01.118195+00
6d5d2e96-c5ad-4507-86ba-17ac97abcbf0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-01-31	2025-01-31 11:37:00+00	2025-01-31 11:38:00+00	3.120000	3.130000	200.0000	long	3.250000	0.000000	-1.25	-0.2003	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:03.375144+00	2025-09-03 18:47:03.37673+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:03.371Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1410b4eae8e440a685ed31dcefe293454e022478ddf874ca82b41fe2ab0610f0", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are pleased to announce that in a special gene", "datetime": "2025-01-31T12:30:00.000Z", "headline": "Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9db868b831a3aac1bc60c4b02c6f1158f3747a05f4b17498e2537d80e81ff517", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (\\"NLS\\" or the \\"Company\\"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).", "datetime": "2025-01-30T12:30:00.000Z", "headline": "NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:03.375+00	5	completed	2025-09-03 18:47:03.37673+00
6483d304-d727-4f43-9038-ee0240dc2e6a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-02-10	2025-02-10 11:37:00+00	2025-02-10 11:37:00+00	2.740000	2.800000	200.0000	long	3.250000	0.000000	8.75	1.5967	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:03.894081+00	2025-09-03 18:47:03.894836+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:03.892Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=96c4da49a260e6291f10dd59318e9449a207d1b6abb2495eb2aebb271f341161", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a leading biotechno", "datetime": "2025-02-10T12:30:00.000Z", "headline": "NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:03.893+00	5	completed	2025-09-03 18:47:03.894836+00
e33cc384-92a8-4451-a2fe-ae95b626c122	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NLSP	2025-02-10	2025-02-10 12:12:00+00	2025-02-10 12:14:00+00	2.810000	2.830000	600.0000	long	8.890000	0.000000	5.11	0.3034	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.4075+00	2025-09-03 18:47:04.408505+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:04.404Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=96c4da49a260e6291f10dd59318e9449a207d1b6abb2495eb2aebb271f341161", "source": "Yahoo", "summary": "NLS Pharmaceutics Ltd. (\\"NLS\\") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (\\"Kadimastem\\") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing \\"off-the-shelf\\" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a leading biotechno", "datetime": "2025-02-10T12:30:00.000Z", "headline": "NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:04.407+00	5	completed	2025-09-03 18:47:04.408505+00
84346238-c8e3-44aa-8cf4-51738bfd5106	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NBY	2025-01-10	2025-01-10 11:33:00+00	2025-01-10 11:40:00+00	0.690000	0.750000	800.0000	long	10.390000	0.000000	41.45	7.5617	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.103657+00	2025-09-03 18:47:05.105447+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:47:05.099Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:05.103+00	5	completed	2025-09-03 18:47:05.105447+00
cfc81afd-0e4d-413a-a84f-7601d0e94801	2d96cef2-7502-44ff-a7a9-17713d4a7a42	28059P303	2025-01-13	2025-01-13 11:30:00+00	2025-01-24 17:09:00+00	0.270000	0.300000	1000.0000	long	10.090000	0.000000	19.99	7.3595	Round trip: 4 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:05.413454+00	2025-09-03 18:50:16.837846+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 16179, "analysisTimestamp": "2025-09-03T18:47:05.411Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:05.413+00	5	completed	2025-09-03 18:50:16.837846+00
5eb6a4f1-4bec-4d41-91a3-2f3d9fe36750	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G33277131	2025-01-10	2025-01-10 10:56:00+00	2025-01-10 10:56:00+00	0.550000	0.510000	200.0000	short	3.700000	0.000000	4.50	4.0827	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.713897+00	2025-09-03 18:50:18.854179+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:04.709Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.713+00	5	completed	2025-09-03 18:50:18.854179+00
eed5b0db-7103-4e85-9cbc-7b5b71f1aad9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PHIO	2025-01-14	2025-01-14 11:03:00+00	2025-01-14 11:04:00+00	3.650000	3.730000	200.0000	long	3.830000	0.000000	11.17	1.5301	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.974984+00	2025-09-03 18:47:05.976644+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:05.969Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2751a7aad6b7a417941efc3d2ccb5aeb051efedad81df35b79ba0ee39421499d", "source": "Yahoo", "summary": "Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,063,670 shares of its common stock at a purchase price of $3.00 per share in a registered ..", "datetime": "2025-01-14T12:00:00.000Z", "headline": "Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=8c2026ef82db60b6e199ae71783045ef89c5978e7fd785ae6fd3f98079e7f0d5", "source": "Yahoo", "summary": "On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2", "datetime": "2025-01-13T17:45:44.000Z", "headline": "Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=7527449cac05f687e796b5ba1764927dd1b6de08cb32c15c0684d74fb9ae2d1c", "source": "Yahoo", "summary": "Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2", "datetime": "2025-01-13T12:45:00.000Z", "headline": "Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:05.974+00	5	completed	2025-09-03 18:47:05.976644+00
4de25751-3e80-4f39-849e-a1ae796e2c0b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TPET	2025-01-16	2025-01-16 12:37:00+00	2025-01-16 12:38:00+00	2.300000	2.110000	200.0000	long	3.260000	0.000000	-41.26	-8.9696	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.988584+00	2025-09-03 18:47:14.990538+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:14.985Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a4985ce8bdbd6d275781668c109a4d93e689b6bae9d12fc33f6845eeb28f19f6", "source": "Yahoo", "summary": "Bakersfield, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Trio Petroleum Corp (NYSE American: “TPET”, “Trio” or the “Company”), a California-based oil and gas company, announced that as of January 7,2025, the Company had fully repaid senior secured convertible promissory notes with an aggregate principal of $1.6 million (the “Notes”). The Notes were issued in connection with two separate financings funded by two institutional investors (the “Investors”) in in April 2024 and June of 2024. As previously", "datetime": "2025-01-16T13:30:00.000Z", "headline": "Company retires remaining Outstanding Convertible Investments", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:14.988+00	5	completed	2025-09-03 18:47:14.990538+00
20767967-25e0-4c11-9284-831061a528d5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TRIB	2025-01-28	2025-01-28 11:30:00+00	2025-01-28 11:31:00+00	1.030000	0.970000	200.0000	long	3.220000	0.000000	-15.22	-7.3883	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.146502+00	2025-09-03 18:47:17.148734+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:17.142Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9f8be03b27134adbe9020329bf576b7196098ffb19e47ebacff3b85b24f6242d", "source": "Yahoo", "summary": "Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system.", "datetime": "2025-01-28T12:20:00.000Z", "headline": "Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.146+00	5	completed	2025-09-03 18:47:17.148734+00
c94f6bfc-07f9-443f-b82e-e5f4c18cd03b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	03835L405	2025-04-02	2025-04-02 20:44:00+00	2025-04-02 20:44:00+00	2.030000	1.980000	300.0000	short	3.970000	0.000000	11.24	1.8456	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:01.753006+00	2025-09-03 18:49:59.747139+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:01.416Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:01.752+00	5	completed	2025-09-03 18:49:59.747139+00
efd87d9d-f87a-4f8c-9d18-b27e3aa1ad55	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLXN	2025-01-29	2025-01-29 11:20:00+00	2025-01-29 11:20:00+00	2.020000	2.030000	200.0000	long	3.250000	0.000000	-1.25	-0.3094	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.406859+00	2025-09-03 18:47:17.408959+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:17.402Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=fafbc20caf3be19205db4b0718e57543ff1f4808c712614aa6be945bc2b33073", "source": "Yahoo", "summary": "Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary s", "datetime": "2025-01-29T22:30:00.000Z", "headline": "Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=58218e7f2578ddbd46e80ced376534616f451395edf3a59e8383cd68ce3ec7d2", "source": "Yahoo", "summary": "NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions.", "datetime": "2025-01-29T14:59:00.000Z", "headline": "PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=38fced3dc7bfaaef73fe9ab6b13805a869ab85564a5b87ca2871a9bd6550d474", "source": "Yahoo", "summary": "New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastasesCayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new pre", "datetime": "2025-01-28T13:29:00.000Z", "headline": "Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.406+00	5	completed	2025-09-03 18:47:17.408959+00
9028b122-eca8-450f-98a8-5cf515235d62	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CJMB	2025-02-06	2025-02-06 11:43:00+00	2025-02-06 13:37:00+00	6.700000	7.110000	1700.0000	long	18.590000	0.000000	677.75	5.9501	Round trip: 8 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:37.858374+00	2025-09-03 18:47:37.860502+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 114, "analysisTimestamp": "2025-09-03T18:47:37.181Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=4756f3bceb34f6bf1e27ee223aec73a196dcce96327ec5af6ed6c07d31a3a991", "source": "Yahoo", "summary": "SPRING BRANCH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the closing of its previously announced initial public offering (the “Offering”) of 1,280,000 shares (the “Shares”) of common stock (“Common Stock”) at an initial public offerin", "datetime": "2025-02-06T21:29:00.000Z", "headline": "Callan JMB Announces Closing of $5.12 Million Initial Public Offering", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:37.858+00	5	completed	2025-09-03 18:47:37.860502+00
e39104e0-c788-4fe8-9e49-a9440f8272bb	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 18:00:00+00	2025-03-24 18:00:00+00	1.970000	1.840000	300.0000	short	3.970000	0.000000	35.48	6.0016	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:06.201576+00	2025-09-03 18:47:06.203668+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:06.197Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:06.201+00	5	completed	2025-09-03 18:47:06.203668+00
33051b0f-5286-4cbe-a6ad-30e05587b975	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:13:00+00	2025-03-18 12:14:00+00	2.940000	3.000000	300.0000	long	3.980000	0.000000	15.01	1.7037	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:01.122067+00	2025-09-03 18:48:01.123323+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:01.119Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:01.121+00	5	completed	2025-09-03 18:48:01.123323+00
56c75d2c-a0ca-4294-a6c7-8705a77b273f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 13:25:00+00	2025-03-26 13:25:00+00	2.560000	2.690000	300.0000	long	3.980000	0.000000	35.02	4.5599	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:08.025455+00	2025-09-03 18:47:08.026996+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:08.023Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:08.025+00	5	completed	2025-09-03 18:47:08.026996+00
162c256f-d36b-4981-a325-cc91ab4576a9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 13:26:00+00	2025-03-26 13:30:00+00	2.890000	3.190000	900.0000	long	11.940000	0.000000	259.62	9.9777	Round trip: 4 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:08.350227+00	2025-09-03 18:47:08.352374+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:47:08.345Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:08.349+00	5	completed	2025-09-03 18:47:08.352374+00
0f0eeef8-e574-412b-b88d-ab4c40a9d74d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 13:32:00+00	2025-03-26 13:33:00+00	3.360000	3.480000	300.0000	long	3.980000	0.000000	31.06	3.0784	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:09.014546+00	2025-09-03 18:47:09.016995+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:09.010Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:09.014+00	5	completed	2025-09-03 18:47:09.016995+00
d03bb4de-26ca-4e02-b6b9-8a854e1201c8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	THAR	2025-03-24	2025-03-24 12:05:00+00	2025-03-24 12:07:00+00	1.550000	1.600000	600.0000	long	7.930000	0.000000	24.17	2.6019	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:20.125874+00	2025-09-03 18:48:20.127113+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:20.122Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e10ba4b5191fb575a4d18adca8967bd4d0b25212c373014da1976612152574be", "source": "Yahoo", "summary": "BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (\\"Tharimmune\\" or the \\"Company\\"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...", "datetime": "2025-03-24T12:00:00.000Z", "headline": "Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:20.125+00	5	completed	2025-09-03 18:48:20.127113+00
e8157493-4baa-4700-8bb6-0e026a9c88b0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-27	2025-03-27 13:34:00+00	2025-03-27 17:45:00+00	4.450000	5.790000	1900.0000	long	17.440000	0.000000	2520.23	29.7782	Round trip: 5 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:11.578416+00	2025-09-03 18:47:11.580503+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 251, "analysisTimestamp": "2025-09-03T18:47:11.571Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d8f694dc53e9725168ec0e14e4dd2975df464bbde6c0da80e80a96cdd27bc14e", "source": "Yahoo", "summary": "LONDON, March 27, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") has agreed to grant Energi Holdings Limited (“Energi”) an exclusivity period of 8 weeks to conduct due diligence subject to Energi increasing its non-binding all-cash takeover proposal to acquire the non-affiliated shareholders of VivoPower at an enterprise valuation of US$180 million. This represents an increase from US$120 million. Energi is an Abu Dhabi-headquartered energy sol", "datetime": "2025-03-27T17:15:00.000Z", "headline": "VivoPower Agrees to Grant Exclusivity to Energi Subject to Increase in Non-Binding All-Cash Takeover Offer to Enterprise Value of US$180 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:11.577+00	5	completed	2025-09-03 18:47:11.580503+00
d269f0e5-73e8-4336-8e04-ddca7bcdf6cd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DATS	2025-03-25	2025-03-25 14:22:00+00	2025-03-25 14:23:00+00	5.110000	5.250000	300.0000	long	4.010000	0.000000	38.44	2.5077	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:25.799332+00	2025-09-03 18:48:25.80096+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:25.794Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=845a8530cbbe56da7ca98f0696960ef7f7fc0b59986c1e8ea7c58e71953e9339", "source": "Yahoo", "summary": "Company to sponsor and participate in the upcoming Photo Managers Conference 2025, the premier conference for photo professionals New Brunswick, NJ, March 25, 2025 (GLOBE NEWSWIRE) -- DatChat, Inc. (Nasdaq: DATS) (“DatChat” or the “Company”), a secure messaging and social media company, today announced that its Myseum Social Media Platform for storing and sharing digital photos and content is now available as a download on Apple iOS and Android devices. The Company also announced its sponsorship", "datetime": "2025-03-25T12:40:00.000Z", "headline": "DatChat Launches Myseum Social Media Platform for Apple iOS and Android Platforms", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:25.799+00	5	completed	2025-09-03 18:48:25.80096+00
e26b552a-78a3-4187-b3e7-425af684c9be	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 18:14:00+00	2025-03-24 18:14:00+00	3.110000	2.960000	300.0000	short	3.980000	0.000000	41.92	4.4916	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:06.20863+00	2025-09-03 18:47:06.210278+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:06.205Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:06.208+00	5	completed	2025-09-03 18:47:06.210278+00
2d660ff0-e017-4d81-bdf2-f13d52a38062	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 18:30:00+00	2025-03-24 18:30:00+00	3.610000	3.660000	300.0000	long	3.990000	0.000000	11.52	1.0639	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:06.486636+00	2025-09-03 18:47:06.487927+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:06.484Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:06.486+00	5	completed	2025-09-03 18:47:06.487927+00
998cf11c-e274-4131-ac1c-893d5692e5a1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:15:00+00	2025-03-18 12:15:00+00	3.300000	3.210000	300.0000	short	3.980000	0.000000	24.01	2.4228	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:01.130376+00	2025-09-03 18:48:01.132554+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:01.124Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:01.13+00	5	completed	2025-09-03 18:48:01.132554+00
b57497ac-0911-4293-aca1-4f2161935162	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 20:59:00+00	2025-03-24 20:59:00+00	3.200000	3.270000	300.0000	long	3.980000	0.000000	17.02	1.7729	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:07.753344+00	2025-09-03 18:47:07.755446+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:07.749Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:07.753+00	5	completed	2025-09-03 18:47:07.755446+00
b4707007-0ee7-497b-befa-2c9d2e2d7f01	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:16:00+00	2025-03-18 12:23:00+00	3.230000	3.320000	1200.0000	long	15.930000	0.000000	97.08	2.5079	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:01.34564+00	2025-09-03 18:48:01.346836+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:48:01.341Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:01.345+00	5	completed	2025-09-03 18:48:01.346836+00
398dbe31-4866-4a53-b8b5-5a7dccf7af0e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	03835L405	2025-04-03	2025-04-03 10:36:00+00	2025-04-03 11:20:00+00	3.380000	3.050000	1800.0000	long	23.860000	0.000000	-623.80	-10.2531	Round trip: 7 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:49:02.785098+00	2025-09-03 18:49:57.749951+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 44, "analysisTimestamp": "2025-09-03T18:49:02.779Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:02.784+00	5	completed	2025-09-03 18:49:57.749951+00
235831b1-fb49-4533-97d7-a613708c7e02	2d96cef2-7502-44ff-a7a9-17713d4a7a42	03835L405	2025-04-03	2025-04-03 10:14:00+00	2025-04-03 10:32:00+00	3.160000	3.260000	900.0000	long	11.940000	0.000000	78.75	2.7727	Round trip: 4 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:49:02.417021+00	2025-09-03 18:49:58.246787+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 18, "analysisTimestamp": "2025-09-03T18:49:02.097Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:02.416+00	5	completed	2025-09-03 18:49:58.246787+00
a7cacfe2-3999-46f9-951e-e43df5950647	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 18:34:00+00	2025-03-24 18:34:00+00	3.770000	3.660000	300.0000	short	3.990000	0.000000	29.31	2.5915	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:06.75203+00	2025-09-03 18:47:06.753795+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:06.747Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:06.751+00	5	completed	2025-09-03 18:47:06.753795+00
2d6d7520-b1c9-45e4-9bf5-c4634cf70586	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 18:39:00+00	2025-03-24 18:39:00+00	4.040000	4.070000	600.0000	long	7.980000	0.000000	7.77	0.3202	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:07.080321+00	2025-09-03 18:47:07.08167+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:07.076Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:07.079+00	5	completed	2025-09-03 18:47:07.08167+00
3797bb8f-a239-4e4b-bac7-1930e54220ae	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 20:27:00+00	2025-03-24 20:30:00+00	2.850000	2.900000	600.0000	long	5.650000	0.000000	23.36	1.3653	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:07.746082+00	2025-09-03 18:47:07.748307+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:47:07.741Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:07.745+00	5	completed	2025-09-03 18:47:07.748307+00
b722780f-e60f-4c30-a1e8-596bdb0ed80c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 13:39:00+00	2025-03-26 13:40:00+00	3.990000	4.070000	300.0000	long	3.990000	0.000000	20.52	1.7160	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:09.547092+00	2025-09-03 18:47:09.549769+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:09.541Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:09.546+00	5	completed	2025-09-03 18:47:09.549769+00
5bce72af-0be3-44da-a29e-3d169ba27466	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLRX	2025-02-03	2025-02-03 12:01:00+00	2025-02-03 12:01:00+00	2.510000	2.750000	200.0000	long	2.350000	0.000000	46.15	9.2024	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.606221+00	2025-09-03 18:47:11.609024+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:11.600Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a5e75afa0bafe0dc41dd6d57322488fa6ed89477b58a6c3e16c5df248309012d", "source": "Yahoo", "summary": "HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT047349", "datetime": "2025-02-03T13:00:00.000Z", "headline": "Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:11.606+00	5	completed	2025-09-03 18:47:11.609024+00
b2d4f5d0-b77b-4316-bf34-f5ca6e657bc8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLRX	2025-02-03	2025-02-03 12:01:00+00	2025-02-03 12:02:00+00	2.590000	2.650000	200.0000	long	2.350000	0.000000	9.65	1.8629	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.615624+00	2025-09-03 18:47:11.618161+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:11.611Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a5e75afa0bafe0dc41dd6d57322488fa6ed89477b58a6c3e16c5df248309012d", "source": "Yahoo", "summary": "HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT047349", "datetime": "2025-02-03T13:00:00.000Z", "headline": "Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:11.615+00	5	completed	2025-09-03 18:47:11.618161+00
ac4e0559-820b-4349-bc31-8b95ad804393	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AIFF	2025-01-14	2025-01-14 11:46:00+00	2025-01-14 11:46:00+00	3.060000	3.000000	200.0000	short	4.260000	0.000000	7.74	1.2647	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:12.603548+00	2025-09-03 18:47:12.604762+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:12.598Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72af5da11b7dc93c2be2dcf5d4f59b0a2cf2bfaf455517c3126893447ed1ff50", "source": "Yahoo", "summary": "Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patientsKENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research to assess a patient’s brain age - an estimat", "datetime": "2025-01-14T12:45:00.000Z", "headline": "Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:12.603+00	5	completed	2025-09-03 18:47:12.604762+00
c8da70f1-c6fa-41da-b8fe-01b664805c96	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-24	2025-03-24 21:02:00+00	2025-03-24 21:07:00+00	3.370000	3.400000	1600.0000	long	13.880000	0.000000	35.52	0.6589	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:08.020779+00	2025-09-03 18:47:08.022163+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:08.017Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f39c1c2eefc9c940bd1af41b6beeec70e4eca7b60d5aa52ff2f383be61a597c5", "source": "Yahoo", "summary": "Unsolicited takeover proposal is not hostile and from an Emirates headquartered energy solutions group Proposal encompasses the buyout of all non-affiliated free float shares and the privatization of VivoPower LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") confirmed today that it has received an unsolicited non-binding takeover proposal from Energi Holdings Limited (“Energi”), an Abu Dhabi headquartered energy solutions compan", "datetime": "2025-03-24T17:45:00.000Z", "headline": "VivoPower Receives Non-Binding All Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:08.02+00	5	completed	2025-09-03 18:47:08.022163+00
daa0851c-6944-4444-8ea4-b5592641a76e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 12:28:00+00	2025-03-18 12:55:00+00	3.040000	3.140000	3000.0000	long	28.210000	0.000000	286.79	3.1498	Round trip: 8 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:02.021665+00	2025-09-03 18:48:02.023505+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 27, "analysisTimestamp": "2025-09-03T18:48:02.017Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:02.021+00	5	completed	2025-09-03 18:48:02.023505+00
a2f73356-ba8b-48c6-a9dc-f04644e5c101	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 13:44:00+00	2025-03-26 13:45:00+00	4.300000	4.360000	300.0000	long	3.990000	0.000000	15.72	1.2199	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:09.845482+00	2025-09-03 18:47:09.847285+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:09.840Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:09.845+00	5	completed	2025-09-03 18:47:09.847285+00
a8061495-601e-446e-896d-87d8d6f8f384	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 14:10:00+00	2025-03-26 14:10:00+00	4.930000	4.800000	300.0000	short	4.000000	0.000000	35.60	2.4065	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:10.101321+00	2025-09-03 18:47:10.103244+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:10.096Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:10.1+00	5	completed	2025-09-03 18:47:10.103244+00
4705d87c-65cb-4a76-92e5-a0d4cff9da04	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-26	2025-03-26 14:43:00+00	2025-03-26 14:45:00+00	4.730000	4.460000	600.0000	long	6.630000	0.000000	-171.06	-6.0214	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:10.388858+00	2025-09-03 18:47:10.390479+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:10.381Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=4c0610cfb44e19bbcaebaaca6d6031e5c0a2707f376291b9f9bff3dff62ef7f6", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where VivoPower International PLC (NASDAQ:VVPR) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]", "datetime": "2025-03-25T12:47:37.000Z", "headline": "Why VivoPower International (VVPR) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:10.388+00	5	completed	2025-09-03 18:47:10.390479+00
18e2b356-2ef2-4f93-8eb6-c034b68446df	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-27	2025-03-27 11:20:00+00	2025-03-27 11:26:00+00	4.680000	4.740000	600.0000	long	7.980000	0.000000	30.18	1.0756	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:10.656792+00	2025-09-03 18:47:10.657967+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:47:10.653Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d8f694dc53e9725168ec0e14e4dd2975df464bbde6c0da80e80a96cdd27bc14e", "source": "Yahoo", "summary": "LONDON, March 27, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") has agreed to grant Energi Holdings Limited (“Energi”) an exclusivity period of 8 weeks to conduct due diligence subject to Energi increasing its non-binding all-cash takeover proposal to acquire the non-affiliated shareholders of VivoPower at an enterprise valuation of US$180 million. This represents an increase from US$120 million. Energi is an Abu Dhabi-headquartered energy sol", "datetime": "2025-03-27T17:15:00.000Z", "headline": "VivoPower Agrees to Grant Exclusivity to Energi Subject to Increase in Non-Binding All-Cash Takeover Offer to Enterprise Value of US$180 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:10.656+00	5	completed	2025-09-03 18:47:10.657967+00
46604636-a78b-4bda-8880-2871ba64bfff	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BIAF	2025-01-13	2025-01-13 12:03:00+00	2025-01-13 12:03:00+00	1.350000	1.180000	200.0000	short	3.240000	0.000000	30.76	11.3926	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.588245+00	2025-09-03 18:47:11.589834+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:11.581Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dfc549f4bcd89b7ec044be3cbfca25332e4b151dc56705cd1666e4b52fe17a15", "source": "Yahoo", "summary": "SAN ANTONIO, January 13, 2025--bioAffinity Technologies reports positive results of the 2024 beta test market launch of CyPath Lung in Texas.", "datetime": "2025-01-13T13:00:00.000Z", "headline": "bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:11.588+00	5	completed	2025-09-03 18:47:11.589834+00
45fd6339-4acb-4717-8ec2-9208726517bc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SCNX	2025-03-18	2025-03-18 13:31:00+00	2025-03-18 13:32:00+00	2.940000	2.990000	600.0000	long	7.950000	0.000000	25.14	1.4272	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:02.327837+00	2025-09-03 18:48:02.32927+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:02.324Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3e5c07a6558cc43d7f91edde5dbd2cfe6292bc8ab882a105162ad1901717b9d2", "source": "Yahoo", "summary": "TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a", "datetime": "2025-03-18T12:05:00.000Z", "headline": "SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:02.327+00	5	completed	2025-09-03 18:48:02.32927+00
eb3a56e1-d691-47a8-bd70-8d6534dad66c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VVPR	2025-03-27	2025-03-27 12:51:00+00	2025-03-27 12:51:00+00	4.590000	4.620000	300.0000	long	3.990000	0.000000	5.01	0.3638	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:10.882247+00	2025-09-03 18:47:10.883457+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:10.879Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d8f694dc53e9725168ec0e14e4dd2975df464bbde6c0da80e80a96cdd27bc14e", "source": "Yahoo", "summary": "LONDON, March 27, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") has agreed to grant Energi Holdings Limited (“Energi”) an exclusivity period of 8 weeks to conduct due diligence subject to Energi increasing its non-binding all-cash takeover proposal to acquire the non-affiliated shareholders of VivoPower at an enterprise valuation of US$180 million. This represents an increase from US$120 million. Energi is an Abu Dhabi-headquartered energy sol", "datetime": "2025-03-27T17:15:00.000Z", "headline": "VivoPower Agrees to Grant Exclusivity to Energi Subject to Increase in Non-Binding All-Cash Takeover Offer to Enterprise Value of US$180 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=2be7cd71e9bf53836774a33500d1aa4b7be19f4925af26b8b82ef40d9def2e91", "source": "Yahoo", "summary": "OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesda", "datetime": "2025-03-26T17:59:35.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=59d04e1ebdab8e3d6b0a1790b65625b4856452322a88ac313ff5329601bc6819", "source": "Yahoo", "summary": "LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) (\\"VivoPower\\" or the \\"Company\\") is pleased to update that it is in advanced bilateral negotiations with Energi Holdings Limited (“Energi”) in relation to its unsolicited non-binding takeover proposal. Energi is an Abu Dhabi-headquartered energy solutions company established in 2014 with US$1 billion of revenues and offices in the Middle East, Africa, South Asia, Europe, and Southeast Asia (www.energi.ae). The un", "datetime": "2025-03-26T13:25:00.000Z", "headline": "VivoPower in Advanced Bilateral Negotiations on All-Cash Takeover Offer at Enterprise Value of US$120 Million", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:10.882+00	5	completed	2025-09-03 18:47:10.883457+00
8bd0e5e6-71f1-4259-b86c-3d9106d90228	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AIFF	2025-01-14	2025-01-14 11:45:00+00	2025-01-14 11:45:00+00	2.600000	2.730000	200.0000	long	4.260000	0.000000	20.74	3.9885	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:12.595401+00	2025-09-03 18:47:12.597048+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:12.590Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72af5da11b7dc93c2be2dcf5d4f59b0a2cf2bfaf455517c3126893447ed1ff50", "source": "Yahoo", "summary": "Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patientsKENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research to assess a patient’s brain age - an estimat", "datetime": "2025-01-14T12:45:00.000Z", "headline": "Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:12.595+00	5	completed	2025-09-03 18:47:12.597048+00
10686b19-3eb2-4961-a1fd-8c10253ee8e3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BLNE	2025-03-26	2025-03-26 10:50:00+00	2025-03-26 10:50:00+00	3.050000	3.120000	300.0000	long	3.990000	0.000000	17.01	1.8590	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:03.360397+00	2025-09-03 18:48:03.362111+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:02.649Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d3155706ee7117688f1940006c5ebf8f2e1ee00a753a3c11d9b035e0942acfb8", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 26, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-26T16:42:00.000Z", "headline": "Beeline CEO Invests Another $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c9c2575420a71e98eb3b106ce9f32f0317fc850400bf857287013e9e3f58df84", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 25, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-25T12:30:00.000Z", "headline": "Beeline CEO Invests an Additional $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:03.36+00	5	completed	2025-09-03 18:48:03.362111+00
16ffb4e2-03be-4ba1-9f8f-7cfc0b69e8ca	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-24	2025-03-24 20:08:00+00	2025-03-24 20:10:00+00	1.460000	1.530000	600.0000	long	7.930000	0.000000	34.07	3.8893	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:20.654685+00	2025-09-03 18:48:20.655869+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:20.128Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:20.654+00	5	completed	2025-09-03 18:48:20.655869+00
fd2f2f59-6cce-4d88-a1c8-35a580f20a9b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-04-03	2025-04-03 11:35:00+00	2025-04-03 11:35:00+00	1.940000	2.120000	600.0000	long	7.940000	0.000000	99.37	8.5491	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:32.211343+00	2025-09-03 18:48:32.212251+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:31.680Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:32.211+00	5	completed	2025-09-03 18:48:32.212251+00
20e2c5ac-a1c2-4b9c-bc33-0267b52bb8e6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLRX	2025-01-13	2025-01-13 12:33:00+00	2025-01-13 12:34:00+00	3.100000	3.130000	100.0000	long	2.630000	0.000000	0.37	0.1194	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.59571+00	2025-09-03 18:47:11.59879+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:11.590Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b81de13f6931e293d1f02c58cb9618c5ab6282b60931e3b8a9c10d148b09a89a", "source": "Yahoo", "summary": "Health care stocks advanced late Monday afternoon, with the NYSE Health Care Index up 0.9% and the H", "datetime": "2025-01-13T21:08:28.000Z", "headline": "Sector Update: Health Care Stocks Rise Late Afternoon", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=f1f302e488d86e5703bee7a68f61eb68931e421cff7260de4f9d6af6a1bacde5", "source": "Yahoo", "summary": "Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer HOUSTON and CAMBRIDGE", "datetime": "2025-01-13T13:00:00.000Z", "headline": "Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:11.595+00	5	completed	2025-09-03 18:47:11.59879+00
6bcf93a6-bda1-405f-9938-8148c0357d9c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BLNE	2025-03-18	2025-03-18 12:33:00+00	2025-03-18 12:33:00+00	3.250000	3.280000	300.0000	short	3.080000	0.000000	-12.62	-1.2944	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:02.646668+00	2025-09-03 18:48:02.648392+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:02.330Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d67550b3d4b9eb51ac6e554349b7e54a23aa125bc8825062dee22486407d1987", "source": "Yahoo", "summary": "Any Insiders Who Purchase Stock Must Hold For at Least 6 Months Providence, Rhode Island--(Newsfile Corp. - March 18, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE) today announced that its Board of Directors has approved a limited waiver of the company's insider trading policy, permitting board members and officers to purchase company stock. This decision comes in response to requests from at least two directors who believe the stock is currently undervalued.Under the terms of ...", "datetime": "2025-03-18T21:50:00.000Z", "headline": "Beeline Board of Directors Approves Waiver of Insider Trading Policy", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=aeb79658fac56532257a4d2c908905428b6bc585d62559e85a7637c2262c88b8", "source": "Yahoo", "summary": "Bob 2.0: The Next Evolution in AI-Powered Mortgage Sales Providence, Rhode Island--(Newsfile Corp. - March 18, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), a leader in AI-driven mortgage technology, has launched Bob 2.0, the next evolution of its AI-powered sales agent, driving a 6X increase in qualified leads over human agents while running 24/7 at minimal cost.\\"Bob changes the game for scaling front-end mortgage operations,\\" said Nick Liuzza, CEO of Beeline. \\"With Bob we're able ...", "datetime": "2025-03-18T13:00:00.000Z", "headline": "Beeline's AI Sales Agent 'Bob 2.0' Delivers 6X More Leads than Human Chat - Revolutionizing Mortgage Sales at Near Zero Cost", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:02.646+00	5	completed	2025-09-03 18:48:02.648392+00
5532b1b7-4c5b-4db5-9fac-e0059310fabb	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLRX	2025-03-26	2025-03-26 12:02:00+00	\N	14.240000	\N	667.0000	long	62.590000	0.000000	0.00	0.0000	Open position: 12 executions	f	lightspeed	position	\N	{}	2025-09-03 18:47:11.629306+00	2025-09-03 18:58:00.008845+00	[]	\N	\N	t	10000.0000	0.9500	\N	80.00	basic_time_based	{"signals": [], "holdTimeMinutes": 232245, "analysisTimestamp": "2025-09-03T18:47:11.628Z"}	f	\N	[]	f	\N	\N	5	completed	2025-09-03 18:47:11.630734+00
514fae0b-1f20-4a09-9425-64a2e02cbc4d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ADD	2025-01-14	2025-01-14 11:04:00+00	2025-01-14 11:09:00+00	2.490000	2.390000	600.0000	long	8.860000	0.000000	-64.34	-4.3123	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.907854+00	2025-09-03 18:47:11.908961+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:11.904Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:11.907+00	5	completed	2025-09-03 18:47:11.908961+00
418044f8-928f-4004-acb0-3230da5a3b84	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PALI	2025-01-16	2025-01-16 12:21:00+00	2025-01-16 12:26:00+00	1.870000	1.910000	200.0000	long	3.250000	0.000000	4.75	1.2701	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.979422+00	2025-09-03 18:47:14.982581+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:14.976Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1c1235d6788561ba9753ed16ce6b40fccede5d217c4f678cc46e8516d470caf2", "source": "Yahoo", "summary": "Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeut", "datetime": "2025-01-16T13:00:00.000Z", "headline": "Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:14.979+00	5	completed	2025-09-03 18:47:14.982581+00
d112b324-2481-4089-a815-27716c2f7b67	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-24	2025-03-24 20:12:00+00	2025-03-24 20:17:00+00	1.630000	1.590000	800.0000	long	11.870000	0.000000	-46.83	-3.5858	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:21.304325+00	2025-09-03 18:48:21.306061+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:48:21.300Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:21.304+00	5	completed	2025-09-03 18:48:21.306061+00
34b10885-9bc3-41cd-9fb2-066d0ce26bf1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLRX	2025-02-03	2025-02-03 12:03:00+00	2025-02-03 12:03:00+00	2.460000	2.430000	200.0000	short	2.350000	0.000000	3.65	0.7419	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.625778+00	2025-09-03 18:47:11.627541+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:11.622Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a5e75afa0bafe0dc41dd6d57322488fa6ed89477b58a6c3e16c5df248309012d", "source": "Yahoo", "summary": "HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT047349", "datetime": "2025-02-03T13:00:00.000Z", "headline": "Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:11.625+00	5	completed	2025-09-03 18:47:11.627541+00
f8d6d5ee-83db-4785-88b7-80083ed1b269	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SNGX	2025-01-14	2025-01-14 11:31:00+00	2025-01-14 11:31:00+00	4.120000	4.120000	200.0000	long	2.350000	0.000000	-2.35	-0.2852	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:12.578626+00	2025-09-03 18:47:12.580696+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:12.574Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=c1e8119804cc3d57b0db8ee20d5ec5c44ba86183027d85afece11a26128f030b", "source": "Yahoo", "summary": "Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneou", "datetime": "2025-01-14T12:30:00.000Z", "headline": "HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8dfc7063a6832057868b867b5684107fd39a0866aa2551d8783d686d25dea37d", "source": "Yahoo", "summary": "On Tuesday, Soligenix Inc. (NASDAQ:SNGX) announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL), a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection. Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with H", "datetime": "2025-01-14T12:15:17.000Z", "headline": "EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=56933bfa73b28ef1846fdfdb4da8cad6d78654a23675087a954f90e36f12b0e6", "source": "Yahoo", "summary": "By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Additional Positive Data for IIS of HyBryte in CTCL On January 14, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced additional positive data from the open-label, investigator-initiated study (IIS) of HyBryte (synthetic hypericin) for patients with cutaneous T cell lymphoma (CTCL) for up to 12 months. During the study", "datetime": "2025-01-14T10:09:00.000Z", "headline": "SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:12.578+00	5	completed	2025-09-03 18:47:12.580696+00
72194188-48e1-4e87-a8d7-e792c6dad79d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	34546R100	2025-01-27	2025-01-27 11:46:00+00	2025-01-27 11:54:00+00	2.460000	2.090000	600.0000	long	8.840000	0.000000	-231.84	-15.7286	Round trip: 4 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:16.868668+00	2025-09-03 18:50:14.316604+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 8, "analysisTimestamp": "2025-09-03T18:47:16.863Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:16.868+00	5	completed	2025-09-03 18:50:14.316604+00
fb78ffa1-367c-467d-a940-37e8d4cdd01c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMBO	2025-01-16	2025-01-16 11:50:00+00	2025-01-16 11:51:00+00	2.920000	2.970000	200.0000	long	3.250000	0.000000	6.75	1.1558	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.961729+00	2025-09-03 18:47:14.963835+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:14.958Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e3c609add8f8f87503af823dcee9cdea8ee3c39249f061ca88fd3904e4dd55b6", "source": "Yahoo", "summary": "Argus Research, an independent investment research firm, has launched Equity Report coverage on Ambow Education Holding Ltd. (NYSEAM:AMBO).", "datetime": "2025-01-16T12:45:00.000Z", "headline": "Argus Research Initiates Equity Report Coverage on Ambow Education Holding Ltd. (NYSEAM: AMBO)", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:14.961+00	5	completed	2025-09-03 18:47:14.963835+00
1d8c203d-cefc-4472-beef-d1b0efdc3af3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMIX	2025-01-17	2025-01-17 12:01:00+00	2025-01-17 12:02:00+00	3.760000	3.940000	200.0000	long	3.260000	0.000000	32.74	4.3537	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.018487+00	2025-09-03 18:47:15.02352+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:15.015Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=16c1296f0b6b2c17d21343402aeb7a19bb150c0174686961ab41b1626a70a1f7", "source": "Yahoo", "summary": "Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a", "datetime": "2025-01-17T13:00:00.000Z", "headline": "Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:15.018+00	5	completed	2025-09-03 18:47:15.02352+00
7ce0f34c-dfe2-44b6-910c-f3454fbf8a75	2d96cef2-7502-44ff-a7a9-17713d4a7a42	INM	2025-01-21	2025-01-21 11:43:00+00	2025-01-21 11:47:00+00	8.720000	8.280000	50.0000	long	2.080000	0.000000	-24.08	-5.5229	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.456925+00	2025-09-03 18:47:15.45961+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:47:15.453Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2d06fbf6b200a5e1d16d9195267041a570cb6b2f411cb1e8b0371e8940c00cdb", "source": "Yahoo", "summary": "INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile showed a reduction of several key neuroinflammatory genes in the brainVancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\\"InMed\\" or the \\"Company\\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candid", "datetime": "2025-01-21T12:30:00.000Z", "headline": "InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:15.456+00	5	completed	2025-09-03 18:47:15.45961+00
11b6beb7-94d6-443a-9e51-d83ed57a0a49	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NVNI	2025-01-29	2025-01-29 13:19:00+00	2025-01-29 13:20:00+00	6.200000	6.240000	100.0000	short	3.410000	0.000000	-7.85	-1.2670	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.048373+00	2025-09-03 18:47:18.050142+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.044Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:18.048+00	5	completed	2025-09-03 18:47:18.050142+00
b81daf3d-6a4e-4907-8adb-770680affe76	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BLNE	2025-03-26	2025-03-26 10:54:00+00	2025-03-26 10:54:00+00	3.710000	3.590000	300.0000	short	3.990000	0.000000	32.01	2.8760	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:03.619458+00	2025-09-03 18:48:03.620697+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:03.615Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d3155706ee7117688f1940006c5ebf8f2e1ee00a753a3c11d9b035e0942acfb8", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 26, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-26T16:42:00.000Z", "headline": "Beeline CEO Invests Another $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c9c2575420a71e98eb3b106ce9f32f0317fc850400bf857287013e9e3f58df84", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 25, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-25T12:30:00.000Z", "headline": "Beeline CEO Invests an Additional $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:03.619+00	5	completed	2025-09-03 18:48:03.620697+00
5d1df466-58eb-4c7e-b0c4-0d1ccbef0b87	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NMHI	2025-01-14	2025-01-14 11:11:00+00	2025-01-14 11:12:00+00	3.220000	3.120000	200.0000	long	3.250000	0.000000	-23.25	-3.6102	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:11.912066+00	2025-09-03 18:47:11.913271+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:11.909Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b32df0ae814aec7bcdae1af1b68bcce66f66f6bc98383585d40fc66495ab7d69", "source": "Yahoo", "summary": "Nature's Miracle Holding Inc. (NASDAQ: NMHI) (\\"Nature's Miracle\\" or the \\"Company\\"), a leader in vertical farming technology and infrastructure, today announced that on January 13, 2025, the Company received written notice (the \\"Notice\\") from The Nasdaq Stock Market LLC (\\"Nasdaq\\") indicating that the Nasdaq Hearings Panel has determined to delist the Company's common stock and warrants from Nasdaq due to the Company's failure to comply with minimum shareholder's equity requirement under Nasdaq Li", "datetime": "2025-01-14T22:50:00.000Z", "headline": "Nature's Miracle Holding Inc. Announces Receipt of Delisting Notification from Nasdaq", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d674c7ec68ef60ae21fd56de4160369a13812c9c07f0b9750436bb6df2be8cea", "source": "Yahoo", "summary": "ONTARIO, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nature's Miracle Holding, Inc. (Nasdaq: NMHI) (\\"Nature's Miracle\\"), a growing agriculture technology company providing equipment and services to growers, announced that it entered into a Securities Purchase Agreement (\\"SPA\\") with a single institutional investor (\\"Investor\\") on January 10, 2025. The SPA allows Nature's Miracle, subject to customary conditions, to sell up to $29.7 million in the aggregate of a newly-designated class of convertible", "datetime": "2025-01-14T13:00:00.000Z", "headline": "D. Boral Capital Served as Placement Agent to Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a660732b97cfc421c096058a8b59ea83bfb7da6ef695391141754c616ab939ca", "source": "Yahoo", "summary": "Nature's Miracle Holding, Inc. (Nasdaq: NMHI) (\\"Nature's Miracle\\"), a growing agriculture technology company providing equipment and services to growers, announced that it entered into a Securities Purchase Agreement (\\"SPA\\") with a single institutional investor (\\"Investor\\") on January 10, 2025. The SPA allows Nature's Miracle, subject to customary conditions, to sell up to $29.7 million in the aggregate of a newly-designated class of convertible preferred stock to the Investor.", "datetime": "2025-01-13T13:30:00.000Z", "headline": "Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:11.911+00	5	completed	2025-09-03 18:47:11.913271+00
893477c4-e598-41d8-99bf-bb5eabd07f98	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-02	2025-04-02 20:51:00+00	2025-04-02 20:52:00+00	54.910000	55.040000	100.0000	long	2.780000	0.000000	10.22	0.1861	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:03.748003+00	2025-09-03 18:49:03.749394+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:03.480Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:49:03.747+00	5	completed	2025-09-03 18:49:03.749394+00
974d7d4d-f474-4033-b5a1-b4d1373e646e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SNGX	2025-01-14	2025-01-14 11:31:00+00	2025-01-14 11:31:00+00	3.680000	4.140000	200.0000	long	3.260000	0.000000	88.74	12.0571	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:12.571387+00	2025-09-03 18:47:12.573459+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:12.566Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=c1e8119804cc3d57b0db8ee20d5ec5c44ba86183027d85afece11a26128f030b", "source": "Yahoo", "summary": "Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneou", "datetime": "2025-01-14T12:30:00.000Z", "headline": "HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8dfc7063a6832057868b867b5684107fd39a0866aa2551d8783d686d25dea37d", "source": "Yahoo", "summary": "On Tuesday, Soligenix Inc. (NASDAQ:SNGX) announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL), a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection. Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with H", "datetime": "2025-01-14T12:15:17.000Z", "headline": "EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=56933bfa73b28ef1846fdfdb4da8cad6d78654a23675087a954f90e36f12b0e6", "source": "Yahoo", "summary": "By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Additional Positive Data for IIS of HyBryte in CTCL On January 14, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced additional positive data from the open-label, investigator-initiated study (IIS) of HyBryte (synthetic hypericin) for patients with cutaneous T cell lymphoma (CTCL) for up to 12 months. During the study", "datetime": "2025-01-14T10:09:00.000Z", "headline": "SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:12.57+00	5	completed	2025-09-03 18:47:12.573459+00
9dd7b3d9-306b-444f-b015-a1fb35b425d3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BLNE	2025-03-26	2025-03-26 11:00:00+00	2025-03-26 11:00:00+00	4.160000	4.180000	300.0000	long	3.990000	0.000000	2.01	0.1611	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:04.279671+00	2025-09-03 18:48:04.282202+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:04.274Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d3155706ee7117688f1940006c5ebf8f2e1ee00a753a3c11d9b035e0942acfb8", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 26, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-26T16:42:00.000Z", "headline": "Beeline CEO Invests Another $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c9c2575420a71e98eb3b106ce9f32f0317fc850400bf857287013e9e3f58df84", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 25, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-25T12:30:00.000Z", "headline": "Beeline CEO Invests an Additional $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:04.279+00	5	completed	2025-09-03 18:48:04.282202+00
fedda064-e9a8-4c19-89c3-a6e08d4ca1fe	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BLNE	2025-03-26	2025-03-26 11:12:00+00	2025-03-26 11:15:00+00	3.930000	4.110000	500.0000	long	7.940000	0.000000	81.06	4.1231	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:04.57728+00	2025-09-03 18:48:04.578895+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:04.573Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d3155706ee7117688f1940006c5ebf8f2e1ee00a753a3c11d9b035e0942acfb8", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 26, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-26T16:42:00.000Z", "headline": "Beeline CEO Invests Another $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c9c2575420a71e98eb3b106ce9f32f0317fc850400bf857287013e9e3f58df84", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 25, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-25T12:30:00.000Z", "headline": "Beeline CEO Invests an Additional $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:04.576+00	5	completed	2025-09-03 18:48:04.578895+00
72e613a2-674a-4961-a327-11f8fad348b2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SNGX	2025-01-14	2025-01-14 11:33:00+00	2025-01-14 11:34:00+00	4.380000	4.620000	200.0000	long	4.280000	0.000000	42.72	4.8767	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:12.586876+00	2025-09-03 18:47:12.589017+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:12.582Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=c1e8119804cc3d57b0db8ee20d5ec5c44ba86183027d85afece11a26128f030b", "source": "Yahoo", "summary": "Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneou", "datetime": "2025-01-14T12:30:00.000Z", "headline": "HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8dfc7063a6832057868b867b5684107fd39a0866aa2551d8783d686d25dea37d", "source": "Yahoo", "summary": "On Tuesday, Soligenix Inc. (NASDAQ:SNGX) announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL), a type of cancer that starts in the T-lymphocytes, a type of white blood cell that fights infection. Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with H", "datetime": "2025-01-14T12:15:17.000Z", "headline": "EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=56933bfa73b28ef1846fdfdb4da8cad6d78654a23675087a954f90e36f12b0e6", "source": "Yahoo", "summary": "By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Additional Positive Data for IIS of HyBryte in CTCL On January 14, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced additional positive data from the open-label, investigator-initiated study (IIS) of HyBryte (synthetic hypericin) for patients with cutaneous T cell lymphoma (CTCL) for up to 12 months. During the study", "datetime": "2025-01-14T10:09:00.000Z", "headline": "SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:12.586+00	5	completed	2025-09-03 18:47:12.589017+00
82bc8ec8-77fe-4e01-b27d-6f22b007c87e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	EVAX	2025-01-15	2025-01-15 12:03:00+00	2025-01-24 12:06:00+00	4.200000	8.360000	800.0000	long	11.920000	0.000000	3316.12	98.6060	Round trip: 5 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:14.948624+00	2025-09-03 18:47:14.950685+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 12963, "analysisTimestamp": "2025-09-03T18:47:14.937Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ca5e503ec80efc095a01914cc1f27ebebab4d509dc088d8841f3fe3632bfcbd0", "source": "Yahoo", "summary": "Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company’s lead asset EVX-01. Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advance", "datetime": "2025-01-15T13:00:00.000Z", "headline": "Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=594dea30c64b0f28efca79b189fe800ed67d96d32658ae4265dd5cf720e5bc12", "source": "Yahoo", "summary": "By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it", "datetime": "2025-01-15T10:13:00.000Z", "headline": "EVAX Adjusts Share Ratio", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c57419828a2689de2ea134e6e3b0cdc5e86c756ecdad54dfea49c7eb8f7ca07f", "source": "Yahoo", "summary": "COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing ten (10) ordinary shares to a new ADS ratio of one", "datetime": "2025-01-14T21:05:00.000Z", "headline": "Evaxion announces completion of ADS ratio change", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:14.948+00	5	completed	2025-09-03 18:47:14.950685+00
dcf92b7e-ac88-4266-a916-f8cbeef9b543	2d96cef2-7502-44ff-a7a9-17713d4a7a42	INDP	2025-03-18	2025-03-18 13:42:00+00	2025-03-18 13:44:00+00	1.380000	1.420000	1200.0000	long	15.850000	0.000000	39.35	2.3848	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:06.09589+00	2025-09-03 18:48:06.097133+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:05.790Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=eba570c8fc2da7c9c824c9259684691ecb6548995401b2872eacfa4d5349c491", "source": "Yahoo", "summary": "New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumorsNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhib", "datetime": "2025-03-18T12:00:00.000Z", "headline": "Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:06.095+00	5	completed	2025-09-03 18:48:06.097133+00
b3b213af-9f93-48a2-8f0e-fe2379854377	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRZO	2025-01-17	2025-01-17 12:20:00+00	2025-01-17 12:22:00+00	2.390000	2.410000	200.0000	long	3.250000	0.000000	0.75	0.1569	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.009461+00	2025-09-03 18:47:15.013712+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:15.004Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:15.009+00	5	completed	2025-09-03 18:47:15.013712+00
196e98e2-c078-493c-bb3f-d8503abbe88d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-21	2025-03-21 15:37:00+00	2025-03-21 15:38:00+00	6.720000	6.580000	1000.0000	short	11.870000	0.000000	130.23	1.9373	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:09.127171+00	2025-09-03 18:48:09.128145+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:09.124Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:09.127+00	5	completed	2025-09-03 18:48:09.128145+00
fb53f90a-d57d-4940-abb1-dedf3febb132	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-21	2025-03-21 15:52:00+00	2025-03-21 16:02:00+00	6.730000	6.460000	1300.0000	short	13.470000	0.000000	331.53	3.7919	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:09.414305+00	2025-09-03 18:48:09.416273+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:48:09.409Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:09.413+00	5	completed	2025-09-03 18:48:09.416273+00
fbc2549c-ce4a-42ed-83de-844593b578dd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AIFF	2025-02-11	2025-02-11 11:45:00+00	2025-02-11 11:47:00+00	4.190000	4.450000	800.0000	long	9.410000	0.000000	197.49	5.8898	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:12.849144+00	2025-09-03 18:47:12.850329+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:12.845Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=81a18e819c550c5882e75dd4666fc209656b6d8c8dc7892c8190a6782590a88e", "source": "Yahoo", "summary": "Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For the first time, Firefly also unveils a new strategic initiative to build the world’s first foundation model of the human brain using its BNA™ technology KENMORE, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain", "datetime": "2025-02-11T12:45:00.000Z", "headline": "Firefly Neuroscience Accepted into NVIDIA Connect Program", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:12.848+00	5	completed	2025-09-03 18:47:12.850329+00
e8d85b3c-2bf8-482e-8123-bc8af46a8778	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AIFF	2025-02-13	2025-02-13 11:22:00+00	2025-02-13 11:24:00+00	14.460000	14.660000	200.0000	long	3.100000	0.000000	36.57	1.2644	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:13.154988+00	2025-09-03 18:47:13.156943+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:13.149Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:13.154+00	5	completed	2025-09-03 18:47:13.156943+00
a89a7148-ccba-4dce-a29c-8a351d95c3fd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BLNE	2025-03-26	2025-03-26 11:17:00+00	2025-03-26 11:18:00+00	4.140000	4.020000	300.0000	long	3.990000	0.000000	-39.99	-3.2198	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:05.23065+00	2025-09-03 18:48:05.233292+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:05.223Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d3155706ee7117688f1940006c5ebf8f2e1ee00a753a3c11d9b035e0942acfb8", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 26, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-26T16:42:00.000Z", "headline": "Beeline CEO Invests Another $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c9c2575420a71e98eb3b106ce9f32f0317fc850400bf857287013e9e3f58df84", "source": "Yahoo", "summary": "Since December 2024 Beeline CEO has invested $4,045,802 in Beeline demonstrating confidence in its business Providence, Rhode Island--(Newsfile Corp. - March 25, 2025) - Beeline Holdings, Inc. (NASDAQ: BLNE), an emerging FinTech mortgage lender, today announced that Chief Executive Officer and Co-Founder, Nick Liuzza, has invested an additional $900,000 into the company's ongoing Series G convertible equity offering. The investment was made at $5.10 per share on an as-converted basis (not includ", "datetime": "2025-03-25T12:30:00.000Z", "headline": "Beeline CEO Invests an Additional $900,000 in Series G Offering Priced at a 205% Premium to Market Price and Donates Warrants to St. Jude Children's Research Hospital", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:05.23+00	5	completed	2025-09-03 18:48:05.233292+00
72be4dd1-3816-4dee-90cb-670106260c4a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	EVAX	2025-02-04	2025-02-04 10:57:00+00	2025-02-04 10:58:00+00	4.530000	4.580000	200.0000	long	4.280000	0.000000	5.72	0.6313	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.955055+00	2025-09-03 18:47:14.957078+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:14.951Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:14.954+00	5	completed	2025-09-03 18:47:14.957078+00
0507fa14-61b5-4840-86f8-cd3f9b78e4e0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRZO	2025-01-17	2025-01-17 12:14:00+00	2025-01-17 12:14:00+00	2.310000	2.350000	200.0000	short	3.250000	0.000000	-11.25	-2.4351	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.001817+00	2025-09-03 18:47:15.003582+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:14.999Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:15.001+00	5	completed	2025-09-03 18:47:15.003582+00
f8ace3aa-7e2e-4d3b-9a1f-c68c73ffb23c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LAES	2025-03-18	2025-03-18 14:02:00+00	2025-03-18 14:13:00+00	3.460000	3.490000	1000.0000	long	13.920000	0.000000	16.83	0.4864	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:06.680341+00	2025-09-03 18:48:06.682118+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 11, "analysisTimestamp": "2025-09-03T18:48:06.373Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=47e1694a65b7fdc24016645f6e6a8774ae6b3ce2dc36db916b8ca2579774e3c8", "source": "Yahoo", "summary": "SEALSQ (NasdaqCM:LAES) experienced a 45% price surge last week, a period marked by significant corporate developments. The launch of a $20 million SEALQUANTUM.com investment underscores the company's commitment to advancing quantum computing and AI. Additionally, the establishment of SEALSQ Singapore Ltd aims to bolster its semiconductor capabilities in Asia. These moves align with broader trends in technological advancement, drawing investor interest despite overall market declines. While...", "datetime": "2025-03-18T18:14:38.000Z", "headline": "SEALSQ (NasdaqCM:LAES) Surges 45% With Launch Of US$20 Million SEALQUANTUM.com Investment", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=39725fa94d0a1005035cb75e913f48e650114c631d56a70513696fac8f8d69f4", "source": "Yahoo", "summary": "Geneva, Switzerland, March 18, 2025 (GLOBE NEWSWIRE) -- Technology Powered by WISeKey Root of Trust Installed in Over 6 Billion Devices SEALSQ NASDAQ QUANTUM DAYhttps://youtu.be/V1mikulV3LA?si=gOMpL4TKr4VTS3TR SEALSQ Corp (NASDAQ: LAES) (\\"SEALSQ\\" or \\"Company\\"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that 1.75 billion devices worldwide have been secured by its microprocessors since the Compa", "datetime": "2025-03-18T14:00:00.000Z", "headline": "SEALSQ Achieves a New Milestone: Secures 1.75 Billion Devices Worldwide with Hybrid Cryptographic Model, as Demand for Post-Quantum Chips Accelerates", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:06.679+00	5	completed	2025-09-03 18:48:06.682118+00
904d448f-c904-466d-adb7-d7e950a66ff7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-29	2025-01-29 13:47:00+00	2025-01-29 13:47:00+00	5.170000	5.270000	100.0000	long	2.340000	0.000000	7.66	1.4816	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.056253+00	2025-09-03 18:47:18.058245+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:18.051Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=4f93c92814bcf8644a2801d8b8d10d4f343f99422496ff790e3e82bd7aa07412", "source": "Yahoo", "summary": "Expected acquisition of Swifty Global would contribute strong historical financials and significant growth potentialSCOTTSDALE, Arizona, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a Stock Purchase Agreement (SPA) to acquire 99.13% of the issued and outstanding capital stock of", "datetime": "2025-01-29T14:00:00.000Z", "headline": "Signing Day Sports Executes Stock Purchase Agreement to Acquire Majority of Capital Stock of Dear Cashmere Group Holding Company d/b/a Swifty Global", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:18.055+00	5	completed	2025-09-03 18:47:18.058245+00
0fefbdd2-46e5-4bea-9d91-e928b6a6d095	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SKBL	2025-01-30	2025-01-30 11:21:00+00	2025-01-30 11:23:00+00	5.980000	5.460000	100.0000	long	2.190000	0.000000	-54.19	-9.0619	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:19.563606+00	2025-09-03 18:47:19.565743+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:19.557Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:19.563+00	5	completed	2025-09-03 18:47:19.565743+00
f2bb1b0a-8319-421f-82f9-47549b502a34	2d96cef2-7502-44ff-a7a9-17713d4a7a42	89357L402	2025-03-21	2025-03-21 11:09:00+00	2025-03-21 11:35:00+00	0.960000	0.980000	1000.0000	long	13.690000	0.000000	10.15	1.0572	Round trip: 5 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:07.006705+00	2025-09-03 18:50:02.269682+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 26, "analysisTimestamp": "2025-09-03T18:48:06.683Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:07.006+00	5	completed	2025-09-03 18:50:02.269682+00
930b3522-3e92-4fa7-84a4-444ba83d0890	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G2161Y125	2025-01-30	2025-01-30 11:15:00+00	2025-01-30 11:18:00+00	1.400000	1.410000	200.0000	long	3.240000	0.000000	-1.24	-0.4429	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.333026+00	2025-09-03 18:50:13.312641+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:47:18.329Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:18.332+00	5	completed	2025-09-03 18:50:13.312641+00
caede5e8-1ac2-44f2-97ce-e278a62a49fd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ELAB	2025-03-21	2025-03-21 12:05:00+00	2025-03-21 12:05:00+00	9.120000	8.960000	300.0000	short	4.020000	0.000000	42.93	1.5691	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:07.49009+00	2025-09-03 18:48:07.491446+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:07.287Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3aef48fa16edc60c5a2e3c64d9749026d538d026a64067ed4eed21b4f55fefb6", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company’s common stock, par value $0.0001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market und", "datetime": "2025-03-21T18:41:00.000Z", "headline": "PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=7b013e1a4688d9084c056076b9e18efdaa7c21274318bf685ee9c256c6bdc9e9", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. Details of these transactions are available in the Company’s Form 8-K filings on www.sec.gov. The Company will consider repurchasing additional shares from other investors who wish to sell, subject to market conditions and other considerations. Share", "datetime": "2025-03-21T12:00:00.000Z", "headline": "PMGC Holdings Announces Share Repurchases from Existing Shareholders", "sentiment": "neutral"}]	t	negative	2025-09-03 18:48:07.489+00	5	completed	2025-09-03 18:48:07.491446+00
5209998d-fb00-4f44-9fed-0ac459c2489c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSTX	2025-01-15	2025-01-15 11:42:00+00	2025-01-15 11:42:00+00	7.200000	7.090000	200.0000	short	3.690000	0.000000	17.45	1.2126	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:13.836485+00	2025-09-03 18:47:13.838864+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:13.831Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9da81f6a78a9ae540903179a9d0212b90b4213190dbcdc03af5e7cf572438be4", "source": "Yahoo", "summary": "NEW YORK, January 15, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res", "datetime": "2025-01-15T14:17:00.000Z", "headline": "OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:13.836+00	5	completed	2025-09-03 18:47:13.838864+00
a7f14c00-ccce-4831-9e32-7ee463c9b3f5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSTX	2025-01-15	2025-01-15 11:43:00+00	2025-01-15 11:43:00+00	8.070000	7.740000	200.0000	short	2.820000	0.000000	63.18	3.9145	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.402213+00	2025-09-03 18:47:14.404274+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:14.396Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9da81f6a78a9ae540903179a9d0212b90b4213190dbcdc03af5e7cf572438be4", "source": "Yahoo", "summary": "NEW YORK, January 15, 2025--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res", "datetime": "2025-01-15T14:17:00.000Z", "headline": "OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:14.401+00	5	completed	2025-09-03 18:47:14.404274+00
111077b9-37e7-4228-9f23-e979dec90afc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-21	2025-03-21 15:30:00+00	2025-03-21 15:31:00+00	6.800000	6.870000	600.0000	long	8.030000	0.000000	31.57	0.7733	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:08.880282+00	2025-09-03 18:48:08.882079+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:08.208Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:08.879+00	5	completed	2025-09-03 18:48:08.882079+00
52b342d9-fa2d-4b4d-8626-ecf6ece1b8c5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRZO	2025-01-17	2025-01-17 11:57:00+00	2025-01-17 11:57:00+00	2.220000	2.180000	400.0000	short	5.900000	0.000000	10.10	1.1374	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.995884+00	2025-09-03 18:47:14.997984+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:14.991Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:14.995+00	5	completed	2025-09-03 18:47:14.997984+00
5a23f663-9627-4d03-8366-6a9e6b6a1a7e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G0447T100	2025-03-27	2025-03-27 20:02:00+00	2025-03-27 20:02:00+00	0.920000	0.940000	300.0000	long	3.840000	0.000000	3.18	1.1522	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:36.380586+00	2025-09-03 18:50:01.75196+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:36.064Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:36.38+00	5	completed	2025-09-03 18:50:01.75196+00
954da3e6-e3a4-4e77-9adf-291ddf0cec62	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-24	2025-03-24 11:55:00+00	2025-03-24 14:48:00+00	6.900000	6.270000	1869.0000	short	28.000000	0.000000	1149.98	8.9219	Round trip: 11 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:11.196328+00	2025-09-03 18:48:11.198632+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 173, "analysisTimestamp": "2025-09-03T18:48:10.914Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:11.195+00	5	completed	2025-09-03 18:48:11.198632+00
d76d6510-e403-4968-9629-a22390fa7973	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-24	2025-03-24 15:05:00+00	2025-03-24 20:46:00+00	6.740000	6.640000	2300.0000	short	40.430000	0.000000	185.22	1.1948	Round trip: 18 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:11.413301+00	2025-09-03 18:48:11.414405+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 341, "analysisTimestamp": "2025-09-03T18:48:11.410Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:11.413+00	5	completed	2025-09-03 18:48:11.414405+00
ec5d9fc4-bbf3-4b1b-b518-50c3df98785a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DRMA	2025-03-27	2025-03-27 12:38:00+00	2025-03-27 12:38:00+00	1.910000	1.830000	300.0000	short	3.970000	0.000000	20.03	3.4956	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:36.016215+00	2025-09-03 18:48:36.019783+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:36.010Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc12715f203cb808edbfb01a7515a88d4a93255326160a73a983fe696729ca80", "source": "Yahoo", "summary": "Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) (\\"Dermata\\" or the \\"Company\\"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events", "datetime": "2025-03-27T12:00:00.000Z", "headline": "BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:36.015+00	5	completed	2025-09-03 18:48:36.019783+00
9966d738-cac2-4d67-a6f6-8773cb7ed773	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PALI	2025-01-16	2025-01-16 12:01:00+00	2025-01-16 12:03:00+00	2.670000	2.480000	200.0000	long	3.250000	0.000000	-42.15	-7.8800	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:14.970292+00	2025-09-03 18:47:14.97302+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:14.965Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1c1235d6788561ba9753ed16ce6b40fccede5d217c4f678cc46e8516d470caf2", "source": "Yahoo", "summary": "Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the treatment of UC Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeut", "datetime": "2025-01-16T13:00:00.000Z", "headline": "Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:14.97+00	5	completed	2025-09-03 18:47:14.97302+00
6038f779-28f7-40d7-ac65-a4d7c1e56b78	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BTCT	2025-01-17	2025-01-17 12:25:00+00	2025-01-17 12:25:00+00	7.110000	7.230000	50.0000	long	2.080000	0.000000	3.92	1.1027	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.034322+00	2025-09-03 18:47:15.035951+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:15.030Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:15.034+00	5	completed	2025-09-03 18:47:15.035951+00
44964d1e-77de-4a87-bb80-ff2bf02553ac	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NIXX	2025-01-21	2025-01-21 11:31:00+00	2025-01-21 15:49:00+00	5.100000	4.730000	400.0000	long	5.880000	0.000000	-153.54	-7.5246	Round trip: 2 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:15.446912+00	2025-09-03 18:47:15.448151+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 258, "analysisTimestamp": "2025-09-03T18:47:15.442Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=affb77fe8b7000dd33fe67fbd4b71882de85f9e2092ed6f30d5b09a43854a687", "source": "Yahoo", "summary": "Nixxy, Inc, (NASDAQ:NIXX), or \\"Nixxy\\" or the \\"Company,\\" today announced it has commenced a private offering (the \\"Offering\\"), subject to market and other conditions, of up to $50 million aggregate principal amount of its zero-coupon convertible notes ...", "datetime": "2025-01-21T13:07:00.000Z", "headline": "Nixxy Commences Private Offering of up to $50 million of Bitcoin Secured Convertible Notes", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:15.446+00	5	completed	2025-09-03 18:47:15.448151+00
b6aa655a-09fc-4fa0-add4-dd4b35c1643c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BACK	2025-01-28	2025-01-28 11:07:00+00	2025-01-28 11:07:00+00	1.770000	1.740000	200.0000	short	4.260000	0.000000	1.74	0.4915	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:16.873481+00	2025-09-03 18:47:16.875865+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:16.870Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=44252f2ef5006128c4baa2163b6ad3317e26b1d9471faa3dc9d79adef7a3fc13", "source": "Yahoo", "summary": "Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond. Why Proteins Matter – Beyond Genomics Although genomics (gene-based) testing has become common, pa", "datetime": "2025-01-27T21:10:00.000Z", "headline": "IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:16.873+00	5	completed	2025-09-03 18:47:16.875865+00
d455e82b-7d92-4715-9d22-57a7adddccb6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	YIBO	2025-01-28	2025-01-28 11:14:00+00	2025-01-28 11:19:00+00	5.980000	5.740000	400.0000	long	5.940000	0.000000	-99.94	-4.1816	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.135832+00	2025-09-03 18:47:17.137386+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:17.132Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:17.135+00	5	completed	2025-09-03 18:47:17.137386+00
1aa7e837-f1cb-4682-9bc0-0d70b3b7dbd1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLXN	2025-03-17	2025-03-17 12:18:00+00	2025-03-17 12:18:00+00	1.570000	1.630000	300.0000	long	3.970000	0.000000	13.46	2.8543	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.424837+00	2025-09-03 18:47:17.426592+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:17.419Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b5fbf77b14685bae1e7e69bed5384ec5f1979c6aa58a3004a3ae6a19d018049c", "source": "Yahoo", "summary": "NEW YORK, March 17, 2025--PESG Research releases a report covering Silexion Therapeutics’ (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.", "datetime": "2025-03-17T12:15:00.000Z", "headline": "PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.424+00	5	completed	2025-09-03 18:47:17.426592+00
68cd30f4-fd97-4a9e-ac1a-3191460787ae	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-04-03	2025-04-03 11:39:00+00	2025-04-03 11:39:00+00	2.540000	2.670000	900.0000	long	11.930000	0.000000	102.07	4.4592	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:32.453516+00	2025-09-03 18:48:32.454957+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:32.451Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:32.453+00	5	completed	2025-09-03 18:48:32.454957+00
edbcb884-0764-476c-8ee1-d9743564f99a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AMIX	2025-01-17	2025-01-17 12:09:00+00	2025-01-17 12:12:00+00	3.210000	3.250000	200.0000	long	3.250000	0.000000	4.75	0.7399	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.028124+00	2025-09-03 18:47:15.029562+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:47:15.025Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=16c1296f0b6b2c17d21343402aeb7a19bb150c0174686961ab41b1626a70a1f7", "source": "Yahoo", "summary": "Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a", "datetime": "2025-01-17T13:00:00.000Z", "headline": "Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:15.027+00	5	completed	2025-09-03 18:47:15.029562+00
8083af56-3243-41c0-99b5-c89eddc76c28	2d96cef2-7502-44ff-a7a9-17713d4a7a42	QLGN	2025-01-28	2025-01-28 12:26:00+00	2025-01-28 12:27:00+00	5.040000	5.120000	100.0000	long	2.640000	0.000000	5.86	1.1639	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.157237+00	2025-09-03 18:47:17.15857+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:17.150Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=bd07aac134ca4d0237e501d6de07f36e78b01ca46fb3cb8f41bdf97b6874f670", "source": "Yahoo", "summary": "Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)announced today they will be the first investors participating in the 2025 bridge round of funding for NanoSynex. NanoSynex will be raising up to $500,000. “We are very excited to participate and be the first investors to commit in this round of funding for NanoSynex. The technology they are developing will help the world of Antimicrobia", "datetime": "2025-01-28T13:00:00.000Z", "headline": "Qualigen to participate in next funding round for NanoSynex", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:17.157+00	5	completed	2025-09-03 18:47:17.15857+00
325d714e-4f59-4377-9dd0-fbde9cfc3d89	2d96cef2-7502-44ff-a7a9-17713d4a7a42	UCAR	2025-03-24	2025-03-24 11:20:00+00	2025-03-24 12:45:00+00	3.450000	3.020000	2200.0000	long	25.640000	0.000000	-959.43	-12.6438	Round trip: 6 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:17.399164+00	2025-09-03 18:47:17.400917+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 85, "analysisTimestamp": "2025-09-03T18:47:17.394Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e4ad0929efa9306291262043aaac7e88c94d23866c244d020fc3f69c213d8313", "source": "Yahoo", "summary": "U Power Limited (Nasdaq: UCAR), a world leader in rapid battery swapping technology for EV's, (\\"U Power\\" or the \\"Company\\") announced today that it has signed a joint venture agreement between its Thai subsidiary, U SWAP, and SUSCO Public Company Limited (BK: SUSCO), a publicly listed energy provider with a robust network of fueling stations throughout Thailand. The joint venture will deploy U Power's innovative UOTTA battery-swapping technology across SUSCO's extensive station network, significa", "datetime": "2025-03-24T11:00:00.000Z", "headline": "U Power Limited (Nasdaq: UCAR) Announces Landmark Joint Venture with SUSCO, Targeting Thailand's Multi-Billion EV Infrastructure Boom", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.398+00	5	completed	2025-09-03 18:47:17.400917+00
6392597c-d274-409a-89f1-a759ea3bb647	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OCEA	2025-01-29	2025-01-29 12:38:00+00	2025-01-29 12:38:00+00	0.630000	0.600000	200.0000	long	2.780000	0.000000	-8.36	-6.6349	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.031194+00	2025-09-03 18:47:18.032798+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:18.027Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a53e2981dd7932f87f6aa6dddf87c4bd69558dc61f10153589ea1ee224609a4a", "source": "Yahoo", "summary": "Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Health (NIH) to advance their groundbreaking malaria vaccine research. In parallel, recent U.S. Food and Drug Administration (FDA) Guidance on lipid-encapsulated vaccines may offer an expedited development pathway for their innovative approa", "datetime": "2025-01-29T13:30:00.000Z", "headline": "Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.03+00	5	completed	2025-09-03 18:47:18.032798+00
d0a16cc7-8052-4af9-90f9-fa0895269dc3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-31	2025-01-31 12:27:00+00	2025-01-31 12:28:00+00	4.300000	4.310000	200.0000	long	3.270000	0.000000	-1.27	-0.1477	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.106737+00	2025-09-03 18:47:18.107988+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.102Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.106+00	5	completed	2025-09-03 18:47:18.107988+00
a8de21e7-b693-4da8-b7dd-5d38b039ee63	2d96cef2-7502-44ff-a7a9-17713d4a7a42	JG	2025-01-27	2025-01-27 11:44:00+00	2025-01-27 11:44:00+00	18.620000	19.190000	200.0000	long	2.440000	0.000000	111.56	2.9957	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:16.098547+00	2025-09-03 18:47:16.100301+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:16.094Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3aea8f15c6be52c1b82b23dda61d9ea316691eb8f2f682eb73bcad87cbb9a057", "source": "Yahoo", "summary": "The integration expands GPTBots.ai's ecosystem.", "datetime": "2025-01-27T17:22:00.000Z", "headline": "Aurora Mobile Shares Rise 136% After Integrating DeepSeek R1 into AI Platform", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=f64d808e6aeef2818e2a04747f990d0bb556bdc10e7a0894712fa185b650dff5", "source": "Yahoo", "summary": "SHENZHEN, China, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its leading enterprise AI agent platform, GPTBots.ai, has integrated the innovative DeepSeek R1 large language model (LLM). This addition further enhances GPTBots.ai’s robust ecosystem of AI capabilities, which already includes some of the most advanced LLMs in the marke", "datetime": "2025-01-27T10:00:00.000Z", "headline": "Aurora Mobile’s GPTBots.ai Integrates DeepSeek R1 LLM", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:16.098+00	5	completed	2025-09-03 18:47:16.100301+00
be3f1c6c-44ca-451b-a82c-40d9ab595fbd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TRIB	2025-01-28	2025-01-28 11:22:00+00	2025-01-28 11:22:00+00	1.030000	1.050000	400.0000	long	5.890000	0.000000	1.91	0.4636	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.140404+00	2025-09-03 18:47:17.141934+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:17.138Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9f8be03b27134adbe9020329bf576b7196098ffb19e47ebacff3b85b24f6242d", "source": "Yahoo", "summary": "Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system.", "datetime": "2025-01-28T12:20:00.000Z", "headline": "Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.14+00	5	completed	2025-09-03 18:47:17.141934+00
fbe899b1-db53-4523-96ba-e0019ed5b9eb	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLXN	2025-03-17	2025-03-17 12:16:00+00	2025-03-17 12:16:00+00	1.340000	1.510000	300.0000	long	3.970000	0.000000	46.40	11.5242	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.416389+00	2025-09-03 18:47:17.418103+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:17.410Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b5fbf77b14685bae1e7e69bed5384ec5f1979c6aa58a3004a3ae6a19d018049c", "source": "Yahoo", "summary": "NEW YORK, March 17, 2025--PESG Research releases a report covering Silexion Therapeutics’ (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.", "datetime": "2025-03-17T12:15:00.000Z", "headline": "PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.416+00	5	completed	2025-09-03 18:47:17.418103+00
7259c54e-37d5-457a-81fd-23890fc19a73	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G2161Y125	2025-01-30	2025-01-30 12:21:00+00	2025-01-30 12:31:00+00	1.080000	0.980000	600.0000	long	8.780000	0.000000	-68.78	-10.6142	Round trip: 4 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:19.020965+00	2025-09-03 18:50:12.81767+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:47:19.011Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:19.02+00	5	completed	2025-09-03 18:50:12.81767+00
17795b19-e326-42e5-9129-796656c62427	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DJT	2025-01-29	2025-01-29 12:33:00+00	2025-01-29 12:34:00+00	33.850000	34.150000	100.0000	long	2.270000	0.000000	27.73	0.8192	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.016371+00	2025-09-03 18:47:18.019341+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.010Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=513eab4debea95b224fdc37848eaaf81b02c0d6a0e89e139fee672f569c88c8c", "source": "SeekingAlpha", "summary": "Trump Media's strategy of diversifying into multiple sectors without establishing a strong foothold in any one area is concerning and unsustainable. Learn more on DJT stock here.", "datetime": "2025-01-29T18:07:08.000Z", "headline": "Trump Media & Technology Group Stock Soars On A Nothingburger", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8811ffb68be81a7d61db1f11a8128efcfc38117e93221781cebf3bc94df8c8a6", "source": "Finnhub", "summary": "WASHINGTON — Meta has agreed to pay $25 million to settle a lawsuit filed by President Donald Trump against the company after it suspended his accounts following the Jan. 6, 2021, attack on the...", "datetime": "2025-01-29T17:57:00.000Z", "headline": "Meta agrees to pay $25 million to settle lawsuit from Trump after Jan. 6 suspension", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=adeae802aed265e7de852169300bd0fb1f8445708307e353511ca7c76a1db0a7", "source": "Yahoo", "summary": "Yahoo Finance host Josh Lipton dives into the latest Wall Street stock news on today's segment of Market Minute. Trump Media & Technology (DJT, DJTWW) stock is moving higher after it announced it will expand into the financial services market. The company has secured funding of up to $250 million, which will be custodied by Charles Schwab (SCHW). Shares of T-Mobile (TMUS) also rose after the company issued strong guidance based on its fourth quarter earnings results. The company expects to add 5.5 million to 6 million new paid subscribers in 2025. Finally, Teva Pharmaceutical (TEVA) stock is under pressure after the company issued a softer-than-expected outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Angel Smith", "datetime": "2025-01-29T17:43:34.000Z", "headline": "Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9bbfe439f83efd0539fa6a768a86a9a09c77d9b479ed78190b8f6a2fa03b3d91", "source": "Yahoo", "summary": "Trump Media & Technology Group (DJT, DJTWW) has announced plans to enter the financial services sector, unveiling a new division called Truth.Fi. The expansion will be backed by up to $250 million in funding from Charles Schwab (SCHW). The company plans to roll out various investment products and services through Truth.Fi in 2025. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith", "datetime": "2025-01-29T16:16:23.000Z", "headline": "Trump Media to enter financial sector with Truth.Fi", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=9178864a59d4ce41cd417a2dcaf31eeac62f0c70453868d25b08308bcc5ac45c", "source": "Yahoo", "summary": "Carson Block, founder and chief investment officer of Muddy Waters Capital, said he \\"wouldn't touch\\" meme coins.", "datetime": "2025-01-29T15:27:41.000Z", "headline": "Meme coins a sign of 'speculative frenzy' in markets, famed short seller says", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8f684c24f5641f57385e9baad049235ad02dafdf6e8fc5737a51a5698f10a961", "source": "SeekingAlpha", "summary": "Trump's focus on meme coins like TRUMP and MELANIA has affected the growth of Truth Social. The stock has had irrational values, but at some point it will trade based on fundamentals.", "datetime": "2025-01-29T15:03:17.000Z", "headline": "Trump Media: Mostly Ignored By The President", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=0e023576d688971eebf77719a91a920e71c5e838539b92429487f6ee2a235c46", "source": "Yahoo", "summary": "Trump Media & Technology Group will expand into financial services.", "datetime": "2025-01-29T14:59:00.000Z", "headline": "DJT stock pops after Trump Media announces expansion into financial services", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=196c2e8fcf587cdb6676409c26b20186e95306f77339de2154bdee1472de3777", "source": "Yahoo", "summary": "Trump Media jumped early Wednesday after it announced it is wading into the financial services world.", "datetime": "2025-01-29T14:53:25.000Z", "headline": "Why Donald Trump Stock Is Surging After A 12% Decline This Month", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bdf3851577de61d3a2aac9281167f4a5f2c32638fc6251f38e787722465d326d", "source": "Finnhub", "summary": "TMTG Launches Truth.Fi Brand, Plans to Build Investment Vehicles Based on America-First Principles SARASOTA, Fla., Jan. 29, 2025 -- Trump Media and Technology Group Corp. , operator of the...", "datetime": "2025-01-29T08:32:03.000Z", "headline": "Trump Media Announces Expansion into Financial Services", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:18.015+00	5	completed	2025-09-03 18:47:18.019341+00
53c2ed15-e333-40bc-8fba-f83547ead9c2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G2161Y125	2025-01-30	2025-01-30 11:07:00+00	2025-01-30 11:10:00+00	1.160000	1.230000	200.0000	long	3.240000	0.000000	10.76	4.6379	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.327051+00	2025-09-03 18:50:13.820437+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:47:18.323Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:18.326+00	5	completed	2025-09-03 18:50:13.820437+00
b8e8fc3f-bab3-4b0f-b41e-44c8fabea1f8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-31	2025-01-31 11:12:00+00	2025-01-31 11:12:00+00	3.640000	3.610000	200.0000	short	3.260000	0.000000	2.74	0.3764	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.078426+00	2025-09-03 18:47:18.080852+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:18.073Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.077+00	5	completed	2025-09-03 18:47:18.080852+00
500a3a77-7286-484f-afe8-42e6a582a3a2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	UCAR	2025-01-29	2025-01-29 11:06:00+00	2025-01-29 11:08:00+00	5.440000	5.050000	100.0000	long	2.640000	0.000000	-41.80	-7.6816	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.163375+00	2025-09-03 18:47:17.165447+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:17.159Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a9002575e3ae6d79af3cd2138fde768f7d1b48fd1a5c6316c32ce7a393351080", "source": "Yahoo", "summary": "U Power Limited (Nasdaq: UCAR) (the \\"Company\\" or \\"U Power\\"), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced that it has signed a cooperation agreement with Ezzy Transporter (Thailand) Company Limited (\\"Ezzy Transporter\\") to establish Greendrive Tech Co. Ltd., (\\"Greendrive\\" or the \\"Joint Venture\\"), a joint venture company dedicated to the market expansion and sale of electric vehicles in Thailand. Per the", "datetime": "2025-01-29T12:00:00.000Z", "headline": "U Power and Ezzy Transporter Establish Joint Venture to Bring UOTTA Battery-Swapping Solutions to Thailand", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.163+00	5	completed	2025-09-03 18:47:17.165447+00
0b461763-0a36-4b57-a649-1763e4e516d4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ELAB	2025-03-21	2025-03-21 12:07:00+00	2025-03-21 12:07:00+00	8.260000	8.370000	300.0000	long	3.120000	0.000000	29.88	1.2058	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:07.797432+00	2025-09-03 18:48:07.799351+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:07.792Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3aef48fa16edc60c5a2e3c64d9749026d538d026a64067ed4eed21b4f55fefb6", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company’s common stock, par value $0.0001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market und", "datetime": "2025-03-21T18:41:00.000Z", "headline": "PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=7b013e1a4688d9084c056076b9e18efdaa7c21274318bf685ee9c256c6bdc9e9", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. Details of these transactions are available in the Company’s Form 8-K filings on www.sec.gov. The Company will consider repurchasing additional shares from other investors who wish to sell, subject to market conditions and other considerations. Share", "datetime": "2025-03-21T12:00:00.000Z", "headline": "PMGC Holdings Announces Share Repurchases from Existing Shareholders", "sentiment": "neutral"}]	t	negative	2025-09-03 18:48:07.797+00	5	completed	2025-09-03 18:48:07.799351+00
a9643134-38a3-43d6-863f-b5f70f300c96	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNFA	2025-01-29	2025-01-29 13:16:00+00	2025-01-29 13:17:00+00	1.250000	1.250000	200.0000	long	3.240000	0.000000	-1.76	-0.7060	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.040914+00	2025-09-03 18:47:18.042972+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.035Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=57291b5032cab20681f134339b548806b1722b69eb4b4ea08babeb4711d322ad", "source": "Yahoo", "summary": "BALTIMORE, January 29, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (\\"TNF\\" or the \\"Company\\"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management.", "datetime": "2025-01-29T14:15:00.000Z", "headline": "TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.04+00	5	completed	2025-09-03 18:47:18.042972+00
d076869e-2043-41eb-b04d-c27e2d677f80	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ELAB	2025-03-21	2025-03-21 12:08:00+00	2025-03-21 12:12:00+00	8.170000	8.190000	600.0000	long	6.700000	0.000000	4.16	0.0848	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:08.006464+00	2025-09-03 18:48:08.007746+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:08.003Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=3aef48fa16edc60c5a2e3c64d9749026d538d026a64067ed4eed21b4f55fefb6", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company’s common stock, par value $0.0001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market und", "datetime": "2025-03-21T18:41:00.000Z", "headline": "PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=7b013e1a4688d9084c056076b9e18efdaa7c21274318bf685ee9c256c6bdc9e9", "source": "Yahoo", "summary": "NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. Details of these transactions are available in the Company’s Form 8-K filings on www.sec.gov. The Company will consider repurchasing additional shares from other investors who wish to sell, subject to market conditions and other considerations. Share", "datetime": "2025-03-21T12:00:00.000Z", "headline": "PMGC Holdings Announces Share Repurchases from Existing Shareholders", "sentiment": "neutral"}]	t	negative	2025-09-03 18:48:08.006+00	5	completed	2025-09-03 18:48:08.007746+00
950451ac-b358-4b1b-b151-ace6611a7530	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-21	2025-03-21 16:09:00+00	2025-03-21 16:11:00+00	6.250000	6.000000	1000.0000	short	10.360000	0.000000	239.64	3.8342	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:09.703595+00	2025-09-03 18:48:09.70503+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:09.699Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:09.703+00	5	completed	2025-09-03 18:48:09.70503+00
4af8f79a-e803-401e-998f-6a7c76fa5b9d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-21	2025-03-21 16:39:00+00	2025-03-21 16:45:00+00	5.900000	5.550000	500.0000	short	5.170000	0.000000	169.83	5.7569	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:09.976102+00	2025-09-03 18:48:09.977381+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:48:09.972Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:09.975+00	5	completed	2025-09-03 18:48:09.977381+00
12571436-4f11-4390-89a5-df99ee53f826	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GLTO	2025-03-21	2025-03-21 17:13:00+00	2025-03-21 23:50:00+00	5.820000	5.980000	1600.0000	short	19.870000	0.000000	-287.51	-3.0899	Round trip: 5 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:10.629203+00	2025-09-03 18:48:10.631158+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 397, "analysisTimestamp": "2025-09-03T18:48:10.624Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:10.629+00	5	completed	2025-09-03 18:48:10.631158+00
9d03db8e-f1df-4cdc-bad0-1078ed53ba98	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-02	2025-04-02 20:57:00+00	2025-04-02 21:07:00+00	54.990000	54.760000	150.0000	long	4.150000	0.000000	-38.32	-0.4646	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:03.994852+00	2025-09-03 18:49:03.995827+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:49:03.992Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:49:03.994+00	5	completed	2025-09-03 18:49:03.995827+00
d0c629e8-5435-4ddc-8097-666c9d97e827	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SLXN	2025-03-17	2025-03-17 12:19:00+00	2025-03-17 12:24:00+00	1.540000	1.570000	1200.0000	long	15.860000	0.000000	26.14	1.4191	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.72575+00	2025-09-03 18:47:17.727876+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:17.720Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b5fbf77b14685bae1e7e69bed5384ec5f1979c6aa58a3004a3ae6a19d018049c", "source": "Yahoo", "summary": "NEW YORK, March 17, 2025--PESG Research releases a report covering Silexion Therapeutics’ (NASDAQ: SLXN)* latest developments: Silexion, a clinical-stage biotechnology company recently delivered potentially transformative preclinical data for its SIL204 therapeutic candidate. The latest findings represents a critical milestone in the fight against KRAS-driven cancers, particularly pancreatic cancer, showcasing significant potential in addressing one of oncology's most challenging targets.", "datetime": "2025-03-17T12:15:00.000Z", "headline": "PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.725+00	5	completed	2025-09-03 18:47:17.727876+00
6fb7ebf1-b92b-4cd3-af53-b5d3872ff846	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OCEA	2025-01-29	2025-01-29 12:34:00+00	2025-01-29 12:35:00+00	0.630000	0.650000	200.0000	long	2.800000	0.000000	0.94	0.7460	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.023653+00	2025-09-03 18:47:18.025218+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.020Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a53e2981dd7932f87f6aa6dddf87c4bd69558dc61f10153589ea1ee224609a4a", "source": "Yahoo", "summary": "Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Health (NIH) to advance their groundbreaking malaria vaccine research. In parallel, recent U.S. Food and Drug Administration (FDA) Guidance on lipid-encapsulated vaccines may offer an expedited development pathway for their innovative approa", "datetime": "2025-01-29T13:30:00.000Z", "headline": "Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.023+00	5	completed	2025-09-03 18:47:18.025218+00
605aaa3e-9ae5-4ad6-b6b3-454116864081	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-31	2025-01-31 11:19:00+00	2025-01-31 11:19:00+00	3.950000	3.950000	200.0000	long	2.980000	0.000000	-3.98	-0.5038	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.08952+00	2025-09-03 18:47:18.091504+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:18.082Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.089+00	5	completed	2025-09-03 18:47:18.091504+00
576a8ac6-d85a-45fd-9b35-a1f88b0a0706	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BNZI	2025-01-30	2025-01-30 11:01:00+00	2025-01-30 11:02:00+00	2.640000	2.650000	200.0000	long	3.250000	0.000000	-1.25	-0.2367	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.32029+00	2025-09-03 18:47:18.321542+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.315Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:18.32+00	5	completed	2025-09-03 18:47:18.321542+00
0b67d34c-58b5-4d54-935a-128536c6c5ae	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CYCN	2025-02-03	2025-02-03 12:24:00+00	2025-02-03 12:25:00+00	4.650000	4.730000	200.0000	long	3.260000	0.000000	12.74	1.3699	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:21.021313+00	2025-09-03 18:47:21.023666+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:21.009Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:21.018+00	5	completed	2025-09-03 18:47:21.023666+00
b2adbbd5-03d7-45f4-9bb9-7dfbbf54bb83	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CYCN	2025-02-03	2025-02-03 13:40:00+00	2025-02-03 13:41:00+00	4.410000	4.300000	400.0000	long	5.920000	0.000000	-49.46	-2.8046	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:21.289164+00	2025-09-03 18:47:21.291564+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:21.282Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:21.288+00	5	completed	2025-09-03 18:47:21.291564+00
d0e2a1c4-3c27-48b7-8bb7-e044501668b7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	IVVD	2025-02-03	2025-02-03 11:06:00+00	2025-02-03 11:57:00+00	0.420000	0.440000	2000.0000	long	21.310000	0.000000	1.57	0.1848	Round trip: 6 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:21.619611+00	2025-09-03 18:47:21.621952+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 51, "analysisTimestamp": "2025-09-03T18:47:21.292Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=59000260091f558fe26ca5ae28df9f3b14438aa08075c584f20fd49621209a48", "source": "Yahoo", "summary": "Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administrationPhase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are supported by antiviral activity data from Invivyd's standard virologic assessments Pooled, blinded adverse events (AEs) to date are mild or moderate and thus far deemed unrelated to study drug or largely related to injection site reaction or infusion r", "datetime": "2025-02-03T12:00:00.000Z", "headline": "Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ee90f6bf4e3470efe035346c7054811d20aaa7e2e9ce77fbde0050fe7832f7b4", "source": "Yahoo", "summary": "Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 millionPreliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction compared to Q3 2024 operating costs and expenses of $71.6 millionPreliminary ending 2024 cash and cash equivalents of $69.3 million and $10.9 million of accounts receivableContinues to target near-term (by end of 1H 2025) profitability with existing cash and ca", "datetime": "2025-02-03T11:55:00.000Z", "headline": "Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:21.619+00	5	completed	2025-09-03 18:47:21.621952+00
b77f707e-e944-448e-b73f-218c3f5bab3d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	IBO	2025-03-21	2025-03-21 23:22:00+00	2025-03-21 23:22:00+00	4.080000	4.500000	300.0000	short	2.190000	0.000000	-128.19	-10.4730	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:12.340158+00	2025-09-03 18:48:12.342386+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:11.697Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=0902a7f5bb78284122f61fd30561a0eba5779ff83029c4ab1b17857244a9e4d0", "source": "Yahoo", "summary": "HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO)", "datetime": "2025-03-21T18:38:00.000Z", "headline": "Impact Biomedical Inc. Announcement Stock Activity/Pricing", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=39f8399fcef159c9ae4b619c65d83ffeba22571e7fd939769a532ae875bce39a", "source": "Yahoo", "summary": "We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Impact Biomedical Inc. (NYSEAMERICAN:IBO) stands against other micro-, small-cap firms that dominate Thursday’s gains. The stock market edged lower on Thursday, erasing gains from the previous trading day that was […]", "datetime": "2025-03-21T10:34:43.000Z", "headline": "Why Impact Biomedical Inc. (IBO) Surged On Thursday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:12.339+00	5	completed	2025-09-03 18:48:12.342386+00
39eb8837-d36d-4591-ace8-3bc3fccd02e5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VINC	2025-01-29	2025-01-29 12:01:00+00	2025-01-29 12:02:00+00	2.360000	2.390000	200.0000	long	4.260000	0.000000	1.74	0.3686	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:17.733396+00	2025-09-03 18:47:17.735645+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:17.729Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f615be7f0767739e2f8c6b7da6e7aee4bdafa9f3ded66fcc1395cbdd4c0e9e67", "source": "Yahoo", "summary": "Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory’s anti-TROP2", "datetime": "2025-01-29T13:00:00.000Z", "headline": "Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:17.733+00	5	completed	2025-09-03 18:47:17.735645+00
8236e8c4-a2a6-48e8-947d-c2efc7c53a4e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-31	2025-01-31 10:59:00+00	2025-01-31 11:00:00+00	3.490000	3.560000	200.0000	long	3.260000	0.000000	10.74	1.5387	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.067443+00	2025-09-03 18:47:18.070417+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.060Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.067+00	5	completed	2025-09-03 18:47:18.070417+00
f9748321-fb32-40a9-ac51-a53a6cb1d0f0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SPAI	2025-01-30	2025-01-30 12:08:00+00	2025-01-30 12:08:00+00	3.450000	3.590000	100.0000	long	2.630000	0.000000	11.77	3.4116	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:19.600517+00	2025-09-03 18:47:19.60198+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:19.596Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=c8eb256aab1f4c166f03e1b4328c903a8412e4a540c0a5a9f76e80fb8864a8f6", "source": "Yahoo", "summary": "AVENTURA, Fla., January 30, 2025--Safe Pro Group Inc. (Nasdaq: SPAI) (\\"Safe Pro\\" or the \\"Company\\"), a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, today announced that it has entered into a multi-year Memorandum of Understanding (MOU) with NIBULON Ltd. (NIBULON) to cooperate on addressing Ukraine’s agriculture crisis which has sustained billions in damages and losses due to the ongoing war.", "datetime": "2025-01-30T13:02:00.000Z", "headline": "Safe Pro Enters Multi-Year Agreement for its Patented Drone AI Demining Platform with Ukraine’s Leading Grain Export and Agricultural Organization NIBULON Ltd.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:19.6+00	5	completed	2025-09-03 18:47:19.60198+00
9f329ed3-68ec-4a30-a7c7-c21b3e4c86ea	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AISP	2025-01-31	2025-01-31 12:32:00+00	2025-01-31 12:38:00+00	4.760000	4.800000	600.0000	long	8.900000	0.000000	17.28	0.6051	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:20.99176+00	2025-09-03 18:47:20.992876+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:47:20.163Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=88940fdfb7bce0df112bde4b9d53d4325d92d49d3b615b79a5c298029c0fe80e", "source": "Yahoo", "summary": "Acropolis Enterprise Video and Data Management Platform Supports Operational and Physical Security Requirements for Global Locations REDMOND, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today announced it has been awarded an additional one (1) year system maintenance and sustainment contract for an existing Fortune 100 customer leveraging the Com", "datetime": "2025-01-31T13:31:00.000Z", "headline": "Airship AI Secures Follow-On Seven-Figure Contract Award with Fortune 100 Transportation & E-Commerce Company", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:20.991+00	5	completed	2025-09-03 18:47:20.992876+00
7bf11f1c-6711-4db4-940c-84e059226599	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-31	2025-01-31 11:24:00+00	2025-01-31 11:25:00+00	4.230000	4.020000	200.0000	long	2.990000	0.000000	-44.99	-5.3180	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.098462+00	2025-09-03 18:47:18.100068+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:18.092Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.097+00	5	completed	2025-09-03 18:47:18.100068+00
759b2da3-fbba-49fb-9626-a7a2078b903b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SGN	2025-01-31	2025-01-31 13:30:00+00	2025-01-31 13:30:00+00	4.870000	4.920000	400.0000	long	6.980000	0.000000	12.22	0.6274	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:18.312884+00	2025-09-03 18:47:18.314522+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:18.307Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=812f6898aa208e588be9c2de7328aa7129314dc4856cb3e2f52749c7058d8596", "source": "Yahoo", "summary": "Includes National and Specified Regional CombinesIncludes National and Specified Regional CombinesSCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced the signing of a new Sponsorship Agreement with the U.S. Army Bowl, extending its rights as “National Recruiting Partner”. The Sponso", "datetime": "2025-01-31T11:30:00.000Z", "headline": "Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:18.31+00	5	completed	2025-09-03 18:47:18.314522+00
c4d8ce81-3bf4-4978-be00-5bdf3509fa29	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CRGX	2025-01-30	2025-01-30 11:47:00+00	2025-01-30 17:43:00+00	3.560000	3.390000	200.0000	long	2.950000	0.000000	-37.83	-5.3066	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:19.579471+00	2025-09-03 18:47:19.582249+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 356, "analysisTimestamp": "2025-09-03T18:47:19.573Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e88438f4a26cdccc6611c64dddb60ccdf3d048357dc90eaf3053a3f50030c552", "source": "Yahoo", "summary": "Cargo Therapeutics (CRGX) shares tumbled 74% after the company said Wednesday it plans to discontinu", "datetime": "2025-01-30T18:56:33.000Z", "headline": "Top Midday Decliners", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=d3f211f12f40eef1bbbe37c2ae2c58b1fe3015f7f9a0694a422f58775b09c316", "source": "Yahoo", "summary": "Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.", "datetime": "2025-01-30T09:34:37.000Z", "headline": "Cargo to drop lead CAR-T therapy, lay off staff after study setback", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=a68d8781f4c8d59d8ede7470603cec8f9645437390f4c4e10f1f705545478c09", "source": "Yahoo", "summary": "CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a workforce reduction of approximately 50%.Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation,", "datetime": "2025-01-29T21:05:00.000Z", "headline": "CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=61d81a1f11d7b2612b6f342c43ef69f986e9ccc0b98d95b26c9cc7a6adf5e2c6", "source": "Finnhub", "summary": "The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. for violations of the securities laws.INVESTIGATION DETAILS: The investigation...", "datetime": "2025-01-29T20:21:04.000Z", "headline": "CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=25b7788a2c1a501cdbadda49ac232c54c25e02646f5fe847cf6264f02b85c438", "source": "Finnhub", "summary": "The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. for violations of the securities...", "datetime": "2025-01-29T19:46:04.000Z", "headline": "CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a423d9f752b4cb7ca990a4ef78253d3beaceda570cd341f46029cf6b1ec4af07", "source": "Finnhub", "summary": "By Connor Hart Tesla logged higher revenue in the fourth quarter. The electric-car maker's revenue increased to $25.71 billion from $25.17 billion a year earlier. The company said that automotive...", "datetime": "2025-01-29T19:16:40.000Z", "headline": "Stocks to Watch : Tesla, IBM, Microsoft, Lam Research, Cargo Therapeutics", "sentiment": "neutral"}]	t	negative	2025-09-03 18:47:19.579+00	5	completed	2025-09-03 18:47:19.582249+00
ab0f0a4e-dc3d-418a-b691-d4ea03fb26c8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CYCN	2025-01-31	2025-01-31 13:42:00+00	2025-01-31 13:43:00+00	4.090000	4.060000	200.0000	short	4.280000	0.000000	2.30	0.2811	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:21.005176+00	2025-09-03 18:47:21.007254+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:21.000Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:21.005+00	5	completed	2025-09-03 18:47:21.007254+00
2f2dc23c-0ba0-4cd9-a061-9b0db752ee79	2d96cef2-7502-44ff-a7a9-17713d4a7a42	REBN	2025-02-03	2025-02-03 13:34:00+00	2025-02-03 13:35:00+00	5.370000	5.460000	200.0000	long	4.280000	0.000000	12.87	1.1983	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:25.412892+00	2025-09-03 18:47:25.414495+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:25.137Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:25.412+00	5	completed	2025-09-03 18:47:25.414495+00
273c2288-f98d-42eb-863f-f81d6f3cea4b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	REBN	2025-02-03	2025-02-03 13:36:00+00	2025-02-03 13:36:00+00	5.850000	5.800000	200.0000	short	4.280000	0.000000	5.18	0.4430	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:25.756322+00	2025-09-03 18:47:25.758323+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:25.748Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:25.756+00	5	completed	2025-09-03 18:47:25.758323+00
f65c083f-72da-4b48-a35c-35dc29441ad2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	KTTA	2025-02-05	2025-02-05 11:00:00+00	2025-02-05 11:00:00+00	3.960000	4.120000	200.0000	long	3.260000	0.000000	28.74	3.6288	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:32.32967+00	2025-09-03 18:47:32.330849+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:32.072Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:32.329+00	5	completed	2025-09-03 18:47:32.330849+00
250b9d52-48f6-454b-b412-fdea54fbb46c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LIPO	2025-02-11	2025-02-11 10:58:00+00	2025-02-11 10:59:00+00	5.360000	5.400000	400.0000	long	5.940000	0.000000	10.70	0.4991	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:36.381871+00	2025-09-03 18:47:36.384124+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:35.713Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=964bcaab94c0c973a42fd48a8f64b2a1e04749161a512d3cbbb4fe39e3589a33", "source": "Yahoo", "summary": "Firefly Neuroscience (AIFF) shares were up more than 170% in recent trading after the company said i", "datetime": "2025-02-11T18:34:07.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=16a0a2a94181f0de31e160a0402834d4accab79ab22bbd25abffe834ac08c35e", "source": "Yahoo", "summary": "Lipella Pharmaceuticals' (LIPO) shares jumped nearly 35% in recent Tuesday trading after the company", "datetime": "2025-02-11T18:10:01.000Z", "headline": "Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=0079ff882ecc21e6393b28014d7d3eaae7f77f3d954ec1b49c9252839b2a0216", "source": "Yahoo", "summary": "On Tuesday, Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (OLP). LP-310 demonstrated a strong safety profile, with no product-related serious adverse events (SAEs) or patient dropouts. The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks 1,", "datetime": "2025-02-11T15:52:36.000Z", "headline": "Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=96678b45f5e24e63fb23f5e2f96f185a7e769e17f79e03af6e6feff5cc59dc89", "source": "Yahoo", "summary": "LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) --", "datetime": "2025-02-11T10:46:00.000Z", "headline": "Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:36.381+00	5	completed	2025-09-03 18:47:36.384124+00
68368180-d699-43ef-ba2a-e63b6b1a5ce5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LIPO	2025-02-11	2025-02-11 11:05:00+00	2025-02-11 11:34:00+00	4.810000	4.920000	1000.0000	long	14.800000	0.000000	90.33	1.8769	Round trip: 6 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:36.654649+00	2025-09-03 18:47:36.656363+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 29, "analysisTimestamp": "2025-09-03T18:47:36.649Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=964bcaab94c0c973a42fd48a8f64b2a1e04749161a512d3cbbb4fe39e3589a33", "source": "Yahoo", "summary": "Firefly Neuroscience (AIFF) shares were up more than 170% in recent trading after the company said i", "datetime": "2025-02-11T18:34:07.000Z", "headline": "Top Midday Gainers", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=16a0a2a94181f0de31e160a0402834d4accab79ab22bbd25abffe834ac08c35e", "source": "Yahoo", "summary": "Lipella Pharmaceuticals' (LIPO) shares jumped nearly 35% in recent Tuesday trading after the company", "datetime": "2025-02-11T18:10:01.000Z", "headline": "Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=0079ff882ecc21e6393b28014d7d3eaae7f77f3d954ec1b49c9252839b2a0216", "source": "Yahoo", "summary": "On Tuesday, Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (OLP). LP-310 demonstrated a strong safety profile, with no product-related serious adverse events (SAEs) or patient dropouts. The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks 1,", "datetime": "2025-02-11T15:52:36.000Z", "headline": "Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=96678b45f5e24e63fb23f5e2f96f185a7e769e17f79e03af6e6feff5cc59dc89", "source": "Yahoo", "summary": "LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) --", "datetime": "2025-02-11T10:46:00.000Z", "headline": "Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:36.654+00	5	completed	2025-09-03 18:47:36.656363+00
5e05cb12-ba30-4cf5-92db-e161b9940591	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PTNT	2025-02-06	2025-02-06 11:32:00+00	2025-02-06 11:50:00+00	0.890000	0.970000	800.0000	long	11.410000	0.000000	45.99	6.4293	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:36.924008+00	2025-09-03 18:47:36.925755+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 18, "analysisTimestamp": "2025-09-03T18:47:36.657Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:36.923+00	5	completed	2025-09-03 18:47:36.925755+00
5e614ef9-7ecc-4a50-afd3-996269c89a4a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BDRX	2025-02-12	2025-02-12 11:33:00+00	2025-02-12 11:33:00+00	6.590000	6.350000	200.0000	short	2.360000	0.000000	45.62	3.4613	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:48.593182+00	2025-09-03 18:47:48.594201+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:48.590Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cc30cd99c35e016ef7340d00fde49bbf2315ee92c5f986684133392bad4703b2", "source": "Yahoo", "summary": "Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration ...", "datetime": "2025-02-12T12:30:00.000Z", "headline": "Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:48.593+00	5	completed	2025-09-03 18:47:48.594201+00
35f41a3c-7aa9-4d9d-bd36-4f1177b7ac7d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	STAI	2025-01-30	2025-01-30 12:31:00+00	2025-01-30 12:31:00+00	1.990000	2.040000	200.0000	long	3.250000	0.000000	6.75	1.6960	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:19.899107+00	2025-09-03 18:47:19.900407+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:19.602Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=5b3ee9905d4e142c8d85f9dbfcb8a432817664926bf26ea99a81a91a88518697", "source": "Yahoo", "summary": "Buford, GA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems, Inc. (NASDAQ: STAI, ScanTech, or ScanTech AI), a security solutions provider offering one of the world’s most advanced non-intrusive “fixed-gantry” CT screening technologies, proudly announced today the successful deployment and operational launch of its cutting-edge ‘fixed-gantry’ computed tomography (CT) security scanners at multiple nuclear power facilities across Canada. Ontario Power Generation (OPG) has chosen ScanTech’s ne", "datetime": "2025-01-30T13:30:00.000Z", "headline": "ScanTech AI Systems, Inc. Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:19.898+00	5	completed	2025-09-03 18:47:19.900407+00
5a7fc032-de9f-4665-9d33-c1c1e484b839	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MYSZ	2025-03-28	2025-03-28 15:23:00+00	2025-03-28 15:26:00+00	1.630000	1.680000	600.0000	long	7.930000	0.000000	22.13	2.2582	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.538171+00	2025-09-03 18:48:40.53941+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:40.531Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cd09eca8bb5a63801e46e9020b783614a52c11d6f9496f375c8b74b129f56a6f", "source": "Yahoo", "summary": "MySize, Inc. (NASDAQ: MYSZ) (TASE: MYSZ.TA) (\\"MySize\\" or the \\"Company\\"), an omnichannel e-commerce platform and provider of AI-driven sizing solutions for the retail industry, today reported financial and operational results for the twelve months ended December 31, 2024.", "datetime": "2025-03-28T12:30:00.000Z", "headline": "MySize Reports 2024 Full-Year Financial Results: Revenue Grows 18% to $8.26 Million and Cash Reserves More Than Double", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:40.537+00	5	completed	2025-09-03 18:48:40.53941+00
b6074954-cf82-4d3a-9042-02640c302437	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CYCN	2025-01-31	2025-01-31 13:38:00+00	2025-01-31 13:38:00+00	3.760000	3.740000	200.0000	long	3.260000	0.000000	-6.30	-0.8382	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:20.996876+00	2025-09-03 18:47:20.999067+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:20.993Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:20.996+00	5	completed	2025-09-03 18:47:20.999067+00
2ff19a0b-8da6-4ba8-b276-1fd699a0bd8b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GHRS	2025-02-03	2025-02-03 11:09:00+00	2025-02-03 11:13:00+00	20.550000	20.790000	200.0000	long	2.990000	0.000000	45.75	1.1133	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:22.852169+00	2025-09-03 18:47:22.854114+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:47:22.275Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=42485621b4a2f95abc93d044f0f1dd7419e1c87a99478e33257f8025fbdf8175", "source": "Yahoo", "summary": "DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase u", "datetime": "2025-02-03T21:03:00.000Z", "headline": "GH Research Announces Proposed Public Offering", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c7f5f73d963aa5097935f4145ac1cd2855178dba60a163c4a756e360c0f1be01", "source": "Yahoo", "summary": "The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.", "datetime": "2025-02-03T12:07:00.000Z", "headline": "Shares of psychedelics biotech nearly double on depression data", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=c7da7ca8a11b41ccc48e1074e3de4e9d792f4478df535a41e84852afe1d5dd7f", "source": "Yahoo", "summary": "Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerat", "datetime": "2025-02-03T12:00:00.000Z", "headline": "GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:22.851+00	5	completed	2025-09-03 18:47:22.854114+00
12084622-cdf3-468d-9a80-41a84120f3d7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	REBN	2025-02-07	2025-02-07 12:31:00+00	2025-02-07 12:32:00+00	6.190000	6.240000	400.0000	long	5.940000	0.000000	14.06	0.5679	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:26.667571+00	2025-09-03 18:47:26.669655+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:25.991Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=65bda1312d31902fe4ed0fd6115e0506d92f324fbd9eea7d76db93cec33ab21f", "source": "Yahoo", "summary": "Financing Provides Operating Liquidity and Positions Reborn Coffee for Expansive Growth, Flagship Openings, and Industry InnovationBREA, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (Nasdaq: REBN), a leader in the specialty coffee market, today announced has entered into a securities purchase agreement and a common stock purchase agreement for up to a total of $60 million in financing commitments with Arena Investors, LP (“Arena”) and Arena Business Solutions Global SPC II, Ltd.", "datetime": "2025-02-07T13:31:00.000Z", "headline": "Reborn Coffee Announces Financing Commitments of up to $60.0 Million", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:26.667+00	5	completed	2025-09-03 18:47:26.669655+00
c762905b-72af-467b-b5e3-7320b51d592e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	QNTM	2025-02-04	2025-02-04 11:04:00+00	2025-02-04 11:04:00+00	5.300000	5.330000	200.0000	long	2.360000	0.000000	3.64	0.3434	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:27.141482+00	2025-09-03 18:47:27.143515+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:26.916Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e2613f638487e696e17ce83b65327a3520df4e3e0d1e9dad9dc1b90db2b1904f", "source": "Yahoo", "summary": "SAN JOSE, Calif., February 04, 2025--Quantum® Corporation (NASDAQ: QMCO) (\\"Quantum\\" or the \\"Company\\"), a leader in solutions for AI and unstructured data, today announced it will release financial results for its fiscal third quarter 2025 on Wednesday, February 12, 2025, after the markets close.", "datetime": "2025-02-04T13:00:00.000Z", "headline": "Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ba9dc503ad8d72f44fbe383ed26af80f4f3af9458bcfe541b9b016a868672394", "source": "Yahoo", "summary": "Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and HangoverTORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-bl", "datetime": "2025-02-04T12:03:00.000Z", "headline": "Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:27.141+00	5	completed	2025-09-03 18:47:27.143515+00
f9330748-45fa-4445-b2a0-34cedf265cbe	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BCTX	2025-02-03	2025-02-03 11:49:00+00	2025-02-03 11:55:00+00	6.160000	6.150000	400.0000	long	4.360000	0.000000	-7.86	-0.3191	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:23.966781+00	2025-09-03 18:47:23.968945+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:47:23.704Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=c0ce088af795798f9298fe3e62162dd9e87d602987171efa57090fcfd98c8e8a", "source": "Yahoo", "summary": "PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, o", "datetime": "2025-02-03T21:45:00.000Z", "headline": "BriaCell Therapeutics Announces Proposed Public Offering of Common Shares", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f30ca29e08bba61a8ba4f3a50b5158a92539169a4b6f1303ccdde456a3b9951a", "source": "Yahoo", "summary": "Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity related to the treatment; Patient remains on studyUnprecedented result in first patient dosed supports Bria-OTS™ personalized immunotherapy approachOngoing Phase 1/2a dose escalation study to evaluate Bria-OTS™, BriaCell's personalized off-the-shelf immunotherapy in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE N", "datetime": "2025-02-03T12:30:00.000Z", "headline": "BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:23.966+00	5	completed	2025-09-03 18:47:23.968945+00
739cc92c-e324-4f58-804b-6ab85bccbec6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	M97838128	2025-02-03	2025-02-03 11:59:00+00	2025-02-03 11:59:00+00	1.310000	1.290000	200.0000	short	3.240000	0.000000	0.76	0.2901	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:24.602569+00	2025-09-03 18:50:08.801453+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:23.969Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:24.602+00	5	completed	2025-09-03 18:50:08.801453+00
5d3bd893-e3a9-4d2c-a204-cad9f4546858	2d96cef2-7502-44ff-a7a9-17713d4a7a42	QNTM	2025-02-04	2025-02-04 11:07:00+00	2025-02-04 11:07:00+00	6.800000	6.700000	100.0000	short	2.640000	0.000000	7.36	1.0824	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:27.14952+00	2025-09-03 18:47:27.151845+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:27.145Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e2613f638487e696e17ce83b65327a3520df4e3e0d1e9dad9dc1b90db2b1904f", "source": "Yahoo", "summary": "SAN JOSE, Calif., February 04, 2025--Quantum® Corporation (NASDAQ: QMCO) (\\"Quantum\\" or the \\"Company\\"), a leader in solutions for AI and unstructured data, today announced it will release financial results for its fiscal third quarter 2025 on Wednesday, February 12, 2025, after the markets close.", "datetime": "2025-02-04T13:00:00.000Z", "headline": "Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ba9dc503ad8d72f44fbe383ed26af80f4f3af9458bcfe541b9b016a868672394", "source": "Yahoo", "summary": "Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and HangoverTORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-bl", "datetime": "2025-02-04T12:03:00.000Z", "headline": "Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:27.149+00	5	completed	2025-09-03 18:47:27.151845+00
682443f0-e9be-4766-beb4-e17648e03f80	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CORT	2025-03-31	2025-03-31 12:11:00+00	2025-03-31 13:32:00+00	96.070000	90.000000	300.0000	short	6.550000	0.000000	1813.46	6.2924	Round trip: 5 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:42.55577+00	2025-09-03 18:48:42.557332+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 81, "analysisTimestamp": "2025-09-03T18:48:42.224Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1de1314ae942b362cadb9a69cc55dd3edfebcdeee9bdf1ca03a85dbe0dae47a5", "source": "Yahoo", "summary": "US benchmark equity indexes are on track to close mixed on Monday, as markets get ready for more tar", "datetime": "2025-03-31T19:50:42.000Z", "headline": "Equity Markets Mixed Ahead of Tariff Announcements", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=eb0fa99f6b53f82b141706719c880d2a56cc2419566809d3c5fd7a8b5ddfafb8", "source": "Yahoo", "summary": "Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).", "datetime": "2025-03-31T18:48:45.000Z", "headline": "Why Is Corcept (CORT) Stock Soaring Today", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=06e177117db570d6d58941d7a02bbf5c45cf4da59bf7df0a1e6982c002d71606", "source": "Yahoo", "summary": "Corcept Therapeutics (NasdaqCM:CORT) recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for platinum-resistant ovarian cancer. This announcement, emphasizing a significant improvement in progression-free and overall survival, aligns with the company’s 8% share price uptick over the last quarter. Despite broader market challenges and a slide in major indices like the S&P 500 and Nasdaq, Corcept’s...", "datetime": "2025-03-31T18:39:01.000Z", "headline": "Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5a69c2ec12e45ff16f1991de6cff7fce00f0bf9c0a57f65974d650755842e607", "source": "Yahoo", "summary": "Josh Lipton takes a closer look at the top stories on Wall Street on today's Market Minute: NewsMax (NMAX) stock skyrockets after going public, Celsius Holdings (CELH) pops on a Truist analyst upgrade, and Corcept Therapeutics (CORT) climbs on positive drug trial results.Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.", "datetime": "2025-03-31T17:20:39.000Z", "headline": "NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=41e545936b2d448c6d025af9d81cb969a6e898e02379823870ae787b99832a8d", "source": "Yahoo", "summary": "Here are some stocks on the move for Monday, March 31. Yum Brands (YUM) is searching for a new CEO as current head David Gibbs plans to retire in early 2026, after 36 years with the company. Corcept Therapeutics (CORT) shares are rising after a successful trial for its ovarian cancer drug. Shares of Hut 8 (HUT) are on the move after announcing a new venture with the Trump family to launch a bitcoin mining venture. To watch more expert insights and analysis on the latest market action, check out more Wealth here.", "datetime": "2025-03-31T15:51:17.000Z", "headline": "Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21e142fb339f93299400de8d6b6c678b21870e2e58f47f25a49f02544aa2a06b", "source": "Finnhub", "summary": "Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The company's...", "datetime": "2025-03-31T13:41:03.000Z", "headline": "Corcept's ovarian cancer drug cuts disease progression in study, shares jump", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=2e2fce8effdf56bce168eedb2b9fd3039695b0948a7cf0a80f606e9bf7c2badf", "source": "Yahoo", "summary": "Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to tre", "datetime": "2025-03-31T12:38:57.000Z", "headline": "Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bd0256efb4c2d703b28306c7bc33e6e1b82bdfc7a0e22441169960d576ec4fdb", "source": "Yahoo", "summary": "REDWOOD CITY, Calif., March 31, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progressi", "datetime": "2025-03-31T12:00:00.000Z", "headline": "Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:42.555+00	5	completed	2025-09-03 18:48:42.557332+00
2bdf28d4-af23-4e13-b493-1a7a399a9d45	2d96cef2-7502-44ff-a7a9-17713d4a7a42	QNTM	2025-03-28	2025-03-28 13:17:00+00	2025-03-28 13:22:00+00	10.570000	10.380000	1500.0000	short	14.660000	0.000000	267.69	1.6882	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:28.093959+00	2025-09-03 18:47:28.095131+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:27.825Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9334826f12a2f741a3a5d0b9598484b2b75cba683f3f770c7ab401c86d4cab17", "source": "Yahoo", "summary": "Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets TORONTO, ONTARIO / ACCESS Newswire / March 28, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ...", "datetime": "2025-03-28T13:15:00.000Z", "headline": "Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=3799878c81cbac5e365e06c90113701719302605769aace442f8e48c2e588153", "source": "Yahoo", "summary": "TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company. Mr. Terry Lynch Mr. Lynch is widely known and respecte", "datetime": "2025-03-27T11:00:00.000Z", "headline": "Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:28.093+00	5	completed	2025-09-03 18:47:28.095131+00
26ac1359-5827-4b80-af7d-114a800d416e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ICCT	2025-04-03	2025-04-03 15:24:00+00	2025-04-03 15:27:00+00	5.080000	4.960000	1200.0000	long	15.980000	0.000000	-166.88	-2.7366	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:43.46833+00	2025-09-03 18:48:43.46965+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:43.212Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:43.468+00	5	completed	2025-09-03 18:48:43.46965+00
904cd33c-af0a-493f-847d-19bdcfebe5c5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	QNTM	2025-02-04	2025-02-04 11:13:00+00	2025-02-04 11:13:00+00	6.570000	6.770000	100.0000	long	3.410000	0.000000	16.09	2.4490	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:27.158208+00	2025-09-03 18:47:27.161021+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:27.153Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e2613f638487e696e17ce83b65327a3520df4e3e0d1e9dad9dc1b90db2b1904f", "source": "Yahoo", "summary": "SAN JOSE, Calif., February 04, 2025--Quantum® Corporation (NASDAQ: QMCO) (\\"Quantum\\" or the \\"Company\\"), a leader in solutions for AI and unstructured data, today announced it will release financial results for its fiscal third quarter 2025 on Wednesday, February 12, 2025, after the markets close.", "datetime": "2025-02-04T13:00:00.000Z", "headline": "Quantum to Release Fiscal Third Quarter 2025 Financial Results on Wednesday, February 12, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ba9dc503ad8d72f44fbe383ed26af80f4f3af9458bcfe541b9b016a868672394", "source": "Yahoo", "summary": "Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and HangoverTORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-bl", "datetime": "2025-02-04T12:03:00.000Z", "headline": "Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:27.158+00	5	completed	2025-09-03 18:47:27.161021+00
f413fd79-3fa8-4294-9609-924d7c7ded37	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CPIX	2025-02-04	2025-02-04 11:31:00+00	2025-02-04 11:31:00+00	2.940000	3.120000	200.0000	long	3.360000	0.000000	32.64	5.5510	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:28.10035+00	2025-09-03 18:47:28.101704+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:28.096Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9030e52ad3bfe9a484daa6217b808b0cce52fa96040d6bff3267e91602e0aceb", "source": "Yahoo", "summary": "On Tuesday, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on T", "datetime": "2025-02-04T18:31:48.000Z", "headline": "Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f87241a2a5ca3d165cf15c0296cce343fe1127046e593469bebcc27b288f1e14", "source": "Yahoo", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac c", "datetime": "2025-02-04T12:30:00.000Z", "headline": "Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:28.1+00	5	completed	2025-09-03 18:47:28.101704+00
d99e6b18-c18f-41ec-babe-198081ca9f94	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GWAV	2025-02-12	2025-02-12 19:15:00+00	2025-03-20 10:50:00+00	0.300000	0.270000	20000.0000	long	178.800000	0.000000	-688.03	-11.5845	Round trip: 8 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:31.548272+00	2025-09-03 18:47:31.549652+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 51335, "analysisTimestamp": "2025-09-03T18:47:30.854Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=360873b82af8890e94fe9c08d22942b320e167ab36604e9af1b290192e9e14cc", "source": "Yahoo", "summary": "Greenwave Technology Solutions, Inc. (Nasdaq: GWAV) (\\"Greenwave\\" or the \\"Company\\"), today announced it is preparing for significant demand increases for its 100% domestically-sourced scrap metal products, including steel, aluminum, copper, and zorba. Prices for domestic scrap metal have surged in February 2025 and are expected to go higher.", "datetime": "2025-02-11T16:00:00.000Z", "headline": "Greenwave Technology Solutions, Inc. Preparing for Massive Demand Influx Amid 25% Tariffs on Steel and Aluminum Without Exceptions or Exemptions", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:31.548+00	5	completed	2025-09-03 18:47:31.549652+00
f8d146c7-67d4-44f9-857f-67cc0fb684c0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	20678X205	2025-02-07	2025-02-07 12:01:00+00	2025-02-07 12:01:00+00	3.670000	3.790000	400.0000	long	5.230000	0.000000	43.05	2.9331	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:41.373973+00	2025-09-03 18:50:05.760429+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:40.725Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:41.373+00	5	completed	2025-09-03 18:50:05.760429+00
f8d5dede-911d-4594-859e-526db89ceb03	2d96cef2-7502-44ff-a7a9-17713d4a7a42	KTTA	2025-02-05	2025-02-05 11:02:00+00	2025-02-05 11:02:00+00	4.500000	4.470000	200.0000	short	4.280000	0.000000	0.72	0.0801	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:32.341392+00	2025-09-03 18:47:32.343096+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:32.338Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:32.341+00	5	completed	2025-09-03 18:47:32.343096+00
a801d84c-b16a-47f1-b9d0-d314571b7aab	2d96cef2-7502-44ff-a7a9-17713d4a7a42	71902K303	2025-03-31	2025-03-31 12:15:00+00	2025-03-31 12:17:00+00	1.030000	1.010000	900.0000	long	11.880000	0.000000	-26.97	-2.9185	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:40.048254+00	2025-09-03 18:50:06.278167+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:39.755Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:40.048+00	5	completed	2025-09-03 18:50:06.278167+00
0bb698bb-c87c-43d6-908d-f41df90555bd	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LTRY	2025-02-07	2025-02-07 10:58:00+00	2025-02-07 11:00:00+00	1.850000	1.910000	200.0000	long	4.260000	0.000000	7.74	2.0919	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:40.349938+00	2025-09-03 18:47:40.351379+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:40.049Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:40.349+00	5	completed	2025-09-03 18:47:40.351379+00
15009cd4-a7a3-443f-bf34-061167e05e77	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-24	2025-03-24 10:53:00+00	2025-03-24 11:35:00+00	3.590000	3.420000	2000.0000	long	27.850000	0.000000	-371.65	-5.1769	Round trip: 6 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:13.402022+00	2025-09-03 18:48:13.403515+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 42, "analysisTimestamp": "2025-09-03T18:48:12.885Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:13.401+00	5	completed	2025-09-03 18:48:13.403515+00
049e9e1e-c30e-432f-961d-90cd6fe8838c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CPIX	2025-02-04	2025-02-04 11:32:00+00	2025-02-04 11:33:00+00	2.780000	2.840000	400.0000	long	5.910000	0.000000	18.65	1.6757	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:28.726422+00	2025-09-03 18:47:28.728538+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:28.721Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9030e52ad3bfe9a484daa6217b808b0cce52fa96040d6bff3267e91602e0aceb", "source": "Yahoo", "summary": "On Tuesday, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on T", "datetime": "2025-02-04T18:31:48.000Z", "headline": "Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f87241a2a5ca3d165cf15c0296cce343fe1127046e593469bebcc27b288f1e14", "source": "Yahoo", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac c", "datetime": "2025-02-04T12:30:00.000Z", "headline": "Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:28.725+00	5	completed	2025-09-03 18:47:28.728538+00
82c2a0ff-9feb-406b-bcd5-b57126235d37	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GWAV	2025-02-04	2025-02-04 12:08:00+00	2025-02-10 11:10:00+00	0.370000	0.400000	13000.0000	long	126.550000	0.000000	267.50	5.6331	Round trip: 11 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:29.367265+00	2025-09-03 18:47:29.369155+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 8582, "analysisTimestamp": "2025-09-03T18:47:29.131Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=062a80aa391534d1a163e1e3e8e456e3cc48d4c8deab8360c3605f9d64b6e499", "source": "Yahoo", "summary": "Greenwave Technology Solutions, Inc. (\\"Greenwave\\" or the \\"Company\\") (Nasdaq: GWAV), a leader in metal recycling, is raising revenue guidance to $47–$50 million for FY 2025 following President Trump's announcement of sweeping tariffs on steel, aluminum, and copper imports.", "datetime": "2025-02-04T13:08:00.000Z", "headline": "Greenwave Technology Solutions, Inc. Raises Revenue Guidance to $47-$50 Million for FY 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8727ea3006fc2ad862078b89c232cb0f902a20607dc3b42cc3f5eecc8c975148", "source": "Yahoo", "summary": "Greenwave Technology Solutions, Inc. (\\"Greenwave\\" or the \\"Company\\") (Nasdaq: GWAV), a leader in metal recycling, is primed for significant revenue acceleration following President Trump's announcement of sweeping tariffs on steel, aluminum, and copper imports. These aggressive trade measures are expected to drive sharp price increases for domestically sourced metals, positioning Greenwave as a critical supplier in an increasingly protectionist market.", "datetime": "2025-02-03T09:10:00.000Z", "headline": "Greenwave Technology Solutions, Inc. Poised for Explosive Growth Amid New Steel, Aluminum, and Copper Tariffs", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:29.366+00	5	completed	2025-09-03 18:47:29.369155+00
dfae9fb7-c6ce-4e67-97cf-f49f01503f2d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BDRX	2025-02-12	2025-02-12 11:34:00+00	2025-02-12 11:39:00+00	5.850000	6.070000	800.0000	long	11.930000	0.000000	160.99	3.4403	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:48.877845+00	2025-09-03 18:47:48.879259+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:48.874Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cc30cd99c35e016ef7340d00fde49bbf2315ee92c5f986684133392bad4703b2", "source": "Yahoo", "summary": "Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration ...", "datetime": "2025-02-12T12:30:00.000Z", "headline": "Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:48.877+00	5	completed	2025-09-03 18:47:48.879259+00
5b85a6c1-8463-442e-bf33-a204da3e8521	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NAKA	2025-02-13	2025-02-13 11:05:00+00	2025-02-14 14:12:00+00	3.010000	3.040000	2000.0000	long	28.910000	0.000000	24.65	0.4090	Round trip: 9 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:51.433336+00	2025-09-03 18:47:51.435118+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1627, "analysisTimestamp": "2025-09-03T18:47:51.126Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:51.433+00	5	completed	2025-09-03 18:47:51.435118+00
df30def0-5113-4a53-bc96-d5302e120fa0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PYXS	2025-02-26	2025-02-26 11:32:00+00	\N	1.080000	\N	12000.0000	long	71.350000	0.000000	0.00	0.0000	Open position: 6 executions	f	lightspeed	position	\N	{}	2025-09-03 18:47:52.072658+00	2025-09-03 18:47:52.076411+00	[]	\N	\N	f	\N	\N	\N	80.00	basic_time_based	{"signals": ["Market open entry"], "holdTimeMinutes": 272596, "analysisTimestamp": "2025-09-03T18:47:52.071Z"}	f	\N	[]	f	\N	\N	5	completed	2025-09-03 18:47:52.076411+00
46e59ae1-76e6-4475-b1f6-dd394b5c0733	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MGRM	2025-03-17	2025-03-17 13:54:00+00	2025-03-17 13:55:00+00	3.640000	3.650000	600.0000	long	7.970000	0.000000	1.45	0.0664	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:56.177252+00	2025-09-03 18:47:56.178852+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:55.826Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=0e586474c64d48762e820521c7cc5e2bf04a62baeb5d843942d2956b9b6917f4", "source": "Yahoo", "summary": "Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its ...", "datetime": "2025-03-17T11:00:00.000Z", "headline": "Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:56.177+00	5	completed	2025-09-03 18:47:56.178852+00
fbdc029e-7c7b-4035-bdd9-af4c88bf3bc7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CPIX	2025-02-04	2025-02-04 11:53:00+00	2025-02-04 11:55:00+00	2.840000	2.890000	200.0000	long	4.260000	0.000000	4.74	0.8345	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:28.734627+00	2025-09-03 18:47:28.736466+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:28.729Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9030e52ad3bfe9a484daa6217b808b0cce52fa96040d6bff3267e91602e0aceb", "source": "Yahoo", "summary": "On Tuesday, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on T", "datetime": "2025-02-04T18:31:48.000Z", "headline": "Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f87241a2a5ca3d165cf15c0296cce343fe1127046e593469bebcc27b288f1e14", "source": "Yahoo", "summary": "Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac c", "datetime": "2025-02-04T12:30:00.000Z", "headline": "Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:28.734+00	5	completed	2025-09-03 18:47:28.736466+00
964239b7-1400-4299-bc02-fdab6113daf0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	KTTA	2025-02-05	2025-02-05 11:00:00+00	2025-02-05 11:00:00+00	3.750000	3.570000	200.0000	short	4.280000	0.000000	30.72	4.1015	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:32.335907+00	2025-09-03 18:47:32.337298+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:32.333Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:32.335+00	5	completed	2025-09-03 18:47:32.337298+00
af6ef801-4581-464f-8f57-7f4c411bfb85	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ACB	2025-02-05	2025-02-05 11:20:00+00	2025-02-05 11:22:00+00	4.170000	4.230000	400.0000	long	5.930000	0.000000	16.11	0.9647	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:33.718903+00	2025-09-03 18:47:33.720936+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:33.400Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=240f6514b371be9599638ed2aae6dcad2a0c6027f55ffaede4d9ab1338e92fd1", "source": "Yahoo", "summary": "International medical cannabis revenue grew 112%.", "datetime": "2025-02-05T19:42:52.000Z", "headline": "Aurora Cannabis Reports Record Revenue and Profit in Q3 Fiscal 2025", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=df0e1acb072b065107caf97041302ca010e1b062f14abfe86a53edc9968e592d", "source": "Yahoo", "summary": "ACB earnings call for the period ending December 31, 2024.", "datetime": "2025-02-05T19:15:17.000Z", "headline": "Aurora Cannabis (ACB) Q3 2025 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=68ca33ee6de23dfdfaeb8de3d59001a74ee098a1a2e95d10262265fc425bb128", "source": "Yahoo", "summary": "Aurora Cannabis (ACB) delivered earnings and revenue surprises of 50% and 9.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?", "datetime": "2025-02-05T13:50:03.000Z", "headline": "Aurora Cannabis Inc. (ACB) Surpasses Q3 Earnings and Revenue Estimates", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=39164d4b66ac68569fd9f9277302e4cd8508d6c8d7e958abf71338de3a155b2c", "source": "SeekingAlpha", "summary": "Aurora Cannabis Inc. (NASDAQ:ACB) Q3 2025 Earnings Conference Call February 5, 2025 8:00 AM ETCompany ParticipantsKevin Niland - Director of Strategic...", "datetime": "2025-02-05T12:23:55.000Z", "headline": "Aurora Cannabis Inc. (ACB) Q3 2025 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=14ee4e7903cc914538da19915123c61589cf45b8ac0b98139bdc6602edd613fa", "source": "SeekingAlpha", "summary": "The following slide deck was published by Aurora Cannabis Inc.", "datetime": "2025-02-05T11:14:15.000Z", "headline": "Aurora Cannabis Inc. 2025 Q3 - Results - Earnings Call Presentation", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:33.718+00	5	completed	2025-09-03 18:47:33.720936+00
02cb4570-0f94-45bd-af55-2d6e31acffc3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PNBK	2025-02-10	2025-02-10 10:59:00+00	2025-02-10 11:00:00+00	2.850000	2.910000	200.0000	long	3.810000	0.000000	8.19	1.4368	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:42.963047+00	2025-09-03 18:47:42.965953+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:42.959Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:42.962+00	5	completed	2025-09-03 18:47:42.965953+00
8bd25f9d-aef8-4ac0-af2b-a8bea75bfaac	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GRCE	2025-02-10	2025-02-10 12:05:00+00	2025-02-10 12:10:00+00	3.120000	3.140000	900.0000	long	9.610000	0.000000	8.29	0.2948	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:46.158869+00	2025-09-03 18:47:46.160677+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:45.796Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=53217ca2f5742f77ae868a2a4b8ddca1a62a14489b994fc670cee19f6c143b42", "source": "Yahoo", "summary": "Grace Therapeutics (GRCE) rose nearly 8% in recent Monday trading after it said it entered into secu", "datetime": "2025-02-10T18:44:08.000Z", "headline": "Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=251611d572bb994eabef6fc5fe7c2c403940117dc7498a2a0d3285efcd84818a", "source": "Yahoo", "summary": "On Monday, Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH). aSAH is bleeding over the brain’s surface in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. The study met its primary endpoint and provides evidence of clinical benefit compared to orally administere", "datetime": "2025-02-10T17:05:59.000Z", "headline": "Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=54e534aba4b37bef1b4867191df9fd3b73bf4229ff3badcaf1aed8b91f9e60ee", "source": "Yahoo", "summary": "Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 million in potential warrant exercise proceeds for an aggregate of up to approximately $30 million in potential total gross proceeds PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therap", "datetime": "2025-02-10T13:05:00.000Z", "headline": "Grace Therapeutics Announces Private Placement Financing of up to $30 Million", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f83b017c51f0c1bb5f53f42fdfb2963fabe0c86565b1ee665f337ae636308989", "source": "Yahoo", "summary": "Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion t", "datetime": "2025-02-10T13:01:00.000Z", "headline": "Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:46.158+00	5	completed	2025-09-03 18:47:46.160677+00
2bb5b4e5-7d2c-4407-b93a-06544bbdd15a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	71902K303	2025-03-27	2025-03-27 12:18:00+00	2025-03-27 12:42:00+00	0.910000	0.640000	2000.0000	long	23.650000	0.000000	-555.43	-30.6803	Round trip: 6 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:39.753132+00	2025-09-03 18:50:06.77939+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 24, "analysisTimestamp": "2025-09-03T18:47:39.748Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:39.752+00	5	completed	2025-09-03 18:50:06.77939+00
cb9d5b07-7943-454f-a01b-7cb1b1082cf7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	71902K303	2025-03-27	2025-03-27 12:16:00+00	2025-03-27 12:17:00+00	1.070000	1.100000	600.0000	long	7.920000	0.000000	12.69	1.9847	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:39.468584+00	2025-09-03 18:50:07.321598+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:39.139Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:39.468+00	5	completed	2025-09-03 18:50:07.321598+00
d4c52114-b262-4053-a962-9b8057fabfa1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	71902K303	2025-02-06	2025-02-06 12:17:00+00	2025-02-06 18:40:00+00	2.080000	2.130000	600.0000	long	7.040000	0.000000	22.28	1.7843	Round trip: 3 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:39.138592+00	2025-09-03 18:50:07.782011+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 383, "analysisTimestamp": "2025-09-03T18:47:38.482Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:39.138+00	5	completed	2025-09-03 18:50:07.782011+00
eac89a62-2af1-4146-adc1-a51084bf995d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	KTTA	2025-02-05	2025-02-05 11:02:00+00	2025-02-05 11:04:00+00	4.110000	4.150000	400.0000	long	6.580000	0.000000	8.75	0.5316	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:32.539829+00	2025-09-03 18:47:32.541344+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:32.536Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:32.539+00	5	completed	2025-09-03 18:47:32.541344+00
128ed5f7-1a98-4aac-8080-2311dbbc6dc6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	87978U108	2025-02-10	2025-02-10 12:01:00+00	2025-02-10 12:03:00+00	0.930000	0.890000	1200.0000	long	16.960000	0.000000	-68.18	-6.1233	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:44.57693+00	2025-09-03 18:50:04.272767+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:44.239Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:44.576+00	5	completed	2025-09-03 18:50:04.272767+00
5b902936-c3d6-417d-9c14-5c78132e8309	2d96cef2-7502-44ff-a7a9-17713d4a7a42	KTTA	2025-02-05	2025-02-05 11:14:00+00	2025-02-05 11:16:00+00	3.860000	3.890000	400.0000	long	6.520000	0.000000	4.98	0.3224	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:32.815113+00	2025-09-03 18:47:32.817155+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:32.809Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:32.814+00	5	completed	2025-09-03 18:47:32.817155+00
7d5c7424-d376-4e2d-a594-bc8a8c571ca9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	KTTA	2025-02-05	2025-02-05 11:48:00+00	2025-02-05 12:01:00+00	3.170000	3.090000	800.0000	long	11.810000	0.000000	-78.29	-3.0840	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:33.125631+00	2025-09-03 18:47:33.127707+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 13, "analysisTimestamp": "2025-09-03T18:47:33.120Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc5b12f38a9d2ff6be8624e5f86d93567d9ced481dd140908f5fa48f74787bee", "source": "Yahoo", "summary": "SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced tha", "datetime": "2025-02-05T11:59:00.000Z", "headline": "Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:33.125+00	5	completed	2025-09-03 18:47:33.127707+00
df6eccc5-a74d-4080-8770-89c2b5df1fe6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ACRV	2025-02-05	2025-02-05 12:02:00+00	2025-02-05 14:25:00+00	6.960000	7.090000	800.0000	long	10.080000	0.000000	95.32	1.7120	Round trip: 3 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:34.782237+00	2025-09-03 18:47:34.784364+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 143, "analysisTimestamp": "2025-09-03T18:47:33.980Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a08790abad74390c7835ce5660f761a452d5f5ff2e4fe2c47d38f51d22c2a810", "source": "Yahoo", "summary": "We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to take a look at where Acrivon Therapeutics, Inc. (NASDAQ:ACRV) stands against other AI news and ratings investors are keeping their eye on. How AI Is Shaping Global Power and Innovation Josh […]", "datetime": "2025-02-05T20:45:31.000Z", "headline": "Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=3af5da94ee252a1ae6e25b37ee3051c93c97ee4d99a82eb3089279f754369f69", "source": "Yahoo", "summary": "The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with endometrial cancer and other tumor types Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient selection (p-value = 0.009) Drug-tailor", "datetime": "2025-02-05T13:00:00.000Z", "headline": "Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5cee45d540b006f65d6cee17b522c46c1c60dcdea5114d62fef4d93a9a04ae08", "source": "Finnhub", "summary": "By Chris Wack Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the...", "datetime": "2025-02-05T08:36:41.000Z", "headline": "Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification", "sentiment": "neutral"}]	t	positive	2025-09-03 18:47:34.782+00	5	completed	2025-09-03 18:47:34.784364+00
8b01c162-4946-49eb-a2f8-20eaa6d0ca2b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LIPO	2025-02-06	2025-02-06 10:59:00+00	2025-02-06 11:00:00+00	5.470000	5.610000	200.0000	long	4.280000	0.000000	23.72	2.1682	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:35.473484+00	2025-09-03 18:47:35.475384+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:35.130Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f35a17dd18547671af7bcdadeb19952898e5d1e7ec009a014fa6d6a09f7f470b", "source": "Yahoo", "summary": "PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to provide tar", "datetime": "2025-02-06T11:00:00.000Z", "headline": "Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:35.473+00	5	completed	2025-09-03 18:47:35.475384+00
206fe5a2-a57d-479d-b633-2b8863ab0ad2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	EQ	2025-02-06	2025-02-06 12:03:00+00	2025-02-06 12:08:00+00	0.920000	0.980000	600.0000	long	8.650000	0.000000	23.99	4.3310	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:38.169689+00	2025-09-03 18:47:38.171402+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:37.861Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=98ded5096b9dead40deb7a620cbe10ad7ab2b2c13b6de29399023f067e1bf3c3", "source": "Yahoo", "summary": "Itolizumab achieved a clinical remission rate of 23.3% in ulcerative colitis patients.", "datetime": "2025-02-06T21:18:49.000Z", "headline": "Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=af92eb458d193862fdb2653083b127e89c2cf2093405a6686edccfe8c3fce11c", "source": "Yahoo", "summary": "LA JOLLA, Calif., February 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC).", "datetime": "2025-02-06T13:00:00.000Z", "headline": "Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:38.169+00	5	completed	2025-09-03 18:47:38.171402+00
5913fb72-aaa1-4cda-9739-e976034114a2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-24	2025-03-24 13:33:00+00	2025-03-24 13:34:00+00	4.270000	4.280000	600.0000	long	7.990000	0.000000	-7.33	-0.2858	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:13.646746+00	2025-09-03 18:48:13.648114+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:13.644Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:13.646+00	5	completed	2025-09-03 18:48:13.648114+00
15aaceb7-6b08-46ba-a959-ceae18232b09	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PNBK	2025-02-10	2025-02-10 10:54:00+00	2025-02-10 10:56:00+00	2.770000	2.820000	200.0000	long	4.260000	0.000000	5.74	1.0361	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:42.95632+00	2025-09-03 18:47:42.95809+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:42.279Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:42.955+00	5	completed	2025-09-03 18:47:42.95809+00
9615d633-8f42-44f3-96d6-eaebc73eb3b4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-02	2025-04-02 21:23:00+00	2025-04-02 21:24:00+00	54.060000	54.100000	100.0000	long	2.780000	0.000000	1.25	0.0231	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:04.27978+00	2025-09-03 18:49:04.28096+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:04.277Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:49:04.279+00	5	completed	2025-09-03 18:49:04.28096+00
dd4c580f-9b76-43d7-b17c-22cdc51d6b15	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-24	2025-03-24 13:36:00+00	2025-03-24 13:37:00+00	4.490000	4.520000	300.0000	long	3.990000	0.000000	6.00	0.4455	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:13.916855+00	2025-09-03 18:48:13.918374+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:13.913Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:13.916+00	5	completed	2025-09-03 18:48:13.918374+00
e0b51e88-5a66-4335-811c-2d2472013c2b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	20678X205	2025-02-07	2025-02-07 12:04:00+00	2025-02-07 13:38:00+00	2.890000	2.920000	3200.0000	long	47.220000	0.000000	49.36	0.5331	Round trip: 11 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:47:41.710967+00	2025-09-03 18:50:05.271534+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 94, "analysisTimestamp": "2025-09-03T18:47:41.708Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:41.71+00	5	completed	2025-09-03 18:50:05.271534+00
2fc303b7-def0-4e80-b552-b5dc67233d2f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CLSD	2025-02-10	2025-02-10 11:07:00+00	2025-02-12 16:56:00+00	1.120000	1.060000	1100.0000	long	16.520000	0.000000	-74.35	-6.0529	Round trip: 5 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:43.904343+00	2025-09-03 18:47:43.906108+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3229, "analysisTimestamp": "2025-09-03T18:47:43.213Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d36b9597fb65a841996c31e0bac4c32967e00a80f76d8119a9d53192b5c67603", "source": "Yahoo", "summary": "- BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design -ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and", "datetime": "2025-02-10T12:05:00.000Z", "headline": "Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:43.903+00	5	completed	2025-09-03 18:47:43.906108+00
191cd412-4fce-4455-bc20-d6e8e6e1fe03	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-24	2025-03-24 19:25:00+00	2025-03-24 19:26:00+00	12.680000	12.910000	100.0000	long	2.660000	0.000000	20.64	1.6280	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:14.574999+00	2025-09-03 18:48:14.57671+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:14.571Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:14.574+00	5	completed	2025-09-03 18:48:14.57671+00
10187771-9876-4cbf-b38e-51c85d157f01	2d96cef2-7502-44ff-a7a9-17713d4a7a42	VSTTF	2025-02-11	2025-02-11 11:02:00+00	2025-03-12 12:35:00+00	0.770000	0.980000	24000.0000	long	306.590000	0.000000	4821.35	26.2314	Round trip: 21 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:49.560951+00	2025-09-03 18:47:49.562982+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 41853, "analysisTimestamp": "2025-09-03T18:47:49.555Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:49.56+00	5	completed	2025-09-03 18:47:49.562982+00
25fabbca-2d3c-4836-866e-b99dc069404f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	IINN	2025-02-11	2025-02-11 11:40:00+00	2025-02-11 11:45:00+00	0.940000	0.980000	1000.0000	long	10.140000	0.000000	31.96	3.4138	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:49.864125+00	2025-09-03 18:47:49.86536+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:47:49.564Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=5006e31038ef0336f4897e8950743333093a4345429716ae96566236f41755ac", "source": "Yahoo", "summary": "Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (\\"Inspira\\" or the \\"Company\\"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections.", "datetime": "2025-02-11T12:00:00.000Z", "headline": "Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=53ba033a97aa2faf0fe77e3fe9c9e9057151262de866f1c95b5fe8afba714b2e", "source": "Yahoo", "summary": "On Tuesday, Inspira Technologies OXY B.H.N. (NASDAQ:IINN) announced positive initial results from its previously reported collaboration with Ennocure MedTech to develop a novel bio-electronic treatment for preventing bloodstream infections. In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over 24 hours. The technology, which uses physical electric stimulation rather than chemic", "datetime": "2025-02-11T11:45:42.000Z", "headline": "EXCLUSIVE: Inspira and Ennocure's Bio-Electronic Tech Uses Electric Stimulation to Help Prevent IV-Related Infections", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:49.863+00	5	completed	2025-09-03 18:47:49.86536+00
de1f2f5a-e4b6-4c52-9473-00c7d9d6966d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PEVM	2025-02-13	2025-02-13 10:42:00+00	2025-02-13 11:02:00+00	0.590000	0.640000	2000.0000	long	24.810000	0.000000	74.47	6.2684	Round trip: 5 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:50.869968+00	2025-09-03 18:47:50.872082+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 20, "analysisTimestamp": "2025-09-03T18:47:50.185Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:50.869+00	5	completed	2025-09-03 18:47:50.872082+00
79b26b2e-9d44-4c74-867f-f0ed7ae255ca	2d96cef2-7502-44ff-a7a9-17713d4a7a42	00941Q203	2025-03-17	2025-03-17 12:57:00+00	2025-03-17 12:57:00+00	1.330000	1.390000	300.0000	short	3.970000	0.000000	-21.97	-5.5063	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:54.642678+00	2025-09-03 18:50:02.754865+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:54.226Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:54.642+00	5	completed	2025-09-03 18:50:02.754865+00
2ab76c62-abe4-42d2-88d9-010d7cf790e0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G14492121	2025-03-14	2025-03-14 15:20:00+00	2025-03-14 15:22:00+00	1.880000	1.980000	900.0000	long	11.900000	0.000000	81.91	4.8519	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:52.774081+00	2025-09-03 18:50:03.754775+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:52.434Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:52.773+00	5	completed	2025-09-03 18:50:03.754775+00
a24911f5-2b21-4f98-b631-f16d1c3d874c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BDRX	2025-02-10	2025-02-10 12:30:00+00	2025-02-10 12:40:00+00	8.180000	7.100000	300.0000	long	4.050000	0.000000	-328.55	-13.3856	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:47.369594+00	2025-09-03 18:47:47.372056+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:47:46.854Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e5504cdbf4b7d3cfdd52375215e667f260bfcdbff1d2d8c184068d5926465c47", "source": "Yahoo", "summary": "February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and", "datetime": "2025-02-10T13:30:00.000Z", "headline": "Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:47.369+00	5	completed	2025-09-03 18:47:47.372056+00
c7353302-7632-417e-8aa5-d6acd7ff7c74	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-24	2025-03-24 20:32:00+00	2025-03-24 20:32:00+00	15.950000	16.160000	300.0000	long	2.740000	0.000000	60.26	1.2594	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:14.840366+00	2025-09-03 18:48:14.841375+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:14.837Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:14.84+00	5	completed	2025-09-03 18:48:14.841375+00
9576b0fc-3844-4c16-9847-df9e0dbfda6e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BDRX	2025-02-12	2025-02-12 11:31:00+00	2025-02-12 11:31:00+00	6.150000	6.500000	200.0000	long	2.370000	0.000000	67.63	5.4984	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:48.012855+00	2025-09-03 18:47:48.014264+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:47.676Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cc30cd99c35e016ef7340d00fde49bbf2315ee92c5f986684133392bad4703b2", "source": "Yahoo", "summary": "Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration ...", "datetime": "2025-02-12T12:30:00.000Z", "headline": "Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:48.012+00	5	completed	2025-09-03 18:47:48.014264+00
87dc3b27-f2cc-45b0-91a5-058e39f2dee6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-03	2025-04-03 10:12:00+00	2025-04-03 10:14:00+00	53.510000	53.140000	100.0000	long	2.770000	0.000000	-39.77	-0.7432	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:05.185467+00	2025-09-03 18:49:05.187477+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:49:04.535Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}]	t	positive	2025-09-03 18:49:05.185+00	5	completed	2025-09-03 18:49:05.187477+00
f14f7d20-79af-491e-ace9-9f9ddcd67ff5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BDRX	2025-02-12	2025-02-12 11:32:00+00	2025-02-12 11:32:00+00	6.290000	6.280000	200.0000	long	3.270000	0.000000	-4.45	-0.3537	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:48.297496+00	2025-09-03 18:47:48.298684+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:48.294Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cc30cd99c35e016ef7340d00fde49bbf2315ee92c5f986684133392bad4703b2", "source": "Yahoo", "summary": "Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration ...", "datetime": "2025-02-12T12:30:00.000Z", "headline": "Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:48.297+00	5	completed	2025-09-03 18:47:48.298684+00
0f2042b4-c933-47d9-8955-1b50e56574c8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TRNR	2025-02-11	2025-02-11 12:02:00+00	2025-02-11 12:03:00+00	1.970000	2.030000	200.0000	long	2.800000	0.000000	9.20	2.3350	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:49.869491+00	2025-09-03 18:47:49.87096+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:49.866Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=fed798df6edf4dd2cc3cea1603cd3183889129e89998cd2554447ab08b04acd6", "source": "Yahoo", "summary": "AUSTIN, TX / ACCESS Newswire / February 11, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) (\\"TRNR\\" or \\"the Company\\"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced it had signed a binding transaction ...", "datetime": "2025-02-11T13:00:00.000Z", "headline": "Interactive Strength Inc. (Nasdaq:TRNR) Signs Binding Agreement to Acquire Sportstech, a Profitable $40M+ Revenue Connected-Fitness Equipment Business", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:49.869+00	5	completed	2025-09-03 18:47:49.87096+00
8a09a033-4b3c-4212-96b4-b20551f4233f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-24	2025-03-24 20:34:00+00	2025-03-24 20:36:00+00	16.220000	16.250000	300.0000	long	4.710000	0.000000	4.22	0.0867	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:15.495919+00	2025-09-03 18:48:15.497453+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:15.491Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc508be4c49ad53683b56fb4e31652e6387b1a27959b49c686a7fdc6cd27ef3f", "source": "Yahoo", "summary": "MicroAlgo (MLGO) said Monday that it plans to issue new shares at $0.8 per share to fulfill a debt o", "datetime": "2025-03-24T18:01:38.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7d8050ae05bffd79dc30b194c8fea5add31f65ab83cdb62382f7c66b83fd2bf6", "source": "Yahoo", "summary": "SHENZHEN, March 24, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share. Shenzhen, China, March. 24, 2025 – MicroAlgo Inc. (NASDAQ: MLGO), (the “Company”or \\"MicroAlgo\\"), today announced the plan to issue more new shares. Considering that MicroAlgo Inc. entered into a convertible bond purchase agreement with creditors on October 7, 2024, with a total amount of US$20 million. These bonds have a maturity period of 360 days. According t", "datetime": "2025-03-24T13:15:00.000Z", "headline": "MicroAlgo Inc. plans to issue additional new shares at an offering price of $0.8 per share.", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:15.495+00	5	completed	2025-09-03 18:48:15.497453+00
02f756ab-6add-43ca-b9aa-f5a2c5c8a45a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRFX	2025-02-18	2025-02-18 12:30:00+00	2025-02-18 12:43:00+00	3.310000	3.820000	100.0000	long	2.640000	0.000000	48.36	14.6103	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:51.440524+00	2025-09-03 18:47:51.442113+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 13, "analysisTimestamp": "2025-09-03T18:47:51.436Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=378b5652bb219f615111472f1696d37d3446cc53500f952007f20bf90418f6c0", "source": "Yahoo", "summary": "DeepSolar brings new customer base in creation, including major utility-scalesolar operators and independent power producers, whilebreaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (\\"PainReform\\" or the \\"Company\\"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established ther", "datetime": "2025-02-18T13:30:00.000Z", "headline": "PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:51.44+00	5	completed	2025-09-03 18:47:51.442113+00
e5bad97a-6e12-4e94-86ba-c2f49bb4eaa8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SRXH	2025-02-19	2025-02-19 11:30:00+00	2025-03-12 13:30:00+00	2.370000	1.580000	1000.0000	long	11.230000	0.000000	-801.28	-33.7801	Round trip: 3 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:52.065544+00	2025-09-03 18:47:52.06699+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 30360, "analysisTimestamp": "2025-09-03T18:47:51.781Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:52.065+00	5	completed	2025-09-03 18:47:52.06699+00
80b7c5dd-3942-4d42-a5c4-161cb9a7bbb3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-04-01	2025-04-01 12:35:00+00	2025-04-01 12:35:00+00	30.910000	31.050000	100.0000	long	2.260000	0.000000	11.74	0.3798	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:17.496113+00	2025-09-03 18:48:17.497572+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:17.211Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:17.495+00	5	completed	2025-09-03 18:48:17.497572+00
61b5a4fb-7568-43e4-b4e9-fd07d49cc906	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CAPS	2025-03-17	2025-03-17 12:01:00+00	2025-03-17 12:02:00+00	4.130000	3.830000	300.0000	long	3.990000	0.000000	-93.78	-7.5696	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:54.22437+00	2025-09-03 18:47:54.22567+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:53.683Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:54.224+00	5	completed	2025-09-03 18:47:54.22567+00
4af9d7e1-aaf4-4368-aa59-a20c4d19b534	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G14492121	2025-03-14	2025-03-14 15:35:00+00	2025-03-14 15:48:00+00	1.900000	1.600000	3000.0000	long	38.290000	0.000000	-938.71	-16.4674	Round trip: 5 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:53.02475+00	2025-09-03 18:50:03.263973+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 13, "analysisTimestamp": "2025-09-03T18:47:53.022Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:53.024+00	5	completed	2025-09-03 18:50:03.263973+00
95074c72-0a8d-47ef-a831-8039da34cdb5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MGRM	2025-03-17	2025-03-17 14:15:00+00	2025-03-17 14:22:00+00	3.890000	3.900000	1900.0000	long	25.890000	0.000000	-15.62	-0.2112	Round trip: 6 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:57.082994+00	2025-09-03 18:47:57.083787+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:47:57.079Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=0e586474c64d48762e820521c7cc5e2bf04a62baeb5d843942d2956b9b6917f4", "source": "Yahoo", "summary": "Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its ...", "datetime": "2025-03-17T11:00:00.000Z", "headline": "Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:57.082+00	5	completed	2025-09-03 18:47:57.083787+00
d87c1991-d9b9-4d5f-a407-c3605d38dc9e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	RDHL	2025-03-18	2025-03-18 11:04:00+00	2025-03-18 11:15:00+00	3.130000	3.260000	600.0000	long	5.190000	0.000000	73.53	3.9140	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:58.131212+00	2025-09-03 18:47:58.133081+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 11, "analysisTimestamp": "2025-09-03T18:47:57.845Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2918b67360b5cd2bb7825d08c3b9656e03298d5f22b7a5724898ab7f83617203", "source": "Yahoo", "summary": "RedHill Biopharma Ltd. (NASDAQ: RDHL) (\\"RedHill\\" or the \\"Company\\"), a specialty biopharmaceutical company, today announced its plan to submit a UK Marketing Authorisation Application (MAA) for Talicia for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP), a fast-track regulatory process for UK drug approvals based on a recognized reference approval. Utilizing the U.S. Food and Dr", "datetime": "2025-03-18T11:00:00.000Z", "headline": "RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:58.13+00	5	completed	2025-09-03 18:47:58.133081+00
a0094961-5f4a-4d10-9ea5-eaf27c696530	2d96cef2-7502-44ff-a7a9-17713d4a7a42	RDHL	2025-03-18	2025-03-18 11:16:00+00	2025-03-20 10:52:00+00	2.950000	2.590000	4000.0000	long	52.790000	0.000000	-1474.69	-12.5038	Round trip: 7 executions	f	lightspeed	swing	\N	{}	2025-09-03 18:47:58.43835+00	2025-09-03 18:47:58.440059+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2856, "analysisTimestamp": "2025-09-03T18:47:58.433Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=2918b67360b5cd2bb7825d08c3b9656e03298d5f22b7a5724898ab7f83617203", "source": "Yahoo", "summary": "RedHill Biopharma Ltd. (NASDAQ: RDHL) (\\"RedHill\\" or the \\"Company\\"), a specialty biopharmaceutical company, today announced its plan to submit a UK Marketing Authorisation Application (MAA) for Talicia for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP), a fast-track regulatory process for UK drug approvals based on a recognized reference approval. Utilizing the U.S. Food and Dr", "datetime": "2025-03-18T11:00:00.000Z", "headline": "RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:58.438+00	5	completed	2025-09-03 18:47:58.440059+00
74418d14-6696-4ab5-a1cd-0241d50029ec	2d96cef2-7502-44ff-a7a9-17713d4a7a42	HYPR	2025-03-17	2025-03-17 13:05:00+00	2025-03-17 13:07:00+00	1.150000	1.150000	600.0000	long	7.920000	0.000000	-4.92	-0.7162	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:55.289747+00	2025-09-03 18:47:55.291877+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:54.644Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=4515376e525f46df259efc45fcdadc081fceac8cfe28504f42be3531e38f2cc1", "source": "Yahoo", "summary": "GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. “I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on", "datetime": "2025-03-17T20:05:00.000Z", "headline": "Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=71e4c69c8073282280f091c5d2a391a686c573a56f9e5c5232b587b5bf73ea82", "source": "SeekingAlpha", "summary": "Hyperfine, Inc. (NASDAQ:HYPR) Q4 2024 Results Conference Call March 17, 2025 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz -...", "datetime": "2025-03-17T19:43:03.000Z", "headline": "Hyperfine, Inc. (HYPR) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=fb8457042d6c01dfcffa711cfe0dbd261b9a0437daae04314970025f6d1ff181", "source": "Yahoo", "summary": "GUILFORD, Conn., March 17, 2025--Hyperfine and NVIDIA collaboration aims to make portable MRI faster, smarter, and more accessible worldwide.", "datetime": "2025-03-17T13:00:00.000Z", "headline": "Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:55.289+00	5	completed	2025-09-03 18:47:55.291877+00
62ead7bc-01b2-4062-b4f3-dbe1ecea33e2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MGRM	2025-03-17	2025-03-17 13:58:00+00	2025-03-17 13:59:00+00	3.400000	3.450000	900.0000	long	11.890000	0.000000	33.50	1.0947	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:56.837985+00	2025-09-03 18:47:56.840338+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:56.831Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=0e586474c64d48762e820521c7cc5e2bf04a62baeb5d843942d2956b9b6917f4", "source": "Yahoo", "summary": "Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its ...", "datetime": "2025-03-17T11:00:00.000Z", "headline": "Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:47:56.837+00	5	completed	2025-09-03 18:47:56.840338+00
b0ff6a90-c803-4cd6-b997-ef1f07b4ce1c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-26	2025-03-26 12:07:00+00	2025-03-26 12:08:00+00	13.560000	13.630000	300.0000	long	2.720000	0.000000	18.28	0.4494	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:16.004197+00	2025-09-03 18:48:16.005759+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:15.784Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=93ca8e0620df899e4a210a0c4ebb6764c83627cc05200d09ae2d9359f1c4da21", "source": "SeekingAlpha", "summary": "Discover why MicroAlgo Inc.'s stock rally lacks fundamentals, driven by debt repayment tactics. Explore risks and projected drop to $3.50. Click for my MLGO update.", "datetime": "2025-03-26T12:49:01.000Z", "headline": "MicroAlgo: Rally Has No Legs", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=19607bf1608d2fc202f6712f589f2c15c20f620afc9905bc89f87596f2ef7fa4", "source": "Yahoo", "summary": "We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where MicroAlgo Inc. (NASDAQ:MLGO) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the green […]", "datetime": "2025-03-25T12:49:15.000Z", "headline": "Why MicroAlgo (MLGO) Skyrocketed on Monday?", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:16.003+00	5	completed	2025-09-03 18:48:16.005759+00
93cae1d7-e20e-4063-8545-de0ccecf072e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 15:25:00+00	2025-04-07 15:25:00+00	38.970000	39.090000	100.0000	long	2.730000	0.000000	9.27	0.2379	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:06.011518+00	2025-09-03 18:49:06.012553+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:05.696Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:06.011+00	5	completed	2025-09-03 18:49:06.012553+00
ba3e7f62-288b-4ed1-a6bd-8ff13ea5495f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 15:26:00+00	2025-04-07 15:28:00+00	38.860000	39.040000	100.0000	long	2.280000	0.000000	15.72	0.4045	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:06.288154+00	2025-09-03 18:49:06.289566+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:49:06.284Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:06.287+00	5	completed	2025-09-03 18:49:06.289566+00
daac3f21-dbec-4000-9f00-a2fe0500af89	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 16:14:00+00	2025-04-07 16:20:00+00	39.420000	39.510000	200.0000	long	4.450000	0.000000	13.55	0.1719	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:08.017844+00	2025-09-03 18:49:08.019002+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:49:08.014Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:08.017+00	5	completed	2025-09-03 18:49:08.019002+00
6ca06a91-d87c-4792-82f5-311757ac1747	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ARQT	2025-03-17	2025-03-17 16:02:00+00	2025-03-17 16:09:00+00	16.430000	16.740000	800.0000	long	10.560000	0.000000	240.01	1.8264	Round trip: 6 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:57.576591+00	2025-09-03 18:47:57.577751+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:47:57.344Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96", "source": "SeekingAlpha", "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.", "datetime": "2025-03-17T22:58:23.000Z", "headline": "Why Organon Is A Top Pick For Income Investors", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=e7540a7d1c7f21e68df2ef163e5026b02cf0a66a473fe1cde09a540729d800f6", "source": "Yahoo", "summary": "Arcutis Canada, Inc., a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, announced today that Health Canada has approved PrZORYVE® (roflumilast cream 0.15%), for the treatment of mild to moderate atopic dermatitis (AD) in adults and children ages 6 years and older. The approval of this once-daily topical cream formulation of roflumilast marks a significant milestone, providing Canadian patients, caregivers and healthcare providers with a novel, steroid", "datetime": "2025-03-17T11:00:00.000Z", "headline": "ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:57.576+00	5	completed	2025-09-03 18:47:57.577751+00
c88b2bd1-a7c9-4927-9f69-27a50deb1459	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MLGO	2025-03-28	2025-03-28 13:31:00+00	2025-03-28 13:32:00+00	17.280000	16.990000	300.0000	long	2.970000	0.000000	-89.43	-1.7251	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:16.559126+00	2025-09-03 18:48:16.560859+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:16.251Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cc03e1992fc827281bf6a106ede84b21a6fab1d58a0edfced68e843eceb5a3c7", "source": "Yahoo", "summary": "WiMi Hologram Cloud (WiMi) announced it has increased its stake in MicroAlgo (MLGO) to 67.65% and committed to a ten-year lock-up period for all currently owned MicroAlgo shares. As of March 27, WIMI Hologram Cloud holds 40,000 Class A ordinary shares, 1,810,658 Class A ordinary shares (restricted), and 44,878,261 Class B ordinary shares of MicroAlgo, representing a total equity stake of 67.65% of MicroAlgo’s total shares outstanding. WIMI has no plans to sell or otherwise dispose of any Microal", "datetime": "2025-03-28T13:21:12.000Z", "headline": "WiMi Hologram Cloud raises stake in MicroAlgo to 67.65%", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=3b4ef94eebd23444c12abf9dca1ae3438f9c8650ffc021e80ca125a4830eaea3", "source": "Yahoo", "summary": "We recently published a list of 12 Popular Penny Stocks on Robinhood to Watch. In this article, we are going to take a look at where MicroAlgo Inc. (NASDAQ:MLGO) stands against other popular penny stocks on Robinhood to watch. The stock market is navigating a complex landscape influenced by geopolitical tensions, trade policies, and shifting […]", "datetime": "2025-03-27T14:10:04.000Z", "headline": "Is MicroAlgo Inc. (MLGO) the Popular Penny Stock on Robinhood to Watch?", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:16.558+00	5	completed	2025-09-03 18:48:16.560859+00
d0bd2cf0-3643-4476-8d9a-f62e067a885f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ADTX	2025-03-18	2025-03-18 11:23:00+00	2025-03-18 11:33:00+00	5.090000	5.130000	2300.0000	long	30.690000	0.000000	65.86	0.5627	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:59.602281+00	2025-09-03 18:47:59.60367+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:47:59.082Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f6393d9fd646e3f36925909a988d8d67f0d3e01e60de59dd8228b1e53d961241", "source": "Yahoo", "summary": "Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the", "datetime": "2025-03-18T11:22:00.000Z", "headline": "Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=42b92a2a1b2c83725d57a0eb037509bf9f934b21388806c4842833c110dd196e", "source": "Yahoo", "summary": "MOUNTAIN VIEW, Calif., March 17, 2025--Aditxt, Inc. (NASDAQ: ADTX) (\\"Aditxt\\" or the \\"Company\\"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2", "datetime": "2025-03-17T12:15:00.000Z", "headline": "Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:59.602+00	5	completed	2025-09-03 18:47:59.60367+00
1987808a-98ad-4c49-ba78-af231471c094	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ADTX	2025-03-18	2025-03-18 13:47:00+00	2025-03-18 13:47:00+00	6.650000	6.620000	300.0000	short	4.010000	0.000000	4.81	0.2411	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:59.899722+00	2025-09-03 18:47:59.901036+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:59.896Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=f6393d9fd646e3f36925909a988d8d67f0d3e01e60de59dd8228b1e53d961241", "source": "Yahoo", "summary": "Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the", "datetime": "2025-03-18T11:22:00.000Z", "headline": "Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=42b92a2a1b2c83725d57a0eb037509bf9f934b21388806c4842833c110dd196e", "source": "Yahoo", "summary": "MOUNTAIN VIEW, Calif., March 17, 2025--Aditxt, Inc. (NASDAQ: ADTX) (\\"Aditxt\\" or the \\"Company\\"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2", "datetime": "2025-03-17T12:15:00.000Z", "headline": "Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025", "sentiment": "positive"}]	t	positive	2025-09-03 18:47:59.899+00	5	completed	2025-09-03 18:47:59.901036+00
4720c7ae-6539-4e3f-a917-9436902f5c4b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	XHLD	2025-03-24	2025-03-24 11:07:00+00	2025-03-24 11:08:00+00	1.840000	1.890000	600.0000	long	7.940000	0.000000	22.84	2.0703	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:19.197903+00	2025-09-03 18:48:19.199534+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:18.662Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=81163ccb9c9e8bd97ffa62d104d576b0906e471134bad53b121e3105ba280adc", "source": "Yahoo", "summary": "TEN Holdings, Inc. (NASDAQ: XHLD) (\\"TEN Holdings\\" or the \\"Company\\"), a provider of event planning, production, and broadcasting services, today announced the Company's ability to add conversational artificial intelligence (\\"AI\\") solutions to its service offering through a new partnership announced by V-Cube Inc., its controlling shareholder.", "datetime": "2025-03-24T13:15:00.000Z", "headline": "TEN Holdings, Inc. to Add Conversational AI Solutions to Service Portfolio", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:19.197+00	5	completed	2025-09-03 18:48:19.199534+00
5f067d88-03a4-453a-97ea-82002cffed00	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 15:30:00+00	2025-04-07 15:31:00+00	39.360000	39.370000	100.0000	long	2.730000	0.000000	-1.73	-0.0440	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:06.566227+00	2025-09-03 18:49:06.567775+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:06.562Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:06.565+00	5	completed	2025-09-03 18:49:06.567775+00
d3f335eb-c006-4345-bce8-c2c656e2b849	2d96cef2-7502-44ff-a7a9-17713d4a7a42	XHLD	2025-03-24	2025-03-24 13:46:00+00	2025-03-24 13:56:00+00	2.320000	2.120000	1500.0000	long	19.840000	0.000000	-317.14	-9.1164	Round trip: 5 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:19.471869+00	2025-09-03 18:48:19.473286+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:48:19.467Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=81163ccb9c9e8bd97ffa62d104d576b0906e471134bad53b121e3105ba280adc", "source": "Yahoo", "summary": "TEN Holdings, Inc. (NASDAQ: XHLD) (\\"TEN Holdings\\" or the \\"Company\\"), a provider of event planning, production, and broadcasting services, today announced the Company's ability to add conversational artificial intelligence (\\"AI\\") solutions to its service offering through a new partnership announced by V-Cube Inc., its controlling shareholder.", "datetime": "2025-03-24T13:15:00.000Z", "headline": "TEN Holdings, Inc. to Add Conversational AI Solutions to Service Portfolio", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:19.471+00	5	completed	2025-09-03 18:48:19.473286+00
fa3349fb-2321-4a51-9b74-c4c9ad603a8a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 16:11:00+00	2025-04-07 16:11:00+00	39.140000	39.230000	100.0000	long	2.730000	0.000000	6.27	0.1602	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:07.231961+00	2025-09-03 18:49:07.234122+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:07.229Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:07.231+00	5	completed	2025-09-03 18:49:07.234122+00
62a5eb7e-c4b4-4bb4-b263-ff699fc35b78	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 10:52:00+00	2025-03-25 11:00:00+00	3.000000	3.310000	1600.0000	long	21.400000	0.000000	485.84	10.1386	Round trip: 5 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:22.474376+00	2025-09-03 18:48:22.475417+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 8, "analysisTimestamp": "2025-09-03T18:48:21.567Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:22.474+00	5	completed	2025-09-03 18:48:22.475417+00
3ef8d738-cd00-4c3d-b5db-c70730d1b425	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 11:22:00+00	2025-03-25 11:22:00+00	3.650000	3.700000	300.0000	long	4.000000	0.000000	11.00	1.0046	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:23.623153+00	2025-09-03 18:48:23.624193+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:23.620Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:23.622+00	5	completed	2025-09-03 18:48:23.624193+00
6d856ffb-e185-4262-8ae2-185e03117cb6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 11:29:00+00	2025-03-25 13:33:00+00	5.130000	5.210000	3100.0000	long	27.920000	0.000000	203.08	1.2762	Round trip: 6 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:25.192553+00	2025-09-03 18:48:25.194407+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 124, "analysisTimestamp": "2025-09-03T18:48:25.187Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:25.192+00	5	completed	2025-09-03 18:48:25.194407+00
81781831-4f29-4376-accb-5ab857006caf	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 16:12:00+00	2025-04-07 16:13:00+00	39.420000	39.540000	200.0000	long	4.450000	0.000000	20.55	0.2607	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:07.766411+00	2025-09-03 18:49:07.767841+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:07.749Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:07.766+00	5	completed	2025-09-03 18:49:07.767841+00
5ff3ee7e-baf5-4d11-a27c-dab6fb319a35	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 11:01:00+00	2025-03-25 11:11:00+00	3.600000	3.640000	3000.0000	long	41.770000	0.000000	91.23	0.8457	Round trip: 7 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:22.777831+00	2025-09-03 18:48:22.779036+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:48:22.775Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:22.777+00	5	completed	2025-09-03 18:48:22.779036+00
e54d2b71-d12e-46ac-b5f7-ce18b6ddd29f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 11:18:00+00	2025-03-25 11:19:00+00	3.540000	3.710000	300.0000	long	4.000000	0.000000	47.00	4.4256	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:22.98896+00	2025-09-03 18:48:22.990163+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:22.985Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:22.988+00	5	completed	2025-09-03 18:48:22.990163+00
3381ce66-f1cd-44a2-a027-722b502ea98b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 11:23:00+00	2025-03-25 11:25:00+00	3.950000	3.990000	900.0000	long	11.950000	0.000000	21.05	0.5916	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:24.151633+00	2025-09-03 18:48:24.153124+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:24.148Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:24.151+00	5	completed	2025-09-03 18:48:24.153124+00
f7552c7a-62c0-4c7c-952f-766793c55bf7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 11:28:00+00	2025-03-25 11:28:00+00	4.540000	4.900000	300.0000	long	4.010000	0.000000	103.99	7.6351	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:24.676978+00	2025-09-03 18:48:24.680529+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:24.672Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:24.676+00	5	completed	2025-09-03 18:48:24.680529+00
92858781-a01f-4854-8730-2d606385c553	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 19:18:00+00	2025-04-07 19:19:00+00	41.160000	41.230000	100.0000	long	2.740000	0.000000	4.26	0.1035	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:08.668476+00	2025-09-03 18:49:08.67023+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:08.665Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:08.668+00	5	completed	2025-09-03 18:49:08.67023+00
68b3b8ab-9f1d-45c1-abc0-bf8035555e63	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:23:00+00	2025-03-26 11:23:00+00	3.580000	3.250000	300.0000	short	4.930000	0.000000	92.57	8.6312	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:27.907848+00	2025-09-03 18:48:27.909076+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:27.903Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:27.907+00	5	completed	2025-09-03 18:48:27.909076+00
42ae21e5-2632-47f2-a457-bbdd84f50661	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:24:00+00	2025-03-26 11:25:00+00	3.960000	4.100000	900.0000	long	11.530000	0.000000	115.70	3.2475	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:28.192984+00	2025-09-03 18:48:28.194329+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:28.190Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:28.192+00	5	completed	2025-09-03 18:48:28.194329+00
8b100660-4480-4f09-8c5f-1703166588d6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TNON	2025-03-25	2025-03-25 14:00:00+00	2025-03-25 14:05:00+00	4.080000	4.110000	600.0000	long	7.970000	0.000000	10.51	0.4290	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:25.480284+00	2025-09-03 18:48:25.481426+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:48:25.477Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=ff8b28a0f0068f0f5dea48dccb9ea7c3f6382be04d798743577bb66b3d686911", "source": "Yahoo", "summary": "Tenon Medical (TNON) said Tuesday it agreed to sell $1.5 million worth of shares to a healthcare-foc", "datetime": "2025-03-25T17:38:01.000Z", "headline": "Top Midday Gainers", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=27dedce434240b8122c96af310f39cbd6d336aebcbbef98036b37f13ca8f3618", "source": "Yahoo", "summary": "LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered ...", "datetime": "2025-03-25T16:45:00.000Z", "headline": "Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddfb46b31b1192c79d8079e4e0d4d3b39ad74bec8730ecdbe969638de6cbd2b2", "source": "Yahoo", "summary": "~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) (\\"Tenon\\" or the \\"Company\\"), a company transforming care for ...", "datetime": "2025-03-24T20:05:00.000Z", "headline": "Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:25.48+00	5	completed	2025-09-03 18:48:25.481426+00
ff735cf4-7022-41f4-8b6d-630fb0ccef3e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 19:49:00+00	2025-04-07 19:54:00+00	40.680000	40.920000	200.0000	long	4.460000	0.000000	43.54	0.5352	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:08.986713+00	2025-09-03 18:49:08.987848+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:49:08.984Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:08.986+00	5	completed	2025-09-03 18:49:08.987848+00
3f84ae58-8e63-4a78-9727-db06233be38e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:46:00+00	2025-03-26 11:47:00+00	3.450000	3.510000	300.0000	long	3.980000	0.000000	14.02	1.3546	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:29.749878+00	2025-09-03 18:48:29.751042+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:29.747Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:29.749+00	5	completed	2025-09-03 18:48:29.751042+00
2dbd6b41-c903-493d-9590-44436552b52f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 12:32:00+00	2025-03-26 12:33:00+00	4.180000	4.250000	300.0000	long	3.990000	0.000000	17.01	1.3565	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:30.062766+00	2025-09-03 18:48:30.064167+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:30.059Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:30.062+00	5	completed	2025-09-03 18:48:30.064167+00
c40d4a7e-5944-4238-a47b-85a4d925ce1b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TQQQ	2025-04-07	2025-04-07 19:58:00+00	2025-04-07 19:58:00+00	41.190000	41.220000	100.0000	short	2.740000	0.000000	-5.74	-0.1394	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:09.265391+00	2025-09-03 18:49:09.266454+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:09.262Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:09.265+00	5	completed	2025-09-03 18:49:09.266454+00
1f978e2f-8857-40ff-af85-6923bf256db4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	LPTX	2025-03-26	2025-03-26 11:01:00+00	2025-03-26 11:04:00+00	0.450000	0.480000	300.0000	long	3.960000	0.000000	4.54	3.3630	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:26.103743+00	2025-09-03 18:48:26.105286+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:25.802Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d77a774ea29a7677409eab718e629ac5c4de250e2cc83799f23fd0dfca4a0ffd", "source": "Yahoo", "summary": "Leap Therapeutics, Inc. (NASDAQ:LPTX) presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm). The trial enrolled patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The updated analysis shared on Wednesday includes the overall r", "datetime": "2025-03-26T17:29:11.000Z", "headline": "Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=b7538ee6822a1a11f04f904db759e723e588f458830c99ee5645edbb282f0963", "source": "Yahoo", "summary": "Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that s", "datetime": "2025-03-26T12:31:51.000Z", "headline": "Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ec276ebf79d7c3a3a4daefc53fb2457cf836847965ff8b4d27008e9111b895f9", "source": "Yahoo", "summary": "Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.", "datetime": "2025-03-26T11:05:00.000Z", "headline": "Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=f7bcb5f2d3877d7a3a20e4e9fa7e6009a3523054c52668476272d74c18af64bc", "source": "Yahoo", "summary": "Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, global study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal", "datetime": "2025-03-26T11:00:00.000Z", "headline": "Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:26.103+00	5	completed	2025-09-03 18:48:26.105286+00
afd288c2-a475-4a20-9ba3-50dd485b76e6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:19:00+00	2025-03-26 11:21:00+00	2.480000	2.790000	900.0000	long	11.940000	0.000000	265.23	11.8733	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:26.999372+00	2025-09-03 18:48:27.000505+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:26.752Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:26.999+00	5	completed	2025-09-03 18:48:27.000505+00
68e49e64-dee6-443e-8c3f-6de1cb9b0fcb	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TIVC	2025-04-03	2025-04-03 11:46:00+00	2025-04-03 11:48:00+00	5.110000	5.000000	600.0000	long	7.990000	0.000000	-76.99	-2.5111	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:11.865615+00	2025-09-03 18:49:11.867281+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:49:11.863Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:11.865+00	5	completed	2025-09-03 18:49:11.867281+00
4f6d58b9-0d6f-4e9c-9a66-6f3865d84d5f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:21:00+00	2025-03-26 11:22:00+00	2.890000	3.050000	600.0000	long	7.960000	0.000000	82.04	4.7231	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:27.295935+00	2025-09-03 18:48:27.297118+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:27.292Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:27.295+00	5	completed	2025-09-03 18:48:27.297118+00
7dca1f5e-8ec9-489f-9bf0-a460a8f2c90d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TIVC	2025-04-03	2025-04-03 11:55:00+00	2025-04-03 11:55:00+00	5.150000	5.280000	600.0000	long	8.000000	0.000000	74.02	2.3978	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:12.118042+00	2025-09-03 18:49:12.119511+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:12.114Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:12.117+00	5	completed	2025-09-03 18:49:12.119511+00
5bb82821-e7af-479f-83ed-21fab5df4442	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:26:00+00	2025-03-26 11:26:00+00	3.930000	4.060000	300.0000	long	3.990000	0.000000	36.00	3.0534	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:28.516067+00	2025-09-03 18:48:28.517106+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:28.513Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:28.515+00	5	completed	2025-09-03 18:48:28.517106+00
458a8613-093e-4093-8c00-5821564d75ed	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:27:00+00	2025-03-26 11:29:00+00	3.750000	3.800000	600.0000	long	7.980000	0.000000	22.53	1.0009	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:28.767436+00	2025-09-03 18:48:28.76875+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:28.765Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:28.767+00	5	completed	2025-09-03 18:48:28.76875+00
ee94a294-f5c0-426f-b5a1-3693263cc4bc	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 11:30:00+00	2025-03-26 11:31:00+00	3.900000	4.090000	300.0000	long	4.000000	0.000000	53.00	4.5299	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:29.409382+00	2025-09-03 18:48:29.411427+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:29.404Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:29.409+00	5	completed	2025-09-03 18:48:29.411427+00
ff0b4bf3-137a-4707-a62a-85c9b4eff528	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 13:22:00+00	2025-03-26 13:22:00+00	4.250000	4.170000	300.0000	short	3.990000	0.000000	20.01	1.5694	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:30.31763+00	2025-09-03 18:48:30.31874+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:30.315Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:30.317+00	5	completed	2025-09-03 18:48:30.31874+00
3769c3e8-92c6-4f1b-95ed-21f5165bb21b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PENG	2025-04-02	2025-04-02 20:09:00+00	2025-04-02 20:19:00+00	19.910000	19.510000	100.0000	short	2.230000	0.000000	37.77	1.8970	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:10.260156+00	2025-09-03 18:49:10.261446+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 10, "analysisTimestamp": "2025-09-03T18:49:09.965Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=aa8903c4b74963f72b6e8b94fe332e881d0b1638f26ed519179f5beac5c0a86b", "source": "Yahoo", "summary": "MILPITAS, Calif., April 02, 2025--Penguin Solutions today reported financial results for Q2 fiscal 2025 and the planned retirement of COO & President of Integrated Memory Jack Pacheco.", "datetime": "2025-04-02T20:05:00.000Z", "headline": "Penguin Solutions Reports Q2 Fiscal 2025 Financial Results", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=98838a64d97d7d4825e0bb00c87da92c7b0dcaf460e63d1b7ce81611a943f289", "source": "SeekingAlpha", "summary": "Penguin Solutions, Inc. (NASDAQ:PENG) Q2 2025 Earnings Conference Call April 2, 2025 4:30 PM ETCompany ParticipantsSuzanne Schmidt - Investor RelationsMark...", "datetime": "2025-04-02T19:28:34.000Z", "headline": "Penguin Solutions, Inc. (PENG) Q2 2025 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ed08ec8f97f2da5b2b6fbd96b371628677de5a9ef335fdc9232d1d5aa6f5e7a8", "source": "SeekingAlpha", "summary": "The following slide deck was published by Penguin Solutions, Inc.", "datetime": "2025-04-02T16:28:56.000Z", "headline": "Penguin Solutions, Inc. 2025 Q2 - Results - Earnings Call Presentation", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:10.259+00	5	completed	2025-09-03 18:49:10.261446+00
71d57a00-d1c1-47ea-8a88-1206e84e169c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 13:30:00+00	2025-03-26 13:31:00+00	4.040000	4.070000	600.0000	long	7.970000	0.000000	7.93	0.3269	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:30.523786+00	2025-09-03 18:48:30.524983+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:30.520Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:30.523+00	5	completed	2025-09-03 18:48:30.524983+00
e62c8aa4-1ad0-41a1-af3a-119919eeffc6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TIVC	2025-04-03	2025-04-03 10:31:00+00	2025-04-03 10:32:00+00	4.530000	4.480000	300.0000	long	4.000000	0.000000	-20.41	-1.5002	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:11.197894+00	2025-09-03 18:49:11.199208+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:10.928Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:11.197+00	5	completed	2025-09-03 18:49:11.199208+00
928ece38-8645-4e62-9e44-35ddca92c249	2d96cef2-7502-44ff-a7a9-17713d4a7a42	USAR	2025-04-04	2025-04-04 13:32:00+00	2025-04-04 13:40:00+00	9.500000	9.900000	1500.0000	long	13.980000	0.000000	588.17	4.1268	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:14.812485+00	2025-09-03 18:49:14.816546+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 8, "analysisTimestamp": "2025-09-03T18:49:14.159Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:14.811+00	5	completed	2025-09-03 18:49:14.816546+00
03ea71e1-32cc-4194-953f-f70c51ca2a1c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-03-26	2025-03-26 13:35:00+00	2025-03-26 13:37:00+00	3.670000	3.600000	300.0000	long	3.990000	0.000000	-23.94	-2.1765	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:30.72277+00	2025-09-03 18:48:30.724061+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:30.720Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=72ba58743bf1415f0e06fb02d6a4809421e23c13446d9ee3e7af2ae948bd29f6", "source": "Yahoo", "summary": "Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.", "datetime": "2025-03-26T11:16:00.000Z", "headline": "Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=cf870bf536947e41d323033e5291274367a8e91ca8bc26c4941ff00e5495e379", "source": "Yahoo", "summary": "OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.", "datetime": "2025-03-25T11:00:00.000Z", "headline": "OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:30.722+00	5	completed	2025-09-03 18:48:30.724061+00
d1dd9d94-14f5-46a7-9556-57f9db0c39d5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-04-03	2025-04-03 12:22:00+00	2025-04-03 12:23:00+00	2.240000	2.250000	600.0000	long	7.940000	0.000000	-1.94	-0.1443	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:33.611838+00	2025-09-03 18:48:33.613015+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:33.609Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:33.611+00	5	completed	2025-09-03 18:48:33.613015+00
cab9d6dd-2ba3-4f2a-8967-a1dd03b28e81	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ALDX	2025-04-03	2025-04-03 12:30:00+00	2025-04-03 15:02:00+00	1.370000	1.480000	5000.0000	long	70.590000	0.000000	485.61	7.0904	Round trip: 9 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:49:13.041246+00	2025-09-03 18:49:13.042313+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 152, "analysisTimestamp": "2025-09-03T18:49:12.771Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e752008d38f5074628f34260cf8ef0378f9cccf813c43b2bd268208a43c25d2f", "source": "Yahoo", "summary": "Shares of Aldeyra Therapeutics plummeted nearly 75% Thursday morning after the Food and Drug Administration said the company's dry eye disease drug has not proven to be effective in enough studies.", "datetime": "2025-04-03T14:24:53.000Z", "headline": "Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddac3ec28edf1a9120e6c9e61a99416560ab779431870f20e5baf28e22ba2211", "source": "Finnhub", "summary": "Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. for potential violations of the federal securities laws.If you invested in Aldeyra...", "datetime": "2025-04-03T12:35:03.000Z", "headline": "ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d96a5cf9603791058105a7dd42537339269a298f2066f23d2e9cce8d817ad3f7", "source": "Yahoo", "summary": "LEXINGTON, Mass., April 03, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing", "datetime": "2025-04-03T12:00:00.000Z", "headline": "Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:13.041+00	5	completed	2025-09-03 18:49:13.042313+00
bb43f686-6cd2-4a57-9f0d-445499ff5f8d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-04-03	2025-04-03 11:43:00+00	2025-04-03 11:44:00+00	2.300000	2.390000	900.0000	long	11.910000	0.000000	69.09	3.3377	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:33.104069+00	2025-09-03 18:48:33.105616+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:33.094Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:33.103+00	5	completed	2025-09-03 18:48:33.105616+00
c993702b-013c-4e59-89f7-3ec809dc3c64	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-04-03	2025-04-03 12:28:00+00	2025-04-03 12:29:00+00	2.460000	2.450000	300.0000	long	3.980000	0.000000	-6.98	-0.9458	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:33.616052+00	2025-09-03 18:48:33.617972+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:33.613Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:33.615+00	5	completed	2025-09-03 18:48:33.617972+00
c2ed2a4c-bf32-40fc-94d7-d1211bab990c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	WKSP	2025-03-27	2025-03-27 11:48:00+00	2025-03-27 11:51:00+00	4.200000	4.240000	600.0000	long	5.290000	0.000000	19.58	0.7773	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:35.089893+00	2025-09-03 18:48:35.090834+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:34.416Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=947ad62ab78197dae2ad761ed74cc9ef482fc529b0bb33bd60ac9094ffb88725", "source": "SeekingAlpha", "summary": "Worksport Ltd. (NASDAQ:WKSP) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ETCompany ParticipantsSteven Rossi - CEOMichael Johnston - CFOFaran Ali...", "datetime": "2025-03-27T22:03:42.000Z", "headline": "Worksport Ltd. (WKSP) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ec70e42aa4b83dfa2b3a5762cf25d356a87b465b326401dddef7171eea3f9fae", "source": "Yahoo", "summary": "Company Outlines Strong Momentum in Margins, Revenue, and Business Growth Entering 2025 West Seneca, New York--(Newsfile Corp. - March 27, 2025) - Worksport Ltd. (NASDAQ: WKSP) (\\"Worksport\\" or the \\"Company\\"), a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, today announced financial results and significant operational achievements for fiscal year 2024. Marking a transformational year with record reve", "datetime": "2025-03-27T11:46:00.000Z", "headline": "Worksport Ltd. Reports Fiscal Year 2024 Results, Achieves 455% Year-Over-Year Revenue Growth", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:35.089+00	5	completed	2025-09-03 18:48:35.090834+00
ba0efabf-e22a-4cdc-aaa9-da9c42f7f635	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DRMA	2025-03-27	2025-03-27 12:30:00+00	2025-03-27 12:36:00+00	2.280000	2.280000	2100.0000	long	28.270000	0.000000	-23.56	-0.4931	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:35.995673+00	2025-09-03 18:48:35.998175+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:48:35.335Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc12715f203cb808edbfb01a7515a88d4a93255326160a73a983fe696729ca80", "source": "Yahoo", "summary": "Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) (\\"Dermata\\" or the \\"Company\\"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events", "datetime": "2025-03-27T12:00:00.000Z", "headline": "BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:35.995+00	5	completed	2025-09-03 18:48:35.998175+00
eb58f21d-dd3f-4c28-b57d-a3be3d73ea3d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MYSZ	2025-03-28	2025-03-28 20:29:00+00	2025-03-28 20:31:00+00	2.030000	2.080000	300.0000	long	3.970000	0.000000	11.03	1.8112	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.54397+00	2025-09-03 18:48:40.545034+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:40.540Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cd09eca8bb5a63801e46e9020b783614a52c11d6f9496f375c8b74b129f56a6f", "source": "Yahoo", "summary": "MySize, Inc. (NASDAQ: MYSZ) (TASE: MYSZ.TA) (\\"MySize\\" or the \\"Company\\"), an omnichannel e-commerce platform and provider of AI-driven sizing solutions for the retail industry, today reported financial and operational results for the twelve months ended December 31, 2024.", "datetime": "2025-03-28T12:30:00.000Z", "headline": "MySize Reports 2024 Full-Year Financial Results: Revenue Grows 18% to $8.26 Million and Cash Reserves More Than Double", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:40.543+00	5	completed	2025-09-03 18:48:40.545034+00
353b46bd-3c8f-4dc2-b5cb-e6db63a40dbf	2d96cef2-7502-44ff-a7a9-17713d4a7a42	OSRH	2025-04-03	2025-04-03 15:04:00+00	2025-04-03 15:06:00+00	2.600000	2.540000	300.0000	long	3.980000	0.000000	-21.59	-2.7693	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:33.622375+00	2025-09-03 18:48:33.625242+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:33.618Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=02a28c71d19729974b229cd1dbc1f5c89f0bde6fb9f914ccc37adb1100c742e2", "source": "Yahoo", "summary": "OSR Holdings, Inc. (\\"OSR\\") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund (\\"Innovation Fund\\"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes wo", "datetime": "2025-04-03T11:30:00.000Z", "headline": "OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:33.622+00	5	completed	2025-09-03 18:48:33.625242+00
e0d9feff-35eb-4300-ba28-45e98a9b6b7d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ALDX	2025-04-03	2025-04-03 15:48:00+00	2025-04-03 15:57:00+00	1.620000	1.720000	2000.0000	long	26.430000	0.000000	175.37	5.4127	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:49:13.700849+00	2025-09-03 18:49:13.70377+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 9, "analysisTimestamp": "2025-09-03T18:49:13.694Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e752008d38f5074628f34260cf8ef0378f9cccf813c43b2bd268208a43c25d2f", "source": "Yahoo", "summary": "Shares of Aldeyra Therapeutics plummeted nearly 75% Thursday morning after the Food and Drug Administration said the company's dry eye disease drug has not proven to be effective in enough studies.", "datetime": "2025-04-03T14:24:53.000Z", "headline": "Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddac3ec28edf1a9120e6c9e61a99416560ab779431870f20e5baf28e22ba2211", "source": "Finnhub", "summary": "Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. for potential violations of the federal securities laws.If you invested in Aldeyra...", "datetime": "2025-04-03T12:35:03.000Z", "headline": "ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d96a5cf9603791058105a7dd42537339269a298f2066f23d2e9cce8d817ad3f7", "source": "Yahoo", "summary": "LEXINGTON, Mass., April 03, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing", "datetime": "2025-04-03T12:00:00.000Z", "headline": "Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:13.7+00	5	completed	2025-09-03 18:49:13.70377+00
dd47c96b-8995-4071-b871-ae804b0fae21	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PROP	2025-03-26	2025-03-26 17:20:00+00	2025-03-26 17:24:00+00	5.710000	5.520000	300.0000	long	2.650000	0.000000	-59.59	-3.4788	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:34.221065+00	2025-09-03 18:48:34.222584+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:33.929Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=a4a0591f541a0221be8b0572b44794b39b69664ef8e5d53eba312f7c3c59c8ae", "source": "Yahoo", "summary": "Pro-Forma Reserve Data Pro-Forma Reserve Data Reconciliation of Non-GAAP Measure Reconciliation of Non-GAAP Measure Expands footprint in DJ Basin to ~55,000 net acres and inventory life to ~10 years Increases average daily production by ~25,700 net BOEPD Immediately accretive and maintains strong balance sheet Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company,” “Prairie,” “we,” “our” or “us”), today announced the successful closing of its previous", "datetime": "2025-03-26T22:45:00.000Z", "headline": "Prairie Operating Co. Completes Transformative Acquisition from Bayswater", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=83ba72412d03dcc5995e1bd6e0a5192bdb6c6e362927bc1eb9b90d7affe4052c", "source": "Yahoo", "summary": "HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Prairie Operating Co. (“Prairie,” the “Company,” “we,” or “our”) (Nasdaq: PROP) announced today the pricing of an underwritten public offering of $38.5 million (the “Common Stock Offering”) of shares of its common stock, par value $0.01 (“Common Stock”) at a price to the public of $4.50 per share. The underwriters have a 30-day option to purchase up to an aggregate value of $5.8 million of additional shares of Common Stock. Net proceeds to Prairie from", "datetime": "2025-03-25T02:35:00.000Z", "headline": "Prairie Operating Co. Announces Pricing of Common Stock Offering", "sentiment": "neutral"}]	t	positive	2025-09-03 18:48:34.22+00	5	completed	2025-09-03 18:48:34.222584+00
3f6cb6dd-c954-4854-8dae-5bf9c2f20f33	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DRMA	2025-03-27	2025-03-27 12:37:00+00	2025-03-27 12:37:00+00	1.980000	1.930000	300.0000	short	3.970000	0.000000	11.03	1.8569	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:36.006594+00	2025-09-03 18:48:36.009019+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:36.000Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc12715f203cb808edbfb01a7515a88d4a93255326160a73a983fe696729ca80", "source": "Yahoo", "summary": "Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) (\\"Dermata\\" or the \\"Company\\"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events", "datetime": "2025-03-27T12:00:00.000Z", "headline": "BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:36.006+00	5	completed	2025-09-03 18:48:36.009019+00
09bd04f2-bcc6-47cf-a9e1-500284bc9e1a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DRMA	2025-03-27	2025-03-27 12:43:00+00	2025-03-27 12:44:00+00	2.170000	2.070000	300.0000	long	3.970000	0.000000	-33.97	-5.2181	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:36.028051+00	2025-09-03 18:48:36.030493+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:36.021Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc12715f203cb808edbfb01a7515a88d4a93255326160a73a983fe696729ca80", "source": "Yahoo", "summary": "Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) (\\"Dermata\\" or the \\"Company\\"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events", "datetime": "2025-03-27T12:00:00.000Z", "headline": "BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:36.027+00	5	completed	2025-09-03 18:48:36.030493+00
a0f1a3e3-4515-426c-83e5-727426fcf348	2d96cef2-7502-44ff-a7a9-17713d4a7a42	G0447T100	2025-03-27	2025-03-27 20:06:00+00	2025-03-27 20:10:00+00	0.970000	0.990000	600.0000	long	7.840000	0.000000	2.03	0.3470	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:36.383585+00	2025-09-03 18:50:01.281022+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:36.381Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:36.383+00	5	completed	2025-09-03 18:50:01.281022+00
ebbe6d1c-d248-4b08-beb8-e8f1792a7024	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DRMA	2025-03-27	2025-03-27 13:08:00+00	2025-03-27 13:09:00+00	2.190000	2.230000	300.0000	long	3.970000	0.000000	8.03	1.2222	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:36.056932+00	2025-09-03 18:48:36.06314+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:36.032Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc12715f203cb808edbfb01a7515a88d4a93255326160a73a983fe696729ca80", "source": "Yahoo", "summary": "Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) (\\"Dermata\\" or the \\"Company\\"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events", "datetime": "2025-03-27T12:00:00.000Z", "headline": "BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:36.056+00	5	completed	2025-09-03 18:48:36.06314+00
a3080211-b8ca-432b-b776-d65e0c83fc7b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 10:57:00+00	2025-03-28 10:59:00+00	11.720000	11.910000	600.0000	long	6.330000	0.000000	110.25	1.5683	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:37.393435+00	2025-09-03 18:48:37.394561+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:37.391Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:37.393+00	5	completed	2025-09-03 18:48:37.394561+00
3724f756-08a8-4fd9-8713-b66c7b99e3f9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 11:14:00+00	2025-03-28 11:19:00+00	12.650000	12.850000	900.0000	long	8.140000	0.000000	170.66	1.4988	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:37.606332+00	2025-09-03 18:48:37.607219+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:48:37.604Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:37.606+00	5	completed	2025-09-03 18:48:37.607219+00
c476ea71-35fa-4264-b958-8dd116fc2978	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 11:37:00+00	2025-03-28 11:37:00+00	12.110000	11.950000	300.0000	short	4.060000	0.000000	43.01	1.1839	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:38.554519+00	2025-09-03 18:48:38.555995+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:38.551Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:38.554+00	5	completed	2025-09-03 18:48:38.555995+00
3ff6888d-fc3c-49ee-8a72-9e7747092c02	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 10:45:00+00	2025-03-28 10:49:00+00	10.200000	10.310000	300.0000	long	4.060000	0.000000	31.04	1.0148	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:37.130409+00	2025-09-03 18:48:37.131628+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:37.127Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:37.13+00	5	completed	2025-09-03 18:48:37.131628+00
76c8e4f6-4681-4011-a5e0-e655022a9b29	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 11:41:00+00	2025-03-28 11:44:00+00	12.290000	12.030000	600.0000	long	5.410000	0.000000	-160.87	-2.1817	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:38.861082+00	2025-09-03 18:48:38.862577+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:38.857Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:38.86+00	5	completed	2025-09-03 18:48:38.862577+00
87d2444f-2b39-4bd8-9e18-866d4edf98a9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MYSZ	2025-03-28	2025-03-28 15:23:00+00	2025-03-28 15:23:00+00	1.640000	1.640000	300.0000	long	3.970000	0.000000	-3.73	-0.7582	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.529267+00	2025-09-03 18:48:40.530571+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:40.527Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=cd09eca8bb5a63801e46e9020b783614a52c11d6f9496f375c8b74b129f56a6f", "source": "Yahoo", "summary": "MySize, Inc. (NASDAQ: MYSZ) (TASE: MYSZ.TA) (\\"MySize\\" or the \\"Company\\"), an omnichannel e-commerce platform and provider of AI-driven sizing solutions for the retail industry, today reported financial and operational results for the twelve months ended December 31, 2024.", "datetime": "2025-03-28T12:30:00.000Z", "headline": "MySize Reports 2024 Full-Year Financial Results: Revenue Grows 18% to $8.26 Million and Cash Reserves More Than Double", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:40.529+00	5	completed	2025-09-03 18:48:40.530571+00
df78b0d6-c343-439e-ad78-c2fd25db6cf1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CTOR	2025-03-31	2025-03-31 10:59:00+00	2025-03-31 11:00:00+00	1.280000	1.240000	300.0000	long	3.970000	0.000000	-15.97	-4.1589	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.80104+00	2025-09-03 18:48:40.802739+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:40.546Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:40.8+00	5	completed	2025-09-03 18:48:40.802739+00
02d73ba3-e784-4be7-9fc3-a2c6da522f51	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NWTG	2025-03-31	2025-03-31 11:21:00+00	2025-03-31 11:22:00+00	2.110000	2.120000	300.0000	long	3.970000	0.000000	-0.97	-0.1532	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:41.129927+00	2025-09-03 18:48:41.131221+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:40.805Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=79163191a40436280aca77950677bea6b2a0f28f8a0dfb8b3b4dff1a61df9316", "source": "Yahoo", "summary": "CAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (Nasdaq: NWTG), a developer of performance-focused golf equipment, today announced it will host an earnings call to discuss its fourth quarter and full-year 2024 financial results on Monday, March 31, 2025 at 4:30PM ET. Earnings Call Details• Date: March 31, 2025• Time: 4:30 PM ET• Participant Listening Options: Participant Listening: 1-877-407-0779 or 1 201-389-0914Callme™: https://callme.viavid.com/viavid/?call", "datetime": "2025-03-31T18:05:00.000Z", "headline": "Newton Golf Company to Host Fourth Quarter and Full-Year 2024 Earnings Call on March 31, 2025", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bb0deecca1f87093052f92898e9bab0c709e3193bba3ef9b8057b3f5f127a631", "source": "Yahoo", "summary": "Report includes tenfold revenue growth and significant gross margin expansionCAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (Nasdaq: NWTG) (“Newton Golf” or the “Company”), a leader in premium golf equipment innovation, today announces financial results for the fourth quarter and full year ended Dec. 31, 2024. The Company delivered record revenue growth, strong margin expansion, and continued operational momentum, supported by strategic product launches, inte", "datetime": "2025-03-31T11:00:00.000Z", "headline": "Newton Golf Company Announces Fourth Quarter and Full Year 2024 Financial Results", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:41.129+00	5	completed	2025-09-03 18:48:41.131221+00
cf488d3e-5ddf-436b-8824-d6c24a39ee0e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ICCT	2025-04-03	2025-04-03 15:29:00+00	2025-04-03 15:31:00+00	4.710000	4.380000	900.0000	long	11.960000	0.000000	-307.58	-7.2583	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:43.753324+00	2025-09-03 18:48:43.75446+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:43.750Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:43.753+00	5	completed	2025-09-03 18:48:43.75446+00
64c27085-dba9-4e56-b708-c876a172130b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ICCT	2025-04-03	2025-04-03 15:34:00+00	2025-04-03 15:34:00+00	4.760000	4.850000	900.0000	long	11.980000	0.000000	69.92	1.6325	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:44.199307+00	2025-09-03 18:48:44.20161+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:44.193Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:44.198+00	5	completed	2025-09-03 18:48:44.20161+00
505d5227-f994-4646-9009-01fde18f317e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ICCT	2025-04-07	2025-04-07 13:31:00+00	2025-04-07 13:31:00+00	7.970000	7.950000	500.0000	short	6.710000	0.000000	4.29	0.1076	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:46.17756+00	2025-09-03 18:48:46.179095+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:45.337Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:46.177+00	5	completed	2025-09-03 18:48:46.179095+00
7c777208-253d-4da7-9e54-81e7d0f4523b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CMPX	2025-04-01	2025-04-01 11:02:00+00	2025-04-01 11:02:00+00	2.110000	2.350000	300.0000	long	2.620000	0.000000	70.46	11.1501	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:47.292089+00	2025-09-03 18:48:47.294169+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:46.465Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=fc2fac104b7e4481c2d20564b8202667db3df00699d7f313d5b431796600a096", "source": "Yahoo", "summary": "Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.The", "datetime": "2025-04-01T11:00:00.000Z", "headline": "Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=59e0fdd339dd4de1204aca64d1054bb349887484f8d25fec6fdde5ba876d4fcb", "source": "Yahoo", "summary": "Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecifi", "datetime": "2025-03-31T20:05:00.000Z", "headline": "Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:47.291+00	5	completed	2025-09-03 18:48:47.294169+00
c0a4ba2d-3dce-4b52-a215-02f2838b4fd6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	NMAX	2025-04-01	2025-04-01 14:58:00+00	2025-04-01 15:01:00+00	142.870000	147.450000	50.0000	long	3.240000	0.000000	225.76	3.1604	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:49.350208+00	2025-09-03 18:48:49.351521+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:49.061Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=024740b04506c7e924c4ab06d1de663f0638da4feb9508ff8039ac1cb0680b1c", "source": "Yahoo", "summary": "Newsmax's (NMAX) stock skyrocketed an incredible 735% following its initial public offering (IPO), with founder Christopher Ruddy's stake now worth $8.4 billion. Market Domination Overtime host Josh Lipton and Barron associate editor Al Root highlight the wealth generated by this spike while noting that analysts advise against chasing these volatile moves. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.", "datetime": "2025-04-01T20:42:27.000Z", "headline": "Newsmax stock continues to skyrocket after IPO", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=9e5b391fd534e001329a62e6f0ef7c14278c2a454d034b4482029994ffd3722b", "source": "SeekingAlpha", "summary": "Newsmax stock soared 1,236%, but overvaluation, net losses, and litigation risks make it a high-risk investment.", "datetime": "2025-04-01T16:57:37.000Z", "headline": "Newsmax Is Significantly Overvalued And Deserves To Plummet", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=26ea3998f243c700240dbc79735342d3ead9c5f4a9e38b384221c16254256bd0", "source": "Yahoo", "summary": "On today's Market Minute, Julie Hyman takes a closer look at the trending stories on Wall Street, including NewsMax (NMAX) extending its post–initial public offering (IPO) gains, Jefferies downgrading airline stocks Delta (DAL), American Airlines (AAL), and Southwest (LUV), and rising sales for General Motors (GM). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.", "datetime": "2025-04-01T16:17:20.000Z", "headline": "NewsMax surges, airlines downgraded, GM sales rise: Market Minute", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=158a77000c60c960b030c606011cc14c571e725a8d8c18a09541a68494f36ee8", "source": "SeekingAlpha", "summary": "Despite strong revenue growth and no debt, Newsmax's cash burn and operating losses pose some short-term financial risks. Read more about NMAX stock here.", "datetime": "2025-04-01T16:06:17.000Z", "headline": "Newsmax: Sell The IPO Craze", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=00614d7e5747898fac217a4b0ab86a8d90f0d186ca972a98f35a649d2cb01b13", "source": "Yahoo", "summary": "Trading was halted multiple times due to volatility, with 6.17 million shares exchanged.", "datetime": "2025-04-01T15:54:34.000Z", "headline": "Newsmax Shares Surge More Than 700% in Volatile Market Debut", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=680cd3d0dc3a2375f78c3c079d4b503fd932dc1848b9713fc2572a55beb4bda6", "source": "SeekingAlpha", "summary": "Newsmax Inc.'s 17x surge defies fundamentals and faces profitability challenges. Here's why experts urge caution on highly speculative NMAX stock.", "datetime": "2025-04-01T15:30:45.000Z", "headline": "Newsmax: Beware A 'Meme' Stock Dislocated From Fundamentals", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=b9f3ae81a0ad2400755dbe576ae553a58036ce0d8da85e9539e3424e3bebf51f", "source": "Yahoo", "summary": "Newsmax stock (NMAX) soared as high as 173% Tuesday, extending its massive 735% gain on Monday following the conservative cable news outlet’s IPO.", "datetime": "2025-04-01T14:07:53.000Z", "headline": "Newsmax stock soars, pushing market cap north of $20 billion after shocking IPO success", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a94b0d0c89e39ba1bcc4dc5830614136c6cc8bcf7cedd2d777f8d4c11d0a4176", "source": "Yahoo", "summary": "The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.", "datetime": "2025-04-01T12:55:00.000Z", "headline": "NYSE Content advisory: Pre-Market Update + Newsmax Shares Pop 735% in NYSE Debut", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=e92a43e26322a7ec3b975f09eea1c32513789248ddc55a3769aa5ea3ff54aff8", "source": "SeekingAlpha", "summary": "Goldman Sachs has cut its S&P 500 target for the second time this month as its economists raised their projection of a U.S. recession to 35%.", "datetime": "2025-03-31T15:06:00.000Z", "headline": "Wall Street Lunch: Goldman Gets Gun-Shy", "sentiment": "neutral"}]	t	positive	2025-09-03 18:48:49.349+00	5	completed	2025-09-03 18:48:49.351521+00
893f9e38-5a18-4c96-a6a8-63b11c177704	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 11:22:00+00	2025-03-28 11:24:00+00	12.760000	12.430000	300.0000	long	4.060000	0.000000	-104.26	-2.7236	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:37.893593+00	2025-09-03 18:48:37.894729+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:37.891Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:37.893+00	5	completed	2025-09-03 18:48:37.894729+00
97a8667a-2240-4f1e-86a9-18cd5038096d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 12:29:00+00	2025-03-28 12:43:00+00	12.010000	12.110000	700.0000	long	9.450000	0.000000	64.12	0.7630	Round trip: 6 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:39.531062+00	2025-09-03 18:48:39.532858+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 14, "analysisTimestamp": "2025-09-03T18:48:39.525Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:39.53+00	5	completed	2025-09-03 18:48:39.532858+00
4764ad8d-dde2-4642-8d3c-3fa837a5bacf	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ALDX	2025-04-03	2025-04-03 15:59:00+00	2025-04-03 16:33:00+00	1.750000	1.570000	3500.0000	long	43.040000	0.000000	-687.54	-11.1986	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:49:13.942102+00	2025-09-03 18:49:13.943445+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 34, "analysisTimestamp": "2025-09-03T18:49:13.939Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=e752008d38f5074628f34260cf8ef0378f9cccf813c43b2bd268208a43c25d2f", "source": "Yahoo", "summary": "Shares of Aldeyra Therapeutics plummeted nearly 75% Thursday morning after the Food and Drug Administration said the company's dry eye disease drug has not proven to be effective in enough studies.", "datetime": "2025-04-03T14:24:53.000Z", "headline": "Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=ddac3ec28edf1a9120e6c9e61a99416560ab779431870f20e5baf28e22ba2211", "source": "Finnhub", "summary": "Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. for potential violations of the federal securities laws.If you invested in Aldeyra...", "datetime": "2025-04-03T12:35:03.000Z", "headline": "ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d96a5cf9603791058105a7dd42537339269a298f2066f23d2e9cce8d817ad3f7", "source": "Yahoo", "summary": "LEXINGTON, Mass., April 03, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing", "datetime": "2025-04-03T12:00:00.000Z", "headline": "Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:13.941+00	5	completed	2025-09-03 18:49:13.943445+00
3cf8fff2-8750-4d57-80dc-86421bc9387c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 12:47:00+00	2025-03-28 12:47:00+00	12.720000	12.720000	300.0000	long	4.060000	0.000000	-3.64	-0.0954	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:39.84633+00	2025-09-03 18:48:39.847336+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:39.842Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:39.845+00	5	completed	2025-09-03 18:48:39.847336+00
2c8f0724-3812-430d-ab0e-738690928c44	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 13:33:00+00	2025-03-28 13:33:00+00	12.780000	12.980000	300.0000	long	2.700000	0.000000	57.33	1.4953	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.106593+00	2025-09-03 18:48:40.107856+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:40.104Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:40.106+00	5	completed	2025-09-03 18:48:40.107856+00
1656ca06-e611-4dad-be42-ca2c1dd2f148	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BJDX	2025-04-07	2025-04-07 11:00:00+00	2025-04-07 11:00:00+00	7.790000	7.940000	300.0000	long	3.580000	0.000000	41.42	1.7724	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:15.079015+00	2025-09-03 18:49:15.080246+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:15.076Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b1667048767b94a30ddcd18336eac7bebf8bddba5a011061cad95c2ab2738b4e", "source": "Yahoo", "summary": "ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exe", "datetime": "2025-04-07T21:21:00.000Z", "headline": "Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:15.078+00	5	completed	2025-09-03 18:49:15.080246+00
4f6ef56d-cb65-4a1f-b6d5-e2698e0f478d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BJDX	2025-04-07	2025-04-07 11:19:00+00	2025-04-07 11:26:00+00	9.800000	9.380000	1000.0000	long	14.120000	0.000000	-431.78	-4.4065	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:16.287251+00	2025-09-03 18:49:16.289976+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:49:16.282Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b1667048767b94a30ddcd18336eac7bebf8bddba5a011061cad95c2ab2738b4e", "source": "Yahoo", "summary": "ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exe", "datetime": "2025-04-07T21:21:00.000Z", "headline": "Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:16.286+00	5	completed	2025-09-03 18:49:16.289976+00
cf02fe9b-5e4b-4237-9bb1-57a8a1d6c85d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	MESA	2025-04-07	2025-04-07 12:04:00+00	2025-04-07 12:10:00+00	0.910000	0.950000	3500.0000	long	44.580000	0.000000	90.97	2.8522	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:18.119066+00	2025-09-03 18:49:18.121979+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 6, "analysisTimestamp": "2025-09-03T18:49:17.467Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=35c58f6a5c3a08a455dc7abd226974504f569d00abd8fcb4f511c44d34439c59", "source": "Yahoo", "summary": "Mesa Air and Republic Airways are joining forces, wiping debt and betting big on a unified regional flight empire.", "datetime": "2025-04-07T19:47:50.000Z", "headline": "Two Struggling Airlines Just Merged to Create a $1.9B Powerhouse--Here's What Investors Need to Know", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=8bb6487d6bf03a55e0d8fb4f32f3cd42d9ea3d4a032195a4746832ccf2a5bd5d", "source": "SeekingAlpha", "summary": "", "datetime": "2025-04-07T15:55:40.000Z", "headline": "Mesa Air Group Merger With Republic Airways Was The Only Outcome", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=5f8e3182bf4e83599026c2e19771c337cb6773b0aed372b78085d14ec3b7914a", "source": "Yahoo", "summary": "Mesa Air's (MESA) shares jumped intraday Monday after the Mesa Airlines parent agreed to merge with", "datetime": "2025-04-07T15:25:59.000Z", "headline": "Mesa Air Strikes All-Stock Deal to Merge With Republic Airways", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=58d4ca3b66826c9671087c1d0384474cdb59d253f4be4e1d863dc48e42125693", "source": "Yahoo", "summary": "Republic Airways and Mesa Air Group have agreed to merge and create a publicly-traded regional airline in an all-stock transaction.", "datetime": "2025-04-07T14:47:00.000Z", "headline": "Republic Airways, Mesa Air to Merge", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=6a794a09200435a3fbecab6b886e0e065423da59338a30e831b171e9e6e131d2", "source": "Yahoo", "summary": "Mesa Air Group shares soared Monday morning on news the carrier had agreed to merge with fellow regional carrier Republic Airways in an all-stock transaction.", "datetime": "2025-04-07T13:57:46.000Z", "headline": "Mesa Air Group Stock Soars as Regional Carrier Agrees To Merge With Republic Airways", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=356fb07541e46ca851278e09fa24a3ba278af95b5055c42cd0ac3b4af4024aa2", "source": "Yahoo", "summary": "Republic Airways and Mesa Air Group Inc. are combining in an all-stock deal that will create a regional airline with access to more planes to service routes.  Specific financial terms of the deal weren't disclosed in a statement Monday.  Republic, started in 1974, has a fleet of more than 240 Embraer 170/175 aircraft and carried about 17.5 million passengers on more than 300,000 flights last year.", "datetime": "2025-04-07T12:50:46.000Z", "headline": "Regional airlines Republic Airways, Mesa Air Group are combining in an all-stock deal", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=3a094a801a6787ea4f186d2776bfe8d0ec85becac3532015b7b8d7409ec4e9e2", "source": "SeekingAlpha", "summary": "Our top story so far, the stock market has gone from edgy to jumpy to as nervous as a long-tailed cat in a room full of rocking chairs â if youâll forgive the technical terms.", "datetime": "2025-04-07T12:33:00.000Z", "headline": "Wall Street Lunch: Volatility Rules The Day", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=bd315f12419830d1217fc689ccee1f89a2e0f332fe39c05e7defb35a4027c81d", "source": "Yahoo", "summary": "The combined company, which would operate as Republic Airways Holdings Inc, will have a single fleet of about 310 Embraer 170/175 aircraft.  Republic shareholders would own 88% of the combined company, while Mesa's would own a minimum of 6% and up to 12% depending on meeting certain pre-closing criteria.  The combined company is expected to remain listed on the Nasdaq under a new ticker symbol \\"RJET\\".", "datetime": "2025-04-07T12:04:12.000Z", "headline": "Mesa Air, Republic Airways in merger deal to create larger regional airline", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=e3646cf37864d1b7ab52bf3032281e3ef770b7e8b00fb3c5ba66061c58ec5d23", "source": "Yahoo", "summary": "Mesa Air Group Inc (MESA) and Republic Airways Holdings said Monday that they have entered into a de", "datetime": "2025-04-07T11:30:42.000Z", "headline": "Mesa Air Group to Merge With Republic Airways in All-Stock Transaction", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=a631ab1fa207c7581e309c061f9b99648a07e4093993a4d0a41d3cea4805eb6d", "source": "Yahoo", "summary": "Republic Airways Holdings Inc. and Mesa Air Group, Inc. (NASDAQ: MESA) today announced that they have entered into a definitive agreement to merge and create a leading publicly-traded regional airline company in an all-stock transaction. Upon closing, the combined company will be renamed Republic Airways Holdings Inc. and is expected to remain NASDAQ-listed under the new ticker symbol \\"RJET\\".", "datetime": "2025-04-07T10:58:00.000Z", "headline": "Republic Airways and Mesa Air Group to Combine, Creating America's Regional Airline of Choice", "sentiment": "neutral"}]	t	positive	2025-09-03 18:49:18.118+00	5	completed	2025-09-03 18:49:18.121979+00
51779a0f-7d6a-4a09-b86a-5dde1f4f5bdf	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 15:49:00+00	2025-03-28 15:53:00+00	10.140000	10.260000	300.0000	long	4.400000	0.000000	29.62	0.9734	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.327426+00	2025-09-03 18:48:40.328767+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:40.324Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:40.327+00	5	completed	2025-09-03 18:48:40.328767+00
e679892b-c45a-46cb-88bb-c746c357361a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	PRTG	2025-03-28	2025-03-28 16:27:00+00	2025-03-28 16:28:00+00	10.660000	10.750000	300.0000	long	2.690000	0.000000	25.36	0.7933	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:40.525441+00	2025-09-03 18:48:40.526589+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:40.523Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7569a2fa7523107ab5324c669d8e6d47c9ce3279cccdd1eb2d219e11c943401e", "source": "Yahoo", "summary": "Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibodyDOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma", "datetime": "2025-03-27T20:15:00.000Z", "headline": "Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:40.525+00	5	completed	2025-09-03 18:48:40.526589+00
1226c5bc-737f-4689-906d-574c4a62317d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BJDX	2025-04-07	2025-04-07 11:03:00+00	2025-04-07 11:04:00+00	8.810000	8.530000	300.0000	long	4.030000	0.000000	-88.03	-3.3307	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:15.75808+00	2025-09-03 18:49:15.7653+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:49:15.752Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=b1667048767b94a30ddcd18336eac7bebf8bddba5a011061cad95c2ab2738b4e", "source": "Yahoo", "summary": "ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exe", "datetime": "2025-04-07T21:21:00.000Z", "headline": "Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:15.757+00	5	completed	2025-09-03 18:49:15.7653+00
5a8a6701-def2-46dc-81ba-cbd81d43641a	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 11:36:00+00	2025-04-07 11:49:00+00	54.300000	54.790000	100.0000	long	2.780000	0.000000	46.22	0.8512	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:57.918765+00	2025-09-03 18:48:57.920466+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 13, "analysisTimestamp": "2025-09-03T18:48:57.635Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:48:57.918+00	5	completed	2025-09-03 18:48:57.920466+00
ad7724dd-c41b-4850-a5c2-6ae75efb048e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TEVA	2025-04-07	2025-04-07 11:31:00+00	2025-04-07 11:34:00+00	13.990000	14.080000	100.0000	long	2.210000	0.000000	6.79	0.4853	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:16.941085+00	2025-09-03 18:49:16.94221+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:49:16.613Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc380499b6c5b10aa2cdb8fbb47da9a9e3a531ceccfc66f5c5a7e588b1a8ac60", "source": "Yahoo", "summary": "EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsun", "datetime": "2025-04-07T12:00:00.000Z", "headline": "Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=aa061066f0d21ee9afc2e2c0bcb1ef758ad19033735560bf36f2f265ca57ed56", "source": "Yahoo", "summary": "If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva’s dedication to expanding access to innovat", "datetime": "2025-04-07T11:30:00.000Z", "headline": "Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention", "sentiment": "neutral"}]	t	positive	2025-09-03 18:49:16.94+00	5	completed	2025-09-03 18:49:16.94221+00
fb07cb4f-b5cd-4b67-8d63-150068297eed	2d96cef2-7502-44ff-a7a9-17713d4a7a42	TEVA	2025-04-07	2025-04-07 15:44:00+00	2025-04-07 16:08:00+00	13.830000	13.730000	500.0000	short	5.280000	0.000000	44.77	0.6474	Round trip: 2 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:49:17.234331+00	2025-09-03 18:49:17.235589+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 24, "analysisTimestamp": "2025-09-03T18:49:17.231Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dc380499b6c5b10aa2cdb8fbb47da9a9e3a531ceccfc66f5c5a7e588b1a8ac60", "source": "Yahoo", "summary": "EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsun", "datetime": "2025-04-07T12:00:00.000Z", "headline": "Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=aa061066f0d21ee9afc2e2c0bcb1ef758ad19033735560bf36f2f265ca57ed56", "source": "Yahoo", "summary": "If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva’s dedication to expanding access to innovat", "datetime": "2025-04-07T11:30:00.000Z", "headline": "Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention", "sentiment": "neutral"}]	t	positive	2025-09-03 18:49:17.234+00	5	completed	2025-09-03 18:49:17.235589+00
f2b12f67-17b1-4aa1-973e-67571694b7d6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	BCDA	2025-03-31	2025-03-31 12:01:00+00	2025-03-31 12:05:00+00	3.140000	3.210000	1200.0000	long	14.040000	0.000000	69.96	1.8578	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:41.584569+00	2025-09-03 18:48:41.585703+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:41.322Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=dfc056157315d933f70980cdca71714042ac559904fbdff5255d838b9583a978", "source": "SeekingAlpha", "summary": "BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter Altman -...", "datetime": "2025-03-31T23:30:56.000Z", "headline": "BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=7f199eb721b316b4dfe8d59453c86b7935fde655197942e4b4d8454ccffac457", "source": "Yahoo", "summary": "SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register fo", "datetime": "2025-03-31T17:39:00.000Z", "headline": "BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=9740c76341b4c831b7267673738310ce0ba2bc4be2b4fff58098e51749e6d165", "source": "Yahoo", "summary": "Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell TherapyPatient improvements through two years suggest single dos", "datetime": "2025-03-31T12:00:00.000Z", "headline": "Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:41.584+00	5	completed	2025-09-03 18:48:41.585703+00
6e116a2e-b7bb-4fdf-bf72-482039eec344	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ICCT	2025-04-01	2025-04-01 10:59:00+00	2025-04-01 11:00:00+00	3.080000	3.140000	300.0000	long	4.930000	0.000000	13.07	1.4145	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:42.888117+00	2025-09-03 18:48:42.889464+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:42.558Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:42.887+00	5	completed	2025-09-03 18:48:42.889464+00
7eb3f5d6-1663-470b-86d5-7043d28973ab	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ICCT	2025-04-03	2025-04-03 15:39:00+00	2025-04-03 15:43:00+00	4.730000	4.470000	900.0000	long	11.970000	0.000000	-247.56	-5.8120	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:44.553473+00	2025-09-03 18:48:44.555609+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 4, "analysisTimestamp": "2025-09-03T18:48:44.548Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:44.553+00	5	completed	2025-09-03 18:48:44.555609+00
aad108ec-d370-4264-a75f-99809db33d6d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CNTM	2025-04-03	2025-04-03 12:01:00+00	2025-04-03 12:02:00+00	0.790000	0.810000	300.0000	long	3.600000	0.000000	2.04	0.8608	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:54.917326+00	2025-09-03 18:48:54.918658+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:54.914Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=485e35221b06bd6036247f1662ad99ffd31c7f660a70fd429e60328677bb3372", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, yesterday announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity (implying a $46.5 million equi", "datetime": "2025-04-03T12:00:00.000Z", "headline": "ConnectM Board to Evaluate $46.5 Million Buy-Out Offer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d1ad68a524da7f550ec475136ace61d229514ce9616a6f6fba939351046dabcd", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.", "datetime": "2025-04-02T12:00:00.000Z", "headline": "ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:54.917+00	5	completed	2025-09-03 18:48:54.918658+00
6a9d198c-ee73-439e-8a5d-efef2dedf106	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SBFM	2025-04-02	2025-04-02 13:39:00+00	2025-04-02 19:34:00+00	3.410000	2.190000	2500.0000	long	35.680000	0.000000	-3085.06	-36.1571	Round trip: 7 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:55.160967+00	2025-09-03 18:48:55.162365+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 355, "analysisTimestamp": "2025-09-03T18:48:55.158Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=bbe9312d254ae911454864e251877ca1ffbdcf14386f454f732aa5a50f18470e", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, ...", "datetime": "2025-04-02T17:20:00.000Z", "headline": "Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=865be0a113449dbc5bf2a1140822c155d1abd9fd239033a547e493c41351672c", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (\\"We\\", \\"Our\\", the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology ...", "datetime": "2025-04-02T12:00:00.000Z", "headline": "Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=232798cd3ea7e8d451347b503419f1ddeefa7f71baa0cb5696ee2d8da099d175", "source": "Yahoo", "summary": "FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \\"Company\\"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals ...", "datetime": "2025-04-01T21:09:00.000Z", "headline": "Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year", "sentiment": "positive"}]	t	neutral	2025-09-03 18:48:55.16+00	5	completed	2025-09-03 18:48:55.162365+00
31f6bc86-a598-49ae-911b-230a978a5044	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CSAI	2025-04-01	2025-04-01 15:13:00+00	2025-04-01 15:13:00+00	8.350000	8.410000	300.0000	long	2.680000	0.000000	15.32	0.6116	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:50.345971+00	2025-09-03 18:48:50.348191+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:50.007Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1c305e3d9070bd3da5013665aae1d807284abdc536599e6d72338f7df32caa92", "source": "Yahoo", "summary": "Broad-Based Sales Growth: New Customers Up 30%, Subscriptions Up 48%, Remote Guarding Up 404%, Hardware Sales Up 250% AI Surveillance Platform Proves Effective, Scalable, and Regulation-Ready PALO ALTO, CA, March 31, 2025 (GLOBE NEWSWIRE) -- Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a cloud-based video surveillance platform with artificial intelligence (“AI”) and computer vision analytics, today provided a business update and reported financial", "datetime": "2025-03-31T20:30:00.000Z", "headline": "Cloudastructure Reports 2024 Year-End Results: Revenue Up 124% Year-over-Year; Gross Profit Turns Positive", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:50.345+00	5	completed	2025-09-03 18:48:50.348191+00
67f88e91-80cf-40fd-b7ca-fc0547495314	2d96cef2-7502-44ff-a7a9-17713d4a7a42	AREB	2025-04-07	2025-04-07 12:19:00+00	2025-04-07 12:21:00+00	17.990000	16.500000	200.0000	long	4.330000	0.000000	-302.57	-8.4080	Round trip: 3 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:49:18.980937+00	2025-09-03 18:49:18.982904+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:49:18.693Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=8ab2b1e511bb0fde04e2bf94c1d31a65dd9292f0b5f235bc65b30f19dbd559d4", "source": "Yahoo", "summary": "American Rebel Holdings Inc. Forged in Freedom, Fueled by Growth, Focused on the Future Forged in Freedom, Fueled by Growth, Focused on the Future NASHVILLE, TN, April 07, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), the creator of American Rebel Beer (americanrebelbeer.com) and a leading provider of safes, personal security, and patriotic lifestyle apparel, today issued a corporate update summarizing several recent developments that", "datetime": "2025-04-07T12:15:00.000Z", "headline": "American Rebel Holdings Issues Corporate Update Highlighting Recent Key Milestones and Strategic Growth Initiatives", "sentiment": "positive"}]	t	positive	2025-09-03 18:49:18.98+00	5	completed	2025-09-03 18:49:18.982904+00
db3eff94-4ae7-4076-89e3-97107e905188	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CSAI	2025-04-01	2025-04-01 16:39:00+00	2025-04-01 16:46:00+00	9.060000	9.190000	1000.0000	long	14.080000	0.000000	118.45	1.3073	Round trip: 4 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:50.612951+00	2025-09-03 18:48:50.615053+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:48:50.608Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1c305e3d9070bd3da5013665aae1d807284abdc536599e6d72338f7df32caa92", "source": "Yahoo", "summary": "Broad-Based Sales Growth: New Customers Up 30%, Subscriptions Up 48%, Remote Guarding Up 404%, Hardware Sales Up 250% AI Surveillance Platform Proves Effective, Scalable, and Regulation-Ready PALO ALTO, CA, March 31, 2025 (GLOBE NEWSWIRE) -- Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a cloud-based video surveillance platform with artificial intelligence (“AI”) and computer vision analytics, today provided a business update and reported financial", "datetime": "2025-03-31T20:30:00.000Z", "headline": "Cloudastructure Reports 2024 Year-End Results: Revenue Up 124% Year-over-Year; Gross Profit Turns Positive", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:50.612+00	5	completed	2025-09-03 18:48:50.615053+00
4f173dc8-a4ce-4042-8280-b237fba06d50	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CSAI	2025-04-01	2025-04-01 16:51:00+00	2025-04-01 16:53:00+00	9.380000	9.330000	300.0000	long	2.680000	0.000000	-16.81	-0.5976	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:51.032473+00	2025-09-03 18:48:51.034598+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:51.028Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=1c305e3d9070bd3da5013665aae1d807284abdc536599e6d72338f7df32caa92", "source": "Yahoo", "summary": "Broad-Based Sales Growth: New Customers Up 30%, Subscriptions Up 48%, Remote Guarding Up 404%, Hardware Sales Up 250% AI Surveillance Platform Proves Effective, Scalable, and Regulation-Ready PALO ALTO, CA, March 31, 2025 (GLOBE NEWSWIRE) -- Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”), a cloud-based video surveillance platform with artificial intelligence (“AI”) and computer vision analytics, today provided a business update and reported financial", "datetime": "2025-03-31T20:30:00.000Z", "headline": "Cloudastructure Reports 2024 Year-End Results: Revenue Up 124% Year-over-Year; Gross Profit Turns Positive", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:51.032+00	5	completed	2025-09-03 18:48:51.034598+00
aa5bb742-1ede-42a7-9838-5e195319f6c5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DFDV	2025-04-07	2025-04-07 13:01:00+00	2025-04-07 13:03:00+00	9.970000	10.050000	500.0000	long	6.510000	0.000000	34.89	0.6998	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:21.239025+00	2025-09-03 18:49:21.241482+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:49:21.232Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:21.238+00	5	completed	2025-09-03 18:49:21.241482+00
796d760f-af6b-4a1f-8deb-af00c9bf855e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	HOTH	2025-04-02	2025-04-02 12:00:00+00	2025-04-02 12:01:00+00	1.070000	1.080000	300.0000	long	3.960000	0.000000	-0.96	-0.2991	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:52.313667+00	2025-09-03 18:48:52.315265+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:51.652Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7ba8a5c66aaca544e7489bc53d53c7d651f3df9d45cc84ac4f55d40715a19b49", "source": "Yahoo", "summary": "Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's di", "datetime": "2025-04-02T12:02:00.000Z", "headline": "Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=a76e014a2b2b356c964086e2b6e8fc4f3b9009933d22629289fa1760a07f71f7", "source": "Yahoo", "summary": "Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-ALZ, in improving cognitive function and reducing neuroinflammation in Alzheimer's disease (AD).", "datetime": "2025-04-02T11:58:00.000Z", "headline": "Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:52.313+00	5	completed	2025-09-03 18:48:52.315265+00
d300d5e6-9917-4ffd-8b19-9f93470fbea5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	WTF	2025-04-02	2025-04-02 11:16:00+00	2025-04-02 11:19:00+00	18.650000	18.840000	200.0000	long	3.440000	0.000000	33.68	0.9027	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:51.649414+00	2025-09-03 18:48:51.651126+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:51.308Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=c7b06e7569a544bfa7c0d614fce2d5c29a8cbf7fc42cf1313bb044a25e728e6b", "source": "SeekingAlpha", "summary": "Waton Financial's IPO saw extreme volatility, with shares surging to $20 before falling to $8. Find out why I expect WTF stock return to its IPO level of $4.", "datetime": "2025-04-02T15:30:13.000Z", "headline": "Waton Financial: Complex Structure Poses Downside Risk", "sentiment": "negative"}, {"url": "https://finnhub.io/api/news?id=cb6a39e667666dd948356d9ce6b51c0979777531382103ebd84d0f7c205d9fb8", "source": "Yahoo", "summary": "HONG KONG, April 02, 2025 (GLOBE NEWSWIRE) -- Waton Financial Limited (“WTF” or the “Company”), a British Virgin Islands-incorporated holding company that provides securities brokerage and financial technology services primarily through its Hong Kong subsidiaries, Waton Securities International Limited and Waton Technology International Limited, today announced the closing of its initial public offering of 4,375,000 ordinary shares, no par value per share (the “Ordinary Shares”), at a public off", "datetime": "2025-04-02T15:20:00.000Z", "headline": "Waton Financial Limited Announces Closing of Initial Public Offering with Simultaneous Full Exercise of the Over-Allotment Option", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d142fa2be19116e2d0c11a22a1a294459d349ce4b4eba5315c8cddb44c61876b", "source": "Yahoo", "summary": "HONG KONG, April 01, 2025 (GLOBE NEWSWIRE) -- Waton Financial Limited (“WTF” or the “Company”), a British Virgin Islands-incorporated holding company that provides of securities brokerage and financial technology services primarily through its Hong Kong subsidiaries, Waton Securities International Limited and Waton Technology International Limited, today announced the pricing of its initial public offering of an aggregate of 4,375,000 ordinary shares, no par value per share (the “Ordinary Shares", "datetime": "2025-04-01T15:00:00.000Z", "headline": "Waton Financial Limited Announces Pricing of Initial Public Offering", "sentiment": "neutral"}]	t	negative	2025-09-03 18:48:51.649+00	5	completed	2025-09-03 18:48:51.651126+00
9acf57c0-fd2f-40de-959a-93bb7a7e2dd5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	GRRR	2025-04-07	2025-04-07 12:25:00+00	2025-04-07 12:28:00+00	15.270000	15.470000	200.0000	long	3.420000	0.000000	36.58	1.1978	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:19.640129+00	2025-09-03 18:49:19.642151+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:49:19.634Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=50a9909eacfdd29b4384b0083d7130ab660ccb508152478c69ba5237511aa453", "source": "Yahoo", "summary": "Bangkok, Thailand--(Newsfile Corp. - April 7, 2025) - Gorilla Technology Group Inc. (NASDAQ: GRRR) (\\"Gorilla\\" or the \\"Company\\") today, announced a landmark partnership with Toyota Material Handling Warehouse Solutions (Thailand), to co-develop intelligent warehouse automation technologies for Toyota's global customers.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10783/247571_2c1947b94486287d_001full.jpgThis collaboration brings together Gorilla'", "datetime": "2025-04-07T12:00:00.000Z", "headline": "Gorilla Technology Group Signs Strategic Partnership with Toyota Material Handling Solutions (Thailand) to Power Global Smart Warehousing Transformation", "sentiment": "positive"}]	t	positive	2025-09-03 18:49:19.639+00	5	completed	2025-09-03 18:49:19.642151+00
3c109eec-1435-470f-9527-583f9b0870f7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CNTM	2025-04-03	2025-04-03 12:00:00+00	2025-04-03 12:01:00+00	0.780000	0.820000	900.0000	long	10.810000	0.000000	25.19	3.5888	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:54.912919+00	2025-09-03 18:48:54.913942+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:54.219Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=485e35221b06bd6036247f1662ad99ffd31c7f660a70fd429e60328677bb3372", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, yesterday announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity (implying a $46.5 million equi", "datetime": "2025-04-03T12:00:00.000Z", "headline": "ConnectM Board to Evaluate $46.5 Million Buy-Out Offer", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=d1ad68a524da7f550ec475136ace61d229514ce9616a6f6fba939351046dabcd", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.", "datetime": "2025-04-02T12:00:00.000Z", "headline": "ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:54.912+00	5	completed	2025-09-03 18:48:54.913942+00
31e497be-27cd-4c24-a41e-ae831f921000	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DFDV	2025-04-07	2025-04-07 12:45:00+00	2025-04-07 12:45:00+00	9.050000	9.220000	88.0000	long	2.020000	0.000000	12.94	1.6248	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:20.435359+00	2025-09-03 18:49:20.436611+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:20.187Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:20.435+00	5	completed	2025-09-03 18:49:20.436611+00
26735ce1-e09d-42ad-ab49-488221134457	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DFDV	2025-04-07	2025-04-07 12:47:00+00	2025-04-07 12:47:00+00	9.420000	9.510000	500.0000	long	5.160000	0.000000	38.84	0.8245	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:20.73162+00	2025-09-03 18:49:20.732717+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:20.727Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:20.731+00	5	completed	2025-09-03 18:49:20.732717+00
3f9d46b6-35a4-40b5-b54e-14cca28f55a4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ALLO	2025-04-07	2025-04-07 12:30:00+00	2025-04-07 14:16:00+00	1.490000	1.500000	1000.0000	long	8.950000	0.000000	4.05	0.2724	Round trip: 4 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:49:20.183715+00	2025-09-03 18:49:20.185662+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 106, "analysisTimestamp": "2025-09-03T18:49:19.923Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=4313f8f1d029f8f0be12c05a9827c4e29bdb1a75c14d5f1b55586d37c835d0ec", "source": "Yahoo", "summary": "Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therapeutic Benefit, Expanding Treatment Potential Across a Range of Autoimmune IndicationsLeverages Proprietary Dagger® Technology to Reduce or Eliminate Lymphodepletion, Potentially Expanding Access to a Broader Patient PopulationPhase 1 RESOLUTION Trial Initiation Planned for Mid-2025 with Initial Proof", "datetime": "2025-04-07T12:30:00.000Z", "headline": "Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:49:20.183+00	5	completed	2025-09-03 18:49:20.185662+00
87f421d1-426a-4c93-ba22-e8bf3de7a71b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	HOTH	2025-04-02	2025-04-02 12:06:00+00	2025-04-02 12:23:00+00	1.010000	1.050000	1800.0000	long	23.720000	0.000000	46.72	2.5748	Round trip: 5 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:52.60338+00	2025-09-03 18:48:52.604478+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 17, "analysisTimestamp": "2025-09-03T18:48:52.600Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=7ba8a5c66aaca544e7489bc53d53c7d651f3df9d45cc84ac4f55d40715a19b49", "source": "Yahoo", "summary": "Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's di", "datetime": "2025-04-02T12:02:00.000Z", "headline": "Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=a76e014a2b2b356c964086e2b6e8fc4f3b9009933d22629289fa1760a07f71f7", "source": "Yahoo", "summary": "Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-ALZ, in improving cognitive function and reducing neuroinflammation in Alzheimer's disease (AD).", "datetime": "2025-04-02T11:58:00.000Z", "headline": "Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:52.603+00	5	completed	2025-09-03 18:48:52.604478+00
1e6a01ad-69ee-4302-87ee-46349c30f96b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SIDU	2025-04-02	2025-04-02 12:30:00+00	2025-04-02 12:31:00+00	1.710000	1.840000	900.0000	long	11.900000	0.000000	109.51	7.1211	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:48:53.545195+00	2025-09-03 18:48:53.546343+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:48:52.851Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=9f05814eeaf8d0c71cd8f40eb28da8a428aa640014a3a14fd9ae42a9f97fab70", "source": "Yahoo", "summary": "CAPE CANAVERAL, Fla., April 02, 2025--Sidus Space (NASDAQ: SIDU) (the \\"Company\\" or \\"Sidus\\"), an innovative, agile space mission enabler, announced today the decision to move forward with, and broaden the scope of, a preliminary agreement valued at approximately $120 million with Lonestar Data Holdings. The agreement defines the collaboration between Sidus and Lonestar to design, build and provide on-orbit support for six lunar data storage spacecraft, marking a significant milestone in advancing", "datetime": "2025-04-02T12:30:00.000Z", "headline": "Sidus Space Signs Extended and Amended Preliminary $120M Agreement with Lonestar for Lunar Data Storage Spacecraft", "sentiment": "positive"}]	t	positive	2025-09-03 18:48:53.544+00	5	completed	2025-09-03 18:48:53.546343+00
17138191-3fe0-40d0-9efa-d0be39302350	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DFDV	2025-04-07	2025-04-07 13:28:00+00	2025-04-07 13:28:00+00	14.340000	14.940000	500.0000	long	4.530000	0.000000	295.47	4.1209	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:21.775273+00	2025-09-03 18:49:21.77741+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:21.769Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:21.774+00	5	completed	2025-09-03 18:49:21.77741+00
14da47b2-006a-406f-b89e-1c9584f1afe6	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CNTM	2025-04-02	2025-04-02 12:32:00+00	2025-04-02 12:32:00+00	0.970000	0.960000	900.0000	short	11.670000	0.000000	-3.39	-0.3887	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:53.893757+00	2025-09-03 18:48:53.895048+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:53.547Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d1ad68a524da7f550ec475136ace61d229514ce9616a6f6fba939351046dabcd", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.", "datetime": "2025-04-02T12:00:00.000Z", "headline": "ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:53.893+00	5	completed	2025-09-03 18:48:53.895048+00
132b8ee0-affb-401f-b5a0-c5b633f44c9e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	CNTM	2025-04-02	2025-04-02 12:33:00+00	2025-04-02 13:36:00+00	1.040000	1.100000	7000.0000	long	94.670000	0.000000	319.62	4.3869	Round trip: 7 executions	f	lightspeed	day_trading	\N	{}	2025-09-03 18:48:54.216647+00	2025-09-03 18:48:54.21838+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 63, "analysisTimestamp": "2025-09-03T18:48:54.214Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=d1ad68a524da7f550ec475136ace61d229514ce9616a6f6fba939351046dabcd", "source": "Yahoo", "summary": "ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (\\"ConnectM\\" or the \\"Company\\"), a high-growth technology company on the leading edge of the energy economy, today announced that it has received a non-binding proposal offering $1.60 per share in cash from its three largest institutional investors—SriSid LLC, Arumilli LLC, and Win-Light Global Co. Ltd.—to acquire all remaining outstanding shares of the Company and transition ConnectM into a privately held entity.", "datetime": "2025-04-02T12:00:00.000Z", "headline": "ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors", "sentiment": "neutral"}]	t	neutral	2025-09-03 18:48:54.216+00	5	completed	2025-09-03 18:48:54.21838+00
e7ad79ce-34fa-4078-aa75-b3fcb8b17570	2d96cef2-7502-44ff-a7a9-17713d4a7a42	DFDV	2025-04-07	2025-04-07 13:30:00+00	2025-04-07 13:30:00+00	15.140000	15.620000	500.0000	long	4.550000	0.000000	233.35	3.0817	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:22.273887+00	2025-09-03 18:49:22.274857+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:22.271Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:22.273+00	5	completed	2025-09-03 18:49:22.274857+00
9c40614d-1977-43cc-866d-13ade35b7069	2d96cef2-7502-44ff-a7a9-17713d4a7a42	03835L405	2025-04-02	2025-04-02 21:20:00+00	2025-04-02 21:20:00+00	2.600000	2.620000	300.0000	long	3.980000	0.000000	2.02	0.2590	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:49:01.768189+00	2025-09-03 18:49:58.759517+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:49:01.760Z"}	f	\N	[]	f	neutral	2025-09-03 18:49:01.768+00	5	completed	2025-09-03 18:49:58.759517+00
1bbe564d-0de2-41e7-8611-87db9e8146f7	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-02	2025-04-02 20:36:00+00	2025-04-02 20:38:00+00	39.110000	39.860000	100.0000	long	2.740000	0.000000	72.26	1.8476	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:55.763688+00	2025-09-03 18:48:55.765122+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:55.436Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:48:55.763+00	5	completed	2025-09-03 18:48:55.765122+00
8dee3216-7bec-499b-a6b1-8f4b90407d5c	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 11:53:00+00	2025-04-07 11:53:00+00	54.890000	54.730000	100.0000	short	2.780000	0.000000	13.22	0.2408	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:58.599388+00	2025-09-03 18:48:58.600895+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:48:58.595Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:48:58.599+00	5	completed	2025-09-03 18:48:58.600895+00
0dd0eb75-158a-4419-9f9b-4b7e87c942ca	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 12:58:00+00	2025-04-07 13:00:00+00	53.360000	53.940000	100.0000	long	2.770000	0.000000	55.23	1.0350	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:59.752329+00	2025-09-03 18:48:59.753275+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:59.749Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:48:59.752+00	5	completed	2025-09-03 18:48:59.753275+00
3d5859f3-7ce0-4980-93df-21b2f733f258	2d96cef2-7502-44ff-a7a9-17713d4a7a42	90137F400	2025-01-13	2025-01-13 11:37:00+00	2025-01-13 11:38:00+00	7.070000	6.600000	200.0000	long	3.270000	0.000000	-96.27	-6.8132	Round trip: 2 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:05.957553+00	2025-09-03 18:50:15.829388+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:05.954Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:05.957+00	5	completed	2025-09-03 18:50:15.829388+00
6f5b1051-d41c-4c99-a689-31065f053154	2d96cef2-7502-44ff-a7a9-17713d4a7a42	90137F400	2025-01-13	2025-01-13 11:31:00+00	2025-01-13 11:31:00+00	7.140000	7.350000	400.0000	long	6.560000	0.000000	79.42	2.7828	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:05.688671+00	2025-09-03 18:50:16.346509+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:05.686Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:05.688+00	5	completed	2025-09-03 18:50:16.346509+00
2817070c-bf93-4443-9bad-ab7bd79aa0b5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	83006G203	2025-01-29	2025-01-29 11:00:00+00	2025-01-29 11:03:00+00	1.400000	1.450000	200.0000	long	4.260000	0.000000	5.74	2.0500	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.706269+00	2025-09-03 18:50:19.3619+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:47:04.702Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.706+00	5	completed	2025-09-03 18:50:19.3619+00
c8c472ea-06da-43c6-af94-bdf28d969fc1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	83006G203	2025-01-08	2025-01-08 12:04:00+00	2025-01-08 12:04:00+00	2.750000	2.870000	200.0000	long	4.260000	0.000000	19.74	3.5891	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.701258+00	2025-09-03 18:50:19.859489+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:04.699Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.701+00	5	completed	2025-09-03 18:50:19.859489+00
36fe0338-75d9-4c0a-96a8-fc85fde12b63	2d96cef2-7502-44ff-a7a9-17713d4a7a42	83006G203	2025-01-08	2025-01-08 12:03:00+00	2025-01-08 12:03:00+00	2.250000	2.900000	200.0000	long	3.810000	0.000000	125.19	27.8200	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:04.698602+00	2025-09-03 18:50:20.360782+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:04.696Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.698+00	5	completed	2025-09-03 18:50:20.360782+00
0b112c0a-4a3b-4dd5-8f17-4410286c3dc0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	97382D501	2025-01-08	2025-01-08 12:01:00+00	2025-01-08 12:01:00+00	0.420000	0.400000	200.0000	short	3.550000	0.000000	0.01	0.0120	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:04.411499+00	2025-09-03 18:50:20.847662+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:04.409Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:04.411+00	5	completed	2025-09-03 18:50:20.847662+00
1258401a-b7d8-43b8-8f76-03d2458bc650	2d96cef2-7502-44ff-a7a9-17713d4a7a42	81728A108	2025-01-08	2025-01-08 11:35:00+00	2025-01-08 11:36:00+00	0.670000	0.720000	200.0000	long	3.890000	0.000000	5.51	4.1243	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:02.694559+00	2025-09-03 18:50:21.354769+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:02.691Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:02.694+00	5	completed	2025-09-03 18:50:21.354769+00
3beb6591-f283-4add-b80d-3ec074784e03	2d96cef2-7502-44ff-a7a9-17713d4a7a42	89458T205	2025-01-03	2025-01-03 11:09:00+00	2025-01-03 11:10:00+00	0.830000	0.830000	200.0000	long	4.050000	0.000000	-4.14	-2.5054	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.265286+00	2025-09-03 18:50:21.873669+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:46:56.262Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.265+00	5	completed	2025-09-03 18:50:21.873669+00
f08d29e6-a1b5-4519-9d14-db7dca34c27d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	89458T205	2025-01-03	2025-01-03 11:07:00+00	2025-01-03 11:07:00+00	0.890000	0.880000	200.0000	short	4.120000	0.000000	-1.92	-1.0774	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:56.258149+00	2025-09-03 18:50:23.061062+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:46:56.255Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:56.258+00	5	completed	2025-09-03 18:50:23.061062+00
3097d30d-c397-4137-a979-2abe3c65f395	2d96cef2-7502-44ff-a7a9-17713d4a7a42	655187300	2025-02-04	2025-02-04 12:01:00+00	2025-02-04 12:08:00+00	9.770000	9.330000	100.0000	long	3.660000	0.000000	-47.66	-4.8782	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:46:55.365282+00	2025-09-03 18:50:25.082413+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 7, "analysisTimestamp": "2025-09-03T18:46:55.361Z"}	f	\N	[]	f	neutral	2025-09-03 18:46:55.365+00	5	completed	2025-09-03 18:50:25.082413+00
cbb37db1-2e27-48b8-8983-4864192ef4b0	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-02	2025-04-02 20:40:00+00	2025-04-02 20:42:00+00	39.690000	40.080000	100.0000	long	2.740000	0.000000	36.26	0.9136	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:56.441985+00	2025-09-03 18:48:56.444292+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:56.436Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:48:56.441+00	5	completed	2025-09-03 18:48:56.444292+00
f478e991-8d68-4532-ac67-1cf8ec62ef05	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-02	2025-04-02 21:07:00+00	2025-04-02 21:10:00+00	39.800000	40.100000	100.0000	long	2.290000	0.000000	27.71	0.6962	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:56.718394+00	2025-09-03 18:48:56.725896+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 3, "analysisTimestamp": "2025-09-03T18:48:56.710Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:48:56.718+00	5	completed	2025-09-03 18:48:56.725896+00
d84ded0e-a97c-4f17-87a7-60a7d3b1e696	2d96cef2-7502-44ff-a7a9-17713d4a7a42	76090R309	2025-04-02	2025-04-02 11:32:00+00	2025-04-02 11:40:00+00	0.770000	0.730000	600.0000	long	7.010000	0.000000	-31.40	-6.8262	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:48.494909+00	2025-09-03 18:50:00.264776+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 8, "analysisTimestamp": "2025-09-03T18:48:47.830Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:48.494+00	5	completed	2025-09-03 18:50:00.264776+00
f9ee3e7d-bc03-469d-9de9-3448b0b84f87	2d96cef2-7502-44ff-a7a9-17713d4a7a42	76090R309	2025-04-01	2025-04-01 11:10:00+00	2025-04-01 11:12:00+00	0.940000	0.950000	900.0000	long	11.590000	0.000000	-1.00	-0.1183	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:47.829756+00	2025-09-03 18:50:00.756919+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:47.296Z"}	f	\N	[]	f	neutral	2025-09-03 18:48:47.829+00	5	completed	2025-09-03 18:50:00.756919+00
5f97cdc2-e673-422a-a110-26002c488c35	2d96cef2-7502-44ff-a7a9-17713d4a7a42	20678X205	2025-02-10	2025-02-10 12:20:00+00	2025-02-10 12:20:00+00	2.800000	2.970000	400.0000	long	5.910000	0.000000	62.87	5.6189	Round trip: 1 executions	f	lightspeed	momentum	\N	{}	2025-09-03 18:47:42.278151+00	2025-09-03 18:50:04.771227+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:42.033Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:42.277+00	5	completed	2025-09-03 18:50:04.771227+00
4a70d2b0-d498-4844-9291-fbb698fd43d2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	M2R43K362	2025-02-04	2025-02-04 12:33:00+00	2025-02-04 12:34:00+00	1.410000	1.430000	400.0000	long	5.890000	0.000000	4.67	0.8295	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:32.071065+00	2025-09-03 18:50:08.288593+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:31.550Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:32.07+00	5	completed	2025-09-03 18:50:08.288593+00
e7f6cc69-3367-42db-bd98-dda2521714f4	2d96cef2-7502-44ff-a7a9-17713d4a7a42	40423R105	2025-02-03	2025-02-03 11:29:00+00	2025-02-03 11:38:00+00	0.700000	0.730000	1000.0000	long	13.000000	0.000000	11.43	1.6238	Round trip: 5 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:23.41903+00	2025-09-03 18:50:09.321145+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 9, "analysisTimestamp": "2025-09-03T18:47:23.413Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:23.418+00	5	completed	2025-09-03 18:50:09.321145+00
424f4d85-a70f-4bff-a5bb-5dd8ec8e207f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	40423R105	2025-02-03	2025-02-03 11:23:00+00	2025-02-03 11:25:00+00	0.780000	0.820000	400.0000	long	6.060000	0.000000	9.67	3.0857	Round trip: 3 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:23.410536+00	2025-09-03 18:50:09.820162+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:47:23.407Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:23.41+00	5	completed	2025-09-03 18:50:09.820162+00
a9702cb2-b03f-4c96-9562-3ae6c4695ead	2d96cef2-7502-44ff-a7a9-17713d4a7a42	40423R105	2025-02-03	2025-02-03 11:21:00+00	2025-02-03 11:22:00+00	0.650000	0.690000	200.0000	long	2.840000	0.000000	4.68	3.6083	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:23.405213+00	2025-09-03 18:50:10.297687+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:23.400Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:23.404+00	5	completed	2025-09-03 18:50:10.297687+00
faf5f61f-5673-4275-ac70-a2a13569b711	2d96cef2-7502-44ff-a7a9-17713d4a7a42	40423R105	2025-02-03	2025-02-03 11:21:00+00	2025-02-03 11:21:00+00	0.700000	0.650000	200.0000	short	2.850000	0.000000	6.53	4.6958	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:23.398045+00	2025-09-03 18:50:10.804197+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:22.855Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:23.397+00	5	completed	2025-09-03 18:50:10.804197+00
bc40c0af-d521-42e3-a1c0-1a2daf7b644e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	73017P102	2025-01-30	2025-01-30 12:03:00+00	2025-01-30 12:03:00+00	1.870000	1.880000	200.0000	long	3.250000	0.000000	-1.25	-0.3342	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:19.595383+00	2025-09-03 18:50:11.318456+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:19.592Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:19.595+00	5	completed	2025-09-03 18:50:11.318456+00
1d3d6253-6416-402c-ab37-1f9f9dc83086	2d96cef2-7502-44ff-a7a9-17713d4a7a42	73017P102	2025-01-30	2025-01-30 12:02:00+00	2025-01-30 12:02:00+00	1.980000	1.980000	200.0000	long	3.250000	0.000000	-2.55	-0.6451	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:19.58906+00	2025-09-03 18:50:11.82974+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:19.584Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:19.588+00	5	completed	2025-09-03 18:50:11.82974+00
51fdf604-f317-4d2b-ab59-48667bdc8613	2d96cef2-7502-44ff-a7a9-17713d4a7a42	48669G204	2025-01-30	2025-01-30 11:32:00+00	2025-01-30 11:32:00+00	1.850000	1.870000	200.0000	long	3.250000	0.000000	0.75	0.2027	Round trip: 1 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:19.571838+00	2025-09-03 18:50:12.321297+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 0, "analysisTimestamp": "2025-09-03T18:47:19.567Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:19.571+00	5	completed	2025-09-03 18:50:12.321297+00
36839bce-0786-4b92-a3ad-b6fa4360a054	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-02	2025-04-02 21:27:00+00	2025-04-02 21:29:00+00	40.300000	40.410000	100.0000	long	2.740000	0.000000	8.26	0.2050	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:57.386199+00	2025-09-03 18:48:57.387542+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:57.381Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=07e171ac6bb6f4e40261aa4c5b8dd03a833210d533696f245daa302556095fa8", "source": "SeekingAlpha", "summary": "Historically, when the S&P 500 has fallen 10% and yield on 10-yr USTs has declined 50+ bps, the economy has been heading into recession ~70% of the time. We reached both milestones in March.", "datetime": "2025-04-02T13:25:00.000Z", "headline": "Heads-Up", "sentiment": "neutral"}, {"url": "https://finnhub.io/api/news?id=21dfcca00b8e4d55189d4ce1e281b42d9c4f8abc73a93539a74ffeef71a863d1", "source": "SeekingAlpha", "summary": "Immediately after the 2024 presidential elections, positive animal spirits catapulted the stock market higher due to hopes of stimulating tax cuts and deregulation legislation.", "datetime": "2025-04-02T02:50:00.000Z", "headline": "Animal Spirits To Animal Hibernation", "sentiment": "positive"}, {"url": "https://finnhub.io/api/news?id=ca60640280516ac1c9c954fcd794e650c28ecca0e6cd211ea64974acd8461cf8", "source": "SeekingAlpha", "summary": "ProShares UltraPro Dow30 ETF is a popular leveraged ETF for swing trading, but its 3X leverage factor causes drift. Read why UDOW ETF is a Hold.", "datetime": "2025-04-01T08:00:00.000Z", "headline": "UDOW And Leveraged ETFs Drift Update", "sentiment": "neutral"}]	t	positive	2025-09-03 18:48:57.386+00	5	completed	2025-09-03 18:48:57.387542+00
c9c0b43f-cb0e-4383-b51d-58d570d253de	2d96cef2-7502-44ff-a7a9-17713d4a7a42	42328V801	2025-01-21	2025-01-21 11:05:00+00	2025-01-21 11:06:00+00	1.060000	1.200000	200.0000	long	4.260000	0.000000	22.74	10.7264	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:47:15.050024+00	2025-09-03 18:50:14.824247+00	[]	\N	\N	f	\N	\N	\N	70.00	fast_path	{"signals": [], "holdTimeMinutes": 1, "analysisTimestamp": "2025-09-03T18:47:15.045Z"}	f	\N	[]	f	neutral	2025-09-03 18:47:15.049+00	5	completed	2025-09-03 18:50:14.824247+00
ca2141f1-ed0b-4b15-bcfd-67f1d5ce9afb	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 12:02:00+00	2025-04-07 12:04:00+00	54.370000	54.420000	100.0000	long	2.780000	0.000000	2.22	0.0408	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:58.868697+00	2025-09-03 18:48:58.869706+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 2, "analysisTimestamp": "2025-09-03T18:48:58.866Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:48:58.868+00	5	completed	2025-09-03 18:48:58.869706+00
fbc846b9-e8c3-443f-ae14-b41ed2fc4608	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 12:13:00+00	2025-04-07 12:18:00+00	55.090000	55.240000	100.0000	long	2.780000	0.000000	12.22	0.2218	Round trip: 2 executions	f	lightspeed	scalper	\N	{}	2025-09-03 18:48:59.101471+00	2025-09-03 18:48:59.102506+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"holdTimeMinutes": 5, "analysisTimestamp": "2025-09-03T18:48:59.099Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:48:59.101+00	5	completed	2025-09-03 18:48:59.102506+00
4da614e0-15e4-4bb5-8be4-ee476dd82c74	2d96cef2-7502-44ff-a7a9-17713d4a7a42	SQQQ	2025-04-07	2025-04-07 15:00:00+00	2025-04-07 15:59:00+00	49.740000	49.500000	175.0000	long	5.090000	0.000000	-47.09	-0.4825	Round trip: 4 executions	f	lightspeed	day_trading		{}	2025-09-03 18:49:01.414346+00	2025-09-24 21:06:22.909621+00	[]	\N	\N	f	\N	\N	\N	70.00	time_based	{"reclassified": true, "holdTimeMinutes": 59, "analysisTimestamp": "2025-09-24T21:06:22.906Z"}	f	\N	[{"url": "https://finnhub.io/api/news?id=84ebae131ccd52fdd8d94824f3ba5a6898de9a142fb9ee0db11f6fee3b61eec7", "source": "SeekingAlpha", "summary": "It's still guesswork as to whether a US recession is inevitable as markets struggle to price in a dramatically altered macro outlook due to the rising risk of a global trade war.", "datetime": "2025-04-07T10:50:00.000Z", "headline": "Is A U.S. Recession Inevitable?", "sentiment": "negative"}]	t	negative	2025-09-03 18:49:01.414+00	5	completed	2025-09-03 18:49:01.415376+00
\.


--
-- Data for Name: trading_personality_profiles; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.trading_personality_profiles (id, user_id, primary_personality, personality_confidence, scalper_score, momentum_score, mean_reversion_score, swing_score, avg_hold_time_minutes, avg_trade_frequency_per_day, preferred_timeframes, uses_momentum_indicators, uses_mean_reversion_indicators, uses_volume_analysis, uses_pattern_recognition, risk_tolerance, position_sizing_consistency, stop_loss_discipline, personality_performance_score, optimal_strategy_adherence, total_trades_analyzed, analysis_start_date, analysis_end_date, created_at, updated_at) FROM stdin;
1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	scalper	1.00	89	7	1	3	1	4.45	\N	f	f	f	f	medium	0.00	0.00	0.70	0.50	424	2025-01-02	2025-04-07	2025-09-03 19:01:22.381772	2025-09-03 19:01:22.381772
\.


--
-- Data for Name: user_achievements; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.user_achievements (id, user_id, achievement_id, earned_at, progress, metadata) FROM stdin;
48406c29-a1f8-4779-bcbd-aa4ae67eccef	2d96cef2-7502-44ff-a7a9-17713d4a7a42	bcee9c07-674f-4970-a6f0-02de6083673e	2025-09-03 17:56:35.677859+00	0	{"total_trades": "1"}
590d31c0-8203-42ca-b4dd-67395359a10f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	78896be6-2519-49da-8097-9cd588da13c8	2025-09-03 17:56:35.679903+00	0	{"achievement_type": "achievement_page_visit", "earned_immediately": true}
c4bbe075-e4c3-4159-9fe5-7ae8b6541b04	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3c5320cb-9cc2-43ec-bdef-01652f013d10	2025-09-03 17:56:35.681163+00	0	{"achievement_type": "dashboard_visit", "earned_immediately": true}
afb5b496-f3ee-4ca4-8940-beb91dfa31f8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	fff95281-3dc7-46a7-8c87-fdcd61fd249e	2025-09-03 17:56:35.685601+00	0	{"achievement_type": "registration", "earned_immediately": true}
26bdac29-d258-4e2e-9b51-6bbf2d955762	2d96cef2-7502-44ff-a7a9-17713d4a7a42	5c9f0c32-aeb8-4684-80b0-d742b0fa66d3	2025-09-03 17:56:35.92695+00	0	{"first_profit_date": "2025-09-03T17:56:35.925Z"}
ff2669d1-ef18-4b33-b1ad-30dd2986f71f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2f84e098-fbc3-412d-8f34-59bb8841a661	2025-09-03 17:56:35.940245+00	0	{"max_duration_minutes": 5}
7e6712f0-ae1f-4daa-8513-bf2ecdcfafd1	2d96cef2-7502-44ff-a7a9-17713d4a7a42	39768f1a-63ac-4c32-b4f2-82d2542d4133	2025-09-03 17:56:35.944677+00	0	{"min_ratio": 3}
8c0322ba-3f33-48d0-b100-977051ec8412	2d96cef2-7502-44ff-a7a9-17713d4a7a42	a69ec499-8fcf-438d-a7e0-fa39c0d43787	2025-09-03 17:56:36.498714+00	0	{"required_count": 3, "symbols_traded": "3"}
4e9bea30-a0d9-451d-84f8-537860ec6d80	2d96cef2-7502-44ff-a7a9-17713d4a7a42	ec7eb93a-7a35-423b-9a43-2351a7bb8262	2025-09-03 17:56:36.505151+00	0	{"trade_date": "2025-02-18T00:00:00.000Z", "daily_volume": "2000.0000", "target_shares": 1000}
919808b7-8212-4262-ac55-2e3b768896e8	2d96cef2-7502-44ff-a7a9-17713d4a7a42	377b3e65-9bfe-40f8-b5ba-373b5514d031	2025-09-03 17:56:38.428929+00	0	{"total_trades": "10"}
1c7cbb8f-ddf5-4d02-a4f5-b1e00f8189f2	2d96cef2-7502-44ff-a7a9-17713d4a7a42	4077e5cc-5110-48ac-93f8-b38aa59818de	2025-09-03 17:56:44.17245+00	0	{"min_profit": 500}
c61a8188-ebad-44ae-acce-00d17a85a343	2d96cef2-7502-44ff-a7a9-17713d4a7a42	57ef7bdf-1e0d-471a-bc94-4d04e365e35c	2025-09-03 17:56:48.965742+00	0	{"required_days": 5, "streak_length": "5"}
c4f7d07e-c17a-440e-8d06-ed8abe0b83e5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	43d6b4ad-5599-4a54-b3c8-ac701a4dfe98	2025-09-03 17:56:54.521465+00	0	{"win_rate": 56.00000000000001, "winning_trades": "28", "trades_analyzed": "50"}
7fe90e88-90ef-4b02-91d9-8ea6c18fc30b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e8e342b8-d82f-4d57-a8b1-84413b28b0a7	2025-09-03 17:56:59.898059+00	0	{"min_size": 5000}
0c43cfd5-c0b7-4048-9ed8-bce08f589c1e	2d96cef2-7502-44ff-a7a9-17713d4a7a42	3fd056e5-4f18-44e7-8056-d0075ed8bc62	2025-09-03 17:57:04.045397+00	0	{"trade_date": "2025-02-11T00:00:00.000Z", "daily_volume": "24200.0000", "target_shares": 10000}
2ba9c4ef-8172-474a-ad4c-b066671ab9d3	2d96cef2-7502-44ff-a7a9-17713d4a7a42	e1ddbf74-8fbb-4254-bc37-c8ebe99b0f74	2025-09-03 17:57:04.051951+00	0	{"min_size": 10000}
cdeacc4e-3b18-4baa-b0ed-b0c98235e5c9	2d96cef2-7502-44ff-a7a9-17713d4a7a42	2b12d089-8b18-4c6b-afba-f2f981f32d8a	2025-09-03 17:57:04.053456+00	0	{"min_profit": 1000}
b2f0e690-e8fb-4dda-ac7d-733692ea749f	2d96cef2-7502-44ff-a7a9-17713d4a7a42	bb796b96-d02a-4a76-9b5a-e199c94229d5	2025-09-03 17:57:04.056629+00	0	{"min_profit": 1500}
ae889a9c-a5bc-4aea-9c96-28707a69a225	2d96cef2-7502-44ff-a7a9-17713d4a7a42	26f017b9-30e2-4457-a0a7-aaf2312ad0fd	2025-09-03 17:58:12.149076+00	0	{"total_trades": "100"}
296a3d0e-3e79-4632-a874-7a1ce4d7e61d	2d96cef2-7502-44ff-a7a9-17713d4a7a42	27c163c3-ecfa-441c-838d-9a78dcd10664	2025-09-03 17:58:21.48167+00	0	{"after_hour": 20, "late_trades": "2"}
0782e3c5-261c-4e50-aa48-7e4107d30dd5	2d96cef2-7502-44ff-a7a9-17713d4a7a42	58e5510a-369e-4ad2-bd18-cb5f335d64ef	2025-09-03 18:21:21.69231+00	0	{"before_hour": 9, "early_trades": "1"}
20766dcb-a8f9-4f81-a433-30d18ffa87de	2d96cef2-7502-44ff-a7a9-17713d4a7a42	c14a90cc-1a88-4626-8a31-94d1513b8aca	2025-09-03 18:48:42.576706+00	0	{"min_size": 25000}
\.


--
-- Data for Name: user_challenges; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.user_challenges (id, user_id, challenge_id, status, progress, started_at, completed_at, metadata) FROM stdin;
\.


--
-- Data for Name: user_gamification_stats; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.user_gamification_stats (user_id, total_points, achievement_count, challenge_count, current_streak_days, longest_streak_days, last_achievement_date, level, experience_points, badges, updated_at) FROM stdin;
2d96cef2-7502-44ff-a7a9-17713d4a7a42	4995	22	0	0	5	2025-09-03 18:48:42.578108+00	5	4995	[]	2025-09-25 19:21:40.619061+00
\.


--
-- Data for Name: user_peer_groups; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.user_peer_groups (user_id, peer_group_id, joined_at, is_active) FROM stdin;
\.


--
-- Data for Name: user_settings; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.user_settings (id, user_id, email_notifications, public_profile, default_tags, import_settings, theme, created_at, updated_at, account_equity, trading_strategies, trading_styles, risk_tolerance, primary_markets, experience_level, average_position_size, trading_goals, preferred_sectors, ai_provider, ai_api_key, ai_api_url, ai_model, statistics_calculation) FROM stdin;
b7011ff4-a37d-435a-91e3-01be554e1632	2d96cef2-7502-44ff-a7a9-17713d4a7a42	t	f	\N	{}	light	2025-09-03 17:56:02.309313+00	2025-09-03 20:19:20.779682+00	0.00	{}	{}	moderate	{}	intermediate	medium	{}	{}	ollama		http://192.168.2.13:11434	gemma3:4b	average
2edcd9e7-3f0a-4485-bc25-ed52394511d7	5115e1a1-42cb-4532-94d1-331f82d361d4	t	f	\N	{}	light	2025-09-04 00:37:37.416069+00	2025-09-04 00:37:37.416069+00	0.00	{}	{}	moderate	{}	intermediate	medium	{}	{}	gemini	\N	\N	\N	average
\.


--
-- Data for Name: users; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.users (id, email, username, password_hash, full_name, avatar_url, is_verified, is_active, timezone, created_at, updated_at, verification_token, verification_expires, reset_token, reset_expires, role, admin_approved, two_factor_secret, two_factor_enabled, two_factor_backup_codes, two_factor_enabled_at, tier, notify_news_open_positions, notify_earnings_announcements, notify_price_alerts, notify_trade_reminders, notify_market_events, trial_used) FROM stdin;
2d96cef2-7502-44ff-a7a9-17713d4a7a42	test@test.com	test	$2a$10$40XqbkF4sn5L5dBk1bW7MOyylLKZksoSj9aEOgh1HOAhDkLhrsiJ2	test	\N	t	t	UTC	2025-09-03 17:56:02.306106+00	2025-09-03 17:56:02.306106+00	\N	\N	\N	\N	admin	t	\N	f	\N	\N	pro	t	t	t	t	f	f
5115e1a1-42cb-4532-94d1-331f82d361d4	testfree@test.com	testfree	$2b$10$92IXUNpkjO0rOQ5byMi.Ye4oKoEa3Ro9llC/.og/at2.uheWG/igi	Test Free User	\N	t	t	UTC	2025-09-04 00:37:10.949618+00	2025-09-04 00:37:10.949618+00	\N	\N	\N	\N	user	t	\N	f	\N	\N	free	t	t	t	t	f	f
\.


--
-- Data for Name: watchlist_items; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.watchlist_items (id, watchlist_id, symbol, added_at, notes) FROM stdin;
70b4e2b9-3602-4d8a-a41d-c36b60693f3c	0afaae8d-27b2-4634-9d9f-401075da184b	PYXS	2025-09-03 19:43:02.846635	\N
\.


--
-- Data for Name: watchlists; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.watchlists (id, user_id, name, description, is_default, created_at, updated_at) FROM stdin;
0afaae8d-27b2-4634-9d9f-401075da184b	2d96cef2-7502-44ff-a7a9-17713d4a7a42	Default		f	2025-09-03 19:42:52.917768	2025-09-03 19:42:52.917768
\.


--
-- Data for Name: win_loss_streaks; Type: TABLE DATA; Schema: public; Owner: trader
--

COPY public.win_loss_streaks (id, user_id, streak_type, current_length, streak_start_date, last_trade_date, total_pnl, trade_ids, baseline_position_size, max_position_size, is_active, created_at, updated_at) FROM stdin;
\.


--
-- Name: admin_settings_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.admin_settings_id_seq', 24, true);


--
-- Name: cusip_lookup_queue_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.cusip_lookup_queue_id_seq', 409, true);


--
-- Name: loss_aversion_events_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.loss_aversion_events_id_seq', 1, true);


--
-- Name: migrations_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.migrations_id_seq', 101, true);


--
-- Name: personality_drift_tracking_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.personality_drift_tracking_id_seq', 1, false);


--
-- Name: personality_peer_comparison_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.personality_peer_comparison_id_seq', 1, false);


--
-- Name: personality_trade_analysis_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.personality_trade_analysis_id_seq', 1, false);


--
-- Name: stock_split_check_log_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.stock_split_check_log_id_seq', 43, true);


--
-- Name: stock_splits_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.stock_splits_id_seq', 39, true);


--
-- Name: symbol_categories_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.symbol_categories_id_seq', 174, true);


--
-- Name: sync_metadata_sync_version_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.sync_metadata_sync_version_seq', 1, false);


--
-- Name: tick_data_cache_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.tick_data_cache_id_seq', 1, false);


--
-- Name: tick_data_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.tick_data_id_seq', 1, false);


--
-- Name: trade_hold_patterns_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.trade_hold_patterns_id_seq', 424, true);


--
-- Name: trade_split_adjustments_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.trade_split_adjustments_id_seq', 1, true);


--
-- Name: trading_personality_profiles_id_seq; Type: SEQUENCE SET; Schema: public; Owner: trader
--

SELECT pg_catalog.setval('public.trading_personality_profiles_id_seq', 1, true);


--
-- Name: achievement_milestones achievement_milestones_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.achievement_milestones
    ADD CONSTRAINT achievement_milestones_pkey PRIMARY KEY (id);


--
-- Name: achievements achievements_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.achievements
    ADD CONSTRAINT achievements_key_key UNIQUE (key);


--
-- Name: achievements achievements_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.achievements
    ADD CONSTRAINT achievements_pkey PRIMARY KEY (id);


--
-- Name: admin_settings admin_settings_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.admin_settings
    ADD CONSTRAINT admin_settings_pkey PRIMARY KEY (id);


--
-- Name: admin_settings admin_settings_setting_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.admin_settings
    ADD CONSTRAINT admin_settings_setting_key_key UNIQUE (setting_key);


--
-- Name: alert_notifications alert_notifications_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.alert_notifications
    ADD CONSTRAINT alert_notifications_pkey PRIMARY KEY (id);


--
-- Name: analytics_cache analytics_cache_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.analytics_cache
    ADD CONSTRAINT analytics_cache_pkey PRIMARY KEY (id);


--
-- Name: analytics_cache analytics_cache_user_id_cache_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.analytics_cache
    ADD CONSTRAINT analytics_cache_user_id_cache_key_key UNIQUE (user_id, cache_key);


--
-- Name: api_keys api_keys_key_hash_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.api_keys
    ADD CONSTRAINT api_keys_key_hash_key UNIQUE (key_hash);


--
-- Name: api_keys api_keys_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.api_keys
    ADD CONSTRAINT api_keys_pkey PRIMARY KEY (id);


--
-- Name: behavioral_alerts behavioral_alerts_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_alerts
    ADD CONSTRAINT behavioral_alerts_pkey PRIMARY KEY (id);


--
-- Name: behavioral_patterns behavioral_patterns_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_patterns
    ADD CONSTRAINT behavioral_patterns_pkey PRIMARY KEY (id);


--
-- Name: behavioral_settings behavioral_settings_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_settings
    ADD CONSTRAINT behavioral_settings_pkey PRIMARY KEY (id);


--
-- Name: behavioral_settings behavioral_settings_user_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_settings
    ADD CONSTRAINT behavioral_settings_user_id_key UNIQUE (user_id);


--
-- Name: challenges challenges_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.challenges
    ADD CONSTRAINT challenges_key_key UNIQUE (key);


--
-- Name: challenges challenges_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.challenges
    ADD CONSTRAINT challenges_pkey PRIMARY KEY (id);


--
-- Name: cusip_lookup_queue cusip_lookup_queue_cusip_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_lookup_queue
    ADD CONSTRAINT cusip_lookup_queue_cusip_key UNIQUE (cusip);


--
-- Name: cusip_lookup_queue cusip_lookup_queue_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_lookup_queue
    ADD CONSTRAINT cusip_lookup_queue_pkey PRIMARY KEY (id);


--
-- Name: cusip_mappings cusip_mappings_cusip_user_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_mappings
    ADD CONSTRAINT cusip_mappings_cusip_user_id_key UNIQUE (cusip, user_id);


--
-- Name: cusip_mappings cusip_mappings_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_mappings
    ADD CONSTRAINT cusip_mappings_pkey PRIMARY KEY (id);


--
-- Name: device_tokens device_tokens_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.device_tokens
    ADD CONSTRAINT device_tokens_pkey PRIMARY KEY (id);


--
-- Name: device_tokens device_tokens_user_id_device_token_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.device_tokens
    ADD CONSTRAINT device_tokens_user_id_device_token_key UNIQUE (user_id, device_token);


--
-- Name: devices devices_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.devices
    ADD CONSTRAINT devices_pkey PRIMARY KEY (id);


--
-- Name: diary_attachments diary_attachments_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.diary_attachments
    ADD CONSTRAINT diary_attachments_pkey PRIMARY KEY (id);


--
-- Name: diary_entries diary_entries_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.diary_entries
    ADD CONSTRAINT diary_entries_pkey PRIMARY KEY (id);


--
-- Name: diary_entries diary_entries_user_id_entry_date_entry_type_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.diary_entries
    ADD CONSTRAINT diary_entries_user_id_entry_date_entry_type_key UNIQUE (user_id, entry_date, entry_type);


--
-- Name: enrichment_cache enrichment_cache_cache_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.enrichment_cache
    ADD CONSTRAINT enrichment_cache_cache_key_key UNIQUE (cache_key);


--
-- Name: enrichment_cache enrichment_cache_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.enrichment_cache
    ADD CONSTRAINT enrichment_cache_pkey PRIMARY KEY (id);


--
-- Name: equity_history equity_history_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.equity_history
    ADD CONSTRAINT equity_history_pkey PRIMARY KEY (id);


--
-- Name: equity_snapshots equity_snapshots_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.equity_snapshots
    ADD CONSTRAINT equity_snapshots_pkey PRIMARY KEY (id);


--
-- Name: features features_feature_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.features
    ADD CONSTRAINT features_feature_key_key UNIQUE (feature_key);


--
-- Name: features features_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.features
    ADD CONSTRAINT features_pkey PRIMARY KEY (id);


--
-- Name: gamification_privacy gamification_privacy_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.gamification_privacy
    ADD CONSTRAINT gamification_privacy_pkey PRIMARY KEY (user_id);


--
-- Name: global_enrichment_cache global_enrichment_cache_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.global_enrichment_cache
    ADD CONSTRAINT global_enrichment_cache_pkey PRIMARY KEY (id);


--
-- Name: import_logs import_logs_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.import_logs
    ADD CONSTRAINT import_logs_pkey PRIMARY KEY (id);


--
-- Name: instance_config instance_config_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.instance_config
    ADD CONSTRAINT instance_config_key_key UNIQUE (key);


--
-- Name: instance_config instance_config_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.instance_config
    ADD CONSTRAINT instance_config_pkey PRIMARY KEY (id);


--
-- Name: job_queue job_queue_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.job_queue
    ADD CONSTRAINT job_queue_pkey PRIMARY KEY (id);


--
-- Name: leaderboard_entries leaderboard_entries_leaderboard_id_user_id_recorded_at_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.leaderboard_entries
    ADD CONSTRAINT leaderboard_entries_leaderboard_id_user_id_recorded_at_key UNIQUE (leaderboard_id, user_id, recorded_at);


--
-- Name: leaderboard_entries leaderboard_entries_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.leaderboard_entries
    ADD CONSTRAINT leaderboard_entries_pkey PRIMARY KEY (id);


--
-- Name: leaderboards leaderboards_key_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.leaderboards
    ADD CONSTRAINT leaderboards_key_key UNIQUE (key);


--
-- Name: leaderboards leaderboards_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.leaderboards
    ADD CONSTRAINT leaderboards_pkey PRIMARY KEY (id);


--
-- Name: loss_aversion_events loss_aversion_events_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.loss_aversion_events
    ADD CONSTRAINT loss_aversion_events_pkey PRIMARY KEY (id);


--
-- Name: migrations migrations_filename_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.migrations
    ADD CONSTRAINT migrations_filename_key UNIQUE (filename);


--
-- Name: migrations migrations_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.migrations
    ADD CONSTRAINT migrations_pkey PRIMARY KEY (id);


--
-- Name: news_cache news_cache_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.news_cache
    ADD CONSTRAINT news_cache_pkey PRIMARY KEY (id);


--
-- Name: news_cache news_cache_symbol_news_date_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.news_cache
    ADD CONSTRAINT news_cache_symbol_news_date_key UNIQUE (symbol, news_date);


--
-- Name: notification_preferences notification_preferences_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notification_preferences
    ADD CONSTRAINT notification_preferences_pkey PRIMARY KEY (id);


--
-- Name: notification_preferences notification_preferences_user_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notification_preferences
    ADD CONSTRAINT notification_preferences_user_id_key UNIQUE (user_id);


--
-- Name: notification_read_status notification_read_status_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notification_read_status
    ADD CONSTRAINT notification_read_status_pkey PRIMARY KEY (id);


--
-- Name: notification_read_status notification_read_status_user_id_notification_type_notifica_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notification_read_status
    ADD CONSTRAINT notification_read_status_user_id_notification_type_notifica_key UNIQUE (user_id, notification_type, notification_id);


--
-- Name: notifications notifications_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notifications
    ADD CONSTRAINT notifications_pkey PRIMARY KEY (id);


--
-- Name: overconfidence_events overconfidence_events_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.overconfidence_events
    ADD CONSTRAINT overconfidence_events_pkey PRIMARY KEY (id);


--
-- Name: overconfidence_settings overconfidence_settings_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.overconfidence_settings
    ADD CONSTRAINT overconfidence_settings_pkey PRIMARY KEY (id);


--
-- Name: overconfidence_settings overconfidence_settings_user_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.overconfidence_settings
    ADD CONSTRAINT overconfidence_settings_user_id_key UNIQUE (user_id);


--
-- Name: peer_groups peer_groups_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.peer_groups
    ADD CONSTRAINT peer_groups_pkey PRIMARY KEY (id);


--
-- Name: personality_drift_tracking personality_drift_tracking_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_drift_tracking
    ADD CONSTRAINT personality_drift_tracking_pkey PRIMARY KEY (id);


--
-- Name: personality_peer_comparison personality_peer_comparison_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_peer_comparison
    ADD CONSTRAINT personality_peer_comparison_pkey PRIMARY KEY (id);


--
-- Name: personality_trade_analysis personality_trade_analysis_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_trade_analysis
    ADD CONSTRAINT personality_trade_analysis_pkey PRIMARY KEY (id);


--
-- Name: price_alerts price_alerts_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.price_alerts
    ADD CONSTRAINT price_alerts_pkey PRIMARY KEY (id);


--
-- Name: price_monitoring price_monitoring_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.price_monitoring
    ADD CONSTRAINT price_monitoring_pkey PRIMARY KEY (id);


--
-- Name: price_monitoring price_monitoring_symbol_unique; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.price_monitoring
    ADD CONSTRAINT price_monitoring_symbol_unique UNIQUE (symbol);


--
-- Name: refresh_tokens refresh_tokens_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.refresh_tokens
    ADD CONSTRAINT refresh_tokens_pkey PRIMARY KEY (id);


--
-- Name: refresh_tokens refresh_tokens_token_hash_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.refresh_tokens
    ADD CONSTRAINT refresh_tokens_token_hash_key UNIQUE (token_hash);


--
-- Name: revenge_trade_tick_analysis revenge_trade_tick_analysis_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trade_tick_analysis
    ADD CONSTRAINT revenge_trade_tick_analysis_pkey PRIMARY KEY (id);


--
-- Name: revenge_trade_tick_analysis revenge_trade_tick_analysis_user_id_revenge_trade_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trade_tick_analysis
    ADD CONSTRAINT revenge_trade_tick_analysis_user_id_revenge_trade_id_key UNIQUE (user_id, revenge_trade_id);


--
-- Name: revenge_trading_events revenge_trading_events_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trading_events
    ADD CONSTRAINT revenge_trading_events_pkey PRIMARY KEY (id);


--
-- Name: round_trip_trades round_trip_trades_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.round_trip_trades
    ADD CONSTRAINT round_trip_trades_pkey PRIMARY KEY (id);


--
-- Name: stock_split_check_log stock_split_check_log_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.stock_split_check_log
    ADD CONSTRAINT stock_split_check_log_pkey PRIMARY KEY (id);


--
-- Name: stock_split_check_log stock_split_check_log_symbol_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.stock_split_check_log
    ADD CONSTRAINT stock_split_check_log_symbol_key UNIQUE (symbol);


--
-- Name: stock_splits stock_splits_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.stock_splits
    ADD CONSTRAINT stock_splits_pkey PRIMARY KEY (id);


--
-- Name: stock_splits stock_splits_symbol_split_date_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.stock_splits
    ADD CONSTRAINT stock_splits_symbol_split_date_key UNIQUE (symbol, split_date);


--
-- Name: strategy_classification_history strategy_classification_history_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.strategy_classification_history
    ADD CONSTRAINT strategy_classification_history_pkey PRIMARY KEY (id);


--
-- Name: subscriptions subscriptions_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.subscriptions
    ADD CONSTRAINT subscriptions_pkey PRIMARY KEY (id);


--
-- Name: subscriptions subscriptions_stripe_customer_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.subscriptions
    ADD CONSTRAINT subscriptions_stripe_customer_id_key UNIQUE (stripe_customer_id);


--
-- Name: subscriptions subscriptions_stripe_subscription_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.subscriptions
    ADD CONSTRAINT subscriptions_stripe_subscription_id_key UNIQUE (stripe_subscription_id);


--
-- Name: symbol_categories symbol_categories_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.symbol_categories
    ADD CONSTRAINT symbol_categories_pkey PRIMARY KEY (id);


--
-- Name: symbol_categories symbol_categories_symbol_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.symbol_categories
    ADD CONSTRAINT symbol_categories_symbol_key UNIQUE (symbol);


--
-- Name: sync_metadata sync_metadata_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.sync_metadata
    ADD CONSTRAINT sync_metadata_pkey PRIMARY KEY (id);


--
-- Name: tags tags_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tags
    ADD CONSTRAINT tags_pkey PRIMARY KEY (id);


--
-- Name: tags tags_user_id_name_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tags
    ADD CONSTRAINT tags_user_id_name_key UNIQUE (user_id, name);


--
-- Name: tick_data_cache tick_data_cache_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tick_data_cache
    ADD CONSTRAINT tick_data_cache_pkey PRIMARY KEY (id);


--
-- Name: tick_data_cache tick_data_cache_symbol_date_start_timestamp_end_timestamp_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tick_data_cache
    ADD CONSTRAINT tick_data_cache_symbol_date_start_timestamp_end_timestamp_key UNIQUE (symbol, date, start_timestamp, end_timestamp);


--
-- Name: tick_data tick_data_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tick_data
    ADD CONSTRAINT tick_data_pkey PRIMARY KEY (id);


--
-- Name: tick_data tick_data_symbol_timestamp_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tick_data
    ADD CONSTRAINT tick_data_symbol_timestamp_key UNIQUE (symbol, "timestamp");


--
-- Name: tier_overrides tier_overrides_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tier_overrides
    ADD CONSTRAINT tier_overrides_pkey PRIMARY KEY (id);


--
-- Name: tier_overrides tier_overrides_user_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tier_overrides
    ADD CONSTRAINT tier_overrides_user_id_key UNIQUE (user_id);


--
-- Name: trade_attachments trade_attachments_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_attachments
    ADD CONSTRAINT trade_attachments_pkey PRIMARY KEY (id);


--
-- Name: trade_comments trade_comments_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_comments
    ADD CONSTRAINT trade_comments_pkey PRIMARY KEY (id);


--
-- Name: trade_hold_patterns trade_hold_patterns_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_hold_patterns
    ADD CONSTRAINT trade_hold_patterns_pkey PRIMARY KEY (id);


--
-- Name: trade_split_adjustments trade_split_adjustments_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_split_adjustments
    ADD CONSTRAINT trade_split_adjustments_pkey PRIMARY KEY (id);


--
-- Name: trade_split_adjustments trade_split_adjustments_trade_id_split_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_split_adjustments
    ADD CONSTRAINT trade_split_adjustments_trade_id_split_id_key UNIQUE (trade_id, split_id);


--
-- Name: trades trades_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trades
    ADD CONSTRAINT trades_pkey PRIMARY KEY (id);


--
-- Name: trading_personality_profiles trading_personality_profiles_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trading_personality_profiles
    ADD CONSTRAINT trading_personality_profiles_pkey PRIMARY KEY (id);


--
-- Name: global_enrichment_cache unique_symbol_date; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.global_enrichment_cache
    ADD CONSTRAINT unique_symbol_date UNIQUE (symbol, trade_date);


--
-- Name: user_achievements user_achievements_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_achievements
    ADD CONSTRAINT user_achievements_pkey PRIMARY KEY (id);


--
-- Name: user_achievements user_achievements_user_achievement_unique; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_achievements
    ADD CONSTRAINT user_achievements_user_achievement_unique UNIQUE (user_id, achievement_id);


--
-- Name: user_challenges user_challenges_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_challenges
    ADD CONSTRAINT user_challenges_pkey PRIMARY KEY (id);


--
-- Name: user_challenges user_challenges_user_id_challenge_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_challenges
    ADD CONSTRAINT user_challenges_user_id_challenge_id_key UNIQUE (user_id, challenge_id);


--
-- Name: user_gamification_stats user_gamification_stats_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_gamification_stats
    ADD CONSTRAINT user_gamification_stats_pkey PRIMARY KEY (user_id);


--
-- Name: user_peer_groups user_peer_groups_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_peer_groups
    ADD CONSTRAINT user_peer_groups_pkey PRIMARY KEY (user_id, peer_group_id);


--
-- Name: user_settings user_settings_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_settings
    ADD CONSTRAINT user_settings_pkey PRIMARY KEY (id);


--
-- Name: user_settings user_settings_user_id_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_settings
    ADD CONSTRAINT user_settings_user_id_key UNIQUE (user_id);


--
-- Name: users users_email_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.users
    ADD CONSTRAINT users_email_key UNIQUE (email);


--
-- Name: users users_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.users
    ADD CONSTRAINT users_pkey PRIMARY KEY (id);


--
-- Name: users users_username_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.users
    ADD CONSTRAINT users_username_key UNIQUE (username);


--
-- Name: watchlist_items watchlist_items_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.watchlist_items
    ADD CONSTRAINT watchlist_items_pkey PRIMARY KEY (id);


--
-- Name: watchlist_items watchlist_items_symbol_unique; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.watchlist_items
    ADD CONSTRAINT watchlist_items_symbol_unique UNIQUE (watchlist_id, symbol);


--
-- Name: watchlists watchlists_name_user_unique; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.watchlists
    ADD CONSTRAINT watchlists_name_user_unique UNIQUE (user_id, name);


--
-- Name: watchlists watchlists_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.watchlists
    ADD CONSTRAINT watchlists_pkey PRIMARY KEY (id);


--
-- Name: win_loss_streaks win_loss_streaks_pkey; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.win_loss_streaks
    ADD CONSTRAINT win_loss_streaks_pkey PRIMARY KEY (id);


--
-- Name: win_loss_streaks win_loss_streaks_user_id_is_active_key; Type: CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.win_loss_streaks
    ADD CONSTRAINT win_loss_streaks_user_id_is_active_key UNIQUE (user_id, is_active);


--
-- Name: idx_achievement_milestones_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_achievement_milestones_user ON public.achievement_milestones USING btree (user_id);


--
-- Name: idx_alert_notifications_alert; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_alert ON public.alert_notifications USING btree (price_alert_id);


--
-- Name: idx_alert_notifications_deleted_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_deleted_at ON public.alert_notifications USING btree (deleted_at) WHERE (deleted_at IS NULL);


--
-- Name: idx_alert_notifications_sent; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_sent ON public.alert_notifications USING btree (sent_at DESC);


--
-- Name: idx_alert_notifications_sent_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_sent_at ON public.alert_notifications USING btree (sent_at);


--
-- Name: idx_alert_notifications_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_symbol ON public.alert_notifications USING btree (symbol);


--
-- Name: idx_alert_notifications_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_user ON public.alert_notifications USING btree (user_id);


--
-- Name: idx_alert_notifications_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_alert_notifications_user_id ON public.alert_notifications USING btree (user_id);


--
-- Name: idx_analytics_cache_user_expires; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_analytics_cache_user_expires ON public.analytics_cache USING btree (user_id, expires_at);


--
-- Name: idx_api_keys_active; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_api_keys_active ON public.api_keys USING btree (is_active) WHERE (is_active = true);


--
-- Name: idx_api_keys_expires_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_api_keys_expires_at ON public.api_keys USING btree (expires_at) WHERE (expires_at IS NOT NULL);


--
-- Name: idx_api_keys_key_hash; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_api_keys_key_hash ON public.api_keys USING btree (key_hash);


--
-- Name: idx_api_keys_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_api_keys_user_id ON public.api_keys USING btree (user_id);


--
-- Name: idx_behavioral_alerts_status; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_behavioral_alerts_status ON public.behavioral_alerts USING btree (status);


--
-- Name: idx_behavioral_alerts_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_behavioral_alerts_user_id ON public.behavioral_alerts USING btree (user_id);


--
-- Name: idx_behavioral_patterns_detected_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_behavioral_patterns_detected_at ON public.behavioral_patterns USING btree (detected_at);


--
-- Name: idx_behavioral_patterns_type; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_behavioral_patterns_type ON public.behavioral_patterns USING btree (pattern_type);


--
-- Name: idx_behavioral_patterns_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_behavioral_patterns_user_id ON public.behavioral_patterns USING btree (user_id);


--
-- Name: idx_behavioral_settings_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_behavioral_settings_user_id ON public.behavioral_settings USING btree (user_id);


--
-- Name: idx_cache_expires_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cache_expires_at ON public.tick_data_cache USING btree (expires_at);


--
-- Name: idx_cache_symbol_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cache_symbol_date ON public.tick_data_cache USING btree (symbol, date);


--
-- Name: idx_cusip_mappings_cusip; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_mappings_cusip ON public.cusip_mappings USING btree (cusip);


--
-- Name: idx_cusip_mappings_lookup; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_mappings_lookup ON public.cusip_mappings USING btree (cusip, user_id);


--
-- Name: idx_cusip_mappings_source; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_mappings_source ON public.cusip_mappings USING btree (resolution_source);


--
-- Name: idx_cusip_mappings_ticker; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_mappings_ticker ON public.cusip_mappings USING btree (ticker);


--
-- Name: idx_cusip_mappings_unique_global_ticker; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_cusip_mappings_unique_global_ticker ON public.cusip_mappings USING btree (ticker) WHERE (user_id IS NULL);


--
-- Name: INDEX idx_cusip_mappings_unique_global_ticker; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON INDEX public.idx_cusip_mappings_unique_global_ticker IS 'Ensures each ticker maps to only one CUSIP globally (user overrides allowed)';


--
-- Name: idx_cusip_mappings_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_mappings_user_id ON public.cusip_mappings USING btree (user_id);


--
-- Name: idx_cusip_mappings_verified; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_mappings_verified ON public.cusip_mappings USING btree (verified);


--
-- Name: idx_cusip_queue_cusip; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_queue_cusip ON public.cusip_lookup_queue USING btree (cusip);


--
-- Name: idx_cusip_queue_priority; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_queue_priority ON public.cusip_lookup_queue USING btree (priority DESC, created_at);


--
-- Name: idx_cusip_queue_status; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_cusip_queue_status ON public.cusip_lookup_queue USING btree (status);


--
-- Name: idx_device_tokens_active; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_device_tokens_active ON public.device_tokens USING btree (active);


--
-- Name: idx_device_tokens_platform; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_device_tokens_platform ON public.device_tokens USING btree (platform);


--
-- Name: idx_device_tokens_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_device_tokens_user_id ON public.device_tokens USING btree (user_id);


--
-- Name: idx_devices_fingerprint; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_devices_fingerprint ON public.devices USING btree (device_fingerprint);


--
-- Name: idx_devices_last_active; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_devices_last_active ON public.devices USING btree (last_active);


--
-- Name: idx_devices_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_devices_user_id ON public.devices USING btree (user_id);


--
-- Name: idx_diary_attachments_diary_entry_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_attachments_diary_entry_id ON public.diary_attachments USING btree (diary_entry_id);


--
-- Name: idx_diary_entries_entry_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_entries_entry_date ON public.diary_entries USING btree (entry_date);


--
-- Name: idx_diary_entries_entry_type; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_entries_entry_type ON public.diary_entries USING btree (entry_type);


--
-- Name: idx_diary_entries_market_bias; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_entries_market_bias ON public.diary_entries USING btree (market_bias) WHERE (market_bias IS NOT NULL);


--
-- Name: idx_diary_entries_tags; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_entries_tags ON public.diary_entries USING gin (tags);


--
-- Name: idx_diary_entries_user_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_entries_user_date ON public.diary_entries USING btree (user_id, entry_date);


--
-- Name: idx_diary_entries_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_diary_entries_user_id ON public.diary_entries USING btree (user_id);


--
-- Name: idx_enrichment_cache_cache_key; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_enrichment_cache_cache_key ON public.enrichment_cache USING btree (cache_key);


--
-- Name: idx_enrichment_cache_created; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_enrichment_cache_created ON public.enrichment_cache USING btree (created_at);


--
-- Name: idx_enrichment_cache_expires; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_enrichment_cache_expires ON public.enrichment_cache USING btree (expires_at) WHERE (expires_at IS NOT NULL);


--
-- Name: idx_enrichment_cache_symbol_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_enrichment_cache_symbol_date ON public.enrichment_cache USING btree (symbol, entry_date);


--
-- Name: idx_equity_history_user_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_equity_history_user_date ON public.equity_history USING btree (user_id, date);


--
-- Name: idx_equity_history_user_date_unique; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_equity_history_user_date_unique ON public.equity_history USING btree (user_id, date);


--
-- Name: idx_equity_snapshots_user_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_equity_snapshots_user_date ON public.equity_snapshots USING btree (user_id, snapshot_date);


--
-- Name: idx_equity_snapshots_user_date_unique; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_equity_snapshots_user_date_unique ON public.equity_snapshots USING btree (user_id, snapshot_date);


--
-- Name: idx_features_feature_key; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_features_feature_key ON public.features USING btree (feature_key);


--
-- Name: idx_features_required_tier; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_features_required_tier ON public.features USING btree (required_tier);


--
-- Name: idx_global_enrichment_cache_created; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_global_enrichment_cache_created ON public.global_enrichment_cache USING btree (created_at);


--
-- Name: idx_global_enrichment_cache_expires; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_global_enrichment_cache_expires ON public.global_enrichment_cache USING btree (expires_at) WHERE (expires_at IS NOT NULL);


--
-- Name: idx_global_enrichment_cache_symbol_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_global_enrichment_cache_symbol_date ON public.global_enrichment_cache USING btree (symbol, trade_date);


--
-- Name: idx_job_queue_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_job_queue_created_at ON public.job_queue USING btree (created_at);


--
-- Name: idx_job_queue_status_priority; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_job_queue_status_priority ON public.job_queue USING btree (status, priority, created_at) WHERE ((status)::text = 'pending'::text);


--
-- Name: idx_job_queue_trade_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_job_queue_trade_id ON public.job_queue USING gin (((data -> 'tradeId'::text))) WHERE (data ? 'tradeId'::text);


--
-- Name: idx_job_queue_type; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_job_queue_type ON public.job_queue USING btree (type);


--
-- Name: idx_job_queue_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_job_queue_user_id ON public.job_queue USING btree (user_id);


--
-- Name: idx_leaderboard_entries_board_rank; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_leaderboard_entries_board_rank ON public.leaderboard_entries USING btree (leaderboard_id, rank);


--
-- Name: idx_leaderboard_entries_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_leaderboard_entries_user ON public.leaderboard_entries USING btree (user_id);


--
-- Name: idx_loss_aversion_user_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_loss_aversion_user_date ON public.loss_aversion_events USING btree (user_id, analysis_end_date DESC);


--
-- Name: idx_news_cache_checked_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_news_cache_checked_at ON public.news_cache USING btree (checked_at);


--
-- Name: idx_news_cache_symbol_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_news_cache_symbol_date ON public.news_cache USING btree (symbol, news_date);


--
-- Name: idx_notification_preferences_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_notification_preferences_user_id ON public.notification_preferences USING btree (user_id);


--
-- Name: idx_notification_read_status_notification; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_notification_read_status_notification ON public.notification_read_status USING btree (notification_type, notification_id);


--
-- Name: idx_notification_read_status_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_notification_read_status_user_id ON public.notification_read_status USING btree (user_id);


--
-- Name: idx_notifications_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_notifications_created_at ON public.notifications USING btree (created_at);


--
-- Name: idx_notifications_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_notifications_user_id ON public.notifications USING btree (user_id);


--
-- Name: idx_overconfidence_events_ai_generated_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_overconfidence_events_ai_generated_at ON public.overconfidence_events USING btree (ai_generated_at);


--
-- Name: idx_overconfidence_events_ai_provider; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_overconfidence_events_ai_provider ON public.overconfidence_events USING btree (ai_provider);


--
-- Name: idx_overconfidence_events_severity; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_overconfidence_events_severity ON public.overconfidence_events USING btree (severity);


--
-- Name: idx_overconfidence_events_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_overconfidence_events_user_id ON public.overconfidence_events USING btree (user_id);


--
-- Name: idx_overconfidence_events_win_streak_start; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_overconfidence_events_win_streak_start ON public.overconfidence_events USING btree (win_streak_start_date);


--
-- Name: idx_overconfidence_settings_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_overconfidence_settings_user_id ON public.overconfidence_settings USING btree (user_id);


--
-- Name: idx_peer_comparison_user_type; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_peer_comparison_user_type ON public.personality_peer_comparison USING btree (user_id, personality_type);


--
-- Name: idx_personality_drift_tracking_user_date_unique; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_personality_drift_tracking_user_date_unique ON public.personality_drift_tracking USING btree (user_id, analysis_date);


--
-- Name: INDEX idx_personality_drift_tracking_user_date_unique; Type: COMMENT; Schema: public; Owner: trader
--

COMMENT ON INDEX public.idx_personality_drift_tracking_user_date_unique IS 'Unique constraint for personality drift tracking - one analysis per user per date';


--
-- Name: idx_personality_drift_user_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_personality_drift_user_date ON public.personality_drift_tracking USING btree (user_id, analysis_date DESC);


--
-- Name: idx_personality_profiles_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_personality_profiles_user ON public.trading_personality_profiles USING btree (user_id);


--
-- Name: idx_personality_profiles_user_unique; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_personality_profiles_user_unique ON public.trading_personality_profiles USING btree (user_id, analysis_end_date);


--
-- Name: idx_price_alerts_active; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_price_alerts_active ON public.price_alerts USING btree (is_active) WHERE (is_active = true);


--
-- Name: idx_price_alerts_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_price_alerts_symbol ON public.price_alerts USING btree (symbol);


--
-- Name: idx_price_alerts_triggered; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_price_alerts_triggered ON public.price_alerts USING btree (triggered_at);


--
-- Name: idx_price_alerts_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_price_alerts_user ON public.price_alerts USING btree (user_id);


--
-- Name: idx_price_monitoring_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_price_monitoring_symbol ON public.price_monitoring USING btree (symbol);


--
-- Name: idx_price_monitoring_updated; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_price_monitoring_updated ON public.price_monitoring USING btree (last_updated DESC);


--
-- Name: idx_refresh_tokens_device_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_refresh_tokens_device_id ON public.refresh_tokens USING btree (device_id);


--
-- Name: idx_refresh_tokens_expires_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_refresh_tokens_expires_at ON public.refresh_tokens USING btree (expires_at);


--
-- Name: idx_refresh_tokens_family_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_refresh_tokens_family_id ON public.refresh_tokens USING btree (family_id);


--
-- Name: idx_refresh_tokens_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_refresh_tokens_user_id ON public.refresh_tokens USING btree (user_id);


--
-- Name: idx_revenge_tick_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_revenge_tick_created_at ON public.revenge_trade_tick_analysis USING btree (created_at);


--
-- Name: idx_revenge_tick_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_revenge_tick_symbol ON public.revenge_trade_tick_analysis USING btree (symbol);


--
-- Name: idx_revenge_tick_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_revenge_tick_user ON public.revenge_trade_tick_analysis USING btree (user_id);


--
-- Name: idx_revenge_trading_events_trigger_timestamp; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_revenge_trading_events_trigger_timestamp ON public.revenge_trading_events USING btree (trigger_timestamp);


--
-- Name: idx_revenge_trading_events_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_revenge_trading_events_user_id ON public.revenge_trading_events USING btree (user_id);


--
-- Name: idx_round_trip_trades_completed; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_round_trip_trades_completed ON public.round_trip_trades USING btree (is_completed);


--
-- Name: idx_round_trip_trades_entry_time; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_round_trip_trades_entry_time ON public.round_trip_trades USING btree (entry_time);


--
-- Name: idx_round_trip_trades_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_round_trip_trades_symbol ON public.round_trip_trades USING btree (symbol);


--
-- Name: idx_round_trip_trades_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_round_trip_trades_user_id ON public.round_trip_trades USING btree (user_id);


--
-- Name: idx_stock_split_check_log_last_checked; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_stock_split_check_log_last_checked ON public.stock_split_check_log USING btree (last_checked_at);


--
-- Name: idx_stock_splits_processed; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_stock_splits_processed ON public.stock_splits USING btree (processed) WHERE (processed = false);


--
-- Name: idx_stock_splits_symbol_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_stock_splits_symbol_date ON public.stock_splits USING btree (symbol, split_date DESC);


--
-- Name: idx_strategy_classification_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_strategy_classification_created_at ON public.strategy_classification_history USING btree (created_at);


--
-- Name: idx_strategy_classification_history_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_strategy_classification_history_created_at ON public.strategy_classification_history USING btree (created_at);


--
-- Name: idx_strategy_classification_history_trade_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_strategy_classification_history_trade_id ON public.strategy_classification_history USING btree (trade_id);


--
-- Name: idx_strategy_classification_history_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_strategy_classification_history_user_id ON public.strategy_classification_history USING btree (user_id);


--
-- Name: idx_strategy_classification_trade_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_strategy_classification_trade_id ON public.strategy_classification_history USING btree (trade_id);


--
-- Name: idx_strategy_classification_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_strategy_classification_user_id ON public.strategy_classification_history USING btree (user_id);


--
-- Name: idx_subscriptions_status; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_subscriptions_status ON public.subscriptions USING btree (status);


--
-- Name: idx_subscriptions_stripe_customer_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_subscriptions_stripe_customer_id ON public.subscriptions USING btree (stripe_customer_id);


--
-- Name: idx_subscriptions_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_subscriptions_user_id ON public.subscriptions USING btree (user_id);


--
-- Name: idx_symbol_categories_industry; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_symbol_categories_industry ON public.symbol_categories USING btree (finnhub_industry);


--
-- Name: idx_symbol_categories_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_symbol_categories_symbol ON public.symbol_categories USING btree (symbol);


--
-- Name: idx_sync_metadata_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_sync_metadata_created_at ON public.sync_metadata USING btree (created_at);


--
-- Name: idx_sync_metadata_entity; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_sync_metadata_entity ON public.sync_metadata USING btree (entity_type, entity_id);


--
-- Name: idx_sync_metadata_sync_version; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_sync_metadata_sync_version ON public.sync_metadata USING btree (user_id, sync_version);


--
-- Name: idx_sync_metadata_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_sync_metadata_user_id ON public.sync_metadata USING btree (user_id);


--
-- Name: idx_tick_created_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_tick_created_at ON public.tick_data USING btree (created_at);


--
-- Name: idx_tick_symbol_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_tick_symbol_date ON public.tick_data USING btree (symbol, date);


--
-- Name: idx_tick_symbol_timestamp; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_tick_symbol_timestamp ON public.tick_data USING btree (symbol, "timestamp");


--
-- Name: idx_tier_overrides_reminder_tracking; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_tier_overrides_reminder_tracking ON public.tier_overrides USING btree (reminder_sent_at, expiration_sent_at) WHERE (reason ~~* '%trial%'::text);


--
-- Name: idx_tier_overrides_trial_expiry; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_tier_overrides_trial_expiry ON public.tier_overrides USING btree (expires_at, tier) WHERE (reason ~~* '%trial%'::text);


--
-- Name: idx_tier_overrides_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_tier_overrides_user_id ON public.tier_overrides USING btree (user_id);


--
-- Name: idx_trade_analysis_trade; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_analysis_trade ON public.personality_trade_analysis USING btree (trade_id);


--
-- Name: idx_trade_analysis_unique; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_trade_analysis_unique ON public.personality_trade_analysis USING btree (trade_id);


--
-- Name: idx_trade_analysis_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_analysis_user ON public.personality_trade_analysis USING btree (user_id);


--
-- Name: idx_trade_comments_deleted_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_comments_deleted_at ON public.trade_comments USING btree (deleted_at) WHERE (deleted_at IS NULL);


--
-- Name: idx_trade_comments_trade_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_comments_trade_id ON public.trade_comments USING btree (trade_id);


--
-- Name: idx_trade_hold_patterns_outcome; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_hold_patterns_outcome ON public.trade_hold_patterns USING btree (user_id, is_winner);


--
-- Name: idx_trade_hold_patterns_trade; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_hold_patterns_trade ON public.trade_hold_patterns USING btree (trade_id);


--
-- Name: idx_trade_hold_patterns_unique; Type: INDEX; Schema: public; Owner: trader
--

CREATE UNIQUE INDEX idx_trade_hold_patterns_unique ON public.trade_hold_patterns USING btree (trade_id);


--
-- Name: idx_trade_hold_patterns_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_hold_patterns_user ON public.trade_hold_patterns USING btree (user_id);


--
-- Name: idx_trade_split_adjustments_trade_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trade_split_adjustments_trade_id ON public.trade_split_adjustments USING btree (trade_id);


--
-- Name: idx_trades_confidence; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_confidence ON public.trades USING btree (confidence);


--
-- Name: idx_trades_enrichment_status; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_enrichment_status ON public.trades USING btree (enrichment_status) WHERE ((enrichment_status)::text <> 'completed'::text);


--
-- Name: idx_trades_entry_time; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_entry_time ON public.trades USING btree (entry_time) WHERE (entry_time IS NOT NULL);


--
-- Name: idx_trades_exit_time; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_exit_time ON public.trades USING btree (exit_time) WHERE (exit_time IS NOT NULL);


--
-- Name: idx_trades_has_news; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_has_news ON public.trades USING btree (has_news) WHERE (has_news = true);


--
-- Name: idx_trades_news_events; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_news_events ON public.trades USING gin (news_events) WHERE (jsonb_array_length(news_events) > 0);


--
-- Name: idx_trades_news_sentiment; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_news_sentiment ON public.trades USING btree (news_sentiment) WHERE (news_sentiment IS NOT NULL);


--
-- Name: idx_trades_public; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_public ON public.trades USING btree (is_public) WHERE (is_public = true);


--
-- Name: idx_trades_round_trip_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_round_trip_id ON public.trades USING btree (round_trip_id);


--
-- Name: idx_trades_strategy_confidence; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_strategy_confidence ON public.trades USING btree (strategy, strategy_confidence) WHERE (strategy IS NOT NULL);


--
-- Name: idx_trades_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_symbol ON public.trades USING btree (symbol);


--
-- Name: idx_trades_tags; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_tags ON public.trades USING gin (tags);


--
-- Name: idx_trades_trade_date; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_trade_date ON public.trades USING btree (trade_date);


--
-- Name: idx_trades_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_trades_user_id ON public.trades USING btree (user_id);


--
-- Name: idx_user_achievements_earned_at; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_achievements_earned_at ON public.user_achievements USING btree (earned_at);


--
-- Name: idx_user_achievements_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_achievements_user_id ON public.user_achievements USING btree (user_id);


--
-- Name: idx_user_challenges_user_status; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_challenges_user_status ON public.user_challenges USING btree (user_id, status);


--
-- Name: idx_user_peer_groups_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_peer_groups_user ON public.user_peer_groups USING btree (user_id);


--
-- Name: idx_user_settings_preferred_sectors; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_settings_preferred_sectors ON public.user_settings USING gin (preferred_sectors);


--
-- Name: idx_user_settings_primary_markets; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_settings_primary_markets ON public.user_settings USING gin (primary_markets);


--
-- Name: idx_user_settings_statistics_calculation; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_settings_statistics_calculation ON public.user_settings USING btree (statistics_calculation);


--
-- Name: idx_user_settings_trading_goals; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_settings_trading_goals ON public.user_settings USING gin (trading_goals);


--
-- Name: idx_user_settings_trading_strategies; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_settings_trading_strategies ON public.user_settings USING gin (trading_strategies);


--
-- Name: idx_user_settings_trading_styles; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_user_settings_trading_styles ON public.user_settings USING gin (trading_styles);


--
-- Name: idx_users_admin_approved; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_users_admin_approved ON public.users USING btree (admin_approved);


--
-- Name: idx_users_two_factor_enabled; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_users_two_factor_enabled ON public.users USING btree (two_factor_enabled);


--
-- Name: idx_watchlist_items_symbol; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_watchlist_items_symbol ON public.watchlist_items USING btree (symbol);


--
-- Name: idx_watchlist_items_watchlist; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_watchlist_items_watchlist ON public.watchlist_items USING btree (watchlist_id);


--
-- Name: idx_watchlists_user; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_watchlists_user ON public.watchlists USING btree (user_id);


--
-- Name: idx_win_loss_streaks_active; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_win_loss_streaks_active ON public.win_loss_streaks USING btree (is_active);


--
-- Name: idx_win_loss_streaks_type; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_win_loss_streaks_type ON public.win_loss_streaks USING btree (streak_type);


--
-- Name: idx_win_loss_streaks_user_id; Type: INDEX; Schema: public; Owner: trader
--

CREATE INDEX idx_win_loss_streaks_user_id ON public.win_loss_streaks USING btree (user_id);


--
-- Name: equity_history equity_history_updated_at_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER equity_history_updated_at_trigger BEFORE UPDATE ON public.equity_history FOR EACH ROW EXECUTE FUNCTION public.update_equity_history_updated_at();


--
-- Name: equity_snapshots equity_snapshots_updated_at_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER equity_snapshots_updated_at_trigger BEFORE UPDATE ON public.equity_snapshots FOR EACH ROW EXECUTE FUNCTION public.update_equity_snapshots_updated_at();


--
-- Name: trades strategy_classification_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER strategy_classification_trigger AFTER UPDATE ON public.trades FOR EACH ROW EXECUTE FUNCTION public.log_strategy_classification();


--
-- Name: tier_overrides tier_override_delete_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER tier_override_delete_trigger AFTER DELETE ON public.tier_overrides FOR EACH ROW EXECUTE FUNCTION public.reset_trial_used_on_delete();


--
-- Name: tier_overrides tier_override_insert_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER tier_override_insert_trigger AFTER INSERT ON public.tier_overrides FOR EACH ROW EXECUTE FUNCTION public.set_trial_used_on_insert();


--
-- Name: trades trigger_cleanup_trade_jobs; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER trigger_cleanup_trade_jobs AFTER DELETE ON public.trades FOR EACH ROW EXECUTE FUNCTION public.cleanup_trade_jobs();


--
-- Name: trades trigger_log_strategy_classification; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER trigger_log_strategy_classification AFTER UPDATE ON public.trades FOR EACH ROW EXECUTE FUNCTION public.log_strategy_classification_change();


--
-- Name: enrichment_cache trigger_update_enrichment_cache_timestamp; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER trigger_update_enrichment_cache_timestamp BEFORE UPDATE ON public.enrichment_cache FOR EACH ROW EXECUTE FUNCTION public.update_enrichment_cache_timestamp();


--
-- Name: global_enrichment_cache trigger_update_global_enrichment_cache_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER trigger_update_global_enrichment_cache_updated_at BEFORE UPDATE ON public.global_enrichment_cache FOR EACH ROW EXECUTE FUNCTION public.update_global_enrichment_cache_updated_at();


--
-- Name: cusip_mappings trigger_validate_cusip_ticker_uniqueness; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER trigger_validate_cusip_ticker_uniqueness BEFORE INSERT OR UPDATE ON public.cusip_mappings FOR EACH ROW EXECUTE FUNCTION public.validate_cusip_ticker_uniqueness();


--
-- Name: achievements update_achievements_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_achievements_updated_at BEFORE UPDATE ON public.achievements FOR EACH ROW EXECUTE FUNCTION public.update_updated_at();


--
-- Name: admin_settings update_admin_settings_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_admin_settings_updated_at BEFORE UPDATE ON public.admin_settings FOR EACH ROW EXECUTE FUNCTION public.update_admin_settings_updated_at();


--
-- Name: api_keys update_api_keys_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_api_keys_updated_at BEFORE UPDATE ON public.api_keys FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: behavioral_alerts update_behavioral_alerts_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_behavioral_alerts_updated_at BEFORE UPDATE ON public.behavioral_alerts FOR EACH ROW EXECUTE FUNCTION public.update_behavioral_updated_at();


--
-- Name: behavioral_patterns update_behavioral_patterns_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_behavioral_patterns_updated_at BEFORE UPDATE ON public.behavioral_patterns FOR EACH ROW EXECUTE FUNCTION public.update_behavioral_updated_at();


--
-- Name: behavioral_settings update_behavioral_settings_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_behavioral_settings_updated_at BEFORE UPDATE ON public.behavioral_settings FOR EACH ROW EXECUTE FUNCTION public.update_behavioral_updated_at();


--
-- Name: cusip_mappings update_cusip_mappings_updated_at_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_cusip_mappings_updated_at_trigger BEFORE UPDATE ON public.cusip_mappings FOR EACH ROW EXECUTE FUNCTION public.update_cusip_mappings_updated_at();


--
-- Name: device_tokens update_device_tokens_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_device_tokens_updated_at BEFORE UPDATE ON public.device_tokens FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: devices update_devices_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_devices_updated_at BEFORE UPDATE ON public.devices FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: diary_entries update_diary_entries_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_diary_entries_updated_at BEFORE UPDATE ON public.diary_entries FOR EACH ROW EXECUTE FUNCTION public.update_diary_entries_updated_at();


--
-- Name: features update_features_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_features_updated_at BEFORE UPDATE ON public.features FOR EACH ROW EXECUTE FUNCTION public.update_subscription_updated_at();


--
-- Name: gamification_privacy update_gamification_privacy_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_gamification_privacy_updated_at BEFORE UPDATE ON public.gamification_privacy FOR EACH ROW EXECUTE FUNCTION public.update_updated_at();


--
-- Name: instance_config update_instance_config_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_instance_config_updated_at BEFORE UPDATE ON public.instance_config FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: notification_preferences update_notification_preferences_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_notification_preferences_updated_at BEFORE UPDATE ON public.notification_preferences FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: overconfidence_events update_overconfidence_events_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_overconfidence_events_updated_at BEFORE UPDATE ON public.overconfidence_events FOR EACH ROW EXECUTE FUNCTION public.update_overconfidence_updated_at();


--
-- Name: overconfidence_settings update_overconfidence_settings_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_overconfidence_settings_updated_at BEFORE UPDATE ON public.overconfidence_settings FOR EACH ROW EXECUTE FUNCTION public.update_overconfidence_updated_at();


--
-- Name: price_alerts update_price_alerts_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_price_alerts_updated_at BEFORE UPDATE ON public.price_alerts FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: revenge_trade_tick_analysis update_revenge_trade_tick_analysis_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_revenge_trade_tick_analysis_updated_at BEFORE UPDATE ON public.revenge_trade_tick_analysis FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: revenge_trading_events update_revenge_trading_events_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_revenge_trading_events_updated_at BEFORE UPDATE ON public.revenge_trading_events FOR EACH ROW EXECUTE FUNCTION public.update_behavioral_updated_at();


--
-- Name: round_trip_trades update_round_trip_trades_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_round_trip_trades_updated_at BEFORE UPDATE ON public.round_trip_trades FOR EACH ROW EXECUTE FUNCTION public.update_round_trip_trades_updated_at();


--
-- Name: stock_splits update_stock_splits_updated_at_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_stock_splits_updated_at_trigger BEFORE UPDATE ON public.stock_splits FOR EACH ROW EXECUTE FUNCTION public.update_stock_splits_updated_at();


--
-- Name: subscriptions update_subscriptions_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_subscriptions_updated_at BEFORE UPDATE ON public.subscriptions FOR EACH ROW EXECUTE FUNCTION public.update_subscription_updated_at();


--
-- Name: symbol_categories update_symbol_categories_updated_at_trigger; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_symbol_categories_updated_at_trigger BEFORE UPDATE ON public.symbol_categories FOR EACH ROW EXECUTE FUNCTION public.update_symbol_categories_updated_at();


--
-- Name: tick_data_cache update_tick_data_cache_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_tick_data_cache_updated_at BEFORE UPDATE ON public.tick_data_cache FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: tick_data update_tick_data_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_tick_data_updated_at BEFORE UPDATE ON public.tick_data FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: tier_overrides update_tier_overrides_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_tier_overrides_updated_at BEFORE UPDATE ON public.tier_overrides FOR EACH ROW EXECUTE FUNCTION public.update_subscription_updated_at();


--
-- Name: trade_comments update_trade_comments_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_trade_comments_updated_at BEFORE UPDATE ON public.trade_comments FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: trades update_trades_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_trades_updated_at BEFORE UPDATE ON public.trades FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: user_gamification_stats update_user_gamification_stats_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_user_gamification_stats_updated_at BEFORE UPDATE ON public.user_gamification_stats FOR EACH ROW EXECUTE FUNCTION public.update_updated_at();


--
-- Name: user_settings update_user_settings_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_user_settings_updated_at BEFORE UPDATE ON public.user_settings FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: users update_users_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_users_updated_at BEFORE UPDATE ON public.users FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: watchlists update_watchlists_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_watchlists_updated_at BEFORE UPDATE ON public.watchlists FOR EACH ROW EXECUTE FUNCTION public.update_updated_at_column();


--
-- Name: win_loss_streaks update_win_loss_streaks_updated_at; Type: TRIGGER; Schema: public; Owner: trader
--

CREATE TRIGGER update_win_loss_streaks_updated_at BEFORE UPDATE ON public.win_loss_streaks FOR EACH ROW EXECUTE FUNCTION public.update_overconfidence_updated_at();


--
-- Name: achievement_milestones achievement_milestones_achievement_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.achievement_milestones
    ADD CONSTRAINT achievement_milestones_achievement_id_fkey FOREIGN KEY (achievement_id) REFERENCES public.achievements(id);


--
-- Name: achievement_milestones achievement_milestones_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.achievement_milestones
    ADD CONSTRAINT achievement_milestones_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: alert_notifications alert_notifications_price_alert_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.alert_notifications
    ADD CONSTRAINT alert_notifications_price_alert_id_fkey FOREIGN KEY (price_alert_id) REFERENCES public.price_alerts(id) ON DELETE CASCADE;


--
-- Name: alert_notifications alert_notifications_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.alert_notifications
    ADD CONSTRAINT alert_notifications_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: analytics_cache analytics_cache_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.analytics_cache
    ADD CONSTRAINT analytics_cache_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: api_keys api_keys_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.api_keys
    ADD CONSTRAINT api_keys_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: behavioral_alerts behavioral_alerts_pattern_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_alerts
    ADD CONSTRAINT behavioral_alerts_pattern_id_fkey FOREIGN KEY (pattern_id) REFERENCES public.behavioral_patterns(id) ON DELETE CASCADE;


--
-- Name: behavioral_alerts behavioral_alerts_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_alerts
    ADD CONSTRAINT behavioral_alerts_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: behavioral_patterns behavioral_patterns_trigger_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_patterns
    ADD CONSTRAINT behavioral_patterns_trigger_trade_id_fkey FOREIGN KEY (trigger_trade_id) REFERENCES public.trades(id) ON DELETE SET NULL;


--
-- Name: behavioral_patterns behavioral_patterns_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_patterns
    ADD CONSTRAINT behavioral_patterns_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: behavioral_settings behavioral_settings_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.behavioral_settings
    ADD CONSTRAINT behavioral_settings_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: challenges challenges_reward_achievement_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.challenges
    ADD CONSTRAINT challenges_reward_achievement_id_fkey FOREIGN KEY (reward_achievement_id) REFERENCES public.achievements(id);


--
-- Name: cusip_mappings cusip_mappings_created_by_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_mappings
    ADD CONSTRAINT cusip_mappings_created_by_fkey FOREIGN KEY (created_by) REFERENCES public.users(id);


--
-- Name: cusip_mappings cusip_mappings_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.cusip_mappings
    ADD CONSTRAINT cusip_mappings_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id);


--
-- Name: device_tokens device_tokens_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.device_tokens
    ADD CONSTRAINT device_tokens_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: devices devices_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.devices
    ADD CONSTRAINT devices_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: diary_attachments diary_attachments_diary_entry_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.diary_attachments
    ADD CONSTRAINT diary_attachments_diary_entry_id_fkey FOREIGN KEY (diary_entry_id) REFERENCES public.diary_entries(id) ON DELETE CASCADE;


--
-- Name: diary_entries diary_entries_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.diary_entries
    ADD CONSTRAINT diary_entries_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: equity_history equity_history_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.equity_history
    ADD CONSTRAINT equity_history_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: equity_snapshots equity_snapshots_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.equity_snapshots
    ADD CONSTRAINT equity_snapshots_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: gamification_privacy gamification_privacy_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.gamification_privacy
    ADD CONSTRAINT gamification_privacy_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: import_logs import_logs_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.import_logs
    ADD CONSTRAINT import_logs_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: job_queue job_queue_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.job_queue
    ADD CONSTRAINT job_queue_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: leaderboard_entries leaderboard_entries_leaderboard_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.leaderboard_entries
    ADD CONSTRAINT leaderboard_entries_leaderboard_id_fkey FOREIGN KEY (leaderboard_id) REFERENCES public.leaderboards(id) ON DELETE CASCADE;


--
-- Name: leaderboard_entries leaderboard_entries_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.leaderboard_entries
    ADD CONSTRAINT leaderboard_entries_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: loss_aversion_events loss_aversion_events_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.loss_aversion_events
    ADD CONSTRAINT loss_aversion_events_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: notification_preferences notification_preferences_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notification_preferences
    ADD CONSTRAINT notification_preferences_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: notification_read_status notification_read_status_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notification_read_status
    ADD CONSTRAINT notification_read_status_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: notifications notifications_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.notifications
    ADD CONSTRAINT notifications_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: overconfidence_events overconfidence_events_outcome_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.overconfidence_events
    ADD CONSTRAINT overconfidence_events_outcome_trade_id_fkey FOREIGN KEY (outcome_trade_id) REFERENCES public.trades(id) ON DELETE SET NULL;


--
-- Name: overconfidence_events overconfidence_events_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.overconfidence_events
    ADD CONSTRAINT overconfidence_events_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: overconfidence_settings overconfidence_settings_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.overconfidence_settings
    ADD CONSTRAINT overconfidence_settings_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: personality_drift_tracking personality_drift_tracking_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_drift_tracking
    ADD CONSTRAINT personality_drift_tracking_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: personality_peer_comparison personality_peer_comparison_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_peer_comparison
    ADD CONSTRAINT personality_peer_comparison_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: personality_trade_analysis personality_trade_analysis_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_trade_analysis
    ADD CONSTRAINT personality_trade_analysis_trade_id_fkey FOREIGN KEY (trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: personality_trade_analysis personality_trade_analysis_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.personality_trade_analysis
    ADD CONSTRAINT personality_trade_analysis_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: price_alerts price_alerts_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.price_alerts
    ADD CONSTRAINT price_alerts_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: refresh_tokens refresh_tokens_device_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.refresh_tokens
    ADD CONSTRAINT refresh_tokens_device_id_fkey FOREIGN KEY (device_id) REFERENCES public.devices(id) ON DELETE CASCADE;


--
-- Name: refresh_tokens refresh_tokens_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.refresh_tokens
    ADD CONSTRAINT refresh_tokens_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: revenge_trade_tick_analysis revenge_trade_tick_analysis_trigger_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trade_tick_analysis
    ADD CONSTRAINT revenge_trade_tick_analysis_trigger_trade_id_fkey FOREIGN KEY (trigger_trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: revenge_trade_tick_analysis revenge_trade_tick_analysis_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trade_tick_analysis
    ADD CONSTRAINT revenge_trade_tick_analysis_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: revenge_trading_events revenge_trading_events_trigger_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trading_events
    ADD CONSTRAINT revenge_trading_events_trigger_trade_id_fkey FOREIGN KEY (trigger_trade_id) REFERENCES public.trades(id) ON DELETE SET NULL;


--
-- Name: revenge_trading_events revenge_trading_events_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.revenge_trading_events
    ADD CONSTRAINT revenge_trading_events_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: round_trip_trades round_trip_trades_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.round_trip_trades
    ADD CONSTRAINT round_trip_trades_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: strategy_classification_history strategy_classification_history_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.strategy_classification_history
    ADD CONSTRAINT strategy_classification_history_trade_id_fkey FOREIGN KEY (trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: strategy_classification_history strategy_classification_history_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.strategy_classification_history
    ADD CONSTRAINT strategy_classification_history_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: subscriptions subscriptions_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.subscriptions
    ADD CONSTRAINT subscriptions_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: sync_metadata sync_metadata_device_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.sync_metadata
    ADD CONSTRAINT sync_metadata_device_id_fkey FOREIGN KEY (device_id) REFERENCES public.devices(id);


--
-- Name: sync_metadata sync_metadata_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.sync_metadata
    ADD CONSTRAINT sync_metadata_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: tags tags_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tags
    ADD CONSTRAINT tags_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: tier_overrides tier_overrides_created_by_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tier_overrides
    ADD CONSTRAINT tier_overrides_created_by_fkey FOREIGN KEY (created_by) REFERENCES public.users(id);


--
-- Name: tier_overrides tier_overrides_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.tier_overrides
    ADD CONSTRAINT tier_overrides_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: trade_attachments trade_attachments_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_attachments
    ADD CONSTRAINT trade_attachments_trade_id_fkey FOREIGN KEY (trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: trade_comments trade_comments_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_comments
    ADD CONSTRAINT trade_comments_trade_id_fkey FOREIGN KEY (trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: trade_comments trade_comments_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_comments
    ADD CONSTRAINT trade_comments_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: trade_hold_patterns trade_hold_patterns_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_hold_patterns
    ADD CONSTRAINT trade_hold_patterns_trade_id_fkey FOREIGN KEY (trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: trade_hold_patterns trade_hold_patterns_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_hold_patterns
    ADD CONSTRAINT trade_hold_patterns_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: trade_split_adjustments trade_split_adjustments_split_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_split_adjustments
    ADD CONSTRAINT trade_split_adjustments_split_id_fkey FOREIGN KEY (split_id) REFERENCES public.stock_splits(id);


--
-- Name: trade_split_adjustments trade_split_adjustments_trade_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trade_split_adjustments
    ADD CONSTRAINT trade_split_adjustments_trade_id_fkey FOREIGN KEY (trade_id) REFERENCES public.trades(id) ON DELETE CASCADE;


--
-- Name: trades trades_round_trip_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trades
    ADD CONSTRAINT trades_round_trip_id_fkey FOREIGN KEY (round_trip_id) REFERENCES public.round_trip_trades(id) ON DELETE SET NULL;


--
-- Name: trades trades_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trades
    ADD CONSTRAINT trades_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: trading_personality_profiles trading_personality_profiles_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.trading_personality_profiles
    ADD CONSTRAINT trading_personality_profiles_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: user_achievements user_achievements_achievement_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_achievements
    ADD CONSTRAINT user_achievements_achievement_id_fkey FOREIGN KEY (achievement_id) REFERENCES public.achievements(id) ON DELETE CASCADE;


--
-- Name: user_achievements user_achievements_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_achievements
    ADD CONSTRAINT user_achievements_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: user_challenges user_challenges_challenge_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_challenges
    ADD CONSTRAINT user_challenges_challenge_id_fkey FOREIGN KEY (challenge_id) REFERENCES public.challenges(id) ON DELETE CASCADE;


--
-- Name: user_challenges user_challenges_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_challenges
    ADD CONSTRAINT user_challenges_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: user_gamification_stats user_gamification_stats_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_gamification_stats
    ADD CONSTRAINT user_gamification_stats_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: user_peer_groups user_peer_groups_peer_group_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_peer_groups
    ADD CONSTRAINT user_peer_groups_peer_group_id_fkey FOREIGN KEY (peer_group_id) REFERENCES public.peer_groups(id) ON DELETE CASCADE;


--
-- Name: user_peer_groups user_peer_groups_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_peer_groups
    ADD CONSTRAINT user_peer_groups_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: user_settings user_settings_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.user_settings
    ADD CONSTRAINT user_settings_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: watchlist_items watchlist_items_watchlist_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.watchlist_items
    ADD CONSTRAINT watchlist_items_watchlist_id_fkey FOREIGN KEY (watchlist_id) REFERENCES public.watchlists(id) ON DELETE CASCADE;


--
-- Name: watchlists watchlists_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.watchlists
    ADD CONSTRAINT watchlists_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- Name: win_loss_streaks win_loss_streaks_user_id_fkey; Type: FK CONSTRAINT; Schema: public; Owner: trader
--

ALTER TABLE ONLY public.win_loss_streaks
    ADD CONSTRAINT win_loss_streaks_user_id_fkey FOREIGN KEY (user_id) REFERENCES public.users(id) ON DELETE CASCADE;


--
-- PostgreSQL database dump complete
--

\unrestrict DKauiaF7rQePasK8CBZx6ot95rTwiqenGTU4Wwl0PYCJWig5hH8GliOr3YrX0PL

--
-- PostgreSQL database cluster dump complete
--

